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Introduction
“Europe will not be made all at once, or according to a single plan. 
It will be built through concrete achievements which first create a de facto 
solidarity.”
Robert Schuman, Declaration of 9th May 1950
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the reSearch coNtext
When in January 2018, the European Commission published its proposal for an EU Regula-
tion on Health Technology Assessment (HTA) cooperation, most observers were caught by 
surprise. The proposal comprised articles foreseeing harmonisation of certain aspects of 
HTA, a policy domain falling under EU Member States competences. Soon the question 
regarding the application of the subsidiarity principle was raised, as the role of the EU in this 
area was not well understood. Although considered by some as a new policy field in which 
convergence was being pursued, the process of HTA cooperation in Europe had nonetheless 
been set in motion some twenty-five years earlier by so-called ‘HTA doers’. From a purely HTA 
arena initiative, seeking to develop the quality and quantity of HTA and its use in national 
decision-making processes, it progressively evolved into an important European health policy 
issue.
Health Technology Assessment (HTA) has emerged in the mid-1970s in the USA before it 
spread a few years later to Europe where it has been developed in a variety of ways across 
the EU Member States. HTA is often considered as an aid to national health policy processes 
permitting to address health care resource constraints and ensure access to safe and efficient 
health care (Raftery 2011). Assessments of health technologies regard a wide range of issues 
comprising medical, social, economic and ethical aspects related to the availability and use of 
a health technology. The aim is “to inform the formulation of safe, effective, health policies 
that are patient focused and seek to achieve best value” (www.eunethta.eu).
Health technology refers to many aspects of the health care system ranging from pharma-
ceuticals, medical devices, diagnostic and treatment procedures, rehabilitation and preven-
tion methods as well as the management of systems where health care is provided (Banta 
2003:122). The relationship between HTA and national decision-making processes varies 
strongly among European countries. Differentiation can be found in terms of organisational 
agency approaches, the scope of the assessments, methodologies used as well as assess-
ments’ input in pricing and reimbursement processes and/or clinical guidelines. A partial 
explanation for this is to be found in the variety of health care systems in Europe governed 
by distinct policy and funding mechanisms (Garrido et al. 2008:83).
HTA cooperation in Europe has taken off in the early 1990s upon the initiative of actors 
developing HTA in various EU Member States. At that time, few countries in Europe un-
dertook assessments of health technologies and HTA expertise was scarce. When national 
health systems increasingly came under financial and budgetary constraints due to an aging 
population and the introduction of new and often expensive health technologies, the need 
to develop HTA in Europe became more widespread. Whilst systematic assessment of health 
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technologies gradually became a common feature across Europe, the approaches used in 
HTA and the input of HTA in regulatory processes were all but homogeneous.
At present, the European situation is characterised by a multiplicity of HTA bodies in Europe, 
each referring to different domestic health policy systems and decision-making processes 
based on divergent underlying values. In these circumstances, duplication of assessments 
can occur, potentially even producing different outcomes and impacts on regulatory pro-
cedures. Conversely, similar HTA conclusions and regulatory decisions can be based on 
independent assessments enshrined in distinct scientific traditions (e.g. Kanavos et al. 2010). 
To address these diversities, promote efficiency, enhance the input of HTA in national regula-
tory processes and increase capacity-building in European countries less familiar with HTA, 
cooperation initiatives between European HTA agencies have sought to reach some form of 
convergence of assessment practices.
These cooperation initiatives have risen from within the HTA community itself. As a very young 
scientific field searching its place in domestic health policy and decision-making processes, 
HTA agencies quickly recognised the need and common interest to work together. Building 
upon cooperation experience on the international level, HTA agencies in Europe aimed at 
fostering cooperation within the European Union framework by seeking support from the 
European institutions. These initiatives coincided with the ratification of the Maastricht Treaty 
which introduced public health as new policy domain of the EU. Hence, although resulting 
from an HTA arena initiative, HTA cooperation in Europe has quickly become associated to 
the development of EU health policy.
Since the start of HTA cooperation in Europe, three distinct periods can be identified. The first 
is situated from 1992-2001 and regards the initial cooperation initiatives with the implemen-
tation of projects establishing the basis of European HTA collaborative work. Three projects 
have been implemented during this time span: EUR-ASSESS (1994-1997), HTA-Europe 
(1997-1998) and ECHTA/ECAHI (1999-2001). The second phase runs from 2001-2005 and 
addresses developments in the field of European health policy which have been essential 
for the establishment of new HTA networks framing the cooperation in Europe. The third 
phase covers the period from 2006 to the present day and regards the attempts to develop 
and implement a sustainable EU framework for HTA cooperation through networks, such 
as, ‘EUnetHTA’ and the ‘HTA Network’, established by the European Commission (further 
referred to in this thesis as the ‘EU HTA Network’). Finally, in 2018, an EU Regulation on HTA 
cooperation in Europe has been proposed by the European Commission and its adoption 
process is, to date, ongoing.
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To organise the cooperation efforts, recourse to networking has, most often, been the cho-
sen approach. Since the first cooperation initiatives, all subsequent European HTA networks 
have been able to count upon the support of the European Commission. Not restricting 
its involvement to support-lending policies, the Commission has in the course of the years 
become a key-actor in the cooperation processes. Congruence between HTA cooperation 
objectives and EU health policy, has led to agenda-alignment between both arenas. The 
latter permitted HTA to find its place on the EU policy agenda and to become in 2004 a 
‘political priority’ on the EU institutional level.
In areas where the EU has only limited regulatory competences, such as health policy, soft 
governance could be a means to develop cooperation between European actors operat-
ing on multiple levels. Since the EU governance turn of the 2000s, the use of networks to 
implement policy processes has become a common feature in the Union. Although various 
governance modes have been applied in networks, use of soft governance in these structures 
has nevertheless been a privileged approach to produce new EU policy options and build 
support for these on behalf of domestic institutional representatives and stakeholders. In 
HTA cooperation too, the EU has resorted to networks to pursue its policy objectives through 
soft governance which comprised, besides HTA, wider EU public health policy issues.
This thesis will outline the events that have led to the present situation of HTA coopera-
tion in Europe. It will underscore how HTA cooperation has been co-constructed by actors 
stemming from the HTA arena, high level Member States representatives and the European 
Commission. Convergence of practices and the establishment of a European framework for 
HTA cooperation have been common objectives pursued since the early cooperation initia-
tives. Considering the nature of HTA, falling under domestic decision-making processes, soft 
governance applied within networks has been the approach adopted to achieve that goal. 
However, as HTA aims to give input in domestic regulatory processes, it needs to respond to 
a (hard) regulatory policy requirements. The question thus arises to what extent cooperation 
and convergence of practices on a European level can be structured through soft governance, 
as the various national HTA regulations may hinder the establishment and implementation of 
new common European HTA agreements.
the reSearch oBjectiveS aND reSearch queStioNS
This thesis focuses on the governance of the HTA cooperation processes within the EU 
health policy framework. It seeks to understand how European HTA cooperation has been 
structured within the wider process of European integration and the development of an EU 
health policy. As the EU has very limited regulatory competences in this policy domain, the 
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role of soft governance is central to structure HTA collaboration and establish convergence 
of practices in this policy field. This research will seek to understand how soft governance 
has shaped HTA cooperation in the European Union through networking.The overarching 
research question of the thesis is formulated as follows:
- Research Question: To what extent has soft governance, though networking, structured 
HTA cooperation within the framework of the European Union?
To delimitate the scope of this Research Question (RQ), three Sub-Research Questions (SRQ) 
will be formulated which all relate to the overarching research question. These SRQ will 
permit to structure the research in a comprehensive manner by focusing on specific areas 
of the collaboration efforts: 1) the establishment of common methodologies and tools as 
pre-requisites for ‘joint work’1; 2) uptake of joint work in national decision-making processes 
regarding pricing and reimbursement; 3) synergies between HTA and EU Market Authorisa-
tion regulation of pharmaceuticals. The first and second area are related to each other as 
besides the ability of developing common tools, methodologies and assessments, it is of in-
terest to evaluate to what extent these are also used in national regulatory processes, as this 
represents an essential element of HTA. The first two areas are related to the overarching RQ 
by focusing on the goal of the cooperation efforts and the impact on the national regulatory 
environment. The third area connects the HTA cooperation to the European regulatory arena. 
It relates to the overarching RQ by looking on the impact of European HTA cooperation 
efforts on established European regulatory frameworks.
As aforementioned, the establishment of joint work in HTA, requires to proceed according 
to common methodologies, tools and practices. As HTA cooperation falls under exclusive 
national competences, convergence of practices can only be achieved through voluntary 
cooperation processes among HTA actors of the EU Member States. The first sub-research 
question will therefore examine the role of soft governance in the definition and implemen-
tation of strategic policy objectives leading to convergence of HTA tools, methodologies and 
practices in the EU. This question is being formulated as follows:
- Sub-Research Question 1: Can convergence and harmonisation of HTA tools, methodolo-
gies and practices be achieved through soft governance in an EU setting?
1 The term ‘joint work’ refers to the development of common methodologies, tools and joint health 
technology assessments. It includes literature reviews, structured information for rapid or full 
HTAs, Early Dialogues or scientific advice on Research & Development planning and study design 
(European Commission 2016: 4).
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Second, HTA informs national decision-making processes regarding pricing and reimburse-
ment. Again, these processes fall under the exclusive national competences of the Member 
States. As, such, even if an assessment of a health technology has been the result of a 
collaborative effort on a European level, Member States remain free to decide whether they 
want to use this ‘joint HTA’ or other forms of ‘joint work’ as input for the national regulatory 
processes. The latter is also referred to as ‘uptake’. The second focus point of this research 
regards the question whether soft governance instruments have an impact on the use of 
common HTA tools, methodologies and practices in national decision-making processes. 
Hence, the second sub-research question in this thesis has been formulated as follows:
- Sub-Research Question 2: Can national uptake of joint work in HTA be achieved through 
the use of soft governance in an EU setting?
Third, in the EU there is also a strong relationship between market access assessment of 
pharmaceuticals and HTA processes of these same technologies. Indeed, before a pharma-
ceutical product may be commercialised on the EU Internal Market, it needs to receive a 
European Market Authorisation from the European Medicines Agency (EMA). To deliver such 
an authorisation, the EMA will assess a product on the basis of its safety and efficacy profile. 
Once a product has received EU authorisation, it will have to go through a European and/or 
national HTA process which partly will assess similar domains as done by the EMA. Attempt 
are being made to streamline the EMA processes with EU HTA processes. The third sub-
research question will therefore examine whether synergies can be established through soft 
governance between HTA processes and European regulatory processes of pharmaceuticals. 
It has been formulated as follows:
- Sub-Research Question 3: Can synergies be established through soft governance be-
tween HTA and European regulatory processes of pharmaceuticals?
methoDology
The role of soft governance in structuring HTA cooperation within the EU framework will be 
examined through the prism of network analysis. As outlined above, networks are a central 
feature in European HTA cooperation and are considered by the EU as an adequate forum 
to pursue specific policy objectives via soft governance modes and instruments. To this end, 
a research framework has been developed upon the concepts of ‘governance networks’, 
‘metagovernance’ and ‘network governance’ and comprises specific soft-governance-related 
factors potentially impacting governance networks’ typologies and network governance ef-
fectiveness.
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Empirical data has been gathered through the examination of the academic literature, grey 
literature, semi-structured personal interviews, written contributions of key-actors in the field 
and personal observations during attendance of international conferences organised by HTA 
Networks and/or the European Commission. The data gathered will be presented in part B of 
the thesis. Data related to the development of HTA networks has been structured according 
to the five stages of a policy cycle, as defined by Howlett, Ramesh and Perl (2009). Structur-
ing this data by means of the five stages of a policy cycle allows for a systematic presentation 
of both the developments taking place in the HTA arena as well as in EU health policy and 
which can then be related to one another. Data related to specific developments taking place 
on an EU institutional level has been presented according to three policy streams: the EU 
health policy stream, the pharmaceutical policy stream and the social policy stream.
In Part C, the data will be examined through a systematic network analysis based on the 
research framework. This analysis should allow us to answer the research questions in a 
comprehensive and argumentative way by addressing the specific domains defined in the 
three sub-research questions regarding governance practices in European HTA cooperation: 
1) convergence and harmonisation of HTA tools, methodologies and practices, 2) uptake of 
joint work in national regulatory processes and 3) synergies between HTA and EU market 
access regulation of pharmaceuticals. The examination of these issues through the three 
sub-research questions will permit to address the overarching research question regarding 
the role of soft governance in structuring HTA cooperation within the framework of the 
European Union.
The thesis is composed of three parts. Part A establishes the theoretical and research frame-
work. As the topic of this research finds itself at the intersection of two different academic 
fields – health policy and EU governance - contextualisation of the topic in these fields is 
necessary. As such, the first chapter will define our understanding of HTA cooperation and 
how it relates to national and European regulatory processes (e.g. market authorisation and 
pricing and reimbursement decisions). It will also examine the literature on HTA cooperation 
processes and seek to identify any research gaps. Chapter 2 aims at contextualising HTA 
cooperation in the EU health policy and governance architecture. The allocation of compe-
tences is a central feature herein as it determines governance modes available to specific 
health policy fields such as HTA. This chapter will in particular focus on the implementation 
of soft governance through the so-called New Modes of Governance (NMG) developed since 
2001 in the EU governance architecture. One of the approaches used by the EU in the 
implementation of NMG is networking. Recourse to networks as a means to implement soft 
governance modes and instruments will be examined in chapter 3. This chapter will explore 
how networks relate to national and European governance and policy-making approaches. 
It will then identify key-concepts related to networks such as: governance networks, meta-
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governance and network governance. The research framework designed in chapter 3 will be 
based on these key-concepts and will focus in particular on the typology of networks and the 
effectiveness of networks. Effectiveness being defined here as ‘goal attainment’. Through 
the examination of the literature, soft governance-related factors affecting typology and 
network effectiveness have been identified and will be used as tools to answer the research 
questions defined above.
Part B outlines the findings of the empirical research on European HTA cooperation. It is 
structured according to the three development periods outlined above. Chapter 4 regards 
the development of the early cooperation projects which have taken place from 1992 to 
2001. Chapter 5 is focused on the ‘interlude’ period from 2001 to 2006 and addresses in 
particular the developments regarding EU health policy and which have laid the basis of the 
future HTA cooperation processes. The examination focuses on three different policy streams 
affecting HTA cooperation: the EU health policy stream providing the institutional frame-
work of HTA cooperation; the social policy stream, providing soft governance instruments 
in HTA cooperation and the pharmaceutical policy stream, providing key content to HTA 
cooperation. Chapter 6 regards the period since 2006 with the creation of HTA networks 
such as EUnetHTA and the EU HTA Network and the attempts of the European Commission 
to embed HTA cooperation in an EU regulatory framework.
Part C regards the critical examination of the empirical findings by applying network analysis 
based on the research framework of chapter 3. Chapter 7 is therefore divided in three sec-
tions. The first, based on the concept of governance networks, seeks to identify the typolo-
gies of the various European HTA cooperation initiatives. The second, based on network 
governance, regards the effectiveness of these networks in reaching the objectives set. A 
third section addresses the question whether in European HTA cooperation, metagovernance 
has been identified, The outcome of this examination will permit to relate the findings to 
the research questions which will be answered in chapter 8 drawing the final conclusion of 
the thesis. This concluding chapter will furthermore highlight the strengths and weaknesses 
of the research, its limitations as well as topics requiring further research and policy recom-
mendations.
coNtriButioN to reSearch
The contribution the research will make to the academic literature is three-fold. First, to 
date, no exhaustive account exists on HTA cooperation in Europe by examining the subject 
from an EU governance perspective. Most publications either present HTA practices and their 
impact in individual countries or highlight main development stages of HTA networks and 
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their contribution to HTA collaboration in Europe (see also section 1.4.). However, to my 
knowledge, no systematic analysis exists whereby the general internal HTA networks’ gover-
nance processes are brought into relation with EU health policy. Moreover, many publications 
only briefly refer to the initial HTA networks and posit the start of the collaboration in 2006. 
Consequently, there is a tendency to disregard on the one hand the connectivity between the 
networks since they originated and on the other hand the connectivity between EU health 
policy and HTA cooperation. Indeed, the latter is rooted in the initial cooperation initiatives 
and is further developed in the ‘interlude’ period from 2001-2006.
Second, though networks, by their intrinsic characteristics, become a favourable forum for 
the development of soft governance, few publications examine soft governance through 
the prism of network analysis. Most often, particular soft governance instruments will be 
examined as to their role and effectiveness in (EU) policy-making (e.g. Scott and Trubek 
2002; City and Rhodes 2007, Héritier and Lehmkuhl 2011a, Schmidt 2006, Follesdal 2010). 
Proceeding through network analysis in the examination of soft governance, permits to 
combine knowledge rooted in different academic disciplines and herewith provide innovative 
insights on the subject.
Finally, by retracing the process of HTA cooperation since its origins till the proposal of an 
EU Regulation in this area, this research also gives account of the emanation of a new EU 
policy area and of the development of new EU legislative tools in a domain of restricted EU 
competences.


PART A
THEORETICAL FRAMEWORK

1 Health Technology 
Assessment in Europe 
“When one undertakes any action, one must not speculate about whether it 
will succeed.”
Jean Monnet, Memoirs
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1.0. iNtroDuctioN
European cooperation in Health Technology Assessment (HTA) reflects a dynamic interplay 
between two distinct processes: the organisation and financing of national health systems 
and European integration. Examining the development of European HTA cooperation pro-
cesses requires to have a good understanding of the place of HTA in national health policy 
processes as well as of the development of European health policies. This chapter aims to 
situate HTA cooperation within the national and European health policy contexts. It also 
examines which attention it has received in the academic research and which aspects still 
remain under researched.
The first section of the present chapter will address what is understood by Health Technol-
ogy Assessment. The second section will develop the role of HTA in domestic health policy 
processes and how it has been developed in diverse ways across the EU Member States in 
terms of content, methodology and weight in regulatory processes. This diversity of ap-
proaches underpinned the cooperation initiatives among HTA agencies seeking to reinforce 
and develop their activities. Section three of this chapter will outline the broad stages of the 
HTA cooperation process in Europe having triggered attention and support of the European 
Commission. It will also address the numerous challenges faced in the quest to elaborate 
common European approaches and methodologies in HTA.
The literature review, set out in section four, brings to the fore how European HTA coopera-
tion has been discussed in the academic literature. Three main strands in this regard have 
been identified. The first concerns publications elaborating on the general developments of 
HTA in Europe and the different (institutional) approaches that have been chosen in vari-
ous countries. The second strand highlights diversity in methodological and policy aspects 
regarding HTA in Europe and discusses to which extent and how challenges could be ad-
dressed. The third strand of the literature discusses European HTA cooperation initiatives by 
presenting the various projects and their outputs and outcomes in this field. This review also 
allows to identify several gaps in the literature on European HTA cooperation initiatives which 
will be discussed in section five.
1.1. health techNology aSSeSSmeNt DeFiNeD
To address the problem of rising health care expenditures and ensuring access to safe and ef-
ficient health care, EU Member States have developed since the late 1980s so-called ‘Health 
Technology Assessments’ (HTA) as an aid to decision-making (Raftery 2011). Health Tech-
nology Assessment (HTA) refers to” the systematic evaluation of properties, effects, and/or 
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impacts of health care technology” (www.inahta.org). As such, “it summarises information 
about medical, social, economic and ethical issues related to the use of a health technol-
ogy” (Kristensen 2006). Health technology has been defined as “the application of scientific 
knowledge in health care and prevention” covering a wide range of aspects of the health 
care system ranging from pharmaceuticals, medical devices, medical and surgical procedures, 
diagnostic and treatment methods, rehabilitation and prevention methods as well as the 
management of systems where health care is provided (Banta 2003:122; Nielsen, Santamera, 
Vondeling 2008: 20; www.inahta.org).
HTA is linked to policy-making since it is aimed at giving input into decision-making processes, 
such as, pricing and reimbursement of health technologies, clinical guidelines and hospital 
investments which makes it also a highly politicised process (O’Donnell et al. 2009; Thatcher 
2010). The HTA process of pharmaceuticals differs from other health technologies as it can 
take place only after EU market authorisation through the European Medicines Agency (EMA) 
has been obtained. This authorisation is based on the (centralised) evaluation of data regard-
ing the safety and efficacy profile of the product (benefit-risk assessment). Once the EMA has 
issued a positive recommendation, the European Commission will authorise to market the 
product in the EU (www.ema.eu). Following this process, products will enter an assessment 
process on a national or regional level which will further evaluate the products as to their 
safety profile, effectiveness compared to other available products on the market as well as to 
aspects related to cost-effectiveness, legal, social and ethical matters. The outputs of these 
assessments can be used in decision-making processes regarding pricing and reimbursement 
of the assessed products.
The HTA process of medical devices differs in many regards from the one of pharmaceuticals. 
These differences are related to the regulatory environment, the pre-marketing evaluation 
assessments, the characteristics of medical devices2, the life-cycle of medical devices3 as well 
as the industrial development environment4. Conversely to pharmaceutical products, no 
harmonised approach exists for medical devices regarding EU market approval. For a device 
to be marketed in the EU it needs to obtain a CE mark. This decentralised process involves 
2 Unique characteristics of medical devices are for example: the incremental innovation of a devices 
leading often to a short lifespan, the device-operator interaction (learning curve and handling), 
level of risk, economic or organisational implications etc. (Rummel, Hawlik,and Wild 2016:20)
3 Medical devices evolve rapidly, often due to incremental innovations leading to product modifica-
tions. The latter can have an impact on the assessment process as well as on the (clinical) studies 
related to them (Rummel, Hawlik,and Wild 2016:21).
4 The majority of medical devices companies are Small and Medium sized Enterprises (SMEs), 
whereas the pharmaceutical industry is characterised by large multinational companies (Rummel, 
Hawlik,and Wild 2016:23; Medtech Europe 2015).
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pre-marketing evaluation through competent authorities and their designated Notified Bod-
ies. Once the CE mark has been acquired, the product can enter the market and national 
assessment processes can take place. These processes differ however highly amongst the EU 
Member States as to the level of clinical evidence requested, the timing of an assessment and 
the methodologies applied (Rummel, Hawlik,and Wild: 2016). Although several EU Directives 
adopted in the 1990s created a framework to regulate safety and marketing of medical 
devices, the rapid development of devices as well as events pointing to safety concerns of 
some of them, has led to the adoption in 2017 of a new EU Regulation on Medical Devices 
and In Vitro Diagnostics (Regulation EU 2017/745 and Regulation EU 2017/746). The aim 
was to strengthen pre-market conformity assessments, post-marketing control and supervi-
sion and offer the possibility to trace devices throughout the life cycle.
Hence, the introduction and prescription of health technologies in European Member States 
follows a particular path which differs from other products which can be marketed in the 
European Union. Indeed, although resulting from an industrial process, health technologies 
may have a potential impact on health care and, as such, fall under the health policies of the 
Member States. Health policy contains multiple facets and regards besides sanitary measures 
also economic, fiscal, budgetary and social concerns. The market authorisation and diffusion 
of health technologies reflect all these issues as besides the assessment of the quality and 
safety of the products, their prescription and use will also be based on assessment of the 
technologies related to other policy aspects (e.g. economic, social, legal, ethical).
No uniform approach regarding health policy and the organisation of health systems exists 
in Europe as the latter depends on the underlying social security structures as well as on 
social, legal, fiscal and economic policies of each Member State. Similarly, although market 
authorisation for pharmaceuticals has been centralised at the EU level, the process for other 
technologies as well as the pricing and reimbursement policies of all health technologies still 
differ across the EU and fall under the exclusive competences of the Member States. The way 
health care funding is organised also differs highly in the EU but, most commonly, health care 
systems function either on a tax-based funding system or a social health insurance system 
(Saltman 2004:16)5.
Most EU Member States strive to base the reimbursement decision-making process of a 
health technology on an assessment which examines short and long-term consequences of 
5 General taxation systems can be found in countries such as the United Kingdom, Finland, Sweden, 
Spain, Portugal, Italy and Greece. Social Health Insurance Systems can be found in countries such 
as Austria, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Latvia, Lithuania, 
Luxembourg, the Netherlands, Slovakia and Poland (Saltman 2004:3)
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the diffusion of that technology. Hence, besides quality and safety issues, HTA can address 
also other domains such as the effectiveness of a product compared to similar products on 
the market (relative effectiveness assessments, REA), the costs of a product compared to 
its effectiveness (cost-effectiveness assessments), the impact of the product on the health 
budget as well as societal, ethical or legal implications linked to the introduction of the 
product on the national market (Banta 2003; Jonsson and Banta 2009).
The goal of health technology assessment is to provide policy-makers with information on 
policy alternatives and thus to support decision-making in the health sector by a systematic 
assessment of health technologies under medical, economic, social and ethical aspects (Banta 
and Oortwijn 2000; Banta 2009). HTA is often also considered as a bridge between research 
and decision-making (Batista and Hodge 1995). Indeed, HTA has been developed by build-
ing further on knowledge stemming from different methodological streams such as policy 
analysis, evidence-based medicine, health economic evaluation and social and humanistic 
sciences (Kristensen 2009: 336).
By systematically assessing health technologies, efficient and equitable resources alloca-
tion may be achieved in health care, improving herewith also cost-controlling strategies. 
Moreover, the fact that the HTA covers many different domains also permits to identify 
underutilisation or overutilisation of some products and can have, as such, an impact on 
price-setting (Cookson and Maynard 2000). Price regulation and reimbursement decision-
making processes are often interrelated and HTA can give input to both type of processes. 
For example, the analysis of the target population, the incidence of the disease on the overall 
population and the availability of alternative treatments allows to assess which consequences 
reimbursement of the product would have on the health budget depending on the price set.
Whilst HTA has received a lot of attention in the framework of regulatory processes of phar-
maceuticals or medical devices, it is important to understand that it concerns a wide range 
of different health technologies which all affect the health systems and are thus concerned 
by health policy and the organisation of health care in a country aiming to improve public 
health. For example, screening policies or medical and surgical procedures as well as the or-
ganisational and supportive systems within which such care is provided can be subject of an 
HTA (Banta 2003: 122). Hence, when examining HTA cooperation processes, it is important 
to keep in mind that HTA encompasses both health technologies and health interventions6.
6 Health Technology Assessment has originally been developed in the Office for Technology Assess-
ment in the US, assessing a broad range of other technologies. This can explain the broad scope 
of technology assessment in health care (see further 1.4.1. and 4.1.1).
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As the aim of HTA is to inform health care decision-making, there exists a clear relationship 
between HTA and public health policies as the latter target the overall population and regard 
the management of collective health (Brooks 2012). As underscored by Acheson (1988), 
public health can be defined as the “art and science of preventing disease, prolonging life and 
promoting health through organised efforts of society”. In this sense, HTA can be considered 
as a tool for knowledge management and permits to inform decision-making processes seek-
ing to promote public health. This can be translated in pricing and reimbursement processes, 
as outlined above, but HTA can also inform the development of clinical guidelines, treatment 
decisions or public health strategies (e.g. prevention) (Røttingen, Gerhardus and Garrido 
2008). As underscored by Garrido, Zentner, and Busse (2008), “In general, HTA can be ap-
plied: first, to all interventions supplied by the health system (e.g. medical services, drugs, 
diagnostics, etc.), second, to interventions into the health care system (e.g. organisation of 
service delivery, financing of the system, etc.) and third, to health interventions outside the 
health care system (e.g. environmental policies that aim at healthy living conditions)”.
Several definitions have tried to encompass the many aspects covered by HTA. Two of them 
stand out in the academic literature. One has been developed by the International Network 
of Agencies for Health Technology Assessment (INAHTA) which describes health technology 
assessment as “a multidisciplinary field of policy analysis. It studies the medical, social, ethical 
and economic implications of development, diffusion, and use of health technology” (www.
inahta.org). In the European context, another definition defines HTA as a “multidisciplinary 
process that summarises information about the medical, social, economic and ethical issues 
related to the use of a health technology in a systematic, transparent, unbiased, robust 
manner. The aim is to inform the formulation of safe, effective health policies that are patient 
focused and seek to achieve best value” (Kristensen 2006).
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Most recently scholars have published yet another definition of HTA seeking to encompass all 
dimensions of the process. This definition comprises also four explanatory notes7. It defines 
HTA as “a multidisciplinary process that uses explicit methods to determine the value of a 
health technology at different points in its lifecycle. The purpose is to inform decision-making 
in order to promote an equitable, efficient, and high-quality health system” (O’Rourke, 
Oortwijn and Schuller 2020).
Most definitions of HTA underscore the multidisciplinary aspect of HTA which we find back in 
the three definitions given above. However, while they highlight the multidisciplinary aspects 
in a similar way, the second and third definitions presented above are more explicit in defin-
ing the aim of HTA by underscoring that the essence of an HTA is to inform the formulation 
of health policies. HTA in this thesis will be understood as defined in the second definition, 
which is, to date, also the HTA definition used by the European Commission (European 
Commission 2018; 2018a). The third definition having been published at the end of the 
research process could not have been taken into account in the research process. However, 
the manner in which HTA is understood in this dissertation is fully consistent with the latest 
definition published.
1.2. hta aND NatioNal policy proceSSeS
1.2.1. Diversity in methodologies, assessment domains and their 
inclusion in HTA
By seeking to inform decision-making processes, HTA plays a particular role in health policy 
processes. Health policy responds to many different definitions which often reflect various 
7 The four accompanying notes are: “Note 1: A health technology is an intervention developed to 
prevent, diagnose or treat medical conditions; promote health; provide rehabilitation; or organize 
healthcare delivery. The intervention can be a test, device, medicine, vaccine, procedure, program, 
or system (definition from the HTA Glossary; http:// htaglossary.net/health+technology).
 Note 2: The process is formal, systematic, and transparent, and uses state-of-the-art methods to 
consider the best available evidence.
 Note 3: The dimensions of value for a health technology may be assessed by examining the intend-
ed and unintended consequences of using a health technology compared to existing alternatives. 
These dimensions often include clinical effectiveness, safety, costs and economic implications, 
ethical, social, cultural and legal issues, organisational and environmental aspects, as well as wider 
implications for the patient, relatives, caregivers, and the population. The overall value may vary 
depending on the perspective taken, the stakeholders involved, and the decision context.
 Note 4: HTA can be applied at different points in the lifecycle of a health technology, that is, 
pre-market, during market approval, post-market, through to the disinvestment of a health tech-
nology” (O’Rourke, Oortwijn and Schuller 2020).
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underlying interests or goals pursued by policy-makers. As such, according to Busse, Mays 
and Walt (2012:7), from an economic point of view, one can underscore the role of health 
policy in allocating scarce resources available for health. From an organisational point of view, 
one can highlight the policies permitting to influence the determinants of health to improve 
public health. From a medical point of view, one can focus on the health services delivered 
to individuals. One could also add to these, the social and ethical dimensions concerned 
by health policy. HTA contributes to all these different facets of health policy and should 
therefore not be reduced to only its cost-containment dimension, as it also permits to take 
into account the other facets of health policy mentioned above (e.g. medical, organisational, 
social, ethical). Indeed, HTA, as aforementioned, seeks to contribute to the formulation of 
health policy by providing (evidence-based) information and as such plays a role in the way 
health care priorities are set and service provision is delivered.
Although HTA is primarily targeted at decision-makers, it concerns a wide range of stake-
holders as it can have an influence in the access and timing of availability of new technolo-
gies to patients. Hence, it regards those that decide upon the availability of the technology 
on the market (e.g. health policy decision-makers), the end-users (e.g. patients), the ones 
that will prescribe the technologies (e.g. health care professionals), organisations that will 
reimburse (partially) the technology (e.g. social security system, private insurance companies) 
and of course those that have developed and will sell the technology (e.g. industry). All 
stakeholder groups are potentially concerned by HTA which could contribute to a timely and 
cost-effective marketing of new effective and safe health technologies permitting to improve 
the general delivery of health services in a given state.
Besides safety and effectiveness aspects, attention for HTA on behalf of decision-makers 
stems from its potential impact on the health budget. As the health budgets in EU Member 
States’ have increasingly come under pressure, HTA is often associated with cost-containment 
policies. Health systems decision-makers need to ensure that effective and safe health tech-
nologies are available on the market at a given price, offering so-called ‘value for money’, 
justifying coverage and which will not undermine the budget allocated to health care costs. 
The price should thus respond to the needs of patients, ‘payers’ and manufacturers. Hence, 
often decisions will be based on the incremental value of the technology and on the ‘value 
for money’ associated with the use of the new technology compared to current practice in 
the health system (Henshall and Schuller 2013:3).
To ensure a technology responsiveness to real-world challenges of the health systems, the 
notions of ‘(incremental) value’ and ‘value for money’ often underpin decisions made by 
policy-makers, insurance companies or even health care institutions (e.g. hospitals). New 
technologies brought on the market need to respond to both notions, hence the need to 
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develop methods and analytical approaches permitting to identify them. HTA, in its large 
understanding - as outlined in the two aforementioned definitions - permits to assess both 
‘value’ and ‘value for money’. The notion of ‘value’ can be considered in a broad sense 
by taking into account what ‘value’ represents to patients, caregivers, society as well as 
decision-makers. As such, HTA represents a link between innovation and assessment of value 
(Henshall and Schuller 2013). However, as many interpretations can be given to the notion of 
‘value’, many methodologies have also been developed to assess this notion in HTA.
Value for money is often a criterion brought to the fore by health care package decision-
makers and other so-called ‘payers’ of health care expenditures (e.g. insurance companies). 
However, this notion should not be reduced to the sole cost analyses or cost-benefit analyses 
(CBA) (measuring the effects of the introduction and diffusion of a technology in monetary 
units). Drawing upon health economics, value for money can also be expressed in cost-
effectiveness analyses (CEA) (measuring the effect in clinically relevant parameters or health 
benefits in natural units (e.g. costs per life saved or costs per avoided stroke). Often these 
CEA apply a so-called ‘incremental cost-effectiveness ratio’ (ICER) using decision-analytic 
modelling based on quality-adjusted life years (QALYs). In most cases, CEAs seek to inform a 
particular decision by identifying possible alternatives that could be taken to improve health 
of a patient facing choices between mutually exclusive alternatives (Drummond et al. 2015).
Hence, assessing health gain requires being able to measure health effects both in a positive 
as in a negative way (main health outcome and side-effects which can have an impact on 
health-related quality of life). Lately, the idea of ‘real world effectiveness’ (RWE) has become 
more widespread and used increasingly in health economic analyses. This approach is based 
on the use of data generated by real-world settings (e.g. data of registries) additional to, for 
example, clinical studies based on Randomised Controlled Trials (RCTs) often used in CEAs. 
Hence, different health economic approaches exist across Europe and no standardisation of 
methods in this regard is being developed. Moreover, economic analyses are not always part 
of HTAs as some countries prefer not to include them in the assessments. However, as they 
permit to take into account the notion of ‘value for money’ in its different interpretations 
and, as such, can inform decision-making on price-setting and reimbursement packages, 
an increasing number of countries do include economic assessments, at some point, in the 
assessment procedure of health technologies. For some countries this approach can even 
represent the core and most essential part of the HTA process.
Besides the assessment of value, other aspects are also frequently part of an HTA. No uniform 
approach exists however regarding the elements to be assessed in an HTA. The EUnetHTA 
network has developed a so-called HTA ‘Core Model’, including nine domains which can 
potentially being included in an HTA and which are increasingly considered in HTA processes. 
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These domains comprise: 1) Health problem and current use of technology; 2) Description 
and technical characteristics of technology; 3) Safety; 4) Clinical effectiveness; 5) Costs and 
economic evaluation; 6) Ethical analysis; 7) Organisational aspects; 8) Social aspects; 9) Legal 
aspects (www.eunethta.eu). Hence, when discussing HTA, it is important to examine first 
which domains are concerned in the assessments, as the approach can highly vary across 
agencies and countries. Some will encompass in their assessments all domains or will high-
light the importance of costs- and economic aspects, whilst others will consider only the first 
four domains as essential. Moreover, methodologies used to assess the different domains 
show many disparities across the European agencies carrying out an HTA.
The first four domains - also considered as the clinical aspects of the assessments - are most 
commonly being considered in an HTA. Indeed, to assess a new or existing technology, one 
needs to place it in its context. The first domain therefore focuses on the health problem and 
population targeted, the epidemiology as well as the burden of the disease on individuals 
and on the society. Moreover, it gives a description of the availability and patterns of use of 
the technology and the alternatives available on the market. The second domain gives an 
overall understanding regarding the technical aspects of the technology and its function-
ing including investments and information needed for use. The third and fourth domains 
regarding clinical efficacy and safety, are often based on RCTs and describe the efficacy or 
effectiveness of the technology in terms of health outcomes, function and patients’ quality 
of life. They also look at potential direct or indirect harm that can result from use of the 
technology or from particular patient characteristics (EUnetHTA 2016a).
The inclusion of the fifth domain, assessing costs and economic impacts highly varies among 
EU countries and is still a controversial issue in many debates on HTA and even more so 
on HTA cooperation and convergence of practices. Indeed, the domain is closely linked to 
economic and fiscal policies as it can have a direct impact on pricing and reimbursement 
negotiations and decisions. Moreover, this domain is considered as being highly context 
specific. As aforementioned, methodological approaches regarding cost effectiveness differ 
across agencies and countries and bear the potential to influence outcomes of the assess-
ments (e.g. specific criteria/endpoints used; choice of comparators; calculation methods) 
(Eddy 2009; Angelis, Lange and Kanavos 2018).
The last four domains (ethical analysis, organisational, social and legal aspects), although 
regularly recognised as important and justifying the context-specificity of HTA, bear often 
the least weight in many HTAs and are still under-researched in terms of HTA cooperation 
(Lehoux and William-Jones 2007; Lysdahl et al. 2016). Indeed, since the early days of HTA 
development, it has been considered that HTA should encompass not just clinical and eco-
nomic issues but also ethical and social implications (Banta and Perry 1997). These domains 
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are however also subject to controversy which may explain the limited inclusion of them in 
HTAs (e.g. in vitro fertilisation, preimplantation genetic diagnosis). Moreover, the need to 
assess social and ethical issues can differ according to the country in which it is - or seeks to 
be - introduced (Lehoux and William-Jones 2007).
1.2.2. Diversity in policy approaches towards HTA
We have seen above how approaches regarding methodologies and domain inclusion in 
HTAs vary among different HTA agencies, even between those operating within the same 
country. As HTA has developed in numerous ways in the EU Member States and reflects still 
today a high variety in the way it is structured, no standardised practices exist regarding HTA. 
Hence, whilst the assessments are based on solid scientific approaches, different HTAs done 
on the same technology in different countries can result into different conclusions (Nicod 
and Kanavos 2016). This is however not the only diversity in approaches towards HTA. The 
manner in which the assessments are considered in the decision-making processes regarding 
health technologies also presents dissimilitude.
The understanding of the notions of assessments and appraisal play a role in the divergence 
of policy approaches regarding HTA. Stevens and Milne (2004:11) define the former as “the 
analytical process of gathering and summarising information about health technologies” and 
he latter as “the political process of making a decision about health technologies”. Hence, 
assessments in this perspective, refer to a scientific process based on different methodologi-
cal streams (e.g. evidence-based medicine, health economic evaluation, policy analysis, social 
and humanistic sciences) while appraisal refers to the role of policy-makers in making a deci-
sion based on the assessment (Kristensen et al. 2009:33). Others, underscore that “appraisal 
is a consideration of the outputs of the assessment process within the context of additional 
information supplied by relevant parties” (Oortwijn et al. 2013). In this perspective, the ap-
praisal of the product and how this will find its place in the given health system is context 
specific and explains national differences, even if they are based on the same HTAs. Hence, 
even if manufacturers develop their products to be marketed globally, technologies will still 
have to undergo separate assessments and appraisals in each (national) market.
The disparity in approaches is also reflected in the literature where the boundaries between 
assessment, appraisal and decision-making are not always established at the same levels. As 
such, some will consider domains dealing with social and ethical issues as part of the ap-
praisal process, while for others this is still part of the assessment process. Similarly, some will 
consider some aspects of the cost-effectiveness assessment as part of the decision-making 
process whilst for others this is either part of the assessment or the appraisal process (or 
both). This confusion can be related to the weight and value given to each of the domains in 
respectively the assessments, appraisal and decision-making process.
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Thatcher (2010:4) underscores how sometimes processes referring to assessment, ap-
praisal and decision-making take place within the same institutions whereby boundaries can 
somehow be blurred. Conversely, in some countries these processes can take place across 
different (public and private) institutions/agencies. Moreover, blurred boundaries between 
assessment, appraisal and decision-making can also result from the fact that they are, to a 
certain extent, intrinsically linked. The setting of endpoints in clinical studies, for example, 
can be related to the appraisal phase which will value whether these endpoints are relevant 
in a specific case and as such have an impact on the decision-making. Similarly, an appraisal 
process can implicitly give more weight to certain assessment domains (e.g. what is prevail-
ing in a particular case: cost-effectiveness or social/ethical issues?) Moreover, the appraisal 
and decision-making processes can also add issues not included as such in the assessment 
processes (Garrido, Zenter and Busse 2008:61). As such, separating assessment from ap-
praisal remains to a certain extent debatable and no generally accepted definitions about the 
concepts exists to date (see also e.g. Van der Wilt, Gerardus and Oortwijn 2017).
The absence of consensus regarding the understanding and definitions of assessment and 
appraisal infers in political debates regarding European HTA cooperation as it touches upon 
competence issues of Member States. By separating assessment from appraisal, the divi-
sion of competences between the EU and the domestic level is indirectly addressed. Indeed, 
considering assessments in the sense of providing scientific information about the selected 
HTA domains and serving as input in decision-making processes (which would handle the 
appraisal process of HTAs) detaches them from domestic decision-making procedures, falling 
under the exclusive Member State competences. Hence, as the debate about assessment 
and appraisal is still ongoing it bears the potential to influence European HTA cooperation 
because of competencies’ related issues.
According to Garrido, Zenter and Busse (2008:61), decisions regarding health technolo-
gies need to be based on information regarding context-free factors of the technology as 
well as on context-dependent factors. “An assessment (i.e. HTA report) can provide such 
information as it is a summary of the relevant research on context-free and context-sensitive 
evidence”. However, context sensitive information is not always available in research and 
needs to be brought into the process in the decision-making processes (by Garrido, Zenter 
and Busse 2008:61). Hence, the importance to always take into account contextual factors 
when analysing HTA and in particular cooperation between HTA agencies (Hutton, Trueman 
and Facey 2008; Barron et al. 2015).
Although designed to be politically ‘neutral’ and based on a solid scientific approach, HTA 
can become politicised as it can feed into specific policy processes on a particular issue 
(e.g. ethical issues, political pressure). We have seen above how health policy is linked to 
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other policies (social, fiscal, financial and economic). The weight of the health sector on the 
European economies represents almost 10% of the GDP (Garrido 2008:162). With the rapid 
technological developments, policy-makers face not just budgetary constraints, but are also 
confronted with pressure from stakeholder groups (e.g. patient organisations) seeking to 
have fast access to these new technologies (Garrido et al. 2009:46). Hence, trade-offs need 
to be made between health concerns (safe and efficient medicines), budgetary concerns 
(affordability of health technologies and sustainability of the health system) and economic 
concerns (development of the industry as driver of the economy).
As such, HTA finds itself in various policy processes and involving the many stakeholders 
concerned by the policy. Moreover, instead of being used in a neutral manner based on sci-
entific research, HTA can be used “as ammunition in political debates” (Nielsen, Santamera, 
Vondeling 2008:23-24). Increased stakeholder participation and request for more transpar-
ency, sometimes also results in increased pressure on regulatory bodies who seek to gain 
trust from the wider public to ensure their legitimacy. Especially in fields such as genetics or 
stem cell research appraisal, the conflicting perspectives of patient groups, industry, scientists 
or religious groups can impact decision-making (Blume 2008). As such, HTA conclusions can 
be used either to post-pone action or at the contrary to support implementation of the new 
technology.
The challenge for HTA is thus to provide information which is based on solid scientific (e.g. 
evidence-based) methods permitting to estimate future benefits and risks for both the health 
system as the end-users of the technology (Henshall and Schuller 2013:5). As it can find itself 
at the cross-roads of different policy areas, the assessment, appraisal and decision-making 
processes based on HTAs can become politised. No uniform methodological approach to 
HTA exists in Europe and even within a single Member State, different methods can be used 
in different agencies. As such, to date, when a manufacturer develops a new health technol-
ogy for the EU market, a separate HTA will be realised in each Member State. As HTA is a 
time-consuming and costly exercise, avoiding duplication of assessments may be beneficial 
for all stakeholders. This observation has led to the cooperation efforts among HTA agencies 
which have started in the 1990s. In the next section we will outline the development of the 
different collaboration initiatives and the challenges faced by these.
1.3. hta aND eu cooperatioN iNitiativeS
HTA has been introduced in Europe in the mid-1980s and was based on the work initiated 
in the Office for Technology Assessment which had been created in 1972 in the USA (Banta 
2009; Thatcher 2010). Since HTA was a very young discipline, representatives of agencies 
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from all over the world gathered in international societies (e.g. ISTAHC, INAHTA) and sought 
to exchange their knowledge and experiences. The first European cooperation initiatives 
among HTA agencies were born inside these international societies and took place almost 
simultaneously with the setup of the first HTA agencies in Europe (Boehm and Landwehr: 
2013:15). The aim was to enhance the quality of the assessments and to develop HTA in 
countries where it did not yet exist. The underlying idea was that enhancing the quality and 
the quantity of HTA would allow for a better uptake of HTA in the national decision-making 
processes and also permit the development of HTA in countries having limited experiences in 
this field (personal interview 2).
The first cooperation initiatives at a European level coincided with an increased attention 
for HTA on a national level due to the rapid development of new technologies, procedures 
and care pathways impacting the national health care budgets (Henshall and Schuller 2013). 
Considering the diversity of approaches in HTA, the numerous duplication of assessments 
made on the same technologies, as well as the need for HTA capacity-building, questions 
were raised on what should be considered as best practices in HTA as well as on the manner 
to develop ‘joint HTAs’ between several HTA agencies across various countries. The idea 
to ‘harmonise’ HTA permitting to cooperate better and avoid duplications has been pres-
ent from the start. However, as underscored by Hutton,Trueman, and Facey (2009: 455), 
harmonisation can refer to different elements. It can concern 1) the harmonisation of ap-
proaches and processes, 2) the harmonisation of methods and evidence requirements or 3) 
the harmonisation of decisions.
Harmonisation of decisions has never been the objective of the cooperation efforts as this 
is intrinsically linked to domestic health policy-processes. However, increased standardisa-
tion of HTA methods and procedures has always been one of the prime objectives allowing 
“a wider range of HTAs in Europe to be undertaken and also help improve links between 
technology assessment and decision making” (Kristensen 2006). The challenge was thus to 
streamline methods and practices of various HTA agencies in Europe which applied different 
criteria in HTA regarding issues, such as, technologies to be assessed, data requirements and 
analytical designs (Boehm and Landwehr 2013:15). Moreover, according to those consider-
ing assessments and appraisal as two distinct processes, convergence in assessments would 
still leave room for individual domestic appraisals of the assessments, taking into account 
context-specific elements on a national or regional basis.
The more the cooperation process evolved, the more the issue of ‘transferability’ came to the 
forefront as a key-concept regarding convergence in HTA practices. Gradually, it became clear 
that the feasibility to transfer work done jointly on a European level to the national context 
depended on different factors such as the HTA domains concerned. As such, the transfer-
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ability potential of joint work seemed the highest in the first four domains often referred to 
as ‘Relative Effectiveness Assessments’ or ‘Clinical Assessments’8 whereas it seemed rather 
problematic in the five remaining domains: Cost and economic analysis; Ethical analysis; 
Organisational aspects; Social aspects; Legal aspects (see further chapter 6).
Moreover, streamlining methodologies and practices required to overcome challenges linked 
to other important aspects of HTA in Europe. The latter regarded, amongst others, organisa-
tional approaches and policy-making aspects. Indeed, some countries having organised HTA 
by adopting a centralised approach where HTA is being carried out by one central agency 
(e.g. France). Other countries having organised HTA in a decentralised way where HTA are 
realised by several independent agencies (e.g. Spain, the Netherlands). Agencies can be 
public or private and can provide information for decision-making either on a national basis 
or on a regional basis (Garrido et al. 2008:32; see also Dragborg et al. 2005 for an overview).
Moreover, as mentioned above, disparities amongst Member States’ HTA agencies also 
reside in the nature of the agencies, some conducting both assessments and appraisals (e.g. 
France), while in other countries the processes are separated (e.g. UK, the Netherlands). As 
such, methodological differences can be observed amongst them as well as across agencies 
in a single country. Some agencies focusing on clinical effectiveness and may or not include 
costs-effectiveness. Other, considering ethics and the social impacts of the diffusion of the 
technology in their assessments (Garrido et al. 2008: 40). The variety of approaches, partly 
finding its origins in the variety of health systems functioning and organisations can have an 
impact on the uptake of HTA in decision-making processes9 (Garrido et al. 2008:83).
Although consensus exists within the HTA arena regarding the fact that HTA should be firmly 
rooted in scientific research, opinions differ as to the scientific methods that should be used 
in HTA. Moreover, methodology is often related to uptake in decision-making processes. 
Indeed, whether decisions will be considered legitimate, partly depends on the validity of 
the assessments results. The latter will depend on the methods used. To date, no consensus 
exists on what an ‘optimal HTA’ should refer to (Cookson and Maynard 2000), neither on 
the adequacy of the methods used. Relatively little controversy exists regarding the need to 
prioritise health technologies candidates for evaluation, as it is not feasible to assess all new 
8 The first four domains are: 1. Health problem and current use of technology; 2. Description and 
technical characteristics of technology; 3. Safety; 4. Clinical effectiveness (www.eunethta.eu).
9 Some studies have highlighted the variety of criteria applied in coverage decision-making such 
as appropriateness, budget restraints, cost-effectiveness, innovation or need. No strict guidelines 
exist, however, on how to operationalise these criteria or to weigh them against one another 
(Manjusha, Bending and Hutton 2009; Garrido et al. 2006).
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technologies entering onto the market. However, differences in approaches to prioritisation 
still exists. Methodologies used in economic evaluations represent maybe the area where 
divergences across countries and agencies and (health) economists are the highest, as they 
play an important role in the domestic decision-making process and are intrinsically linked to 
value attribution (see above). Moreover, the timing of doing an HTA is a matter of debate, as 
positions range from assessing a new technology as early as possible, to post-marketing as-
sessments (so as to inform on whether a product should remain available and be reimbursed 
or be withdrawn from the market or removed from reimbursement baskets).
Despite these differences, significant progress has been made in finding common meth-
odological approaches since first the cooperation projects. Today, several tools have been 
developed to establish a common basis for cooperation such as a European ‘core HTA 
model’, guidelines and other tools (e.g. databases). These objectives have not been achieved 
overnight and result from a long and still-ongoing cooperation process which has started 
in 1994 with the EUR-ASSESS project (1994-1997). This project was the first in its kind 
and was followed-up by two other projects HTA-Europe (1998) and ECHTA/ECAHI (1999-
2001). These projects permitted to exchange information and experience regarding HTA on 
emerging technologies and priority-setting. From the start, one of the objectives regarded 
the establishment of ‘joint assessments’ and the coordination of the findings and resources 
necessary to carry out an HTA (ECHTA/ECAHI 2001:8). Moreover, the establishment of a 
permanent network structure was considered to be the most appropriate way to conduct 
the cooperation efforts.
The European Commission has very soon recognised the potential impact of HTA on the 
national health system. As such, it has given its financial support to the first cooperation 
initiatives. In 2003, it included HTA in the High Level Process of Reflection on Patient Mobility 
and Healthcare, permitting the topic to enter onto the EU political agenda and be discussed 
on the highest expert level. The experts recognised the importance of HTA cooperation in 
Europe and invited the European Commission to reflect upon the establishment of a sustain-
able network of HTA (European Commission 2003a:6). To take the recommendation of the 
high-level reflection process further, the European Commission established the High Level 
Group on health services and medical care (HLG) in 2004. This HLG developed a new project 
called the ‘EUnetHTA project’, which continued the work began in the early cooperation 
projects. This project further developed in three so-called ‘Joint Actions’ between the newly 
establish EUnetHTA network and the European Commission.
All projects aimed at the establishment of a sustainable structure for HTA cooperation which 
could develop and implement practical tools to provide reliable, timely, transparent and 
transferable information to contribute to HTA in Member States (EUnetHTA 2009). As such, 
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the different projects of EUnetHTA sought to reduce overlap and duplication of efforts and 
promote a more effective use of resources. The latter should also contribute to increase 
uptake of HTA in national decision-making processes, strengthen the link between HTA 
and health care policy and develop HTA in countries with limited experience in the matter 
(EUnetHTA 2009). Many different tools have been developed throughout the different Joint 
Actions focusing on the establishment of joint work (methodologies, tools10), uptake (re-use 
of joint work and impact on decision-making processes) and adopting a life-cycle approach 
(priority setting/Horizon Scanning, evidence generation and so-called Early Dialogues seeking 
to streamline evidence required for regulatory purposes and HTA purposes).
The adoption of a Cross-Border Health Care Directive (2011/24/EU) has permitted to take 
further the HTA cooperation process in Europe as the Directive created a legal basis for HTA 
cooperation between EU Member States. Building upon the provisions laid down in the Di-
rective, the European Commission established a new EU HTA Network in 2014 which gathers 
national authorities responsible for HTA. Its focus is on the strategic and policy coordination 
of HTA relevant issues in the EU. The EUnetHTA network would since continue to operate 
as the scientific and technical arm of the EU HTA Network until 2020, after which a new 
sustainable (financial and organisational) structure should be implemented to support EU 
cooperation in the field of HTA.
Despite the efforts and progress made, duplication of assessments still take place and uptake 
of joint assessments in national decision-making processes is rather low. Barriers which have 
been identified so far point to issues such as methodology, resources and national regulatory 
processes (legal conditions) (Kleijnen et al. 2015; Garrido et al. 2009:44-45). Cultural differ-
ences are also sometimes mentioned as a barrier to uptake and harmonisation of methods 
in the wider sense (Lux and Karner 2013). Moreover, some reports are context-specific and 
their transferability to other contexts seems problematic. Similarly, sometimes legal and 
ethical information can be context-specific and difficult to adapt in another setting (Garrido 
et al. 2009:45). Trust seems to be another important aspect in the reluctance of national 
policy-makers to base their decisions on assessments that have been done on a cross-border 
basis. Finally, the quality and timely availability are brought to the fore as critical success 
factors to ensure a better uptake of joint work (Kleijnen et al. 2015). Hence, despite potential 
costs- and time savings, in practice, many countries continue to develop HTA according to 
domestic approaches.
10 As methodologies and tools developed by EUnetHTA we can cite: a core HTA model common 
reporting standards; a model to implement joint assessments; adaptation tool kits to use HTA done 
by other agencies and adapt it to the local requirements; tools to monitoring the development of 
HTA in countries with limited experience, databases to share HTA data and results.
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To overcome the problems of insufficient uptake of joint work and to boost cooperation 
amongst EU Member States, the European Commission has made in January 2018 a proposal 
for the adoption of a new EU Regulation on HTA. This proposal aims at providing the basis 
for permanent and sustainable cooperation at the EU level. It proposes ‘the use of common 
tools, methodologies and procedures in four areas: 1) on joint clinical assessments focusing 
on the most innovative health technologies with the most potential impact for patients; 2) on 
joint scientific consultations whereby developers can seek advice from HTA authorities; 3) on 
identification of emerging health technologies to identify promising technologies early; and 
4) on continuing voluntary cooperation in other areas” (European Commission 2018). This 
proposal stipulates that for the pharmaceutical products and medical devices where a joint 
clinical assessment has been made, Member States cannot organise a similar assessment on 
a national level. Assessment of non-clinical (e.g. economic, social, ethical) aspects of health 
technology is in this proposal still conceived as individual EU Member State exercise leaving 
the possibility for cooperation and uptake of the results on a voluntary basis. The decision-
making processes on pricing and reimbursement fall outside the scope of this proposal as this 
remains an exclusive competence of national Member States. The proposal can only enter 
into force and be applicable if it will be accepted by the EU Parliament and the Council of 
Ministers.
Although initiated from within the HTA community itself, the European Commission’s im-
plication in the European HTA cooperation process has been determinant for its course of 
action. From granting only financial support in 1994 to becoming a full-fledged partner in 
the HTA Joint Actions, the Commission has gradually taken the driver’s seat and steered the 
developments in this field. Moreover, several initiatives launched by the Commission have 
permitted to lift HTA cooperation to an EU institutional level. The most recent proposal for 
an EU Regulation in the field of HTA cooperation is another example of the role of the EU in 
seeking to establish a sustainable European cooperation in health technology assessment.
In the following section we will examine how these HTA cooperation processes in Europe 
have been examined in the literature. We will proceed by first looking at publications about 
the general development of HTA in Europe before addressing literature specifically examining 
European HTA cooperation processes.
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1.4. reSearch oN europeaN hta cooperatioN: literature 
review
If one leaves out the scientific publications reporting on the results of a specific HTA made on 
a health technology, the literature on HTA remains rather limited11. Focusing essentially on the 
publications which have examined HTA cooperation in Europe, the literature becomes even 
more scarce and is being addressed predominantly by the HTA arena itself. Most publications 
focus on a few central issues such as the (historical) development of HTA and the relationship 
between HTA and policy-making/regulatory issues (in particular pricing and reimbursement). 
Another important part of the literature is dedicated to individual or multi-country reports 
on the state of HTA and its impact on decision-making. Methodological issues of HTA are 
also increasingly being debated in the academic literature and mostly regard evidence-based 
decision-making and economic evaluations.
HTA related to pharmaceuticals receive most attention followed by research done on HTA 
and medical devices (e.g. Siebert, Clauss and Carlisle et al. 2002; Altenstetter and Permanand 
2007; Sorenson and Kanavos 2011; Kirisits and Redekop 2013; Fuchs et al. 2017; Olberg et 
al. 2017). Little attention is given to other types of health technologies. Other issues such 
as HTA and priority setting (e.g. Oortwijn 2000; Anell 2004; Oliver, Mossialos and Robinson 
2004) and the participation of stakeholders in HTA have also received attention in the aca-
demic literature but to a much lesser extent (e.g. Nielsen et al. 2009; Gauvin et al. 2010; 
Houÿez et al. 2011; Gorry et al. 2015; see further section 1.4.2).
In this section we will briefly outline the key-aspects brought forward in the literature on 
HTA. The aim here is not to present an exhaustive overview of the literature but to highlight 
the main topics and positions discussed in relation to EU HTA cooperation initiatives. As 
such, in the examination of the literature, we have identified three main strands which we 
will outline hereafter. The first part of this section will regard publications on the general 
development of HTA in Europe. The second sub-section will be focused on methodological 
and policy aspects brought to the fore in the literature related to HTA cooperation in Europe. 
The third sub-section will examine publications that have treated more specifically the HTA 
cooperation processes in Europe. The final sub-section will highlight the gaps in the literature 
as regards EU cooperation in HTA.
11 As this thesis will focus on the governance aspects of HTA cooperation, this non-exhaustive over-
view of the literature will not treat individual HTA reports.
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1.4.1. Development of Health Technology Assessment
Early publications on the development of HTA aimed at underscoring the role of HTA as a 
valuable tool for decision-makers to assess safety, (cost-)effectiveness, quality of care and 
patient outcomes. Most publications draw back on the establishment of HTA in the Office for 
Technology Assessment (OTA), which closed in 1995 (e.g. Battista and Hodge 1999: Banta 
and Oortwijn 2000b; Jonsson 2002; Stevens Milne and Burls 2003; Banta 2003; O’Donnell 
et al. 2009). The OTA had been established upon request of the American Congress to re-
spond to the need of policy-makers regarding information on the rapid development of new 
technologies and their intended and unintended impact on society. Health technology has 
been included in this approach. Against this background HTA has been first conceptualised 
in 1976 (Banta 2003; 2009; O’Donnell et al. 2009; Meneu 2015).
Many publications elaborating on the general developments in the field of HTA outline how 
from the US, the concept of HTA has been established and further developed in many other 
countries across the world such as Canada, Australia, Europe and later to Asia and Latin 
America (e.g. Perry, Gardner and Thamer 1997; Stevens Milne and Burls 2003; Banta 2003, 
Garrido and Busse 2005; Blume 2009; O’Donnell et al. 2009). Sivalal (2009) underscores 
how the development of HTA has been most successful in developed countries whereas less 
developed countries would maybe even need HTA the most. Whilst HTA became increasingly 
recognised as tool for policy-makers in decision-making processes, no uniform model of 
HTA existed across the continents. Several analytical accounts have sought to highlight the 
similarities and differences between HTA agencies (e.g. Banta et al. 1995; Perry, Gardner and 
Thamer 1997; Dragborg et al. 2005; see also the multi-country analyses below).
Most often however, these publications regard the presentation of individual countries 
or present a multi-country comparison. In the literature, the United Kingdom (UK) stands 
out in terms of academic attention received. The National Institute for Health and Clinical 
Excellence (NICE) established in 1999 in the United Kingdom is indeed one of the most 
researched agencies. This can partly be explained because of its role and weight in the 
domestic decision-making process as the National Health Service (NHS) has to implemented 
recommendations made by NICE (e.g. Woolf and Henshall 2000; Stevens and Milner 2004; 
Milewa 2006; Schandler 2007, Sorenson et al. 2008; O’Donnell 2009; Drummond and 
Sorenson 2009; Drummond 2009; Longworth et al. 2013). The Swedish model is also often 
presented, focusing on the Swedish Agency for HTA (SBU) established in 1987 as one of 
the first European HTA agency (together with the Catalan Agency for HTA) (e.g. Carlsson et 
al. 2000; Jonsson, Banta and Scherstén 2001; Carlsson 2004; Schwarzer and Siebert 2009; 
O’Donnell et al. 2009; Jonsson 2009). Finally, the Canadian experience in HTA is also often 
used as a reference in international comparisons (e.g. Menon and Topfer 2000; Borowski, 
Brehaut, and Hailey 2007; Battista et al. 2009; Menon and Stafinski 2009).
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Many publications have presented the role and impact of HTA in specific countries. As it is 
not our aim to give an exhaustive list of these, we will just highlight a few of them. Multi-
country analyses have been made by scholars such as Banta and the US Congress (1995) 
outlining the development of HTA in Australia, Canada, France, Germany, the Netherlands, 
Sweden and the United Kingdom. Chinitz (2004) focuses his research on the UK, the Neth-
erlands, Sweden and France, Dragborg et al. 2005 presents a multi-country review including 
Denmark, Sweden, the Netherlands, Norway, the United Kingdom, Canada, Australia and 
the USA. Schwartzer and Siebert (2009) include Germany, the United Kingdom, France, and 
Sweden in their research. An analysis of HTA in central and eastern European countries has 
been made by e.g. Sorenson, Kanavos and Karamalis (2009). Other publications presenting 
a multi-country approach are e.g. Healy and Pugatch 2009 (Australia, Canada, Germany 
and UK); Kanavos et al. 2010 (Canada, England, Australia, Sweden, France and Scotland); 
Oortwijn et al. 2013 (comparison HTA in middle-income countries (e.g. Brazil, India, Malay-
sia) with Australia, Canada, and United Kingdom); Del Llano-Señarís 2015 (France, Germany, 
Spain, Sweden, United Kingdom); Fisher, Heisser and Stargardt 2016 (Germany, England, 
Scotland and Australia).
An important strand of the HTA literature regards analyses of individual countries, such as, 
Australia (Bulfone, Younie and Carter 2009; Hailey 2009b): Austria (e.g. Wild 2006; 2009); 
USA (e.g. Sullivan et al. 2009; Luce and Singer Cohen 2009); Belgium (e.g. Cleemput and Van 
Wilder 2009); Denmark (e.g. Sigmund and Kristensen 2002; 2009); Finland (e.g. Lauslahti 
et al. 2000; Mäkelä, and Roine 2009); France (e.g. Chevreul and Durand-Zaleski 2009; Weill 
and Banta 2009; Orvain and Matillon 2004; Barron et al. 2015), Germany (e.g. Gerhardus 
2006; Nachtnebel et al. 2015; Nasser and Sawicki 2009; Perleth, Gibis and Gohlen 2009, 
Schwarzer and Siebert 2009); Hungary (Gulacsi et al. 2009); Italy (e.g. Favaretti et al. 2009); 
Norway (e.g. Mørland 2009); Spain (De Sola-Morales and Granados 2009); The Netherlands 
(e.g. Banta, Oortwijn, and Van Beekum 1995; Bos 2000, Berg, Van der Grinten and Klazinga 
2004; Banta and Oortwijn 2009); the UK (Woolf and Henshall 2000; Stevens and Milner 
2004; Schandler 2007; Sorenson et al. 2008; Drummond 2009; Longworth et al. 2013).
The research done on HTA in the individual countries brings to the fore both similarities and 
disparities in the development and institutionalisation of HTA. Most agencies have been 
created and have developed their activities in a rather depoliticised manner and receiving 
state aid or other types of institutional funding and support in the production of HTA reports. 
However, as the financial pressure on the national health budget increased overtime, the 
need for HTA also increased and more emphasis was put in the publications on the relation-
ship between HTA and cost-containment. Chinitz (2004) underscores how this situation has 
impacted the political accountability of the agencies in many countries.
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One of the striking differences between the HTA agencies regards their (institutional) status 
and role in the decision-making process. In some countries a decentralised approach (e.g. 
Sweden, Italy) has been adopted whereas in other countries it is characterised by a more 
centralised control (e.g. France12). Research has underscored how a centralised control is 
often more associated with an enhanced role in decision-making whereas a decentralised 
organisation of HTA agencies reduces their impact and can lead to competition among 
them (Chinitz 2004:57). However, the degree of centralisation or decentralisation can vary 
depending on whether one looks at the assessment process of HTA and the appraisal pro-
cess. As such, in one country (e.g. England) assessment can be organised in a decentralised 
way (several HTA agencies conducting assessment and delivering a report) but the appraisal 
process will be centralised. Conversely, in other countries (e.g. France) the assessment phase 
will take place in a single entity whereas the appraisal and decision-making processes will 
take place in several institutions13. Moreover, in some countries, recommendations of HTA 
agencies will be binding whereas in others this will not be the case.
As underscored by several scholars (Garrido et al. 2008; Barron et al. 2015), the organisation 
of HTA is often related to the organisation of the health systems in general which display a 
high degree of variation across the EU countries. These disparities stem from their genesis 
and development and lead to differences in the way financial resources are obtained and 
distributed. It also impacts on the manner in which service provision is organised and who 
participates in that process (Garrido, Zenter and Busse 2008:55). All systems however have 
in common the need to decide upon health technologies and their availability to patients. 
Sola-Morales and Granados (2009:88) point to the fact that the introduction of “HTA in 
decision-making processes is unique and linked to the local context”.
1.4.2. Methodological and policy approaches in HTA
Besides institutional and organisational aspects, other disparities between HTA agencies exist 
and regard, in particular, methodological and policy approaches related to HTA. As such, 
the scope (domains, processes and methods used), dissemination (diffusion and reaching 
the policy area for decision-making) and implementation (impact on the population and 
society) of HTAs can vary amongst countries and even amongst agencies within a country 
(Schwartzer and Siebert 2009). Differences in the organisation and financing of the health 
12 In France the Haute Autorité de Santé (HAS) plays a central role in the HTA process regarding 
assessments and excluding cost-effectiveness analyses. However, other institutions such as the 
Commission de Transparence (TS), the Comité Economique des Produits de Santé (CEPS) and 
the Union Nationale des Caisses d’Assurance Maladies (UNCAM), la Commission d’Evaluation 
Economique et de Santé Publique (CEESP) play an important role in the pricing and reimbursement 
process.
13 See footnote 8.
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systems also impact the role of HTA in a given country. Similarly, the role of HTA can also 
affect the methodology and dissemination of the assessments. As such, agencies will have 
different requirements regarding the information needed to conduct the assessments and 
may also differ in the way evidence is being interpreted (Dragborg et al. 2005; Kanavos et 
al. 2010).
As regards the scope and methodologies used, whilst most agencies include clinical aspects 
and, to a lesser extent, economic aspects, real differences exist regarding the inclusion of 
HTA domains related to social impact, ethics, psychological reactions of patients (Dragborg et 
al. 2005; Duthi and Bond 2011; Lehoux and William-Jones 2007). Moreover, not all agencies 
apply the same standards to the process. As such, criteria to include clinical evidence in the 
assessments differ as do the methods used in the calculation of cost-effectiveness (e.g. Eddy 
2009; Weatherly et al. 2009; Angelis, Lange and Kanavos 2018). Moreover, the weight of the 
different domains is not always the same across the agencies and reflects to a certain extent 
societal (and political) norms and expectations. Some (e.g. Sweden (TLV), France (HAS), Ger-
many (G-BA)) emphasize quality and safety issues in appraisal and decision-making processes 
whereas others (e.g. UK (NICE)) also give important weight to cost-effectiveness issues in 
those. Finally, the choice of comparators can also vary. Some agencies including the current 
best alternative, others the cheapest available comparator and others use a comparison with 
placebo (Chalikidou et al. 2009; Kanavos et al. 2010; Angelis, Lange and Kanavos 2018).
Methodological issues have been widely discussed in the literature (e.g. Cookson, R. and A. 
Maynard 2000; Kristensen, Hørder and Poulsen 2001; Busse, Orvain, Garrido et al. 2002; 
Draborg and Andersen 2005, Drummond et al. 2015; Kanavos and Efthymiaou 2017). Sev-
eral publications address the development of models facilitating the prioritisation of health 
assessment topics (e.g. Oortwijn 2000; Oliver, Mossialos and Robinson 2004). Many elabo-
rate on techniques permitting to assess expected costs and benefits of health interventions. 
Although, as aforementioned, not all HTA agencies include in their assessment economic 
analyses, an important part of the publications discussing methodological issues will focus 
their attention on this domain. ‘Value for money’ is a central concept underpinning these 
publications and the methodologies being discussed (e.g. Davies, Drummond, Papanikoloau 
1999; Drummond and Sculpher 2005; OECD 2005; Sorenson, Drummond and Kanavos 
2008; Henschke, Sundmacher and Busse 2013; Henshall and Schuller 2013; Shah et al. 2014; 
Barron et al. 2015; Culyer 2015). Some publications underscore how the need to display 
‘value for money’ is mostly present in high income countries so as to demonstrate that public 
money was spent appropriately. However, cost-effectiveness concerns are also represented 
in middle-income countries (Gulasci et al. 2009; Sorensen, Kanavos and Karamalis 2009). 
Moreover, in this strand of the literature, the use of relative effectiveness in HTA has also 
been increasingly addressed (Eichler et al. 2010; Sorenson 2010; Kleijnen et al. 2012; 2015.)
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Within the literature strand on methodological issues, the use of multiple criteria decision-
analytic modelling in HTA occupies an important place. Multiple criteria decision analysis 
(MCDA) aims to offer a support framework for decision-making in areas where multiple 
(and sometimes conflicting) criteria need to be considered (and weighted) and its use in 
HTA has significantly increased over the past decade. The aim is to offer a more systematic 
approach and address shortcomings in HTA (Angelis and Kanavos 2016). This has led to the 
development of guidelines for best practices and the development of specific models of 
assessments in this regard. However, these models can differ as to their structure, use of data 
and consistency (Philipps 2006; Abellán-Perpiñán 2015; Drummond et al. 2015; Angelis and 
Kanavos 2016; Marsh et al. 2016; Marsh et al. 2017; Angelis, Lange and Kanavos 2018).
In the literature on HTA, many publications address policy and regulation issues, as meth-
odologies regarding economic evaluations are commonly targeted to inform reimbursement 
decisions. Many scholars therefore underscore the need to consider the link between HTA 
and the decision-making process (e.g. Harris et al. 2001; Marinoni 2012; Drummond et 
al. 2008; Drummond 2015, Meneu 2015; Del Llano-Señarís, and Campillo-Artero 2015). 
The use of evidence for pricing and reimbursement purposes receives growing attention 
in the literature on HTA and regulatory issues. (e.g. Garattini, Cornago and De Compadri 
2007; Hutton, Trueman and Facey 2008; Drummond et al. 2011; Drummond 2012; Akehurst 
2017). Although HTA and coverage or regulatory processes have different missions, some 
scholars examine whether communication and cooperation between both areas could be 
improved to facilitate timely patient access to innovative treatments (e.g. Henshall et al. 
2011; Frønsdal et al. 2012; Berntgen et al. 2014).
Similarly, the issue of ‘uncertainty’ has been a central feature in many publications, as is 
the concern for transparency and validity of the results (Porzsolt et al. 2005; Philipps et al. 
2006; Hutton, Trueman and Facey 2008; Richardson 2016; Brixner et al. 2017; Akehurst et 
al. 2017). In this regard, conditional reimbursement to address innovation and (early) access 
to health care intervention, is increasingly present in the academic debate. Indeed, when 
innovative and ‘promising’ therapies enter the market, their impact on health and the health 
system may still be uncertain. Additional data may therefore be needed from a real-world 
perspective. Several publications address the need to develop framework and international 
guidelines to address this issue (e.g. Chalkidou et al. 2008; Quentin et al. 2009; Carbonneil, 
Quentin, Lee-Robin 2009; Henshall and Schuller 2013; Makadi et al. 2016; Kanavos et al. 
2017).
Akehurst et al. (2017) underscore the variation between HTA and reimbursement processes 
in Europe and highlight the influence of particular sources of information which can im-
pact decision-making differently. Similarly, Nicod and Kanavos (2016) underscore how the 
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variations observed in HTA recommendations based on the same technologies could lead to 
different coverage decisions and, as a result, to unequal access to medicines across countries. 
Moreover, it could also reflect weaknesses in HTA methodologies. The scholars have sought 
to identify criteria which would explain the variations in decision-making processes and 
proposed a methodological framework aiming “to account for (part of) the unexplained 
heterogeneity in HTA recommendations across settings” (Nicod and Kanavos 2016:44). 
Similarly, Allen et al. (2017) have examined HTA and reimbursement decisions over four 
countries14 and brought to the fore how differences in activities could be explained by the 
different mandates of the agencies and the unique political, social and population needs. The 
difference in recommendations made was related to the risk perception of the agencies and 
the choice of comparators in clinical and cost-effectiveness studies.
1.4.3. Convergence of HTA practices
To address this important diversity in methodology and practices, some argue for a har-
monised EU approach of (economic) evaluation methodologies (e.g. Cookson and Hutton 
2002). As underscored by Hutton, Trueman and Facey (2008:511; 513), ”Harmonisation has 
the potential to avoid duplication of effort for both manufacturers and HTA bodies involved 
in preparing and reviewing HTA submissions for innovative technologies. However, it also 
carries risks of loss of local control over decisions, the application of general data standards 
which are not universally accepted and slowing the rate of development of innovation in 
the analytical disciplines supporting HTA. (…) Therefore, whereas some aspects of economic 
evaluation remain highly context-specific, there is scope for further exploration of harmoni-
sation of others”.
Since the implementation of the EUnetHTA project (2006-2008), the topic of harmonisa-
tion of HTA has received increased attention. Many publications examine the outputs and 
outcomes of the European projects. They outline the different tools, guidelines and meth-
odologies having been developed within different European collaboration initiatives (e.g. 
Kristensen et al. 2009a, Kristensen et al. 2009b; Lampe et al. 2009; Pasternack et al. 2009, 
Kristensen 2012; Boehm and Landwehr 2013; Huic et al. 2013; Gillespie, and Cerbo 2014; 
Woodford, Huic and Teljeur 2014; Kristensen et al. 2017). As such one can mention the HTA 
Core Model developed by EUnetHTA and offering a standard structure composed of the HTA 
ontology, methodological guidance and a common reporting structure. This model, available 
as a full model or as one focused on rapid effectiveness assessment, covers besides safety, 
effectiveness and economics also domains covering organisational, patient, social and legal 
aspects (Kristensen et al. 2017: 244). European harmonisation regarding relative effective-
ness assessment is another issue which has been examined by several scholars seeking to 
14 Australia, Canada, England and Scotland (Allen et al. 2017).
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identify barriers and success factors for international collaboration in the field (e.g. Kleijnen 
et al. 2015; Kleijnen 2016).
In this regard, one can mention the publications related to other EU funded projects in the 
field of HTA such as the AdHopHTA project, focusing on collaborative efforts to produce 
HTAs for hospitals. The publications highlight progress made in this sector but with still disap-
pointing results as to the impact of HTA on hospital-based decision-making (e.g. Gagnon 
et al. 2014; Cicchetti et al. 2015; Halmesmäki, Pasternack and Roine 2015; Kidholm et al. 
2015, Sampietro-Colom and AdHopHTA 2015). The Integrate-HTA project has also received 
some attention in the academic literature. This EU funded initiative aims at developing con-
cepts and methods to make patient-centered assessments of complex health technologies. 
It challenges the idea that assessment, appraisal and decision-making should be considered 
as distinct processes. The authors also critically assess attempts of frameworks that seek to 
integrate these to some extent (e.g. some forms of Multi Criteria Decision Analysis). Publica-
tions related to this project bring to the fore alternative methods permitting to develop an 
integrated approach of HTA. The latter underscores that collection of facts and evidence 
should not be detached from the aim of the overall the evaluative exercise, “which is to 
explore how health technologies help, or prevent, us from realising final ends or basic hu-
man good” (e.g. Van der Wilt, Gerardus and Oortwijn 2017; Lysdahl et al. 2016; Bond and 
Weeks 2017; Wahlster et al. 2017, Bijlmakers et al. 2017; Lampe and Schnell-Inderst, 2017) 
Another example of an EU-funded HTA project presented in the academic literature is the 
Advance-HTA project which seeks to develop methodological tools and practices related to 
the application and implementation of HTA (e.g. Nicod et al. 2017).
Hutton, Trueman and Facey (2008:514) are the authors of one of the few publications refer-
ring to other attempts of HTA harmonisation across the world. They cite for example efforts 
made in New Zealand, Canada and in the USA where guidelines have been developed by 
the Managed Care Pharmacy (AMCP) generating a common standard for HTA formulary 
submissions. The Canadian experience is more often cited in relation to EU cooperation in 
the field of HTA. Indeed, the work accomplished by the Canadian Agency for Drugs and 
Technologies in Health (former Canadian Coordinating Office for Health Technology) has 
been underscored by several scholars and cited as an example for the EU cooperation (e.g. 
Sanders 2002; McDaid 2003; Hailey 2007; Menon and Stafinski 2009).
Hutton, Trueman and Facey (2008) make a distinction between different aspects of HTA 
where perspectives of convergence of practices are not the same. Indeed, more consensus 
is to be found regarding the feasibility for harmonisation of clinical evidence which is less 
context-dependent and more easily transferrable than economic evidence which is more 
context-sensitive. Ethical, social and legal issues in HTA are under-researched and it remains 
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unclear to what extent harmonisation in these fields can take place (see also Sacchini et 
al. 2009; Den Exter, Santuari and Sokol 2015; Abrishami, Oortwijn and Hofmann 2017). 
Whereas decision-making processes are still highly diverse in the EU, some believe conver-
gence regarding the conceptual stages of decision-making could be made.
Harmonising practices regarding uptake of HTA in decision-making processes is still often 
considered as being far-fetched. (Schwarzer and Siebert 2009). As aforementioned, countries 
adopt various policy approaches regarding HTA. Whether the recommendations are used in 
decision-making processes depends on several factors. Kanavos et al. (2010) brings to the 
fore that the differences in impact of HTA can be related to national priorities, responsibility 
and membership of HTA bodies, differences in processes and timeframes, implementation 
or not of HTA recommendations or the ability to engage in price negotiations (Kanavos 
et al. 2010). Impact on decision-making processes can also be affected by the bodies and 
stakeholders participating in the assessment and appraisal process. Moreover, the extent 
to which stakeholders are involved in the process varies. The latter has received increased 
attention in the literature over the past decade. However, publications on this issue mostly 
concern involvement of patients and to a lesser extent the industry (Schubert 2002; Hivon 
et al. 2005; Sorenson et al. 2008; Nielsen et al. 2009; Gauvin et al. 2010; Bowman-Busato 
2011; Facey 2011; Cavazza and Jommi 2012; Gorry et al. 2015. Houÿez et al. 2011; Hansen 
and Lee 2013; Tantchou Dipankui 2015; Abelson et al. 2016).
Gerhardus and Dintsios (2005) underscore the difficulty to assess impact on decision-making 
processes and the need to develop study designs and methods permitting a valid assessment 
of the issue. Indeed, so far only few studies have been made, displaying a disparity in the 
results and methodological flaws, making it difficult to draw solid conclusions related to the 
impact of HTA on decision-making processes. Some scholars underscore how the impact of 
HTA in policy processes depends on effective and timely applications in decision-making pro-
cesses and on the overall transparency of the HTA process (Sorenson et al. 2008). Moreover, 
the need to develop better methodological approaches to well align problem definitions 
between HTA agencies, policy-makers and end-users has also been addressed by several 
scholars (Moret-Hartman, van der Wilt, and Grin 2007; Atienza Merino and Varela Lema 
2008; Henshall et al. 2013).
Hence, attention given to European cooperation in the field of HTA has addressed several 
important issues related to the convergence of practices, methodologies and policies. Most 
publications have done so by underscoring the differences and similarities between countries 
and agencies. Particular attention has been given to methodological issues, especially regard-
ing cost-effectiveness assessments of medicines. This has often been used as input in the 
debate about regulatory aspects of pricing and reimbursement and countries specificities in 
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this regard. An increasing amount of publications have addressed the cooperation efforts 
made in the EU context relating mostly on the objectives and outputs of the projects. Little 
attention is given however to the governance aspects of this cooperation process which has 
been set in motion some twenty-five years ago.
1.4.4. Research gap in the literature on European HTA collaboration
As discussed in the previous section, EU cooperation in the field of HTA has received some 
attention in academic research. Most publications however were focused on methodological 
and regulatory issues or presented outputs and outcomes of cooperation initiatives such as 
the EUnetHTA network and its predecessors (EUR-ASSESS, HTA-Europe, ECHTA/ECAHI) and 
related initiatives (e.g. AdHopHTA, INTEGRATE- HTA, Advance HTA, MedtechHTA). Whilst the 
support and participation of the European Commission is often mentioned, little research has 
examined in depth the role of the European Union in structuring the cooperation process.
Health Technology Assessment, whilst being a scientific exercise is, as outlined above, also 
strongly linked to wider policy processes on the European and Member State level. Use 
of HTA in decision-making and regulatory processes and its impact on the organisation of 
the national health system turns HTA into an issue of public policy and becomes subject 
of governance processes both at the EU and the domestic level. Moreover, the increased 
participation of stakeholders in the process underscores how HTA is not solely a scientific 
exercise but also undergoes influence from political, economic, industrial, civil and public 
policy actors. Although research has increasingly been focused on the relationship between 
HTA and policy-making since the appeals of scholars in the early 2000s (e.g. Oliver, Mossialos 
and Robinson 2004), few have focused on the role of the EU in this process and even less 
on the role of HTA in EU health policy which have developed almost simultaneously with the 
uptake of HTA in Europe.
Interest for and implication in HTA cooperation on behalf of the European Commission has 
been underscored in several publications relating about the European projects (e.g. Jonsson 
2002; Banta 2003; Kristensen et al. 2009; Nachtnebel et al. 2015). Whilst pointing to the 
role of the European Commission in this process, no analysis is made of the underlying 
governance mechanisms steering HTA cooperation in Europe and allowing the European 
Commission to play an important role herein. Boëhm and Landwehr (2013) underscore how 
the European Commission has promoted the emergence of HTA as an EU new policy field 
and how temporary projects develop into a more lasting network structure with a solid 
organisational basis. However, they remain dubitative about the potential of convergence 
in this field. Indeed, they believe that “given this long list of context-specific characteristics 
and countless tiny setscrews of health technology assessments it becomes clear that the 
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Europeanisation of HTA is unlikely to result in convergent outcomes” (Boëhm and Landwehr 
2013: 16).
Gorry et al. (2015) give a brief overview of how HTA has been promoted by the European 
Commission at the EU level. They underscore how it has supported the early EU HTA coop-
eration projects and recognised HTA as a ‘political priority’ in 2004. The inclusion of HTA 
cooperation in the Directive on Cross-Border health care (2011/24/EU) has permitted to 
further develop HTA cooperation as a new policy objective of the EU. They also highlight 
how, since 2008, the EMA has been officially authorised to work with HTA bodies. These 
developments have led to a repositioning of the various actors in the field of HTA. They point 
to the fact that whilst, till recently, HTA was a rather depoliticised field, this may change 
in the future. They also underscore how most publications do not refer to the exact role 
and position of the pharmaceutical industry in this. Moreover, in their opinion, mobilisation 
around HTA at the EU scale will impact upon national systems of pricing and reimbursement 
and tensions over ‘sovereignty’ remain present (Gorry et al. 2015: 130-131). Hence, accord-
ing to the authors, the discussion on HTA cooperation is two-fold. One level is concerned by 
scientific knowledge and its transferability. The second level is concerned with the how such 
a system of pooled assessment data would fit national appraisal. “many actors fear that an 
EU-scale assessment system will inexorably threaten national modes of appraisal” (Gorry et 
al. 2015: 132).
Given the specificity of Health Technology Assessment, publications regarding European 
cooperation processes have been mostly present in academic literature strongly related to 
medical and health policy matters. Review of the subject in the European governance litera-
ture shows that, besides the publications mentioned above, very few other scholars from 
this academic field have given attention to HTA cooperation from a European governance 
perspective. Similarly, our research has not been able to identify attention for the governance 
aspects of European HTA cooperation processes in literature emanating from other academic 
schools such as public policy, management or administration studies. In this regard, it is 
however interesting to underscore the publication of Fierlbeck, Gardner and Levy (2018), 
examining HTA cooperation in the Canadian context from a New Public Governance (NPG) 
perspective. The authors come to the conclusion that the governance instruments recom-
mended by NPG have contributed to the development and integration of HTA in Canada., 
As some of these soft governance instruments resemble those used in the European context, 
this approach can be of real interest for our research. However, the analysis is exclusively 
based on the Canadian context and does not address governance of the European HTA 
cooperation process.
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This research will aim to fill what we have identified as a gap in the literature, and which 
refers to the governance of European HTA cooperation processes. We will focus our research 
on the examination of governance modes used by European HTA networks and by the Euro-
pean Commission and try to understand how the interaction between both policy levels has 
structured HTA cooperation in Europe.
1.5. coNcluSioN
This chapter has outlined the development of Health Technology Assessment in its general 
and European contexts. As a multidisciplinary process, HTA seeks to summarise information 
about medical, social, economic and ethical issues related to the introduction and diffusion 
of a health technology in a given market. Aiming to inform decision-making processes and 
the formulation of safe and effective health policies, HTA relates to health policy processes. 
How the two areas are articulated in a country varies according to organisation of the health 
system as well as to other context-specific factors. Moreover, HTA responds to many different 
approaches regarding scope, methodologies and practices implemented. The assessment, 
appraisal and decision-making processes related to an HTA will also differ across agencies 
and countries which explains why several assessments made on a single technology can lead 
to different outcomes.
Faced by increased budgetary constraints, an aging population and a rising number of in-
novative and expensive technologies being developed, HTA agencies in Europe have sought 
to establish cooperation mechanisms. These would allow them to exchange experiences and 
develop best practices, avoid duplication of assessments and develop HTA in countries where 
it was not present. Support of the European Commission has been given first essentially 
through financial support to different projects in the field and later also as a partner in Joint 
Actions on HTA. The Directive on Cross-Border Health Care (2011/24/EU) adopted in 2011 
has given a legislative basis to establish a sustainable cooperation mechanism in the field 
of HTA. In 2018, the European Commission introduced a Proposal for a Regulation on HTA 
cooperation in Europe as another step to reach this objective.
The developments outlined above, show the EU implication in the development of HTA 
cooperation processes. Although a lot of attention is given in the literature on HTA to the 
challenges of HTA cooperation and convergences of HTA methodologies and practices, little 
attention has been given to governance mechanisms steering these cooperation processes. 
Whilst most publications do highlight the role of the European Commission in this process, 
so far, no research has been done on the governance modes used to steer HTA cooperation 
and how these are related to the wider EU health policy developments.
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This research aims to fill this gap by examining HTA cooperation from an EU governance per-
spective. Situating HTA cooperation in the wider EU health policy requires however to have 
a good understanding of the particular developments in the field of European health policy 
on the one hand as well as of the governance modes applied in EU policy-making processes 
on the other. The next chapter will therefore seek to contextualise HTA cooperation in the EU 
health policy and governance architecture.


2 HTA Cooperation in the EU 
health policy and governance 
architecture
“To achieve success, we shall need a great deal of tenacity and patience,
 both within our own countries and in negotiations between the Govern-
ments themselves.”
Robert Schuman, Council of Europe 10th December 1951
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2.0. iNtroDuctioN
HTA cooperation is an initiative that stems from the HTA arena itself and has been launched 
to promote HTA in Europe and enhance the quality of the assessments to ensure their uptake 
in national policy-making processes. The first initiatives launched in the early 1990s were 
project-based and gathered HTA experts from different European countries. No specific 
connection with EU health policy was to be made at the launch of the initiative apart from 
funding that had been requested and obtained through a specific EU research programme. 
The first cooperation initiatives however coincided with the launch of a dedicated EU public 
health policy which took off with the insertion of an article on public health in the Maastricht 
Treaty (1992).
The attention and support for HTA cooperation by the European Commission would grow 
simultaneously with the advancement of the EU public health policy. In the first HTA coopera-
tion projects, the EU support would be limited to financial aid. However, gradually, HTA has 
been identified by the European Commission officials as bearing the potential to play an 
important role in the development of the EU health systems. The Commission’s role and 
involvement in the cooperation process would then profoundly change. As the development 
of HTA cooperation and EU health policy have progressively become intertwined, a good 
understanding of the EU governance processes and EU (public) health policy is of prime 
importance. At the core of these processes lays the issue of the division of competences be-
tween the EU and the Member States which defines the governance modes and instruments 
available to the EU. This division will also play a role in HTA cooperation seeking to establish 
convergence in the development of tools, methodologies and practices.
The EU competences in the field of health care are defined by the Treaties and based on a 
division of competence between the EU and the Member States. Although they have evolved 
over the years, the EU competences are limited and distributed over different policy areas 
(e.g. public health, environment, Internal Market, employment). Member States remain the 
key actors when it comes to health policy in Europe and often enjoy exclusive competences 
in a health policy related field. Management of health services and medical care for example 
falls entirely under the responsibility of the Member States. As such, the EU cannot interfere 
in the definition of domestic health policies which comprises HTA (Art 168 TFEU).
Despite the very restrictive definition of competences regarding health policy, the EU has 
nevertheless been able to exert some influence over public health issues in the EU Mem-
ber States. This has resulted on the one hand from so-called ‘uninvited Europeanisation’ 
of health policies stemming from a ‘spill-over process’ of Internal Market policies (Greer 
2006; 2009) and on the other hand by means of soft policy instruments. HTA cooperation is 
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primarily being concerned by the latter. Indeed, in policy areas which fall under the exclusive 
competences of the Member States, the EU institutions can often only make use of soft 
policy instruments to promote cooperation between Member States.
To well understand the role of soft governance in structuring HTA cooperation in the EU, 
we will need to situate the latter in the wider environment of EU health policy and the 
governance modes used in this policy area. The present chapter will therefore first set out 
the broad development stages of EU health policy and outline the different governance 
modes available to the EU institutions in this area. The second part of this chapter will focus 
more specifically on the so-called New Modes of Governance which have been introduced 
by the European Commission in the 2000s and consists of soft governance instruments to 
promote European integration processes. EU health policy and thus also the EU support to 
HTA cooperation have been structured according to these innovative governance modes, 
which comprise networking.
2.1. hta cooperatioN coNtextualiSeD withiN eu health 
policy
2.1.1. The Development of EU Health Policy
Because of the highly diverse organisation of health systems in the EU Member States, as well 
the high interdependency between health care, economic, fiscal and social policies, a need 
for convergence of health policy at a European level has never really been considered feasible 
nor desirable. No reference to health policy is therefore to be found in the founding treaties 
of what is today the European Union (EU). The failed attempt to create a European Health 
Community in 1952-1954 (Davesne and Guigner 2013), underscores how, already in the 
early days of the EU integration process, Member States were reluctant to pool competences 
in this field at a European level.
Although the underlying reasons holding back Member States from shifting part of their 
health policy competences to the supranational level have varied in the course of the EU 
integration process (see for an extensive account of the project Davesne and Guigner 2013; 
Vollaard et al. 2016), the predominant feature is that no significant powers would be given 
to the EU in the field of health policy. The competence allocation as codified in the Lisbon 
Treaty states in this regard that: “The Union action shall respect the responsibilities of the 
Member States for the definition of their health policy and for the organisation and delivery 
of health services and medical care. The responsibilities of the Member States shall include 
the management of health services and medical care and the allocation of the resources 
assigned to them” (Art 168 (7) TFEU).
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Despite the fact that the organisation of Member States’ health systems remains an exclusive 
national competence, a specific European health policy has nevertheless emerged and has 
grown in importance over the years, becoming an official EU policy field since the insertion of 
a specific Public Health Article in the Maastricht Treaty (1992). Small but not insignificant revi-
sions in subsequent treaties, reveal the gradual extension of EU’s competences in this policy 
area which hasn’t been the result of ‘classic integration policies’. Instead, the expansion of 
specific European health policies has emanated from different political, economic and legal 
processes in other policy areas which have also shaped the diverse policy modes adopted by 
the EU in the health policy field (Greer 2009, Mossialos et al. 2010).
In particular, public health threats (e.g. the BSE crisis15) have been identified as having acted 
as catalyser for an increased EU involvement in health policy (Randall 2000b). Public health 
concerns related to the uptake of diseases such as cancer and HIV/AIDS as well as drug 
dependency in the 1980s and 1990s had led to the awareness that a coordinated action on 
EU level might be necessary and possible. Common European actions such as the “Europe 
against Cancer” campaign launched in 1985 have contributed to increased salience for the 
issue and its appearance on the EU political agenda (Randall 2000; Greer et al. 2014:38). The 
Maastricht Treaty has created the opportunity to formalise the new EU approach on Public 
Health by inserting a dedicated article (art. 152 TEU) on public health in the Treaty (Randall 
2000a; 2000b; Greer et al. 2014: 38-40).
The first legal provisions on EU health policy bear traces of what could be considered to 
be a ‘political insertion’. Indeed, four out the eight areas allocating competences to the EU 
reflected domains in which cooperation on a European level had been developed despite the 
absence of formal competences attributed to the Union in these areas: drug dependence, 
cancer, AIDS and other communicable diseases and health promotion. The four new spheres 
of EU influence targeted the monitoring and surveillance of disease, injury prevention, 
pollution-related diseases and rare diseases (Randall 2000a:140). Still, the provisions referred 
to in article 152 TEU lay worlds apart to what is commonly understood by ‘health policy’ on 
a national level. Hence, the impact of this article on health policies, would it be on a national 
or European level, will remain very limited.
Notwithstanding the restrictive basis for EU action in the Treaties, a European dimension of 
health policy has nevertheless developed, increasingly affecting the organisation of domestic 
policies. In the literature, scholars have explained this by pointing to the (unintended) effects 
of Internal Market related policy decisions and rulings of the Court of Justice of the Euro-
pean Union (CJEU) on domestic health policies (e.g. Greer 2009; Randall 2000b; Hervey and 
15 BSE stands for ‘Bovine spongiform encephalopathy’, also called ‘mad cow disease’.
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Vanhercke 2010). Greer (2006) qualifies these developments as “uninvited Europeanization” 
in health policy, hereby basing his observations on the so-called neo-functional “spill-over 
effect” as identified by Haas (1958). Indeed, since the Single European Act, the application 
of the principle of free movement of people, goods, services and capital has led the CJEU to 
pronounce itself on health policy related issues, using an ‘Internal Market-based’ approach 
in the assessment of the cases.
A striking example of this is cross-border health care which has received increased attention 
since the Kohll and Decker cases in 1999. The subsequent CJEU decisions on similar cases 
of health care services or goods pursued by patients outside their state of social security af-
filiation, have progressively shaped specific EU patient mobility provisions. By establishing as 
such a ‘parallel route’ to reimbursement of cross-border health care, already regulated by the 
Regulations 1408/71 and 883/2004, tensions inevitably aroused, creating the need for legal 
certainty on the issue. It took however almost a decade before a new Directive on “Patients’ 
Rights in Cross-Border healthcare” (2011/24/EU) has been adopted (commonly referred to as 
the Cross-Border Health Care Directive; see also Nys and Goffin 2011, Palm and Glinos 2010; 
Sauter 2008; Wismar et al. 2011).
In the literature, detailed accounts are given of similar situations where domestic health care 
provisions have been impacted by European policy decisions taken in another policy area. 
Considering the specific nature of health policy, the implementation of provisions can be 
sometimes problematic and often creates a need for further clarification and coordination on 
a European level. This can involve rulings of the CJEU applying (market) integration policies 
in health policy areas, whereby its decisions become European jurisprudence, having effect 
in all Member States (as for example in cross-border patient mobility).
This inevitably raises questions on the role of the Court pronouncing itself on sensitive 
(ethical) issues in policy domains falling traditionally under Member States’ competences (see 
further McKee and Mossialos 2006). Hence, applying Internal Market provisions in health 
policy related fields seems to be a rather delicate and contentious exercise. All too conscious 
about the far-reaching consequences its jurisprudence in health matters can have, the Court 
sometimes opts not to pronounce itself on specific issues. This was for example the case 
regarding quality and safety standards in professional mobility of health professionals, when 
the Court refrained to legislate on the issue, leaving it up to the Member States to deal 
with the subject (see e.g. Nickless 2001:82; Peeters, McKee and Merkur 2010:632; Greer 
2006:142).
Similarly, the development of a specific European social policy (in particular since the adop-
tion of the Social Charter in the Amsterdam Treaty (1997)) has impacted EU’s involvement in 
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health-related issues. The impact of the Working Time Directive on the organisation of hos-
pital practices is another example of how a decision taken in one policy field can have direct 
consequences on domestic health care settings (see e.g. Greer 2006: Greer 2009: 45-46). 
Another sensitive question regards the application of competition law and public procure-
ment provisions to the health sector. In this area too, tensions have arisen on the national 
level where the support of health care institutions is considered as a core-component of the 
national welfare state and should not be confused with state aid (for a detailed account on 
this topic see e.g. Mossialos and Lear 2012: Prosser 2010: Hatzopoulos 2010).
Finally, the EU treaty provisions also call for a high level of health protection in the definition 
and implementation of all Union policies and activities (Article 168 TFEU). Although this 
ambitious aim may not always be easy to implement, it has led, in some cases, to legal provi-
sions such as the Product Safety Directive (2001/95/EC) which creates a framework for safety 
requirements for consumer products (including medical devices). Another example is the 
‘Horizontal’ Liability Directive (89/374/EEC) aiming to protect consumers against defective 
products. Protection of human health has also been underscored in Article 9 TFEU. Finally, 
the Charter of Fundamental Rights, which has become binding since the adoption of the 
Lisbon Treaty (2007) foresees some provisions which are indirectly related to health mat-
ters. The most important in this regard is Article 35, which refers to the right of “access to 
preventive health care and the right to benefit from medical treatment under the conditions 
established by national law and practices”16.
Hence, as underscored by many scholars (e.g. Mossialos et al. 2010; Brooks 2012; Greer 
et al. 2014), European health policy is characterised by what Scharpf (2002) has called a 
“constitutional asymmetry” referring to the fact that the EU is promoting on the one hand 
market-efficiency policies and on the other (often national-based) social protection policies. 
The former being predominant in comparison to the latter. Moreover, as we have seen above, 
and as underscored by Mossialos et al. (2010:4-5), a “fundamental contradiction” lays at 
the core of EU health policy. On the one hand the European Treaties state that health is an 
exclusive competence of the Member States, but on the other hand, as the domestic health 
systems are concerned by people, goods and services, they become also directly or indirectly 
subject to EU law and policies.
16 Other articles in the European Charter of Fundamental Rights referring indirectly to health matters 
are: the right to human dignity (Article 1), the right to live (Article 2), the right of persons with 
disabilities (Article 26) the right to the protection of personal data (Article 8), the right to freedom 
of conscious (Article 10) (potentially affecting professionals in the medical field.
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This leads thus to the delicate question of the allocation of competences between the EU 
and the Member States. Moreover, although health represents a core component of the 
welfare provisions in all EU Member States, these countries highly differ in their organisa-
tion, financing and governance of the domestic health system (Brooks 2012, Steffen 2005). 
Finally, would it be on a national or European level, the governance of health policy is often 
not centralised but can be fully or in part governed on multiple levels. In countries such as 
Spain, regions play an important role in the definition and implementation of health policies. 
Similarly, as health touches upon many other policy areas, on a European level too, decisions 
affecting national health systems can be dealt with in different Directorate Generals (DG) 
of the European Commission, despite the existence of dedicated DG to Health DG Santé 
(formerly DG Sanco) 17.
Health governance in Europe is thus characterised by a high diversity of governance systems, 
involving multiple levels and players. Considering its high interdependency with financial, 
social and economic policies, it can be affected by decisions taken outside the health policy 
area. Especially on the European level, this has led to the situation where health-related 
matters indirectly became subject to European law and policies leading gradually to an exten-
sion of EU’s involvement in health policy. The role of the CJEU should be underscored here. 
Indeed, by basing itself on the Treaties it has seized the opportunity to create new legal 
provisions affecting domestic health policies and hence ‘interfere’ legally in what is in many 
health-related issues considered to be domestic affairs. Consequently, this has raised the 
question of the allocation of competences in health policy and it seems that the line, as it has 
been drawn in the European Treaties underscoring the exclusive competences of the Member 
States, is more and more blurred.
The allocation of competences and governance modes are interrelated in the EU governance 
setting. Indeed, the level of competence in a given policy field will determine the governance 
modes available to the EU. As such, the European Union can have exclusive competence 
in some fields (e.g. customs union, competition policy, monetary policy, commercial policy) 
(Art. 3 TFEU). It can however also share its competences with Member States (e.g. Internal 
Market, social policy, consumer protection agriculture and fisheries, some aspects of public 
health) (Art. 4 TFEU). Finally, as defined by article 6 TFEU, in some areas the EU has only 
the competence to support, coordinate or supplement actions of the Member States (e.g. 
human health, industry policy, culture, tourism, education).
17 Randall (2000) had already underscored the diversity of health issues in which one can detect 
EU engagement where health policy matters are spread over many different DG (18 out of 24 in 
2000).
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A variety of governance instruments exists at the EU level. Their application will however 
depend on the competences allocated to the governing body. In the following section we 
will therefore outline the different governance modes used in EU health policy and see how 
these relate to the competences conferred to it in the different health policy sub-areas. 
This will permit a better understanding of how the introduction of soft governance modes 
have created an opportunity for the EU to further extend its powers in the field of health 
policy and why these innovative governance instruments have been used to support HTA 
cooperation in Europe.
2.1.2. The allocation of competences and governance modes in European 
health policy
Although codified by the Treaties, the allocation of competences between the EU and 
Member State level is an evolutionary process in which actors seek to strike a balance be-
tween “high politics” of the EU and “functional appropriateness” of a policy mode (Wallace 
2010:90). Hence, the challenge is to define a governance mode respecting the allocation 
of competences as defined by the Treaties and permitting to define objectives and secure 
outcomes as commonly agreed upon by twenty-seven Member States each responding to 
distinctive socio-economic conditions, policy practices and legal frameworks (Wallace 2010).
As Europe moved further along the path of integration, different policy instruments and 
mechanisms have been implemented by the European institutions ranging from the classic 
‘Community method’, the EU regulatory mode, the distributional mode to “intensive trans-
governmentalism” and ‘open policy coordination’ (for an extensive overview see e.g. Wallace 
2010; Nugent 2010). It is the variety of policy modes and the way they co-exist across the 
different EU policy sectors that makes the European policy-making system so singular. As 
EU’s involvement in health issues has mostly resulted from the extension of policies originally 
designed in and for other policy areas, the health sector too is characterised by a “hybridiza-
tion of policy modes” (Wallace, Pollack and Young 2010:484) where a variety of governance 
modes are structuring health policy on a European level and are affecting domestic health 
systems.
The heterogeneity in EU governance practices can partly be traced back to the different levels 
of competence which are conferred to the European institutions as codified in the European 
Treaties. According to the principle of conferred powers (Art. 5 TFEU) the EU institutions can 
act only in those areas where the Treaties give them power to act. Hence, specific governance 
modes will be adopted at the European level depending on whether a policy field falls under 
the exclusive competences of the EU (Art. 3 TFEU), shared competences between Member 
States and the EU (Art. 4 TFEU) or under the main competence of the Member States (Art. 
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6 TFEU). As outlined above, in case of the latter, the EU has only the power to support, 
coordinate or supplement Member States’ actions (Art. 6 TFEU).
Although, health policy issues can be affected by EU decision-making processes taken in an 
area where the EU has exclusive competences, health policy taken stricto sensu is concerned 
only by the last two categories. Indeed, the EU Treaties stipulate that only certain aspects of 
public health policy fall under the shared competences of the EU and others (e.g. organisa-
tion of the health systems) fall under the exclusive competences of the Member States. For 
example, in cases regarding the protection and improvement of human health, “the Union 
shall have competence to carry out actions to support, coordinate or supplement the actions 
of the Member States” (Art. 6 TFEU).
The latter also implies that the ‘subsidiarity principle’ should be applied as stipulated in article 
5 (3) of the Treaty of the European Union (TEU). The subsidiarity principle refers to the fact 
that “in areas which do not fall within its exclusive competence, the Union shall act only if 
and so far as the objectives of the proposed action cannot be sufficiently achieved by the 
Member States, either at a central level or at a regional and local level, but can rather, by 
reason of scale or effects of the proposed action, be better achieved at Union level”.
Even though the insertion of a dedicated public health article in the Maastricht treaty has 
represented a big step forward in shaping a European health policy, the competences con-
ferred to the Union in this policy field remain however quite limited. Article 168 of the Lisbon 
Treaty (replacing the public health article of the former treaties) still clearly stipulates that EU 
action in health policy shall come “as a complement” to national policies. It furthermore de-
limitates EU action to “encouragement policies” and “support-lending policies” in particular 
in cross-border cooperation.
Some amendments in the Lisbon Treaty have nevertheless created an opening to further 
extend the EU’s competences by introducing soft policy instruments at the disposal of the 
Commission to promote the coordination of policies and programmes between Member 
States (Art. 168 (2)). This is in line with article 6 TFEU (EU competence to support coordi-
nate or supplement actions of Member States). These policies can be shaped through the 
establishment of guidelines and indicators, the organisation of exchange of best practices 
and specific monitoring and evaluation mechanisms. It is on the basis of these governance 
instruments that HTA cooperation will be structured by the EU institutions.
2.1.3. EU governance modes and European HTA cooperation
EU cooperation in Health Technology Assessment finds itself at the cross-roads of different 
domestic and EU governance modes. HTA enters the public policy arena after a health tech-
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nology has been accepted on the EU market and before it is being considered in domestic 
decision-making processes regarding the price and reimbursement of this technology18. In the 
case of pharmaceuticals, market authorisation is an exclusive EU competence since medicines 
are being considered as goods which fall under Internal Market regulations. Assessments 
of the products are made based on safety and efficacy criteria developed by the European 
Medicines Agency (EMA)19. The EMA, as an EU regulatory agency, is the only authority in the 
EU entitled to authorise commercialisation of medicines in the EU.
Once a pharmaceutical product has received EU market authorisation, it can undergo a 
‘domestic’ HTA process. As we have outlined in the previous chapter, the outcome of the 
assessment will be used in national pricing and reimbursement decision-making processes. 
The latter falls under the exclusive competences of the Member States and domestic gover-
nance modes as it regards the domestic organisation of health systems. As such, use of HTA 
as input in domestic regulatory and decision-making processes lays outside the EU scope. 
Hence, the EU cannot not interfere in pricing and reimbursement policies regarding health 
technologies that enter or are already on the market. In this regard it is important to keep 
in mind that pricing and reimbursement of health technology bear, besides a public health 
concern, also economic, legal and fiscal aspects for which national governments wish to 
remain in full control.
Reimbursement policies (and the related pricing policies) are organised in a variety of man-
ners across the EU. As underscored by Saltman, Busse and Figueras (2004: xiii), “different na-
tions with different histories, cultures and political experiences, have long since constructed 
different institutional arrangements for funding and delivering health services”. As such, 
health care systems differ for example in the type of revenue generation, some functioning 
via private insurance, others via taxation (either direct or indirect, national or local, general or 
hypothecated), social health insurance or charges and co-payments (Saltman 2004). Funding 
can be either private or public (or a mix of both) which corresponds to different underlying 
principles since public funding will seek to ‘redistribute resources across the population” and 
private funding will serve individual needs (Robinson 2011:44).
18 Assessment processes linked to market authorisation of pharmaceuticals given by the European 
Medicines Agency or those linked to CE marking given by Notified Bodies, could to some extent 
be considered as part of an assessment process of a health technology. The present research will 
however consider these processes as being dissociated from the assessment process taking place 
on a national level after market authorisation is given.
19 This Agency has been created with the strong backing of the industry which invoked the Article 
100A of the Maastricht Treaty, designed to facilitate completion of the Internal Market through the 
harmonisation of national laws (Permanand and Mossialos 2005:74).
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HTA needs to inform the decision-making processes regarding pricing and reimbursement 
policies of technologies. Besides public health considerations, these processes will also be 
based on economic, social, political, legal and ethical issues. As Member States organise 
their health systems differently, decisions using HTA input may also vary. Harmonising these 
decisions is thus generally not considered feasible nor desirable. HTA cooperation in Europe 
does not seek harmonisation of decision-making regarding pricing and reimbursement in 
Europe for the reasons explained above. However, convergence of practices and methodolo-
gies regarding the assessments themselves is an aim shared among many actors in the field 
and has triggered the first cooperation efforts as we will outline in part B of this thesis. The 
aim here is to upgrade the quality of HTA and consequently its uptake in national decision-
making processes. Although the use or not of HTA outputs, as such, falls under Member 
States’ competences, the EU does have the right to lend support to the cooperation efforts 
in this area. The governance mode available to this competence is based on Article 6 TFEU 
and refers to so-called ‘open coordination policy’.
This governance mode based on ‘OECD techniques’ was originally intended as a “mecha-
nism of transition from nationally rooted policy-making to an EU collective regime” (Wallace 
2010:98-99). In this mode, the Commission can act “as developer of networks of experts 
or epistemic communities, or of stakeholders and/or civil society, and accumulating techni-
cal arguments in favour of developing a shared approach to promote modernization and 
innovation” (Wallace 2010:99). The Commission can also have recourse to independent 
experts or convene high-level groups of national experts and ministers to develop policy 
options. Techniques such as peer pressure, ‘benchmarking’, and policy comparisons are be-
ing implemented and are considered to encourage policy learning. Dialogue with specialist 
committees and soft-law commitments are also features that characterise this governance 
mode (Wallace 2010:99). From an initially transition mode, this coordination mode has been 
developed into a policy mode of its own right, and falls under the so-called ‘New Modes of 
Governance’ (NMG) (Wallace 2010:99; European Commission 2001).
NMG have been implemented in many different policy areas with mixed results (see e.g. 
Idema and Kelemen 2006; Héritier 2006; Kröger 2009; Diedrichs 2008). Research has shown 
that these innovative governance means, also called soft governance modes, have been im-
plemented in particular in areas where Member States agree that common action is required 
but where decision-making powers lay mostly on the domestic levels (e.g. research policy, 
environmental reform, social policy) (Shaw 2008). Implementation of soft governance modes 
is also observed in sensitive areas where the Community method encounters sovereignty 
concerns and where Member States seek to protect their autonomy and domestic legacies 
from EU interference. Moreover, uncertainty over EU decision-making has also triggered the 
resort to soft governance instruments (Diedrichs, Reiners and Wessels 2011:29).
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NMG do not come as a substitute to the more traditional governance forms but are often 
added to the existing hybrid decision-making structure of the EU which is characterised by 
the co-existence of different governance modes (Diedrichs, Reiners and Wessels 2011:45; 
Héritier 2006:21). The manner in which NMG find their place in the EU governance architec-
ture varies, as different patterns of change in governance modes can be observed. As such, 
a shift from traditional governance means to innovative forms of governance can take place. 
The opposite, however, has also been observed in cases where NMG have failed to produce 
policy decisions. Finally, traditional and innovative soft governance modes can be operating 
simultaneously. The outcome of the latter varies. Either the different governance modes 
reinforce or complement each other. They may, however, also undermine each other or have 
no effect on each other (Héritier and Lehmkuhl 2011:62).
Open coordination policy and soft governance modes - which are in the case of European 
HTA cooperation the only EU governance modes available - have triggered much discussion 
as to their role in the EU integration process. As they are being implemented in sensitive 
areas or areas falling outside the EU exclusive competence, the question of EU competence 
extension via NMG has been raised. Indeed, if no regulatory authority exists in a certain area 
to bring about ‘hard law’ favouring EU integration process, soft law procedures may well be 
an alternative to bring the EU integration efforts further. To get a profound insight of the 
role of soft governance in structuring HTA cooperation in Europe, it is therefore of prime 
importance to well understand what these innovative governance modes refer to and what 
role they play in the broader EU governance architecture and EU health policy-making. The 
next section will outline these issues permitting us to contextualise HTA cooperation in the 
wider EU context.
2.2. DevelopmeNt oF New moDeS oF goverNaNce iN the eu 
goverNaNce architecture
2.2.1. Multiple understandings of ‘governance’
‘Governance’ is a concept responding to many different definitions and can be used in a 
public private or international setting. Some have examined it as a means to reduce state 
intervention by, for example, establishing new regulatory bodies (Stoker 1994). Others refer 
to the notion in a corporate environment where new steering activities have been developed 
based on principles such as open access to information or accountability of individuals 
(Rhodes 1996:654). Governance can also be understood as ‘ New Public Management’ based 
on private sector management methods applied in the public sector, (Osborne and Gaebler 
1993; Aucoin 1995; Hood 1983). In international institutions, ‘governance’ is also often 
related to the notion of ‘good governance’, responding in itself to many different terminolo-
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gies referring to notions, such as, effective public management, transparency, accountability, 
democratisation, anticorruption policies and respect of human rights20 (Maldonado 2010; 
Rhodes 1996; Punyaratabandhu 2004: 2).
Governance can be related to governmental activities but can also imply participation of 
formal governmental organisations as well as informal non-governmental mechanisms. To 
Rosenau (1992:3-6), one can speak about “governance without government when there 
are ‘regulatory mechanisms’ in a sphere of activity which function effectively even though 
they are not endowed with by formal authority”. Kooiman (1993:258) considers governance 
as “the pattern or structure that emerges in a socio-political system as ‘common’ result 
or outcome of the interacting intervention efforts of all involved actors”. He underscores 
how, in this pattern, social self-organisations are complimentary to traditional hierarchical 
governing organisations. Moreover, public and private actors share the responsibility and 
accountability of interventions.
The different notions of governance as outlined above either put the accent on a distinctive 
mode of government or refer to the coordination of individual activities or any form of social 
order. Governance analysed within the European context also brings to the fore the various 
understandings of ‘European governance’. Saurugger (2009:236) identifies three concep-
tualisations of European governance: multilevel governance, networking governance and 
the New Modes of Governance. Although distinct they are all three somehow connected. 
The three understandings underscore the relatively weak formalisation of decision-making 
processes characterising EU decision-making processes where public policies are being devel-
oped and implemented at different levels within the system.
According to Saurugger (2009: 233-236), these processes are characterised by the interac-
tion of multiple state and private actors as well as by the complexity of the negotiation 
processes which take place on different levels. Instead of hierarchical or subordinated rela-
tions between actors, the European governance approach refers to a system of exchange 
between equal actors seeking a common solution for their problems. Governance within 
20 The terminology first appeared in a World Bank report of 1989 regarding sustainable growth in 
Africa: “Sub-Saharian Africa, from Crisis to Sustainable Growth” (Maldonado 2010: 4; http://web.
worldbank.org). Initially the concept of ‘good governance’ has been defined in 1992 by the World 
Bank as “the manner in which power is exercised in the management of a country’s economic and 
social resources for development” (Santiso 2001:3). As such the concept referred to public sector 
management, accountability, legal development frameworks and transparency (Maldonado 2010: 
5-10). However, progressively the understanding of the term ‘good governance’ has broadened to 
include other issues such as anti-corruption policy or participation. It is often associated to liberal 
economic perspectives adopted in international institutions ((Maldonado 2010; Rhodes 1996).
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the European context, in this perspective, is based on cooperation mechanisms between all 
concerned actors as well as on learning processes rather than competition.
Jachtenfuchs and Kohler-Koch (1999) consider EU governance as an interaction of state and 
social actors in a multilevel organisational structure, seeking common solutions to what is 
considered problematic or a desirable goal to achieve. However, her definition also includes 
the notion of unitary action and compliance. Hence, to Jachtenfuchs and Kohler-Koch 
(1999:14) “‘governance’ is about the way and means in which the divergent preferences 
of citizens are translated into effective policy choices, about how the plurality of societal 
interests are transformed into unitary action and the compliance of social actors is achieved. 
The essence of governance just like that of government is to reach binding decisions”.
Jachtenfuchs and Kohler-Koch’s definition shares some traits with the one set out by the 
World Health Organisation (WHO) which considers governance as a political process which 
requires to balance competing influences and demands. Focusing on the health sector, the 
WHO understands by governance “a wide range of steering and rule-making related func-
tions carried out by governments/decisions makers as they seek to achieve national health 
policy objectives that are conducive to universal health coverage” (www.who.int). Moreover, 
the WHO underscores that governance comprises collaborating with other sectors, including 
the private sector and civil society, to promote and maintain population health in a participa-
tory and inclusive manner.
In the present research we will understand governance in the sense described by Jachtenfuchs 
and Kohler-Koch and the WHO, highlighting the importance of the interaction between 
state and non-state actors in translating societal influences and demands into effective 
policy choices taken and implemented in a participatory and inclusive manner by the actors 
involved. In the sections below, we will examine how each of these aspects (i.e. inclusiveness, 
deliberative decision-making, multi-level participation, compliance) are also inherent to New 
Modes of Governance, introduced in the EU at the turn of the Millennium and underpinning 
EU health policy.
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2.2.2. European political and economic developments preparing the 
governance turn
Besides developments in public management on a national level21, the emergence of in-
novative governance modes could be explained by political and economic developments 
that have affected the EU integration process at the turn of the millennium. On the one 
hand, the EU faced the challenge of completing the European Monetary Union (EMU). On 
the other hand, it had to prepare the enlargement of the Union to candidate countries from 
Central and Eastern Europe. The project of adopting a new EU Constitutional Treaty sought 
to respond to the many challenges faced by the EU, in particular the low rate of economic 
growth, a high unemployment rate and a weak global competitiveness position (Héritier and 
Rhodes 2011:49; Bermeo 2001; European Parliament 2010).
Moreover, EU governance practices came under strong public scrutiny with the resignation 
of the Santer-Commission in 1999 which had been accused of fraud, nepotism and financial 
mismanagement (Judge and Earnshaw 2002). The sudden departure of all European Com-
missioners was an unprecedented event and seriously undermined public confidence in the 
institution. The legitimacy of the Commission’s practices and decisions was openly being 
questioned. Calls for more transparency in the governance practices of all EU institutions 
were increasingly heard in both public as academic debates. This quest for more transpar-
ency in EU institutional practices came on top of an already ongoing debate regarding the 
21 Since the 1980s, several movements emerged seeking to bring about administrative reform. These 
reforms have led to the introduction of new governance instruments in the US and in EU Member 
States (e.g. ‘management by objectives; performance measures). The ‘New Public Management’ 
(NPM), can be cited as an example hereof (see further on NPM: Aucoin 1990; Hood 1991; Osborne 
and Gaebler 1992; Gray and Jenkins 1995, Dunsire 1995).
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so-called ‘democratic deficit’ of the Union (De Schutter, Lebessis and Patterson 2001: 4; 
Lebessis and Paterson 2001:15)22.
Hence, the serious economic and political challenges faced by the new Prodi Commission 
appointed in September 1999, required in a certain sense to depart from the previous 
governance practices and develop adequate policies to successfully take up the gauntlet. 
Implementing “New Modes of Governance” becomes the first and most important EU 
strategic objective as defined by the Prodi-Commission (European Commission 2000a). In 
its official communication on the subject, the Commission highlights how the other three 
objectives (enhance the voice of the EU in world affairs, create a new economic and social 
agenda and enhance the quality of life) depend on de governance forms chosen (European 
Commission 2000a).
These NMG were not entirely new to the Commission as ‘open coordination policies’ inspired 
by national developments related to new management modes had already been tested in 
two EU policy areas. The first regarded the “Broad Economic Policy Guidelines (BEPG)” which 
had been established in the light of completing the EMU and which primarily served to 
coordinate the economic policies of the Member States (Nugent 2010: 297). Soft policy 
coordination instruments had also been implemented in the European Employment Strategy 
(EES) emanating from new provisions in the Amsterdam Treaty establishing a European 
Employment Policy (art 125-130) (see further Goetschy 1999; Vellutti 2010).
22 The concept of democratic deficit which has become a key-aspect of the discussions regarding 
the need for governance reforms of the EU, failed to respond to a commonly accepted defini-
tion and still gives way to many different understandings (Weiler et al. 1995; Follesdal and Hix 
2006; Bellamy and Castiglione 2000; Moravcik 2002; Majone 1998). Critical assessments on the 
democratic practices within the EU point for example to the lack of parliamentary control on the 
executive (Council, Commission) and the weak powers of European Parliament (Follesdal and Hix 
2006: 534-537). Some (e.g. Reif and Schmitt, 1980) also underscore the lack of real party politics 
and European election campaigns serving as “second-order national contests” expressing often 
protest-votes regarding domestic policies (see further Hix, 1999; March 1998; Marks et al., 2002; 
Kousser, 2004; Hix 2002; Hix and Marsh, 2005). Others point to the technocratic policy-making 
processes taking place in a complex institutional architecture which create a distance between the 
EU institutions and ordinary citizens (Wallace and Smith, 1995). Finally, others underscore how 
policy decisions do not necessarily reflect voters’ preferences. The latter can potentially lead to a 
‘policy drift’ where domestic decision-makers choose the EU level to pursue their policies so as to 
circumvent the national control of parliaments, courts and civil society (Scharpf 1999; Follesdal 
and Hix 2006:537). The multitude of perceptions adopted around the notion of democratic deficit 
nourished the debate on the need for governance reforms.
84 Chapter 2
NMG aimed enhancing citizens’ participation in European affairs, increase effectiveness and 
transparency of the European institutions and build new forms of partnerships within a mul-
tilevel European governance structure (Lebessis and Paterson 2000). The importance given 
to open coordination policies was also underscored in the Lisbon Agenda launched a few 
months after Prodi’s Communication on the Strategic Objectives of the EU. This important 
document cites innovative forms of governance as a mean to achieve the new goal set by 
the European Council: making the EU “the most competitive and dynamic knowledge-based 
economy in the world capable of sustainable economic growth with more and better jobs 
and greater social cohesion” (European Council 2000).
The manifestation of the Commission’s governance turn can be found in its White Paper 
on European Governance (European Commission 2001l) issued a year later, but already an-
nounced in Romano Prodi’s first speech before the European Parliament in February 2000. 
According to the newly elected president, New Modes Governance should respond to the 
needs of an enlarged Union and revise the division of labour between the EU institutions, 
hereby offering “a new and more democratic form of partnership between the different 
levels of governance in Europe” (European Commission 2000b). In other words, NMG were 
considered to be the means to address the most critical issues the EU had to address in the 
early 2000s.
The introduction of NMG does not mean however that the EU abandoned the traditional 
governance modes. All the contrary, an important part of the White Paper on Governance 
(2001) still concerns the classical community mechanisms which – though they need to be 
improved - are considered by the Commission as the preferred governance models to pursue 
EU integration (European Commission 2001; Scott and Trubek 2002:8). Moreover, the White 
Paper explicitly states that NMG “should not be used when legislative action under the 
Community level is possible” (European Commission 2001:22).
The Commission also underscores in this document how “[e]ffective decision-making also 
requires the combination of different policy instruments (various forms of legislation, pro-
grammes, guidelines, use of structural funding etc.) to meet Treaty objectives” (European 
Commission 2001:16). This approach is consistent with the “hybridization of policy modes” 
(Wallace, Pollack and Young 2010:484) characterising the European policy-making system as 
we have seen above. This governance mix does not regard only the modes used but also, as 
underscored by Börzel (2010:191), the levels (regional, national and European) concerned.
2.2.3. Innovative governance Instruments
New Modes of Governance can be implemented by using various governance instruments 
ranging from framework Directives, voluntary agreements, co- and self-regulation and 
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networks. As underscored by Scott and Trubek (2002) a certain number of characteristics 
distinguish NMG from traditional hierarchical forms of governance. NMG for example are 
expected to show a higher level of deliberation and power sharing with stakeholders, coor-
dination between multiple governance levels and informal guidelines allowing for diversity 
and flexibility (see also Idema and Kelemen 2006:110). These traits characterising NMG show 
many similarities with the management approach implemented in New Public Management 
in particular regarding the importance given to notions of inclusiveness, accountability, ef-
ficiency, effectiveness and deliberation among actors operating in multiple settings.
The White Paper on European Governance (European Commission 2001) outlines how the 
innovative governance practices should be implemented in an EU setting. It highlights in this 
respect the need to establish a stronger link between institutional and non-state (national) 
actors by means of consultation methods, partnership agreements, networking, risk assess-
ment and risk management (through expert committees). Developing a culture of evaluation 
and feed-back is another objective pursued by the implementation of NMG. As such, soft 
governance methods should encourage voluntary co-operation, exchange of best practices, 
defining common targets and guidelines for Member States.
A particular EU approach of co/self-regulation has been developed by means of the so-called 
“Open Method of Coordination” (European Commission 2001:19-22). The latter refers to an 
iterative process comprising interrelated stages whereby Member States agree to cooperate 
on a voluntary basis. These stages include: the joint diagnosis of a problem; the establishment 
of objectives to overcome the problems; the agreement on guidelines on how to achieve the 
objective; the establishment of (quantitative or qualitative) indicators and benchmarks as 
means to compare best practices; monitoring and periodic evaluation using in particular peer 
review to favour mutual learning processes (European Council 2000; De la Porte, Pochet and 
Room 2001:293).
Benchmarking refers in open coordination policies to “a process of mutual learning and 
continuously improving performance by exchanging information and good practice and 
identifying excellence according to objectives to which the parties have committed them-
selves”. It is closely related to peer review of the procedures for coordinating national policies 
and the comparability of data and transparency of indicators. Indeed, based on indicators 
or common reference factors, quantifiable objectives can be set permitting to evaluate the 
performance of participating actors and ensure an effective multilateral monitoring or coor-
dination (European Commission 2002: 202).
In this new governance architecture as outlined in the White Paper on European Governance, 
networks play an important role. They are considered to be a mean to achieve the wider 
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goals of the Commission: increase public participation and upgrade EU policy-making and, in 
this sense, contribute to enhance effectiveness and legitimacy of the EU integration process. 
According to the Commission, “networks link businesses, communities, research centres, 
and regional and local authorities at a European or even global level. These networks can 
enhance the success of Community policies. The Commission will work more closely together 
with them to enable them to contribute to decision shaping and policy execution” (European 
Commission 2001; Schout and Jordan 2003: 4-6).
Moreover, networks play directly a role in the Commission’s desire for more consultation and 
are also often representing a network of national agencies within the European agencies. 
Even in the benchmarking exercises promoted as a new governance mode in the White 
Paper, networks do play a prominent role. Hence, in the Commission’s vision of governance, 
giving significant weight to notions as ‘decentralisation’ and ‘partnerships’, networks permit 
to facilitate and complement these new policy objectives (European Commission 2001; 
Schout and Jordan 2003:7).
Although the importance of networks has been underscored in the White Paper, experts 
focusing on this issue, acknowledged that “at the European level, we are only at the start of 
the learning curve with respect to the use of networks as tools for public policies” (European 
Commission 2002: 252). Indeed, in the preparatory phase of the White Paper, a separate 
working group on “coherence and cooperation in a networked Europe” had examined the 
role of networks in the new governance architecture (European Commission 2002: 198). 
The mission of this working group was to identify a typology of networks and recommend 
architectures and management practices for ensuring network efficiency, inclusiveness, 
representativeness, transparency and accountability (European Commission 2002: 251).
The White Paper on European governance does not give an explicit definition of networks, 
nor clarifies their role or operational modes (Schout and Jordan 2003:8). However, the work-
ing group preparing the White Paper has identified four types of networks interacting with 
the European Union: 1) networks for information and assistance to citizens and organisations 
on Commission policies or programmes; 2) networks for consultation when defining or re-
viewing a policy or programme; 3) networks for implementing and adapting EU policies such 
as programmes or legislation; 4) networks for developing policies/policy-making (including 
regulation) (European Commission 2002: 255).
Networks are in this view considered as potential instruments to develop public policies in 
Europe or even as “a powerful tool to help solve many of the problems inherent in European 
governance”. Indeed, experts regard them as being able to “provide the flexibility required 
to deal with the wide diversity and sometimes fundamental differences existing between 
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administrative cultures and structures in Europe” (European Commission 2002: 254). The 
report underscores how networks permit in particular to address major challenges of the 
EU: maintain the democratic nature of the EU and its legitimacy and make the subsidiarity 
principle operational (European Commission 2002:254).
Although aiming to enhance democratic legitimacy, accountability, participation and effec-
tiveness of European governance, no consensus exists whether the open and decentralised 
approach of coordination actually reaches that goal (e.g. Kröger 2009; Citi and Rhodes 2007; 
Héritier and Lehmkuhl 2011; Schmidt 2006). Networking is in this regard too, considered 
as a mean to ensure transparency, inclusiveness, accountability “by a systematic sharing 
of information and experience, coordination of actions undertaken, and simplification of 
procedures” (European Commission 2002: 204). We will examine in part B to which extent 
this can be verified in European HTA cooperation which has been predominantly developed 
by means of networking. To understand why the European Commission has chosen this soft 
governance approach to support HTA cooperation in Europe, it is important to understand 
the how this approach relates to European integration policies in the wider European gover-
nance architecture, as explained in the following section.
2.3. role oF New moDeS oF goverNaNce iN the eu 
goverNaNce architecture
Many academics have analysed whether and how NMG have an impact on the effective-
ness of EU policy-making. Some stressing their role to find solutions in situations of political 
deadlock through the inclusion of stakeholders while respecting the autonomy of Member 
States. In this respect some believe soft governance procedures to be durable and eventually 
even preparing for hard-law solutions. Others, however have a more critical view on the 
effectiveness of NMG and underscore the difficulty to ensure compliance in decision-making 
processes as participation is based on voluntarism (Kröger 2009; Citi and Rhodes 2007:21).
Similarly, NMG are considered by some to positively impact the democratic legitimacy and 
transparency of the EU decision-making processes. They point to the level of inclusion and 
participation from the conception to the implementation of various actors concerned by a 
policy. In particular, the role of expert networks to establish common agreements would 
positively impact decision-making and develop an environment of interaction leading to 
the establishment of trust and confidence among the different stakeholders involved. This 
inclusive approach of NMG has however also raised criticism as to whether these new gov-
ernance modes would not present a way to circumvent traditional legislative and political 
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decision-making and thus put at stake, rather than increase, the democratic legitimacy of the 
EU (e.g. Héritier and Lehmkuhl 2011; Schmidt 2006).
Finally, some have underscored how NMG could have a positive impact on policy-making 
by favouring discourse and learning processes which lay at the heart of political processes 
and could induce policy change (e.g. De la Porte and Pochet 2002; Scharpf 2002; Knill and 
Lensshaw 2003). Different academic schools have examined in this respect the importance 
of values and beliefs in the development of policy-making processes (Schmidt and Radae-
lli 2004; Haas 1990). Innovative governance modes would also favour learning processes, 
producing information, support problem-solving and establish best practices (Eberlein and 
Kewer 2004; De la Porte, Pochet an Room 2001; Trubek and Mosher 2003). Discourse and 
the use of argumentation would also serve to “disentrench settled practices” and permit 
to “reconsider the definition of group, institutional and even national practices” (Sabel and 
Zeitlin 2008).
Guigner (2007) has examined the impact of soft policy instruments such as the Open method 
of Coordination (OMC) in the field of EU health policy (e.g. health information policy) (see 
further on OMC e.g. Borras and Jacobsson 2004). He underscores how exchange of ideas 
and experiences in formal and informal fora (e.g. European Health Forum, ‘comitology’, 
expert working groups) can lead to the Europeanisation of EU health policy. His research un-
derscores how by means of socialisation and ‘argued persuasion’ actors can gradually adopt 
new ideas and practices. He refers to the latter as “constructivist cognitive Europeanisation” 
which according to him can have an important influence on the health policy-making pro-
cesses in Europe (Guigner 2007:274-279). Critical assessments as regard the virtues of NMG 
through discourse and learning underscore, however, how the impact of the latter remains 
difficult to assess (e.g. Scharpf 2002; Héritier 2003; Rhodes 2005; Trubek and Trubek 2005).
Hence, NMG have been implemented by the EU institutions as means to improve effective-
ness, transparency and democratic legitimacy of the EU. These innovative governance modes 
are characterised by the interaction mechanism, voluntary and non-binding decision-making 
procedures and the importance of discourse and learning mechanisms among the participat-
ing actors. As outlined above, the White Paper on European Governance underscored how 
these NMG should reinforce the principle of proportionality and subsidiarity. The latter is of 
major importance in areas of exclusive competence of the Member States such as HTA. In the 
next section we will therefore examine the relationship between soft governance modes in 
the EU and the principle of subsidiarity and why this may have an impact on the distribution 
of competences between the EU and the Member States.
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2.4. New moDeS oF goverNaNce aND the SuBSiDiarity 
priNciple
2.4.1. Subsidiarity responding to multiple interpretations
Besides striving for more effectiveness, transparency and democratic legitimacy, the gover-
nance reforms proposed in the White Paper on European Governance were also designed to 
address the issue of proportionality and subsidiarity inherent in EU policy-making processes. 
According to the Commission, the political principles underpinning the overall EU gover-
nance architecture should reinforce the principles of proportionality and subsidiarity from the 
conception of the policy to the implementation. Hence, the Commission underscores here 
the importance to systematically check whether (a) (…) “public action is really necessary, 
(b) if the European level is the most appropriate one; and (c) if the measures chosen are 
proportionate to those objectives” (European Commission 2001:8).
Referring to the principle of subsidiarity within the framework of New Modes of Governance 
is as such not astonishing since, as outlined above, open coordination as governance practice 
is considered to be particularly appropriate in politically sensitive policy areas where Member 
States often hold exclusive competences, and which should be governed within the respect 
of the subsidiarity principle. However, referring to the principle of subsidiarity within the 
framework of NMG is politically not completely neutral since the concept comprises a strong 
political dimension (Van Kersbergen and Verbeek 1994; 2004). One of the reasons for that 
lays in the multiple understandings and definitions that have been attributed to the notion 
of subsidiarity.
The subsidiarity principle in an EU understanding has formally been introduced Maastricht 
Treaty (1992). The numerous debates that took place prior to the treaty insertion of this 
concept, failed to adopt a commonly accepted European understanding of subsidiarity (Van 
Kersbergen and Verbeek 2004: 151). To some, it is even the ambiguity in interpretation 
that has permitted to turn this principle into a treaty-based provision (e.g. Endo 1994; Van 
Kersbergen and Verbeek 2004). Although support for the introduction of the concept in 
the Treaty was given by most political leaders, their views regarding the exact definition 
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of subsidiarity differed23 (Van Kersbergen and Verbeek, 1994, 221–226). The absence of a 
uniform understanding of one of the key concepts in the European decision-making archi-
tecture can however have far reaching consequences in EU policy-making. In particular in 
the field of NMG these different understandings may allow for a transfer in the allocation 
of competences between the EU and the Member States (Scott and Trubek 2002: 6-8; Van 
Kersbergen and Verbeek 2004; Tholoniat 2010).
The principle of subsidiarity has been defined in Article 3b of the Maastricht Treaty its 
definition has not changed since: “The Community shall act within the limits of the powers 
conferred upon it by this Treaty and of the objectives assigned to it therein. In areas which 
do not fall within its exclusive competence, the Community shall take action, in accordance 
with the principle of subsidiarity, only if and in so far as the objectives of the proposed action 
cannot be sufficiently achieved by the Member States and can therefore, by reason of the 
scale or effects of the proposed action, be better achieved by the Community. Any action 
by the Community shall not go beyond what is necessary to achieve the objectives of this 
Treaty” (Art 5 TEU).
Depending on the analytical framework used, different meanings have been attributed to 
the principle of subsidiarity. Most often a distinction is made between so-called positive or 
negative concept of subsidiarity (Endo 1994). Subsidiarity as a positive concept refers to the 
fact that a (higher) entity has the possibility or obligation to act towards a (lower) entity, if 
the lower entity cannot accomplish its objectives in a satisfactory way or if the higher entity is 
assigned to intervene. Subsidiarity understood within a negative interpretation points to the 
fact that a (higher) entity has not the right to intervene in the affairs of the lower entity if the 
23 Van Kersbergen and Verbeek (2004:152) identify three different varieties of the philosophy of 
subsidiarity represented among the European leaders in 1992. The first, supported by the Christian 
democrats, considered subsidiarity “as a flexible criterion in order to determine the extent to which 
the state can legitimately interfere in society”. The second emanated from a (German) legalistic 
view of subsidiarity, embraced the idea that responsibility should be bore by decentralised public 
(rather than private) authorities (see also Goetz, 1995: 102). The third variety of subsidiarity (partly 
supported by the British Conservative Party) “referred to the legitimization of state intervention in 
order to protect the state’s citizens from unwanted effects of capitalism”.
HTA Cooperation in the EU health policy and governance architecture 91
lower entity can reach its objectives by itself, or if the higher entity has not been assigned to 
intervene (Endo 1994)24.
No clear criteria exist indicating when the higher or lower level are considered capable of 
accomplishing objectives in a satisfactory way. Interpretation of the latter could be based on 
goal attainment, efficiency or necessity criteria. However, the lack of objective appraisal of 
these criteria makes the application of the subsidiarity principle a challenging exercise and 
politically charged. In this sense, subsidiarity is considered by some as a mean to strengthen 
EU integration policies in cases where the EU level would be considered to be more ap-
propriate to establish policies in a certain field (Scott and Trubek 2002; Van Kersbergen and 
Verbeek 2004). In the next section we will highlight how associating the subsidiarity principle 
to New Modes of Governance further triggers questions as regard the competence extension 
from the Member State level to the EU.
2.4.2. Competence extension through NMG and the application of the 
subsidiarity principle
By introducing the possibility to have recourse to New Modes of Governance in policy areas 
where competences are either shared or fall exclusively under the responsibility of Member 
States, the Commission has added new governance instruments to its arsenal. Ambiguity 
exists however as regards the role these soft governance modes play in EU policy processes. 
Some considering them as a mean to favour integration policies while others regard them as 
a mean to safeguard Member States’ control of EU policies (Diedrichs, Reiners and Wessels 
2011:22-23). Similarly, the principle of subsidiarity can be considered either as a way to 
safeguard Member States’ interests and decision-making powers or as a means to enhance 
EU competences in new policy fields. The relationship between the subsidiarity principle and 
NMG brings to the fore two aspects which may influence governance processes taking place 
in the EU.
24 The dual positive or negative interpretation of subsidiarity as an organising principle of the rela-
tions between State and society was already present in the early works on subsidiarity such as 
the encyclical “Quadragesimo Anno” of Pope Pius XI published in 1931 and considered to be 
the first publication where subsidiarity as function has been explicitly mentioned (Endo 1994). 
In this encyclical, the Church sought that subsidiarity should function as a mean to restrict state 
intervention in associations. In this sense it gave a negative interpretation of the concept. However, 
as underscored by Endo (1994:624), the encyclical also underscored the duties of the state inter-
vention and did built further upon the encyclical “Rerum Novarum” written four decades before 
by Pope Leo XIII underscoring the obligation of the State in the field of social reform. The latter 
could be interpreted as a positive understanding of the subsidiarity principle (Endo 1994:624).
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First, it seems that the combination of two politically ambiguous concepts (i.e. NMG and 
Subsidiarity principle) may influence the outcome of governance processes. Due to the 
“room for manoeuvre” offered by NMG to the Commission, ‘windows of opportunity’ may 
appear, permitting the extension of the Commission’s influence in sensitive areas (e.g. health 
care). Having recourse to NMG in the implementation of supportive and coordinating mea-
sures, offers the Commission the possibility to take action in policy areas where, according to 
the treaties, it has no specific competences, while fully respecting the subsidiarity principle. 
Hence, since both the subsidiarity principle and NMG find support by those fostering further 
integration as well as by those seeking to limit it, the Commission’s actions may be imple-
mented without hindrance.
The second rapprochement which can be made between subsidiarity and NMG regards 
the envisaged aims of the latter as underscored in the Lisbon Agenda and White Paper 
on Governance (i.e. increasing efficiency and effectiveness of EU’s (integration) policies and 
transparency). By implementing an open coordination policy in areas of exclusive or shared 
competences, the Commission’s actions are limited to promoting cooperation policies and 
lending support to those policies. Since the Member States remain in full possession of 
their competences, the Commission does not trespass its powers as defined in the Treaties. 
However, the promotion and support of cooperation activities are often facilitated through 
the allocation of financial and administrative support. Hence, in a certain policy area, specific 
network activity can be financed through EU programmes (e.g. through grants or in kind) or 
support activities within related DGs. Via these kinds of mechanisms, the Commission has 
the potential to progressively become a key-player in the policy-making process since the 
boundaries between ‘coordinating’ Member States’ policies and ‘steering’ their policies in a 
certain area become increasingly blurred.
A possible outcome stemming from this dual relationship between NMG and the subsidiarity 
principle is that through the implementation of NMG, the action of the Commission could in 
practice alter the allocation of competences and enhance its own influence on a particular 
policy domain. A two-fold explanation could be given in this regard but should however be 
further examined. First, by being in the situation permitting to determine which actions to 
support or not, the EU institution can adopt a steering function in particular policy areas. 
The more support for coordinated action, the more chance that Member States will develop 
a similar/coherent approach to particular policy problems. Through dialogue and learning 
processes underpinning NMG, Member States’ policies could slowly but certainly converge. 
If harmonisation was not the aim envisaged at the beginning of the policy coordination 
process, it can in the end result in policy actions which could de facto be assimilated to 
convergence policies.
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Second, in those situations where a certain degree of convergence has been attained as a re-
sult of EU’s support to cooperation initiatives, it will become particularly difficult to determine 
which level is the most appropriated to deal with the particular policy, especially considering 
the role of the Commission as key-player in the coordination of policies. As the coordination 
is already being steered by the supranational level, it takes only one more step to determine 
that that level is the most appropriated level to undertake action. Conversely, it will be hard 
to argue that Member States are in a better position to bear that responsibility. This is the 
second point where the application of New Modes of Governance impacts the application 
of the subsidiarity principle.
In conclusion, the NMG emerged as a strategic objective of the new Prodi Commission and 
as instruments to attain the objectives of the Lisbon Council. As such, they became formal 
policy instruments of the EU with the intention to strengthen the transparency of the Union’s 
policies through an inclusive governance approach; insure effectiveness and efficiency 
through new and flexible governance instruments; and reinforce the subsidiarity principle by 
the establishment of new mechanisms in the policy process facilitating the exchange of expe-
rience and permitting the achievement collectively of context-specific solutions on complex 
policy issues (Lebessis and Paterson 2001:8). In the following chapters we will examine how 
these soft governance policies have been implemented in the field of HTA cooperation and 
to which extend they have favoured or not convergence of practices.
2.5. coNcluSioN
We have seen in the first part of this chapter how EU health policy has been developed either 
through a spill-over of Internal Market-based policies or by means of soft governance. The 
competences of the EU in the field of health policies are laid down in the treaties (e.g. Art. 
4, 6 and 168 (TFEU)). The use of HTAs in national decision-making processes is considered as 
falling under the exclusive competences of the Member States. Although the EU has no say 
in the input of HTA into domestic pricing and reimbursement decision-making processes, it 
may lend support to HTA cooperation within the European Union. The public health article 
in the Lisbon Treaty (Art. 168 TFEU) underscores how soft governance modes can be used in 
these kinds of situations while respecting the subsidiarity principle.
The second part of this chapter has outlined the development of innovative governance 
modes in the EU and which comprise the recourse to networks. These New Modes of Gov-
ernance have been developed to address the challenges of enhancing the effectiveness, 
participation, and democratic legitimacy of EU governance practices. NMG intrinsically bear 
the potential to become heavily politicised as they may be used by the Commission as a 
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mean to extend its jurisdiction. In particular when relating NMG to the subsidiarity principle, 
impacts on the division of competencies between the EU and the Member State level may 
occur.
HTA cooperation in Europe has taken place within this context of EU integration chal-
lenges and governance modes developed to address those. Having outlined EU health policy 
developments and governance instruments available in this area will permit us to better 
situate HTA cooperation processes and the governance modes applied in them. Indeed, HTA 
cooperation in Europe has been structured by means of networks. The EU has played a major 
role in supporting and developing these networks and has even integrated HTA cooperation 
as one of its own policy objectives. The development of HTA cooperation in Europe and 
the development of EU health policy have progressively been intertwined and have been 
structured on the basis of the new governance approach launched at the turn of the century. 
Networking has played a major role in these processes.
Getting a profound insight of the governance of HTA cooperation in Europe requires thus 
to situate these cooperation processes into the broader EU governance developments as 
they have had a profound impact on them. New Modes of Governance and in particular 
networking have been chosen to develop HTA cooperation processes in Europe. In the next 
chapter we will examine how soft governance can be implemented in governance networks 
and how these relate to national and European policy-making. Based on our findings in de 
literature we will design a research framework allowing to explore, through network analysis, 
how soft governance has structured European HTA cooperation within a EU framework.


3 Research design 
 
“Everybody is ambitious. The question is whether he is ambitious to be or 
ambitious to do.”
Jean Monnet, Memoirs
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3.0. iNtroDuctioN
In European HTA cooperation, the conjunction between the HTA arena and the EU institu-
tions takes place within networks. For the HTA arena, uniting in the form of a network is 
a means to achieve the objectives of enhancing the quality, quantity and uptake of HTA in 
national decision-making processes regarding health technologies. For the EU institutions, 
lending support to European HTA networks and coordinate their activities, is a mean to de-
velop EU health policy and have an influence on the national health systems. The HTA arena 
needed the EU support to develop its activities. The EU arena needed the HTA networks to 
enter the domestic health systems. The governance processes of the HTA networks have, 
since the beginning, been based on voluntary cooperation and soft governance modes. This 
approach perfectly matched the New Modes of Governance available to the EU in health 
policy-making.
From the outset, HTA cooperation has developed through the setup of specific project-based 
networks aiming to establish a sustainable European HTA cooperation framework. These 
networks have responded to different forms of composition and governance structures and 
practices. Although they have emanated from an HTA expert community, they have gradu-
ally been integrated into EU health policy-making processes. Hence, HTA networks have 
undergone influence of management and governance procedures laying within and outside 
the EU-scope. Networking has been a means for HTA actors to unite their competences and 
knowledge for specific HTA-related objectives. Salience for this matter has been developed 
within the EU Commission which has supported and, in a later stage, coordinated these 
cooperation initiatives, partly to develop broader EU health policy objectives.
In this chapter we will highlight the interplay between soft governance and networks in the 
EU governance architecture. Although various governance modes can be implemented in 
networks, these structures intrinsically present characteristics favouring the implementation 
of soft governance instruments. As such, they are often considered by the EU as an adequate 
forum to pursue specific aims in sensitive policy areas where its competences are limited. 
Yet, EU recourse to networks is not restricted to areas of soft governance, as governance 
based on networking can take place in all other EU governance modes (e.g. Börzel and 
Heard-Laureote 2009). Similarly, and as underscored above, whilst soft governance can be a 
privileged mode in networks, other governance practices can be observed in networks (e.g. 
Klijn and Koppenjan 2016).
Hence, networks, can intrinsically function as a medium through which various soft gover-
nance instruments can be diffused. We have seen in the previous chapter how soft gover-
nance could, for example, avoid political deadlock through voluntarism, inclusiveness and 
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participation and establish favourable conditions for hard-law decision-making. Applied to 
networks, these elements will relate to a network’s membership structure. Moreover, actors’ 
incentives, rationality and preferences for particular policy choices can be influenced by learn-
ing processes and shared values and understanding. These elements will come forward in 
network formation and network socialisation. Similarly, horizontal coordination, importance 
of legal certainty, policy entrepreneurs and the presence of a shadow of hierarchy have been 
brought to the fore as playing a role in the effectiveness of soft governance. These features 
will find their expression in network governance. Hence, soft governance can be examined 
through the prism of networks. Networking being considered here as an instrument of soft 
governance and networks as a medium through which other forms of soft governance 
instruments can be applied. Adopting this approach in our research offers the possibility to 
associate HTA cooperation networks with EU soft governance modes and examine the role 
of soft governance in structuring HTA cooperation within an EU framework.
In order to better understand the governance processes of HTA cooperation through 
networking, this chapter will first address the role of networks in national and European 
policy-making processes and outline the concepts of governance networks, metagovernance 
and network governance. Our research framework will be built upon these concepts repre-
senting the external structure of the research framework. To understand how governance 
networks have been governed both from the ‘inside’ (network governance) as from the 
‘outside’ (metagovernance), the framework addresses two particular aspects of governance 
networks and network governance: network typologies and network effectiveness. Both 
will be examined within the scope of soft governance. These concepts represent the inner 
structure of the research framework.
This chapter is organised according to the key-concepts of the research framework. The 
first section will set out what is understood by governance networks and will outline how 
they operate in national and European policy-making processes. The second section will 
elaborate on the ‘governance of governance networks’ by external actors, also referred to 
as ‘metagovernance’. Of interest here is to examine how this concept is applicable to the EU 
setting. The third section will turn to the governance of networks from a network perspective 
and outline operational aspects of network governance rooted in soft governance modes. 
It will explain how network governance can touch upon network characteristics (network 
typology) as well as on network effectiveness. The notion effectiveness and how this relates 
to network governance in our research will be explained in this section as well. The last part 
of this chapter will be focused on constructing the research framework based on the central 
concepts outlined above. This research framework will be used to examine the empirical data 
outlined in Part B. The latter should allow us to answer the research questions as defined in 
the introduction of the thesis.
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3.1. goverNaNce NetworkS
3.1.1. Governance networks in national policy-making processes
Networks have been studied across different academic schools such as political science, 
policy analysis, and organisational studies (Sandström and Carlsson 2008: 497). This explains 
the important variety in approaches and comprehension of what networks refer to. Many 
different concepts of networks have been developed across these academic fields such as 
‘advocacy coalitions’ (Sabatier and Jenkins-Smith: 1993), ‘implementation structure’ (Hjern 
and Porter, 1993), ‘Iron triangles’ (Jordan and Schubert, 1992), ‘issue networks’ (Heclo 
1978), ‘policy communities’ (Jordan 1990) and ‘subgovernments’ (Rhodes 1990). Networks 
used as resources for policy development and implementation can also be referred to as 
‘governance networks’.
Governing by having recourse to networks differentiates itself from the more traditional 
forms of governance also known as “buy, make or ally” (Williamson 1985) referring to 
market regulation (characterised by competition rules), state regulation (characterised by 
hierarchical command and control forms of governance) and cooperation mechanisms 
(characterised by negotiations and trust) (Provan and Kenis 2008). Instead, public policymak-
ing, implementation and service delivery could be achieved “through a web of relationships 
between autonomous yet interdependent government, business and civil society actors“ 
(Klijn and Koppenjan 2016:11).
The concept of ‘governance networks’ is closely related to the one of ‘policy networks’ de-
veloped in the 1980s and associated to state and public-policy reforms (Rhodes 1997, Smith 
1999, Stoker 2000, Smith 2002). It has been argued that policy networks have developed 
following the neoliberal turn of the 1980s and the introduction of New Public Management. 
The latter, operating often via ‘agentification’ and outsourcing service delivery, had created 
a fragmented public sector, generating the need for horizontal coordination among public 
and private actors (Torfing and Sorensen 2014:332). Hence, due to an increased complexity 
in policy issues and policy processes including a variety of actors and institutions at multiple 
levels, some considered that so-called ‘wicked problems’ could not adequately be solved 
through either a state-only or a market-only approach. Policy networks have been presented 
as a third way permitting to compensate for limitations of both state and market regulation 
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and respond to societal changes creating new dynamics25 (Kooiman 1993; Jessop 2002; Klijn 
and Koppenjan 2004; Sorensen and Torfing 2007).
The concept of governance networks draws a lot on the understandings of policy networks 
but has developed as a separate research agenda. From a political science perspective, Torf-
ing and Sorensen (2014) have presented four different approaches on governance networks 
being developed within the new institutionalism school of thought. All four approaches 
underscore the presence of specific elements which can be related to soft governance. From 
a historical institutionalism perspective, some researchers (Jessop 1998; Kickert et al. 1997, 
Rhodes 1997), underscore how networks serve as a medium for interest mediation between 
interdependent actors whereby networks are constituted following strategic calculations of 
self-interested collective actors. Governance networks are formed through an incremental 
bottom-up process and allow actors to find “joint solutions to joint problems” (Torfing and 
Sorensen 2014: 337). Networks can be used by public authorities to pursue specific objectives. 
Mutual interdependence and the development of common norms, values and perceptions 
underpin negotiation processes, learning and compromise formation whereby interests and 
objectives of public and private actors can be transformed (Torfing and Sorensen 2014: 337).
Researchers adopting the perspective of rational choice institutionalism (e.g. Kooiman 2003; 
Mayntz 1993; Scharpf 1994), will consider governance networks as “arenas for horizontal 
coordination between autonomous actors who interact in and through different negotiation 
games” (Torfing and Sorensen 2014: 337). Network formation follows a functional response 
to changes in society and traditional governing approaches. Governance networks are 
considered as “game-like structures” functioning by anticipation of potential gains from the 
network through pooling resources and the build-up of mutual trust. Incentive structures 
facilitate collective action and conflict-resolution. Moreover, network formation can result 
from either the objective to avoid potential problems or situations (‘negative coordination’) 
25 The term ‘policy network’ has been introduced in the 1990s as a generic label to describe various 
forms of interest mediations (March and Rhodes 1992). Policy networks were categorised in terms 
of participants, stability and internal consensus. According to Börzel (1998:260), “a policy network 
includes all actors involved in the formulation and implementation of a policy in a policy sector. 
They are characterised by predominantly informal interactions between public and private actors 
with distinctive, but interdependent interests, who strive to solve problems of collective action on 
a central, non-hierarchical level”. To some (e.g. Rhodes 1994), the proliferation of networks would 
lead to a “hollowed-out state” as there would be an increased need of the state to rely upon other 
organisations for the delivery of services. Others, however, have pointed to a transformation of 
state power, exercised in new ways as a result of the development of partnerships and networks 
(Pierre and Peters 2000; Torfing and Sorensen 2014:335).
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or from the search for common solutions to a particular problem through mutual engage-
ment and interactions (‘positive coordination’) (Torfing and Sorensen 2014: 337).
Normative institutionalism approaches will underscore how actors can be normatively inte-
grated through a new set of rules, norms, values and perceptions that may be developed in a 
governance network which will contribute to developing a shared logic of appropriate action 
(March and Olson 1995, Powell and Di Maggio 1991). This theory also adopts the perspec-
tive that networks are created through a bottom-up process and are further developed on 
the basis of institutional logics of appropriateness and interdependencies. Adjustments can 
take place as a result of mutual learning process. Actor interaction will be based on a shared 
logic of appropriate action and conflicts can be resolved through solidarity and commonly 
adopted rules (Torfing and Sorensen 2014: 338; March and Olson 1995: 45-89).
Finally, the governmentality theory, developed by scholars, such as, Dean (1999), Foucault 
(1991) and Rose and Miller (1992), consider governance networks as means for self-regu-
lation of actors in a particular policy field which act, however, within an given institutional 
framework and respond to specific regulatory norms , performance standards and practices 
in adequation with overall (institutional) policy objectives. In this sense, governance networks 
are considered as a mean for government “to recruit social actors as vehicles of the exercise 
of power”. Actors may however resist and oppose these “normalising power strategies” 
which can lead to the development of conflicts (Torfing and Sorensen 2014: 338)
What characterises governance networks and which is underscored in most approaches, is 
the presence of multi-level interactions among network actors and between the network 
and external actors. Huppé et al. (2012:2), for example, underscores how the combination 
of diverse participants from different levels (local, national, global) and sectors not only “ag-
gregate resources, but are structured to take advantage of the fact that each participating 
sector brings different resources to the fore”. More recently, Klijn and Koppenjan (2016:11) 
define governance networks as “more or less stable patterns of social relations between 
mutually dependent actors, which cluster around a policy problem, a policy programme, and/
or a set of resources and which emerge, are sustained, and are changed through a series of 
interactions”.
Hence, participants in a governance network rely upon each other but their relationship is not 
structured around a hierarchical command and control model and no superior-subordinate 
relationship exists among the participating organisations (see also O’Toole 1997; Keast, Man-
dell and Brown 2006). The network partners are not necessarily equal in terms of authority 
and relationships (Klijn 2008). Negotiations contain elements of bargaining but are linked to 
a “wider framework of deliberation that facilitates learning and common understanding” 
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(Scharpf 1994; Sorensen and Torfing 2007:10). The aim of the network is to regulate a 
particular policy field, but it does necessarily operate in a specific political and institutional 
environment which “both facilitates and constrains their capacity for self-regulation” (So-
rensen and Torfing 2007:10).
No uniform understanding of the concept of governance networks exists. However, the 
definition of Sorensen and Torfing (2007:9) covers most aspects highlighted in the different 
schools of thoughts. In this definition, governance networks are qualified as “1. a relatively 
stable horizontal articulation of interdependent, but operationally autonomous actors; 2. 
who interact through negotiations; 3 which take place within a regulative, normative, cogni-
tive and imaginary framework; 4. that is self-regulating within limits set by external agencies; 
and 5. which contributes to the production of public purpose”.
Combining this definition with other aspects of governance networks highlighted above 
brings us to the following list of characteristics of a governance network:
Characteristics Governance Networks
More or less stable pattern of relationships of social actors clustering around policy problem/resources, emerging, 
sustaining and changing though interactions1
Stable horizontal relations of interdependent, autonomous actors (public private, civil society), not necessarily equal 
in authority and relationships2, 3
Interaction through negotiations based on deliberation, learning and common understanding2
Interactions in regulative, normative, cognitive and imaginary framework2
Self-regulating within limits set by external agencies2
Actors aggregate different resources4
Contributes to public purpose2,3,4
Table 3.1. General characteristics governance networks
1Klijn and Kloppenjan (2016), 2Sorensen and Torfing (2007), 3Klijn (2008), 4Huppé, Cneech and Knob-
lauch (2012)
These attributes allow to determine whether a network could be qualified as governance 
network. However, different networks although responding to the characteristics of a 
governance network could also present distinct features which would further characterise 
them. As such, governance networks could respond to different reasons of establishment, 
different membership structures, resources and governance modes. The combination of 
these characteristics in one governance network can be considered as a specific network’s 
typology. Examining governance network typologies allows us to better understand how 
specific networks have been created according to which incentives, strategic calculations or 
specific support or constrain measures received (Herting 2007; Klijn and Koppenjan 2016, 
Rhodes and Bevir 2007). Moreover, the membership of a governance network may impact 
Research design 105
the strategic directions decided upon or may explain why certain objectives have or not been 
reached. The composition of a network also gives information about the background of 
its members (public, private, non-profit), whether the membership structure will be homo-
geneous or heterogeneous or will be open to new members or not (Koliba 2011Agranoff 
2007;Schaap 2007; Peters 2007; Sandström and Carlsson 2008). Similarly, use of available 
resources will also characterise network governance and will have an influence on manage-
ment and implementation strategies and choices (Koliba 2011). Finally, power distribution 
within a governance network will be a consequence of a specific network governance ap-
proach and can vary according to for example horizontal, asymmetric or centralised power 
distribution (Börzel and Panke 2007; Sorenson and Törfing 2007; Provan and Kenis 2007; 
Schout and Jordan 2003).
Hence, although networks can respond to specific characteristics which would qualify them 
as governance networks, each network itself will respond to a specific typology referring 
to its establishment, memberships structure, resources and governance modes. As these 
features will differ in the various governance networks and relate to various soft governance 
instruments used. The way networks will function in a specific environment and the manner 
in which they will set specific objectives and seek to attain them may also vary. In this sense, 
network typology at one hand can have an influence on the governance practices of a 
network and at the other hand can be a part of a governance strategy itself (e.g. determin-
ing membership, governance modes). For analytical purposes we address the typology of 
networks as part of characteristics of governance networks whilst recognising the role it 
plays in network governance, concept we will outline below.
3.1.2. Governance networks in European policy-making processes
Following general changes in domestic policy-making processes as outlined above, EU policy-
making too becomes characterised by the interaction of multiple state and private actors as 
well as by the complexity of the negotiation processes. Policy networks will increasingly play 
a key role in these processes as they are considered to be a means to respond to the needs 
of private interest groups as well as European, national and sub-national interests (Marks 
1993:392; Saurugger 2009:233-236). This new style of policy-making within the EU, cor-
responds, according to some observers, to a “transformation of governance” (Hix 1998:40; 
Jachtenfuchs and Kohler-Koch 1999). The inclusion of non-state actors in the governance 
process of the EU is being referred to by others as a genuine ‘governance turn’ in the EU 
(e.g. Kohler-Koch and Rittberger 2006; Rhodes 2012). The ‘White Paper on European gover-
nance’ published in 2001, integrates these practices in the official governance approach of 
the EU, as we have outlined in chapter 2. Recourse to soft governance instruments is a major 
constituent in this new strategy.
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The new governance approach within the European context is based on cooperation-mecha-
nisms between all concerned actors as well as on learning processes rather than competition 
(Saurugger 2009:236). Networks play a particular role in this governance architecture in 
which emphasis is made on the non-hierarchical modes of interaction between state and 
non-state actors, interdependent relationships between public and private actors as well 
as the importance of expertise and discourse and the problem-solving capacity of network 
governance. Whereas decisions are still being made on specific levels in the EU decision-
making systems, networks modify actor’s preferences and bring new issues on the agenda 
(Saurugger 2009:243-245).
As the inclusion of private actors and networks play an important role in the definition and 
implementation of EU policies (Kooiman 1993; Rhodes 1997; Mayntz 1998), some research-
ers have tried to clarify whether “the EU could be conceptualised as a form of governance by 
networks or governance in networks” (Börzel and Heard-Laureote 2009:139). Governance 
by networks referring here to a system where authorative allocation is being negotiated 
between the state and societal actors. The governance in networks approach considers that 
the EU decision-making system is being dominated by governmental actors. To elucidate 
this question, Börzel and Heard-Laureote proceeded by looking at the functional aspects of 
networks in the EU policy process and their normative implications.
Although they do recognise that, since the inception of the EU, networks have played a part 
in policy formulation and implementation, they believe that relationships between networks 
and EU institutions are asymmetrical and do not correspond to governance by networks 
(Börzel and Heard-Laureote (2009:139). They point to a “shadow of hierarchy” (See also 
Héritier 2011) present in EU decision-making which should therefore call for caution not 
to overestimating the role of private actors in the EU. Hence, according to Börzel and 
Heard-Laureote, governance in networks corresponds to a better conceptualisation of EU 
governance as “Instances of network governance are rare compared to forms of governance 
entailing combinations of supranational hierarchy, intergovernmental negotiations and 
market competition” (Börzel and Heard-Laureote (2009:140)
The scholars also underscore that networks have proliferated in the EU and have been used 
by private actors to seek access and influence at the EU institutional level by offering exper-
tise and support. Drawing upon work of Obradovic and Vizcaino (2007), they also point to 
the fact that “the European Commission has made strategic use of them to strengthen their 
position in EU policy-making. Networks lend significant power to the European Commission, 
which often acts as a broker drawing on the resources provided by private actors (expertise, 
acceptance) to shape the formulation and implementation of EU policies according to its 
interests. While it takes advantage of private actor resources to increase its action capac-
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ity, the Commission seeks to preserve its autonomy and has little interest in extending the 
involvement of private actors beyond consultations” (Börzel and Heard-Laureote 2009:140).
Hence, as underscored by Börzel and Heard-Laureote (2009:146), “networks have the 
potential to support all the forms of governance in the EU, ranging from supranational 
hierarchy, intergovernmental negotiations to market competition and rare forms of genuine 
network governance”. The authors point to the White Paper on European Governance 
(2001) which underscores the importance of networks in the implementation of New Modes 
of Governance as they permit to establish relationships between multiple actors on multiple 
levels. According to the Commission, these networks can enhance the success of Community 
policies (European Commission 2001b). By working more closely with networks through the 
use of soft governance instruments and “enable them to contribute to decision shaping and 
policy execution”, the Commission seeks to increase public participation and enhance effec-
tiveness and legitimacy of the EU integration process (European Commission 2001b; Schout 
and Jordan 2003: 4-6). Through ‘decentralisation’ and ‘partnerships’, networks permit to 
facilitate and complement these new policy objectives (European Commission 2001b; Schout 
and Jordan 2003:7).
Although the very notion of networks is clearly present in the White Paper on governance, 
no explicit definition of these can be found. Moreover, as underscored by Schout and 
Jordan (2003:8), very little attention is given to the difficulties of creating and managing 
transnational networks. It seems that the governance network approach is mostly based 
on national experiences of the kind. Moreover, the role (support policy-making/participate 
in policy-making) and operational modes (self-steering/active steering by EU) of networks 
has not been clarified. Nevertheless, in the course of the years the EU will have recourse to 
governance networks in various ways mainly to support and develop specific policy objec-
tives. The manner in which it does so could be related to so-called meta-governance which 
will be outlined in the section below.
3.2. metagoverNaNce
Governance networks operate within a broader system as they relate directly or indirectly 
to public policy-making. Hence, interaction between governance networks and public 
institutions is often taking place either on a national level and/or on an international level 
depending of the nature of the policy issue. Analysing governance networks requires thus to 
distinguish two levels of analysis: the network-level (network governance and management) 
and the so-called ‘meta-governance’-level (governance of governance networks). The latter 
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can refer to a domestic institutional setting or can involve an international institutional level 
such as the EU institutions.
Many scholars have examined governance networks from the perspective of autonomy and 
self-management (e.g. March and Olsen 1995; Jessop 1998, cited in Triantafilou 2007:190). 
As underscored by Triantafilou (2007:190), often in these perspectives, autonomy equates 
insulation from state power. Strong interdependencies between state and governance net-
works however often exists (e.g. manpower, expertise and finance) and autonomy could 
be actually considered “as a specific constellation between the exercise of power and the 
exercise of freedom” (Triantafilou 2007:190). As governments can and often have recourse 
to networks for service delivery or policy implementation or any other reasons, the question 
arises who actually governs the networks’ actions, the state or the network? (Triantafilou 
2007:190).
The answer is not a clear-cut one and no standard model of metagovernance exists. The 
question is directly related to the development of governance networks which, as outlined 
above, are rooted in public sector reforms where the state delegated tasks and policy imple-
mentation to networks. As governance networks are concerned by policy formulation and 
implementation, it is not astonishing to find strong relationships between public authorities 
and governance networks. Some scholars consider that when it comes to public policy, the 
state remains the central actor but uses a new mix of policy instruments. Instead of resort-
ing to coercive regulatory instruments it will in particular cases or policy areas use a soft 
governance approach. In this new policy-mix, networks will “offer the state new capacities 
to govern by the use of indirect control instruments” (Bevir 2011:186 drawn upon Pierre and 
Peters 2000; Davies 2002, Jessop 2003).
The perspective that states can govern through governance networks refers to the concept 
of ‘meta-governance’. Whilst many scholars point to the interrelationship between public 
authorities and governance networks, no uniform comprehension of the concept ‘metagov-
ernance’ exists. Some consider this as state coordination though informal modes of steering. 
Bevir (2011: 186) for example considers that “the state increasingly steers and regulates sets 
of organisations, governments and networks. These other organisations undertake much 
of the work of governing: they implement policies, provide public services, and at times 
even regulate themselves. The state governs the organisations that govern civil society – the 
governance of governance.”
Although metagovernance is often related to state actors, some scholars (e.g. O’Toole 2007; 
Klijn and Edelenbos 2007) underscore how metagovernance should not be strictly associated 
to public authorities as other societal actors also could fulfil this role by setting rules of a 
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game producing specific outputs and outcomes. Whilst O’Toole (2007:223) does not relate 
metagovernance exclusively to state actors, he does underscore that governments “have a 
major point of leverage that can shape what happens via networks: public policy”. Influence 
of governments or international institutions on networks can take place through informal 
instruments that can affect coordination of positions of network actors. They can also play 
a role in information diffusion in the network regarding e.g. motives and commitments of 
network members or partners. These moves are not always transparent but can play an 
important role in the functioning and output of the network.
In case of discordance within a network regarding policy options, governments and 
international institutions can build connections between actors which did not necessarily 
exists before or can act as a broker in the achievement of policy objectives set by the policy 
network (O’Toole 2007; Huppé, Cneech and Knoblauch 2012:21). New options can evolve, 
or others can become acceptable. In this sense, governmental action can direct the choices 
of governance networks. Finally, through monitoring and enforcement mechanisms, gov-
ernmental authorities or international institutions can influence commitment which have 
been collectively recognised as in the interest of the network. Hence, metagovernance “can 
be important in inducing the production of network outputs and outcomes desired by a 
government” (O’Toole 2007:226).
When preferences of a governance network are aligned with the agenda of the govern-
ment or international institutions, action of public authorities can help shape network 
results appropriately. Instruments used can be persuasion and incentives. Authorities can in 
these cases also persuade network participants “of the value to them of long-term stable 
cooperation rather than short-term, narrowly self-interested calculus” (O’Toole 2007:227). 
These persuasive efforts will be accompanied by notions such as trust, reciprocity, commit-
ment and good faith, which play a role in sifting participants’ perceptions and choices and 
favour the development of stable and durable network solutions. Therefore, the role of 
public authorities in promoting these norms in a network should not, according to O’Toole, 
be underestimated (O’Toole 2007:227).
The research on metagovernance is still relatively young and not many definitions of it have 
been given to date. Sorenson and Torfing (2007) define metagovernance as “a reflexive, 
higher order governance involving 1) the production and dissemination of hegemonic norms 
and ideas about how to govern and be governed; 2) political normative and context-depen-
dent choices among different mechanisms of governance or among different combinations 
of governance in order to prevent dysfunctions and advance particular goals”. They also 
point to the fact that in case of network failure, often some kind of metagovernance will be 
used to resolve the problem (Sorenson and Torfing 2007a:110).
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If some form of public authority steering can be observed in many cases of governance net-
works, Triantafilou (2007:195) warns not to exaggerate “the ability of meta-governance to 
control the outcomes of political processes of networks”. In his understanding, the concept 
of metagovernance should not be reduced to a unitary governor standing above network 
governance, as network governance cannot be reduced to the intentions or will of that 
governor. Whilst no uniform definition about metagovernance exists, the various contri-
butions in the literature do highlight the complex relationship between metagovernance 
and networks where state authorities and networks need to adjust to each other and can 
mutually influence each other.
As outlined above, metagovernance can be considered beyond the conception of state or 
other public authorities. In our research on HTA cooperation, we will consider metagover-
nance only from the perspective of governmental authorities, by encompassing herein the 
European institutional level as this may broaden the analytical perspective of EU support-
lending and coordinating policies in the case of European HTA cooperation. We have 
highlighted how metagovernance can be exercised through soft governance means (e.g. 
persuasion, discourse, diffusion of norms and ideas). Incorporating metagovernance in our 
research framework permits to add a dimension in our network analysis aiming to assess the 
effectiveness of soft governance in HTA cooperation and explore the role of the EU institu-
tions herein. Having explained the concepts of governance networks and metagovernance, 
the following section will focus on network governance and how this can be operationalised 
to examine HTA cooperation networks in Europe.
3.3. Network goverNaNce
The concept of governance networks should be distinguished from the closely related con-
cept of network governance. The latter refers to “the set of conscious steering attempts or 
strategies of actors within governance networks aimed at influencing interaction processes 
and/or the characteristics of these networks” (Klijn and Koppenjan 2016:11). This defini-
tion is characterised by a holistic view of network governance and touches upon both the 
typology of the networks and the effectiveness of the networks in defining and reaching 
a specific goal with given actors. In the section on governance networks, we have seen 
how typology is indeed interrelated with network governance as the latter can influence the 
characteristics of a network during its development process. As such, typology can have an 
influence on the effectiveness of a network in reaching set objectives. However, as outlined 
above, for analytical purposes we will address the typology of networks under the concept of 
governance networks, recognising however the interrelationship of ‘typology’ of governance 
networks and network governance.
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Focusing on network governance points to a network level analysis and relates to the 
strategic objectives of the network. Network governance is often linked to network manage-
ment which can be defined as “the deliberate strategies aimed a facilitating and guiding 
the interaction and/or changing the features of the network with the intent to further the 
collaboration within the network process” (Klijn and Koppenjan 2016:11). Networks are 
established with a certain purpose, in the case of governance networks, this purpose is often 
related to a public policy. For a comprehensive approach of network governance, the analysis 
requires to go beyond decision-making structures and processes and englobe the operational 
aspects of a governance network as well as external factors potentially affecting the network 
in its effectiveness to reach the objectives set.
As the term ‘effectiveness’ may refer to various conceptualisations, we will frame the notion 
of effectiveness of network governance as we understand it in the present research, before 
developing the research framework in section 3.4.
3.3.1. Defining the notion of effectiveness
We have outlined above how governance networks can distinguish themselves, in terms of 
governance, from more hierarchical or market based steering principles. A common aspect 
among governance networks is the use of soft governance modes to reach their goals. As 
aforementioned, New Modes of Governance offer to the EU institutions a means to develop 
or implement specific policy processes through governance networks. Hence, besides analys-
ing the development and the composition of networks, it is important for our research to 
examine what affects the effectiveness of governance networks operating by means of soft 
governance.
To identify factors that have the potential to affect the effectiveness of a governance net-
work, requires first to delimitate the notion of effectiveness as besides the relatively few 
studies made in this regard, various interpretations can be found. As such, one strand in the 
literature, considers that effectiveness should be examined by focusing on internal processes, 
as negotiation between public and private actors forms the basis of a network’s operations 
aiming to formulate and implement policy options. As such, some scholars consider effec-
tiveness in the light of a network’s capacity to adapt to changes based on learning processes 
(e.g. integration theory) (Sorenson and Torfing 2007a). Exploring the internal processes of 
negotiation and interaction between network actors, brings to the fore the importance 
of elements such as social capital, trust, single or double-loop learning, shared values and 
understanding and exchange of knowledge for an effective functioning of the network (e.g. 
Peters 2007; Provan and Kenis 2008; Huppé, Cheech and Knoblauch 2012). Effectiveness 
can also be assessed by examining elements of network failure. In this perspective, Rhodes 
and Bevir (2007) identify the degree of closeness/openness in terms of network participation 
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as well as conflict-resolution or private or public interest serving as elements influencing the 
effectiveness of (social) processes taking place in governance networks.
Effectiveness in governance networks does not respond to a uniform definition and can be 
regarded in various ways depending on the perspective one takes. It is important to highlight 
here that, as underscored by Jessop (2002:236), effectiveness of governance networks can-
not be defined and measured as the effectiveness of the governance of state and markets. 
Moreover, in the literature on networks, the issue of effectiveness is being examined mainly 
through three different angles. These distinguish themselves by the fact that they consider 
effectiveness by focusing either on aspects of process, output or outcome (or a combination 
of two or three aspects).
We have seen above that one of the reasons brought forward to explain the emergence of 
governance networks relates to the presumption that by combining resources and knowl-
edge, governance networks may be more effective in achieving desired results. Within this 
perspective, effectiveness is often considered in the light of outputs. The latter differ from 
so-called outcomes in the sense that they can be measured as concrete, desired and targeted 
‘products’ of the collaboration efforts. Measurement will here be done by comparing the 
results of the collaboration to the original goals set or needs expressed. Hence, effectiveness 
in this perspective is understood in terms of goal attainment or demand satisfaction (Börzel 
and Panke 2007). Considering networks as a mean for service delivery is another example 
of a viewpoint that will give significant attention to outputs in its assessment of network 
effectiveness, even though the process aspects will not be ignored (e.g. Milward and Provan 
2000; Agranoff and Mc Guire 2003).
It is important to highlight here that the notions of output and outcome are sometimes 
used interchangeably in the literature on effectiveness of networks. In our understanding we 
make a distinction between the two notions. Outcomes referring to the (un)desired effects 
of the cooperation efforts which explains why they are indeed closely related to process 
and output. An outcome can for example be a new political or social situation evolving as a 
result of a specific policy implementation by a governance network. The nature of outcomes 
can thus be very diverse. Some theoretical schools will for example consider as outcome a 
network’s problem-solving capacity (e.g. governability theory) or its horizontal coordination 
capacity (across institutions, levels and actors) (Sorenson and Torfing 2007a).
In their efforts to assess effectiveness in terms of output or outcome, many scholars focus on 
the management or governance aspects of networks. Factors favouring effectiveness in this 
sense will be, for example, management competences, governance procedures and resource 
availability (e.g. Klijn, Steijn and Edelenbos 2010). The specific skills needed to manage or 
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steer a governance network will differ from those needed in a private (business) or public 
(administration) environment because of the specific structure and actor composition of the 
network (Klijn 2008: 519). Several researchers have found “strong correlations between 
network management and good outcomes” (e.g. Meier and O’Toole (2001, 2007) Agranoff 
and Mc Guire 2003; Edelenbos and Klijn 2006, cited in Klijn 2008:519).
Evaluating effectiveness can thus be done by exploring processes, outputs and outcomes of a 
governance network. Each of these aspects can be considered in isolation as different factors 
may impact them separately. However, although distinct, they are also interrelated since 
they are elements of the same dynamics of goal pursuit inherent to a governance network. 
The processes may have an impact on the outputs produced and both the processes and 
the outputs may influence the outcomes of a cooperation process. Process and output are 
aspects that lay within the organisational structure and can be influenced by the interaction 
of network actors and network governance and management processes. Being a conse-
quence of the former two aspects, the outcome lays outside the network’s organisational 
and governance scope and cannot necessarily directly be influenced by the network actors 
and the network organisational and governance processes.
As discussed in the section above, a governance network is setup for a specific purpose. This 
purpose – the network’s raison d’être - will define its overarching goal(s). Particular means 
will be developed permitting the network to attain this/these goal(s). The network’s goal 
attainment can be analysed in terms of process, output and outcome. Each of the means 
developed and implemented to reach that overarching goal, can in itself be considered or 
defined as ‘sub-goals’. Hence, the sub-goals become a pre-requisite to attain the ultimate 
goal of the governance network. Moreover, attainment of one sub-goal permits the defini-
tion of the next goal necessary to reach the overarching network’s goal. These dynamics of 
goal pursuit, inherent to a governance network, could also be pictured as a ‘chain of goal 
attainment’. Every (sub)goal is a mean to attaining the next (sub) goal which in the end 
permits the network to reach its overarching goal(s).
Effectiveness of a governance network could thus be considered as the capacity of a network 
to reach its overarching goal(s)s which is being pursuit through a ‘chain of goal attainment’. 
Goal attainment is understood here as “the action or fact of achieving a goal towards which 
one has worked” (Oxford dictionary). In our understanding, goal attainment encompasses 
goal setting and goal achievement.
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3.3.2. Application of network governance effectiveness as ‘goal 
attainment’
The overarching research question of this thesis regards the extent to which soft governance 
has structured HTA cooperation within the framework of the European Union. To delimitate 
the scope of this question, we have formulated three sub-research questions. The first sub-
research question regards the possibility to reach convergence and harmonisation of HTA 
tools, methodologies and practices through soft governance principles. The second refers to 
the uptake of the common tools, methodologies and practices in national decision-making 
processes. The third regards the impact of soft governance in creating synergies between 
HTA cooperative bodies and European regulatory processes (i.e. market authorisation of 
pharmaceuticals).
What these sub-research questions have in common is that they all examine whether in 
European HTA cooperation efforts, a specific goal can be attained by soft governance modes. 
These goals are: SRQ 1) development of common tools, methodologies and practices; SRQ 2) 
uptake of these in national settings, SRQ 3) synergies between HTA and European regulatory 
processes. All of them bear thus an element of effectiveness which could be considered in 
the sense of goal attainment. In all three cases, these goals can be examined through the 
scope of process, output and outcome.
The first sub-research question regards the possibility to reach convergence and harmoni-
sation of HTA tools, methodologies and practices through soft governance principles. The 
output would refer to the realisation of common tools, methodologies and practices which 
can be measured (e.g. common guidelines, joint tools, joint assessments). Reaching conver-
gence or harmonisation through soft governance means, pre-supposes however that the 
collaboration process fulfilled criteria which permitted this to happen (e.g. agreement on 
common standards and approaches upon which the common tools and methodologies are 
based). Outcome would refer in this regard to the effects of the process and outputs on the 
broader environment (e.g. HTA arena, EU health policy, stakeholders’ policies).
The second sub-research question refers to the uptake of the common tools and practices in 
national decision-making processes. Exploring whether and how this has been done would 
require examining it from respectively the output and process point of view. Indeed, on 
the one hand, one can identify the number of national decisions having been made on the 
basis of common tools, methodologies and joint work developed in a European network 
constellation (outputs). On the other hand, using commonly developed tools in a national 
HTA report or using joint assessments as input for national/local decision-making on pricing 
and reimbursement will result of processes in which elements of trust, learning, adaptation 
etc. may play an important role. However, besides process and output, this question also 
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entails an outcome element of effectiveness as these new tools, methodologies and practices 
may impact national decision-making processes.
Similarly, the effectiveness of HTA cooperation in creating synergies between HTA and 
European regulatory process on market authorisation of pharmaceuticals can be examined 
in terms process, output and outcome. Process refers here to the development of com-
mon cognitive frameworks and understandings regarding the desirability and possibility of 
synergies between both arenas. Output refers in this regard to the establishment of com-
mon procedures between HTA and European market authorisation processes accessible to 
pharmaceutical companies (e.g. single-entry point for requests, jointly developed evaluation 
procedures and forms). Outcome points to the consequences of these outputs on the broader 
evaluation processes of health technologies and their impact on market authorisation, pric-
ing and reimbursement.
In the next section we outline the research framework which will be based on several factors 
related to soft governance and playing a role in the typology and in effectiveness of gover-
nance networks. This research framework will be used in Part C for a systematic analysis of 
HTA cooperation in Europe which has taken place essentially through networking.
3.4. the reSearch Framework
To answer the thesis research question aiming to understand to what extent soft governance 
has structured HTA cooperation in Europe, a research framework will be developed in this 
section which will be based on the central concepts outlined in the previous sections: gov-
ernance networks, metagovernance and network governance. This framework will allow 
us to examine the role of soft governance in European HTA cooperation processes through 
the prism of network analysis. As outlined in chapter one and two, HTA cooperation has 
been developed by having recourse to networks. Networks are considered here as a medium 
through which various soft governance instruments can be implemented. Networking also 
connects with the so-called New Modes of Governance, implemented by the EU in sensitive 
areas such as health care where competences are shared or held exclusively by the Member 
States.
Applying the central concepts of ‘governance networks’ and ‘metagovernance’ and ‘network 
governance’ to HTA cooperation, requires to examine the various networks developed since 
the early cooperation initiatives and to determine 1) whether these could be considered as 
governance networks; 2) whether metagovernance has taken place in the case of European 
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HTA cooperation and 3) whether the recourse to soft governance instruments in their net-
work governance approach has contributed in reaching the goals set.
In the sections above we have outlined how, based on the examination of the literature, gen-
eral network characteristics have been identified permitting to examine whether a network 
could be qualified as a governance network. Moreover, besides general governance network 
characteristics, each network can also be examined by focusing on – what we have called - 
its ‘typology’, referring to a network’s specific characteristics (e.g. reasons for establishment, 
membership, governance modes). The network typology is not fixed and chances occurring 
in its typology can result from a network’s governance approach. In this sense, a governance 
network typology is interrelated with its network governance practices. Section 3.4.1. will 
examine factors identified in the literature, related to soft governance, and having a potential 
impact on the typology of a governance network. It will then explore whether these could be 
integrated in the research framework.
Network governance refers to steering attempts and strategies of network actors to influence 
processes and/or network characteristics (Klijn and Koppenjan 2016:11). As such, it is related 
to the strategic objectives of the network and the operational processes to reach those 
objectives. Network governance can be affected by the manner in which members interact, 
the instruments used to implement decisions as well as factors laying outside the network’s 
governance scope. Section 3.4.2. will examine factors identified in the literature, related 
to soft governance, and having a potential impact on the effectiveness of a governance 
network. It will then explore whether these could be integrated in the research framework.
Based on this examination, a research framework can be designed comprising the central 
concepts as well as factors potentially impacting them. The various components of the re-
search framework allow for a detailed examination of European HTA cooperation networks 
from the perspective of ‘governance networks’, and ‘network governance’ which both 
can directly or indirectly related to ‘metagovernance’. This framework should structure the 
examination of the effectiveness of soft governance in European HTA cooperation processes 
through the prism of network analysis.
3.4.1. Factors affecting the typology of governance networks
We have established in section 3.1.1., a list resuming the general characteristics of so-called 
governance networks. However, each governance network itself corresponds to a specific 
set of features that further characterises it. No comprehensive account exists in the literature 
encompassing all elements that could characterise governance networks. Depending on the 
academic perspective, different elements will be brought to the fore. In the following section, 
we will examine features that determine specific attributes of a governance network. We will 
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base our examination on different strands of the literature on governance networks rooted 
in either political science, organisational studies or public policy studies. We have structured 
this analysis according to the following aspects: network formation, network composition 
(membership), network resources and network governance. The aim is to determine whether 
these aspects could be integrated in our research framework as elements permitting to 
examine HTA cooperation networks in the light of governance networks operating via soft 
governance means.
3.4.1.1. Governance network formation
One of the factors having a potential impact on the typology of a network can be found in 
the manner and reasons of its establishment. In the sections above on governance networks 
in national and European policy-making processes, we have outlined several explanatory ac-
counts regarding governance network formation. Many of those were rooted in a functional 
or historical perspective. They referred to state and public-sector reforms and changes in the 
society leading to increasingly complex policy issues and policy processes. These accounts 
related to the emergence of governance networks in general and how these were connected 
to policy-making processes. In this section we will explore in more depth the factors that 
explain the creation of specific governance networks which requires to analyse this issue 
from a different angle.
Hertting (2007:44) for example, examines governance networks from the point of view of ‘goal 
attainment’ and ‘meaning’. He underscores how networks can result from an endogenous 
development process within a group of actors without the intervention of ‘meta-governors’. 
In these cases, the actors’ motivation to participate in the establishment and development 
of a network can be explained by the conviction that “such institutional arrangements will 
help them accomplish some kind of goal or meaning”. Based on this viewpoint, governance 
networks can, according to Hertting, be examined by focusing on contextual incentives 
for network formation, strategic calculations and choices of single interdependent policy 
actors and the interactions and games that could be expected to support or constrain the 
formation and institutionalisation of governance networks. This classification can indeed be 
a useful tool to get a better insight in factors favouring governance network formation and 
institutionalisation.
Contextual incentives can be diverse and whilst Hertting (2007: 47) develops mainly inter-
dependencies in terms of resources and strategic externalities, other researchers point in 
this regard to issues such as the difficulty to deal with ‘wicked problems’ or the need to 
address highly complex policy issues in interdependent policy fields with multi-level actor 
interactions (e.g. Klijn and Koppenjan 2016:12). Incentives to establish or participate in gov-
ernance networks can also be related to factors such as access to information, knowledge 
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and professional expertise (Rhodes and Bevir 2007). Finally, facilitating service delivery or 
policy implementation can also be cited as incentives for governance networks to evolve 
(Klijn and Koppenjan 2016:23).
Strategic calculations and choices of autonomous actors depend on their perceptions of 
problems, strategies and solutions which can vary among the actors of a network. Network 
formation can be considered as an institutional design (Tsebelis 1990 in Hertting 2007:50) 
and permit actors to secure action capabilities and compensate for limited rationality and 
potential opportunistic behaviour. So, establishing governance networks may be a strategy 
for efficient negotiations. However, the informal character of networks where cooperation 
is mostly based on trust also offers a ‘cheap exit strategy’ (Hertting 2007:50). Hence, high 
interdependencies between actors in a same policy area can also cause strategic complexity 
in predicting the course of (inter)actions of actors (Klijn and Koppenjan 2016: 11).
As underscored by Hertting (2007:51), “a governance network is never formed, established 
or institutionalised once and for all”. Participation and ‘use’ of the network needs to be 
continuous for the network to survive. Indeed, the latter will testify of the actors’ recognition 
and identification with it. However, participation can take the form of strategic games such 
as the free rider problem26, the assurance problem27 and the generosity problem28 (Hertting 
2007). Applied to governance networks, these problems often relate to a matter of trust or 
insecurity (lack of assurance) of what the other actors will do. A network may be formed by 
interdependent actors who, although independent cannot always function autonomously. 
Exchange may be necessary to achieve their goals (Hertting 2007: 50). Support or constrain 
to a network will thus depend on how actors value the informal relations and coordination 
based on trust. Balancing between the need for more cooperation and the desire to maintain 
sovereignty will be central (Hertting 2007:55; see also Rhodes and Bevir 2007:7). Network 
formation is easier when actors share a mutual understanding and the perception of the 
policy problem (Hertting 2007: 49; Zafonte and Sabatier 1998).
Governance networks often represent several individual organisations investing in the net-
work formation. The organisations’ representatives will not only have to take into account 
26 The free ride problem refers to a situation where all actors would gain from the cooperation, but 
a single actor would gain more if everybody, but he/she, would cooperate (Hertting 2007:52).
27 The assurance problem refers to a situation where mutual cooperation is the equilibrium. If one 
actor decides not to cooperate, it is rational for the others not to either (Hertting 2007:54)
28 The generosity problem refers to a situation where two parties have a common interest in coor-
dinating so that they will reach an outcome that is superior to the one if they do not cooperate. 
In order to reach a stable cooperation, Actor A has to allow actor B to reach B’s most preferred 
outcome while A accepts a less preferred one” (Hertting 2007:55). Hence generosity is needed.
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the horizontal relationships with other network actors but also vertical connections within the 
organisation they are representing in the network. This can lead to two-fold loyalties: within 
its ‘own’ organisation and within the network. On the one hand, commitment towards the 
network agreements needs to be demonstrated. On the other hand, the agreements made 
in the network also need to be accepted or approved within their own organisation, which 
interests need to be respected in the network. Strong ties within network actors may lead to 
suspicion on the vertical level and negatively affect the role and trustworthiness of the actors 
on the horizontal level (Hertting 2007: 57). Support or constrain to a governance network 
can also be influenced by these aspects.
As network formation can have an impact on the typology of a governance network we 
will integrate this factor in our research framework by relating to this factor the following 
features to be examined in a network formation: incentives, strategic calculations, support 
and constrain.
3.4.1.2. Membership of governance networks
Another factor we have identified in the literature having a potential impact on the typology 
of a network is its composition. Governance networks are composed of different type of 
social actors that pursue certain goals and take up certain roles in the network. Network 
actors can represent the public, private or non-profit sector. Their social background will 
impact on their goal and role in the governance network. Often actors are attuned toward a 
certain level of geographical scale: local, regional national or international. (Koliba 2011: 67). 
As such, actors can be organisations or institutions, committees, departments or individuals. 
Depending on the networks, particular institutions can dominate, whereas in others, the role 
of institutions will not impact the collaboration efforts.
Moreover, as already touched upon above, examining the relationship between the individual 
and the institution or organisation it represents, is important to understand governance 
network dynamics. Network actors may or may not represent the interest of the organisation 
or actors it represents. An individual may thus participate in a governance network without 
necessarily represent the views or interest of the group to which it belongs (Koliba 2011:82). 
Hence when analysing governance networks, it is important to determine whether one looks 
at the whole network as unit analysis (e.g. O’Toole 1990; Rhodes 1997; Agranoff 2007) or 
if one takes also into account individual membership together with the whole network (e.g. 
Agranoff and Mc Guire 2003, Koppenjan and Klijn 2004).
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Governance networks can be open or closed in both a social and cognitive29 understanding 
(Schaap 2007:118). Social closure refers to the degree of acceptance of (new) members 
either within separate units of the network or towards the external environment. In a socially 
open network, membership can relatively easily be extended to new members or the replace-
ment of old members. Social closeness will be more often observed in self-steered networks 
(Schaap 2007: 131). March and Rhodes (1992) argue that self-interest of actors may cause 
closure of a network. In a socially closed network, members do often share the same set of 
basic values. Closeness does not however imply that changes cannot takes place as these 
can be incremental and based on learning processes or result from external stimuli (Schaap 
2007).
Another distinction in composition can be made based on the concept of ‘homogeneity’ or 
‘heterogeneity’ of a network structure. A homogeneous structure refers to a membership 
composition sharing similarities in terms of (e.g. social, professional) actors’ profiles and 
backgrounds. Conversely to a homogeneous actor composition, a heterogeneous actor struc-
ture refers to a set of interdependent actors presenting a variety of social and professional 
backgrounds. Often, in case of a heterogeneous network, the actors will represent various 
stakeholders concerned by the network’s activities and goals (Sandström and Carlsson 2008).
The degree of openness or closure of a network can be related to its degree of homogeneity 
or heterogeneity. Indeed, a network can extend membership to different (new) stakeholders 
or experts. Some researchers posit that a degree of heterogeneity in the network member-
ship is not only inevitable as a network overtime needs to replace members, but also a 
necessity for it to develop, reach its goals and innovate (Peters 2007:72; Sandström and 
Carlsson 2008:517). Both the openness/closure of a network as well as a network’s homoge-
neity/heterogeneity degree bear the potential to affect the interaction between the network 
partners and the internal negotiation processes (Rhodes and March 1992; Schaap 2007; 
Sandström and Carlsson 2008; Huppé, Cheech and Knoblauch 2012).
The second factor identified as potentially impacting the typology of a governance is mem-
bership and will as such be integrated in our research framework, associating to this factors 
the following features: public, private or non-profit membership, relation home-organisation/
network, degree of openness/closure, degree of homogeneity/heterogeneity.
29 Cognitive closure can be interpreted in two ways. It can been interpreted as an inability to perceive 
(actors have no access to an ‘outside reality’ and continue to operate within their own frame of 
references) or un unwillingness to perceive (conscious strategy not to take into account certain 
approaches). Social and cognitive closure interfere with one another (Schaap 2007:119).
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3.4.1.3. Resources of governance networks
Another factor which can impact the typology of governance network is the type and 
amount of resources available to the network. Resources vary in their forms available and 
often also create interdependencies between network actors who can either provide re-
sources or seek for resources in a network. Koliba (2011:87) identified different types of 
resource interdependency: financial, natural (e.g.land), physical (e.g. office space, property), 
human (knowledge and skills, expertise) or social (e.g. social ties, common norms). Moreover, 
resource distribution can also be unequal in a network (Börzel and Panke 2007:155).
Financial resources can take various forms such as public-private partnerships, subsidies or 
grants allocated to the network. These financial resources can be provided by private or 
public sources. Resources can however also take other forms such as in-kind contributions by 
organisations offering administrative services, office space or detaching part of the working 
time of employees to the network.
The participation of experts offering a certain level of knowledge, skills and expertise also can 
be considered as valuable resources for a governance network. Similarly, the establishment 
of new partnerships and the creating of new social ties are considered as network resources 
(Koliba 2011). But resources can also be of a different nature: political, cultural. As such, 
political support and the development of shared social norms could also be counted in as 
important resources for a governance network.
Resources will thus be included in our research framework as third factor potentially impact-
ing the typology of a governance network. It will be considered in relation to the following 
attributes: financial resources, natural/physical resources, social/political resources and hu-
man resources.
3.4.1.4. Governance modes of governance networks
Various forms of governance structures exist across governance networks and as such affect 
the typology of networks. Although different, these governance approaches all share some 
common features. The first is that all governance modes of these networks are based on 
non-hierarchical coordination (Börzel and Panke 2007:155). Whereas hierarchies are based 
on relationships of domination (public actors) and subordination (private actors), relationship 
between actors in governance networks are based on the fact that they share an equal 
status. This, however, does not mean that all actors are equal in terms of authority and 
relationship (Scharpf 1994, Sorenson and Torfing 2007).
Hierarchical coordination is characterised by authorative decision-making where decisions 
can be imposed upon actors (e.g. through administrative orders or judiciary rulings). Non-
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hierarchical coordination - which characterises governance networks - can take place either 
through positive/negative incentives or negotiated compromises. Another mean of coordina-
tion is via learning processes and persuasion. These permit actors to gradually adapt their 
position and integrate new norms and rules which will have an impact on their preferences 
((Börzel and Panke 2007:156).
Steering mechanism in governance networks are quite diverse and differ in the degree of 
autonomy and power distribution. Provan and Kenis (2007) distinguish three main types of 
governance networks. The first type refers to networks with no formal administrative entity 
where all actors participate in the decision-making process. Governance here is characterised 
by decentralised collective self-governance. It can be formal through regular meetings of 
designated organisational representatives or informal through uncoordinated efforts. Net-
work members interact on a more or less equal basis regarding governance. These networks 
depend exclusively on the participation and commitment of all. Hence, network participants 
are responsible for the internal management as well as the implementation of activities and 
the development of external relationships. Provan and Kenis (2007:234) refer to this model 
as a Participant-Governed Network. This type of governance can however be associated to 
inefficiencies. Networks can therefore opt for a more centralised approach of governance.
Governance networks adopting governance modes based on centralisation often function 
on the basis of asymmetric power distribution. In these cases, it is common that one organi-
sation takes the lead. This is often an organisation having sufficient resources and legitimacy 
to play this role. It also provides for administrative support and facilitates the implementation 
of the activities (Provan and Kenis 2008: 235). Hence, this so-called ‘Lead-Organisation’ plays 
a role of project coordinator. Funding is often also regulated by the coordinator through, for 
example, collecting the financial contributions from network members or by applying for 
grants and subsidies. Cost of network administration can be entirely bore by this entity as 
well. Members may design a project coordinator, or the Lead-Organisation may be mandated 
by an external actor (e.g. funding source) (Provan and Kenis 2008: 236). This type of gover-
nance is also called Lead-Organisation Governance (Provan and Kenis 2008:235)
Finally, a governance network may be governed by a separate administrative entity specifi-
cally setup for this purpose. Governance in this case is also centralised and the new entity 
plays a major role in coordinating and sustaining the network. An important distinction 
with the previous model is that the administrative entity is not a member of the network 
but acts as a network broker and its exclusive reason of existence is the coordination of the 
network. The entity may be established by the network members themselves or it has been 
mandated by an external actor. It can be a governmental entity or a non-profit organisation. 
The scale of the entity can vary from a single person network facilitator to a full-fledged 
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organisation comprising for example an executive director, staff, and a governance board. 
In these cases, strategic questions are being dealt with by the board, leaving the operational 
issues to another level. Provan and Kenis (2007: 236) refer to this model as the Network 
Administrative Organisation.
The models above vary thus in the degree of self-steering or active steering (see also Schout 
and Jordan 2003). We have seen above that decision-making processes can be organised 
in different ways according to the governance model adopted. However, these decisions 
are always taken collectively. Whether they are binding is being decided in each network 
separately. No uniform governance approach exists in this regard. Hence, governance modes 
will be integrated in our research framework as the fourth and last factor having a potential 
impact on a network’s typology.
In the next section we will examine network governance from the perspective of effective-
ness. Based on the examination of the literature, we will seek to identify factors, related to 
soft governance, that potentially can have an impact on a network’s effectiveness in terms of 
goal attainment as outlined in section 3.3.2.
3.4.2. Factors affecting effectiveness of network governance
3.4.2.1. Social interaction
Network governance involves, as we have seen above, coordination between interdependent 
but autonomous actors who are gathered in a self-regulated network to achieve a certain 
goal of public interest. As underscored in the definition of Sorenson and Torfing (2007:9) 
outlined above, interaction among these actors takes place though negotiations within a 
regulative, normative, cognitive and imaginary framework. This framework in which delib-
eration takes place, facilitates learning and common understandings (Sorenson and Torfing 
2007:10) which are necessary to establish common values and norms upon which a common 
approach and policy instruments can be developed.
Many scholars underscore the importance of a certain number of concepts which need to be 
present in the interaction and deliberation processes taking place in networks to favour their 
effectiveness. As such we can mention trust, (social) learning processes, mutual understand-
ing, shared values and beliefs and (goal) consensus (e.g. Dedeurwaerdere 2005; Provan and 
Kenis 2008; Klijn, Steijn and Edelenbos 2010). Hence, the social, cultural and professional 
background of the network actors may impact the development of certain network processes. 
These analyses show some similarities with notions present in the literature about epistemic 
communities and the advocacy coalition framework (see further on epistemic communities 
e.g. Haas 1990 and on advocacy coalition framework e.g. Sabatier and Weible 2007).
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To develop our research framework, we will draw on the work of Huppé Cneech and 
Knoblauch (2012:4) who suggest that effectiveness of a network can be analysed through 
social capital, network heterogeneity and collaborative visioning processes. Their research 
encompasses many of the concepts discussed above and which have been identified in the 
literature as playing a role in the effectiveness of networks. Social capital refers here to 
the presence of trust, shared values and understanding, permitting actors to work towards 
common goals. Network heterogeneity and collaborative visioning are important aspects in 
the collaboration between network members and impact social capital.
In examining social capital, Huppé, Cneech and Knoblauch (2012) point to an ‘efficacy 
paradox’ (Voss et al. 2006) which evolves from the necessity to open up a network so as 
to address complex problems with distributed capacity and knowledge. Enhancing capacity 
to solve a problem by including more actors from different backgrounds in the network, 
may actually render the problem-solving more complex as the actors will have different 
interests and views making it more difficult to reach common agreements (Huppé Cneech 
and Knoblauch 2012:6). However, learning processes may help to overcome diversities in 
views, motivations and interests and move towards what the researchers call ‘collaborative 
visioning’ where network actors align their individual strategies to the shared visions and 
network goals.
Hence, collaborative visioning can be achieved through second-order (or double loop) learn-
ing processes. The latter refer to an evolutionary process where problem solving concepts are 
empirically tested. The experience will again feed into the theoretical framework. The aim is 
here to create shared visions which will also add to the members’ sense of commitment to 
the network goals. Collaborative visioning will positively impact social capital. Social capital 
will affect the effectiveness of a network. The higher the social capital in a network, the more 
a network will be able to reach its governance goals (goal attainment) (Huppé, Cneech and 
Knoblauch 2012).
In our analysis to assess the effectiveness of a governance network in terms of goal attain-
ment, some key aspects of the work on social capital of Huppé, Cneech and Knoblauch 
(2012) will integrated as described below. However, as the term ‘social capital’ refers to 
a wider academic agenda including aspects which will not be integrated in our research 
framework, we will refer in our research to term of ‘social interaction’ rather than social 
capital. The degree of social interaction depends on the presence of specific elements that 
can be sorted in two types of categories. The first refers to cognitive/behaviour aspects and 
the second to governance/management aspects. Both categories are interrelated but for 
analytical purposes we will examine them separately by focusing in this section on the first 
category. The second category will be addressed in the next sections.
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Hence, social interaction within a governance network will be partly affected by cognitive 
and ‘behaviour’ aspects of interaction processes between actors (either within the network 
or between network actors and other public or private actors). Four main elements playing 
a role in developing social interaction can be identified: trust, shared values and understand-
ing, learning processes and goal consensus.
Trust is explained by Provan and Kenis (2008:238) as “an aspect of relationship that reflects 
‘the willingness to accept vulnerability based on positive expectations about each other’s’ 
intentions or behaviours’ (Mc Elvily, Perrone and Zaheer 2003:92)”. Understanding the 
importance of trust in network-based interactions requires according to Provan and Kenis 
(2008:238) to focus on the distribution of trust and on the level of reciprocity. A high density 
of trust can be observed in networks were trust is widely spread among network members. 
Conversely, low density of trust reflects that trust is predominantly present within individual 
network dyads or cliques.
Based on this understanding, trust will be more important in the first type of networks 
(Participant-Governed Networks) discussed in section 3.4.1.4. and characterised by shared 
governance, since it will constitute an important basis for cooperation. Collective goals can 
still be accomplished even in case of low trust density. However, in these situations, the 
network governance will most likely take the form of a Lead organisation governance (type 
2) or Network Administrative Organisation (Type 3) (see section 3.4.1.4.). Research of Klijn, 
Edelenbos, Stejin (2010) confirms the importance of trust in achieving better (perceived) out-
comes of governance network (both process and content outcomes). Moreover, their work 
indicates that trust is manageable and can be developed and sustained through network 
specific management strategies. Similarly, Nielsen and Pedersen (1988) point to the role of 
trust in generating compliance with collectively negotiated decisions.
Shared values and understanding are important to develop common languages and allow 
for a better framing (e.g. Peters 2007). The notion of framing is used to describe a process 
for developing common conception of policy issues among a set of actors. Reframing refers 
to changing cognitive maps in a policy which can help resolving policy problems (Schön and 
Rein 1995 in Peters 2007:67; Bevir and Rhodes 2007). Hence the understanding of a policy 
problem in this perspective is not fixed but can evolve. One of the means to develop common 
languages and understandings and (re)frame issues are learning processes.
Learning processes (social and organisational) permit actors to reconsider their context and 
normative beliefs by considering those of others. As we have seen above, learning in an or-
ganisation can take place as a ‘trial and error process’ leading to incremental organisational 
changes (Haas 1990). Actors process quantitative or qualitative information, interpret it and 
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seek to offer a response. This type of learning is also referred to as single-loop learning 
(Argyris and Schön 1978, 1996). Double-loop learning adds an additional dimension as it 
questions the governing practices themselves and integrates the observations in the organi-
sational structure allowing even for radical changes in strategy, structure, objectives etc.
Linking these conceptions to learning in governance networks constituted of expert groups, 
brings us to role of ‘social learning’ which is more concerned with the development of 
(shared) normative beliefs and values. Dedeurwaerdere (2005), underscores the importance 
of social learning in governance networks which respond to many of the characteristics of 
“epistemic communities” as described by Haas and Haas (2002). According to Dedeurwaer-
dere (2005:8), single loop learning will mostly occur in self-regulated networks concerned to 
maintain the stability of the organisation. Basing his observations on the work of Ernst Haas 
(1990), he furthermore underscores how double-loop learning permits a network to build-in 
monitoring and evaluation processes aimed at changing the basic beliefs and fundamental 
principles of the organisation and can redefine its organisational mission if confronted with 
unexpected or ineffective outcomes of its activities.
Goal consensus will partly depend on the development of mutual understandings and shared 
values. Reaching consensus in a network will furthermore also be in function of mutual 
dependence of the network members as well as of the connection of the network with 
other institutions and networks (Peters 2007:67-68). Establishing and developing external 
relationships to facilitate the achievement of goals could actually reduce the effectiveness of 
the network to set and/or achieve its goals as it may reduce internal cohesion (Peters 2007 
68). Hence the tendency to be broadly connected to other networks or institutions so as to 
be more effective into achieving the political goal can negatively affect internal consensus.
In this section we have seen how social interaction can affect the effectiveness of governance 
networks. Social interaction will therefore constitute the first factor in our research framework 
addressing the effectiveness of governance networks in terms of goal attainment and will 
be related to the following features: learning processes, shared values and understanding, 
trust, goal consensus.
3.4.2.2. Governance instruments
As aforementioned, social interaction is closely associated to governance and management 
aspects of a network. Several scholars have pointed how they mutually influence one an-
other. Huppé Cneech and Knoblauch (2012) underscore how the degree of social capital 
can be influenced by governance modes (centralisation), the nature of the actors composing 
the network (density), the strengths of the relationships among actors and leadership. The 
more these aspects will be developed in a network, the higher the social interaction and 
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thus the more effective a network will be. Others point to the impact of social interaction 
on the governance and management of governance networks. As such, it may support the 
development of collaborative governance processes in terms of strengthening governance 
capacity (Adger 2003) improving innovative capacity (Moran 2005), establishing constructive 
processes of communication, social integration and coordination (Evans and Carson 2005), 
or even information processing (Tompkins and Ager 2004, in Huppé, Cneech and Knoblauch 
2012:18).
However, governance and management aspects of a network do not only bear the potential 
of impacting the effectiveness of a governance network through its relationship with social 
interaction. Besides their connection with the latter, the governance and management of a 
network can be examined on a stand-alone basis with regard to their impact on network 
effectiveness. In this section we will focus on governance instruments and how these relates 
to effectiveness in terms of goal attainment in a governance network. In the literature, we 
have identified four aspects linked to governance instruments and governance network ef-
fectiveness: policy instruments, legislative and regulatory instruments, political instruments 
and financial instruments.
Instrument choice is an important element in the process of policy implementation and can 
as such be considered as being part of the governance approach to implement specific poli-
cies. The choice of policy instruments is not a neutral exercise and often also depends on the 
knowledge and resources available. The policy-mix that will be elaborated on the basis of 
policy-instruments aims at reaching the goals set or at resolving particular problems (Bressers 
1998 and Bressers and Klok 1988). Taxonomy of policy instruments is most commonly based 
on instruments used in public policy or state intervention. As such, they can be used to 
support the production of specific goods and services or at processes regulating interaction 
between state and society. They can however also be used within a policy network (Howlett 
2018: 82; Goldsmith and Eggers 2004; Klijn and Koppenjan 2000; 2006).
Howlett (2000) makes a distinction between ‘substantive’ policy instruments and ‘procedural’ 
policy instruments. Substantive policy instruments “are aimed at the delivery of certain goods 
and services to society” (Howlett 2018:80). Procedural policy instruments can affect imple-
mentation processes of a policy seeking to produce outputs. Howlett (2018:80) describes the 
latter as tools that “govern state-society relations and affect the support for and participation 
of actors in government initiatives”. Relationship between governments and networks can 
fall under procedural policy instruments. However, processes taking place within a network 
can also be examined from this perspective as policy-making is affected by the interaction 
of multiple actors (state, non-state and international), which can influence policy delibera-
tions and outcomes (Klijn and Teisman 1998 in Howlett 2018:80; see also Flanagan et al. 
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2011 ). The choice of policy instruments can affect behaviour, interactions and activities of 
policy actors “in developing and choosing policy solutions” (Thatcher and Rein, 2004 in 
Howlett 2018). As underscored by Howlett (2018: 82), “the impact of the deployment of 
such [procedural] tools to affect actor participation in policy networks can range from minor 
alteration of network actor behaviour to more deep-seated and overarching restructuring of 
entire policy subsystems”.
When examining the impact of network governance on the effectiveness in terms of goal 
attainment, other important factors come to the fore related to governance instruments 
and which are of a legal, political or financial nature. Indeed, the legal framework in which 
the network operates has important consequences for network effectiveness, in particular 
regarding matters of output. In some countries (e.g. Sweden, Denmark), specific framework 
laws have supported public services activities of local authorities or private actors. These laws 
have permitted, in some cases, the establishment of governance networks in combination 
with economic incentives and evaluations to steer the implementation of the work (Triantafil-
lou 2007: 191). The interdependencies created between state authorities and private actors 
seem to favour effectiveness of these networks. Case studies have shown that the networks 
created by public intervention did change the way a particular problem was addressed as 
different actors took part in the process leading to the production of new outputs (see 
further Triantafillou 2007).
However, similar conclusions can be drawn from governance networks that have developed 
as a result of other processes. Hence, the analysis of effectiveness of governance networks 
should not be reduced to a zero-sum power distribution but should focus on different meth-
ods and techniques of governing within a wide set of legally binding and non-legally binding 
instruments (Triantafillou 2007). This brings us to an important point regarding effectiveness 
of a governance network in terms of goal attainment. Legally binding decision-making can 
be considered ‘more effective’ in terms of goal attainment but this mode may not always 
be an option in national or EU policy-making for reasons outlined in chapter 2 (e.g. EU 
competence area, sensitive issues, absence of political or civic support).
New governing techniques based on self-steering governance modes “may actually enhance 
the capacity to pursue and implement social and political goals” (Triantafillou 2007:197). 
However, effectiveness of soft governance modes (especially in an EU setting) may actually 
be explained by the presence of a ‘shadow of hierarchy’ (Héritier and Lehmkuhl 2011:62). In 
these cases, the application of soft governance modes is usually combined “with some form 
of governmental prompting or pressure”. Hence, effectiveness of soft governance mode 
may be related to the presence of public authorities and the ‘threat’ of hierarchical decision-
making modes if no consensus is found or results achieved via soft governance modes.
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Political instruments available to the network can create interdependencies (networks/net-
works and state/network) affecting the way how policy issues are being handled. We have 
seen that governance networks are created against the background of a specific policy issue. 
With governments relying increasingly on governance networks to respond to specific policy 
questions, the importance of political instruments available will impact on the effectiveness 
of goal attainment. Of particular interest in this regard is ‘agenda alignment’ between the 
network and the government’s priorities which can impact network outcomes as govern-
ment can use different instruments (persuasion, support, constrain etc.) to structure the 
actions of a networks (O’Toole 2007:227).
However, many other instruments of this nature exist and can affect all stages of the policy 
cycle (e.g. policy formulation, implementation, evaluation). Hence, political instruments can 
be used as a form of support or constrain to the activities of a governance network (political 
support/constrain for new legislation, financial or administrative support/constrain). Taking 
into account the variety of instruments available it is important in our research to examine 
whether political instruments have been used to steer HTA cooperation efforts and how they 
have affected the governance of the networks and the effectiveness in reaching the goals 
set by those networks.
Similarly, financial instruments will also play a role in the governance of networks. Allocation 
of resources by public authorities can bring about interdependencies between the public 
authorities and governance networks, but also between partners within a governance net-
work. Presence of public funding for a particular public issue can support network formation 
and contribute to the production of specific outputs and outcomes. However, commitment 
to the network and network relationships may be fragile and disappear at completion of the 
project and termination of its financing (Triantafillou 2007: 192). Moreover, actors’ motiva-
tion to create a network may be explained by pecuniary concern rather than the pursuit of a 
(normative) goal (Sherlock et al. 2004, in Triantafillou 2007). Financial resources and financial 
sustainability of a network can also potentially affect effectiveness of a governance network 
in the sense of goal attainment. This research will thus seek to identify whether financial 
instruments have been used to steer HTA cooperation in Europe and if so, how this has had 
an impact on the effectiveness of the networks in terms of goal attainment.
In our research framework we will integrate governance instruments as second factor poten-
tially affecting effectiveness of a governance network. This will be related to the following 
features: policy instruments, legislative and regulatory instruments, political instruments and 
financial instruments.
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3.4.2.3. Management
Reaching common goals in terms of concrete measurable outputs in networks with interde-
pendent but autonomous actors remains a certain challenge as in most cases soft governance 
means have to be used. As participation is based on voluntarism and decision-making is often 
non-binding, no coercive management methods can be implemented. As such, goal attain-
ment will also depend on the management practices which can be more or less successful in 
reaching network goals. As underscored by Rhodes and Bevir (2007:85), no specific toolkit 
for managing networks exists. Scholars commonly point to the fact that network manage-
ment distinguishes itself by the fact that it is based on trust whereas bureaucracy is based 
on command and market regulation on price competition (Frances 1991:15, Powell 1991). 
Although many studies have pointed to the relationship between management practices and 
network effectiveness, no consensus exists on which practices are most appropriate in reach-
ing network goals. Consensus in the literature exists only on the fact that if the methods are 
effective, they will most likely be maintained. Conversely, if they do not lead to the desired 
results, they will be abandoned even if they have been accepted internally (Peters 2007:69, 
see also Covaleski and Dinsmith 1988).
Several scholars have studied management skills and techniques in the perspective of 
network output, outcomes and effectiveness. Although these studies have demonstrated a 
relationship between management skills and network effectiveness, many of these studies 
were context specific and their findings cannot necessarily be generalized over other policy 
fields (e.g. Klijn, Steijn and Edelenbos 2010). Moreover, discussing management techniques 
and practices can quickly lead to a normative discussion on the issue, which is not our aim 
here. As we believe that disregarding the effect of management of governance networks 
would be a flaw in our research, we have made the decision to integrate management as a 
third factor potentially affecting the effectiveness of governance networks in terms of goal 
attainment. Based on the literature, we have identified two aspects related to management 
and which are of importance regarding European HTA cooperation: management compe-
tences and management styles.
Management competences (especially regarding network managers) is aspect which is 
commonly highlighted when examining outcomes of governance networks (e.g. Sorensen 
2007, Agranoff and McGuire 2007 Edelenbos, Klijn and Steijn 2011). Those competences 
are compared to those of a mediator or facilitator as a manager has to initiate, facilitate 
and guide interaction processes among actors in the network (Friend, Power, and Yewlett 
1974; Gage and Mandell 1990, in Edelenbos, Klijn and Steijn 2011). Coordination skills are 
another aspect brought to the fore as managers will be responsible for the coordination of 
network arrangements and ensure that new ideas and content can be developed (Rogers 
and Whetten 1982; Scharpf 1978; Koppenjan and Klijn 2004, in Edelenbos, Klijn and Steijn 
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2011). Moreover, ensuring good relationships between network actors is another key aspect 
of effective management since negotiation processes underpin the cooperation processes in 
governance networks. In this regard the notion of ‘embeddedness’, referring to “the way 
actors are connected to the whole network” (Klijn, Steijn and Edelenbos 2010: 1069) has 
been correlated in several studies to network outcomes (Meier and O’Tools 2001, Huang and 
Provan 2007; Kenis and Oerlemans 2008; Klijn, Steijn and Edelenbos 2010). Hence, in the 
examination of management competences we will focus in our research on facilitating and 
coordinating interaction processes whilst connecting actors in these.
In network management two main types of managements styles can be distinguished: project 
management and process management (Edelenbos and Klijn 2009). No consensus exists in 
the literature to determine which one would be most appropriate for public-private network 
management (e.g. governance networks). Each can favour effectiveness of a network in 
terms of goal attainment in a certain way. As such, project management seems to have 
advantages in dealing with complexity (Meredith and Mantel 2000, in Edelenbos and Klijn 
2009). By breaking up the project into consecutive phases a better internal control of the 
project development may be offered. However, in this style of management, less attention 
is given to the environment (stakeholders) of the project. Decision-making will be more cen-
tralised and will not comprise stakeholder consultation. Stakeholders will be informed once 
a decision has been made (Beierle and Cayford 2002; Quah and Tan 2002, in Edelenbos and 
Klijn 2009). Communication will be based on a so-called DAD strategy: Decide, Announce 
and Defend (Edelenbos and Klijn 2009: 314).
Process management distinguishes itself from project management among others by the role 
which is given to stakeholders. The latter are involved from the beginning and consultation 
with them is continuous. Through open dialogue, managers will seek to identify potential 
solutions which take into account (competing) interests of stakeholders. The communication 
will be based on a so-called DDD-strategy: Dialogue, Decide, Deliver (De Bruijn et al. 1998 in 
Edelenbos and Klijn 2009:315). Decision-making is based on collaborative processes which 
take place before the project implementation. Hence, conversely to project management, the 
project is considered to be dynamic and is subject to changes and adjustments throughout 
the process (De Bruijn et al. 2004; Mandel 2001; Agranoff and McGuire 2003 in Edelenbos 
and Klijn 2009:315).
Management will be the third factor of the research framework having a potential impact on 
governance networks’ effectiveness. It will be related to the following features: management 
competences and management styles.
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3.4.2.4. External events
Effectiveness of a governance network can also be affected by external events (Milward 
and Provan 1998). As the network operates in a specific environment, changes within this 
environment may require the network to adapt. Similarly, networks operating with other net-
works can be influenced by social changes taking place in these (Peters 2007:70). Changes 
in governmental practices or priorities may also alter the receptivity of the public authorities 
to the policy issue of the network. It may even require the network to adapt as the network 
influence on decision-making may be affected. Hence, change in the networks’ environ-
ment can affect their functioning and effectiveness. These changes can be of economic, 
ideological, knowledge/technical and institutional in nature (Rhodes and March 1992:259). 
They could even lead to the deinstitutionalisation of a network (Peters 2007:70). Examining 
Governance networks requires thus also to consider the broader environment (Hjern and 
Porter 1981; Peters 2007).
External events will constitute the fourth and last factor in our research framework regarding 
the potential impact on effectiveness of governance networks. It will be related to the follow-
ing attributes: events of a ideological, legal, political or economic nature.
In this paragraph we have outlined various factors, related to soft governance, which can 
affect the effectiveness of a governance network in terms of goal attainment. We have 
structured this analysis according to four main aspects: social interaction, governance instru-
ments and management of a governance network and external events. Each of these aspects 
can be analysed according to a specific set of features. In our research framework, social 
capital will be examined through trust, shared values, learning processes and goal consensus. 
The impact of governance on effectiveness will be examined by focusing on policy instru-
ments, legislative and regulatory instruments, political instruments and financial instruments. 
Management will be explored by focusing on management competences and styles. Finally, 
external events should be included in the analysis as changes of different origins (economic, 
ideological, technical or institutional) can affect the effectiveness of a network in reaching 
its goals.
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METAGOVERNANCE
GOVERNANCE  NETWORKS
Typology
NETWORK GOVERNANCE
Effectiveness (Goal attainment)
Network formation Incentives
Strategic calculations
Support/constrain
Social interaction Learning processes
Shared values and understanding
Trust
Goal consensus 
Membership Public, private, non-profit
Relation home organisation-network
Open/closed
Homogeneous/heterogeneous
Governance instruments Policy instruments
Legislative and regulatory instruments
Political instruments
Financial instruments
Resources Financial
Natural/physical
Social/political
Human 
Management Competences
Styles (project/process management)
Governance modes Horizontal power distribution
Asymmetric power distribution
Centralised power distribution
External events Ideological
Legal
Political
Economic
Table 3.2. Research Framework
3.5. reSearch DeSigN
The research design is developed to address the question regarding the effectiveness of soft 
governance in structuring European HTA cooperation. As the junction point between HTA 
cooperation and EU health policy is situated in networks, we will examine this question 
through the prism of network analysis. Networks are considered here as a medium through 
which soft governance instruments can be implemented. The research framework serves as 
a mean to proceed to a systematic analysis of: 1) the HTA networks typology and whether 
these correspond to so-called governance networks operating via soft governance modes ; 2) 
the extent in which these networks undergo significant influence on behalf of the European 
Commission by soft governance means; 3) the effectiveness of soft governance in reaching 
the networks’ goals set. The detailed analysis of soft governance-related factors potentially 
affecting the typology of governance networks, the effectiveness of network governance or 
metagovernance, will bring to the fore the (in)effectiveness of soft governance in structuring 
HTA cooperation within an EU framework.
Through network analysis, necessary information will be gathered, organised and examined 
to address the general research question regarding the extent to which soft governance has 
structured HTA cooperation within the framework of the EU. In the introduction of this thesis 
we have outlined three areas in which this will be explored, so as to delimitate the scope of 
the research: convergence and harmonisation of HTA tools, methodologies and practices; 
uptake of joint work in national settings and synergies between the HTA arena and EU 
regulatory processes of pharmaceuticals.
134 Chapter 3
The research framework will be applied on the specific European HTA cooperation networks. 
These networks have been selected based on their role and relevance in the cooperation 
initiatives that have been launched in the field of European HTA cooperation. As such, focus 
will be on EUR-ASSESS, HTA-Europe, ECHTA/ECHAI, EUnetHTA and the EU HTA Network. 
Other initiatives taking place through networking and having an impact on the cooperation 
initiatives (e.g. High Level Group on Health Services and Medical care, Pharmaceutical Forum, 
Beneluxa) will be included in the research only in relation to specific topics treated (e.g. 
Relative Effectiveness Assessment, Horizon Scanning).
The data gathered is based on academic literature, grey literature (formal documents of 
national and European institutions, legislative documents, official communications, docu-
mentation HTA networks, meeting reports, informal correspondence of network members, 
network publications, positioning papers) as well as semi-structured in-depth personal 
interviews, written contributions and personal observations through attendance at inter-
national conferences and stakeholder forums, organised by the European Commission and 
HTA Networks.
The interviews have been held either face-to-face, by telephone or by Zoom (video com-
munication). The interview sample consists of 30 interviews and 2 written contributions, 
representing 40 interviewees for a total of 43 interview hours (annex 2). The inclusion criteria 
were based on active participation in an HTA network, type of professional organisation/insti-
tution, and country of professional activity. The types of professional organisation/institution 
were: HTA Network (executive level), HTA Agency, European Commission, Ministry Member 
State, Stakeholder group. Stakeholder representatives were selected on the basis of their 
membership in one of the following stakeholder groups: patients, payers, industry, health 
care providers. Regarding the country of origin, selection has been made based on the size 
of the EU Member States (EU MS) in terms of population: > 30 Mio (‘Big EU MS’), 7-30 Mio 
(‘Middle EU MS’), < 7 Mio (‘Small EU MS’).
Ministries of health were hardly represented in HTA Networks till 2016 (3 on average, from 
small EU MS and no corresponding MS HTA bodies in the networks). Despite the general rise 
in network membership after 2016, the number of ministries represented in the networks 
remained relatively low (8 from predominantly small EU MS). Although the final interview 
sample reflects this representation, we did aim initially for a larger participation of this group 
in our sample. Due to the ongoing adoption procedure of the Commission proposal for a 
Regulation on HTA cooperation, recruitment for interviews became however challenging, 
explaining the final number of MS ministries present in the interview sample.
The final interview sample has been constituted as follows:
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Represented organisation/institution Number of interviewees
HTA Networks 7
European Commission 9
HTA agencies 13
- Big MS (pop. > 30 Mio) 6 
- Middle MS (pop. 7-30 Mio) 4 
- Small MS (pop. < 7 Mio) 3 
Stakeholders 8
- Patients 2 
- Payers 1 
- Industry 3 
- Health care providers 2 
Member States (Ministries of Health) 3
Total 40
Table 3.3. Interview sample
Three interview rounds have been held. The first took place from January to July 2016. The 
second from January to July 2017, the third from March to August 2018. The interviews have 
been recorded (except two), transcribed, and organised (categories, sub-categories, codes) 
allowing for a horizontal and vertical (conventional) content analysis method. The choice to 
work according to this method was motivated by the fact that it allows to examine informa-
tion retrieved directly from the participants without imposing preconceived categories or 
perspectives.
The empirical data gathered will be presented and structured by means of the five stages 
of the policy cycle as developed by Howlett, Ramesh and Perl (2009). Using the policy-cycle 
allows to break down a complex policy process into several stages such as: agenda-setting, 
policy formulation, decision-making policy implementation and policy evaluation. As such, 
the role of multiple actors acting on multiple policy-levels during different timespans can 
be examined. Explanations about each stage of the policy-cycle will be given in part B. The 
empirical data will be analysed in Part C by proceeding to a systematic investigation of all 
factors and their corresponding features constituting the research framework. The outcome 
of the analysis will be applied to the three main areas outlined above and corresponding to 
the sub-research questions. Final conclusions will be drawn in the last chapter of the thesis 
which will address the overarching research question.
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3.6. coNcluSioN
This chapter represents the third and final chapter of Part A of the thesis aiming to establish 
the theoretical framework and research design. Chapter 1 has outlined the development of 
HTA, how it relates to national and European regulatory process and the underlying reasons 
for the development of European cooperation in this field. By reviewing the literature in 
this field, we have identified a research gap regarding the governance processes steering 
European HTA cooperation, which has developed by means of networking. Chapter 2 has 
situated HTA cooperation in the wider EU health policy framework and outlined how the 
division of competences between the EU and its Member States impacts on the governance 
modes available in a certain policy field. It has highlighted how in sensitive fields or fields 
of exclusive Member States’ competences, New Modes of Governance are often the only 
EU governance modes available to support cooperation initiatives. Governance by having 
recourse to networking falls into this scope and has been used by the EU to strengthen HTA 
cooperation initiatives.
Chapter 3 has highlighted the relationship between soft governance and networks in the 
EU governance architecture. It has underscored how networks, though not restricted to the 
implementation of soft governance means, can be considered as an adequate forum for 
the implementation of soft governance instruments, herewith allowing the EU to pursue 
specific aims in sensitive policy areas. The research framework developed in this chapter 
seeks to support the examination of the effectiveness of soft governance in structuring 
HTA cooperation in Europe through the prism of network analysis. It is structured upon the 
central concepts of governance networks, metagovernance and network governance as well 
as soft governance-related factors potentially impacting the typology of the networks and 
their effectiveness in terms of goal attainment. In the next part of this thesis, we will set out 
the empirical data gathered during the research. This data will be examined in part C. The 
outcome of the examination will allow to give a structured answer to the thesis research 
question regarding to which extent soft governance has structured HTA cooperation within 
the framework of the European Union.


PART B
DATA COLLECTION

4 Governance practices 
steering initial European HTA 
cooperation processes
“When you take people from different backgrounds,
put them in front of the same problem, and ask them to solve it, 
they’re no longer the same people. 
They’re no longer there to defend their separate interests, 
and so they automatically take a common view”. 
Jean Monnet, Memoirs
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4.0. iNtroDuctioN
Part B of this thesis presents the data of the empirical research of HTA cooperation in Eu-
rope. It is divided in three chapters each focusing on a particular development stage of the 
cooperation process. The present chapter explores what has triggered the dynamics to foster 
HTA cooperation in Europe and how it has been initially structured in the early cooperation 
initiatives running from 1992 to 2001. This chapter will be followed by chapter 5 outlining 
developments in the EU health policy sector from 2001 to 2006 and which have laid the 
basis for the further developments of HTA cooperation in Europe after 2006 and outlined 
in chapter 6. These chapters will demonstrate how the development of HTA cooperation 
has been taken place essentially through networking and cannot be dissociated from the 
development of a European health policy as both processes have mutually reinforced one 
another.
In chapter 1 we have outlined how health technology assessment – as well as the associated 
policy domains of pricing and reimbursement - refers to a policy domain falling under the 
exclusive competences of the Member States. As such, the role of the European institutions is 
limited, and the subsidiarity principle needs to be respected. To get a more profound insight 
on how this cooperation process has taken place within the given national and European 
institutional structures and legal requirements, we will analyse the development of HTA coop-
eration from a governance perspective. The governance practices applied will be assessed on 
the basis of the five stages of the policy cycle as defined by Howlett, Ramesh and Perl (2009). 
These stages offer the possibility to scrutinise in a systematic manner all important elements 
of governance: agenda setting, policy formulation, decision-making, policy implementation 
and policy evaluation. Moreover, this approach allows for the inclusion of governance as-
pects related to transparency, accountability, participation, power delegation as well as legal, 
administrative, financial and budgetary aspects of project and network governance.
The structure of the present chapter is based on the comparative analysis of the develop-
ments taking place in the HTA arena and the developments linked to HTA taking place during 
the same periods of time in the European health policy field. The chapter will therefore be 
divided in five sections each focusing on a specific stage of the policy cycle regarding both 
HTA cooperation developments and EU health policy developments. Each section starts with 
a brief outline of key aspects of the stage of the policy cycle under examination. These 
aspects will then be confronted with the developments in HTA cooperation and in EU health 
policy. A conclusion at the end of each section will analyse how the developments of both 
levels relate to one another.
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The data presented in the present chapter will be confronted in chapter 7 with the elements 
set out in the research framework. As such, the typology of the networks will be determined 
as well as their effectiveness in reaching the goals set. The later will permit us to answer 
the research questions of this thesis and get a profound insight in the governance of HTA 
cooperation structures and how they are situated within the broader European integration 
process in the field of health care.
4.1. the geNeSiS oF europeaN hta cooperatioN
4.1.1. Setting international cooperation on the HTA agencies’ agenda
Agenda-setting, or “the politics of attention” (Baumgartner and Jones 2005) is the first and 
maybe the most critical stage of a policy-cycle as it determines whether and how the issue 
will be addressed by policy-makers (Howlett et al. 2009: 92). It is most often concerned 
with the questions of how, when and why an issue has made it on the agenda of a political 
system, who participated in the process and why that issue received the attention of policy-
makers rather than another issue.
The agenda setting process of public policy issues can be examined in many different ways30. 
Baumgartner and Jones (2005: ix) consider it as a “process by which a political system pro-
cesses diverse incoming information streams” which need to be attended to, interpreted, 
and prioritized”. As Princen (2011:107-108) underscores, the “agenda determines not just 
which issues will be subjected to decision making” but also regards “the terms by which an 
issue will be discussed”. The latter will have an influence on the options that will be consid-
ered and by whom. Hence, agenda-setting is also a matter of “politics of problem definition” 
(Rochefort and Cobb: 1994), also referred to in the literature as “frames” which comprise 
concepts and assumptions used to structure reality (Benford and Snow 2000; Schön and 
Rhein 1995; Princen 2011).
However, besides frames, one should also look at venues when analysing the agenda-setting 
process. Baumgartner and Jones (1993) have defined ‘venues’ as institutional forums where 
policy decisions are being taken. Drawing upon that perspective, Princen (2011: 119-120) 
underscores how the EU can be considered as a venue compared to national governments 
or international organisations. He underscores however that within the EU different venues 
can also be distinguished (e.g. European Parliament Commission, various Directorate Gener-
als). Receptiveness for issues – prerequisite for issues to make it on the agenda - may be 
30 See further e.g. Kingdon 1995; Cobb, Ross and Ross 1976; Baumgartner and Jones 1993, 2005; 
Princen 2009.
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influenced by the internal organisation and institutional structure of each venue. This follows 
earlier findings on the concept of “organisation is the mobilisation of bias” (Schattschneider’s 
1960:71) referring to political systems creating their own bias by the way they are organised 
and which explains why some issues will find themselves on the organisation’s agenda and 
why others don’t.
Setting European cooperation on the agenda of HTA agencies as well as on the agenda of 
the European Commission has followed a particular path. Initially, the search for cooperation 
between HTA agencies in Europe was not motivated out of the need to address a specific 
public policy problem recognised as such by policy-makers. Since the 1970s and the uptake 
of new technologies in health care, policy-makers and health professionals did show an 
increased interest in assessing the safety, effectiveness, and cost-effectiveness of new tech-
nologies as well as their impact on social, ethical and legal issues in a given country (Goodman 
1988: 10). Rising expenditures due to changes in (an aging) population, disease patterns or 
new demands from the public certainly also played a role for the consideration given to 
HTA (Banta et al. 1997: 134). In the US, the Office for Technology Assessment had been 
established in 1972 for this purpose. This office was the first to reflect upon what content 
could be given to, what was then called, ‘medical technology assessment’ seeking to inform 
the US Congress. The latter could request assessments on a particular innovative technology 
and the information given aimed at informing policy-making processes. OTA could thus be 
considered as an advisory college and laid the basis of what would become HTA (personal 
interview 10). Its example was soon followed by other countries such as Canada, Australia 
and New Zealand which created specific agencies for health technology assessment.
In Europe, HTA was being practiced since the late1970s essentially through workshops 
and discussions among experts within different types of institutions to inform pricing and 
coverage decisions (Sorenson 2009; Thatcher 2010). The first formal European HTA agencies 
have however only been created in 1987 in Sweden (Swedish Council for Health technol-
ogy Assessment (SBU) and in Spain (Catalan Agency for Health Technology Assessment). 
146 Chapter 4
Others followed31 but the situation was characterised by the heterogeneity and diversity of 
these agencies both in their institutional nature as in the methodologies used (Banta et al. 
1997:134). These different approaches are partly explained by underlying cultural differences 
driving national health policies and health economics. The different understandings of the 
role of government in establishing and implementing policies also has contributed to these 
different approaches and has had an impact on how HTA has developed in the various 
countries setting up HTA agencies (personal interview 10).
Some (e.g. Sweden, France) conducting HTA based essentially on existing knowledge (reviews 
of the literature), others (e.g. UK and the Netherlands) conducting also prospective studies 
whereas the CAHTA in Catalonia, for example, chose for an integrated approach based on 
synthesis and prospective studies. Moreover, some agencies functioned by having close ties 
with governmental structures (e.g. France), whereas others adopted a more independent 
and decentralised approach (e.g. The Netherlands) (Banta et al. 1997:134). This all led to 
a more fundamental question on whether a single HTA model was needed or desirable 
(personal interview 10).
The need for HTA cooperation in Europe was expressed almost simultaneously with the 
establishment of HTA agencies in Europe. HTA cooperation on an international level already 
existed since 1984 with the International Society of Technology Assessment in Health Care 
(ISTAHC, since 2003 HTAi32), which had been established upon the initiative of two persons 
who have played a key role in the development of HTA in Europe: Egon Jonsson and David 
Banta. The latter recalls how the idea of cooperation came out of a simple observation: “We 
were just standing at some place - I remember – and [Egon Jonsson] said “all these people 
are working on the same subject and they never meet each other, except at international 
conferences or something, but never for this purpose. It’s stupid, we should be sharing 
31 In France the Agence Nationale de l’Evaluation Medicale (ANDEM) was founded 1989 (later re-
named in Agence Nationale d’Accreditation et d’Evaluation en Sante (ANAES)). Since 2005, HTA is 
being performed by the Haute Autorité de Santé (HAS). In the UK the first official HTA programme 
has been established in 1993 as part of the National Institute for Health Research. Since 1999 HTA 
is being performed by the National Institute for Health and Clinical Excellence (NICE) In Germany, 
the Institute for Quality and Efficiency in Health Care (iQWIG) has been created in 2004. In Italy, 
HTA has started in the 1980s at the National Institute of Health and in a few University Hospitals 
(Favareti et al. 2009). In Austria it took some 15 years from the first research activities on HTA to 
the foundation in 2007 of a formal Austrian HTA-institute (Federal Institute for Quality in Health 
Care (BIQG)) (Wild 2009).
32 ISTAHC had to cease its activities in 2003 due to an overstretched budget. It was however recon-
stituted into Health Technology Assessment international (HTAi) created the same year (Banta et 
al.: 2009: 21).
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information, we should be learning from each other, we should be putting our strengths 
and weaknesses together; (…) Why are different countries doing their own report on the 
same subject? It’s a waste of money, we can’t’ afford to waste money. (…) We have to work 
together. That’s all. That was it. That was all, really” (personal interview 2).
This reasoning also motivated the same actors a few years later to go a step further and 
develop a project aiming to foster cooperation among European actors active in HTA. Infor-
mal discussions with other representatives of newly created agencies in Europe led to the 
understanding that there was a real need to cooperate on a European level (Banta et al 1997: 
134). Besides the search to avoid duplication and allow a better allocation of resources, 
the first cooperation initiatives were driven by the dual objective to enhance the quality 
of HTA as well as the quantity of HTA agencies and subsequently reports issued by them. 
The second being intrinsically linked to the first (personal interview 2). To counter criticism 
targeted at possible bias that could occur as a result of public funding and political pressure, 
the idea was to ensure HTA would be rooted in a solid scientific principles independent of 
all political considerations (Liberati et al. 1997: 193). Hence, highly qualitative assessments 
would increase the chance of uptake in policy decision-making, offering policy-makers the 
possibility to embed health technology related decisions into evidence-based medicine. As 
a result of this process, official recognition for HTA could develop, leading potentially to the 
establishment of new HTA agencies (personal interview 2).
In 1991, the first project proposal aiming to establish cooperation among European HTA 
agencies has been drafted under the denomination of EUR-ASSESS. It was submitted to 
the BIOMED program of the European Commission for the first time in 1992 but initially 
turned down. As no initial contacts had been taken with representatives of the European 
Commission, the project “came in rather cold” (personal interview 2). However, the subject 
did attract the attention of some administrators who approached the authors of the project 
proposal and encouraged them to submit it again (Banta et al. 1997: 134). After having 
introduced some changes upon indications of the EC representative, the project was re-
submitted and approved in 1993 (personal interview 2).
The interest of the HTA community for the project was motivated out of considerations 
strictly linked to the development and recognition of health technology assessment as 
such. It also coincided with the establishment of the International network of HTA agencies 
(INAHTA) created as a consequence of informal meetings of European HTA representatives 
within ISTAHC to promote cooperation between newly created agencies across the world 
(Hailey 2009; Personal interviews 6 and10). The EUR-ASSESS project proposal followed thus 
a specific agenda setting process pursuing objectives of the HTA community. This process 
matched however another agenda-setting process, freshly initiated at the European level.
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4.1.2. Setting HTA on the European agenda
As outlined in chapter 2, EU health policy has known a particular development process. It 
is only in 1992, that a first article about public health has been integrated in the Maastricht 
Treaty. Several adjustments have since been made throughout the various treaty revisions, 
leading to a gradual extension of EU’s competences in this field. However, the dominant 
feature of European public health policy remains the fact that Member States remain respon-
sible for the organisation and management and the delivery of health services and medical 
care as well as for the allocation of necessary resources to this end. EU competences are 
limited to the promotion and coordination of policies and programmes on the basis of soft 
governance instruments (see further section 2.2.2).
HTA cooperation in Europe has been directly concerned by the development process of EU 
public health policy. As outlined above, the first project aiming at establishing HTA coopera-
tion in Europe has been submitted and rejected in 1991 and then re-submitted and accepted 
in 1992, at a time where significant changes took place in the EU health policy field. Indeed, 
till 1992, support for health-related issues was given through specific small-scale programs, 
in the field of Cancer, AIDS/HIV or through research-orientated programs such as the Biomed 
program (which also financed the first EUR-ASSESS project). However, these programs were 
not policy-orientated and did not aim nor permit to develop any specific health policy at the 
EU level.
The Maastricht Treaty, signed in 1992, represented an important change in this regard since 
it offered possibilities for the European Commission to extend its involvement in the health 
policy field on a legal basis. The treaty provisions remained rather vague in this regard leaving 
sufficient room to the Commission to interpret these widely. This interpretation started with 
the heading of Article 152 “Public health” which lacked a commonly accepted definition. 
From the Commission’s point of view, public health concerned “health of the public” and 
the objectives laid down in the Treaty conferred to the European Union the role to look after 
the well-being of the European citizens (personal interview 3). So even though the scope of 
the Treaty objectives could be considered rather narrow by some, in view of the Commission 
they could be – and were - interpreted in a broader sense: improving the health of European 
citizens (personal interview 3).
In this regard, the Commission identified national health systems as one of the domains where 
the EU could bring added value while seeking to improve the health of the public. Indeed, 
the functioning of national health systems which were increasingly under (financial) strain in 
the Member States were governed in many different ways across the Member States. Gath-
ering information on how the different health systems were run and providing information 
and support to Member States permitting them to organise their health systems in the most 
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efficient and cost-effective ways became since the early nineties a constant thread in what 
would develop later as EU health policy. This approach represented a fundamental rupture 
from the way health issues had been tackled by the Commission till then by either addressing 
public health threats (e. g. BSE crisis33) and public health concerns (e.g. cancer, HIV/AIDS) or 
through decisions often taken in another policy field (e.g. professional mobility)34. Hence, the 
work on the first health strategy departed from the previous policies by taking health and 
health systems as a starting point. This subtle but fundamental difference has laid the basis 
for European health policy-making and underpinned all health programs that have been 
developed since the early 2000s.
The interest in health technology assessment on behalf of the Commission has to be 
understood in this context. Commission representatives in charge of developing the EU 
health strategy were introduced to HTA through the EUR-ASSESS project and its initiators 
(personal interview 3). Indeed, HTA was still a very young discipline in the early nineties in 
Europe, and unknown to most Commission officials. However, after a personal briefing on 
the subject, some key Commission representatives rapidly understood the potential impact 
HTA could have on health systems and consequently on the place it could occupy in the 
health strategy of the Commission (personal interview 3). Moreover, a report commissioned 
by the Directorate General V (DG V)35 in 1995 on securing further health improvement and 
greater efficiency in the use of health resources on the European level, also highlighted the 
importance of HTA. The report even recommends that “the Commission should coordinate 
technology assessment throughout the Union to establish the effectiveness of both new 
and existing technology in improving outcome; the appropriate uses of these technologies” 
(Abel-Smith et al. 1995: 130)36.
The increased insight regarding the potential contribution of HTA for improving health in 
Europe on behalf of the (ex) public health policy unit within DG V also impacted the funding 
basis for projects seeking to develop HTA in Europe. If EUR-ASSESS had been financed through 
a research-based funding program of DGXII, its successor, the ‘HTA-Europe project’ received 
financial support from DG V in the course of 1996-1998 (Banta and Oortwijn 2000:300). 
33 Bovine spongiform encephalopathy (BSE), commonly known as mad cow disease.
34 See further on the development of EU health policy e.g. Randall 2000, Greer 2009; Mossialos et 
al. 2010.
35 Directorate General V was responsible for Employment, Industrial Relations and Social Affairs and 
hosted the public health unit.
36 This publication addresses a full chapter on technology assessment based on work of Franco Sassi, 
Research Fellow in Health Economics, London School of Hygiene and Tropical Medicine (Abel-
Smith et al. 1995:VI).
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This trend only further developed with the establishment of DG SANCO, a dedicated DG for 
health, established in 1999 and which funded the ECHTA/ECAHI Project from 2000-200137.
At a very early stage of the development of the EU health strategy, HTA had thus been 
identified as being of strategic importance. It presented an intrinsic link with the national 
health systems and represented an area where Community efforts to coordinate cooperation 
could bring added value. In this sense HTA was considered as offering an opening wedge 
to influence the development of sustainable national health systems and improving the 
health of the European citizens. As a result, HTA has been associated to the very first health 
programs developed by the Commission, which represent the basis of any action in the field 
of EU health policy38.
4.1.3. Conclusion agenda-setting in early European HTA cooperation 
initiatives
Analysing European HTA cooperation in a policy setting requires an examination of the is-
sue at three different levels: the HTA agency level, the national institutional level and the 
European institutional level. We have been able to identify an agenda setting process of HTA 
cooperation in Europe in its very early stages only on the HTA agency level and the European 
institutional level. Although the national institutional level has been involved in the first 
projects by designating agencies for participation in the cooperation process, European HTA 
cooperation was not identified than as a domestic governmental agenda point. This can be 
explained by the fact that the European HTA cooperation process has followed what Princen 
(2009) qualifies as a typical EU agenda-setting process. Agenda-setting on this level is rather 
distinct than the one which can take place in national settings.
Princen (2009) identifies different types of agenda-setting in the EU policy-making process 
depending on the policy area concerned. Were policy-making takes place in a rather routine 
manner (e.g. Internal Market, environment), the agenda setting follows the same pattern 
as in a ‘functioning political system’. Conversely, when policy-making at the EU-level occurs 
37 Grant Agreement No. SI2.122594 (99CVF3-508), Health & Consumer Protection Directorate 
General Grant
38 HTA was however not mentioned in the first “Framework for Action in the Field of Public Health” 
developed in the aftermath of the Maastricht Treaty (1993). This initial strategy document aimed 
at developing work on public health and comprised a series of eight action programs which were 
partly a continuation of work already engaged in by the Commission before the Maastricht Treaty: 
health promotion, cancer, drug dependence, AIDS and other communicable diseases, health 
monitoring, rare diseases, accidents and injuries, and pollution-related diseases (http://ec.europa.
eu/health/programme/policy/eight_programmes/index_en.htm).
.
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in areas where the Union is still ‘in the process of establishing a presence and carving out 
a role for itself’, the European policy-making system should be considered as an ‘evolving 
integration scheme’ (Princen 2009: 9). Policy-making in the field of health care matters, such 
as HTA, follows the second type of agenda-setting processes since the issues appear for the 
first time on the EU agenda.
Princen describes three stages in this agenda-setting process which we can also identify in 
the HTA agenda-setting process. The first refers to the stage in which an issue is debated 
in transnational policy networks39. An issue will rise within these networks, provided that 
the network is strong enough for members to exchange ideas and that a certain degree of 
convergence is met in the policy debates (Princen 2009: 15). This will allow these networks 
to adopt common perspectives on a particular issue. In the case of HTA, ISTAHC (and later 
also INAHTA) can be considered as transnational policy network where informal discussions 
among members have resulted to the adoption of a common objective to establish a strong 
European cooperation network in HTA.
An issue can shift from the transnational policy network agenda to the EU agenda provided 
it finds receptiveness at the EU-level. This will depend both on the characteristics of the EU 
institutions that will be confronted with the issue and on the way the issue will be defined 
(frame) in the transnational network (Princen 2009:15-16). If the frame ‘fits’ the concerns 
and interests of a particular European institution (venue)40, the debate may continue at an 
EU level41. We have seen that although HTA was already known in a certain EU venue (DG 
research), a real debate regarding the development of HTA on the EU-level started when it 
was introduced to the ‘right’ EU venue for this, i.e. the public health unit of DGV. It is here 
that the HTA agencies’ agenda matched the EU agenda.
39 These networks consist of policy experts of national governments and international organisations 
but can comprise also academics, journalists etc. (Princen 2009).
40 Princen (2009: 10) explains agenda-setting dynamics by looking at the combination of ‘venues’ 
(institutional decision-making arenas) and ‘frames’ (also called ‘issue definitions’). Participation of 
actors in decision-making processes will be determined by those. Different venues will have differ-
ent responsibilities for specific policy areas. Hence, their receptiveness for a particular issue will not 
be same. Moreover, venues differ in the authority they have over certain issues as well as in their 
composition (Schattschneider 1960: 71 in Versluis et al. 2011: 119). According to Baumgartner 
and Jones (Howlett et al. 2009: 106; Versluis et al. 2011:119) the EU institutions can be considered 
as ‘venues’ in the sense described above.
41 Princen (2009:16) underscores that an issue can become part of the EU agenda as a result of a 
proactive approach of EU institutions that either have picked up the issues in the debates or have 
initiated a debate about a particular topic themselves and subsequently made policy proposals 
about it.
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Based on an approach developed by Kingdon (1984; see also 1995), Princen (2009: 16) dis-
tinguishes two sorts of EU agendas. The first -the ‘EU’s governmental agenda’ – regards the 
political agenda-setting process during which ‘ideas are floated and perspectives developed’. 
This agenda should be distinguished from the EU ‘decision agenda’ on which issues appear 
when they are ripe for active decision-making. In 2000, we can consider HTA just entering 
on the ‘EU’s governmental agenda’. Ideas about the potential role and place of HTA in the 
overall health strategy of the Commission were indeed ‘floating’ and perspectives of how 
HTA could contribute to reaching broader objectives of what would become the EU health 
policy were still being developed.
HTA making it to the EU’s governmental agenda can, for an important part, be attributed 
to the efforts made by so-called ‘policy entrepreneurs’ in both the HTA as in the European 
Commission arena. Policy entrepreneurs are characterised by “bringing new policy ideas into 
good ‘currency’“ (Mintrom and Vergari 1996: 422). In order words, policy entrepreneurs 
seek to sell their ideas in order to achieve (radical) policy change. They do so by identifying 
the problem, shaping terms of policy debates, networking and building coalitions. The lat-
ter permits them to understand the position of various parties towards an issue and how 
to frame that issue to attract support for it and make best use of available organisational 
resources. Policy entrepreneurs furthermore draw upon their personal resources which in-
clude “intellectual ability, knowledge of policy matters, leadership and team-building skills, 
reputation and contacts, strategic ability, and tenacity” (Mintrom and Vergari 1996: 423). 
All this combined permits policy entrepreneurs to attract the attention of decision-makers 
for a particular policy problem by presenting potential policy responses (see further on policy 
entrepreneurs: Mintrom and Vergari 1996; Kingdon, 1995; Majone, 1988; Smith 1991). 
Persons such as David Banta and Egon Jonsson could be regarded as policy entrepreneurs 
from within the HTA arena. But also within the European Commission some representatives 
such as Bernard Merkel could be cited as examples of policy entrepreneurs with regard to 
European HTA Cooperation. Their personal and professional investment has permitted HTA 
to be framed in such a way that receptiveness on a European level was found within the right 
venue. This has led to renewed commitment to European HTA cooperation on both levels. 
On the HTA agency level this has been shown by the development of new projects (EUR-
ASSESS has been followed-up by HTA-Europe and by the ECHTA/ECAHI). The Commission’s 
commitment to HTA cooperation can be identified through the integration of HTA in the 
health program opening new (policy orientated) funding opportunities.
In the agenda setting phase of the policy cycle we can observe a few elements related to 
what will later be affiliated to New Modes of Governance. The initial idea to start coop-
eration was motivated out of the need to exchange information and experience besides 
increasing value for money. The way policy entrepreneurs have operated by creating formal 
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and informal expert networks and framing the debate in such a way to attract support for 
European HTA cooperation bears also traits which resemble soft policy mechanism in which 
discourse and learning processes are of high importance. One may wonder whether these 
working methods were a continuation of New Public Management working processes used 
in public entities such as the Office for Technology Assessment in the USA.
For a subject to go from the EU’s governmental agenda to the decision agenda, Princen 
(2009) underscores how it will have to overcome two types of blockages. Due to differences 
in perspectives, some policy-makers on the EU level, may want to prevent an issue to appear 
on the decision-making agenda. This will lead to what Princen calls the ‘horizontal blockage’. 
A ‘vertical blockage’ can occur when Member States are reluctant to see the European Union 
trying to play a role in a particular policy (Princen 2009: 16). In the next chapter we will 
analyse into more depth the development of HTA on the EU agendas after 2000 and how 
it has been confronted to the two types of blockages. Before that, we will however first 
examine the development of European HTA cooperation in its early phase through the other 
stages of the policy cycle.
4.2. policy FormulatioN iN iNitial europeaN hta 
cooperatioN proceSSeS
4.2.1. Policy-formulation in early European HTA cooperation initiatives
An essential stage of the policy cycle regards the formulation of the policy itself. In a ‘typi-
cal’ public policy process, policy-formulation consists of identifying, assessing and selecting 
potential options to address a particular policy problem. Part of this process can already take 
place during the agenda-setting stage of the policy cycle (Kingdon 2003: 205; Howlett, 
Ramesh and Perl 2009:110). A large set of actors can participate in the policy formula-
tion stage, representing the interests of different stakeholders concerned by the issue. This 
explains why the process itself never produces neutral outcomes and can appear as highly 
diffuse and disjointed. (Howlett, Ramesh and Perl 2009: 111). Four stages can be identified in 
the policy-formulation process: appraisal, dialogue, formulation and consolidation (Thomas 
2001, in Howlett, Ramesh and Perl 2009). Appraisal is mostly concerned with data and 
evidence collection. Dialogue regards the facilitation of (formal or informal) communication 
between policy actors having different perspectives on the issue. The two first phases result 
in the actual formulation of the policy in the form of draft regulations or legislations (in 
governmental policy processes). The consolidation phase seeks to create consensus and in-
crease support for the policy proposal by providing (formal or informal) feedback and address 
potential objections (Thomas 2001). An intrinsic part of this process is the identification of 
the instruments that need to be used to achieve the objectives defined. Many different policy 
154 Chapter 4
instruments exist and are often tailored to the particular policy objectives42. In the case of 
European HTA cooperation we will see that a mix of governing instruments will be used due 
to the hybrid character of the first cooperation initiatives which respond to an institutional as 
well as a project based policy-formulation approach.
The policy-formulation in EUR-ASSESS (1994-1997), has been highly influenced by the 
organisational set-up of HTA cooperation. The overall objective of the project had been 
defined during the agenda-setting phase and sought to develop the quality and quantity of 
HTA and its up-take in decision-making processes in Europe. The appraisal phase in this first 
European HTA cooperation project did not comprise many actors. The collection of data and 
evidence has mainly been done by the initiators of the project who based themselves on their 
professional experiences and past HTA projects43. On the basis of the information collected, 
the EUR-ASSESS project proposal had been drafted, which can be considered as a sort of 
‘business plan’ of the cooperation initiative. This proposal was structured in a particular way 
where a set of ‘sub-objectives’ have been defined serving as means to attain the strategic 
goal of the initiative.
This approach responded to management techniques that could be identified as being de-
rived from the so-called “Management By Objectives” (MBO) introduced by Drucker (1954), 
developed by Odiorne (1965) and later incorporated in New Public Management (Aucoin 
1990, Politt 2001, Osborne and Gaebler 1992). MBO seeks to set individual objectives in 
each section of the organisation which are directed towards the common organisational 
goal. Hence, the organisation’s strategic objective is being broken up into smaller (unit) 
objectives which are jointly identified with all actors concerned. Accountability for achieving 
the objectives is thus also spread out over multiple levels (Drucker 1954; Odiorne 1965)44.
The organisational setup of EUR-ASSESS that will derive from this approach, will have con-
sequences not just for the policy-formulation process but also for the overall governance of 
HTA cooperation as it doesn’t identify with a hierarchical management structure and instead 
opts for a multi-level, inclusive participatory management style. This structure will remain 
42 See further for a taxonomy on policy instruments: Salomon and Lund 1989; Lowi 1985; Bemel-
mans et al. 1998; Hood 1986.
43 David Banta, who has drafted the EUR-ASSESS project proposal had worked from 1974 to 1983 
at the OTA. Thereafter he has moved to Europe (The Netherlands) where he has been actively 
involved in developing HTA in European countries.
44 We have seen in chapter 3 how these management techniques initially developed in the private 
sector have also been introduced in New Public Management practices reforming public adminis-
tration were the accent in management has been put on “steering rather than rowing” (Osborne 
and Gaebler 1993).
Governance practices steering initial European HTA cooperation processes 155
in place throughout the subsequent projects. In this regard the governance of EUR-ASSESS 
and its successors bears traits that could be associated to New Public Management practices 
where the accent laid, as we have seen in chapter two, on “steering rather than rowing” 
(Osborne and Gaebler 1993). Indeed, the EUR-ASSESS project is headed by a Steering com-
mittee which comprises all project members and which made all policy decisions including 
defining/approving the strategic goal of the project. Even if the main strategic objective of 
EUR-ASSESS had, to a certain extent, already been set by the project initiators, it had to be 
discussed and approved by all participating members in the Steering committee, as was the 
case of the sub-objectives that have been defined to attain the strategic goal. Implementa-
tion of these sub-objectives fell under the responsibility of separate expert units - called 
‘Subgroups’ who were accountable for the outcome of the common work (Banta et al. 
1997).
The definition and content of the project’s (sub)objectives heavily drew upon HTA policy 
implementation developed in the American Office of Technology Assessment (OTA)45 which 
had done some pioneer work on the definition of HTA as well as the development of 
methodological guidelines. The (sub)objectives of the EUR-ASSESS project focused on: 
effectiveness and cost-effectiveness of health care in Europe; methods of priority setting 
and assessing technology in HTA programs; the international applicability of findings and 
dissemination of results; stimulating use of HTA in coverage decisions (Banta 1997: 135). 
Most of these topics have been selected on the basis of OTA reports published in the 1970s 
and 1980s on the identification of technology assessment opportunities, efficacy and safety 
and cost-effectiveness of health technologies considered by HTA ‘doers’ as driving the US 
health policy (OTA 1976; 1978; 1980a; 1980b: personal interview 2)46.
45 The OTA was established as an office of the US Senate in 1972, it actively started to work after 
funding was secured in 1973 and closed in 1995. Its objective was to provide the congress with 
“new and effective means for securing competent, unbiased information concerning the physical, 
biological, economic, social, and political effects of technological applications” and “to serve as 
an aid in the legislative assessment of matters pending before the Congress” (US Congress 1972: 
OTA 1974). Work on HTA within OTA has started in 1974.
46 The establishment of the OTA was closely linked with the implementation of the first US health 
program developed under the impetus of Senator Edward Moore ‘Ted’ Kennedy. HTA in the US has 
always been closely linked to health policy and considered as a mean to deal with the rising costs 
in health care. The OTA operated as an advisory college working for the US congress who could 
ask the OTA to carry out assessments of particular technologies. In this sense it distinguishes itself 
of the European HTA agencies that have been set up after 1990 (Personal interview 2 and 10).
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The inclusion of the other topics resulted mostly from informal dialogues between represen-
tatives of the first HTA agencies in Europe (Banta et al. 1997:134)47. The objectives set out 
in the EUR-ASSESS project have heavily influenced the basic frame-work for the following 
projects ‘HTA-Europe’ (1997-1998), which aimed at reaching the same objectives48. If the 
overall aim to create a sustainable network of HTA cooperation has increased in importance 
in each project, one notable difference between EUR-ASSESS and the subsequent projects 
was that the topic regarding coverage and HTA has disappeared as formal objective, only to 
re-appear a decade later as a (in)formal discussion point in many HTA gatherings. Indeed, 
at the end of the project some participants stressed how dissemination is not sufficient to 
give HTA power. To create a ‘powerful’ HTA having impact on policy-making, it is important 
to establish links between HTA and other (powerful) policy domains such as reimbursement 
(personal interview 10).
The operational structure of the ECHTA/ECAHI project (1999-2001) remains very similar to 
the two previous projects by pursuing a strategic goal to be attainted through the implemen-
tation of sub-objectives by specific working groups. Whilst the main objective remains the 
establishment of a (formal) European network for HTA collaboration, the formulation of the 
sub-objectives distinguishes itself from EUR-ASSESS and HTA-Europe. Indeed, the latter are 
impregnated by European ‘jargon’ of the time and seem to be inspired by developments such 
as the Lisbon agenda (2000) and other Commission initiatives49.
In particular, the first objective of the ECHTA/ECAHI project is interesting in this regard 
as it has even been inserted following an explicit request of the European Commission 
(personal interview 2). This objective underscores that one of the aims of the project is to 
“assess health promotion and disease prevention activities in terms of benefits, risks and 
economic, social and ethical implications as a complement to community health indicators” 
47 Among those were Egon Jonsson, (Sweden), David Banta (the Netherlands), Michael Peckham and 
Chris Henshall (UK), Yves Matillon (France), Alicia Granados (Catalonia), and Richard Cranovsky 
(Switzerland) (Banta 1997: 134)
48 The objectives of the HTA-Europe project were: 1. Contribute to the effectiveness and cost-
effectiveness of health care in Europe through improved HTA, 2. Contribute to the development 
of institutions for health care technology assessment in Europe, 3. Strengthen co-ordination of 
health care technology assessment in Europe, 4. Contribute to the development of methods of 
information transfer among European countries and 5. Furnish guidance to the European Com-
mission concerning how to strengthen and aid co-ordination of HTA activities in Europe (Banta and 
Oortwijn 2000b).
49 The European Council gathered in 2000 in Lisbon defined the so-called Lisbon strategy for the EU 
aiming “to become the most dynamic and competitive knowledge-based economy in the world 
by 2010 capable of sustainable economic growth with more and better jobs and greater social 
cohesion and respect for the environment” (European Parliament 2010:11)
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(ECHTA/ECAHI 2001:15). HTA supporting health promotion and disease prevention activities 
complementing EU health indicators had indeed so far never been an objective formulated 
within the HTA community. The Commission’s request to add this first objective in the project 
proposal could be explained by the fact that the European Commission sought to link HTA to 
a newly established programme on ‘European Community Health Indicators’50 funded from 
1998 to 2008 under the EU health programmes. The aim of this program was to create a 
knowledge and information system to monitor health at the EU level (http://ec.europa.eu/
health/indicators/echi/list/). This initiative is another example of the Commission’s interest in 
HTA and demonstrates how it took an active part in the policy formulation process of HTA 
cooperation. It also allows to understand how HTA was related to the wider EU health policy 
developed by the EU institutions.
The formulation of the second objective in the ECHTA/ECAHI project - to exchange in-
formation on emerging technologies, priority setting and ongoing assessments and their 
evaluations - closely follows the objectives as already set out in EUR-ASSESS (ECHTA/ECAHI 
2001:8). The third objective - to identify possible joint assessments and to co-ordinate find-
ings and existing resources within the community to support joint assessments - however 
distinguishes itself from the previous projects (ECHTA/ECAHI 2001:8). It has an explicit focus 
on “joint assessments” and the coordination of findings and resources within the “commu-
nity” (another European term not identified in the HTA jargon so far). The fourth objective, 
although focusing on methodology as in EUR-ASSESS, is of particular interest since it aims at 
developing and disseminating best practice in undertaking and reporting assessments. The 
development of “best practices” seems to refer here to a new policy instrument promoted 
on a broader level in the EU and in 2001 even formalized as a new mode of governance in 
the Commission’s White Paper on governance (2001). The ECHTA/ECAHI report published 
the same year as the White Paper on Governance underscores that this notion underpins the 
development of HTA cooperation in Europe since it is stated that “the Commission of the 
European Union is supportive of health technology assessment as a means of establishing 
best health practice in the Member States” (ECHTA/ECAHI 2001:7).
The fifth objective points to the development and co-ordination of education and support 
networks for individuals and organisations undertaking or using assessment of health in-
terventions. It also seeks to identify needs in the field and assist in the establishment of 
new provisions (ECHTA:ECAHI 2001:8). This objective shows similarities with the previous 
projects as it focusses on the development of an HTA network to develop the quality of 
HTA and give support to agencies who need it. The sixth objective - to identify and share 
50 In 2013 the European Community Health Indicators was renamed into European Core Health 
Indicators (http://ec.europa.eu/health/indicators/echi/list/)
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successful approaches to link findings of assessments, their contribution to health indicators 
and health care decision-making - stands out compared to the two previous projects (ECHTA/
ECAHI 2001:9). Reference to HTA as contributing to “health indicators” and “health care 
decision-making” points to a link with the new public health program which was being 
developed at the time by the European Commission as we will see in the next section. This 
element underscores how HTA is situated within the broader integration process in health 
policy which has been taken forward by means of the European public health programs.
4.2.2. Policy-formulation in EU public health
As we have seen in the section above, the HTA policy formulation process has been under 
influence of developments in the EU health policy domain. Since EUR-ASSESS (1994-1997), 
objectives have been redefined upon recommendations of Commission’s officials. One could 
consider this as interference on behalf of the European Commission or simply resulting of 
lobbying activities on behalf of HTA representatives seeking to secure financial support. 
However, the uptake of the Commission’s suggestions in the HTA programs for European 
cooperation could also be interpreted as the starting point of a cooperation process between 
two policy arenas that would mutually reinforce each other.
The main objective of the European cooperation process pursued by the HTA arena was to 
reinforce the quality of HTA on a local/national level and multiply the number of agencies 
to enhance the uptake of HTA in national decision-making processes. The main objective 
pursued by the European Commission in developing public health was to improve health 
of the European citizens. The EU strategy chosen to reach that aim was based on the belief 
that one should act within the scope of the health systems of the Member States. The health 
strategies and programs developed by the Commission were structured along that line of 
thought. HTA has been recognised already in the early nineties as bearing the potential to 
impact the health systems (personal interview 3). Hence, the EU health policy-formulation 
process and the European HTA cooperation policy formulation process develop in a parallel 
manner and are intrinsically linked. In this section we will focus on the developments at the 
EU health policy-formulation level so as to better understand its impact on the European HTA 
cooperation process.
As in agenda-setting, the policy formulation stage on an EU level follows a rather different 
path than what can occur on a national level. Moreover, European policy processes differ 
among themselves depending on the policy field responding to different dynamics, including 
different actors and implementing different instruments and venues (Versluis, van Keulen 
and Stephenson 2011:77). Policy-formulation in the EU is an open process with the Com-
mission playing a pivotal role in it, as it has the so-called right of initiative (Kassim 1994:23). 
Through this right allowing it to submit draft (legislative) proposals, the Commission has a 
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significant influence on the formulation of EU policies even though its decision-making pow-
ers are limited (Hix 2005: 74). Policy-making in the EU is characterised by ‘comitology’ which 
refers to different expert committees working on a future Commission’s (legislative) proposal. 
Indeed, if the Commission plays a crucial role in this process, it does not work in isolation as 
it needs to take into account the multiple levels of decision-making and implementation that 
will be concerned by its policy (Versluis, van Keulen and Stephenson 2011).
Hence, the policy-formulation stage concerns besides the Commission, Member States rep-
resentatives who need to prepare the final document on which the Council of Ministers will 
have to pronounce itself. Here too, a draft policy proposal is often being debated in different 
expert committees. The members of expert committees at this level often also offer advice to 
the Commission when it is still in phase of drafting the proposal. At this level, government 
representatives - who can propose amendments to the draft proposal of the Commission 
- seek to reach a consensus on the text before it reaches the official Council of Ministers 
who will have to adopt (or not) the proposal. In case of disagreements, the Committee of 
Permanent Representatives (COREPER), needs to reach an agreement (Versluis, van Keulen 
and Stephenson 2011: 139).
Finally, another institutional player in the policy-formulation process is the European Par-
liament especially in those areas falling under the ‘ordinary legislative procedure’51. In this 
institution too, the policy-formulation process mainly takes place in separate sectorial com-
mittees, dealing with specific policy areas. Each committee is composed of members of the 
51 The ordinary legislative procedure can take up to 3 stages. In the first stage, the European Parlia-
ment (EP) examines the published proposal of the Commission and adopts an opinion or makes 
amendments. The text then goes to the Council which examines the proposals as well as the 
position of the Parliament. The proposal is adopted when a qualified Majority Vote (QMV) has 
been found on the text approved by the EP. However, if the Council does not agree with the EP’s 
amendments or wishes to add new ones, a new ‘common position’ will be adopted (by QMV) and 
will be presented for a second reading to the EP. The proposal will be adopted if the EP agrees 
with the Council’s common position or if no decision on the latter has been taken. The proposal 
will not be adopted if the EP rejects the Council’s common position by a majority vote. If the EP 
proposes amendments to the common position (by an absolute majority vote) the text will return 
to the Commission which can deliver its opinion. In the second stage, the proposal will return for 
a second reading to the Council which can 1) adopt the text by QMV in case the Commission’s 
opinion is positive or 2) adopt the text by unanimity is the Commission’s vote is negative. If the 
Council decides (by QMV) not to approve the EP’s amendments, a conciliation committee will be 
convened (third stage). If no common position can be found, the proposal will not be adopted. If 
the Conciliation committee agrees on a joint text, the proposal can be approved provided it will 
be adopted by both institutions within six weeks (by QMV in the Council and by absolute majority 
vote in the EP). If not, the proposal will not be adopted. (Nugent 2010: 314-319).
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European Parliament representing different political parties. In the case of public health, the 
ENVI committee52 will be responsible to analyse and propose amendments on draft proposals 
of the Commission.
Besides debates taking place on the institutional level, the EU policy-formulation phase 
also includes the interactions of multiple other actors having stake in the proposed draft 
policy such as interest groups, profit and non-profit organisations, all seeking to influence 
the policy-formulation stage so that their interests will be safeguarded. This ‘lobbying’ can 
also be exercised by professional lobbyists equally seeking to influence the process so as to 
defend their (industry) interests.
In the early stages of HTA cooperation in Europe, the actors involved in the European policy-
formulation process were rather limited and mostly concentrated within the Commission. 
In particular, the European Parliament was mostly absent in the formulation of European 
health policy objectives. However gradually, with the revision of the treaties this situation 
will change. The HTA policy formulation process at the European level has to be analysed in 
close relationship with the broader health policy developments as discussed above. In this 
sense, we can identify three crucial factors that have influenced the Commission’s interests 
and involvement in HTA.
The first factor regards the development of the (Public) health programs developed by the 
Commission to ensure the establishment of a legal basis to act in the field of health policy. 
Initially, in the aftermath of the Maastricht Treaty (1992) a “Framework for Action in the Field 
of Public Health” had been adopted. This strategy document aimed at developing work on 
public health and comprised a series of eight action programs which were partly a continu-
ation of work already engaged in by the Commission before the Maastricht Treaty. HTA was 
therefore not targeted by this action plan The actions of the Framework were directed to-
wards health promotion, cancer, drug dependence, AIDS and other communicable diseases, 
health monitoring, rare diseases, accidents and injuries, and pollution-related diseases53.
In order to give a significant effect to the new Maastricht Treaty provisions, the Commission 
quickly started a reflection process upon the establishment of a single public health program 
presenting an integrated approach towards protecting and improving health. As outlined 
before, the entry point of this reflection concerned the health systems which displayed a high 
diversity among the Member States (and which became even more divergent with the en-
52 The ENVI Committee is responsible for issues in the field of Environment, Public health and Food 
Safety.
53 See further: http://ec.europa.eu/health/programme/policy/eight_programmes/index_en.htm
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largement process underway). This approach addressed ‘health’ from an economic perspec-
tive as it sought to help structuring the health systems in a cost-effective and cost-efficient 
way. Ideas such as “health is wealth” and “value for money in health care” slowly became 
part of the EU discourse on public health policy and were adopted by other institutions such 
as the WHO (Personal interview 3; Banta et al. 1997: 133; European Communities 1999; 
Seychell and Hackbart 2013). HTA fitted perfectly well in this new perception of what EU 
health policy ought to be. This certainly facilitated the uptake of HTA in the first public health 
program, aiming at the development of legal and policy instruments, pre-requisite to make 
an impact with the new competences attributed to the Commission in the field of health.
The health strategy of the Commission, as presented in 1998, and which established the 
basis of the future public health program (2003-2008), was built on three policy strands: 
a) health information, b) establishing a rapid response mechanism to health threats and c) 
tackling health determinants through health promotion and disease prevention. HTA was 
concerned by the first strand putting the emphasis on the exchange of best practices “as 
regards the safety, efficacy, effectiveness and cost-effectiveness of different approaches to 
health promotion, prevention, diagnosis and treatment” such as cost-effectiveness of screen-
ing programs and new pharmaceutical products (European Commission 1998: 48).
The aim was to promote, pool and coordinate work done in Member States in related fields 
such as evidence-based medicine, quality assurance and HTA. Gathering and exchanging 
information and improve the dissemination of findings was considered the key to develop 
the health systems of the Member States. Indeed, the Commission did not seek to develop 
an action plan to be implemented ‘from above’ but rather sought to draw upon the experi-
ences of Member States so that mutual learning processes could be driving the process. The 
underlying perspective of the Commission was that by exchanging experiences and expertise 
and through the establishment of networks, better results could be achieved which would 
permit to every Member State to enhance the quality and efficiency of their health systems. 
(European Commission 1998; personal interview 3).
HTA has been since then inserted in the health programs of the European Commission. This 
has played a major role in the development of HTA cooperation in Europe as it became an 
integral part of a new strategy for the development of a specific EU health policy. Hence, 
because health policy was being considered through the scope of ‘health’ by a dedicated 
‘health unit’ of the Commission - rather than through the scope of employment, social 
security or professional mobility – HTA could find its place in the orientations and policies of 
the European institutions. Even more so, HTA could even be considered as one of the drivers 
of the EU health strategy.
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The second factor having influenced the interest and involvement of the Commission in HTA 
regards developments on the EU systemic level with the preparation of a new EU Treaty to 
be signed in Amsterdam at the end of the nineties. Hence, while developing the content of 
the health strategy and first public health program, discussions were underway regarding the 
amendment of the public health article in the future Treaty of Amsterdam adopted in 1997. 
At the time of the Maastricht Treaty (1992), a sort of ‘pro-European’ atmosphere mostly 
dominated European politics and was often reflected in the public opinion of European 
citizens. Many policy areas were touched by integration policies and public health was con-
sidered as a field in which still much could be done (personal interview 3).
However, at the end of the 1990s, the enthusiasm for the European Union was gradually 
replaced by a more critical approach of Member States seeking to secure their powers in 
sensitive areas such as health. The amendments of the public health article in the Amsterdam 
Treaty (1997) reflect this trend. Indeed, the revised article underscores that the Commis-
sion’s action in the field “shall complement national policies (…) and shall fully respect the 
responsibilities of the Member States for the organisation and delivery of health services 
and medical care” (Article 152). The article furthermore reiterates the condition that the 
achievements of the objectives “exclude any harmonisation of the laws and regulations of 
the Member States”. This shift in attitude towards integration policies certainly affected the 
possibilities of the Commission regarding the extension of EU competences in the field of 
public health. The dominating rational regarding EU integration was the completion of the 
single market.
The establishment of the European Medicines Agency (EMA) in 1995 should be understood 
in the same perspective as it sought to facilitate the market authorisation of medicines in 
the European Union through a single application process. However, market authorisation of 
medicines fell under the responsibility of DG III (Industry) and not DG V which was respon-
sible for public health. Moreover, these policies did not concern pricing and reimbursement 
policies as this remained an area of Member States’ competences. In this context, Commis-
sion officials working on the public health program considered HTA to be a manner to “get 
into areas we hadn’t managed to get into” (personal interview 3). As the public health unit 
wasn’t allowed to get into health care specifically, nor into treatment, it sought to work in 
areas presenting a clear health objective. HTA responded to this criterion. Moreover, the 
public health program permitted the Commission to circumvent the limitations set in the 
Amsterdam treaty by developing collaborative policies in areas concerned with improving 
Member States capabilities. Here again, HTA responded to the objectives. (personal interview 
3).
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The third factor impacting the Commission’s interest for HTA is related to the need for 
promoting a social Europe expressed in the late nineties by many different actors. Indeed, 
developments that took place in the field of social affairs had repercussions on the public 
health program in spé. - and thus indirectly for HTA54. Since the Amsterdam Treaty (1997), 
social policy fell under the so-called ‘shared competences’ of the European Union. As a 
result, actions taken on behalf of DG Social Affairs received increased legitimacy (Hervey and 
Vanbrecke 2010: 106). Strengthened by the extension of its powers and seeking to push the 
social policy further on the European agenda, the European Commission initiated in 1999 
a ‘concerted strategy for modernising social protection’. One of the key objectives55 of this 
strategy comprised the aim ‘to ensure high quality and sustainable health care’ (European 
Commission 1999b: 12-14). The argumentation in this document is consistent to the one 
underpinning the health programs and underscores again the rising costs in health care 
as a result of an aging population and innovation in medical technology. The Commission 
therefore stresses the need to “contribute to improve the efficiency and effectiveness of 
health systems so that they achieve their objectives within available resources. To this end, 
ensure that medical knowledge and technology is used in the most effective way possible and 
strengthen co-operation between Member States on evaluation of policies and techniques” 
(European Commission 1999b:15).
The governance mode proposed to launch the new strategy responds to a call of the Euro-
pean Parliament in March 1999 “to set in motion a process of voluntary alignment of objec-
tives and policies in the area of social protection, modelled on the European employment 
strategy56” (EES). Indeed, the EES had introduced a new working method called “The Open 
Method of Coordination” (OMC). The aim than was to address the subsidiarity principle by 
creating a system where the responsibilities between the Member States and the European 
institutions where shared through the establishment of common targets to be defined and 
54 The bridges that can be found between health policy and social policy will remain important for 
the development HTA as for many other health policy fields such as cross-border health care. See 
also chapter 5 and 6.
55 The other objectives listed in the Commission’s communication are 1) to make work pay and to 
provide secure income, 2) to make pensions safe and pension systems sustainable, 3) to promote 
social inclusion (European Commission 1999: 12-14).
56 Resolution on the Commission report to the Council, the European Parliament, the Economic 
and Social Committee· and the Committee of the Regions on “Social Protection in Europe 1997 
(A4- 0099/99).
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implemented by Member States and monitored by the European Commission57 (see also 
Borras and Jacobsson 2004).
Following the example of the EES, the Commission concludes that, the time was ripe ‘to 
deepen the existing co-operation on the European level in order to assist Member States in 
successfully addressing the modernisation of social protection and to formulate a common 
political vision of Social Protection in the European Union’. With this ‘concerted strategy’ 
which would be ‘re-framed’ a few years later in the ‘Open Method of Coordination process 
on social policy’ (European Commission 2005), the Commission took a proactive stand in 
launching the debate regarding the coordination of social systems in the EU. Moreover, by 
introducing the Open Method of Coordination (OMC) in the field of social policy, it prepared 
the ground for the development of coordination in the field of health care. The latter will 
be of high importance for HTA cooperation in Europe as it will find its legal basis in the 
Cross-Border Health Care Directive (2011/24/EU) which emanated from this debate and 
more specifically from the coordination of health insurance systems as we will see in the 
next chapter.
4.2.3. Conclusion policy-formulation in early European HTA cooperation 
initiatives
Throughout the three project-based approaches of HTA cooperation, policy formulation has 
become increasingly formalized. In the first project, this phase was largely being influenced 
by informal dialogues, based on previous experiences and materialized in the form of a 
grant proposal and grant agreement. However, the two subsequent projects responded to 
a more formal process since governance bodies did exist as they had been established in 
the EUR-ASSESS project. Hence, consolidation of the formulation of project objectives in 
the HTA-Europe and in the ECHTA/ECAHI projects has taken place in the various working 
groups were different perspectives were being discussed before they had been adopted 
in the decision-making bodies. However, one should not underestimate the importance of 
informal discussions among partners as well as the informal intervention on behalf of the 
European Commission with regard to the formulation of the project objectives which do also 
have influenced this process (Personal interviews 2 and 6).
Indeed, as outlined above, the policy-formulation regarding the broader EU health policy fol-
lowed a particular path and has had some impacts already on the HTA cooperation projects. 
The health strategy and - in particular the first public health program - of the Commission 
57 The EES becomes a key component of the Lisbon strategy launched in 2000 which aimed at mak-
ing Europe “the most competitive and most dynamic knowledge-based economy in the world” 
(European Parliament 2010).
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has been influenced by governance practices that were introduced at other levels of the 
Commission. By taking the health systems as entry point for the development of the health 
strategy, HTA could find its place in the subsequent program that sought to implement this 
strategy. The methods proposed were based on soft governance modes such as exchange of 
best practices and of information and actually did fit the practices already in place in the HTA 
cooperation projects and which were inspired by NPM. However, to permit the HTA projects 
to benefit from EU funding, it was important that the objectives were consistent with the 
broader EU health strategy. This explains some interventions on behalf of the Commission 
regarding the content and sub-objectives developed in particular since the ECHTA/ECAHI 
project as we have seen above.
It is interesting to notice how a sort of “rapprochement” is being sought by the HTA arena 
as the emphasis put on the EU’s role to support HTA cooperation in Europe increases in 
each project. The HTA-Europe report already recommended that the European Commission 
assists in the establishment of a coordinating mechanism. The ECHTA/ECAHI report goes a 
step further by leaving the initiative up to the Commission as it states that “the European 
Commission should establish a sustainable and properly funded co-ordinating body for an 
EU-wide network of Health Technology Assessment (ECHTA)” (ECHTA/ECAHI 2001: 39, 
emphasis added). Hence, the quest at this stage is to move from an informal network to a 
formal network structure, shifting the role of protagonist of the initiative to the European 
Commission.
Interest for HTA on behalf of the Commission has been reinforced by the fact that HTA offers 
the possibilities to enter in health policy areas so far not visited by the European Commission. 
Moreover, as an integral part of the health system, it permitted the coordination of policies 
seeking to improve Member States capabilities. Soft governance practices are the only real 
instruments available to the Commission especially after the amendments in the Amsterdam 
Treaty reiterating the fact that Commission policies in the field of public health care come as 
a complement to national policies and excluding any harmonisation of laws and regulations 
in this regard. Finally, the developments in the field of social policies – introducing the open 
method of coordination in this policy area will have an impact not only on the governance 
instruments used but also on the uptake of HTA into European legislative acts as will be 
outlined in the next chapter.
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4.3. DeciSioN-makiNg iN iNitial europeaN hta cooperatioN 
proceSSeS
4.3.1. Decision-making in early European HTA cooperation initiatives
The decision-making phase of the policy cycle refers to the stage in which one or more (or 
non) of the policy alternatives envisaged in the previous stages is adopted as the official 
course of action (Howlett Ramesh and Perl 2009: 139). This stage is an inherently political 
process involving key-actors influencing the way final choices will be made. This process 
which can generate ‘winners’ and ‘losers’ is firmly rooted in the two previous stages of the 
policy-cycle. The outcome of this stage is the object of the next stage: policy implementation. 
Decisions can be ‘positive’ in the sense that they seek to alter a given situation or ‘negative’ 
if preserving a ‘status quo’ is the preferred option. Beliefs and values of actors, the nature of 
the relevant subsystem and existing constraints, all can affect the decision-making process 
(Howlett, Ramesh and Perl 2009).
Different theoretical models have been developed seeking to conceptualise public policy 
decision-making processes. Earlier models (e.g. the rational model) emphasized for example 
the role of rationality in the process underscoring the search for maximizing solution to 
complex problems where relevant information is used to assess policy options in a scientific 
manner. Others (e.g. the incremental model) underscored the political aspects in decision-
making where bargaining and negotiations are playing a key-role (Howlett 2009: 143-149). 
Some models have sought to combine both (e.g. Mixed scanned model of Etzioni 1967; ‘po-
liheuristic model’ of Mintz and Geva 1997) or completely refuted both (‘Garbage can model’ 
of Cohen, March and Olsen 1972) underscoring irrational, unpredictable and ambiguous 
elements present in the decision-making process. Weiss (1980: 399-401), has underscored 
how decisions do not always result in a ‘clear-cut’ way nor take place in a single institution 
or are taken at a single point of time. Decisions, according to this point of view, result rather 
over a lengthy period of time, are taken at multiple levels and by multiple actors. Often it is 
not even clear to individuals when a decision has actually been taken. Multiple venues, actors 
and rules occur in the decision-making process each influencing it in a different way (see 
further e.g. Klijn 2001, Timmermans 2001). Moreover, different decision-making processes 
can occur simultaneously and can mutually influence each other as well as actors’ positions 
on an issue (see further e.g. Klijn and Koppenjan 2000, Howlett 2007, Howlett et al. 2009).
As the first European HTA cooperation initiatives were run as projects within a limited time-
frame, one cannot analyse the decision-making process as if it concerned a full-fledged 
public policy. However, we will see, in the next sections, that the topic of HTA cooperation 
in Europe slowly but surely becomes a (European) public policy and that the above outlined 
process can be applied at the European, domestic as well as HTA network level. The first 
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cooperation projects should thus be analysed as part of the evolution process that led to 
the establishment a decade later of a network of a more permanent nature and which had 
repercussions on HTA policy-making.
The decision-making process in the very first project, EUR-ASSESS (1994-1997), distinguishes 
itself from the others as the project has established the governance structures on which the 
subsequent projects and the HTA network have been based. If the first decision to establish 
cooperation among HTA agencies in Europe has been taken in a rather informal way (see 
above), the project which has been set up to achieve this strategic objective did operate 
according to a clearly defined governance matrix comprising a Steering Committee, an Ex-
ecutive Committee and Subgroups. This structure has been maintained throughout the three 
project-based cooperation initiatives. Moreover, one should also include the grant approval 
by the European Commission as part of the decision-making process, as without this, the 
project would probably not have taken place the same way.
The Steering Committee in EUR-ASSESS has been established right from the start and was 
comprised of all partners in the project. At time of the project proposal submission, it com-
prised twelve individuals from ten countries58 all participating with the approval of their 
respective ministerial authorities59. At the end of the project almost all EU countries were 
represented in the Steering Committee. The Steering Committee met five times during the 
three-year long project. Due to the large number of Steering Committee members, making it 
difficult (and expensive) to discuss in depth project policy, an Executive Committee had been 
set up. The latter served to oversee the project implementation between the Steering Com-
mittee meetings. It was composed of the chairs and co-chairs of the so-called ‘subgroups’. 
The subgroups were the actual working units pursuing a specific project objective as defined 
by the Steering Committee: priority setting, methodology, dissemination and evaluation of 
impact and coverage. All subgroups were co-chaired by a partner from the north and one 
from the south. Moreover, the founding partners60 were represented in all subgroups “to 
ensure full input and ready acceptance of the results” (Banta et al. 1997:138). The other 
members were defined on the basis of their expertise and specific interest for a topic. The 
58 Denmark, Germany, Spain, Italy, Greece, Switzerland, Sweden, Spain (Catalonia), France, UK 
(Banta 1997).
59 Except for Germany where ministerial representatives which had been contacted, initially did not 
show any interest in the project. At a later stage, the Ministry of health has designated other 
German participants. (personal interview 2)
60 The founding partners were: the Swedish Council of Health Care Technology Assessment (SBU), 
the U.K. Research and Development Programme, The French Agency for Development of Medical 
Evaluation (ANDEM) and the Catalan Agency for Health Technology Assessment (CAHTA) (Banta 
et al.1997: 139).
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subgroups had to submit a final report to the Steering Committee who would review - and 
if necessary, amend - it, before final adoption and submission to the European Commission. 
Besides these structures, a project coordinator had been appointed who besides liaison work 
between the subgroups61 also endorsed the responsibility of budgetary control (Banta 1997).
In HTA Europe (1997-1998), the governance structure was identical to the one of EUR-
ASSESS. The ECHTA/ECAHI project (1999-2001) also comprised a Steering Committee and 
Executive Committee which functioned in a similar way as the two previous projects. The 
Subgroups were renamed into ‘Working Groups’ but still dealt each with one sub-objective 
serving the overall strategic aim to establish a formal network on HTA cooperation. New in 
this project was the establishment of a ‘Secretariat’ by the project leader who carried the for-
mal legal and financial responsibility over the project. The Secretariat dealt with managerial 
tasks and administrated the financial resources. As such, it reported progress of the Working 
Groups and offered administrative and organisational support to the Steering Committee 
and Working Groups ECHTA/ECAHI 2001: 16).
Although the governance structure in the three projects created clear venues where decisions 
were adopted, it seems that in practice the decision-making process took place in different 
venues and did not take place at a single point of time. For example, when the Steering 
Committee of the ECHTA/ECAHI project met for the first time in 1999, the project proposal 
had already been drafted and submitted. This however did not mean that members of the 
Steering Committee did not have a say in the decisions regarding the outline of the project. 
The different members did meet at different venues such as international meetings organised 
by other organisations or societies. Informal individual discussions and meetings also took 
place with the project coordinators and partners as it had already been the case with the 
setup of the EUR-ASSESS project. Moreover, decisions regarding future collaboration and 
orientation of the collaboration were taken in the Steering and Executive committees from 
the previous projects. In both committees, decisions were taken by consensus.
In the previous section, we have seen that the European Commission was taking part in the 
policy-formulation process, its role is less clear in the decision-making stage of the policy-
cycle. By granting financial support, the Commission did of course play an important role as 
a decision-maker since without that decision the project could not have been implemented in 
the way it has been. However, in the first project-based cooperation initiatives, the Commis-
sion did not interfere in daily management issues of the informal networks. As reports had 
to be submitted to the Commission in the course of the project, the European institution did 
61 The project coordinator acted as secretary on all subgroups and in the Steering and Executive 
committee (Banta 1997).
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have some sort of decision-making power as it could potentially decide to end the coopera-
tion process if it would not have been compliant with the grant proposal. Hence, no real 
direct intervention of the EU is to be observed in the decision-making processes of early HTA 
cooperation initiatives. The involvement of the EU on a decision-making level will however 
change in the future. To understand how this became possible it is important to situate HTA 
in the wider EU decision-making processes in the field of health policy and the repartition of 
competences as we have outlined in chapter two.
4.3.2. HTA cooperation decision-making processes from the EU health 
policy perspective
At first sight, in the period of 1991 - 2001, European decision-making processes in the field 
of health care had no impact on HTA cooperation in Europe. We have seen in the section 
above how the EU was absent in the daily management of the cooperation projects. How-
ever, a closer look at developments on the super-systemic and sub-systemic levels62 sheds 
another light on the situation. Indeed, Treaty changes regarding EU public health policy as 
well as developments on different levels in the Commission have clearly paved the way for 
a closer cooperation in the field of HTA as well as a deeper involvement on behalf of the 
Commission in this regard.
As outlined in the section on policy-formulation, at the time that the Commission was devel-
oping the first public health programme, negotiations were underway regarding what would 
become the Amsterdam Treaty (1997). Treaty amendments are important as they define the 
scope and areas in which the EU institutions can undertake regulatory initiatives. According 
to the principle of ‘conferred powers’ defined in Article 3b of the Maastricht Treaty (Article 5 
TEU) the institutions can act only in those areas where the Treaties give them power to act. 
The article furthermore stipulates that in areas not falling under the exclusive competences 
62 Peterson (1995) identifies three different levels of analysis in EU decision-making processes. A 
‘super-systemic’ level looking at ‘history-making’ decisions (taken in e.g. in the Council or in Inter-
governmental Conferences), a ‘systemic’ level that concerns policy-setting types of decisions and 
a ‘sub-systemic’ level permitting to grasp decision-making in policy-shaping processes. (see further 
also Bache and George 2006: 31-32). Peterson’s categorisation underscores how, depending of 
the policy type, different actors are involved and different processes are being set in motion. 
Wallace, Pollack and Young (2010: 55-61) furthermore stress how EU decision-making processes 
will also differ among the EU policy areas as a result of different institutional decision-making 
structures applicable to them.
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of the Community, the subsidiarity principle63 should be applied’64. Moreover, the Maastricht 
Treaty defined as new objective to make “a contribution to the attainment of a high level of 
health protection” (Article 3(o)).
The public health articles in the subsequent treaties should be read in light of the above. 
Although the public health article in the Maastricht Treaty was relatively modest in scope, 
the revision of this article in the subsequent treaties has gradually permitted the Commis-
sion to develop its initiatives in this policy field. As such, Article 152 of the Amsterdam 
Treaty introduces a new sentence in the very first paragraph stipulating that “a high level 
of human health protection shall be ensured in the definition and implementation of all 
Community policies and activities”. Although this paragraph could be understood as giv-
ing the EU potentially broad powers regarding health policy, this comprehension will be 
tempered by analysing the second part of this paragraph which seems to be a result of 
bargaining between the Commission and the Member States. Indeed, the second part of the 
first paragraph clearly delimitates the scope of EU action which shall come as a ‘complement’ 
to national policies. This action should be aimed at ‘improving public health, preventing 
physical and mental illness and diseases, and obviating sources of danger to physical and 
mental health. Such action shall cover the fight against major health scourges, by promoting 
research into their causes, their transmission and their prevention, as well as health informa-
tion and education’ (Art. 152 (1)).
Indeed, compared to the Article 129 of the Maastricht Treaty, the addition of the following 
line ‘which shall complement national policies, shall be directed towards improving public 
health” testifies of what seems to be a compromise between the Commission and the 
Member States (the first part responding to the interests’ of the Member States and the 
second part to those of the Commission). Finally, in the second paragraph, the article now 
adds the following provision: “The Community shall encourage cooperation between the 
63 The ‘subsidiarity principle’ refers to the fact that ‘in areas which do not fall within its exclusive 
competence, the Union shall act only if and in so far as the objectives of the proposed action 
cannot be sufficiently achieved by the Member States, either at central level or at regional and local 
level, but can rather, by reason of the scale or effects of the proposed action, be better achieved 
at Union level’ (see chapter 2).
64 These articles will be complemented in the Lisbon Treaty (2007) by 2 articles which will direct have 
consequence in the field of health care. Article 4 TFEU states that with regard to public health mat-
ters, powers shall be shared between the EU and the Member States which means that Member 
States are allowed to legislate to the extent that the Union has not legislated (Chalmers, Davies 
and Monti 2010: 208). Article 6 TFEU states that with regard to the protection and improvement 
of human health ‘the Union shall have competence to carry out actions to support, coordinate or 
supplement the actions of the Member States.
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Member States in the areas referred to in this Article and, if necessary, lend support to their 
action”. Although the article reemphasizes the restrictions to Community actions in the field 
of health, it also offers a new legal basis for cooperation initiatives which offers the Commis-
sion new room for manoeuvre65.
Article 129 of the Maastricht Treaty already referred to the co-decision-procedure (Article 
189b) as the decision-making basis of the objectives listed in the public health article. This 
remains the case for the amended Article 152 in the Amsterdam Treaty. However, to avoid 
that Member States lose too much ‘grip’ on this policy field, a new fifth paragraph has been 
added specifically stipulating that “Community action in the field of public health shall fully 
respect the responsibilities of the Member States for the organisation and delivery of health 
services and medical care”.
As the Treaty amendments already display, the late 1990s were characterised by an increas-
ing concern of Member States to see too many powers shifted to the supranational level. 
The same was perceptible in the health policy area which resulted in treaty amendments 
seeking to insert specific exclusions in the public health article so as to limit EU competences 
in this field. The new public health program was being developed against this background 
where the subsidiarity principle was often being referred to by the Member States as a mean 
to slow down the process, leading to Commission initiatives trying “to find ways around it” 
(personal interview 3). One of the ways to do so was by exploiting the little instruments the 
Commission had at its disposal: coordinating and supportive policies.
Even if the Amsterdam Treaty has played a role in decision-making processes strengthen-
ing the coordinating role of the Commission in cooperation initiatives, the most important 
developments in the last decade of the millennium remained the establishment of a single 
public health program which proposal was officially communicated in 1998. This document 
can be considered as a milestone in the field of EU health policy as it marks the beginning of 
a new era in this policy field. By focusing on the three strands of action on information, rapid 
reaction to health threats and health promotion and disease prevention, the Commission can 
reach out to many domains so far not tackled by community policies.
The health program would become the basis for offering financial support to external proj-
ects such as the HTA cooperation projects. Although the new public health program will only 
65 One should notice however, that although, in general, powers of the EU remained weak in the 
field of public health, the Amsterdam Treaty did offer the possibility to make binding EU legislation 
in the field of blood and organs donations and in some veterinary and phytosanitary areas (Article 
152 (4)). Harmonisation of laws and regulations remained however excluded.
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be adopted in 2002, the draft program, officially communicated in 1998 to launch a public 
discussion on the issue, already influenced Commission’s decision-making with regard to 
grants attributed to projects. In this regard, we have seen above how the Commission had 
explicitly asked to insert as first objective in the ECHTA/ECAHI project (submitted in 1998) the 
aim to “assess health promotion and disease prevention activities in terms of benefits, risks 
and economic, social and ethical implications as a complement to community health indica-
tors” (ECHTA/ECAHI 2001:15). This insertion becomes comprehensive when examining it in 
the light of the Commission’s public health program in spé.
Health promotion and disease prevention are indeed the third strand of action of the pro-
posal. Conversely to all other objectives in the ECHTA/ECAHI project, this one had never 
been discussed nor considered before in the previous HTA cooperation projects. HTA is 
indeed indirectly strongly connected to health promotion and disease prevention. However, 
compared to the initial objectives and motivations of the HTA cooperation, the ultimate goal 
of cooperation is herewith lifted to another level. Indeed, the new objective of the ECHTA/
ECAHI project stipulates that the assessment of health promotion and disease prevention 
activities should aim at complementing community health indicators. The latter reveals how 
Commission’s objectives are being diffused into the HTA cooperation program. The prime 
motivation of the initiators of HTA cooperation mostly targeted the upgrade of quality and 
quantity of HTA to insure uptake in national health care decision-making processes. By the 
insertion of this new (community) objective, HTA cooperation is not only directed towards 
national health policy but will also serve European health-policy-making.
The Commission’s proposal for a single public health program furthermore underscores how 
the actions strand on ‘health promotion and disease prevention’ is closely related to the one 
on ‘information’, by which HTA is concerned. Indeed, under the paragraph regarding action 
strand 1 “improving information for the development of public health” the Commission’s 
proposal of 1998 underscores the importance of cooperation and coordination of activities 
in areas such as Evidence-Based Medicine and Health Technology Assessment. The proposal 
stipulates that “co-ordination of work in these fields would be supported and set on a formal 
footing in order to pool the expertise of the centres in the Member States, to gather and 
exchange information, stimulate international studies, and improve the dissemination of 
findings” (European Commission 1998a:13).
It is also noteworthy to stress how the Commission puts a “major emphasis” on “best 
practice in health care” regarding “safety, efficacy, effectiveness and cost-effectiveness 
of different approaches to health promotion, prevention, diagnosis and treatment” (e.g. 
cost-effectiveness of screening programmes, health education programmes, emergency 
services and new pharmaceutical products). It even stresses that to be “fully effective such a 
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Community system and its components should ultimately be based on appropriate networks 
to which Member States would be committed to contribute in respect of the collection, 
processing and transmission of data, and in relation to taking into account the results of the 
analysis and evaluations” (European Commission 1998a: 13);
The 1998 communication of the Commission on its proposal for a new single public health 
program is interesting for our research in two ways. First, it demonstrates how the interest 
of the Commission for HTA - which has started in the early 1990s - has been translated 
into real action points of a future EU health strategy. Second, the document also points 
to the policy instruments that would be used to implement the strategy. Indeed, based on 
the powers conferred to it by the Treaty (mostly restricted to coordinating and supportive 
measures), the Commission will have recourse to soft policy instruments such as the ex-
change of information, best practices and the establishment of networks. The latter also 
points how developments in the field of health policy have been influenced by developments 
taking place in other EU policy areas and in particular social policy which already started to 
implement governance practices which would be later qualified as the ‘Open Method of 
Coordination’ as we have seen above.
4.3.3. Conclusion decision-making in early European HTA cooperation 
initiatives
The decision-making process in the early stages of European HTA cooperation is character-
ised by formal decision-making bodies but which often act on issues having been agreed 
upon in informal fora. Dialogue, exchange of experience and establishment of best practices 
seem to underpin the decision-making process as such. Previous experiences in the earlier 
projects have influenced content and governance aspects and have thus also played a role in 
the decision-making process.
Decision-making power was mostly an internal network process in which key-actors, such 
as project initiators and founding partners seem to have had a preponderant role in the 
definition of strategic objectives and aims to be pursuit. This also resulted of the fact that 
partners joining the cooperation initiatives at a later stage often also had less experience in 
HTA in general and were naturally inclined to follow proposals made by more experienced 
HTA agency representatives.
However, the cooperation process did respond to requirements of transparency since discus-
sions took place in an overt manner and the diverse governance structures offered sufficient 
possibilities for discussion and opposition. Decisions were mostly taken by consensus and no 
issues of discontent partners have been raised in our research. No indication of exclusion of 
(potential) partners has been found. Work within the subgroups/working groups responded 
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however to a more flexible approach as to the manner the objectives were to be reached. At 
this point of time, stakeholders are not involved and national governments do not seem to 
follow closely the cooperation progress made at a European level.
The framework offered by the EC grant agreement has permitted the structuring of participa-
tion as it functioned as a sort of authority since strict respect to the agreement provisions had 
to be presented. In this sense, decisions as to reaching the objectives had a binding character 
and (access to) resources did influence the decision-making process as the Commission could 
- and did – request to amend the project according to its specific wishes. Indeed, by requiring 
the insertion of a new (community) objective, the overall objective of HTA cooperation in 
Europe was lifted to higher level. Instead of pursuing objectives which essentially targeted 
the quality and uptake of HTA at a national-level, the cooperation initiatives served objectives 
linked to the European health strategy. The policy instruments at the disposal of the Commis-
sion to carry out this strategy were based on soft policy governance practices as the treaties 
conferred only coordination and supportive powers to it in this policy field. Elements of the 
Open Method of Communication introduced in the field of social and employment policies 
have also been identified as part of the Commission’s approach towards HTA cooperation.
4.4. policy implemeNtatioN iN iNitial europeaN hta 
cooperatioN proceSSeS
4.4.1. Policy implementation in early European HTA cooperation 
initiatives
Once decisions on the course of an action has been taken, the question regarding the imple-
mentation will rise. How policy decisions will be translated into concrete actions will depend 
on the knowledge and resources available as well as the instruments chosen. Commonly, the 
implementation phase will comprise more actors than in the previous stages of the policy 
cycle. The responsibility of implementing a public policy typically is conferred to civil servants 
or administrators but, depending on the countries, non-governmental organisations or other 
societal actors can also be involved in the process (Howlett, Ramesh and Perl 2009: 160).
Analysing policy implementation in the case of European cooperation in the field of HTA 
requires a departure from the typical public (governmental) policy implementation and 
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implementation models and theories66. To well understand this stage and its impact on 
the cooperation process, one needs to take account of the multiple levels involved in this 
cooperation process. As we have seen, HTA cooperation in its early phase resulted from an 
initiative stemming from within the HTA community. However, involvement of HTA agen-
cies in the cooperation project has been done with the backing of their respecting (health) 
ministries. Moreover, Commission interest in the issue has increased over the years, as it 
considered HTA an important element to pursue the development and implementation of 
an EU health policy.
Another factor to take into account when analysing the policy implementation phase of HTA 
cooperation is the fact that the strategic objective of all projects till 2001 implicitly regarded 
the creation of a permanent network of HTA cooperation in Europe. Hence, although the 
actions to be implemented (sub-objectives) had to take place within a limited project-based 
time-frame, the overall strategic objective regarded a long-term objective, having potential 
implications on the domestic and European level. The actual policy to be implemented 
concerned thus the establishment of a sustainable network for HTA cooperation in Europe. 
However, at the early stage of the cooperation initiatives, stakeholders’ visions (i.e. Member 
States, HTA agencies and the European Commission) on the subject differed regarding the 
organisational structure the network should adopt.
An important aspect of the policy implementation process regards the choice of policy 
design and of policy instruments. This is not a neutral exercise. The selection of various tools 
or instruments will form a policy mix aiming to resolve the policy problem (Bressers 1998: 
Bressers and Klok 1988). Howlett (2000) analyses policy instruments by distinguishing them 
according to their nature: ‘substantive’ or ‘procedural’. The former can potentially influence 
the substance of policy outputs, the latter can affect the “policy processes associated with 
the delivery of those outputs” (Howlett et al. 2009: 169). According to Howlett, Ramesh and 
Perl (2006), this distinction can be applied to a taxonomy of policy instruments such as the 
‘NATO – model’ of Hood (1986) whereby policy instruments are classified in categories of 
Nodality, Authority, Treasure, Organisation.
Although developed to analyse formal public governance institutions, Hood’s ‘NATO model’ 
can assist us in getting a better insight in the policy instruments that have been used in the 
first project-based HTA cooperation initiatives. Hood’s model (1986) outlines how govern-
66 See further on public policy implementation models and theories: Hargrove 1975; Pressman and 
Wildavsky 1984 (program implementation) Barrett 2004; Sabatier 1993; Hjern and Porter 1993; 
Lipsky 1980; Matland 1995; (‘top-down’ versus ‘bottem-up’ debate); Scholz 1984, 1991 (game 
theory); Ellig and Lavoie 1995; Francis 1993; Bozeman 1993 (Principal-agent theory).
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ments confront public policy problems through the use of available information (‘Nodality’), 
their legal powers (‘Authority’), financial resources (‘Treasure’) or the formal organisation 
available to them (‘Organisation’) (Hood 1986; Howlett, Ramesh and Perl 2009: 115). In 
the case of HTA cooperation, the available information was based on the experience of 
the project initiators which has served as a sort of benchmark. No real legal authority in 
terms of command and control is to be identified in these first initiatives which were mostly 
run through self-regulation. However, the rules defined by the financial authority (EC) in 
the grant agreement have framed the initiative and permitted the project coordinator to 
exercise a certain control over the other partners. Conversely, these subsidies also conferred 
a certain authority to the European Commission. Indeed, subsidies can be used as policy 
instrument by an institutional authority and are often considered as a flexible way of govern-
ing without high financial investments and permitting to stimulate innovation (Howlett et al.: 
123). Prerequisite is however that they match the institutional program. In the case of HTA 
cooperation, the grants conferred to the HTA cooperation project did offer the European 
Commission the right to oversee the project and amend it, if it did not comply with the 
broader health policy program that was being developed at that stage (personal interview 
2 and 3).
Applying Howlett’s distinction of substantive and procedural policy instruments to Hood’s 
categorisation permits to identify the building blocks on which a policy mix has been designed 
(Howlett, Ramesh and Perl 2009: 169). Research has shown that a variety of factors intervene 
in the choice of policy instruments. Some consider it as primarily a technical exercise, oth-
ers integrate it in their analysis political factors67. According to Howlett, Ramesh and Perl 
(2009: 172) influencing factors involve “the nature of the sub-system involved and especially 
its propensity to allow new actors and new ideas to penetrate into policy deliberations”. 
Whether an instrument will be able to address a particular issue will depend on the options 
an authority has at its disposal as well as on the implementation context and the manner on 
which choices respond to policy goals and means already implemented. In other words, to 
be effective, policy instruments should be chosen on the basis of their coherence with the 
policy objective and their consistency with former instruments. Policy implementation is thus 
about finding an optimal match between policy goals and policy means permitting to attain 
those goals (Howlett, Ramesh and Perl 2009: 172-173).
Since the first European HTA cooperation initiative, policy implementation has primarily been 
organised on a project-basis. The policy goal was to foster HTA cooperation in Europe and 
to establish a (sustainable) network of HTA cooperation so as to upgrade the quality of HTA 
67 See further on the selection of policy instruments: Howse et al. 1990, Breyer 1979; Mitnick 1980; 
Peters 2002; Doern 1981; Howlett, Ramesh and Perl 2009.
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and its uptake in domestic decision-making processes. The means set in motion to achieve 
the strategic objective was by adopting short term (project) objectives to be implemented by 
smaller expert units having recourse to different type of instruments throughout the three 
projects. As discussed above, this approach shows many similarities with the so-called gov-
ernance technique of ‘management by objectives’ stemming from new public management 
(see also chapter 2).
In EUR-ASSESS (1994-1997) the operational structure is rather simple and straightforward. As 
outlined above, the topics to be developed in the subgroups had been selected on the basis 
of past experience of HTA agencies’ representatives and particular needs identified in some 
Member States (i.e. coverage in Switzerland). As such, four subgroups had been established. 
The first subgroup concentrated its work on priority setting, the second on methodology, 
the third on dissemination and impact of HTA and the fourth focused on coverage. The 
working methods were quite similar across the four subgroups and have been based on the 
collection of information through reviews of the literature, and surveys. The findings were 
analysed, synthetised and discussed during subgroup meetings. Draft principles, conclusions 
and recommendations have been drafted and published in a final report (Banta et al. 1997; 
Henshall et a. 1997; Cranovski et al. 1997, Liberati et al. 1997).
The HTA-Europe project (1997-1998) functioned somewhat differently as its main contribu-
tion consisted in the publication of separate EU country-specific papers (plus Switzerland) 
focusing on the existing health policy and health care system structure and its real or 
potential relation to HTA (European Communities 1999: 30). The aim was here to better 
understand the functioning of HTA in different countries as little information about the latter 
was available (personal interview 10). Country experts drafted the papers which have been 
reviewed, revised and finalized by the Steering Committee. Each paper has been published 
separately. Alongside the country reports, four HTA-related seminars have been organised on 
the following topics: (1) Future changes in health care in Europe and their relation to HTA; 
(2) The use of health outcomes information in health care systems; (3) Opportunities for 
international assessments; (4) Identifying future health technology (European communities 
1999: 31). These topics are closely related of work that would be carried out in the follow-up 
project ECHTA/ECAHI (European Communities 1999).
The ECHTA/ECAHI project (1999-2001), proceeded again by Working Groups each focusing 
on one specific subject to be developed and which was considered necessary to achieve 
the strategic objective of establishing long-lasting cooperation. The topic of the first Work-
ing Group, Health Promotion and Disease Prevention, had been explicitly requested by the 
European Commission and responded to the strategic objectives of the EU health policy 
(see above). The second Working Group focused on a Clearing House Function and Emerg-
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ing Technologies. This topic could be related to the one of ‘priority-setting’ in EUR-ASSESS 
and the workshops in HTA-Europe. The third Working Group started to actively develop 
the concept of European Joint Assessments. This idea was already present in the report of 
the EUR-ASSESS project but had never been tackled in this explicit way. ‘Joint assessments’ 
require similar working methods and are, as such, closely related to issues of methodology 
which were being dealt with in the fourth and fifth working group on Best Practice in Under-
taking and Reporting HTA and Education and Training, the latter focusing more on countries 
where HTA was still emerging. Finally, the sixth Working Group on HTA in Policy and Practice, 
dealt with the dissemination of HTA and its uptake in health-related policy decision-making 
processes (e.g. market access, coverage and pricing). This topic was in line with EUR-ASSESS’s 
Subgroup on dissemination and impact of HTA (ECHTA/ECAHI 2001).
The outputs of the subgroups and working groups can be analysed from different perspec-
tives. First, the work has permitted to collect for the first-time information on HTA practices 
and their impact in the Member States and report this in a number of published articles. But 
more importantly, the project-based stage has played a fundamental role in the development 
of HTA cooperation as the different projects have permitted to lay down the foundations for 
work that has taken place after 2001. In particular, the EUR-ASSESS Subgroup on Methodol-
ogy has played a key-role in establishing a cooperation basis by creating a common reporting 
structure using common elements and a common methodology (Liberati et al. 1997). As we 
have seen above the aim of the cooperation efforts was two -fold: enhance the quality of the 
work to ensure its uptake in policy decision-making processes; create the possibility to re-use 
each other’s findings. The latter with the objective that: “agreement on basic standards will 
then facilitate a process of harmonisation of elements of HTA across groups and countries 
with better comparability and possibly some international division of labor across Europe” 
(Liberati et al. 1997: 191).
Although we will go into more depth on the subject of harmonisation of practices in the 
following chapters, it is important to underscore how the outputs of the very first expert 
group dealing with methodological issues, have framed the assessment structure that was 
developed a decade later68. Moreover, at this point of time, the experts already referred to 
68 The report refers to 13 stages in the assessment process: 1. Definition of the policy question 
2. Definition of the research question 3. Current state of development and use of the health 
technology 4 Technical characteristics of a device 5. Efficacy, safety, and effectiveness of the health 
technology 6. Qualitative synthesis 7. Surrogate endpoint 8. Role and weight of expert opinion 9. 
Social and psychological effects (clear guidelines are necessary here) 10. Economic evaluation 11. 
Use of mathematic modeling 12. Effects on the organisation of health services 13. Ethical aspects 
(Liberati et al. 1997). Many of these stages will be present in the Core HTA model develop by 
EUnetHTA (see chapter 6).
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the importance of what will be called later “relative effectiveness assessment” and which will 
become a key feature in HTA cooperation after 2006. In the ECHTA/ECAHI project, the Work-
ing Group 4 went a step further in developing common methodologies basing themselves 
on best practices and introducing a “Scientific Summary Report” permitting to “critically 
appraise HTA reports to evaluate their reliability” (ECHTA/ECAHI 2001: 22).
The project implementation phase in the early cooperation initiatives reveals that a common 
understanding regarding the ultimate aim of the collaboration was still lacking. Part of the 
tasks of the different expert group was to examine to which extent convergence of practices 
was feasible and desirable. In this sense, the EUR-ASSESS subgroup on Priority setting came 
to the conclusion that no harmonised priority setting process should be established as the na-
tional/regional needs and contexts still considerably varied. The experts do however develop 
a common approach regarding the set-up of a priority system (Henshall et al. 1997: 166-
167). The ECHTA/ECAHI report (2001:20) confirms these findings and furthermore stresses 
the importance of using existing structures (e.g. Euroscan) in any European clearinghouse 
function.
Despite the difficulties of establishing a harmonised approach in HTA practices, call for joint 
work is underscored in one of the subgroup recommendations, as early as in the EUR-ASSESS 
project: “Those responsible for HTA programs should share information on priorities and 
discuss opportunities for joint working on expensive assessments of joint interest, and the 
division between programs of assessments or components of assessments whose results can 
be shared“ (Henshall et al. 1997: 167). The item of joint work is also present in ECHTA/ECAHI 
Working Group 3 who looked for Joint assessment opportunities. The group on priority 
setting also already recognised the importance to include various stakeholders as of the stage 
of priority-setting so as “to achieve commitment to the process and the outcomes” (Henshall 
1997: 164). We will see that this idea will grow in importance over the years and that 
gradually perspectives will change regarding both the (early) involvement of stakeholders69 
and the feasibility of establishing joint work, implying (a certain degree of) convergence of 
practices70.
Even though Coverage received little attention in the early cooperation initiatives, the experts 
working on this subject in the EUR-ASSESS project already stressed the dilemma faced by 
many governments seeking to contain pharmaceutical costs on the one hand and supporting 
at the same time the development of pharmaceutical industry (important for the national 
69 See further about the involvement of stakeholders: chapter 6.
70 Since 2006, joint assessments will become one of the core outputs of the EUnetHTA collaboration 
and EUnetHTA network. See further on joint assessments chapter 6.
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economy in terms of innovation, jobs, growth). Proposing a new model for coverage policy 
integrating HTA71, the experts of the subgroup on coverage appealed for the development 
of a policy which would be more “explicit, rational, and transparent” (Cranovski et al. 1997: 
295). Although disappearing of the network’s agenda for some years, salience for this topic 
will re-appear at a later stage (see chapter 6).
Finally, work of the EUR-ASSESS subgroup on Dissemination concerned an objective directly 
linked to the overall strategic aim: the uptake of HTA in decision-making processes. Here 
again the implementation has resulted mostly in an overview of practices in the different 
Member States. The experts highlighted in this regard the disjunction between HTA ‘do-
ers’ (‘HTA agencies) and HTA users (governmental authorities responsible for the Market 
authorisation, pricing and reimbursement decisions). According to the experts, coordination 
between both groups should be increased and more resources should be allocated for shar-
ing and disseminating results of HTA (Granados et al. 1997: 228-230). The ECHTA/ECAHI 
working group on health promotion and disease prevention confirmed that HTA concerned 
a significant proportion of prevention activities but uptake in domestic policy decisions varied 
in the different Member States (higher in countries with well-established HTA programmes) 
(ECHTA/ECAHI 2000: 18). The ECHTA/ECAHI Working Group 6 continued to gather informa-
tion through surveys and workshops on the manner in which HTA was being disseminated 
and used in domestic policy-making processes. Exchange of best practices was here again a 
recommended instrument to pursue the objective of an increased HTA-uptake in decision-
making processes (ECHTA/EAHI 2001: 23).
4.4.2. Policy-implementation in HTA cooperation from the EU health 
policy perspective
HTA cooperation in the early stages is not directly concerned by what is commonly understood 
by policy-implementation processes taking place on a European level. The latter refer mostly 
to the processes where EU policy decisions are ‘translated’ into national policies. During 
the early phase of HTA cooperation in Europe, an EU public health policy was just emerg-
ing and health policy remained a national competence. Moreover, soft policy instruments 
were not yet an official EU governance mode. As a consequence, HTA cooperation was only 
concerned by the EU through the grant agreements it had signed with the Commission and 
EU policy implementation policies in the area of HTA mostly regarded the respect of the 
agreements signed. We will see in the next chapter that his situation will change as HTA will 
play an important role in the implementation of the EU health programs that will be adopted 
at the turn of the millennium. In 2011, HTA cooperation will even be part of the Cross-
71 This model is comprised of four stages :1) identification of the technology, 2) Literature review, 3) 
Synthesis of available information, 4) a coverage proposal (see further Cranovsky et al. 1997).
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Border Health Care Directive which will have a direct impact on the role of the European 
Commission in HTA cooperation in Europe by giving it a legal basis to take part and steer the 
implementation of different policies regarding HTA in Europe (see further chapter 6).
Hence, from 1991 to 2001 EU decision-making processes regarding HTA cooperation still 
only concerned projects co-financed by the European Commission. The implementation of 
the projects was only overseen by the Commission to ensure the consistency with the project 
proposal being accepted for Community financing. Our interviews with the participants in 
the projects all confirm little or no interference of the European Commission regarding the 
project implementation which was completely managed by the project partners. Although 
we have seen above the use of soft policy instruments (e.g. peer education, exchange of best 
practices) to implement the different program items, these resulted from external influences 
rather than from an EU influence in this regard.
The European Commission has however played a (non-negligible) role in the implementation 
phase of the different projects by having the potential authority to withdraw the financial 
contribution in case of non-respect of the project obligations. In a sense, the project-based 
approach corresponds to a (embryonic) form of self-regulation by sectoral experts (Héritier 
and Lehmkuhl 2011:49) which will be one of the innovative forms of governance that will 
be implemented by the European Commission in the following decade72. Recognising the 
importance and complexity of health technology assessment for the national health systems, 
the European Commission did not interfere in the actual project implementation which was 
run by HTA experts. However, its sole presence as financial contributor and supra-national 
actor having an interest in HTA for its own health program has situated the projects to be 
implemented to a certain extent under the authority of the European Commission. Accord-
ing to the project coordinators of EUR-ASSESS, HTA-Europe and ECHTA-ECAHI, the presence 
of the Commission has facilitated the implementation of the projects as the deliverables had 
to be turned in in time (Personal interviews 2, 4 and 6).
72 Self-regulation by expert communities has been a governance instrument falling under the 
so-called New Modes of Governance and has at first been implemented to deal with complex 
issues of market regulation. In areas of particular high technical complexity, recourse to self- or 
co-regulation permit to gather expertise and resources from within the private sector. This further-
more allows to shift specific regulatory activities from the governmental arena to a Community 
agency (see further Héritier and Lehmkuhl 2011).
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4.4.3. Conclusion policy-implementation in early European HTA 
cooperation initiatives
In the early European HTA cooperation projects the “policy” goal was to foster HTA coop-
eration in Europe and to establish a sustainable network of HTA cooperation (Banta et al. 
1997:13: ECHTA/ECAHI 2001: 11). The implementation approach chosen was project-based 
and organised by means of sub-objectives to be accomplished by smaller expert units. Be-
sides the formal working methods of information collection, literature reviews, surveys and 
reporting methods, the units operated on the basis of soft governance principles.
Although formal governance structures have been established since the very first coopera-
tion project, many objectives have been pursued and decisions taken as a result of informal 
discussions as well as through learning processes. ‘Peer education’ seem to have been 
present since EUR-ASSESS where the experience of some has influenced future practices of 
others as underscored by Banta et al. (1997:141): “During these discussions, considerable 
informal advice has been given, especially to those whose activities are not so mature”. 
Especially in the ECHTA/ECAHI project, the exchange of best practices has become an official 
implementation instrument in several Working Groups to reach some of the sub-objectives 
defined by the Steering Committee (ECHTA/ECAHI 2001).
Similarly, the role of discourse should not be underestimated in the formulation, acceptance, 
adherence and implementation of policy objectives. Before EUR-ASSESS, structured coopera-
tion initiatives in HTA did not exist in Europe. Although the need to share experience was 
identified in many of the existing HTA agencies, defining the goal of the cooperation as well 
as the ‘roadmap’ to reach that goal, required the development of a basis of common beliefs, 
values, ideas and expectations as to the role of HTA in domestic and European policy-making 
contexts. The role of policy-entrepreneurs both on the HTA level as within the European 
Commission has been of high importance herein. To some extent, one can even consider 
that the prime role of the sub- and working groups has been to establish this common basis 
of beliefs, values and expectation on which a future sustainable network could be created.
Moreover, it seems that progressively the project partners started to form a distinct expert 
community that could be identified as an “epistemic community” defined by Haas (1990:349) 
as “transnational networks of knowledge based communities that are both empowered 
through their claims to exercise authoritative knowledge and motivated by shared causal 
and principled beliefs”. Indeed, the more the partners cooperated and shared information 
and experience the more common beliefs and practices were established regarding HTA. As 
such an iterative mutual learning process has been set in motion since the early days of the 
EUR-ASSESS project which has matured in the HTA Europe and ECHTA/ECAHI projects.
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At this stage of the cooperation initiatives, much of the policy implementation regards the 
collection of information and the proposals of theoretical models that could be of use for 
future joint work on HTA. The latter is a notion that is still ‘handled with care’ and the specific 
domestic policy-making settings are often being recalled. The idea of harmonising practices 
is implicitly present in all projects but explicit references to the fact that no standardisation 
or harmonisation should be pursued can also be found (Liberati et al. 1997: 191; Henshall 
et al. 1997; Cranovski et al. 1997). Positioning towards standardisation and convergence of 
practices will slowly but surely shift in the following decade. Joint assessment will even be 
considered, in 2016, as the ‘golden standard’ to achieve73.
Two other factors have played an important role in the implementation phase: voluntarism 
and inclusiveness. These stem from the organisational structure that had been set in place 
since the EUR-ASSESS project. This structure was characterised, as we have seen above, by 
a multi-level, inclusive participatory governance style. Indeed, all early cooperation initiatives 
were shared the fact that they sought to include a maximum of actors involved in HTA, 
creating herewith a sense of adherence to the project objectives amongst them. As in the 
other phases of the policy cycle, members were free to join, or not, the cooperation initiatives 
which were governed by means of self-regulation. It is however especially in the implementa-
tion phase that the impact of a non-binding voluntary approach to cooperation can have a 
decisive impact on the outcome of the project. Clearly, although all partners had a specific 
task, key work has been done by a core-group of participants (Personal interviews 2, 6). 
Adherence to the project objectives was however not the only factor that would explain the 
commitment of the partners to the project. Having to account for the subsidies received from 
the European Commission has clearly also operated as a stimulus to deliver results.
It may be interesting at this point to apply the policy mix model of Howlett and Hood as 
discussed above and laid down in figure 1 (Hood 1986; Howlett, Ramesh and Perl 2009: 
115). As we have seen, the substantive information (Nodality) instruments used in the 
early cooperation initiatives were based on existing published knowledge (literature reviews), 
collection of information regarding domestic HTA settings, peer education/personal experi-
ences, exchange of best practices. The substantive authoritative instruments were based on 
self-regulation (steering committee) and voluntarism (Working groups). The allocation of 
budgets (stemming from the EC grant) for each Sub/Working groups could be considered as 
substantive financial instruments of the cooperation initiatives, having an impact (especially 
in the ECHTA/ECAHI project) on the content and duration of the projects. Organisational 
73 Pilot projects on joint assessments will be launched in 2006 but their importance will gradually 
increase to become one of the core activities in EUnetHTA Joint Action 3 (Work Package 2 joint 
production) (http://www.eunethta.eu/search/apachesolr_search/Joint%20action%203).
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wise, the initiatives could be categorized as project-based ‘informal networks’ operating on 
the basis of small expert units.
The official reporting structure of the European Commission could be considered as a 
procedural information policy instrument since these reports will serve as a basis for the 
extension of institutional support for HTA cooperation on a European level. Some of these 
reports become even the basis of policy documents for use of and commissioned by the Eu-
ropean Commission (e.g. European Commission 199974). Two levels of procedural authority 
instruments can be identified. The first regards the grant agreement framework which sets 
the terms which need to be respected and which give the European Commission the right 
to terminate the project in case of non-respect of the grant agreement. The second level 
regards the internal governance structure in the form of a Steering Committee and an Execu-
tive Committee. The EC (health) programmes through which the specific project subsidies 
have been granted could be considered as the procedural financial agreement. Finally, no 
procedural organisation instrument can be identified in these first cooperation initiatives.
Nodality/Information Authority Treasure Organisation
Substantive
Policy instruments
Existing information
Exchange of experience
Self-regulation
Voluntarism
Sub-Working 
Group budgets
Informal project-
based network
Expert units
Procedural
Policy instruments
Project Reporting
Institutional policy 
documents
Steering committee
Executive Committee
WG chairs
EC Grant agreement
EC (health) 
program
-
Table 4.1. Hood’s NATO-model (1986) applied to early European HTA cooperation initiatives
When analysing the policy instruments used according to this mixed model one can notice 
immediately that the procedural organisational level is lacking. If the substantive policy 
instruments can potentially influence the substance of policy outputs the procedural policy 
instruments can affect the policy processes associated with producing these outputs (Howlet 
et al. 2009: 169). In the case of the early HTA cooperation initiatives, no clear organisa-
tional structure existed which could serve as procedural policy-instrument. The project-based 
structure functioned as an informal network structure, limited within the timeframe of the 
projects. Throughout the projects, ambiguity existed however regarding the fact whether 
the project-based network structure should be or become the sustainable European HTA 
network, which became the strategic goal of the different projects (in particular those after 
EUR-ASSESS). This ambiguity will remain throughout the subsequent initiatives which have 
74 The report Health technology assessment in Europe: The challenge of coordination written by 
Banta and Oortwijn (1999) has been commissioned by the European Commission and served as a 
policy reflection document in the field of HTA.
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been developed after 2006. The lack of the existence of a clear (legal) organisational entity 
coordinating HTA cooperation will indeed impact the policy processes associated with HTA 
cooperation in Europe as we will see in the next chapters.
Awareness of the importance of having such a (legal) entity has been expressed as of the very 
first program (Banta et al. 1997: 142) and has been more clearly reasserted in HTA Europe 
(European Commission 1999: 5; Banta and Oortwijn 2000b:634). A concrete HTA coop-
eration model has been proposed in ECHTA/ECAHI (2001: 25-30). No consensus however 
existed as to the legal form (and associated competences) this entity should adopt. The ques-
tion was associated with national health policy processes which remained under national 
competences. Early reports (e.g. HTA Europe) underscore in this regard the importance of the 
subsidiarity principle and the fact that no new European agency should be established (Banta 
and Oortwijn 2000b: 635).
It is Interesting to notice at this point how the Steering committees of all early cooperation 
projects appeal the European Commission to assist them in the establishment of a formal 
sustainable HTA network. In the first project, assistance refers primarily to financial aid (Banta 
et al. 1997: 143). However, in the HTA-Europe project, this task comprises, besides the coor-
dination of a system design and integration, more than a dozen other actions which were so 
far carried out by expert units in the projects (Banta and Oortwijn 2000b:634). The conclu-
sions of the ECHTA/ECAHI project go a step further and explicitly recommend that “The 
European Commission should establish a sustainable and properly funded co-ordinating 
body for an EU-wide network of Health Technology Assessment” and thus implicitly external-
ize the initiative of establishing a European HTA network to the Commission (ECHTA/ECAHI 
2001: 39). Although the Cross-border Health Care Directive adopted in 2011 will permit the 
establishment of a formal HTA network, the procedural organisational question has, until 
today, not been resolved. As we will see in the next chapter on the developments after 2000, 
this question will have an impact on the HTA policy processes that will be developed after 
the turn of the century.
4.5. policy evaluatioN iN iNitial europeaN hta cooperatioN 
proceSSeS
4.5.1. Evaluation in early European HTA cooperation initiatives
Once a policy has been implemented and even during the implementation phase, it is of 
interest to assess how the policy works in practice. Policy evaluation, the last stage of the 
policy cycle, concerns not just the outcome of the implementation process, it also assesses 
which instruments have been used and whether the objectives have been reached. In other 
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words, policy evaluation is about “effectiveness of a public policy in terms of its perceived 
intentions and results” (Gerston 1997: 120). As a result of the evaluation process, a policy 
problem can be re-conceptualised (leading to a new policy cycle), the policy can also be 
adjusted or discontinued (Howlett Ramesh and Perl 2009: 179). As in the other stages of 
the policy cycle, evaluation is not a neutral process, but contains, together with technical 
elements, also a political dimension (since assessments may influence decision regarding the 
policy (dis)continuation).
Different types of assessments exist. Administrative evaluation will for example assess the 
process, the performance, the effectiveness (value for money) or efficiency of the policy 
(Howlett et al. 2009: 185-188). However, evaluation techniques can also comprise the use of 
performance indicators or benchmarking exercises. Finally, evaluation can also be considered 
in terms of “policy learning”, referring to the fact that evaluation can imply learning processes 
which in turn can trigger policy change. Some consider these processes to be endogenous 
whereby the goals or techniques of a policy can be adjusted in the light of past experiences 
and new information (Hall 199375). Others (e.g. Heclo 1974) refer to external changes in a 
policy environment which may motivate a government to adjust its policy. Assessments can 
be carried out by different sets of actors, governmental or non-governmental depending on 
the subsystems of the political spectrum involved. Hence, evaluation can be carried out by 
politicians, as well as by experts, interest groups, the media or other actors concerned by a 
policy (Howlett, Ramesh and Perl 2009: 183-185).
Different types of evaluation processes can be observed in the early cooperation projects. 
The first is associated to the organisational structure of the initiatives. As we have seen in the 
first part of this chapter, the three projects functioned according to management practices 
correlated to NPM integrating a form of “Management By Objectives” where the common 
strategic goal was split into operational sub-objectives to be implemented by smaller expert 
units. Evaluation of the project has been being carried out during periodic meetings of the 
Executive and Steering Committees which served to evaluate progress made of the sub/
working groups (output – orientated evaluation). Moreover, the Steering Committee was 
responsible for reviewing all draft reports of the sub/working groups before its final ac-
ceptance (Banta et al. 1997). These reports served also as a basis for the annual reports that 
needed to be sent to the European Commission who carried out an administrative evaluation 
assessing the project in terms of output, effectiveness and efficiency.
75 Although according to Hall big changes or so-called paradigm shifts will rather result from exog-
enous shocks (Hall 1993).
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Hence, evaluation was mostly output based and directed towards the goals of the different 
subgroups. It is interesting to notice here that the outcome of most working groups regarded 
the elaboration of an aspect of the state of affairs of HTA in different European countries. 
In EUR-ASSESS (1994-1997) for example, HTA cooperation had been set in motion with 
the aim to upgrade the quality of HTA as well as its uptake in domestic policy-making. To 
achieve this aim, sub-objectives have been formulated and the outcome of the project has 
been measured by looking mainly at the results of the individual subgroups in terms of 
methodology, priority setting, dissemination and coverage. The deliverables of the subgroups 
concerned an elaboration of the state of affairs in each of these areas. Additionally, models 
have been proposed which could serve as a basis for adopting a common approach on these 
issues (Liberati et al. 1997; Henshall et al. 1997; Granados et al. 1997; Cranovski et al. 1997).
Similarly, HTA Europe (1997-1998) concerns primarily a series of publications of the state 
of HTA in EU Member States (Banta and Oortwijn 2000b). In ECHTA/ECAHI (1999-2001), 
the evaluation regards again specifically the outcomes of the individual working groups. 
These also mainly concerned an outline on HTA related practices in Europe such as practices 
on health promotion and disease prevention, early identification/priority setting, existing 
international HTA projects, existing education programs in HTA (ECHTA/ECAHI 2001: 18-23).
Evaluation in these early cooperation initiatives could also be examined through the scope 
of ‘policy learning’. The different EUR-ASSESS reports mention the importance of informal 
working methods among “about 100 or so technology assessors, academic experts, and 
others of many nationalities” permitting an “exchange of knowledge and ideas” which 
“substantially added to the quality of the reports” (Banta et al. 1997:139). The fourth work-
ing group of the ECHTA/ECAHI project, continuing the EUR-ASSESS work on developing 
a common methodology, was even based on the exchange of best practices to identify 
needs for methodological developments (ECHTA/ECAHI 2001: 402:454). The report here 
also testifies of endogenous learning processes that took place within each project but also 
from one project to another and which could lead to some changes as a result of external 
developments. In this case, it led to modifications in the methodological framework initially 
developed by EUR-ASSESS and further amended in ECHTA/ECAHI (ECHTA/ECAHI 2001:403).
4.5.2. Evaluation in HTA cooperation from the EU health policy 
perspective
As in policy evaluation on a governmental level, evaluation processes within an EU setting 
can take place in administrative, political and judicial manner. Regarding the early European 
HTA cooperation initiatives, only the first two types of evaluation processes apply. As we 
have seen in the discussion above on policy implementation, administrative evaluation by 
the European Commission on the implementation of the project as foreseen in the project 
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proposal has played a role to ensure the timely production of deliverables and the respect of 
budget constraints. In this sense the European Commission focused on outputs in terms of 
value for money, achievement of projects goals and managerial performance. The evaluation 
and monitoring has been based on interim and final reports produced by each sub/work-
ing group and submitted by the project coordinators. Through the evaluation in its role as 
financial contributor, the European Commission has had a certain authority over the project.
However, besides the administrative evaluation another evaluation process has taken place 
which could be qualified as ‘political evaluation’. We have seen that, within the HTA com-
munity, evaluation has permitted learning processes to take place. A similar observation can 
be made regarding the European level. As we have seen at the beginning of this chapter, 
most EU officials and administrators were not familiar with HTA until they had been con-
fronted with it in the EUR-ASSESS project proposal. Recognising the need of HTA in the 
overall development of EU health policy, the European Commission has given support to the 
development for HTA cooperation in Europe. As such, the early cooperation projects have 
also permitted bi-directional learning processes between the HTA and the EU (Commission) 
communities. The HTA community has slowly turned into an expert community of which the 
European Commission could take benefit in the development of its political strategy in the 
field of health.
The outputs of the cooperation processes have been integrated in the future health programs 
and a decade later even in the Directive on Cross-Border Health Care. Informal discussions 
among HTA and Commission representatives have permitted an exchange of information 
and experiences and a common reflection on future developments (Personal interviews 2, 3, 
4 and 8). At this stage, different ‘endogenous’ and ‘exogenous learning’ processes (Bennet 
and Howlett 1992) are taking place but all still with a rather ‘low intensity’. In other words, 
the evaluation process of the HTA cooperation initiatives between 1992 and 2001, have 
contributed to the development of the EU health policy agenda. Hence, from a technical 
issue (assessments) HTA cooperation will progressively be politicised to become in 2004 a 
“political priority” for the European Commission (European Commission 2004f) as we will 
outline in the next chapter.
4.5.3. Conclusion evaluation in early European HTA cooperation 
initiatives
Although no clear written administrative evaluation procedures have been established in 
the first projects seeking to foster HTA cooperation in Europe, evaluation processes certainly 
did take place. As the projects were based on a multi-level, non-hierarchical governance 
structure, accountability for the project outcome was shared. Evaluation processes also took 
place on multiple levels, in multiple fora, by multiple actors and in multiple ways. As such, 
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a more administrative based evaluation focused on outcome, effectiveness and efficiency 
took place on a European level and influenced a similar evaluation process within the project 
which was conducted by the Steering committee. This evaluation process was based on the 
assessment of the outcomes of the separate expert working units. Within the individual 
working units, evaluation also took place in the form of learning processes through the 
exchange of experiences and the establishment of best practices.
Evaluation remained in a sense small-scaled but was exercised by different type of actors 
and stakeholders. The processes have been quite influenced by the governance structure 
put in place as well as by practices stemming from New Public Management. Similarly, from 
the EU perspective, administrative evaluation was accompanied by a more political evalu-
ation leading to endogenous and exogenous learning processes. These have permitted a 
better understanding of the potential role of HTA in the wider EU health strategy. Whilst 
all these processes are at this stage rather small-scaled, they will put down the basis for 
more structured administrative and political evaluation processes in the future which will 
contribute to structure the cooperation process within the EU. Moreover, these evaluation 
and learning processes match with governance practices that will be developed after 2001 
in the European Union and more specifically in the field of health policy as we will see in the 
next chapter.
4.6. coNcluSioN
Analysing European collaboration in HTA through the scope of the policy cycle as developed 
by Howlett, Ramesh and Perl (2009), permits the identification of some key features charac-
terising the cooperation processes and structures that have been set up in the early stages 
of HTA cooperation in Europe. We have seen in the sections above how the development 
has been favoured by the subsequent development of two distinct agenda-setting processes: 
one at the level of HTA community and one at the level of the European Union. The fact that 
the two agendas matched has permitted the uptake of HTA cooperation at the European 
institutional level even before any real domestic policy regarding European HTA cooperation 
had been developed in the Member States. The role of policy entrepreneurs at HTA and EU 
level has played an important role in shaping the terms of the policy debates and building 
coalitions to bring the issue forward on the different agendas of the European Union. As a 
result, support for the initiatives has been found, opening the way to secure organisational 
and financial resources.
Analysing the agenda-setting stage of HTA cooperation has also shown how at a very 
early stage the European Commission has understood the role HTA could play in the EU 
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health policy which still had to be created. Hence, both in terms of timing and content, 
the launch of HTA cooperation in Europe and the launch of the EU health policy matched. 
The development path of both have thus been intrinsically linked which explains how the 
European Commission has, from the outset, played a prominent role in the development of 
HTA cooperation in Europe.
The importance of the EU role can be further observed in the policy-formulation process, 
where some interference of the Commission is present as early as the first EUR-ASSESS 
project which has been revised according to informal instructions of the Commission so 
as to have the project approved. In ECHTA/ECAHI this becomes even more apparent since 
the Commission has explicitly requested the insertion of the very first objective of the 
cooperation so as to match other EC initiatives in the field of health policy. Developing 
HTA cooperation on a European level responded to a common interest of both the HTA 
community and the European Commission. The Commission’s ‘interference’ should therefore 
not be seen as a top-down hierarchical control of the Commission over the cooperation 
initiatives. On the contrary, the HTA cooperation projects were characterised by multi-level, 
inclusive participatory governance methods which seem to have been influenced by so-called 
new public management policy instruments such as: management by objectives, participa-
tory governance, shared accountability, performance measures for increased efficiency (e.g. 
best practices, benchmarking). Many of these instruments could also be qualified as soft 
governance instruments as outlined in chapter 2.
The NPM moto ‘steering rather than rowing’ could also be applied to the decision-making 
culture characterising the early European HTA cooperation initiatives. Although formal 
decision-making bodies existed, these acted by consensus, often on issues having already 
been agreed upon in unformal fora. Dialogue, exchange of experience and establishment 
of best practices as well as previous HTA experience seem to underpin the decision-making 
process as such. No direct role of the European Commission can be identified in the decision-
making processes. However, through its grant agreement, the European Commission did, 
to some extent, have an authority over the project ensuring the decisions did respect the 
objectives as set in the formal contract, which as we have seen, also served the higher goal 
of establishing a European health policy.
The implementation processes in the early stage of HTA cooperation have, on the one 
hand, permitted to gather information on HTA practices and their impact on domestic 
policy-making (pre-requisite for further cooperation and eventual convergence of practices). 
On the other hand, they have laid the foundation of the work that has taken place after 
2006, with the creation of an official network on HTA in Europe “EUnetHTA”, which will be 
discussed in the next chapter. Policy implementation in the early cooperation processes has 
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been characterised by the presence of soft governance means such as ‘peer education’ and 
exchange of best practices. Moreover, the role of discourse has also played an important 
role permitting the development of an ‘epistemic community’ (Haas 1990) sharing com-
mon beliefs, values, ideas and expectations as to the role of HTA in domestic and European 
policy-making contexts. This has certainly contributed to the adherence and implementation 
of the defined policy-objectives as well as to the development of iterative mutual learning 
processes that have been identified since the early days of the EUR-ASSESS project and which 
have matured in the HTA-Europe and ECHTA/ECAHI projects. Finally, not underestimating 
the ‘voluntary commitment’ of the partners to deliver project outcomes, one need to stress 
at this point again the fact that the projects were being implemented with the support of 
the European Commission, subsidizing the projects and thus holding the project partners 
accountable for delivering results.
Analysing the European HTA cooperation policy implementation process according to the 
policy mix model of Howlett and Hood (Hood 1986; Howlett, Ramesh and Perl 2009: 115) 
brings to the forefront that a ‘procedural organisational’ instrument is lacking in the early 
HTA cooperation initiatives. This can be explained by the fact that the collaboration was 
project-based and, at the same time, functioned as an informal HTA network within a limited 
timeframe. However, we have also seen that ambiguity existed regarding the vocation of 
the informal network which some considered to be the future sustainable HTA network 
responding to the strategic goal of the projects. The establishment of an organisational entity 
requires however to define its legal status. This question is still today a matter of debate and 
intrinsically linked to notion and understanding of the subsidiarity principle in the European 
Union. The status of what should become a sustainable European HTA network has still not 
been resolved and lays at the heart of the latest developments in European HTA coopera-
tion. It is clear that in the first decade of European cooperation, the question had not been 
resolved by the HTA arena itself. We will see in the next chapter that the positioning of HTA 
cooperation within a wider EU framework will affect this issue.
Finally, evaluation processes in the early collaboration initiatives remain mostly informal. 
Evaluation, which needs to be understood in its broader sense, has taken place on multiple 
levels, in multiple fora, by multiple actors and in multiple ways, including administrative 
output-focused and as endogenous learning processes. Here again, we have seen that the 
assessment processes have been determined by the governance structure put in place since 
EUR-ASSESS where the non-hierarchical governance structure led to a shared accountability. 
The latter remains however relative since, here again, the project partners were operating 
with the financial support of the European Commission which has assessed the projects 
according to its own (administrative) instruments focusing on effectiveness and efficiency. 
192 Chapter 4
In case of unsatisfactory outcomes, the Commission would have had the potential power to 
terminate the financial support for the projects.
The next chapter will focus on an interlude period running from 2001-2006 where no HTA 
cooperation project has taken place. However, important developments taking place in three 
different EU health policy streams have been of major importance for the developments of 
HTA cooperation after 2006 as they laid the basis for the institutional framework, governance 
modes and content of the collaboration efforts.


5 Policy streams structuring 
European HTA cooperation 
“To advance on several fronts at once did not necessarily mean doing so at 
the same speed. 
What mattered was that movement should be general, for only by deeds 
would Europe take shape.”
Jean Monnet, Memoirs
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5.0. iNtroDuctioN
The end of the ECHTA/ECAHI project in 2001, coincided with a number of events taking 
place in the EU at the turn of the millennium and affecting European polities, policies and 
politics. Some of these events were related to broader political and institutional develop-
ments within the EU, but which did have an impact on European health policy-making and 
indirectly also on European cooperation in HTA. In the period running from 1999-2008, 
we can identify three main policy streams that have had a direct or indirect impact on HTA 
cooperation. Whilst HTA cooperation in Europe has been most influenced by developments 
within the EU (public) health policy stream, it has certainly also undergone important influ-
ences from two other policy streams which we will call here: the EU social policy stream and 
the EU pharmaceutical policy stream. The former with regard to the governance instruments 
used in HTA cooperation and the latter with regard to the content developed in the European 
HTA networks.
Each of these policy streams will develop within a different institutional structure: EU public 
health in DG Sanco; social policy within DG Social affairs and Employment and Pharmaceuti-
cal policy within DG Enterprise and Industry. A common feature of these policy streams is the 
presence of (high-level) expert groups or networks set up by the European Commission and 
which have an important influence on the policies being developed in each of these streams. 
This chapter will highlight how HTA cooperation in Europe is concerned by the three different 
policy streams cited above and how these policy streams will cross-each other at some points 
through these networks permitting to structure the future European HTA cooperation.
The first policy stream can be situated at the level of EU (public) health policy and runs pri-
marily within DG Sanco. It has been triggered however outside this institution as complaints 
filed by two citizens living in Luxembourg have set in motion a process seeking to clarify and 
(re-)define the role of the European Union in health policy-making. Ceased on the issue of 
cross-border health care, the cases76 which have been dealt with by the Court of Justice of 
the European Union77 (CJEU) as of 1998, have brought to the fore the complexity of the EU 
health policy field, which embodies not just aspects of public health and health care but also 
relates to social, industrial, economic and financial Member States’ and EU policies. Each 
76 Case C-158/96 Kohll v Caisses de Maladie [1998] ECR I-1931 ; Case C-120/95 Nicolas Decker v 
Caisse de Maladie des employés privés [1998] ECR-I 1831. See further cases listed under footnote 
7.
77 Before 2009 it was often referred to as the European Court of Justice (ECJ) but since the entry 
into force of the Lisbon Treaty the official denomination is Court of Justice of the European Union 
(CJEU). In this dissertation we will always use the latter even though some cases to which we refer 
have been judged before 2009.
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of these policy fields respond to a different attribution of decision-making competences 
between the Member States and the EU. Hence, depending on the qualification of a health 
issue under debate, different levels of decision-making apply (see chapter 2).
The approach the CJEU will adopt in cases related to cross-border health care - qualifying 
the provision of health care as a ‘service’ falling under Internal Market rules - has triggered a 
reflection process which went beyond the issue of patient-mobility and also included HTA. In 
the first section of this chapter, we will examine how this process has laid down the basis of 
the future EU HTA network. We will highlight here the role of expert groups in the definition 
and development of EU health policy and HTA. We will examine in particular the High Level 
Process of Reflection on Patient Mobility and healthcare developments and the High Level 
Group on Health Services and Medical Care. The formal and informal processes having taken 
place in these expert networks have played an important role to bring several aspects of EU 
health care further on the European governmental agenda (Princen 2011). Eventually they 
have contributed to the adoption of a new legislative act in EU health care, comprising an 
article on HTA cooperation. Finally, it is important to understand that these processes took 
place alongside the preparation and implementation of the Public health programme, which 
permitted to secure funding for HTA cooperation in Europe.
The second section of this chapter will focus on the EU social policy stream and will exam-
ine how developments within EU social and employment policies have had repercussions 
on governance modes introduced in EU health policy and subsequently in the set up and 
governance of the future HTA networks. We will highlight in this section how ‘ensuring high 
quality and sustainable health care’ was part of the ‘concerted strategy for modernizing 
social protection’ launched in 1999. This explains how health policy was concerned by EU 
social policies and justifies the implication of DG Employment and Social Affairs in this policy 
area. In this section too, attention will be given to the importance of networks and expert 
groups to promote new governance instruments (OMC) first at a sectorial level (employment 
policy and social policy) and later at the general EU-level by means of the Lisbon strategy and 
White Paper on Governance. These New Modes of Governance also had an important influ-
ence on the amendments of the public health article in the Lisbon treaty. Moreover, it is also 
within expert networks, dedicated to social protection policies, that developments within this 
social policy stream will encounter those of the EU health policy stream. HTA cooperation in 
Europe will benefit from this juncture as it will build upon the political support, governance 
and financial instruments offered by the different institutional structures representing these 
two policy streams (i.e. DG Employment and Social affairs (and its successors); DG Sanco 
(and its successors).
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The third section will outline important developments in the pharmaceutical policy stream 
which will play an important role with regard to the content of the HTA network and the syn-
ergies that will develop with regulatory (pricing and reimbursement) policies. In the European 
governance architecture, pharmaceutical policy, although closely related to (public) health 
policy, is predominantly being dealt with, by DG Enterprise and Industry. Whilst the EU’s 
implication in pharmaceuticals stems from a public health scandal in the sixties, emphasis in 
this policy stream lays in the competitiveness of the pharmaceutical industry and its impact 
on growth and jobs in Europe. Pharmaceuticals are considered as products falling under 
the Internal Market regulations. The respective regulatory frameworks adopted, should be 
considered in this perspective. An important distinction between EU pharmaceutical policy-
making and EU social and (public) health policy-making is related to competences divisions 
between the Member States and the EU, having an impact on the governance instruments 
used in the policy fields. Although a clear common regulatory framework exists regarding the 
market authorisation of pharmaceuticals in Europe, pricing and reimbursement policies still 
remain under the exclusive competences of the Member States. Consequently, two different 
agendas have been developed by the EU regarding both aspects of pharmaceutical policy: 
Market authorisation on the one hand, and Pricing and Reimbursement on the other. In 
the pharmaceutical policy stream, the role of (high-level) expert groups and networks have 
also played a preponderate role and eventually permit to create a rapprochement between 
the two agendas. In this regard, special attention will be given to the G10 Medicines group 
and the Pharmaceutical Forum. These networks, which encompass representatives of DG 
Sanco and DG Enterprise and Industry, will structure an important aspect of the content of 
the future HTA network (e.g. relative effectiveness). HTA will play a pivotal role in creating 
synergies between both aspects of pharmaceutical policy, reinforcing herewith the role of 
HTA in EU health policy as well as in EU pharmaceutical policy.
By giving an outline of the three policy streams underpinning and structuring the develop-
ment of European cooperation in HTA, this chapter aims to demonstrate how the latter 
should not be considered on a stand-alone basis but has to be related to wider developments 
regarding politics, policies and polities in the EU. The future networks on European HTA 
cooperation result from the ‘synergies’ between the politics of experts and stakeholders 
gathered in expert groups, shaping policies in the field of health, social affairs and pharma-
ceuticals within a given polity (DG Sanco, DG Social affairs and employment, DG Enterprise 
and Industry). The bridges between the different policy streams and their related politics 
and polities are created by some networks as illustrated below. This figure also includes EU 
research policy which is of interest as it gives financial support to programmes seeking to 
develop HTA cooperation in specific areas such as hospital-based HTA or complex areas-
HTA. These programs are important as they permit new (EUnetHTA-related) initiatives in HTA 
cooperation to develop. However, our research has not identified any influence of the EU 
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research policy stream on the governance practices of HTA cooperation. Therefore, this policy 
fi eld will be mentioned only in relation to the programs it is fi nancially supporting.
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Figure 5.1. Relations between networks and policy streams in EU HTA-related policy-making processes
5.1. the eu health policy Stream: proviDiNg the 
iNStitutioNal Framework For hta cooperatioN
5.1.1. Defi ning the place of HTA cooperation in the EU health strategy
At fi rst sight, the end of the ECHTA/ECAHI project in 2001 seemed to mark a pause in 
European HTA cooperation initiatives. Indeed, if the previous projects followed each other up 
without delay, fi ve years passed since ECHTA/ECAHI before a new project has been launched 
seeking to consolidate HTA cooperation in Europe78. On the HTA agency level, the situation 
was thus rather calm as no fi nancial support was present to pursue substantial network ini-
tiatives79. On the EU level on the contrary, the turn of the millennium marked the beginning 
of a new era in health policy with the launch of the health programs which would structure 
the future activities of the Commission in the fi eld. HTA cooperation in Europe will benefi t 
78 Another project had been introduced on behalf of the DIMDI in Germany in the early 2000s. This 
project did not receive backing of other HTA agencies and has never been implemented due to a 
lack of funding and support from other HTA agencies (Personal interview 4, 10 and 22).
79 On the international level however, cooperation efforts within networks such as HTAi, and INAHTA, 
continued and comprised many partners of the early European HTA cooperation projects.
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from these developments since it has been integrated in these programs and was considered 
by the European Commission, since the early 1990s, as a field bearing the potential to impact 
health systems in general (see chapter 4).
As such, already in 1998, a Commission communication about the future health program, 
mentioned health technology assessment as one of the areas which should be covered by 
the next health program. This communication was being drafted on the basis of input by 
experts solicited by the Commission to give their ideas and develop concepts in their various 
fields of expertise. It seems that the report “Health Technology Assessment in Europe: the 
Challenge of Coordination (1999), written on request of the European Commission, has 
served this purpose. This report has been drafted by the former coordinators of the HTA-
Europe project and reflected in many aspects the key findings of the projects EUR-ASSESS 
and HTA Europe. Exchange of best practices and coordination of work would be supported 
by the Commission to pool expertise present in the individual Member States and “gather 
and exchange information, stimulate international studies and improve the dissemination of 
findings” (European Commission 1998a:13).
In 2000, the European Commission presents its first proposal of a new public health pro-
gramme to the European Parliament and the Council which need to approve the program 
before it can be adopted. This program is structured along three activity strands and includes 
HTA in the first objective: “To improve information and knowledge for the development of 
public health and the strengthening and maintenance of effective health interventions and 
efficient health systems”. In this document, the Commission refers to the developments 
taking place in the sphere of medical technologies which can contribute to improved health 
status but which will also impact health care budgets. It points to the fact that the “issue 
of affordability and justification of new techniques and products thus inevitably arises”, and 
so far only few new health technologies have been assessed as to their cost-effectiveness. 
(European Commission 2000: 7).
Under the heading ‘Key Characteristics of the Public Health Framework’ the Commission 
underscores that “Technological developments in the health field will be a focus for action in 
the new programme. The Commission intends to strengthen health technology assessment 
structures and mechanisms by supporting collaboration between the agencies involved in 
order to refine methodologies, promote joint working and help disseminate the results of 
studies effectively. New technologies will also be used to collect and disseminate validated 
information” (European Commission 2000: 12). A few paragraphs further, the Commission 
stresses that it will build upon the informal networks which it had already previously sup-
ported but that these “networks will be complemented by new ones in the priority areas 
identified, such as (…) health technology assessment (…)” (European Commission 2000: 
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14). Finally, in the first public health program that will be adopted by the Council and the 
European Parliament in 2002, only one sentence will refer explicitly to HTA80, but this line will 
open the way to further actions as we will see below.
As outlined in chapter 4, the development of a public health program was part of an inter-
nal Commission process that took place since the insertion of a public health article in the 
Maastricht Treaty (1992) and which aimed at developing EU’s public health competencies as 
conferred by the Treaties. However, health policy was also being affected by a much bigger 
process taking place within the European Union: the development of the Internal Market. 
Within this process, some events will impact the EU health policy – and subsequently HTA 
cooperation in Europe – in a much more profound way than what could have been achieved 
solely by the health programs.
In 1998, the Kohll and Decker cases81 that took place before the Court of Justice of the 
European Union (CJEU), marked indeed a turning point in the development of EU health 
policies. These cases - that according to some result of a so-called ‘spill-over process’ in 
European health policy (Greer 2006) - have set in motion a process that has permitted more 
than a decade later the adoption of the Directive 2011/24/EU on Cross-Border Health Care 
(OJEU 2011) and which has led to the establishment of a legal basis for HTA cooperation in 
Europe. Beside a call for legal certainty on reimbursement issues, the Kohll and Decker cases - 
which dealt with the purchase of medical assistance in another EU Member State - launched 
a debate regarding the place of health policy in the wider EU integration process. Indeed, 
in these and similar subsequent cases82 the CJEU reasoned from a single market perspective 
aiming to remove all unjustified restrictions to the free movement of goods, workers, services 
80 In the section Annex: actions and support measures it is stated under the heading “to improve 
health information and knowledge for the development of public health by” (…) “review, analyz-
ing and supporting the exchange of experiences on, health technologies including new informa-
tion technologies.” (OJEC of 9.10.2002, L.271 p. 10.)
81 Case C-158/96 Kohll v Caisses de Maladie [1998] ECR I-1931 ; Case C-120/95 Nicolas Decker v 
Caisse de maladie des employés privés [1998] ECR-I 1831
82 Case C-158/96 Kohll v Caisses de Maladie [1998] ECR I-1931 ; Case C-120/95 Nicolas Decker v 
Caisse de Maladie des employés privés [1998] ECR-I 1831 ; Case C-368/98 Abdon Vanbraekel and 
Others v Alliance nationale des mutualités chrétiennes (ANMC) [2001] ECR I-5363; Case C-157/99 
B.S.M. Geraets-Smits v Stichting Ziekenfonds VGZ and H.T.M. Peerbooms v Stichting CZ Groep 
Zorgverzekeringen [2001] ECR I-5473; Case C-56/01 Patricia Inizan v Caisse primaire d’assurance 
maladie des Hauts-de-Seine [2003] ECR I-12403; Case C-372/04 The Queen on the application of 
Yvonne Watts v Bedford Primary Care Trust [2006] ECR I-4325; Case C-466/04. Manuel Acereda 
Herrera v. Servido Cántabro de Salud [2006] ECR I-5341; Case C-512/08 European Commission v 
French Republic [2010] ECR I-1297.
 See for a detailed account: e.g. Sauter 2008; Palm and Glinos 2010.
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and capital (Articles 34, 45, 56 and 63 TFEU.). According to the Court, medical treatment 
received in another Member State is considered as a service in the meaning of Article 57 
TFEU83. Hence, although health policy fell under the exclusive competences of the Member 
States, CJEU rulings could indeed affect this policy area, as EU law enjoys ‘supremacy’ over 
national law84.
To many EU health ministries’ representatives, health policy should however remain outside 
the Internal Market process and the question was thus how to organise the health systems 
within the EU integration process while fully respecting the legal provisions (personal inter-
view 4). To address this issue, a working group had been created in the High Level Committee 
on Health85 with the explicit mandate to collect information on the impact of Community 
provisions on health systems as well as on cross-border health care and service arrangements. 
Moreover, it had to identify the nature and degree of problems arising and consider options 
for Community and national actions to resolve them (European Commission 2001a).
Two days after the Laeken Council in December 2001, the Committee on Health published 
its report on the issue. The report asserts that “[h]ealth systems comprise many components 
all of which form sub-markets which are subject to Treaty provisions governing the free 
movement of goods and services” (European Commission 2001a: 6). Hence, the authors 
of the report follow the reasoning of the CJEU by stating that the “delivery of health care, 
do not lie outside the jurisdiction of Community law” (European Commission 2001a: 3). 
However, the report also recalls the particular status of health which is “not a typical market” 
and is not “easily subject to the competitive model”. The development of a “proactive and 
broader health policy” is considered a priority for the immediate future in order to avoid that 
Community measures “which will impact on health will continue to be largely influenced 
and dominated by economic considerations and factors and not by health policy interests” 
(European Commission 2001a: 22). To stimulate such a proactive approach, the Committee 
proposes to launch a debate at the domestic and EU level in order to generate discussions, 
reflections and exchange of views and information.
83 This has been asserted for the first time in the Luisi and Carbone case in 1984 and reiterated in 
Spuc v Grogan in 1991. (Joined Cases C-286/82 and C-26/83 83 Graziana Luisi and Guiseppe 
Carbone v Ministera del Tesoro [1984] ECR 377; Case C-159/90 Society for the protection of 
unborn children Ireland Ltd v Stephen Grogan [1991] ECR 1-4685).
84 This principle, which is not as such enshrined in the Treaties but results from CJEU rulings, means 
that it takes ‘precedence over all forms of national law’ (Chalmers, Davies and Monti 2010: 203).
85 The High Level Committee on Health is an advisory body which consists of high level officials from 
the Member States and provides strategic advice on public health issues (European Commission 
2001a).
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A few months later, in February 2002, the Spanish presidency organised an informal meeting 
of health ministers in Malaga where the issue of cross-border health care played a central 
role in the debate86. During this meeting, the findings of the High Level Committee were 
discussed and permitted the topic of ‘patient mobility’ to appear as a formal agenda point at 
the next Council meeting which took place in June 2002 in Luxembourg. The conclusions of 
the Health Council of 2002 state that the Council “recognises that other developments, such 
as those relating to the single market, have an impact on health systems”. Concerned by the 
fact that these should interfere with common principles of solidarity, equity and universality, 
it considered “that there is added value in examining certain health issues from a perspective 
that goes beyond national borders. In this context it welcomes the debate at the seminar of 
health ministers held in Malaga in February 2002 which set out a number of priority issues 
for further cooperation and takes note of the expert discussions on this subject” (Council 
2002). Although the priority issues discussed in Malaga did not comprise HTA87 they will 
permit to launch a wider debate on EU health policy and which will concern HTA cooperation 
in Europe (personal interview 3).
The conclusions of this Council mainly seem to reassert the traditional position of the Mem-
ber States with regard to cross-border health care. However, by the fact that they comprised 
the Council’s mandate to the Commission to pursue a ‘High Level Process of Reflection’, 
they did play a crucial role in terms of agenda-setting. By stating that the issue would be 
re-discussed during the next meeting of the Health Council, patient mobility became more 
steadily present on the ‘EU governmental agenda’ opening herewith a pathway to formal 
HTA cooperation in Europe (Council 2002).
5.1.2. The role of networks in developing the future institutional 
framework of HTA cooperation
5.1.2.1. HTA taken up in the High Level Process of Reflection on Patient 
Mobility and Healthcare
Following the mandate given by the Health Council, DG SANCO launched the requested 
‘High Level Process of Reflection on Patient Mobility and Healthcare Developments in the 
European Union’ (HLPR) which started its work in February 2003. The process was attended 
86 The importance given to the issue by Spain may be explained by the fact that it felt directly 
concerned by the issue since many foreign pensioners resided on its coastline.
87 The issues discussed in Malaga were based on the findings of the High Level Committee and 
concerned cross-border health care, exchange of information and data, implementation of the 
Open Method of Coordination in health, European centers of reference, Reference framework on 
quality Standards, e-health (European Commission 2001a: 23-26).
Policy streams structuring European HTA cooperation 205
by many stakeholders such as the ministers from all EU Member States, members of the 
European Parliament as well as representatives of health care associations88. Although result-
ing from judgements of the Court of Justice of the European Union and the need for legal 
certainty regarding patient’s right in cross-border health care, this process will serve as a 
‘hub’ for other health policy related matters. Indeed, the high level process of reflection did 
not only focus its debates on patient mobility but included in the process other health care 
related issues such as HTA (European Commission 2003a:3). The experts were asked to con-
clude their work by the end of 2003, which they did. In the conclusions of the process, the 
Commission stresses the importance of cooperation “to promote opportunities for access 
to health care (…) while maintaining the financial sustainability of the healthcare systems” 
and points to the fact that this will be even more important in the light of the enlargement 
process (European Commission 2003b: 2). It is precisely under the theme of “European 
cooperation to enable better use of resources” that the topic of HTA has been dealt with89. 
Underscoring the benefits HTA could offer policy-makers and the “present fragmentation 
of HTA across the Union”, the experts invite the Commission to consider how a sustainable 
network of HTA could be organised and funded (European Commission 2003b:6).
It seems that the discussion taking place within the HLPR and the other working groups 
within DG Sanco did have a mutually influence on the developments within those fora. 
Following the adoption of the new public health program in November 2002, the Com-
mission developed its 2003 Health Work Plan. We have seen above that Health Technology 
Assessment was only mentioned in one sentence of the public health program, stating the 
need “to review, analysing and supporting the exchange of experiences on health technolo-
gies including new information technologies.” (OJEC 2002: 10), However, this offered the 
European Commission the opportunity to develop further actions pursuing that aim. Hence, 
under the heading 2.1.5 Promoting best practice and effectiveness, the Work Plan mentions 
that strengthening “the capacity to assess and evaluate health strategies and interventions” 
is the general goal in this field. The paragraph specifies that this should be focused on 
specific priority areas such as “health technologies, including pharmaceuticals”. The key 
actions listed, resume the findings and conclusions of the early cooperation initiatives and 
reports written on the subject (e.g. European Commission 1998:60-6190), and which were 
88 International Mutual Association (AIM), the Standing Committee of the Hospitals of the EU (HOPE), 
the European Health Management Association (EHMA), the European Patients Forum (EPF), the 
European Social Insurance Partners (ESIP), the Standing Committee of European Doctors (CPME) 
(European Commission 2003a:3).
89 The other topics falling under this heading were: ‘rights and duties of patients’, ‘sharing capacity 
and trans-national care’; ‘European centres of reference’ (European Commission 2003b).
90 Report written by former project coordinators of the HTA-Europe project entitled Health Technol-
ogy Assessment in Europe: The challenge of coordination (European Commission 1999).
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already included in the draft proposals of the public health program as we have seen above. 
As such, they mention the need for development of tools and methodologies, common 
approaches and definitions. Action in this field aims, among others, the development of 
a mechanism permitting closer HTA cooperation between Member States and various 
stakeholders, strengthening the collection of information as well as its dissemination; the 
development of methods to evaluate quality and efficiency of health promotion strategies 
and the development of common approaches and consensus methodologies (OJEU 2003).
In April 2004, the European Commission publishes the conclusions of the High Level Process 
of Reflection. This communication forms part of a wider strategy including a separate com-
munication on extending the ‘open method of coordination’ to healthcare and long-term 
care (which will be discussed in the next section). A specific section of the communication is 
dedicated to health technology assessment. The document starts by giving a clear definition 
of what HTA comprises basing itself on the reports of the early HTA cooperation initia-
tives. The core of the section underscores how cooperation in this field is important and 
can build on “projects already supported under the public health programmes to harmonise 
methodology for assessments and to explore the role of health technology assessment in 
the future systems of health care in the Member States”. Moreover, it informs that the 
“Commission plans to establish a coordinating mechanism to link together the different 
projects, organisations and agencies which already exist and to pool results and information 
in a usable and effective way, and will bring forward separate specific proposals, including for 
a study. According to the Commission these initiatives will help to ensure that health systems 
can use their limited resources in the most effective and efficient way (European Commission 
2004f: 29).
The embedment of HTA within a wider understanding of the aims of EU public health can 
also be found in a July 2004 Communication of the EU Health Commissioner David Byrne 
building upon the conclusions of the HLRP. In this document, the importance of developing 
cooperation in the field of Health Technology Assessment is again underscored (European 
Commission 2004d: 11). Establishing synergies there where possible to enhance the ef-
fectiveness and efficiency of health care systems across Europe is presented as essential to 
achieve good health in Europe. This aim is furthermore connected with a broader EU objec-
tive: achieving economic growth and sustainable development. This document reflects how 
attention for health matters within the EU institutions is being promoted through the scope 
of economic competitiveness. It underscores how the so-called disease burden has an impact 
on long-term health expenditures and other social costs (sick-leave, lower productivity etc.). 
Hence, promoting good health and “better spending” on health can serve both individual 
well-being and EU competitiveness (European Commission 2004d:11).
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Support for HTA cooperation should be read in this light. Indeed, the Commissioner 
underscores how scientific and technological progress permits the development of new 
expensive drugs, which need to be assessed properly. This, however, should not undermine 
the competitiveness of the pharmaceutical industry which is considered as a major driver 
of innovation in health care and an important employer in the EU (European Commission 
2004d:11). Finally, the communication stresses how “joint health technology assessment” 
permits to share capacities and save money to national and regional authorities who can 
learn together and share best practise (European Commission 2004d: 18). To take forward 
the recommendations of the HLPR, the Commission establishes a High Level Group on health 
services and medical care which needs to reflect at the practical implementation of European 
Cooperation on health services including HTA (European Commission 2004b: 3-4).
5.1.2.2. HTA as priority topic in the High Level Group on health services and 
medical care
The High Level Group on health services and medical care - set up upon the recommenda-
tions of the high level reflection process – meets for the first time on July 1st 2004. Health 
Technology Assessment has been included as one of the six priority topics91 of the HLG 
which is expected to deliver a first report to the EPSCO Council92 at the end of the year. It 
was agreed during the first meeting that working methods of the HLG would be informal 
and collegial and would meet at least three times a year. The working groups should also 
involve relevant stakeholders and organisations in the field of consultation and expert advice. 
In June 2004, INAHTA93 had offered it services in this sense, underscoring the contribution of 
the (European) members of the network to three previous projects supported by EU funding 
(EUR-ASSESS, HTA Europe, ECHTA/ECAHI) aiming the setup of an HTA network (correspon-
dence INATHA, June 2004). Almost simultaneously, the former Executive Committee of the 
ECHTA/ECAHI project also draws the attention to the Commission that ”an active an efficient 
network already exists”, acknowledging however a low level of activities due to a lack of 
finances. They offer an active collaboration between the network and the Commission in 
establishing a reconstituted network that will meet the goals of the commission and Member 
States (correspondence ECHTA/ECAHI, June 2004). In July 2004, the Commission confirms 
to INAHTA that HTA has been chosen as a priority topic in the High Level Group and that it 
91 The six priority areas of the High Level Group were: Cross-border healthcare purchasing and provi-
sion (including rights and duties of patients); Health professionals, Centres of reference, Health 
Technology Assessment, Information and e-health (including data protection), Health impact 
assessment and health systems (European Commission 2004c).
92 EPSCO Council stands for: Council of Employment, Social Policy, Health and Consumer Protection.
93 INAHTA: International Network of Agencies for Health Technology Assessment (INAHTA)
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will make use of the expertise of INAHTA members (European Commission 2004g; European 
Commission 2004e)94.
The working group on Health Technology Assessment will meet only twice. Sixteen Member 
States participated in the working group which was mostly composed of so-called small EU 
Member States, most of them having, at that time, little or no experience in HTA. However, 
the group also counted some ‘heavy-weights’ in HTA having played an important role in the 
early European cooperation initiatives (EUR-ASSESS, HTA Europe and ECHTA/ECHAI) such 
as Sweden, Denmark, the Netherlands, the United Kingdom and Germany95. Moreover, the 
strong ties that existed between some representatives and international organisations, such 
as INAHTA, have played a role in the drafting process of the report of the working group as 
well as the subsequent developments based on that report96 (Personal interview 7).
During the September 2004 meeting of the HTA working group, the discussion was held on 
the basis of a working paper which had been circulated by the Finish chair of the working 
group. The paper itself had been drafted by a few experts in the field of HTA which had 
been active in the early HTA cooperation initiatives and in INAHTA (Personal Interview 7 and 
22). This document elaborated on ideas for establishing a network on health technology 
assessment at the European level. The Health Program of the European Commission was 
considered as an option to finance the collaboration. The advantages of cooperation are 
underscored and the meeting closes with the agreement that the Chair would circulate a 
summary proposal for comments before the next HLG meeting held a month later.
The October meeting of the HLG-working group on HTA in 2004 concluded with a pilot 
project proposal on European HTA networking. The aim was to make progress within the 
following six areas: developing methods for common core information packages; transfer-
ability of health technology assessments; reporting structures on common core information 
on HTA; quality management procedures for producing HTA; developing tools for identifying 
needs and priority-setting in HTA; developing tool for tailoring common core information to 
94 These INAHTA members had also been involved personally or institutionally in the early European 
cooperation projects and were eager to carry on follow-up initiatives (Personal interviews 4, 7, 
10). The un-coordinated exchange of letters of ECHTA/ECHAI representatives on the one side and 
of INATHTA representatives on the other, seems to point to the positioning of different persons 
seeking to take the lead in the future HTA cooperation projects.
95 The Member States participating in the Working group on HTA were: Belgium, Denmark, Ger-
many, Estonia, Ireland, Cyprus, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Portugal, 
Slovenia, Slovakia, Sweden, United kingdom.
96 The Danish representative in the HLG-Working Group on HTA was at the time of the discussions 
also the Chairman of INAHTA at that time (https://www.ispor.org/Home/GetPersonBio/5307).
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inform health policy within Member States (European Commission 2004e: 3-4). These topics 
show strong similarities with the areas identified in EUR-ASSESS and ECHTA/ECHAI. Indeed, 
one of the authors of the paper confirmed that the reflection was predominantly theoretical 
about which items of the previous experiences should be maintained and what should be 
“made de novo” (personal interview 4).
The working group of the HLG underscores how European networking on HTA did not intent 
to “displace national bodies for health technology assessment” but sought to “maximise 
synergies and avoid duplication between them as well as providing a base of expertise which 
could be used by Member States to develop their own internal capacities and policies” 
(European Commission 2004h:4). Within the working group, a large consensus was found 
on the proposed pilot project which should only be slightly adapted to be integrated in the 
HLG report at the next Health Council so as to underscore the added-value of European 
cooperation on health technology assessment (European Commission 2004e: 4).
The report from the High Level Group to the EPSCO Council in December 2004 can be 
considered as a political milestone in the development of European cooperation in the field 
of HTA. It outlines the current state of HTA in Europe in a context of costly innovations in 
health technologies needing to ensure a high level of patient safety, protect public health and 
develop an optimal use of resources. The HLG underscores how “against this background 
HTA has become a political priority and there is an urgent need for establishing a sustainable 
European network on HTA” (European Commission 2004f:12, emphasis added). Creating a 
sustainable HTA network was thus already then regarded as necessary. However, considering 
the Member States’ competences and control over the health systems, some also acknowl-
edged the challenge it encompassed: “I remember that my counterpart who was around in 
this process (…) said, wow, it is going to be very difficult to see any kind of legal basis for 
any kind of something that could become a permanent sustainable mechanism” (personal 
interview 4).
The HLG report outlines the key tasks of this European HTA network which should address 
“methods for developing common core packages; methods to support transferability of 
assessments, methods for helping Member States to identify and prioritise topics and com-
missioning reports, quality management procedures for the management of common core 
information or joint assessments, tailoring common core information to national health policy 
processes; tools for establishing new agencies, tools for sharing methodologies, expertise 
and practical issues”. Moreover, it refers to the public health program who could support 
the network initially (European Commission 2004f: 2). The HLG stresses the importance 
of collaboration with international organisations such as INAHTA, HTAi, Euroscan, WHO, 
OECD, the Council of Europe and other organisations involved in HTA. It also underscores 
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the value of including patient organisations in this process and carefully consider the role of 
the industry.
In this document, the set-up of the network is conceived in two phases. The first 3-year phase 
would concern the launch of the network with funding from the Public Health Program. Dur-
ing the second phase “a financially sustainable solution for running the network should be 
considered by the Commission and the Member States” (European Commission 2004f: 13). 
The report concludes on this topic by launching a formal appeal to the European Commission 
“to support a pilot project to set up a European HTA Network under an appropriate financing 
mechanism such as EU Public Health Program” (European Commission 2004f: 13).
Although the other working groups of the HLG on health services and medical care continue 
to meet on a regular basis till 2006, no meetings have taken place after November 2004 by 
the group working on health technology assessment within the formal framework of the 
HLG. However, in the meantime substantial progress has been made outside the framework 
of the HLG as Professor Finn B. Kristensen, a Danish representative in the HLG and at that 
time chairman of INAHTA, gathered in February 2005 a taskforce in Copenhagen to work 
on a project proposal to be submitted to the new EC health program. Having to meet the 
deadline in April of the same year, things moved quickly. Members of the previous European 
HTA cooperation projects and INAHTA members have been contacted to work on a project 
proposal aiming to set up an HTA network (personal interview 7; correspondence Danish 
health institute). Finn Kristensen also sought and received support from the Health Evidence 
Network of the World Health Organisation (WHO) then directed by Alicia Granados one of 
the founding members of EUR-ASSESS (Personal interviews 6, 7)97.
The dynamics in Copenhagen were positive and received backing of the Danish Health Insti-
tute. For Finn Kristensen, developing the project by focusing on the health policy processes 
was key: “HTA is only relevant if it has the decision-maker in its head” (personal interview 
7). He was also the person behind the acronym for the new network: EUnetHTA which 
received the support of the taskforce allowing to submit the project to the health program. 
In the minutes of the HLG meeting of June 2006, an update is given on the progress of the 
work on HTA. The minutes mention that Prof. Kristensen has taken the lead of the European 
network for Health Technology Assessment (EUnetHTA project). It furthermore specifies that 
this project has been “set up on the basis of recommendations of the High Level Group from 
97 Some European health policy experts refer to a sort of unspoken competition in the early 2000s 
between the WHO and the European Commission seeking to position itself in health care (Inter-
view 5, 6,7). This could partly explain the request for moral support to the WHO for the European 
HTA Network.
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2004”. Member States are invited to join the project through an advisory group structure 
(European Commission 2006). Chapter 6 will outline the developments of the EUnetHTA 
network. In the next sections we will examine how other developments in the field of EU 
Health policy have played a role in shaping the content and governance modes of HTA 
cooperation in Europe.
5.1.3. The Cross-Border Health Care Directive: setting a legislative basis 
for sustainable HTA cooperation in Europe
The ‘EUnetHTA project’ launched in 2006 and which emanated from the HLG on health 
services and medical care, will be the first of a second generation of HTA cooperation 
projects which will lay down the basis for a formal EU HTA Network established in 2013. 
Indeed, as we will develop in more detail in the next chapter, the first project has been 
followed up by the EUnetHTA collaboration in 2009 and three subsequent EUnetHTA ‘Joint 
Actions’ implemented between 2010-2020. Important progress has been made throughout 
the different Joint Actions which each built further on the work established in the previous 
projects. As such, in the course of the years, despite important disparities that existed in 
the national HTA procedural frameworks and methodologies, substantial progress has been 
made in the development of common methodological guidelines, HTA Core Models, Joint 
HTAs, adaptation toolkits, capacity-building, information management and evidence genera-
tion (see chapter 6). A formal governance structure has also been set up in which stakeholder 
participation gradually increased in importance.
The biggest challenge faced in these programs was to move from the experimental phase of 
developing and testing new tools and processes to the “routinisation” of those where joint 
work98 and re-use of work in national HTAs would become a norm and an integral part of 
regular HTA production processes (EUnetHTA 2015: 2). Indeed, the different methodologies, 
tools and pilot projects developed during the first decade of EUnetHTA’s activities, did not 
permit to really reduce the duplication of work since many agencies continued to follow 
their own agenda in parallel to the one defined and agreed upon in EUnetHTA-network 
(European Commission 2016a). Finally, EUnetHTA has differentiated itself from the early HTA 
cooperation projects by integrating relative effectiveness assessments in its activities (see 
section below) as well as by developing new projects seeking to establish synergies between 
regulatory processes and HTA (e.g. SEED). The latter have gradually gained weight in the 
overall process (see chapter 6).
98 Joint work refers besides the development of common methodologies, tools and joint health 
technology assessments also to literature reviews, structured information for rapid or full HTAs, 
Early Dialogues or scientific advice on R&D planning and study design (European Commission 
2016a: 4).
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Hence, since 2006 and the decision of the HLG on health services and medical care to estab-
lish the first EUnetHTA project, the collaboration efforts have focused on the development of 
a framework for joint HTA production, ensure the uptake of the joint work in national activi-
ties, seeking synergies with European and national regulators and finding a way to guarantee 
the sustainability of the cooperation. These ‘second-generation’ collaboration projects were 
all co-financed by contributions from the Commission and Member States and still project-
based. This temporarily financial and administrative governance structure emphasized the 
need to find a manner permitting to establish a more sustainable cooperation framework 
from both an organisational and financial point of view. So, more than two decades after 
the first EUR-ASSES project, it seemed that the cooperation efforts had hit a ‘glass roof’ since 
the biggest challenge remained the same: establishing a sustainable structure for EU HTA 
cooperation permitting the uptake of joint assessments and reduce the duplication of HTAs 
on a national level.
The establishment of a sustainable form of European HTA cooperation addresses inevitably 
the question of competences in this area. HTA is a domain which falls under Member States 
competences and based on the Treaties, any EU involvement related to HTA shall fully respect 
the national responsibilities in the organisation and delivering of health services and medical 
care (subsidiarity principle). The Article 168 (TFEU) does however confer to the Commis-
sion the right to lend support to cooperation initiatives. This support should not aim at 
harmonising national laws or regulations of the Member States in this area. Hence, the 
Commission’s competences remain rather limited and restricted to soft-governance support 
and coordination means. It is however exactly on this basis that the Commission has been 
able to move forward in the field of cross-border health care and in particular in the field of 
patient mobility, which has become a hub for the development of EU HTA cooperation as will 
be outlined in the next sections.
5.1.3.1. A call for a legal framework on patient-mobility
In 1998, two ‘patient mobility cases’ dealt with by the Court of Justice of the European Union 
(CJEU), had triggered an EU-wide discussion on health care and medical services in vari-
ous high-level expert groups gathering national governmental representatives and chaired 
by the European Commission. In the previous sections, we have examined how HTA had 
become one of the priority areas in these expert groups allowing the topic to move up 
on the European governmental agenda (Princen 2011). However, to fully understand how 
HTA cooperation has been developed, it is important at this stage to relate the discussions 
regarding HTA in the high-level expert groups, within the wider context of patient mobility 
and health care developments in the EU since the turn of the Millennium.
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Indeed, during the timespan of meetings held by the HLPR and the HLG, many other patient-
mobility related cases had been dealt with by the Court of Justice of the European Union 
(CJEU)99. The dominant issue in these cases was related to the reimbursement of cross-border 
health care costs. The latter was for decades regulated by EU social security regulations (e.g. 
Regulations 1408/71, Regulation 883/2004). However, the CJEU legislation – adopting an 
Internal Market approach - had created since 1998 a parallel route to reimbursement. Hence, 
the need to have legal certainty about cross-border health care costs became urgent and had 
been the trigger to put the issue on the EU governmental agenda.
The first legislative attempt to create ‘legal certainty’ on cross-border health care issues (e.g. 
reimbursement) was ceased surprisingly not by a Commission’s directorate responsible for 
social security or health issues, but by DG MARKT (responsible for Internal Market policies). 
The latter published in 2004 -one month before the publication of the conclusions of the 
HLG on Health services and medical care - its first proposal for a ‘Services in the Internal Mar-
ket Directive’ (2006/123/EC) also called ‘the Bolkenstein Directive’. This Directive proposal, 
aiming to develop an Internal Market of Services, included in its Article 23 on the ‘assump-
tion of health costs’ a provision on patent mobility (European Commission 2004j). The first 
proposal became a highly-contested document for reasons that lay well outside the scope of 
our research. Nevertheless, the fact that a health care related issue was included in a Services 
Directive, contributed to the fierce opposition that was set in motion subsequently to its 
publication (Sauter 2008:33). Moreover, it was also feared that the proposed article would 
not permit to create the required legal certainty in patient mobility. The debate triggered by 
the Services Directive proposal led to the request of the European Council and the European 
Parliament to revise the proposal (Council 2005:7, European Parliament 2005:5). The latter 
became a new player in the field of patient-mobility and introduced in 2004 a motion for 
a European Parliament resolution on patient mobility and health care developments in the 
European Union (European Parliament 2005).
In this motion, the European Parliament referred to the “special nature of health care” and 
emphasized that “health care services constitute a service for people in need and cannot, 
therefore, be compared with goods offered for sale”. Hence, a “separate Commission 
proposal” would be needed and health care services should not be included in the gen-
eral Services Directive (European Parliament: 2005:5). Moreover, the Parliament urged the 
Commission “to develop urgently a coherent policy on patient mobility in the light of the 
judgements of the Court of Justice of the European Communities and the Report of the 
High Level Reflection Process on Patient Mobility and Healthcare Developments” (European 
Parliament 2005: 5). Eventually, after extensive debates on the issue in the Council, the 
99 See footnote 71.
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European Parliament and within the different DGs of the European Commission, it has been 
decided in April 2006 to withdraw the Article 23 from the scope of the Services Directive 
(European Commission 2006a).
5.3.1.2. Adopting the Cross-Border Health Care Directive
Building upon the momentum created by the debates around patient mobility in the frame-
work of the Services Directive, and following the call of the European Parliament, the Com-
mission launches in September 2006, a “public consultation on how to ensure legal certainty 
regarding cross-border health services under Community law, and to support cooperation 
between the health systems of the Member States” (European Commission 2006b). Al-
though the main objective of this process regards the application of Treaty provisions on free 
movement to health services, the process also focuses on “a range of specific areas where 
the economies of scale of coordinated action between all Member States could bring added 
value to national health systems”. These areas had been identified in the HLPR and the HLG 
on health services and medical care and comprised HTA (European Commission 2006b). Pub-
lic consultations are a common measure in the working methods of the Commission. They 
are strongly inspired by the White Paper on governance as they aim at giving the Commission 
an insight in stakeholders’ position regarding areas where it could bring an added value100. 
They usually prepare the ground for the drafting of future (legislative) proposals. These public 
consultations are often accompanied by specific assessments, measuring possible impacts 
for the measures foreseen (interview 9). It also permits other EU institutions (e.g. European 
Parliament) to publicly communicate on the issue as has been the case here101.
Based on the outcomes of the public consultation and of the conclusions of the HLG on 
health services and medical care, the Commission submitted in 2008 a proposal for a Direc-
tive on Cross-border health care (European Commission 2008a)102. The main objective of the 
100 The final report summarising the outcome of the public consultation refers to the participation of 
a “wide range of stakeholders”. Indeed 280 responses were given on behalf of participants repre-
senting Member States, regional authorities, national and international (health care) organisations, 
commercial organisations and companies, academia and ‘ordinary’ citizens (European Commission 
2008c).
101 During the consultation period, the Commission received increasing support from the European 
Parliament which adopted several Resolutions with regard to cross-border health care. (European 
Parliament 2007a, 2007b).
102 This proposal was part of the renewed social agenda for the 21st century presented by the Com-
mission and which included a wider range of actions targeting a variety of issues such as Roma 
exclusion or discrimination matters (European Commission 2008b). It was accompanied by the 
publication of the results of an Impact Assessment which had been made on the topic and in 
which almost all DGs had participated (European Commission 2008c).
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Directive was to create legal certainty in the field of reimbursement of cross-border health 
care. For DG Sanco, the proposal on cross-border health care presented however a ‘golden 
opportunity’ to submit, upon the request of the Member States and the European Parliament, 
a legislative act in relation to health care which would also touch upon the improvement of 
health systems. The latter was, as we have seen in the previous chapter, the focus point of 
the Commission since the insertion of the public health article in the Maastricht Treaty (1992) 
(personal interview 3). Hence, whilst the main objective of the Directive concerned patient-
mobility issues, the opportunity was ceased to insert other items which would improve health 
systems. HTA cooperation was one of those (Personal interview 3).
Although in the final version of the Directive 2011/24/EU on the application of patients’ rights 
in cross-border healthcare, most of the initial Commission’s proposals had been “watered 
down”, the new legislative text adopted in 2011 did cover in its chapter IV so-called ‘flanking 
measures’ regarding areas laying outside reimbursement issues of patient mobility and which 
were of particular importance to DG Sanco: mutual assistance and cooperation, recognition 
of prescriptions issued in another Member State (Article 11), establishment of European 
Reference Networks (Article 12), rare diseases (Article 13), e-health (Article 14) and HTA 
cooperation (Article 15). Indeed, in each of these fields, progress was made continuously but 
still on a project-based (network) level, co-financed by the European Commission. In the area 
of HTA, one can mention in this regard the establishment of the ‘EUnetHTA network’ which 
was making substantial progress (see chapter 6) but which was still struggling to create a 
sustainable framework to ensure the continuity of the actions implemented.
From the Commission’s (DG Sanco) point of view, a legislative basis was necessary to develop 
on a lasting basis the work initiated in the areas covered by the flanking measures and which 
permitted the Commission to be active on the level of the health systems. Till then, coop-
eration in these fields could take place only on a temporarily basis by means of programs 
(e.g. public health programs, research programs). However, as underscored by a DG Sanco 
official, sustainable EU cooperation requires a proper governance structure which cannot be 
established without a legal basis. Having these areas included in the Directive would offer the 
possibility to establish sustainable cooperation structures and, in a sense, institutionalise the 
work initiated and carried out so far on a program-basis (Personal interview 3). Establishing a 
sustainable framework for HTA-cooperation was thus one of the objectives pursued by these 
flanking measures in the Directive 2011/24/EU.
As the ‘ordinary legislative procedure’ applied in this case, the Council and European Parlia-
ment had to approve the proposal and could propose amendments to the texts. At the core 
of the discussions laid the sensitive issue of reimbursement of cross-border medical care 
and the proposed text triggered some important disagreements between the Council, the 
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Commission and the European Parliament. After almost three years of debates and after 
having gone through the whole procedure (including two readings in each institution and 
the necessity to organise a conciliation measure in the form of a ‘trilogue’), an agreement has 
been found and the final text has been adopted in February 2011103.
Due to the attention given to the core-content of the proposal (reimbursement matters), 
institutional debates on the ‘flanking measures’ hardly took place. Indeed, a careful analysis 
of the reports of the ENVI committee of the European Parliament and the formal debates 
in the Parliament and the Council, indicates that little attention has been given to these 
measures and in particular to HTA cooperation104 (e.g. European Parliament 2009; 2011). 
Indeed, during the negotiations on the Cross-border Health Care Directive, the representa-
tives of the Member States wanted to ensure that the legislative act would not become a 
financial burden on their health systems. Issues related to safety and quality of care (related 
also to the recent EU enlargement) were also frequently debated but mostly as mean to be 
able to counter the application of the provisions foreseen in the proposal (see further on this 
issue e.g. Palm and Glinos 2010; Palm and Baeten 2011; Wismar et al. 2011).
The financial impact of the Directive on the MS’s health systems laid thus at the core of the 
debates and this is even more interesting as several studies and Impact Assessment had 
actually demonstrated that the impact of cross-border health care on the financial systems 
of the Member States was very limited (less than 1% of public health care expenditure 
(European Commission 2008c; Wismar et al. 2007; 2011)105 and even considered by some 
as a ‘non-issue’. This position was also shared by representatives of DG Sanco who valued 
the debate around patient-mobility mostly because it served the (higher) aim to improve the 
103 Although the Directive 2011/24/EU is based on the CJEU decisions regarding patient-mobility, it is 
being debated whether it has brought any legal certainty as the existing Regulations on the matter 
continue to be applicable and include substantial differences with regard to patient’s rights on 
reimbursement of cross-border health care (see further e.g.; Jelfs and Baeten 2012; Baeten 2012: 
EHMA 2011).
104 In its first reading of the proposal, the European Parliament does indicate that regarding the 
cooperation on management of health technologies “the European Commission (rather than 
Member States) shall, in consultation with the European Parliament, facilitate the establishment of 
a network connecting the national authorities or bodies responsible for health technology assess-
ment” (European Parliament 2009: 2008/0142(COD)).
105 Other studies have pointed to around 0.1%-0.2% of total health care expenditure during the late 
1980s and 1990s, (Hermesse et al. 1997; Palm et al. 2000). It is argued however that these figures 
may be underestimated as they do not include so-called waiver agreements, or out of pocket 
patient expenditures (Bertinato et al. 2005). Nevertheless, a 2003 survey by European Commission 
did not find higher numbers (Bertinato et al.:2005) (see further European Commission 2014:38-
41).
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health systems in the EU. Indeed, the Directive would offer the possibility to create a legal 
basis permitting the Commission to act in the areas where it sought it could make a differ-
ence. Hence, by the fact that the Member States focused their attention on reimbursement 
issues and considered the ‘flanking measures’ as (complex) “niche areas” (of lesser impor-
tance?), the latter did not become the subject of controversial debates. However according 
to some observers, with time, “since the patient mobility issue is not really a particularly large 
problem, it may turn out that the flanking measures will be more important in the long run” 
(personal interview 3).
5.1.3.3. Paving the way for the establishment of the EU Health Technology 
Assessment Network
The insertion of an article on HTA cooperation in the Cross-Border Health Care Directive 
should be examined by keeping in mind the progress made on HTA cooperation in the 
different EUnetHTA projects and the Joint Action that have been implemented during the 
negotiation and adoption phase of the legal act (see chapter 6).These have indeed played an 
essential role in establishing the content of the Article 15 of the Directive 2011/24/EU which 
offers the legal powers to the Commission to setup and manage a “voluntary Network of 
national authorities or bodies responsible for HTA”, permitting it herewith to institutionalise 
HTA cooperation in Europe.
Indeed, the Article 15, outlines in the first paragraph that “the Union shall support and 
facilitate cooperation and the exchange of scientific information among Member States”. 
The network shall be based on “the principle of good governance including transparency, 
objectivity, independence of expertise, fairness of procedure and appropriate stakeholder 
consultations”. The second section outlines the objectives of the network which are in line 
with the previous projects and Joint Actions: “(a) support cooperation between national 
authorities or bodies; (b) support Member States in the provision of objective, reliable, timely, 
transparent, comparable and transferable information on the relative efficacy as well as on 
the short- and long-term effectiveness, when applicable, of health technologies and to en-
able an effective exchange of this information between the national authorities or bodies; (c) 
support the analysis of the nature and type of information that can be exchanged; (d) avoid 
duplication of assessments. The third paragraph specifies that EU aid may be granted to fulfil 
the objectives, the fifth and sixth section specifies how aid may be granted.
The fourth paragraph is of particular interest, since it specifies that the Commission can 
“adopt the necessary measures for the establishment, management and transparent func-
tioning of this network”. This however has to be done in full respect of the Member States’ 
competences “in deciding on the implementation of health technology assessment conclu-
sions and shall not harmonise any laws or regulations of the Member States and shall fully 
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respect the responsibilities of the Member States for the organisation and delivery of health 
services and medical care” (Article 15 (7)).
The developments on the HTA arena level and those on the EU health policy level thus 
mutually reinforced each other: the establishment and activities of the EUnetHTA network 
has permitted the European Commission to propose the adoption of a legislative framework 
to secure this cooperation. Conversely, the article on HTA cooperation inserted in the new 
Directive on cross-border health care has certainly contributed to secure the future coopera-
tion within the form of Joint Actions. In chapter 6 we will examine how this has taken place 
and how the Cross-Border Health Care Directive has served as a basis for the establishment 
of a new policy-orientated EU HTA network and paved the way for a new proposal for an 
Regulation on European HTA cooperation.
We have seen in this section, how HTA cooperation has been impacted by ‘external’ develop-
ments in the EU health policy stream. The Member States’ request for more legal certainty 
on the question of patient mobility has been ceased by the European Commission as an 
opportunity to push forward other important areas of EU health policy among which HTA. 
First by inserting these areas as priority areas of the different expert groups on health (HLPR 
and HLG). The conclusions of these expert groups have been integrated in the ‘flanking 
measures of the Cross-Border Health Care Directive which in the end has offered a legal 
basis to the Commission to pursue its work in areas which can have a direct impact on the 
health systems. HTA cooperation has been one of these. Before outlining in more detail 
these developments in the chapter 6, we will examine two other policy streams which have 
impacted HTA cooperation in Europe.
5.2. the Social policy Stream: proviDiNg SoFt goverNaNce 
iNStrumeNtS For hta cooperatioN
The Prodi Commission, which took office in 1999, sought to reinvigorate the European 
integration process with the launch of the Lisbon agenda seeking to make Europe “the 
most competitive and dynamic knowledge-based economy in the world” (www.europarl.
europa.eu/summits/lis1_en.htm#a). To support this aim, new governance practices have 
formally been introduced based on soft governance instruments such as the Open Method 
of Coordination, discussed in chapter 2. These so-called New Modes of Governance (NMG) 
were based on experiences made in the European Employment Strategy carried out by DG 
Employment and Social affairs. To understand how soft governance instruments have helped 
structuring HTA cooperation in Europe it is important to highlight in this section, the relations 
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between social policy and health policy on the one hand and social policy and employment 
policy on the other.
5.2.1. OMC entering the EU social policy agenda
Social affairs and Employment have been governed within a single DG since 1986. They 
have however become more strongly related policy fields since the Delors’ White Paper on 
Growth, Competitiveness and Employment published in 1993 (European Commission 1993). 
Indeed, in the early nineties, Europe was facing a recession and the Commission was of the 
opinion that a combination of macro-economic and structural policies was needed to pull 
the European Community out of this situation. The underlying idea was also that reducing 
unemployment would reinforce many social objectives defined by the European Commission 
(European Commission 1994:17; Régent 2002:2-3).
With the Amsterdam Treaty (1997), social policy becomes more firmly enshrined in the Trea-
ties and falls under the so-called shared competences between the EU and the Member 
States. As such, social affairs became to play a different role within EU policymaking. More-
over, the Amsterdam Treaty offered also a legislative basis permitting to develop a European 
Employment Strategy (EES) based on newly established ‘coordination strategies’. This EES 
will be officially launched together with the Open Method of Coordination (Luxembourg 
process) during the Santer Commission at the extraordinary Job Summit, taking place on 
22-23 November 1997 in Luxembourg106. This strategy will be continued by the Prodi Com-
mission which takes office in September 1999. In 2000, full employment becomes even one 
of the overarching objectives of the Lisbon strategy and the OMC will be presented as an 
appropriate tool to implement these. The White Paper on governance (European Commis-
sion 2001), published a year later, will further outline how these soft governance means fit 
in the overall governance architecture of the EU (see chapter 2).
Since the insertion of the public health article in the Maastricht treaty (1992) till 1999, EU 
public health policy was governed by the ‘public health unit’ hosted in the DG V responsible 
for Employment and Social Affairs and having launched the EES. Although separate policy 
fields, the fact that both health and social policy were run till 1999 in the same Directorate 
General did create some ties between both policy areas. With the establishment of the new 
DG Sanco under the Prodi Commission in September 1999, health policy could be governed 
separately from social policies to which it was often associated. However, just before the 
creation of a separate DG for public health policy, important developments took place in the 
field of social protection and which will have an impact on health care policy.
106 The EES has been reviewed in 2002 and relaunched in 2005 when economic guidelines have been 
integrated in the Broad Economic Policy Guidelines (European Parliament 2017).
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In the period between the resignation of the Santer Commission (15 march 1999) and 
the entering into office of the Prodi Commission followed by the creation of DG Sanco (1 
September 1999), the Commission (read here DG Employment and Social Affairs) launches 
its ‘concerted strategy for modernising social protection’. This strategy comprised the aim 
“to ensure high quality and sustainable health care”, (European Commission 1999b: 3). The 
strategy “aims at deepening the co-operation between the Member States and the European 
Union, based on exchange of experience, policy discussion and monitoring of ongoing politi-
cal developments in order to identify best practice” (European Commission 1999b: 12). This 
new approach also answered a call of the European Parliament in March 1999, for a “process 
of voluntary alignment of objectives and policies in the area of social protection, modelled on 
the European employment strategy” (European Commission 1999b: 12).
The concerted strategy should be considered within the wider process of the integrated socio-
economic strategy of the Lisbon agenda which comprised the streamlining of economic and 
employment coordination strategies. Economic policy coordination was carried out through 
the so-called Broad Economic Policy Guidelines (BEPGs), multilateral surveillance and the 
Stability and Growth Pact. Employment policy coordination was organised in the framework 
of the European Employment Strategy (EES) implemented through National Action Plans. The 
overall aim of the coordination strategies was to provide full employment, quality at work, 
the promotion of social cohesion and inclusion (European Commission 2003).
EU protection policy aiming to contribute to the promotion of social cohesion and inclusion 
was built on three pillars: social inclusion, pensions and health and long-term care. In line with 
the Lisbon agenda, promoting these policies was closely connected to the Lisbon strategy, 
the BEPG and the EES. The social protection policy (including health and long-term health) 
fell under the responsibility of the same DG responsible for the EES. Moreover, to bring 
forward work in the field of social inclusion and pensions, the OMC had been identified by 
the Lisbon European Council as an appropriated mechanism. Health and long-term care were 
considered by the Commission as key-issues for the development of Europe’s social model 
as they related to social and economic policies in particular and represented almost a third 
of all social expenditure in the EU (European Commission 2005:30). This explains why health 
and long-term health care were included in the Commission’s social policies and remain so 
even after the establishment of a dedicated Public Health Directorate. It furthermore clarifies 
how New Modes of Governance, such as the OMC, were taken into consideration for the 
implementation of health-related policy objectives within the wider social protection policy 
implemented by DG Employment and Social Affairs. It is thus through social policies - which 
themselves are linked to employment policies - that soft governance mechanisms have been 
considered for health-related policies. The ties that existed between the two policy areas 
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before 1999 will still resonate in the early days of DG Sanco and have an indirect impact on 
the governance instruments used in HTA cooperation.
5.2.2. OMC in health care and long-term care policies
Although envisaged in the early 2000s, the OMC has first been introduced in social protec-
tion policies outside health care and long-term care. Based on an invitation of the Brussels 
European Council (2003) to create a coherent framework on social protection within the 
OMC, the Commission did however commit itself to streamline the disparate actions linked 
to social inclusion and pension and “in time cooperation in relation to healthcare and “mak-
ing work pay” into a single Open Method of Coordination” (European Commission 2003). 
Recognising the benefits of the OMC for health and long-term care policies in the EU, the 
Commission (DG Employment and Social affairs) refrains at first however from bringing this 
method into practice in this policy field, as it awaits the conclusions of discussions taking 
place in other processes such as the high level process on patient mobility and health care 
developments and the Intergovernmental Conference (IGC) preparing the Constitutional 
Treaty107. These discussions partly sought to clarify the place and nature of health care policy 
within the wider political, institutional and legislative frameworks of the EU as outlined in 
the previous section.
The excerpt below, taken from the 2003 Commission communication on streamlining the 
OMC in the field of social protection, clearly highlights the different challenges faced by the 
EU regarding health policy, as this policy field is highly connected to other policy areas such 
as social protection (social security and long-term health), economic policies (sustainability 
health systems), public health and patient mobility (safety and quality of health care) and 
Internal Market (pharmaceutical industry). The Commission therefore distinguishes three ar-
eas within health policy: issues related to health and long-term health care, issues relating to 
public health and the advancement of better treatments and issues related to the application 
of Internal Market principles. The same distinction will underpin the reflections regarding the 
application of OMC in health policy.
Questions regarding health and long-term care have not yet been considered in detail within 
cooperation in social protection. Healthcare issues are relevant for the development of Eu-
rope’s social model and its social, economic and employment policies in particular.
107 The project of the ‘Treaty establishing a Constitution for Europe’ had been published in 2004 
(OJEU 2004/C 310/01. 16 December 2004). The project has been abandoned as such, following 
the negative outcomes of the Dutch and French Referenda on this subject.
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Health systems and health policies across the EU are also becoming more interconnected 
than in the past, which raise many health policy issues with a clear European dimension. 
Nevertheless, as recognised in the Joint Report on Health and Long-term Care to the Spring 
2003 European Council, there are very specific circumstances and complexities attaching to 
policy cooperation in this area. A number of joint challenges facing the Member States in 
the area of health and healthcare are currently being assessed in the high level process on 
patient mobility and healthcare developments in the EU.
The European Convention is also looking at how to better define the EU’s role and respon-
sibility in this area. In particular, it will be necessary to specify which methods are the most 
appropriate to deal with social protection issues related to health and long-term care (ensur-
ing access for all based on need and regardless of resources and ensuring that health and 
long-term care needs do not cause poverty to patients and their relatives), issues relating to 
public health and the advancement of better medical treatments and, finally, issues relating 
to the application of Internal Market principles in the area of healthcare (patient mobility, 
free provision of services).
In the light of the conclusions of these processes and depending on the subsequent decisions 
on health taken by the IGC, the Commission will examine the modalities of enhancing policy 
coordination in this field in the context of a streamlined social protection process. (European 
Commission 2003: 8)
In 2004, the Council decides to extend the OMC to areas of health and long-term health 
and the process described above is put in to practice. Hence, from then on, Member States 
will submit each year National Preliminary Policy Statements which will be used by the 
Commission to propose common objectives. A “Joint report on social protection and social 
inclusion” will be issued addressing the key challenges of the fields in which the OMC is 
being implemented: poverty and exclusion, healthcare and long-term care and pensions. The 
reports are based on a quantitative analysis of the economic and demographic contexts and 
developments in the Member States as well as the social situation in the EU and the role and 
effectiveness of social policy. Strategies put into place to address each of the three challenges 
are being outlined and progress made in these fields evaluated. A country profile of each 
Member States constitutes the final part of the (first) reports.
In April 2004, following the conclusions of the HLPR, the Commission will adopt simulta-
neously two interconnected communications. These two documents present “the overall 
strategy for developing a shared vision for the European health care and social protection 
systems” and propose a global strategy for health care systems (European Commission 
2004i: 2; 4). The first communication regards the follow-up of the work of the HLPR and the 
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second refers to use of OMC to support sustainable health care and long-term care polices 
(European Commission 2004a; European Commission 2004i).
The Communication focusing on the conclusions of the HLRP resumes the overall objectives 
to be pursued as a follow up to this process. This document is also of interest as it places HTA 
into the broader EU objective of achieving economic growth and sustainable development 
and to the competitiveness of the pharmaceutical sector (European Commission 2004a:11). 
It furthermore outlines how a coordinating mechanism can be established to support a 
sustainable network on HTA cooperation. OMC is being envisaged as a method to develop 
this initiative, as stated in the text below:
“The Commission plans to establish a coordinating mechanism to link together the different 
projects, organisations and agencies which already exist and to pool results and information 
in a usable and effective way, and will bring forward separate specific proposals, including 
for a study. The cost-effectiveness of health technologies may also be the subject of specific 
objectives within the open method of coordination proposed for health and long-term care. 
These initiatives will help to ensure that patients throughout Europe benefit from care reflect-
ing the latest advances in medical technology, and also that health systems can ensure that 
they are using their limited resources in the most effective and efficient way”. (European 
Commission 2004a:11; italics added).
The second communication on the implementation of the OMC in health care and long-term 
care highlights the importance of health in the European Social Model. It builds further upon 
the Resolution of the European Parliament a month before, calling for “greater cooperation 
on health and long-term health” and calling on the Commission to “present relevant propos-
als in the spring of 2004, allowing the Council to apply the “open method of coordination” 
in this field and adopt common objectives (European Commission 2004i: 2). No explicit 
reference to HTA as such is made in this document but implicitly this policy field is being 
taken into consideration as the text refers to the importance of “appropriate assessments of 
practices and treatments” and the evaluation of costs and benefits of drugs and how this 
should relate to national practices and the development of European cooperation (European 
Commission 2004i: 9).
This communication emphasizes that the added value of the OMC lays in the identification 
of challenges common to all Member States and can support reform in the organisation and 
funding of health care and elderly care. The actions it proposes for the future bear traits of 
the OMC including the use of indicators and country reports covering challenges of national 
health systems, medium-term policy objectives and statistical data. These reports would be 
assessed by the Commission and could be taken into account in the process of streamlin-
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ing social security process discussed above. Each year the conclusions of these assessments 
would be published in a Joint report on social protection and social inclusion.
In 2006, the integrated Open Method of Coordination is introduced and comprises health 
care and long-term care. It will be even further consolidated in 2008 (European Commission 
2008e). Hence, the Joint reports on social protection and inclusion comprise a section on 
health care and long-term care. However, although the policies evaluated in this regard 
do in a sense overlap with those treated by DG Sanco, they mostly relate directly to social 
protection and inclusion policies. As such, the country reports will be focused on issues 
such as reducing inequality in health care (e.g. reducing risk factors through health promo-
tion, prevention activities, increase population coverage, address cultural barriers to use of 
health services). Long-term care is being addressed as a result of demographic ageing and 
socio-economic changes which increase life expectancy and the incidence of invalidity and 
dependency. This requires considering long-term care as a new social risk to be covered by 
social protection policies (European Commission 2008d: 116-117).
Hence, the core content regarding health care and long-term care of the joint reports be-
tween 2005 and 2010 will be based on a macro-analysis of the health systems in the EU 
by focusing in particular on the question of inequalities (access to health care, universal 
coverage, waiting times, lack of general practitioners etc); patient safety (patient-centred 
care) and sustainability and coordination. The latter however covers over the years mainly 
issues of staff shortages and the management of chronic diseases. Long-term care is being 
addressed focusing on the issue of finding the appropriate mix to finance it (private insur-
ance, co-payments etc.) as well as by the shortage of personnel.
Two reports make however a direct reference to HTA. In these reports, one can observe a 
sort of coordination between key-messages and policies developed by DG Sanco and DG 
Employment and Social affairs. In its section on health care, the 2007 Joint Report on social 
protection and social inclusion makes references to the need to maintain a high-quality care 
across the health systems. It encourages health care professionals “to use centrally evaluated 
and accessible clinical guidelines based upon the best available evidence”. It also underscores 
that “national health technology assessment agencies have been established and are cooper-
ating at EU level (EUnet-HTA). They help to ensure that new interventions are effective, safe 
and cost effective” European Commission 2007a:11).
The 2010 report (which will be the last of the kind) gives a general overview of the health 
care and long-term care in the EU focusing again on the key areas cited above. In its section 
regarding the sustainability of health systems, the report underscores how “Technological 
development can increase expenditure by creating new treatment opportunities” and how 
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HTA (including a cost-effective and cost-utility analysis) is being considered as a mean “to 
decide if a certain care intervention or drug should be included in the publicly funded or 
reimbursed basket of care and to what extent, notably in comparison to other interventions 
or drugs” (European Commission 2010: 111). It finally mentions that “building on a number 
of previous actions and projects, the Commission and Member States are currently working 
on a joint initiative aimed at increasing cooperation, sharing information and developing the 
same core methods in the area of HTA” (European Commission 2010:111).
These two passages will be the only ones making a direct reference to HTA. One should 
notice however that this is mentioned in the overview on health policies in the reports and 
does not seem to be really integrated in country reports on health policies which lay at the 
basis of each report. From the above, we can conclude that the OMC has been applied to a 
certain extend to health policy issues within the framework of social protection and inclusion. 
This has permitted to establish an overview and comparison of Member States’ policies in 
this field allowing for the development of some general objectives to be pursued by the EU 
as a whole. If, at times, reference is being made to the importance of HTA regarding the 
sustainability of the health systems, no ‘explicit’ OMC has been implemented in this area. A 
close analysis of the passages in the reports seem to rather indicate that this issue is moving 
upwards on the wider EU health policy agenda and that the importance of HTA is being more 
widely recognised within the European Commission.
5.2.3. OMC and the EU public health strategy: the role of networks
5.2.3.1. High-level expert networks disseminating the soft governance 
approach
From the above, we can observe that even before the publication of the White Paper on 
Governance (2001), soft governance instruments, of the type of OMC, were envisaged to 
promote EU health-policy objectives. This resulted from the connection between social policy 
and the employment policy on the one hand and the inclusion of health care objectives in 
social protection policies. Moreover, the fact that this has been developed at a time were 
public health policy was hosted by DG Employment and Social affairs, further explains the 
proximity and interrelationship that existed between the different policy fields. However, 
with the creation of a separate DG for Health, the implementation of OMC in health-related 
issues by DG employment and Social Affairs has gradually been limited to social protection 
and inclusion policies.
In this sense, it thus doesn’t come as a surprise that the health care related objectives 
comprised in the ‘concerted strategy for modernising social protection’ published by DG 
Employment and Social Affairs showed many similarities with those of the (public) health 
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strategy, outlined in the first section of this chapter. The health strategy was, as we have 
seen, initially developed by the public health unit (hosted within the same DG Employment) 
and later pursued by DG Sanco. One of the ‘common’ objectives between the ‘concerted 
strategy for modernizing social protection’ and the public health strategy was HTA coopera-
tion in Europe. Indeed, the ‘concerted strategy’ comprised, amongst others108, the objective 
“to improve the efficiency and effectiveness of health systems”, make an effective use of 
medical knowledge and technology; strengthening the co-operation between Member 
States on evaluation of policies and techniques; ensure access to high quality health services 
and reduce health inequalities as well as support long-term care of elderly people (European 
Commission 1999b: 14-15).
Hence, as an integral part of social policy, some health-related policies will continue to be 
promoted by the DG Employment and Social affairs even after the establishment of DG 
Health and Consumers (DG SANCO). The dual involvement in health care policy on behalf 
of the Commission is also reflected in its representation in the different high-level expert 
networks. Indeed, representatives of both DGs participated in the High Level Process of 
Reflection on Patient Mobility and Healthcare Developments in the EU, launched in 2002 
and including HTA as a priority topic. We have seen in the sections above how this reflection 
process emanated initially in 1999 from patient-mobility cases at the CJEU which triggered 
discussions on the issue in the High Level Committee of Health. The latter created in April 
1999 the working group on the Internal Market and Health with a mandate to explore 
information on the impact of Community policies on health care and cross-border health 
care and service arrangement. Hence, the work was initiated still under DG Employment and 
Social Affairs (before the establishment of DG Sanco) but the final report has been published 
in 2001 by DG Sanco (European Commission 2001a:4).
Both DGs will remain involved in the follow-up of this process which can thus be explained 
from a polity, policy and politics point of view. Indeed, during the time-span of the meetings 
of the working group on Internal Market and Health, a new institutional structure respon-
sible for EU health policy has been created (i.e. DG Sanco). However, policy-wise, long-term 
health care and issues related to patient mobility and health care (e.g. social security systems, 
long-term care and elderly) still fell under the responsibility of the institutional structure 
responsible for social protection (i.e. DG Employment and Social Affairs). As explained by a 
senior representative of DG Sanco, in the early days of this new directorate, a sort of com-
108 The other objectives listed in the communication are related to the promotion of employability 
and the provision of a secure income; making pensions safe and pension systems sustainable and 
promoting social integration (European Commission 1999).
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petition for health competences did exists between both institutional structures (personal 
interview 3).
Hence, the High Level Process of Reflection on Patient Mobility and healthcare develop-
ments has been launched upon the initiative of both Commissioners Byrne (DG Sanco) and 
Diamantopoulou (DG Employment and Social Affairs). This dual Commission representation 
in these expert networks also offered a dual contribution on behalf of the Commission. The 
participation of DG Employment and Social affairs in the working group on Internal Market 
and healthcare and in the HLPR had, amongst others, an impact on the governance methods 
proposed. As such, the conclusions of the report of the working group do, for example, 
recommend to “implement the method of “open co-ordination” for health (..) by defining 
targets and objectives on the European level, defining, quantifying and qualifying indicators 
and benchmarks, and monitoring, analysing and evaluating the achievements in the Member 
States” (European Commission 2001a: 25-26).
This recommendation will be further worked out in the HLPR. In the February 2003 meeting 
of the HLPR, Commissionner Diamantopoulou refers for example to the fact that, in social 
policy, no new European competences are needed but that the existing means (including 
the OMC) needed to be strengthened. After developing work to implement OMC in social 
exclusion and pensions, the Commissioner stated “that there was now an ongoing exercise 
concerning health and long-term care for the elderly” (European Commission 2003a: 2). 
Hence, the idea of extending OMC to health care will be carried on in the expert working 
groups and integrated in the conclusions of these. Several distinct Commission communica-
tions will be based on these HLPR conclusions which will also be further discussed in Council 
meetings. The two connected 2004 Commission communications setting the global health 
strategy (discussed above) can be cited as an example.
Through consistent discourse in different networks, reflections upon an OMC in health 
policy and related soft governance instruments were being brought to the fore mainly by 
representatives of DG Employment and Social Affairs. Eventually this will lead to the fact 
that these instruments are also being considered in health policy areas laying outside social 
protection policy and will, at times, also regard HTA cooperation. In July 2004, for example, 
the Commissioner David Byrne (DG Sanco) launches a reflection process to define the new 
EU health Strategy. In his communication on this issue, he relates HTA cooperation to sev-
eral items linked to New Modes of Governance such as openness, civil participation, good 
governance as well as Member States “learning together and sharing best practices, sharing 
capacities and saving money on joint health technology assessment” (European Commission 
2004d:11).
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Another connection between OMC and HTA can be found in the report of the High Level 
Group on health services and Medical technologies, prepared in November 2004 for the 
‘Employment, Social Affairs, Health and Consumer Protection Council’ taking place in De-
cember 2004. Referring to the recommendations of the HLRP (in the meantime re-named 
into ‘patient mobility reflection process’) regarding European cooperation to enable better 
use of resources and covering issues such as the evaluation of medical technologies, it is 
stated:
“The task for the High Level Group is to implement these recommendations by developing 
concrete action bringing benefit to patients and helping to improve the effectiveness and 
efficiency of the health systems across the Union while respecting national responsibilities for 
health systems. This should be undertaken in close cooperation with other bodies working 
on relevant issues at European level and ensuring a coherent approach with regard to other 
policy areas, in particular with the open method of coordination on healthcare and long-term 
care”. (European Commission 2004f: 4, italics added).
Although never implemented as such, reference to the OMC will remain present in the HTA 
cooperation processes in Europe. In a 2007 communication of the HTA cooperation project 
“EUnetHTA” regarding the public consultation on the New Health Strategy, OMC is again 
being considered as an appropriated tool to strengthen HTA cooperation in Europe. Here 
too, the connection between HTA and OMC is made via social protection policies:
“During the current EUnetHTA project period (2006-8), the open method of coordination 
for healthcare and long-term care should be the legislative tool for the High Level Group on 
Health Services and Medical care to continue developing mechanisms for practical coopera-
tion on HTA. (…) Concomitant to using the open method of coordination to develop the 
network further into a committed collaboration, legal certainty of such collaboration should 
be provided” (EUnetHTA 2007).
Reference to the implementation of the OMC to HTA cooperation has thus been made at 
several occasions and in several fora. However, in practice, deploying an OMC in health 
policy reflected essentially a willingness on behalf of the DG Employment and Social Affairs. 
The latter included long-term health care and elderly care in its social protection policies. As 
DG Employment and Social affairs seeks to streamline the application of OMC to its social 
protection policies, health care is often associated to OMC in a variety of communications 
emanating from this Directorate General. However, these issues were being dealt with sepa-
rately from the DG Sanco, which most of the time was not involved in OMC related policy 
projects (Personal interview 3).
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The implementation of an explicit OMC in health policy – and thus in HTA cooperation – has 
never been an official objective pursued by DG Sanco (for which it did not have a legislative 
basis conversely to DG Employment and Social Affairs). Nevertheless, if establishing the OMC 
as a formal working procedure was not an objective of DG Sanco, this did not mean that 
the governance instruments used to implement its health strategy - and therefore also HTA 
cooperation - were not quite similar to those applied in the OMC. Indeed, in the 2003 work 
plan of the first health programme, the ‘Promotion of HTA cooperation’ falls even under the 
heading “Promoting best practices and effectiveness”.
5.2.3.2. Soft governance instruments underpinning the health article of the 
Lisbon treaty
The soft governance approach, initiated in DG Employment and Social affairs and later fully 
integrated in the Lisbon strategy, will ultimately have a profound impact on the legislative 
basis of the EU health policy. Indeed, the developments in the High Level Reflection Process 
and the High Level Group as well as the development of the health strategy, have to be 
analysed against the background of the Constitutional Treaty that was being prepared for 
ratification in 2005. Within DG Sanco, during the early 2000s, significant efforts were also 
made to introduce amendments to the public health article of the Constitutional Treaty. Due 
to the rejection of this Treaty proposal in 2005 by some Member States, it was only with the 
adoption of the Lisbon Treaty (2007) that a revised public health article (Article 168 TFEU) has 
been adopted. A close analysis of this article permits to acknowledge that most amendments 
actually refer to the introduction of soft governance principles which closely resembles the 
OMC without formally naming it.
Hence, although only adopted in 2007, these amendments were actually being discussed 
and developed almost simultaneously with the discussions going on in the different expert 
networks outlined in the previous section. Indeed, the call for a debate on the future of 
Europe had been launched at the Laeken European Council in December 2001 (simultane-
ously with the publication of the report of the High Level Committee on health which has 
launched the different high level expert network discussions). This led to the establishment of 
a European Convention which would ultimately lead to a proposal for a ‘European Constitu-
tion’ submitted in June 2004 and signed in October but rejected by the French and Dutch 
citizens in referenda held in May 2005. A close comparison of the proposed amendments 
of the public health article in the ‘Treaty Establishing a Constitution for Europe’ (OJEC 2004) 
with the public health article of the Lisbon Treaty adopted in 2007 shows however that both 
are almost identical.
It is in particular paragraph 2 of art 168 (TFEU) which is most concerned by these soft policy 
related amendments. Indeed, the paragraph recalls that the EU “shall in particular encourage 
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cooperation between the Member States to improve the complementarity of their health 
services in cross-border areas. (…) “in particular initiatives aiming at the establishment of 
guidelines and indicators, the organisation of exchange of best practice, and the preparation 
of the necessary elements for periodic monitoring and evaluation”. Finally, a sentence has 
been added here in which the emphasis is put on cross-border cooperation in health services 
areas.
Paragraph 3 of Article 168 TFEU remains unchanged compared to Article 129 EC and fore-
sees ‘cooperation with third countries and the competent international organisations in the 
sphere of public health’. As with the fourth paragraph of the public health article, the Lisbon 
Treaty stipulates that the achievement of the article’s objectives should be made in accor-
dance with the ordinary legislative procedure in this regard. This procedure (previously called 
‘co-decision procedure’) gives besides the Council, an important role to the European Parlia-
ment (EP) in the decision-making procedure. Indeed, as a co-legislator, the EP has a crucial 
role in the adoption of new legislative proposals in this area. As a result, the parliamentary 
committee responsible for Environment, Public health and Food safety affairs (ENVI109) will 
see its workload increase. We will see that this will play a role in the development of HTA 
cooperation in the future.
Article 168 TFEU furthermore stipulates that the Economic and Social Committee as well as 
the Committee of the Regions need to be consulted before any new legislation in this field. 
Adoption of new legislation should also meet common safety concerns regarding quality 
and safety standards of ‘organs and substances of human origin, blood and blood deriva-
tives’, medicinal products and devices for medical use as well as measures in ‘veterinary and 
phytosanitary fields which have as their direct objective the protection of public health’. 
These provisions were already present in the Maastricht Treaty.
Another innovation regarding health policy in the Lisbon Treaty is the fact that the European 
Parliament and the Council ‘may also adopt incentive measures designed to protect and 
improve human health and in particular to combat the major cross-border health scourges, 
measures concerning monitoring, early warning of and combating serious cross-border 
threats to health, and measures which have as their direct objective the protection of public 
health regarding tobacco and the abuse of alcohol’. However, it is explicitly stated that these 
109 The ENVI committee is responsible for dealing with environment, food safety and public health 
issues at the European Parliament (http://www.europarl.europa.eu/committees/en).
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measures exclude ‘any harmonisation of the laws and regulations of the Member States’ 
(Article 168 (5) TFEU)110.
Finally, the provision in Article 11 TEU introduces new measures regarding the consultation 
of the civil society. It stipulates that ‘[t]he institutions shall maintain an open, transparent and 
regular dialogue with representative associations and civil society’. Indeed, the article can 
also have a potential impact on future relationships between representative organisations 
active in the health policy areas. It is also in line with good governance principles outline in 
the White Paper on Governance (2001).
Although the powers of the EU in the field of health care are limited - making it even to 
be considered by some as a ‘supranational non-topic’ (Lamping 2005: 20) - the Treaties 
give space for manoeuvre to the EU institutions. According to a senior representative of 
DG Sanco, the reason why these soft policy measures had been included (without officially 
referring to OMC) was to enable the Commission to act on the basis of official legislation. 
Although the Lisbon Treaty still conferred only coordinative and support-lending powers to 
the Commission, it did offer a legal basis to extend the Commission’s actions to new domains 
within health policy, by means of soft policy governance instruments. In a way, the Lisbon 
Treaty formalised the manner by which the Commission already worked for almost twenty 
years (Personal interview 3).
Although the amendments seem rather limited in conferring extra powers to the Commis-
sion it did permit the adoption of the Cross-Border Health Care Directive (2011/24/EU) which 
offered, as outlined in the previous section, for the first time a legal basis to act in HTA 
cooperation. It is indeed, on the basis of this Directive that the ‘EU Health Technology Assess-
ment Network’ (EU HTA Network has been established in 2013, herewith institutionalising 
110 Two other points of differentiation with the previous Treaties should be highlighted. The first is 
related to the Charter of Fundamental rights which becomes legally binding under the Lisbon 
Treaty. Different provisions in the Charter are indirectly related to health matters such as the right 
to human dignity (Article 1), the right to life (Article 2), the right to integration of persons with 
disabilities (Article 26), the right to the protection of personal data (Article 8). The latter can be of 
importance with regard to information that is collected by the medical professionals. The right to 
the freedom of conscious (article 10) can affect professionals in the medical field (EHMA 2009). 
The Charter also refers in its Article 34 to social security benefits and social services providing 
protection in case of illness. Finally, Article 35 can have a direct impact on health related matters 
since it refers to the right of ‘access to preventive health care and the right to benefit from medical 
treatment under the conditions established by national law and practices’. Furthermore, it stipu-
lates (once again) that ‘a high level of human health protection shall be ensured in the definition 
and implementation of all Union policies and activities’ (OJEC 2000).
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HTA cooperation in Europe. For a better understanding of the content that will be developed 
in the newly created HTA networks, the third part of this chapter will outline some develop-
ments in the pharmaceutical policy stream and which have impacted the course of action of 
those networks.
5.3. the pharmaceutical policy Stream: proviDiNg key 
coNteNt For hta cooperatioN
Pharmaceuticals and HTA are often considered rather distinct policy areas which are also be-
ing dealt with separately in the EU institutions (HTA falls within the policy areas of DG Santé 
and pharmaceuticals within DG GROW). This distinction is indeed in many respects justified. 
However, as we shall outline in this section, developments in EU pharmaceutical policies 
are of prime importance for the HTA cooperation efforts, both in terms of content and of 
sustainability. To get a more profound insight on how this policy stream has at times crossed 
the one of HTA cooperation and had a profound impact on it, it is important to briefly recall 
some important milestones in the history of EU pharmaceutical policy.
5.3.1. Setting European standards in a common market of 
pharmaceuticals
The EU has been first confronted with the need to develop a specific policy regarding phar-
maceuticals after the Thalidomide scandal in the early 1960s. This sedative drug developed 
in 1953 was considered to be safe (mostly because it made it very difficult to commit suicide 
with it) and became widely prescribed to treat a variety of medical conditions among which 
morning sickness of pregnant women. In 1962-63 however Thalidomide was found to be 
responsible of causing important malformations in unborn children (Dally 1998). This public 
health scandal resulted first in the establishment of national authorities to evaluate the safety 
of drugs (Jeffrey and Jones 1995). Soon these developments led to the adoption of the 
Directive 65/65/EEC on the “approximation of provisions laid down by law, regulation or 
administrative action relating to proprietary medicinal products”. Hence, developed from a 
public health perspective, this Directive sought to lay down some definitions on medicinal 
products and establish guidelines regarding market approval and post-marketing monitoring 
of drugs based on safety, efficacy and therapeutic benefit criteria. Market access was still to 
be granted by competent national authorities (Permanand and Mossialos 2005).
Ten years later, two new Directives (75/318/EEC and 75/319/EEC) will address market ac-
cess of pharmaceuticals through the principle of mutual recognition of national marketing 
authorisations procedures and with the creation of a central coordinating body: the Com-
mittee for Proprietary Medicinal Products (CPMP) (Jeffery and Jones 1995). These and the 
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following legislative documents were however not rooted in a public health perspective but 
rather responded to Internal Market concerns. Indeed, the main objective pursued here was 
to ensure a smooth access of pharmaceuticals on the EU market ruled by free movement 
principles. Introducing the concept of “Mutual recognition”, the Directive 75/318/EEC cre-
ated the possibility for a product having received a market authorisation in one Member 
State to seek marketing authorisation simultaneously in five or more Member States (till 
then a separate procedure had to be followed in each country separately). In practice, the 
implementation of these principles faced resistance from Member States who almost system-
atically objected and sought arbitration from the CPMP whose decisions were non-binding. 
The usual arguments brought forward by the Member States, regarded the fear for potential 
negative health effects. Hence, instead of speeding up the procedure, these two legislative 
instruments caused, in practice, substantial delays (Permanand and Mossialos 2005:51).
In 1983, the Directive 83/570/EEC sought to facilitate implementation of the mutual recogni-
tion concept with the introduction of the ‘Multi State Procedure’, reducing the threshold of 
recipient states from five to two. Although more applications were introduced, it didn’t really 
alter the situation since the Member States still systematically objected market authorisa-
tions requests by this procedure111. Moreover, as the procedure was based on voluntary 
recognition, and as the CPMP could only issue non-binding opinions, the vast majority of 
products were submitted in one of the national routes for product licensing (Jeffrey and 
Jones: 1995:473; Permanand and Mossialos 2005:51).
The arrival of Jacques Delors at the head of the European Commission and his White Paper 
on the completion of the single market published in 1985, gave another impetus to develop 
a single medicines market on pharmaceuticals. Pharmaceuticals were given attention here in 
the light of the fight against illicit trade of drugs (European Commission 1985: 11). Following 
the adoption of the 1986 Single European Act aiming to complete the single market based 
on the principles of free movement of goods services and capital by 1992, a new Directive 
(87/22/EEC) had been adopted in 1987. This time, the so-called ‘concertation procedure’ was 
introduced for biotechnological and other high technology products. The procedure required 
that drug manufacturers submitted market authorisation applications simultaneously to the 
CPMP and a Member State (acting as rapporteur). After having taken into consideration 
possible objections of Members States, the CPMP could recommend an EU-license. Although 
111 By the end of 1993, only one out of more than 300 products submitted in the Multi State Pro-
cedure had been authorised without reasoned objections. The CPMP had to give an opinion in 
more than two-thirds of cases of which about 86 % were in favour of licensing by 1992. There 
are however hardly any cases where identical product datasheets have been agreed across the 
Community (Jeffrey and Jones 1995: 474).
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the procedure was mandatory for products of biotechnological origin, the CPMP arbitration 
was still not binding for other products and, in most cases, thus disregarded by the Member 
States (Jeffreys and Jones 1995: 473).
In the meantime, another issue invited itself on the Commission’s agenda regarding the 
regulation of the pharmaceutical market. The pricing policies of pharmaceutical companies 
(closely linked to their market access strategies) raised concern in many countries. After a 
company had obtained the approval to market their drug, price and reimbursement negotia-
tions would start with each Member State separately. As reimbursement policies can differ 
among the EU Member States, pricing policies are often adjusted accordingly and negotiated 
separately. The price differences that can result from these procedures have given rise among 
others, to so-called parallel trade where wholesalers purchase the product in another Mem-
ber State at a lower price than the one negotiated in their home country. This situation led 
to the adoption of the Price Transparency Directive (89/105/EEC) which set out a number of 
criteria to create transparency in price settings and their inclusion in national health insurance 
systems112. This Directive, which is until today the sole EU legislative document regarding 
pricing of pharmaceuticals, did not aim any harmonisation of pricing or reimbursement 
of pharmaceuticals. Hence, price differences within the EU remains a fact (Chambers and 
Belcher: 1994; Permanand and Mossialos 2005). The Transparency Directive mostly serves 
to ensure that the national pricing and reimbursement procedures are fair, transparent and 
efficient. It is also an instrument permitting the Commission to verify whether Treaty obliga-
tions in terms of free movement and competition are being respected (Hancher 1992: 405).
The situation above resumes the challenges faced by the Commission more than 25 years 
ago and still present today in EU pharmaceutical policy: addressing the four-fold objective of 
ensuring safety, efficiency, equity and financial sustainability of both the health systems and 
the industry. Hence, developing a specific EU policy on pharmaceuticals requires to address 
health policy needs (safety and efficacy) as well as industrial needs (competitive advantage) 
and economic needs (employment, growth). Moreover, this policy field concerns multiple 
stakeholders ranging from those that produce the pharmaceuticals to those that prescribe, 
deliver, research, assess, reimburse and consume them.
112 The main criteria set out in the Transparency Directive and regarding individual pricing and reim-
bursement decisions concern the following: decisions must be taken within a given timeframe 
(90 or 180 days); the applicant receives the communication which includes a statement indicating 
the reasons based on objective and verifiable criteria; applicants can appeal the decision on a 
national level. Moreover, the Directive also concerns other issues such as labelling, packaging, pat-
ent protection, advertisement and sales promotion as well as wholesale distribution (Transparency 
Directive (89/105/EEC) - OJEC 1988)
Policy streams structuring European HTA cooperation 235
As in all policies, trade-offs sooner or later have to be made. The difficulty in this particular 
policy area is that these choices confront public health/health care issues with (conflicting) 
economic/industrial interests and thus concern often ministries of health, finance and trade 
(Mossialos et al. 2010; Permanand and Mossialos 2005b). Hence, a government can seek to 
develop a health care policy based on costs containment and improved efficiency in health 
care services whilst pursuing both the regulation on safe and efficacious medicines. It more-
over will also be responsible for the promotion of research and development and ensuring 
the competitiveness of the pharmaceutical industry (see further Permanand 2006).
This dichotomy and the difficulty to unite the different interests is also reflected in the 
internal organisation of the Commission where public health is being dealt with by one 
Directorate General (DG SANTE) and Industry and economic growth by another (DG GROW). 
Moreover, the allocation of HTA to DG SANTE (and its predecessors) and pharmaceuticals 
to DG GROW (and its predecessors) shows which element is dominating the EU perspec-
tive in the respective policy fields. The allocation to different Directorates has however an 
important impact on the policy development. Indeed, pharmaceutical policy considered from 
an industry perspective, falls into the scope of Internal Market polices which respond to the 
so-called shared competences between the Member States and the EU (Article 4 TFEU). The 
latter refers to the fact that Member States can legislate “to the extent that the Union has 
not legislated” (Chalmers Davies and Monti 2010: 208). Hence, the governance instruments 
available to the EU in the pharmaceutical policy differ from those in the health policy where 
it can mainly resort to soft governance instruments and can act only in the light of the 
subsidiarity principle.
Medicines are thus on the one hand considered as industrial good and their market authorisa-
tion, refers to policies responding to Internal Market principles. On the other hand, in pricing 
and reimbursement procedures, medicines are being considered in the light of the safety 
and efficacy and refer exclusively to national health care policies. This explains why Member 
States are very attached to setting their own pricing and reimbursement rates and are not 
inclined to pursue any harmonisation policies at the EU-level (Hancher 2010:637). In the next 
section, we will outline how the European Commission has developed a separate agenda for 
both aspects of pharmaceutical policy and how eventually some synergies have started to 
appear through HTA cooperation, reinforcing herewith the role of HTA in EU health policy 
and EU pharmaceutical policy. Moreover, this dual approach of considering medicines in the 
light of the Internal Market and in the light of national health care policies lays at the basis 
of a Regulation proposal on HTA cooperation made by the European Commission in 2018 
(chapter 6).
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5.3.2. Creating a European Agency for Pharmaceuticals
In 1992, in the light of the establishment of the single market, a legislative framework 
consisting of three Directives and one Regulation set-out the so-called “future system” on 
pharmaceutical policy (Directive 92/25/EEC: wholesale distribution; Directive 92/27/EEC: 
classification of pharmaceuticals; Directive 92/26/EEC on labelling and packaging; Directive 
92/28/EEC on advertising; Regulation 1786/92 on patent protection113). A year later, two 
new pieces of EU legislation completing this framework, will have a profound impact on 
the pharmaceutical policy of the EU. The Directive 93/39/EEC and the Regulation 2309/93 
announce the establishment of the European Medicines Evaluation Agency, which became 
the entry door to apply for a Market Authorisation of a product license.
The Article 53 of Regulation 2309/93, setting out the objectives of EMEA, resumes the dual 
policy objectives of protecting human health and promoting the completion of the Internal 
Market pursued by the European Commission. Indeed the article stipulates that: “In order to 
promote the protection of human and animal health and of consumers of medicinal products 
throughout the Community, and in order to promote the completion of the Internal Market 
through the adoption of uniform regulatory decisions based on scientific criteria concerning 
the placing on the market and use of medicinal products, the objectives of the Agency 
shall be to provide the Member States and the institutions of the Community with the best 
possible scientific advice on any question relating to the evaluation of the quality, the safety, 
and the efficacy of medicinal products for human or veterinary use, which is referred to it 
in accordance with the provisions of Community legislation relating to medicinal products”.
The EMEA introduced two new procedures. The ‘Centralised Authorisation Procedure,’ 
applicable to biotechnology products and certain other innovative medicines. In this pro-
cedure, the EMEA appointed a rapporteur (usually a Member State) to assess the product 
and produced a report to be submitted to the new CPMP committee114 having to provide 
an opinion on the product. A positive opinion was then communicated to Members States 
and if no objections would be raised it will be adopted by qualified majority in a Standing 
Committee (Jefferys and Jones: 1995). The ‘Decentralised Procedure’, was still based on 
mutual recognition of licenses, as a license granted in one Member State could be expanded 
to others on the basis of the same initial dossier submitted. These other Member State would 
have 90 days to recognise the first license. Objection could be raised only in cases of serious 
public health concerns, in which case a discussion would take place with the rapporteur and 
the countries concerned. In case of persistent disagreement, the case would be submitted to 
113 OJEC 1992; 1992a; 1992b; 1992c; 1992d
114 The CPMP has been renamed in 2001 into Committee for Medicinal Products for Human Use 
(CHMP).
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the CPMP which would issue a binding opinion which could be adopted by qualified majority 
in the Standing Committee.
Binding arbitration by the CMPM distinguishes this new procedure from the previous ones 
and will have a major impact on the role the EMEA will to play in the future. Moreover, after 
a transition period of three years, the procedure became compulsory. A manufacturer had 
to choose between the two routes: the centralised procedure or the national authorisation 
procedure (either via the mutual-recognition procedure or the decentralised procedure115). 
Finally, a new coordination system of pharmacovigilance was also implemented through the 
EMEA. Today, the above outlined authorisation processes are still in place and amendments 
have regarded mostly the extension of the centralised procedure to new medicines116.
Although the authorisation through the national route via the mutual recognition procedure 
and the decentralised procedure still exist for medicines outside the scope of the centralised 
procedure, the vast majority of new innovative medicines receive market license through 
the centralised procedure (EMA 2016:5). Moreover, the name of the Agency has been 
changed in 2009 into European Agency for Medicines (EMA). Similarly, the CMPM had been 
renamed in 2004 into the CHMP117, responsible for preparing the Agency’s opinions on 
questions concerning human medicines and appoints, together with the Pharmacovigilance 
Risk Assessment Committee (PRAC), (co-)rapporteurs to conduct the scientific assessment. 
The PRAC and the Committee on Advance Therapies (CAT) provide input on aspects related 
respectively to risk management and to advanced therapy medicines. After the evaluation, 
the CHMP issues a scientific opinion on whether the medicine may be authorised or not. The 
legal decision to grant or not market authorisation lays within the hands of the European 
Commission which publishes its decisions in the Community Register of medicinal products 
115 The Mutual Recognition Procedure applies where the medicinal product has already received a 
Market Authorisation in a Member State at the time of application. The Decentralised Procedure 
applies where the medicinal product has not received a Market Authorisation in a Member State 
at the time of application.
116 The centralised procedure is compulsory for human medicines containing a new active substance 
to treat: human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS); 
cancer; diabetes; neurodegenerative diseases; auto-immune and other immune dysfunctions; viral 
diseases; medicines derived from biotechnology processes, such as genetic engineering; advanced-
therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines; 
orphan medicines (medicines for rare diseases); veterinary medicines for use as growth or yield 
enhancers. It is optional for other medicines such as those containing new active substances for 
indications other than those stated above; that are a significant therapeutic, scientific or technical 
innovation; whose authorisation would be in the interest of public or animal health at EU level 
(EMA 2016:5).
117 CHMP stands for ‘Committee for Medicinal Products for Human Use’
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for human use. A European public assessment report (EPAR) is published by the EMA both 
in cases of approval or refusal of market authorisation (EMA 2016; www.europa.ema.eu).
As outlined before, the pharmaceutical policy of the European Commission was rooted in 
a single market perspective and predominantly influenced by concerns for the competitive-
ness of its pharmaceutical industry. Partly, this approach has resulted from the fact that 
pricing and reimbursement remain a national competence. Hence, full harmonisation of the 
‘medicines market’ cannot be pursued and policies seeking the convergence of national 
practices need to circumvent the EU lack of competences in this area while respecting the 
subsidiarity principle. Regarding pharmaceuticals, the EU will follow the path of price de-
regulation through competition policies. However, this approach has also triggered fear of 
convergence at higher prices on behalf of patient and consumer groups. In some cases, 
economic concerns form a barrier at Member States’ level, as some national governments 
fear that more competition will negatively affect some local pharmaceutical companies. 
Pricing and reimbursement policies can indeed be used as a mean to offer support to those 
companies (Permanand and Altenstetter 2004: 46).
Hence, although the European Commission has tried to develop its policies to support the 
industry in terms of productivity, competitivity and employment, it is often restricted in its 
‘maneuver space’ in this regard. The Resolution 96/C 136/04 of the Council, adopted in 
1996, is an example of how the Member States and the industry have carefully watched 
over the fact that pricing and reimbursement policies firmly remain a national competence 
as all references to price harmonisation, which were present in earlier drafts, do not ap-
pear anymore in the final draft (Permanand and Altenstetter 2004: 46). The final draft of 
the Resolution further stresses the need to work towards a European industrial policy for 
pharmaceuticals. It underscores once more the presence of intense international competition 
in this field and the new challenges to address, such as the “growing costs of pharmaceuti-
cal research and development” and “the emergence of new technologies”. Therefore, it 
considers that “sufficient profitability is necessary if the European pharmaceutical industry is 
to cover the investment required to guarantee its capacity for innovation and thus ensure its 
competitiveness at international level “.
At this stage, we encounter another obstacle for the EU to pursue its policy in the field of 
pharmaceuticals. At the beginning of this section, we have outlined the Commission’s dilem-
ma to conciliate public health policy objectives (safety, efficacy and quality) with economic 
policy objectives (competitiveness, growth, employment). Having very limited competences 
in the public health field, it has concentrated its efforts in pharmaceutical policy on the ac-
complishment of a ‘Internal Market of medicines’. Price deregulation and competition have 
traditionally constituted an integral part of the establishment of the EU’s Internal Market. 
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However, in this particular policy area, pricing policies remain a national competence and are 
often considered as a tool to strengthen the local pharmaceutical industry. Moreover, pricing 
policies are intrinsically linked to reimbursement policies, which in turn are often directly or 
indirectly related to fiscal policies (depending on the social health insurance systems in the 
Member States118).
Besides the historical heritage having influenced the organisation and functioning of social 
health insurance systems, differences in national regulatory regimes are also due to different 
responses to factors such as health care budget constraints, drug consumption, life-style 
patterns and industry strategies (Permanand and Altenstetter 2004: 47). The latter further 
increase the differences between regulatory systems and make it thus even more difficult to 
establish convergence between policies. Hence, even by addressing pharmaceutical policy 
through the scope of the Internal Market, the European Commission is confronted to the 
application and interpretation of the subsidiarity principle, substantially restricting its margin 
of maneuver. Any efforts of convergence of policies faces Member States’ and industry 
resistance, unwilling to give in regulatory control over pharmaceuticals. We will examine in 
chapter 6 how European cooperation in the field of HTA will trigger some regional initiatives 
to extend the cooperation into price negotiations.
5.3.3. The role of networks in content development of HTA cooperation
5.3.3.1. The G10 process on medicines
In 2000, the DG Enterprise requests a report on the competitive position of the European 
pharmaceutical companies and industries in particular with regard to the US. The report 
Global Competitiveness in Pharmaceuticals: A European Perspective, published in 2001 and 
commonly known as the ‘Pammolli report’, concludes that the European pharmaceutical in-
dustry is losing competitiveness as compared to the USA and that “Europe is lagging behind 
in its ability to generate, organise, and sustain innovation processes that are increasingly 
expensive and organisationally complex” (European Commission 2001c:4-5). Moreover, it 
stipulates that the “growth of the industry in Europe is likely to depend to a good extent 
on factors other than R&D, capital or labour” and points to the regulatory environment in 
this regard (such as licenses from international companies, pricing policies, or peculiarities 
of the public regulatory and health care systems or demand in individual European coun-
tries). Hence, according to the report “the competitiveness of the European pharmaceutical 
industry is negatively affected by the perstistence (sic) of insufficient degrees of competition 
and institutional integration, still centred on domestic and fragmented markets and research 
systems” (European commission 2001c: 8).
118 See further on Social Health Insurance Systems e.g. Saltman, Busse and Figueras: 2004.
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The Pammolli report was published in 2001, simultaneously with the “Review of the Com-
munity Regime for market authorisation for pharmaceutical products” based on an audit on 
the functioning of the EMEA as foreseen by Article 71 of Regulation 2309/93. This process, 
which reviewed the pharmaceutical legislation, focused on four main objectives: guarantee 
a high level of public health protection for Europeans, further complete the Internal Market 
in pharmaceuticals and establish a regulatory framework favourable to the competitiveness 
of European pharmaceutical industry, meet the challenges of EU enlargement and rationalize 
and simplify the system to improve its global coherence, its visibility and the transparency 
of the procedures (European, Commission 2001c). The review process eventually led to 
the adoption of new legislative documents and the amendments of existing ones. We can 
mention here in particular the adoption of Directive 2001/83/EC (amended in 2004 by the 
Directive 2004/27/EC) on human medicines replacing and consolidating the legislative frame-
work on pharmaceuticals, comprising all the aspects of wholesaling, classification, labelling 
packaging and advertising119.
Although the Review process would have important consequences for the functioning and 
influence of the EMEA, the Pammolli report will indirectly also impact HTA cooperation in 
Europe. Indeed, as a response to the conclusions of the report on the competitiveness of the 
European pharmaceutical industry, a High Level Group on innovation and provision of medi-
cines in the European Union has been established. The latter is also known as the ‘G10 group 
on medicines’. The group was constituted of ten members (but with a double representation 
of the European Commission) representing the highest level from different administrations 
and (industrial) organisations120. The presence of Commissioner Liikanen of DG Enterprise 
and Information Society and Commissioner Byrne of DG Health and Consumer Protection, 
both heading the G10, testifies of the willingness to consider competitiveness issues in the 
light of public health and social objectives. Moreover, as stated in the preface, “the enclosed 
report bring (sic) to fruition a process which represents a real departure for industry and 
public health in the European Community”. The G10 Medicines Group was convened as 
a practical measure, in line with the « Lisbon Method » of Open Co-ordination to bring 
together, under European Commission chairmanship, a variety of people who were asked 
119 Directive 65/65/EEC, Directives 75/319/EEC and 75/318/EEC and their respective amendments; 
Directives on wholesaling (92/25/EEC), classification (92/26/EEC), labelling and packaging (92/27/
EEC) and advertising (92/28/EEC).
120 The membership consisted of Health and Industry Ministers from five Member States (France, 
Germany, Portugal, Sweden, United Kingdom), representation from different sectors of the in-
dustry, mutual health funds and a specialist in patient issues. The Group was chaired jointly by 
the Commissioners for Directorate-General for Enterprise and Directorate-General for Health and 
Consumer Protection.
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to identify possible solutions on which it has proved difficult in the past to gain agreement” 
(European Commission 2002a:3).
The group met three times between March 2001 and February 2002 and was organised 
in three working groups each focusing on one of the following agenda areas: Provision of 
Medicines to patients; Single Market, Competition and Regulation; Innovation. Applying the 
approach of the ‘Lisbon method’, the G10 group launched a public consultation in which it 
confronted the issues raised and conclusions reached in the working groups with broader 
stakeholder groups. To increase the transparency of the process, a dedicated website was 
created as well as a programme of workshops (European Communities 2002:9). Moreover, 
the general approach in the working groups was based on examining areas of interest were 
cooperation was possible and to propose “ways forward that might not necessarily require 
legislation”. Benchmarking, the establishment of performance indicators (on competitive-
ness; the treatment of diseases and emerging health threats), the exchange of best practices 
and exchange of information underpin the general approach adopted in the G10 (European 
Commission 2002a).
Pricing and reimbursement structures for medicines were one of the issues being debated 
in the light of improving speed and transparency of national decision-making processes, 
presenting still big differences in the Member States. Related to this debate was the question 
on which basis innovation should be rewarded the most and whether a treatment should 
be judged upon its so-called ‘relative effectiveness’ (i.e. the effectiveness compared to 
treatments that are already available or considered as best available treatment). Indeed, the 
regulatory structure of the EMEA focused on quality, safety and efficacy criteria. However, 
within Member States, increasingly relative clinical and cost-effectiveness criteria were ap-
plied in pricing and reimbursement decision-making procedures.
The G10 group acknowledges that assessment of relative effectiveness falls under the national 
competences but calls for the facilitation of exchange of information on national practices 
within the EU. According to the expert group, this should include reviewing, analysing and 
supporting the exchange of experiences on health technologies, including new information 
technologies. Based on this reflection, one of the final recommendations (recommendation 
nr. 7 on relative effectiveness) issued by the G10 regards the development of HTA:
“The Commission should organise a European reflection to explore how Member States 
can improve ways of sharing information and data requirements to achieve greater 
certainty and reliability for all stakeholders, even if the decisions they take may differ. The 
objective is to foster the development of health technology assessment (HTA), including 
clinical and cost effectiveness, in the Member States and the EU; to improve the value 
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of HTA, to share national experiences and data while recognising that relative evaluation 
should remain a responsibility of Member States”. (European Commission 2002a: 17)
Hence, seeking to “achieve the twin goals of both encouraging innovation and competitive-
ness and ensuring satisfactory delivery of public health and social imperatives”, the European 
Commission departs from traditional harmonisation policies and adopts convergence meth-
ods based on soft governance means (European Commission 2002a: 5). In its final report 
presented in 2002, the G10 calls for a continuation of the process and the implementation 
of the agreed benchmarking exercises through a set of fourteen recommendations.
Based on the report of the G10, the European Commission issued a response in its 2003 
Communication A Stronger European-based Pharmaceutical Industry for the Benefit of the 
Patient – A Call for Action (European Commission: 2003b). The purpose of this communica-
tion was to propose ways to take the G10 recommendations forward and translate them 
into concrete action. Regarding the G10 7th recommendation on relative effectiveness, the 
Commission proposes several actions to be implemented in the timeframe of 2003-2008. 
The first of these proposals regards the establishment of a “forum for Member States to 
generate and share information on common relative effectiveness issues in the context of 
pricing and reimbursement decisions”.
Based on the work already realised in a working group of the Transparency Committee, the 
idea is to develop common methodologies for the assessment of relative effectiveness and 
make a stock-taking exercise on how these assessments are used in the Member States as 
part of pricing and reimbursement decisions. The Commission recalls that relative effective-
ness of a medicine has two components: 1) the added therapeutic value (ATV) referring to 
its clinical effectiveness compared to other treatments); 2) its cost-effectiveness (building on 
ATV and comparing cost considerations). At that time indeed, cost-effectiveness evaluations 
were increasingly used in the pricing and reimbursement decision-making processes in the 
light of rising health care costs.
Still related to the G10 recommendation on relative effectiveness, the Commission issues 
other implementing actions regarding the wider context of public health issues. One of these 
states that:
“The Commission will take forward work on health technology assessment under the 
new Public Health Programme (2003-2008). Proposals are being sought in relation to 
developing mechanisms to bring together competent authorities in the EU and applicant 
countries, and where applicable, other stakeholders with the aim of enabling them to 
co-operate more closely in health technology assessment. This topic is also being pursued 
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under the High Level Process of Reflection on Patient Mobility and Health Care Develop-
ment in the EU” (European Commission 2003b: 11)
We recall here that this statement has been issued in 2003, at the time of the launch of the 
establishment of the High Level Group on Patient Mobility and Cross-Border health care. 
The latter, as we have seen, reflected upon HTA cooperation in a specific working group 
which would eventually lead to the establishment of EUnetHTA (see section 5.1.2). Hence, 
the uptake of HTA in the G10 which focused on pharmaceutical policies indicates how 
HTA cooperation was taken into consideration in different policy streams which developed 
independently although in a parallel way. In the next section, we want to highlight the link 
between HTA and relative effectiveness established in this particular policy stream, since this 
will be of high importance for the future EU HTA cooperation framework and its sustain-
ability.
As indicated in the Commission communication “The G10 Medicines group has served a 
useful purpose serving as a catalyst for ideas and building links between stakeholders. As 
a time-limited exercise the G10 will continue its work till the 2004 EU-enlargement, after 
which work needs to be continued in several ways by all stakeholders concerned” (European 
Commission 2003b: 26). One of the spin-offs of this process will be the establishment of 
the Pharmaceutical Forum which will focus on some of the key-recommendations brought 
forward by the G10121.
5.3.3.2. The establishment of the Pharma Forum and the development of REA
The Pharmaceutical Forum has been launched by the European Commission in 2005 fol-
lowing discussions in the Health Council of June the same year. The process aimed to take 
forward the recommendations issued by the G10 Medicines Group and gathered besides 
the representatives of the European Commission, the Member States, the European Parlia-
ment and EFTA, also a wide range of stakeholders122. The Forum focused its work around 
three key themes: information to patients on diseases and treatment options; pricing and 
121 The Pharmaceutical Forum will focus its work on the recommendations related to information to 
patients, pricing and relative effectiveness. The other recommendations will be addressed by the 
Commission as part of the review of pharmaceutical legislation or in research programmes and 
support to patient groups (European Commission 2008:7).
122 European Patients Forum (EPF), Standing Committee of European Doctors (CPME), Pharmaceutical 
Group of the European Union (PGEU), Association Internationale de la Mutualité (AIM), European 
Social Insurance Platform (ESIP), European Federation of Pharmaceutical Industries & Associa-
tions (EFPIA), European Generic medicines Association (EGA), European Self-Medication Industry 
(AESGP), European Association for Bioindustries (EuropaBio), European Association of Full-Line 
Wholesalers (GIRP) (European Commission 2008:8).
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reimbursement policy; and relative effectiveness. This high-level political platform met once 
a year between 2006 and 2008. It was supported by a Steering Committee and three expert 
working groups which met on a regular basis during the same time frame. The Pharmaceuti-
cal Forum initiative was officially concluded in October 2008. As the political driver, the 
Forum created a political momentum to steer the discussions on competitiveness and related 
public health issues.
The initiative was backed by two DGs concerned by pharmaceutical policies and whose 
representatives at the highest level co-chaired the forum: DG Entreprise and Industry (DG 
ENTR) and DG Health and Consumers123: The Steering Committee served as a bridge to 
provide strategic and operational guidance between the High Level Forum meetings and the 
expert working groups. The Steering Committee was also chaired jointly by DG ENTR and 
DG Health and Consumers and comprised members representing Member States, the Euro-
pean Parliament and stakeholder organisations. It is interesting to notice here that the dual 
representation of DGs was applied only in the working group on Information to patients. The 
working group on Pricing was chaired and co-chaired by representatives of DG ENTR and the 
one on Relative Effectiveness was chaired by a representative of DG Health and Consumers 
and a representative of the Italian Ministry of health. The tasks of the working groups con-
sisted to make concrete progress on the three key topics of the Forum. The working methods 
were based on the Lisbon strategy and included the exchange of best practices to examine 
potential efficiency gains as a way to achieve the three-fold objective: ensure patient access 
to medicines within a sustainable healthcare budget while enhancing the competitiveness of 
the pharmaceutical industry (European Commission 2008:8-9).
Regarding HTA cooperation, two of the three working groups are of interest. Both deal 
with an aspect which, at first sight, seems to be only indirectly concerned by HTA: Relative 
effectiveness and Pricing and Reimbursement. As we have seen above, in the early 2000s, 
both issues are intrinsically linked for the Commission and cooperation between Member 
States on relative effectiveness is considered in the context of pricing and reimbursement 
issues (European Commission 2003b). Relative effectiveness itself contains two aspects ac-
cording to the Commission: the added therapeutic value and its cost-effectiveness (European 
123 The Forum was co-chaired by Vice-President Verheugen representing DG Enterprise and Industry 
and Commissioner Kyprianou, followed by Commissioner Vassiliou representing DG Health and 
Consumers (European Commission 2008: 8).
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Commission 2003b). We will see in the next sections and in chapter 6 how these two themes 
will increasingly influence the work of the HTA cooperation networks124.
The work of the Pharmaceutical Forum’s Working Group on Relative Effectiveness (RE) was 
rooted in the G10 recommendation no 7 which called for “the development of health tech-
nology assessment (HTA), including clinical and cost effectiveness, in the Member States and 
the EU; to improve the value of HTA, to share national experiences and data while recognising 
that relative evaluations should remain a responsibility of Member States” (European Com-
mission 2008:17). The specific aim of the working group on RE was “to assist EU countries 
in applying relative effectiveness assessment systems that can contain pharmaceutical costs 
while also offering a fair reward for innovation” (European Commission 2008f). The link 
between Relative Effectiveness and pricing has also been underscored as the working group 
highlighted how the outcome of relative effectiveness assessments is an aid to identify the 
most valuable medicines, “both in terms of clinical efficiency and cost-effectiveness, and will 
help set a fair price for these medicines” (European Commission 2008f).
As Relative Effectiveness was a rather new concept and did not refer in all countries to the 
same reality or as the same reality was not always defined by the same terminology, the 
working group preceded first through formal and informal exchanges to define some key 
aspects related to this concept. The aim was to to agree upon a common approach towards 
REA (European Commission 2008h, Personal Interview 13). However, as the process was still 
in its very early stages and considering the fact that the discussions were held with parties 
that had different interests at stake (e.g. industry, insurance companies, Member States), it 
was still challenging to translate different ideas in concrete actions points (Personal interview 
13): “It was a very informal exchange (…) [about] a definition on Relative Effectiveness and 
Health Technology Assessment and what the difference was between efficacy and effective-
ness. We have put that down on paper. But as it was still in its infancy at the European 
level, it did not lead to much, also because the Pharma Forum was made up of the industry, 
124 The manner in which they will do so however highly differs. Even their understanding and role 
in relation to HTA will evolve in an unexpected manner. Relative effectiveness will be the key 
component seeking to foster convergence in HTA cooperation and is key in a Regulation proposal 
submitted by the European Commission in 2018 (Personal interview 15, European Commission 
2018). However, REA will be considered then only in its aspect of added therapeutic value re-
garding its clinical effectiveness as compared to other treatments or technologies. Pricing and 
reimbursement issues will be connected to HTA cooperation in several future regional cooperation 
initiatives which have developed independently from (and sometimes in reaction to) European 
cooperation networks supported by the European Commission (Personal interviews 15, 17, see 
also chapter 6).
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insurance companies and Member States, so that was a bit heavy and we couldn’t really do 
much with it” (Personal interview 13).
Nevertheless, three reference documents resuming the outcomes of the work performed 
have been issued by the working group on RE. The first one focused on core principles of RE 
and is of value as it defined common definitions on Efficacy, Relative efficacy, Effectiveness 
and Relative Effectiveness.125 A set of “good practice principles” has been developed as a 
first step to support collaboration and the development of common methodologies in this 
area. The second reference document addressed the issue of data availability to conduct rela-
tive effectiveness assessments (REA) regarding the two main phases of a product’s life: before 
and after Market Authorisation. This document also underscores how “new methodologies 
and scientific principles from other related areas such as health technology assessment could 
be included in the search for existing tools and methods that can be incorporated into rela-
tive effectiveness assessment” (European Commission 2008g:2).
Finally, the third reference document is dedicated to the development of networking and 
collaboration. A mapping exercise had identified twelve existing networks dealing with 
RE, among which EUnetHTA126. The document concludes that instead of creating a new 
network, work on RE should be integrated in one of the existing ones. This becomes also 
one of the official recommendations of the Pharma Forum (Recommendation 6.5, European 
Commission 2008:16). Initially the Slovenian Presidency Initiative (SI) and the MEDEV were 
considered suitable networks which could constitute a basis for the establishment of a future 
network (European Commission 2008f:3). However, both initiatives comprised important 
pro’s and con’s as the SI offered the advantage to have a clear mandate from the Competent 
Authorities of the Member States. It did however focus mainly on pricing and reimbursement 
issues. The MEDEV dealt explicitly with RE of pharmaceuticals but functioned on a purely 
125 Efficacy: is the extent to which an intervention does more good than harm under ideal circum-
stances. Relative efficacy: can be defined as the extent to which an intervention does more good 
than harm, under ideal circumstances, compared to one or more alternative interventions. Ef-
fectiveness is the extent to which an intervention does more good than harm when provided 
under the usual circumstances of health care practice. Relative effectiveness can be defined as the 
extent to which an intervention does more good than harm compared to one or more intervention 
alternatives for achieving the desired results when provided under the usual circumstances of 
health care practice (European Commission 2008f).
126 The twelve networks identified in the mapping exercise comprised : AGREE collaboration, 
EUnetHTA, Guidelines International Network (G-I-N), Medical Evaluation Committee (MEDEV), 
Networking of the Competent Authorities for Pricing and Reimbursement of Pharmaceuticals 
(“Slovenian Presidency Initiative”), Nordic PharmacoEpidemiological Network (NorPEN), European 
Patients’ Forum, Transparency committee, UK, Germany, France Collaboration, Working Group on 
Relative Effectiveness of the Pharmaceutical Forum (European Commission 2014b:3).
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informal basis. Neither one of the networks comprised among its members the industry or 
other stakeholders. Ultimately, EUnetHTA has been identified as suitable platform to further 
develop REA and this topic will even become a key element of the network’s activities as will 
be developed in the next chapter. Although the SI has not taken up REA, it has neverthe-
less played an important role as it has led to the establishment in 2008 of the Network of 
Competent Authorities on Pricing and Reimbursement. This network will later work to some 
extent with EUnetHTA to develop the collaboration between regulators, HTA bodies and 
payers and issues such as adaptive pathways.
The working group on RE comprised among its experts: representatives of the SI, the 
MEDEV and EUnetHTA. The latter was represented by the newly appointed coordinator of 
the EUnetHTA project which just started its activities. Hence, although from the start, it 
had been acknowledged that it was important to exchange information regarding progress 
in both initiatives, EUnetHTA had not been considered at first the appropriate network to 
further develop cooperation on RE despite the fact that many similarities had been identified 
and that it was recognised that work from EUnetHTA could serve as input for the Working 
Group on Relative Effectiveness (European Commission 2006b). It is only later upon strong 
recommendations of the European Commission (DG Sanco) that it has been decided that 
REA would be a priority point within EUnetHTA as of the first Joint Action starting in 2008 
(Personal interview 8).
EUnetHTA has actually been a platform permitting to further develop several other items 
discussed in the Working group on RE. One can mention here the discussions around the 
need to streamline data production for assessments supporting the Market Authorisation 
and data for pricing and reimbursement decisions. The European Public Assessment Report 
(EPAR) of the EMEA is mentioned already in 2006 as a potential tool which could increase 
access to Market Access data which could be useful for pricing and reimbursement deci-
sions. Investigating how the EPAR and the National Public Assessments Reports (NPAR) can 
contribute to REA has been integrated in one of the final recommendations of the Pharma 
Forum (Recommendation 6.4). This item too will be further developed within the framework 
of EUnetHTA at a later stage (see chapter 6).
Moreover, the need to inform the industry as early as possible about what kind of data 
is needed for Market Authorisations and Pricing and Reimbursement decisions, has also 
been highlighted by the experts in the working group on Relative Effectiveness and has 
been integrated in the final Recommendations of the Pharma Forum (Recommendation 
6.3). Collaboration with the pharmaceutical sector in particular on relative effectiveness 
was considered hardly feasible by some representatives of the European Commission and 
of Member States, as they feared strong resistance of this sector who was not eager to see 
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the establishment of joint European relative effectiveness assessments (personal interview 
7). However, the next chapter will outline how the pharmaceutical industry, while remaining 
indeed reluctant to collaborate on joint relative effectiveness assessments, has been very sup-
portive of the European collaboration on Joint Scientific Advice (also called Early Dialogues) 
related to data to be submitted for market authorisation and pricing and reimbursement 
decisions. (see chapter 6).
The other working group of the Pharmaceutical Forum which is of interest for the develop-
ment of HTA cooperation in Europe regards the one on Pricing and Reimbursement. This 
group followed closely the work of the group on RE as both topics are linked. The group on 
Pricing and Reimbursement organised the work in six streams. These concerned issues such 
as the development of a toolbox on pricing and reimbursement assessment, clarifying the 
value of innovation, how to use assessment of innovative medicines into pricing and reim-
bursement decisions, access to medicines and in particular ensuring availability of medicines 
on small markets, assessment of orphan medicines and risk sharing and conditional pricing 
practices.
During the discussions among the experts of the working group, suggestions were made to 
consider a broader use of the databases managed by the EMEA and to reflect upon new clini-
cal trial designs. The possibility to consult regulators in the early phase of the product pipeline 
has been evoked as this would allow for a targeted steering of drug development responding 
to real needs of the society. In its final recommendations, the Pharma Forum stressed the 
need for Member States to “set clear and common expectations on what innovation they 
consider valuable and would reward” as this will allow companies “to give a clear direction 
on healthcare priorities and indications on the evidence needed by authorities, while bringing 
authorities clarity on the mid- to long-term budget needs” (European Commission 2008: 19). 
They also call upon the national systems on pricing and reimbursement to be well aligned 
with systems that assess the value of medicines (Recommendation 8.3).
Two points are worthwhile highlighting at this stage. The first regards the importance that 
is given to the need to develop ‘Early Dialogues’ between the industry and national pricing 
and reimbursement authorities. The underlying idea is that establishing regular dialogue in 
the very early stages of drug development could bring an expanded set of data out of the 
clinical trials that would go beyond the safety, quality and efficacy data, as it could bring 
evidence in the benefits and value of the future drug. Moreover, Early Dialogues would 
allow for more transparency and confidence which would benefit both the companies and 
the future payers. This point has also been highlighted in the working group on RE and will 
become a key item within EUnetHTA where the SEED-project will be further developed into 
a full-fledged cooperation between EUnetHTA and European Medicines Agency permitting 
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pharmaceutical companies to receive at a very early stage information on data required for 
the different regulatory processes (see chapter 6).
The second point which requires particular attention, is the shaping of the ideas around 
“equal access to medicine”. This topic has been present in the debates of the working group 
since the first session. Initially the discussion will be framed around orphan medicines and 
availability of medicines in small and/or low-income countries. Indeed, the non-availability of 
many medicines to small markets is often of economic nature. Economic operators (manu-
factures, wholesalers and pharmacists), which ensure the creation and supply of medicines, 
are driven by economic incentives. If the costs incurred to market the drugs are higher than 
the expected revenues, medicines may not be available on these markets. The importance of 
this topic will develop so as to become included in the final recommendations of the Pharma 
Forum (Recommendation 7). Moreover, in 2007, head of medicines agencies will also seek 
for solutions from a regulatory point of view. A decade later, the European Parliament will 
develop this topic further into various motions and resolutions on equal access to medicines 
in which it calls on the Commission “to propose legislation on a European system for health 
technology assessment as soon as possible” (European Parliament 2016, see also European 
Parliament 2017a).
5.4. coNcluSioN
EU HTA cooperation has gradually developed into a full-fledged European policy being 
debated at the highest level of key-institutions of the European Union. The place which HTA 
occupies at present in the EU health policy framework has not resulted from a top-down 
approach but has developed in a bottom-up manner within different EU policy streams. We 
have identified in this chapter three EU policy areas which have had a profound impact on the 
content and governance of EU HTA cooperation. Developments within the EU (public) health 
policy have favoured the uptake of HTA in policy expert networks which have determined the 
course of action of the EU after 2000. This chapter has demonstrated how these networks 
have picked up the key messages and ideas to structure HTA cooperation developed in the 
early cooperation projects such as EUR-ASSESS, HTA Europe and ECHTA/ECAHI. Hence, the 
learning processes which had taken place in these projects initially on a national/agency level 
continued to be disseminated on an EU institutional level and created wider awareness for 
the need of HTA cooperation in Europe.
The comparison of the initial objectives of the EUR-ASSESS project with the ones of the first 
EUnetHTA project, bring to the fore many similarities. However, by having been integrated 
in the report of the High Level Group on medical care and health services, and as such 
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presented to the Health Council, they have gained political weight as HTA even became a 
“political priority”. As in the early initiatives, policy entrepreneurs have ensured this up-take 
of HTA cooperation at a higher European institutional level though their investment in the 
expert networks and later in the EUnetHTA projects or within specific units of the European 
Commission.
These expert networks, developed under impulse of the European Commission, have also 
permitted the establishment of links between the EU health policy stream and the EU social 
policy stream affecting HTA cooperation in Europe. Indeed, we have outlined in this chapter 
how the expert groups functioned on the basis of soft governance measures. The latter had 
been developed initially by DG Employment and Social Affairs before becoming integrated in 
the Lisbon Strategy and widely implemented in many other policy areas. Although envisaged, 
the implementation of a formal OMC in HTA cooperation, has never taken place. Neverthe-
less, in this area too, through discourse in the expert groups as well as within different 
units and departments of the European Commission, a soft governance approach has been 
considered as a feasible manner to favour cooperation and convergence in health policy 
in general and in HTA cooperation in particular. The most tangible example of this can be 
found in the amendments of the public health article foreseen for the Constitutional treaty 
(2004) but eventually adopted in the Lisbon Treaty (2007). Soft governance also underpinned 
the working methods of the HLPR and the HLG and have been further implemented in the 
subsequent HTA cooperation projects and EUnetHTA Joint Actions.
Finally, the EU pharmaceutical policy stream has also had an important impact on HTA 
cooperation as regard the content of the cooperation processes. We have seen how the 
objectives of HTA cooperation in the expert networks (e.g. HLG) were highly similar to those 
developed in the early HTA cooperation project. However, what will differentiate EUnetHTA 
from the three previous projects, is the integration of relative effectiveness assessments. In 
this chapter, we have outlined how this idea has been developed within the G10 group on 
medicines and the Pharmaceutical Forum. Here too, through these expert groups – working 
on the basis of soft governance principles - synergies have been created between pharma-
ceutical policy at the one hand and EU HTA cooperation projects at the other. These synergies 
will further develop through other aspects initiated in these expert groups. In particular, the 
concepts of early dialogue, Horizon Scanning and equal access to medicines. The latter will 
occupy an important place with HTA cooperation and national and European regulatory 
affairs. (see chapter 6).
Since the early cooperation initiatives, one of the main difficulties to achieve a sustainable 
cooperation in HTA was the lack of a specific legislative basis to act in this policy field. 
However, the debate on patient mobility in Europe has created a window of opportunity in 
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this respect. When developing the future Directive on Cross-Border Health Care and Patients’ 
Rights (2011/24/EU), the European Commission managed to shuffle in policy areas which 
were bearing the potential to impact the national health systems. As the debates in the 
adoption process of the Directive focused almost exclusively on reimbursement issues, the 
flanking measures - including HTA cooperation in Europe – have been adopted without 
hardly any discussion, permitting the establishment of a legal basis for EU HTA cooperation.
In the next chapter we will examine how the European HTA cooperation has been taken 
forward since 2006. Although no formal HTA cooperation has been implemented from 2001-
2006, this ‘interlude period’ in which key aspects of HTA cooperation have been developed 
in expert networks set up under impulse and direction of the European Commission, will 
have been determinant for the further course and governance of HTA cooperation in Europe.

6 Establishing a sustainable 
network for HTA cooperation 
in Europe
“But time is passing, and Europe is moving only slowly on the course to which 
she is so deeply committed…
…what matters is to have an objective clear enough always to be kept in 
sight.”
Jean Monnet, Memoirs
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6.0. iNtroDuctioN
The end of the ECHTA/ECHAI project in 2001 seemed to mark a halt of HTA cooperation in 
Europe. However, as outlined in chapter 5, although no new project had been carried out 
by the HTA arena, HTA cooperation did move forward on the EU agenda through different 
networks operating in three different EU policy streams. Each of these would lay the basis on 
which future HTA cooperation would be structured. As such, the EU health policy stream al-
lowed for the development of a new HTA network proposal (EUnetHTA). Moreover, it offered 
a legal basis to continue support and coordination of HTA cooperation (Lisbon Treaty). The 
Cross-Border Health Care Directive would even present a legal basis for the establishment of 
an EU HTA Network. The social policy stream underpinned the development of soft policy 
means in health care cooperation and the pharmaceutical policy stream designated HTA 
networks to carry on the topics of Relative Effectiveness Assessments and Early Dialogues.
European HTA cooperation, as of the mid 2000s, would be characterised by the establish-
ment of the EUnetHTA network followed by the EU HTA Network. This chapter will therefore 
examine the cooperation process by focusing in particular on these networks. For a system-
atic scrutiny of the events, policy and governance choices, we will follow a similar structure 
as in chapter 3 on the early European HTA cooperation efforts. Hence, by means of the 
five stages of the policy cycle127, we will lay down how the developments in the EUnetHTA 
network are interlinked with the developments in the wider EU health policy leading to the 
establishment of an EU HTA Network and a legislative Commission proposal for a Regulation 
on HTA cooperation. To this end, each paragraph will address a particular stage of the policy 
cycle by analysing the developments on two levels: the HTA arena (through EUnetHTA) and 
the EU health policy-making arena (through developments linked to the EU HTA Network). It 
is important to underscore that this distinction is made only for analytical purposes as both 
processes become highly intertwined the more they progress.
As outlined in chapter 5, the High-Level Group on health services and medical care (HLG), 
elaborated a new project to carry on HTA cooperation in Europe by means of the establish-
ment of a new network called EUnetHTA. In October 2004, the objectives of this ‘EUnetHTA’ 
project had been outlined and it was agreed that finance would be sought in the European 
health program. This project re-launched HTA cooperation in Europe and built further upon 
the work established by the previous projects. In the present chapter we will outline how, 
gradually, it became clear that to create a sustainable network, the project-based governance 
structure would not be sufficient. A so called “Joint Action” will be proposed by the Euro-
127 The five stages of the policy cycle comprise: agenda-setting, policy-formulation, decision-making, 
policy implementation and evaluation (Howlett 2009).
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pean Commission to drive the cooperation efforts further, still project-based though. Until 
today, three Joint Actions have been implemented in which the European Commission not 
only co-finances the initiatives but also becomes a full partner in the cooperation process.
These developments have taken place simultaneously with a new process laying in the EU 
health policy stream and which have led to the adoption of the Directive on the application 
of patients’ rights in cross-border healthcare (2011/24/EU). This legislative act will play an 
important role in EU health care in general, but also in the governance of HTA cooperation 
in particular. Indeed, the Directive foresees in its Article 15, the establishment of a European 
HTA Network which will even more change the role of the Commission in coordinating HTA 
cooperation in Europe. As we will outline in this chapter, the newly established network - 
which we will call in our research the ‘EU HTA Network’ - will take over the role of defining 
the strategic policy orientation of HTA cooperation in Europe and prepare the basis of a 
new proposal from the European Commission for an EU Regulation on HTA cooperation in 
Europe.
Simultaneously to these developments, new regional (intergovernmental) cooperation 
structures will be established in the EU. These will often build upon the work established 
by EUnetHTA but will differ in their network structures, governance modes and final objec-
tives. Hence, from a pure voluntary bottom-up approach originated in the HTA arena, HTA 
cooperation will stand at the end of the 2010 decade before a cross-road where it could 
take the direction of an EU regulatory framework with mandatory aspects to be applied by 
all Member States; or choose for an intergovernmental cluster approach in HTA cooperation. 
The complex processes and interplay between the various policy arenas and stakeholders 
involved, require a close analysis of each stage of the policy cycle so as to acquire a profound 
understanding of the role of the governance processes in structuring the cooperation efforts.
In the following sections we will explore this process by outlining the developments and 
examine them through the lens of the policy cycle. As the changes in governance and policy 
objectives have taken place through small and what could be considered as insignificant 
steps, the data has been explored in detail combining sources from grey literature (e.g. 
official reports, policy positions of (institutional) actors involved), personal interviews and 
written contributions from HTA actors. This data will be further examined in chapter 7 in 
the light of the research framework on network governance outlined in chapter 3, allowing 
us to examine the role of soft governance in structuring HTA cooperation in a European 
framework.
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6.1. ageNDa-SettiNg iN europeaN hta cooperatioN
In the section discussing the agenda-setting process in chapter 4, we have seen that accord-
ing to Baumgartner and Jones (2005), agenda-setting in policy-making is a matter of politics 
of attention. How an item gets on the political agenda depends on the conditions under 
which the information about the issue will be supplied and on how it will be interpreted 
and prioritised. Princen (2009:9-10) underscores how the EU agenda-setting process can 
take place according to two distinct manners depending on whether it takes place in the 
so-called ‘functional political system’ or in a ‘evolving integration scheme”, such as in EU 
health policy, where often issues appear for the first time on the EU agenda. Princen explains 
the EU agenda-setting process by looking at a combination of ‘venues’ and ‘frames’, the 
venues referring to the institutional decision-making arenas and the frames to the ‘issues 
definitions’.
Academic research has also brought to the fore how the agenda-setting process “is influ-
enced by key actors in prevailing policy subsystems, the dominant set of ideas about policy 
problems they espouse, and the kind of institutions within which they operate” (Howlett, 
Ramesh and Perl 2009:107). Kingdon (1984) underscores how agenda setting results from a 
complex interrelationship of ideas, actors and structures in which policy-entrepreneurs play a 
key role by seizing opportunities - or policy windows – to put an issue on the governmental 
agenda. Baumgartner and Jones (1991) have further developed this idea and stress how 
the construction of a political discourse is developed within a specific subsystem by a set of 
actors defining the nature of the (new) ideas. What will influence the agenda-setting process 
in this interpretation, is the ability of some actors to gain control over the interpretation of an 
issue and the way it is going to be discussed and framed. Hence, the way a policy problem 
is presented matters since “when they are portrayed as technical problems rather than as 
social questions, experts can dominate the decision-making process. When the ethical, social 
or political implications of such policies assume center stage, a much broader range of par-
ticipants can suddenly be involved” (Baumgartner and Jones 1991: 1047; see also: Howlett, 
Ramesh and Perl 2009).
The nature of the actors involved in a policy-process can thus have an influence on the 
manner in which an issue will be discussed and put on a national or European policy agenda. 
In this section we will examine how HTA has evolved in the different sub-systems and how, 
gradually, it has been re-framed from a ‘technical issue’ into a social and political one. This 
has allowed HTA cooperation to become an official agenda point in different political settings 
herewith also enlarging the set of actors involved in the process. This section will therefore 
examine the developments in the formal and informal (institutional) settings focusing in par-
ticular on the actors involved and the ideas brought forward by them. It is the combination 
258 Chapter 6
of the choice of venues, frames and actors that has determined the institutional framework 
in which HTA cooperation would be embedded as well as the importance it would get within 
the wider EU health policy.
6.1.1. Agenda-setting process in the EUnetHTA network
The agenda-setting process of the EUnetHTA project finds its origins in the High Level Group 
on health services and medical care (HLG) established in 2003. Indeed, by becoming inte-
grated in the HLG, HTA cooperation moved up in the EU agenda-setting process. Information 
about the role of HTA in the health systems has been brought under the attention of a 
high level policy network which had an important influence regarding the weight given to 
some issues on the EU health policy agenda. This network considered HTA cooperation as 
sufficiently important to prioritise it and dedicate a specific working group to the subject. As 
outlined in chapter 5, the initial conclusions of the early European HTA cooperation projects 
(e.g. EUR-ASSESS, ECHTA/ECAHI) have been further developed in the HLG and have led 
to the creation of the EUnetHTA project submitted and accepted for funding in 2005 and 
implemented from 2006 to 2008.
Although again project-based, the EUnetHTA project bore a fundamental difference with the 
previous HTA cooperation projects. The latter had been submitted by actors of the HTA arena 
and did not receive any formal backing of national or EU high-level decision-makers. The 
project initiators in the 1990s still had to convince decision-makers of the importance HTA for 
the national health systems and how the EU could play a role in this. The EUnetHTA project, 
on the contrary, stemmed from a high-level policy-making venue, recognising the need for 
HTA collaboration to improve the governance of national health systems by ensuring quality 
development and effective use of resources in health care services (Nielsen 2008; see further 
chapter 5). Herewith, HTA cooperation has been lifted to another policy-making level.
Though the collaborators of the early cooperation projects already considered HTA as a 
bridge between science and policy “at an adequate distance from public to have influence, 
but not too far from academia to be credible” (Personal interview 6), the focus within the 
European cooperation projects of the late 1990s remained predominantly on the scientific 
and technical side of HTA cooperation. This will shift in the HLG on health services and medi-
cal care, where a more active stand will be taken to introduce HTA into the policy-making 
level (Personal interview 4). This move can be attributed at one side to ‘policy-entrepreneurs’, 
such as Finn Kristensen, the initiator of the EUnetHTA project, having a scientific background 
but working in a policy-orientated institution. While understanding the scientific rigor neces-
sary in HTA, he also grasped the importance of working with policy-makers to make HTA 
cooperation in Europe sustainable. Due to his different previous professional occupations, 
he had developed a know-how of policy-making mechanisms which, according to him, 
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facilitated to perceive “how to do the HTA work inside of policy-making and planning and 
understanding the need to create something that is actually useful and seen as useful by the 
decision-makers” (Personal interview 4).
At the other side, the broader developments taking place in EU health policy (see chapter 5) 
were also an opportunity for HTA to make this move towards the policy-making level. As it 
was being decided that health policy should stay outside the single market, discussions were 
ongoing regarding the exact place health policy should have within the EU policy architecture 
(Personal interviews 3, 4). Like in the early 1990s, HTA cooperation, in a sense, profited from 
this reflection while at the same time giving food for thought to the Commission on how 
to support the national health systems. Hence, instead of being seen almost exclusively as a 
scientific and technical exercise, HTA was increasingly considered to play a role in addressing 
social, economic and safety issues of EU health policy. The fact that the Commission sought 
to enter into new areas of health policy was, according to some, also reflected in the name 
change of the “Public health program” into “EU health program “ and considered as one of 
the signs of “a constant ‘sled’ or tendency of the Commission to gradually get closer to the 
health systems and not just public health matters” (Personal interview 4).
Incorporating HTA cooperation in the new EU health program (2008-2013), allowed to se-
cure funding for the EUnetHTA project which could then be launched and be put more firmly 
on the agenda of national and EU health policies: “as the call was on its way, it was the time 
to make the move” (Personal interview 4). Hence, as in the early 1990s, the collaboration 
between the HTA arena and the European Commission was considered by the actors in the 
field as a win/win situation (Personal interviews 2, 3, 4 and 8). The difference however with 
the early cooperation period was that, at this period of time, besides financial support, the 
HTA arena could also count on political support on behalf of the EU, as more actors became 
involved in the cooperation process.
Moreover, the place attributed to HTA by EU representatives in health policy initiatives of DG 
Sanco, allowed it to move upwards on the EU governmental agenda and to benefit from 
future initiatives of this Directorate, such as the 2008 proposal of the European Commis-
sion for a Directive in Cross-Border Health Care (EU/2011/24). As a result, whilst clearly an 
HTA arena initiative at first, the ‘ownership’ of the EUnetHTA project gradually shifts, in the 
perceptions of some, to the European Commission. One can find an example of this in the 
opening speech of the first EUnetHTA conference, where the Director General of the French 
Ministry of Health attributes the EUnetHTA initiative to the European Commission. Moreover, 
he also indicates how HTA cooperation has been inserted in the draft proposal for a Directive 
on Patient’s rights in cross-border health care and becomes thus an official agenda point of 
the EU:
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“In 2004, the European Commission proposed to Member States and other European 
countries and organisations to build up a network – EUnetHTA - enabling an effective 
exchange of information with the purpose of developing the methodology of epidemio-
logical studies and clinical trials, finalising practical tools and helping decision making 
processes in public health policy.
More recently, the European Commission included into its draft Directive on the ap-
plication of patients’ rights in to cross-border healthcare, the intention to establish a 
permanent network for health technology assessment, in order to encourage coopera-
tion between competent authorities, supply and exchange of reliable data and improve 
the decision making process by Member States” (www.eunethta.eu).
Hence, establishing a working group on HTA cooperation in the HLG has allowed the topic 
of HTA cooperation to be discussed within the ‘right’ venue, allowing it to enter the national 
and EU agenda-setting processes. As underscored by Schattschneider (1960:71 in Versluis et 
al. 2011:119), venues differ in the authority they have over certain issues as well as in their 
composition. In the case of EU health policy, the HLG appeared to be extremely important 
in drafting the agenda of the wider EU health policy and included herein HTA cooperation. 
It also played a role in establishing bridges between networks developing in various policy 
streams (see chapter 5). Moreover, most of the items discussed in the HLG between Member 
States will be included in the Cross-Border Health Care Directive (EU/2011/24) which will play 
a prominent role in shaping the post-2008 EU health policy.
According to Princen (2009:11), the institutional framework will define within each venue 
the specific tasks, authority and resources allocated to them as well as the persons who will 
participate in the decision-making process and the procedure according to which a deci-
sion will be made. In the case of HTA cooperation, it has been the 2002 Health Council 
which has given the impetus to establish the High Level Process of Reflection leading to the 
establishment of the HLG. The Commission - i.e. DG Sanco and DG Employment and Social 
Affairs - has coordinated the work of the HLPR and of the HLG, represented by senior-level 
representatives of the Member States’ health ministries. Resulting from work in the HLG, the 
EUnetHTA Project (2006-2008) has been able to secure funding and authority to carry out 
the project resulting from the work of both experts’ networks.
The above shows how the initial agenda-setting process of EUnetHTA was situated mostly 
during the period in which the HLG took place, comprising the informal meetings which took 
place in Denmark to prepare the EUnetHTA project (Personal interview 7, see also chapter 
5). The follow-up to the project follows however a distinct agenda-setting process which 
will lay partly within the EUnetHTA project itself and (again) partly within DG Sanco. Indeed, 
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towards the end of the EUnetHTA project, it became clear that, although substantial work 
had been carried out, much would still have to be done to reach the strategic objectives 
defined by the HLG and inserted in the EUnetHTA project. The network structure that had 
been set-up still didn’t respond to any form of financial, organisational or administrative 
sustainability as it only existed within the project framework, primarily funded through the 
EU health program. Moreover, even though important tools and methodologies had been 
developed, many of these had never been tested in real settings. The pilot projects that 
had been realised, still revealed the necessity for important improvements of the models 
developed (Personal interview 8).
Although the main objectives of the project had not been reached at the end of the EU-
netHTA project, many Member States involved in the program did continue to manifest 
interests to pursue the cooperation initiative (Personal interview 4). At that stage, it became 
however clear that “knowing the idea, the ultimate goal of sustainability, you need to figure 
out a flexible but robust solution which allows you through the project-based approach 
to go towards something sustainable. That also relies on the readiness, technical matters 
of cooperation methodology, people working in the HTA agencies and then also taking 
advantage of political readiness” (Personal interview 4). Hence, the challenge was to es-
tablish something which was “concrete, operational and implementable” while having the 
organisational structure enabling researchers, HTA-representatives “to do their work while 
bringing the results into the policy processes and being sustainable despite the project solu-
tion for making it happen” (Personal interview 4).
In order to pursue the initial and ultimate objective of sustainable HTA cooperation in Europe, 
the European Commission proposes to adopt a different approach. In the general EU setting, 
a new type of projects had been introduced in the form of so-called ‘Joint Actions’ (JA). In 
EU health policy, no such a framework had yet been used. Establishing a Joint Action on 
HTA cooperation seemed however suitable to achieve the objectives which remained on the 
agenda of both the Commission and HTA bodies. The Joint Action diverged however from 
the previous project-based approaches by the fact that the Commission’s role would funda-
mentally change. From a funding institution in the EUnetHTA project - approving the project 
proposal and implementation but taking no formal part in the governance and management 
of the project - the Commission’s role would evolve into becoming a full-fledged partner in 
carrying out EU HTA cooperation initiatives.
As underscored by a senior DG SANTE representative: “The painful moment was when we 
had to decide what to do next after the EUnetHTA project. This was a moment in my team 
when we started to reflect again, using the famous phrase: ‘moving from fishing to farming’. 
There was a problem in the health programme. We understood that we do a little bit of 
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fishing, so we have ideas and people are meeting that in grant proposals. We are ready to 
do something more substantial and that goes a little bit like farming. You need to plan, to 
organise, to know where you like to be next year. And this is how the Joint Action came in 
as a tool. We got this tool under discussion with Member States, but we didn’t know how to 
use it (…). The system was new.” (Personal interview 8).
The Joint Actions were not only new to the Commission representatives, it was also new to 
the representatives of the Member States and the HTA bodies who did not always understand 
the Commission’s role in these Joint Actions. Recalling the first meeting to prepare the post-
EUnetHTA project phase, a DG Sanco representative underscored how some participants 
were wondering “Why is the Commission here, telling us what to do? The Commission 
representative answered: “It is called ‘Joint Action’ and Joint Action means: Member States 
and Commission”. Oh, that is what you mean!” (Personal interview 8). Although adjustments 
to this new approach were needed, many Member States did support the new initiative 
as the first Joint Action comprised 33 associated partners and 26 collaborative partners 
(EUnetHTA 2013: xii-xiv). As such, European HTA cooperation remained on the agenda of 
the Commission as well as many HTA agencies.
Most organisations that decided to get involved in the Joint Action had already been engaged 
in the EUnetHTA project and were favourable to pursue the cooperation efforts. However, 
the call to participate in the Joint Action came this time through the respective Ministries of 
health in the different Members States: “If you think of the Joint Actions, those initiatives – as 
far as I understand – always came from the Commission to the Ministry. So, then the Ministry 
of health and social affairs would contact us to invite us to the project” (Personal interview 
18). The choice of HTA agencies and other partners to join the EUnetHTA Joint Action was 
motivated by contextual incentives as well as sometimes more strategic calculations.
As such, some expressed the need to exchange experiences with colleagues from different 
countries as HTA was rather new in their Member State. Others were aware that cooperation 
could allow to avoid duplication and thus be profitable financially or time wise by leveraging 
upon the work of others, receive additional financial resources and compensate for internal 
lack of human resources. The need to build capacity in HTA, receive training and experience 
would also be beneficial to national HTA agencies and would at the same time contribute 
to the harmonisation of processes and methods and the standardisation of best practices. 
For some agencies, participating in an international project would enhance their visibility, 
both nationally and internationally. Some joined simply because of the sense that something 
was moving and that it was better to be inside rather than outside the network (Personal 
interviews e.g. 11, 18, 19, 22, 24, 25, 29).
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The fact that the European Commission became more and more involved in the HTA coopera-
tion also clearly had an impact on the motivation of partners to play a role in the Joint Action: 
”In many discussions it was recognised that it is important to develop collaborative methods 
and then I think that the agencies were very happy about the fact that the Commission was 
active in this and supporting it. So, in that sense, I think it was a mutual win/win situation 
in a way that it was on the political agenda of the Commission and on the other hand, the 
agencies felt that this is important to do” (Personal interview 18).
To ensure a smooth transition between the EUnetHTA project (2006-2008) and the EUnetHTA 
Joint Action (2010-2012), the EUnetHTA collaboration has been implemented in 2009. This 
project ensured continuation of work established in the EUnetHTA project and determined 
the governance, management and work plan of the Joint Action. Financial resources to 
support this interim period came from Member States and their HTA agencies herewith 
showing a real commitment at agency level to drive the initiative further (Personal interview 
4, 18, 22). The first EUnetHTA Joint Action has been succeeded by two other Joint Actions. 
Joint Action 2 has been implemented from 2012-2015 and Joint Action 3 from 2016-2020.
The agenda-setting process of the Joint Actions (JA) 2 and JA 3 have taken place during the 
previous projects and based on internal evaluation processes and external developments. 
Building further upon the work started in the JA1, the JA2 would introduce new areas of 
collaboration with external European regulatory bodies. The general objectives remained the 
same, but collaboration was to be strengthened. Indeed, in the project application of JA2 it is 
underscored how “The JA2 aims at bringing collaboration to a higher level resulting in better 
understanding for the Commission and Member States (MS) of the ways to establish a sus-
tainable structure for HTA in the EU” (EAHC 2010). Moreover, it elaborates on developments 
that have taken place in the wider EU health strategy with the adoption of the Cross-Border 
Health Care Directive in 2011: “Specifically, the JA2 will develop a general strategy, principles 
and an implementation proposal for a sustainable European HTA collaboration according to 
the requirements of Article 15 of the Directive for cross-border healthcare”. (EAHC 2010).
Hence, the ultimate goal remained the establishment of a sustainable cooperation struc-
ture which the Joint Action 1 failed to deliver. The progress made in this collaboration did, 
however, allow to maintain the item on the agenda of the agencies, ministries and of the 
Commission. Even more so, new partners have been invited to join the initiatives and these 
comprised at this stage also organisations representing stakeholders other than HTA agen-
cies. As such, European HTA collaboration entered more firmly on the agenda of organisa-
tions representing the pharmaceutical and medical device industry, insurance companies, 
patients and health care providers.
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The agenda-setting process of Joint Action 3 follows a slightly different path than the one 
of Joint Action 2 as it has been influenced by external events related to the EU health policy 
scene. The ultimate target of creating a sustainable European HTA network had not changed 
- as also the Joint Action 2 still did not deliver this - the means put in motion to achieve 
sustainability would however differ. First, the Commission decided in 2013 to establish the 
policy-orientated EU HTA Network128, created on the basis of Article 15 of the Directive 
on Cross-Border Health Care (2011/24/EU). This would have an impact on the future of 
the EUnetHTA network which will be incorporated in a broader vision of future European 
HTA cooperation. As such, it would become the scientific and technical arm of the EU HTA 
Network who would be responsible for the strategic policy orientations of European HTA 
cooperation. The agenda of the Joint Action 3 would be drafted in line with this perspective. 
Moreover, soon after the establishment of the EU HTA network, the European Commission 
would launch a consultation procedure preparing the ground for the elaboration of a future 
legislative proposal on HTA cooperation in Europe, as will be outlined in the next sections.
Another point of distinction between the Joint Actions 2 and 3 and which affect the agenda 
processes to some extent, regards the membership structure which were still established in 
close cooperation with the Member States’ respective ministries, the European Commission 
and the EUnetHTA secretariat. In Joint Action 2, membership had already increased to a 
total of 69 organisations comprising 49 government-appointed organisations as well as 
regional agencies and not-for-profit organisations producing or contributing to HTA from 
31 countries in Europe (including all EU Member States). In the Joint Action 3, the member-
ship grew even more, to reach a total of 81 organisations (www.eunethta.eu). Although a 
stakeholder policy had already been developed during the first Joint Action, it’s weight on 
the EUnetHTA agenda setting process became more important during Joint Action 2. This 
was also reflected by the number of stakeholder organisations and their involvement in this 
project. Whereas in Joint Action 1, the cooperation took place almost exclusively between 
HTA agencies, this changed in Joint Action 2 where stakeholders became more involved (e.g. 
Personal interviews 12, 13, 23).
Incentives to participate were mainly the same as for those in the Joint Action 1 but at this 
stage other motivations and strategic calculations came to the fore. Indeed, as the develop-
ment of HTA cooperation grew in importance in Europe, some organisations decided to join 
or to take a more active part in the collaboration:
128 The Commission refers to this network as the ‘HTA Network’. In this thesis we will always refer to 
this network as the ‘EU HTA Network’ for a better distinction between the various HTA networks 
that have been created.
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“[Our organisation] has an interest in international development and especially develop-
ments in Europe. So, that is why we participate. As this development grew, the impor-
tance of HTA in Europe grew, we decided to engage a bit more” (Personal interview 22).
“There was a decision on behalf of the leadership of this department that they want to 
speed up HTA. They also want to catch up on HTA and they want to try if they can be 
engaged in a meaningful cooperation” (Personal interview 28).
“For years I was alone, so for me it was really important to work with others. This gave 
me the opportunity to be part of systematic clinical effectiveness and safety. Because 
when you are alone, you cannot do systematic reviews” (Personal interview 11).
Hence, different standpoints motivated organisations to become a new member or become 
more active in the Joint Actions. These motivations varied from the interest to exchange 
experiences, develop expertise and know-how, harmonise practices so as to benefit from 
the different tools developed by EUnetHTA, optimise financial and human resources, develop 
a legal framework as well as build on the personal and institutional relationships that had 
been developed. Moreover, the introduction of specific topics, such as, Relative Effective-
ness Assessments, Early Scientific Advice or Additional Evidence Generation also led some 
organisations to join the initiative (e.g. Personal interviews 4, 11, 14, 19, 22, 27, 28, 30). 
Some organisations also had the impression that the HTA cooperation process would lead to 
some (EU) initiatives which could have an impact on their organisation and work processes 
and preferred thus to take a leading role to ensure that the direction of these developments 
would suit them (e.g. Personal interviews 12, 22, 23, 24, 27) :
“I think the reason to take a larger role in Joint Action 3 was because of the knowledge it 
was going to work towards the permanent HTA cooperation and our desire to influence 
the permanent mechanism of HTA cooperation. That is why we got involved in Joint 
Action 3 in a larger role. Our role in Joint Action 1 and Joint Action 2, I think, primarily 
stems from our interest in working with our European colleagues creating relationships 
with them, understanding how they work and using our HTA experience in order to 
create and improve HTA practices around Europe.” (Personal interview 27).
Representatives of stakeholder groups too became more aware of the growing importance 
of HTA, not just on the European scene but also in their national markets. “We were no 
fools, but we felt that we could not do anything against the HTA ‘steamroller’ and the 
reason why it has been invented. So, we prefer to take part in it so as to limit in any case 
its side effects that bother us the most” (Personal interview 12). Hence, they became more 
involved and started to closely follow the developments from the ‘inside’ by taking part in the 
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different structures that had been established for them (e.g. Stakeholder Forum). Through 
their participation they wanted to ensure the insertion in the EUnetHTA strategy of what they 
considered to be key issues in HTA (e.g. patient access, ethical issues, timely access, evidence 
generation) (e.g. Personal interviews 12, 21, 23, 24, 25).
Although the balance between the arguments in favour regarding partnership in the 
EUnetHTA Joint Actions, bore often more weight than those against, some organisation 
did question the real benefits of it, especially as a certain amount of investment from the 
organisations itself was needed. Moreover, if the gain of time and resources was often a 
motivation to join, some also reported the fact the membership of EUnetHTA actually added 
to the workload of departments which were already under strain: “The agency is not really 
highly involved in reports production for example, because it is a big effort in time and 
personal efforts. (…) So, the benefits are not clear, not obvious. It will still be the activity 
for a small group of persons, personally interested in international cooperation rather than 
a systematic procedure of involvement and using the outcomes of involvement” (Personal 
interview 30). Indeed, when agencies or other stakeholder group joined, the work related to 
EUnetHTA was often allocated to a small group of people and not the priority of the wider 
organisation they belonged to (e.g. Personal interviews 14; 19; 30).
Hence, progress accomplished in the field of HTA cooperation during the first two Joint 
Actions did provide sufficient reasons for the European Commission to allow for a third 
Joint Action as a mean to ensure the continuation of the work and bridge the gap between 
the newly established EU HTA network and the future proposal for a Regulation in the field 
of HTA cooperation. The aims of this (supposedly last) Joint Action in the field of EU HTA 
cooperation should be considered in this perspective. The Joint Action 3 focused on turn-
ing pilots into routinely activities in the Member States and develop a sustainable model 
for the scientific and technical mechanism of a permanent European cooperation on HTA. 
These events demonstrate that HTA cooperation at this stage cannot be examined anymore 
without a close analysis of events at the European institutional level which we will develop in 
the next section following the same time-path as in the current section.
6.1.2. HTA cooperation entering the EU decision-agenda
We have seen in chapter 3, that, based on Princen’s classification of EU agenda’s (2009:15-
16), the early HTA cooperation projects (EUR-ASSESS, HTA-Europe and ECHTA/ECAHI) could 
be considered as an agenda topic debated first in transnational policy networks129. Indeed, 
129 Transnational policy networks consist of policy experts of national governments and international 
organisations but can comprise also academics, journalists etc. (Princen 2009: 15-16, see further 
chapter 3).
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we have highlighted that a certain convergence of policy debates among participants of the 
network and the structure permitted the exchange of ideas. A common perspective on HTA 
cooperation in Europe has emerged in these first cooperation initiatives and have structured 
the future efforts on this issue as we will outline in this section.
Princen (2009:15-16) also demonstrates how an issue can shift from the transnational policy 
network agenda to the EU agenda if there is receptiveness for the issue at the EU-level. The 
latter will depend on the institutional characteristics of the venues within the EU and on the 
way the issue will be framed. Princen (2009:16) underscores how issues can shift to the EU 
agenda if it fits the concerns and interest of a particular institution or by a pro-active ap-
proach of an institution. He distinguishes here the ‘EU’s governmental agenda’ (stage of the 
EU political agenda-setting process, during which ‘ideas are floated and perspectives devel-
oped’) from the ‘EU decision agenda’ (on which issues appear when they are ripe for active 
decision-making). We have outlined in chapter 3 how the newly created DG Sanco did show 
interest for HTA cooperation from the early days on. Putting HTA as a priority topic in the HLG 
and qualifying it as a ‘political priority’ for the Commission can be considered as a pro-active 
approach of the Commission permitting the topic to enter on the EU governmental agenda.
As outlined in the previous section, the EUnetHTA project (2006-2008) can be considered 
as the product of the HTA Workgroup of the HLG on medical care and health services. The 
later was coordinated by DG Sanco and DG Social Affairs and Employment. Whilst the HLG 
met on a regular basis from 2002 to 2006, DG Sanco continued to deploy its health strategy 
and implement its work plan as adopted by the Council. A close analysis of the annual work 
plans of the Commission’s public health strategy shows how the work of the HLG was taking 
into account in the public health program. HTA cooperation can be cited as an example 
hereof. Hence, the HLG states that: “In conclusion, the Working Group on Health Technology 
Assessment proposes that the European Commission support a pilot project to set up a 
European HTA Network under an appropriate financing mechanism such as EU Public Health 
Programme” (European Commission 2004f:13).
To qualify for funding, a project needs to fulfil several criteria and needs to respond to the 
objectives set out in the annual work plan (European Commission 2005a). This programme 
is defined by representatives of the Member States and is coordinated by DG Sanco. It is 
interesting to see how the priorities in the field of HTA, as identified in 2004 in the HLG work 
group on HTA, figure in the 2005 work plan of the EU public health programme. Indeed, the 
2005 work plan states that:
“Work will be carried out following up the high-level process of reflection on patient 
mobility and health care developments in the European Union with the following priori-
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ties: Quality assurance in Europe and health technology assessment: without prejudice 
to projects supported by the Community Research Programme, take stock of activities 
related to quality assurance and improvement and accreditation systems across Europe 
and develop networking and collaboration at EU level covering also patient safety and 
involvement of patients with their care. Necessary studies on performance assessment of 
health care institutions to assess and compare quality strategies need to be developed in 
cooperation with the OECD.” (European Commission 2005a:11)
Based on this work plan, a call for proposals had been issued by DG Sanco in January 2005 
regarding projects qualifying for funding within the public health program (OJEU 2005). The 
project proposal of the HLG workgroup on HTA perfectly matched the objectives and criteria 
set out in the 2005 call for proposals. The latter created thus a favourable ground to take the 
HTA cooperation initiative further, according to the discussions and conclusions of the HLG.
Inserting HTA cooperation as one of the priority areas in the public health programme can be 
identified as preparing the transition of HTA cooperation from the EU governmental agenda 
to the EU decision agenda. Princen (2009: 16) considers that for an issue to move from the 
first to the latter, horizontal (EU level) and vertical blockages (MS Level) should be over-
come130. The fact that HTA cooperation had been discussed in an expert group steered by 
the two DGs involved in health policy, probably facilitated to find consensus on the issue on 
EU level. Moreover, the members of the working groups in the HLG all were representatives 
of Member States. Hence, the HLG has permitted to find consensus on this issue on Member 
State level and has avoided that eventual horizontal or vertical blockages could develop at 
this stage.
The initial shift from the EU governmental agenda to the EU decision agenda can be situ-
ated in 2008 when DG Sanco introduces the proposal of a Directive on Patients’ rights in 
Cross-Border Health Care (2011/24/EU). Indeed, as outlined above, this Directive adopted in 
2011, has inserted EU HTA cooperation in its Article 15. The debates during the adoption 
phase (2008-2011) mainly focused on reimbursement issues. The flanking measures (among 
which HTA cooperation) had not triggered any fierce debates within the different institutions 
having to adopt the legislative act (see chapter 5). The absence of controversy regarding 
HTA in the adoption procedure may also have played a role in the absence of horizontal and 
vertical blockages. The latter has contributed to the fact that HTA has moved smoothly from 
130 Horizontal blockages appear when, due to differences in perspectives, some EU policy-makers may 
want to prevent an issue to appear on the decision-making agenda. Vertical blockages can occur 
when Member States are reluctant to see the European Union trying to play a role in a particular 
policy (Princen 2009: 16).
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the EU governmental agenda to the EU decision agenda. Hence, the consensus found in the 
HLG representing both Commission and Member States’ officials and in the Council and 
European Parliament when discussing the Cross-Border Health Care Directive, has permitted 
HTA cooperation to move further on the EU agenda. Its insertion in the Directive 2011/24/
EU represents in this regard a landmark as it will give the EU Commission a legislative basis 
to act in the HTA policy area.
The adoption and implementation processes of the Directive 2011/24/EU have taken place 
simultaneously with the preparation and implementation of the EUnetHTA Joint Actions. 
The aim pursued in the Directive is actually still the same as the one pursued by the various 
projects since EUR-ASSESS. In chapter 5 (section 5.1.3.3) we have examined the content of 
Article 15 of the Directive 2011/24/EU which offered the legal powers to the Commission to 
setup a “voluntary Network of national authorities or bodies responsible for HTA”, permit-
ting it herewith to institutionalise HTA cooperation in Europe. Hence, the Commission had 
a mandate to establish an EU HTA network, which it will execute in June 2013 (OJEU 2013). 
This newly created EU HTA Network will however closely build on the work so far achieved by 
the EUnetHTA Joint Actions as the latter will become the scientific and technical arm of the 
EU HTA Network which will be responsible for setting the political and strategic objectives of 
network (HTAN 2014). The strategic objectives comprise a broad scope of HTA cooperation; 
fostering cooperation between Member States and stakeholders, develop synergies between 
European and national HTA activities as well as synergies between regulatory and HTA issues 
(HTAN 2014).
From the start, the EU HTA Network will orientate its work to develop a (newly created) 
sustainable structure for HTA cooperation. As such, the 2016-2020 Multiannual Work 
Programme stipulates that “The HTA Network is expected to act as key strategic forum to 
contribute to defining the possible scope, sustainability and governance of the European 
cooperation on HTA, beyond Joint Action 3. (…) During the coming years, one of the main 
objectives for the HTA Network should be to take an active role in clarifying and ensuring 
conditions for a sustainable functioning of the scientific and technical cooperation when the 
EUnetHTA JA3 ends in 2020” (HTAN 2016:3). By creating this new network, the European 
Commission seeks to lift the European HTA cooperation to a strategic policy-level setting the 
agenda for the future cooperation initiatives.
As a policy orientated body, the EU HTA Network membership would be distinct from the EU-
netHTA network. As such, the former would comprise among its members Member States’ 
representatives on a policy level, while work in EUnetHTA would be done by scientists and 
researchers, the so-called ‘ HTA doers’. In both cases, it would be the ministries responsible 
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for health who would appoint members in the networks. In practice, however, overlap in 
membership between both bodies did exist and this could be explained by different reasons.
First, HTA knowledge is often situated in HTA agencies. Hence, HTA expertise can be lacking 
on a ministerial level in some countries. In those cases, ministries would turn to HTA agencies 
to represent them in the EU HTA network: “I know that in the HTA network, fifty percent are 
really people from the Ministries of Health and the others are HTA people also involved in 
EUnetHTA” (personal interview 11). “It tends to be the bigger countries sending people from 
the Ministry and the smaller countries send someone from an agency because they don’t 
have someone with enough expertise in the Ministry” (Personal interview 19).
Second, by proposing membership on a policy-level, the European Commission sought, 
according to some, to “move towards a political network” and “make the ministries more 
interested in HTA” (personal interview 18). The appointment of Member States representa-
tives remained however in the hands of the respective ministries. “It was very difficult for the 
Commission to teach the Member States. The Ministries of Health appoint, and I think that 
was a little unclear. Maybe it could have been built up better from the Commission so that 
the signals had been clearer, that this is actually about strategic policy and not scientific, not 
HTA. What could we do? It is all networking. We talked about it. We couldn’t give any single 
instruction to any partner. (…) It was a process that was not possible for us to influence.” 
(Personal interview 4).
After the setup of the EU HTA Network, the European Commission has launched several 
initiatives in close consultation with this network and which would follow the classical path 
of the development of a new legislative proposal. As such, an impact inception analysis 
will be organised in 2015, proposing five potential scenarios for future HTA cooperation in 
Europe (European Commission 2016). These scenarios ranged from a proposing the status 
quo to an intense level of cooperation on production of joint Full HTA reports and their 
uptake131. In November 2016, the European Commission launches a public consultation on 
HTA cooperation (European Commission 2016c) to formally evaluate the response of all 
stakeholders regarding future HTA cooperation. The latter will be further examined in section 
6.2.2.3.
131 The five scenarios are: 1. The status quo – Joint Action until 2020; 2. Long-term voluntary coopera-
tion (financed by the EU beyond 2020); 3. Cooperation on collection, sharing and use of common 
tools and data; 4. Cooperation on production of joint REA reports and their uptake (cooperation 
on clinical/medical matters); 5. Cooperation on production of joint Full HTA reports and their 
uptake (cooperation on cost-effectiveness) (European Commission 2016).
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This consultation is followed by an Impact Assessment in 2017 which will be published 
simultaneously with the formal proposal of the European Commission for a new Regulation 
on HTA cooperation in January 2018. This proposal foresees that certain aspects of the HTA 
cooperation, such as joint relative effectiveness assessments, will become mandatory for the 
Member States. As a consequence, HTA becomes the subject of (sometimes fierce) debates 
in the Council and European Parliament meetings who, according to the Ordinary Legislative 
Procedure, need to pronounce themselves on this proposal. At this point, HTA cooperation 
has thus been firmly set on the EU decision-making agenda and - as we will develop in 
the following sections - will trigger vertical (within the Council) and horizontal blockages 
(between reluctant Member States in the Council and the Parliament, which will increasingly 
support cooperation in HTA) (e.g. European Council 2014; 2015; 2016; European Parliament 
2015; 2017). By setting HTA on the EU decision-making agenda, all actors concerned by the 
matter will have to clarify their positions regarding the scope and extent HTA cooperation 
in Europe should reach. These positions will be outlined in further detail in the following 
sections on policy- formulation and decision-making.
6.1.3. Conclusion agenda-setting processes in European HTA cooperation
As underscored by Howlett, Ramesh and Perl (2009) the agenda-setting process should not 
be considered in isolation from the other stages of the policy cycle. We have seen in this 
paragraph how indeed each previous project outlined the agenda of the next. This had 
already been the case since the EUR-ASSESS project in the early 1990s. The conclusions of 
the ECHTA/ECAHI project have been taken up in the discussions and project proposals of 
the HTA Work group in the HLG on Medical services and Health Care. Funding for the first 
EUnetHTA project has been secured through the health program as on an EU level the HTA 
objectives had been inserted in the annual health work plan. Similarly, the agenda for the 
Joint Actions was elaborated during the previous exercise to ensure continuity of the project 
as the main objectives (e.g. setting up a sustainable network for HTA cooperation in Europe) 
were still not reached and tools still needed to be further developed.
An important difference between the EUnetHTA activities with the early cooperation efforts 
lays in the fact that HTA cooperation post-2006 is not driven by the HTA actors only. Indeed, 
since its uptake in the high-level reflection process, the issue of European HTA cooperation 
had been officially discussed and supported in high-level policy arenas by both Commis-
sion and Member States’ officials. Whilst the EUnetHTA project will still be run by the HTA 
arena, the Joint Actions will adopt a different approach with the Commission becoming 
a full-fledged partner of the initiative and the EUnetHTA partners being appointed by the 
Member States. Not only did the number of members increase, the typology of its members 
also broadened to include stakeholder groups representing the patients, payers, industry and 
health care professionals. As such, HTA cooperation did not only enter an EU agenda-setting 
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process but also moved up the domestic health policy agenda and became a point of atten-
tion in stakeholder organisations which increasingly felt concerned by the matter.
Being shuffled-in as flanking measure in the Cross-Border Health Care Directive (2011/24/
EU), setting up an HTA Network to support the cooperation becomes a formal action point 
to be implemented by the Commission. With the establishment of the EU HTA Network, 
the Commission alters the governance of the cooperation efforts by separating the policy-
orientation side from the scientific and technical operational side of HTA cooperation. This 
decision is politically not neutral as the strategic orientation of HTA cooperation now falls 
under direct influence of the European Commission which will set the agenda for future EU 
HTA governance initiatives. Moreover, membership of the two networks (i.e. EUnetHTA and 
EU HTA Network) is also affected by the Commission measures which in turn may have an 
impact on strategic decision-making and implementation. In the next sections we will further 
examine to which extent this decision has impacted the course of actions of EUnetHTA and 
other HTA cooperation initiatives. However, at this point it is important to highlight the 
importance of the agenda-setting process for the future developments in HTA cooperation. 
Hence, by means of what could be perceived at times as insignificant steps forward, HTA co-
operation has inserted itself into high-level agenda-setting processes and, as such, developed 
from a technical HTA arena topic into a major EU public health issue.
6.2. policy-FormulatioN iN europeaN hta cooperatioN
The formulation of a policy is an essential stage of the policy cycle. The aim of this stage 
is to identify, assess and select policy options addressing a specific policy problem. Policy-
formulation can already be initiated in the agenda-setting stage of the policy-cycle (Kingdon 
2003: 205; Howlett, Ramesh and Perl 2009:110, see also chapter 4). The role stakeholders 
play in this process is of particular importance. Indeed, at this stage, a large set of actors con-
cerned by the policy can be included and can influence the outcome the process (Howlett, 
Ramesh and Perl 2009: 111).
Policy-formulation can be analysed by breaking up the process into 4 stages: appraisal, 
dialogue, formulation and consolidation (Thomas 2001). Appraisal regards the data and 
evidence collection. Dialogue permits the facilitation of (formal or informal) communication 
between policy actors having different perspectives on the issue. The first two phases result 
in the actual formulation of the policy in the form of draft policy proposals. Seeking sup-
port and creating consensus on this proposal will take place during the consolidation phase 
(Thomas 2001). The identification and choice of policy instruments permitting to reach the 
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objectives set will also take place during the policy-formulation stage (see further Howlett, 
Ramesh and Perl 2009; chapter 4).
In this section, we will examine how policy-formulation has taken place in the EUnetHTA 
network and on an EU institutional level. We will proceed through the scope of four phases 
which make up this process appraisal, dialogue, formulation and consolidation. We will 
seek to identify how this process has developed throughout the different projects and Joint 
Actions as well as in the EU HTA Network. Particular attention will be given to the role and 
interests of the different stakeholders. The examination starts with the EUnetHTA project 
which took place from 2006 to 2008 as it has laid the basis for the subsequent HTA coopera-
tion project (2009) and the Joint Actions (2010-2020). The latter will be discussed following 
the same analysis scope. The section closes with an outline of the policy formulation on an 
EU level with special attention given to the EU HTA Network and the events related to the 
Commission Proposal for a Regulation on HTA cooperation in Europe.
6.2.1. Policy-formulation in the EUnetHTA network
6.2.1.1. Policy-formulation in the EUnetHTA project
The appraisal stage of the first EUnetHTA project can be situated closely to the agenda-setting 
process. Data and information, underpinning the EUnetHTA project, had for an important 
part been gathered from the previous projects. This information has been inserted in the 
different working papers of the HLG which have permitted on the one hand the adoption 
of the final EUnetHTA project proposal. On the other, it has shaped the HTA discourse on a 
national and EU policy level during the discussions in the health Council. The project proposal 
presented in the HLG set out six priority areas which showed strong similarities with those of 
the previous projects (EUR-ASSSES, HTA-Europe and ECHTA/ECAHI). On 30 November 2004, 
the project proposal was integrated in the report of the High Level Group to the Employ-
ment, Social Affairs, Health and Consumer Protection Council which would take place on 
6-7 December 2004.
Besides the six priority areas, defined in the October HLG meeting, the report also mentioned 
two additional objectives which are related to soft governance practices. The so-called Key 
task 7 focused on the development of “tools for information support in the establishment of 
new agencies through benchmarking and training”. Key task 8 addressed the aim for design-
ing and testing “tools for sharing methodologies, expertise and practical issues” (European 
Commission 2004f: 13). The inclusion of the two added objectives reflect the importance 
given to soft governance in the HLG and seem to result from the input of representatives of 
DG Employment and Social Affairs in the HLG as we have outlined in chapter 5.
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These priority areas also reveal a sort of conducting thread since the early cooperation projects 
and which is reflected in the general objectives of the EUnetHTA project. Table 6.1 outlines 
how the priority areas identified by the working group on HTA cooperation in the HLG 
are closely related with the ECHTA/ECAHI project and how they have constituted the basis 
of the EUnetHTA project objectives. The overall goal of developing a sustainable European 
HTA network has, as outlined in chapter 4, been present since the very first EUR-ASSESS 
project. The ECHTA/ECAHI project concluded its final report by submitting an explicit request 
to the European Commission to develop such a network (see chapter 4). Table 6.1 shows 
how this request has been taken up by the experts of the HTA working group of the HLG 
who based their work on the early European HTA cooperation projects and adopted almost 
identical aims. After having been present in the HLG communication to the Health Council 
of December 2004, these objectives have been inserted in the EUnetHTA project proposal 
submitted four months later and will remained present in subsequent projects till the Com-
mission regulatory proposal in 2018.
Whilst the appraisal phase of the EUnetHTA project can be situated mostly in the HLG and 
regarded essentially Member States representatives, the second phase of the policy formu-
lation process – dialogue – has been developed outside this group and included mostly 
representatives of the HTA arena. It can be situated during the short preparatory phase 
before the project submission to the EU public health programme when the Danish Health 
Council representative reached out to the participants of the previous cooperation projects 
(see chapter 5). The content of the proposal has been discussed during the several infor-
mal encounters which took place between the project coordinator, representatives of HTA 
agencies (often former members of the early HTA cooperation projects and members from 
international organisations (e.g. INAHTA) (Personal Interview 7).
The actual ‘policy-formulation’ for the EUnetHTA project has been formally accepted dur-
ing a preparation meeting in Copenhagen in February 2005 where the project proposal 
has been discussed and an agreement has been reached on the proposal to be submitted 
(personal interview 7). The meeting is sometimes being recalled by the absence of the “Big 
4”, referring to persons that could be identified as the ‘policy entrepreneurs’ of the early 
European cooperation initiatives (i.e. David Banta, Egon Jonsson, Alicia Granados and Chris 
Henshall). Although the reasons for this were multiple and linked to changing professional 
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occupations132, it also indicates a shift in policy-making, seeking to position HTA on the 
political spectrum with the support of national decision-making institutions.
Hence, although the input and support on behalf of HTA agencies remained predominant, 
securing political endorsement at different institutional levels will become a goal that will 
be actively pursued by the project coordinator Finn Kristensen. As such, he will multiply 
encounters with policy-makers and in this sense he could be identified as another ‘policy en-
trepreneur’ of HTA cooperation in Europe (Personal interview 7). Indeed, several participants 
in the early stages of EUnetHTA underscore his sense of policy-making: “He understood that 
it was not enough to work within the HTA agencies but that political support was needed”; 
“Finn had sense for policy-making and politics, he played a political game which was not 
always appreciated by all but often understood as necessary to take HTA cooperation a level 
up” (Personal interviews 3, 6).
Seeking support through dialogue is also reflected in the support requested for EUnetHTA to 
the Health Evidence Network (HEN) (see chapter 5). The HEN had been created by the WHO 
and first headed by Egon Jonsson followed up by Alicia Granados, two key players in the 
early European HTA cooperation efforts. It aimed to develop HTA in Europe through an ap-
proach focused on evidence collection and dissemination133. Since 2001, no new European 
HTA project had been implemented and to a certain extent, the HEN sought to fill this gap. To 
avoid any competition between the HEN and the EUnetHTA project, WHO support had been 
requested (and obtained) by the project coordinator of the EUnetHTA project134 (Personal 
interviews 6,7). With the moral support of the WHO adding up to the political support 
received on behalf of DG Sanco, the Council, the project was ready to be launched.
132 Reasons for their absence were multiple: Egon Johnson, had moved to Canada, where he pursued 
his activities in HTA. David Banta, although he had shown interest to remain active in the projects, 
did not wish to take any leadership position, Chris Henshall had taken up responsibilities in the 
HTAi. Alicia Granados was the newly appointed director of the Health Evidence Network (HEN) of 
the WHO. She will become involved in EUnetHTA at a later stage (Personal interviews 2,10,6).
133 The “HEN produces a variety of publications to meet policy-makers’ needs: evidence reports 
synthesizing the best available evidence in response to policy-makers’ questions; joint policy briefs 
and policy summaries, produced with the European Observatory on Health Systems and Polices, 
which synthesize the evidence around specific policy options for tackling key health system issues; 
and HEN summaries of reports, including synopses of the main findings and policy options” (http://
www.euro.who.int).
134 Since the establishment of DG Sanco, a sort of non-written competition could be sensed between 
the WHO and DG Sanco regarding the promotion of health policy issues in Europe (Personal 
interview 5).
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Hence, after intense dialogue in several formal and informal fora, consensus on the project 
has been found (consolidation phase) and its content could be submitted in the form of the 
EUnetHTA project proposal. A close analysis of the sub-objectives of the EUnetHTA project 
(Table 6.2) highlights again the continuity that existed between the EUnetHTA project and 
the early HTA cooperation initiatives. Transmitted through the HLG and, as underscored 
by some participants in the EUnetHTA project: “the experience of previous projects was 
therefore important for informing the development of EUnetHTA” (EUnetHTA: 2008a: 16).
The sub-objectives of the EUnetHTA project can be divided into three strands. The first re-
gards the organisational, structural and communication aspects aiming the development of a 
sustainable European network for HTA. This also includes the evaluation of the projects and 
the functioning of the network. In this first category, a soft governance approach underpins 
these facets of the cooperation. Although the EUnetHTA project still follows a project-based 
approach it seeks to lay down an organisational structure on which a sustainable network 
can be established. The communication strategies are based on exchange of best practices 
and information sharing. Three specific workgroups in EUnetHTA will address these aspects: 
WG1 (Coordination), WG 2 (Communication) and WG 3 (Evaluation). The themes of these 
WG do not find an equivalent in the previous projects. They seem to result from the project 
submission format which is fixed by the European Commission.
The second strand could be considered to be the core of the cooperation initiatives: develop-
ing practical tools enabling the realisation of common assessments that will give input to 
national decision-making processes. This objective was also the driver of the early coopera-
tion projects and incorporates the biggest challenge in terms of outcome. The ultimate aim 
is still to better coordinate HTA activities to avoid duplication of assessments, increase the 
quantity and quality of HTA output and enhance the uptake of joint HTA in national decision-
making processes. This requires not only to agree on a solid methodology but also network 
management and governance skills. The EUnetHTA project has tried to meet the objectives 
of the second strand through activities organised in three different Work Packages (i.e. WP 
4,5 and 6).
WP 4 focused on the setup of an HTA Core Model which should allow for the elaboration of 
joint assessments. This WP can be considered as a follow-up of what had been developed in 
WG 3 (European Joint Assessments) and WG4 (Best practices in HTA) of the ECHTA/ECAHI 
project and even work done in EUR-ASSESS: “When we started this work trying to find out 
how we could work together and structure it, it led to the HTA Core Model. (…) How are we 
going to see this joint work, what is context unspecific or sufficiently context independent to 
be actually valuable across borders. So, there we were going back to some of the structure of 
EUR-ASSESS. The model is that way and EUR-ASSESS was very much reflecting the general, 
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original definitions of HTA that is policy analysis and has a broad scope, is multi-disciplinary, 
all the things they got right. And that came out of people that understood policy analysis” 
(Personal interview 4). Hence, whilst the early HTA cooperation initiatives laid the basis for 
joint work by means of definitions, identification of best practices and methodological de-
velopment, the EUnetHTA project sought to develop a concrete common Core Model which 
should be able to deliver joint HTAs.
Moreover, too ensure the uptake of those common HTAs in Member States, the WP 5 of 
the EUnetHTA project should develop a so-called ‘adaption toolkit’ permitting to adapt the 
outcome of the joint assessments in national contexts and facilitate HTA input in national 
health decision-making processes. Related to this objective and to ensure uptake of joint 
assessments in Member States, WP 6 focused on the development of tools to ensure the 
transferability of the HTA results into health policy-making processes. This work had already 
been initiated in the ECHTA/ECAHI project WG 6 which sought to identify successful ap-
proaches to link findings of assessments to health indicators and health care decision-making 
(see chapter 4).
The third strand of the sub-objectives of the EUnetHTA project regards prioritisation and 
capacity-building. These objectives too, were already present in the early cooperation projects 
(e.g. WG 2 ECHTA/ECAHI on Clearinghouse and emerging technologies). Indeed, to decide 
which health technologies would be subject to a common assessment, prior monitoring of 
new and emerging technologies as well as prioritising these, becomes essential. This was 
the focus of the WP 7 of the EUnetHTA project. Finally, assistance to agencies with limited 
experience in HTA is another aspect integrated in the EUnetHTA project WP 8 and which was 
also already present in the EUR-ASSESS project and the ECHTA/ECAHI project (see chapter 4).
Although stakeholder involvement was an important topic debated in the HLG meetings, 
it did not characterise the first EUnetHTA project. Nevertheless, during the appraisal phase, 
the importance of collaboration with important international HTA organisations, patient 
organisations and NGOs had been underscored (e.g. INAHTA, HTAi, Euroscan, Guidelines 
International Network, Cochrane Collaboration, OECD, WHO, and the Council of Europe). 
According to the Commission, the role of the industry “should be considered carefully as it 
is a major player in the field of HTA as well” (European Commission 2004b). Stakeholder in-
volvement is also mentioned in the EUnetHTA proposal as important “to ensure transparency 
and early involvement of relevant parties in the development process”. However, despite 
these reflections, stakeholders did not play any role in the policy-formulation process of the 
EUnetHTA project. This will change in the following EUnetHTA projects and Joint Actions as 
we will outline in the following section.
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6.2.1.2. Policy-formulation in the EUnetHTA Joint Actions
As in the EUnetHTA project, the appraisal, dialogue, policy formulation and consolidation 
phases of the subsequent projects will mostly take place as a follow-up of the evaluation 
phase of the previous projects. However, a distinction of this phase of the cooperation efforts 
lays in the fact that at the end of the EUnetHTA project, insecurity still existed regarding the 
adoption of the Cross-Border Health Care Directive. The proposal was under examination 
since 2008. As outlined in the sections above, this proposal included an article on European 
HTA cooperation foreseeing the establishment of a formal EU network. Hence, whilst prepar-
ing the EUnetHTA collaboration and the future EUnetHTA Joint Action, the partners were 
aware of the necessity to pursue the collaboration efforts till the adoption of the Directive 
which could potentially affect the manner in which HTA cooperation would be governed as 
highlighted in the final report of the EUnetHTA project:
“In July 2008, the European Commission published the proposal for a directive on cross-
border health care, which provides for the establishment of an EU network for HTA (Ar-
ticle 17). Its intent is to enable Member States to facilitate development and functioning 
of an HTA network that connects national and regional HTA agencies. (…) Alongside this 
high-level European policy work, there is a need to ensure the continuity of EUnetHTA and 
that the work of the Project is used, piloted and developed. So, building on the effective 
collaboration that has been created in the EUnetHTA project, the encouragement of the 
European Commission and the support of the Member States that host EUnetHTA members, 
the partners have decided to create a sustainable, permanent European HTA collaboration 
to ensure continuation of communication, collaboration networks and activities” (EUnetHTA 
2009:16-17).
The appraisal phase (collection of data and evidence) of the first EUnetHTA Joint Action lays 
partly as we have seen in the EUnetHTA project and partly in the EUnetHTA Collaboration. The 
latter had been launched in November 2008 and could be considered as an ‘interim-project’ 
necessary to bridge the gap from the EUnetHTA project to the Joint Actions (EUnetHTA 
2010:1)135. Its main activity regarded the preparations of the formal application for a Joint 
Action on HTA (EUnetHTA Joint Action) including the organisation of the consortium of 
partners and the development of the technical, financial and organisational structure of the 
Joint Action (EUnetHTA 2010: 1).
135 Indeed, the project proposal for the first Joint Action (JA1) was sent to the European Agency for 
Health and Consumers on 20 May 2009 (European Commission 2009). The EUnetHTA Collabora-
tion was therefore prepared in the final stage of the EUnetHTA project.
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Dialogue permitting to facilitate the communication between the actors concerned by the 
EUnetHTA Joint Action has mainly taken place in formal and informal arenas. Indeed, unof-
ficial meetings and discussions had taken place in different fora within Commissions DG 
and HTA agencies permitting to exchange ideas about the continuation of HTA cooperation 
(Personal interview 4). The first official meeting between the national HTA appointed bodies 
and the Commission to setup the Joint Action took place in Brussel on 20 February 2009. 
Ideas for the future Joint Action were presented by both DG Sanco representatives and the 
EUnetHTA coordinator.
By being present in the preparatory meetings, DG Sanco was also in the capacity to influence 
the policy formulation process of the first Joint Action. The introduction of the concept of 
Relative Effectiveness Assessment (REA) is a good example hereof. According to Commis-
sion representatives, in the EUnetHTA project, the main focus had been on setting up the 
EUnetHTA commodities, framework, methodologies etc. However, insufficient progress had 
been made on the actual implementation of joint assessments. Hence, to push the idea of 
joint assessments forward, it introduced the concept of Relative Effectiveness Assessment 
(REA) in the EUnetHTA network during the preparatory meeting of the first EUnetHTA Joint 
Action (Personal interview 8).
REA was a topic that had been brought to the fore in the Pharmaceutical Forum (see chapter 
5). As we have outlined above, this issue did not appear on the agenda in the early European 
HTA cooperation initiatives, neither in the EUnetHTA project. The Commission, steering the 
work from the HLG as well as the activities of the Pharma Forum, did however identify 
EUnetHTA as a suitable framework for the development of REA. A DG SANTE representative 
recalls: “The EUnetHTA project was mainly [about] starting networking, starting some com-
munication tools and so on. After the Pharma Forum came the issue of whether we could do 
assessments together. That was the trigger.” (Personal interview 8).
The proposal on REA had to be implemented alongside the work of EUnetHTA on the HTA 
Core Model, which targeted precisely joint assessments. At that point, it was not entirely 
clear how to articulate the distinction between both approaches on joint assessments: “There 
was something called the high-level Pharmaceutical Forum and there were some discussions 
about relative effectiveness assessments (…). So, that has led to a lot of focus on relative 
effectiveness assessment and not to the broad assessment approach that is reflected in the 
HTA Core Model. I think that in terms of things that come out of EUnetHTA and will be 
influential on the long run, the HTA Core Model is going to be key, and that lays directly on 
the shoulders of EUR-ASSESS” (Personal interview 4).
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Besides the input of the Commission, other suggestions were brought to the fore during the 
preparatory meetings of the Joint Action. Most of these ideas were conceived as a follow-up 
of the EUnetHTA project Work Packages136. However, one new item had been presented 
pointing to the importance of “working with EMEA/national regulatory authorities to assess 
how available information at different bodies can be mutually used” (European Commission 
2009a). Developing synergies between HTA and (European) regulatory authorities will be an 
issue of increasing importance over the years. However, in 2009, the concept of so-called 
‘Early Dialogues’ was rather new in Europe and few HTA agencies applied it in their regula-
tory processes (Personal interview 29). This concept refers to need to establish a structured 
communication between the pharmaceutical industry and regulatory authorities aiming “to 
improve the quality and adequacy of early evidence generation in order to be useful for the 
HTA process of reviewing and synthesising evidence to inform coverage decisions” (www.
eunethta.eu).
Indeed, as studies proving the safety and efficacy of technologies (especially in the case of 
pharmaceuticals) are long and costly, it is important to plan at an early stage the content 
of the study and the type of evidence to be provided. HTA bodies, intervening at a later 
stage of the assessment process, may however request information for coverage purposes 
which will differ from the needs of market access regulators (e.g. additional comparison, 
information on organisational or economic aspects). Moreover, there can be situations where 
evidence is indeed inadequate or insufficient at time of the assessment which consequently 
can generate insecurity and thus become an obstacle to timely access to health technologies. 
Early Dialogues are thus targeted at companies developing health technologies and seeking 
market authorisation and reimbursement access. They aim at exchanging views on scientific 
issues during the different stages of technology development and improve the quality and 
adequacy of initial evidence generation. As such, the HTA process could be facilitated which 
would potentially accelerate the coverage decision-making processes and thus patient access 
to new health technologies (EUnetHTA 2015b; see further 6.4.2.2).
Although the idea to develop common Early Dialogues – also called Joint Scientific Advice – 
had been discussed amongst EUnetHTA partners in 2009, it had not been introduced in the 
first Joint Action which was then being prepared. “In 2009, we could not envisage to have a 
collaborative activity on scientific advice or Early Dialogues as it was just starting at the level 
136 The ideas brought forward by the participants included: capacity-building, non-pharmaceutical 
HTA, core HTA models and their practical application (piloting, including models to cover the 
full life-cycle of technologies from emerging to potentially obsolete), development of tools for 
exchange and dissemination of information on HTA (clearing house function), implementing HTA, 
stakeholder involvement (European Commission 2009a).
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of HTA bodies. So, it is normal that it took a certain time and also, a Joint Action, once it has 
started, you cannot modify its fields of activity” (Personal interview 29). Hence, whilst not 
integrated in the Joint Action 1, the idea has nevertheless been launched during the Joint 
Action 2 as a pilot project called SEED: Shaping European Early Dialogues. It will be continued 
in a work package of the Joint Action 3 and incorporated in the 2018 Commission proposal 
for an HTA Regulation.
Hence, as the Joint Action 1 was being prepared with representatives of DG Sanco, support 
of the latter was guaranteed. Partners in the Joint Actions were being appointed through 
the Ministries of Health, indirectly endorsing thus the initiative as well. This support would 
continue over the subsequent Joint Actions 2 and 3. The adoption of the Cross-Border Health 
Care Directive would further impact the role and support of the Council and Commission 
in the policy formulation process. Indeed, since the adoption of the Directive 2011/24/EU, 
ensuring the continuation of HTA cooperation in Europe became even more important to 
the Commission and the Member States. Moreover, based on Article 15, the Commission 
became responsible for the establishment of a permanent network on HTA cooperation. 
This objective which had been present in all European HTA collaborative projects since 1994, 
but remained unattained, would, henceforth, formally fall under the responsibility of the 
European Commission. As such, it would actually be in line with the one of the formal 
requests of the ECHTA/ECAHI project (see chapter 4).
The policy-formulation process of the Joint Action 2, submitted in May 2011137, has, to a 
large extent, been influenced by the adoption of the Cross-Border Health Care Directive 
(Directive 2011/24/EU) adopted in March 2011 (CBHC Directive). Indeed, the first prepara-
tory meeting of the Joint Action 2 took place on 8 March 2011, one day before the formal 
adoption of the Directive. Agreement on this new legislative act had already been found in 
December 2010 between European Parliament, the Council and the Commission during a 
‘Trilogue’ meeting, (EHMA 2011; www.europolitique.info). Hence, since that date, DG Sanco 
could take into account the fact that it would soon have a mandate to establish an EU HTA 
Network.
During the January 2011 meeting of the EUnetHTA Executive Committee, the EU representa-
tive states indeed that: “an agreement between the Council and the Parliament on the text 
has been reached. In the Directive, HTA is clearly defined as one of the areas of cooperation 
137 The initial deadline was actually set in April 2011. However, considering the recent adoption of 
the CBHC Directive an extension of this deadline has been ask and obtained, setting the new 
submission date on 20 May 2011. The project proposal for the EUnetHTA Joint Action 2 has finally 
been submitted on 23 May 2011 (EUnetHTA 2011b: 71-72).
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between MS which opens a possibility for regular funding of this activity from the Com-
mission. The signing of the Directive is expected for June 2011. It is a bit early to say when 
different steps on implementation of the Directive will take place, however, with regard to 
HTA, the complementary Joint Action on HTA is a main step towards the implementation of 
the Directive regarding HTA cooperation in Europe. The JA2 will serve as a framework for 
how this cooperation could be functioning. Based on that, an agreement could be reached 
between the MS and the Commission on setting up a permanent cooperation on HTA in 
Europe” (EUnetHTA 2011b: 71).
The relation between the Joint Action 2 and the Directive has also been highlighted during 
the second meeting of the JA2 preparation: “JA2 should provide continuity of HTA tools 
from JA1 to JA2, appropriate stakeholder involvement, training and education for partners 
and stakeholders (especially patients and providers of health care), and clear deliverable re-
sults to end of 2015 to inform how Article 15 of the CBHC Directive could work” (EUnetHTA 
2011b:2). Moreover, in the discussion about the implementation period of JA2, the role of 
the Joint Action with regard to the CBHC Directive has been once more underscored: “[JA2] 
ending on Sept 30 2015 with reporting of results at the end of 2015, will provide com-
prehensive information important for national implementation of Article 15, Cross Border 
Health Care (CBHC) Directive although the Directive implementation will begin in October 
2013” (EUnetHTA 2011b:3).
Although it is clear that the JA2 should prepare the ground for the permanent EU HTA 
Network, confusion exists whether the EUnetHTA network will be transformed in the future 
European HTA Network or whether a different approach will be adopted. In absence of 
clarification on the latter, the content and objectives of the JA2 will, however, be defined 
by seeking to be conform to the requirements of the Article 15 of the CBHC Directive (EU-
netHTA 2011b 13-18). This has been reiterated during the EUnetHTA Plenary assembly in 
May 2011: “The general objective of JA2 is to strengthen the practical application of tools 
and approaches to cross-border HTA collaboration with the aims at bringing collaboration to 
a higher level resulting in better understanding by the EC and MS of the ways to establish a 
sustainable structure for HTA in the EU. Specifically, the JA2 will develop a general strategy, 
principles and an implementation proposal for a sustainable EU HTA collaboration according 
to the requirements of Article 15 of CBHC Directive.” (EUnetHTA 20011b:50). In the JA2 ap-
plication to the EAHC, the role of the JA2 is defined as “Thus, the JA2 provides the empirical 
basis needed by the Commission and the MS to make decisions regarding the design and 
running of the voluntary HTA network within the framework of Article 15” (EAHC 2011).
During the preparation of the JA2, the pressure on behalf of the Commission regarding 
expenses and deliverables becomes more tangible and will impact the policy-formulation 
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process. The Commission requiring a stronger commitment regarding the production of joint 
work and in particular joint assessments. The Commission also insists on the production of a 
solid business model for HTA cooperation: “The JA needs to demonstrate savings/efficiencies 
as well as increased quality as a result of cross-country collaboration. There needs to be a 
balance between HTA information production and other production aspects e.g. methods, 
capacity-building and networking with a focus to avoid any excessive allocation of resources 
for non-production such as methodology, administration etc. At the end of JA2 the business 
model should be deliverable and realistic” (EUnetHTA 2011b:8).
The formulation and consolidation phases of the policy-formulation process of Joint Action 
2 can be situated at the time of the adoption of the JA2 project proposal. Its content has 
been discussed among the EUnetHTA partners in several formal meetings (see EUnetHTA 
2011b). Discussions were based on a draft proposal developed by the EUnetHTA Joint Action 
1 coordinator. Input to this had also been given by the Executive Committee and Collaborat-
ing partners. The proposal regarded mostly the continuation of the work established in Joint 
Action 1, taking into account the evaluation within the Working Packages and governing 
structures (EUnetHTA 2011b). The latter is reflected in the strategic and sub-objectives as 
shown in table 6.3. As the policy-formulation process took place with the participation of all 
key-actors, consolidation and support for the policy on behalf of the EU and MS institutions 
was a natural outcome.
Section 6.4 will outline in further detail how these objectives have been implemented. At this 
stage it is interesting to notice a fundamental difference between the objectives of JA1 and 
those of JA2 and JA3 and which is directly related to the CBHC Directive. As in all previous 
projects, the main objective in JA1 is to create a sustainable network of HTA cooperation. 
In JA2 and JA3, this has shifted into the strengthening of the practical application of tools 
and approaches to cross-border HTA collaboration. This is comprehensive when analysing 
the developments on the EU-level which will indeed impact the role of EUnetHTA, as we 
will outline in the next section. Since these are closely connected to the formulation of the 
objectives of JA3, we will discuss the latter in the same section.
6.2.2. Policy-formulation in the EU setting
With the proposal on the CBHC Directive, the Commission builds upon the work established 
in different networks and in particular in the HLG on health care and medical services. 
Indeed, following the removal of an article on health in the Services Directive, which had 
launched the debate in the Council and European Parliament, a window of opportunity was 
offered to DG Sanco to introduce a new proposal specifically aimed at Cross-Border Health 
Care. As outlined in chapter 5, the Commission shuffled in this proposal so-called ‘flanking 
measures’, which were in essence topics discussed in the HLG. The adoption of the CBHC 
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Directive in March 2011, will change the role of the European Commission in the field of 
HTA significantly and will impact the governance of HTA cooperation. Indeed, based upon 
the provision inserted in the Directive, the Commission could depart from the project-based 
approach which, till then, had failed to establish a permanent sustainable structure. Whilst 
the Commission had the mandate to establish a permanent EU HTA Network, the question 
remained which form this structure should adopt. The latter will be at the core of the Com-
mission’s HTA policy formulation process as of 2011. A question that needed to be resolved 
with the Member States, since the Commission still only had coordinating powers in this 
field. Hence, any regulatory proposal on its behalf would have to adopted by the Member 
States, united in the Council, as well as by the European Parliament which, in 2011, would 
not really be concerned by the matter yet.
6.2.2.1. Policy-formulation in the EU HTA Network
The CBHC Directive specified an implementation period of eighteen months regarding the 
provisions to be implemented by the European Commission. Even before the adoption of 
the Directive, DG Sanco had already created a Committee on cross-border health care which 
started to work as of June 2010 on a draft Implementing act regarding the establishment 
and functioning of the HTA network (EUnetHTA 2011b:51). After various discussions within 
the Committee, the Member States and interservice consultations (ISC) on the scope and 
purpose of the future network, the Commission adopted the implementing decision in June 
2013 (OJEU 2013)138. This decision also acknowledged that “the HTA Network shall build on 
the experience gained in previous actions in the field of HTA supported by the Union and 
ensure relevant synergies with ongoing actions” (OJEU 2013). It specified that the “Members 
of the HTA Network shall be national authorities or bodies responsible for HTA designated 
by the participating Member States. Experts may be designated to accompany the Member” 
(OJEU 2013).
If in 2011, the impression was given that EUnetHTA would constitute the basis of the future 
HTA network, this becomes less clear in 2013, once the implementing decision had to be 
carried out and the network formally set up. During the first preparation meeting of the JA2, 
it was being specified that, as the Joint Actions were time-limited projects, a new permanent 
cooperation network formally had to be established through Commission decisions. This 
network had to be set up before the end of the Directive’s transpositions period (October 
2013). As there would be an overlap between the Joint Actions 1 and 2, these projects would 
138 The latter provides “the rules for the establishment, management and transparent functioning 
of the Network of national authorities or bodies responsible for health technology assessment” 
(2013/329/EU).
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have to provide input for the Directive’s transposition regarding the future network activities 
(EUnetHTA 2011b :9).
During the meeting of the EUnetHTA Plenary Assembly in May 2011, upon a question regard-
ing the interaction and perspectives of the JA2 and the future HTA Network, the DG Sanco 
representative stressed that “EUnetHTA will continue to function on its way to a permanent 
structure (the network can keep the name EUnetHTA, or change it)” (EUnetHTA 2011b:51). 
However, during the meeting of the EUnetHTA Executive Committee, in October 2011, it 
was specified that, as this new network had to be established by way of comitology with 
the Member States, it could not be “taken for granted that this Network will be EUnetHTA. 
EUnetHTA should be evaluated based on its experience and influence” (EUnetHTA 2011b: 
14). The Business Model to be developed in the JA2 should play a role in this evaluation 
process.
Meanwhile, the committee continued its work alongside the implementation of the Joint 
Action 1 and 2. In 2013, the EU Network for HTA Cooperation has been officially established 
(HTAN 2014). The strategic objectives of the EU HTA Network comprised a broad scope of 
HTA cooperation and in many ways correspond to those of EUnetHTA: fostering coopera-
tion between Member States and stakeholders, develop synergies between European and 
national HTA activities as well as synergies between regulatory and HTA issues (HTAN 2014). 
From the start, the EU HTA Network will orientate its work to develop a (newly created) 
sustainable structure for HTA cooperation.
The first meeting of the EU HTA Network will take place in October 2013. The meeting 
needed to take a stance on the Multiannual Work programme (MWP) 2014-2016 of the 
new network. A draft MWP had been prepared based on the results of a consultation pro-
cess held earlier. This process had gathered background information around key questions 
regarding the scope of the cooperation at EU level on production of HTA joint work as well 
as the impact of the EU HTA cooperation on national decision-making process. Moreover, 
a cost-benefit study on HTA at EU level had been commissioned by DG Sanco139. The latter 
underscored that increased HTA cooperation at EU level was associated with “significant sci-
entific and economic return for HTA Agencies”. Moreover, production of “joint HTAs” would 
lower production costs per report in the Member States up to 19 million euro per annum 
shared between HTA agencies and industry. Finally, a sustainable cooperation would also 
permit a more efficient use of national resources and make specialised expertise available in 
all EU Member States (Tenhave et al. 2013). Work related to HTA in other networks such as 
139 Ten Have et al. (2013). European Cooperation on Health Technology Assessment. Economic and 
governance analysis of the establishment of a permanent secretariat. Final report.
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the Working Party on Public Health at Senior Level140 and an expert panel on effective ways 
of investing in health141 had also been highlighted by the Commission. Furthermore, the 
European Semester Agenda142 and Country specific recommendations were also identified as 
means where HTA related elements could be integrated since cost-effectiveness and efficient 
use of health care resources would be part of those.
These different studies accompanying the setup of the EU HTA Network can be considered 
as part of the appraisal phase of the EU policy formulation process and shapes the discourse 
which will be further developed in the dialogue phase. Besides the arguments that pleaded 
for increased HTA cooperation in Europe, other issues have been discussed, such as the scope 
of the HTA cooperation process (mostly pharmaceuticals and medical devices or also e.g. 
complex interventions?) or the question whether the EU action should also address issues 
related to the performance of health systems. Finally, the debate also addressed the relation-
ship between the EU HTA Network and previous and existing initiatives in HTA cooperation. 
Similarly, it was being examined whether the EU HTA Network should focus only on clinical 
dimensions of HTA or also include organisational and economic ones (HTAN 2014).
Besides the main goal of establishing a sustainable network for HTA cooperation in Europe, 
two sub-objectives stand out in the discussions of the EU HTA Network. The first regards the 
increase of the production of joint work in the EUnetHTA JA2 which should also lead to a 
better uptake in reports of national or regional HTA agencies. This should be done however 
“within the limits of the EU competences, not interfering in the final decisions made at 
national or regional levels on the uptake, investments and disinvestments in health technolo-
140 The Working Party has set up 5 working groups to look at the following topics: 1) health and the 
European Semester Agenda; 2) Key success factors for investing in health through cohesion policy 
(where HTA is considered as a relevant tool to prioritise investment; and where structural funds 
may also be devoted to reinforce national HTA capacities); 3) Rational use of pharmaceuticals; 4) 
Integrated care and hospital management; 5) Performance assessment of health systems (Euro-
pean Commission 2013a)
141 This panel has been established in 2012 upon the Commission decision 2012/198/6). It aims at 
providing scientific advice and knowledge on the sustainability of health care systems. (https://
ec.europa.eu/health/expert_panel/home_en).
142 “The EU Semester Agenda is a yearly cycle of economic policy coordination lead by the EU Institu-
tions to support Member States in their efforts to meet Europe 2020 targets and implement 
growth-enhancing policies. As part of this process each year the European Commission undertakes 
a detailed analysis of EU Member States’ programmes of economic and structural reforms and 
provides them with recommendations for the next 12-18 months. Member States have to respond 
with National
 Reform Programmes. Healthcare is part of the European Semester” (European Commission 
2013a:4).
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gies” (European Commission 2013a:5). The EU HTA business model - one of the objectives 
of the EUnetHTA JA2 - was considered as mean to enable a broader joint production which 
could also facilitate the reuse of the tools and evidence generation produced at the European 
level into the national decision-making processes.
Second, explore possible synergies of successive phases of technology development, licensing 
and market access was also underscored. This need should be put in relation with the search 
for a faster access to new technologies which was debated in wider health policy circles. 
According to the Commission, processes enabling patients to access new technologies - from 
research to regulatory approval and CE marking – did not interact optimally. Hence, access 
to technologies could be delayed by different requirements made from different regulatory 
authorities (at the EU or national level). Synergy and defragmentation in the process would 
offer a timely patient access to innovative technologies, increase business predictability and 
reduce administrative hurdles for regulators and developers, while maintaining EU safety and 
efficacy criteria (European Commission 2013a:5).
During the first EU HTA Network meeting, the role of the Network and the distinction with 
the work carried out so-far has been explained: “Up to now HTA cooperation has relied on 
capable scientists to do the work but now we also need committed leadership to provide 
the strategic direction and long-term vision, avoid duplication and facilitate national follow 
up and re-use of EU joint work. (…) We are at a turning point: either we accelerate and 
build on results achieved so far or we may need to reconsider the entire initiative” (European 
Commission 2013a). This line will be at the heart of the Commission policy formulation 
process on HTA and will drive most interventions of the European Commission in the HTA 
cooperation process post 2014. In short, the message delivered is: either HTA should deliver 
more tangible results measurable in national HTA and regulatory processes or the Commis-
sion could withdraw all of its support.
The policy-formulation and consolidation phases can be identified in respectively the drafting 
of the First Multiannual Work Plan (MWP) and the adoption of the latter in October 2013. 
To ensure a smooth implementation of the MWP, a working group was established which 
would be responsible for drafting the strategy of the network. Hence a strategic vision of 
the network (including its long-term sustainability) had to be developed and priority areas 
identified, which could be potentially co-funded by the EU. Moreover, the working group 
highlighted the importance of facilitating links with EU policy developments. Reference in 
this sense was made to the EU Semester agenda, the Network of competent authorities for 
pricing and reimbursement as well as the reflection process on sustainable health systems 
(European Commission 2013a). Finally, a possible third Joint Action on HTA was not ruled 
out. (European Commission 2014c:4).
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Since the implementing decision regarding the establishment of the EU HTA Network, the 
policy-formulation process of both networks (i.e. EU HTA Network and EUnetHTA) become 
intrinsically linked. In the following section we will therefore examine this process in both 
networks simultaneously as, in particular since the Joint Action 3, EUnetHTA’s course of 
action will be determined by policy strategies defined in the EU HTA Network.
6.2.2.2. Synergies between policy-formulation of EU HTA Network and 
EUnetHTA Joint Action 3
Comparing the objectives of EUnetHTA and the EU HTA Network brings to the fore many 
areas where they overlap. This can be explained by the fact that, at time of the setup of 
the EU HTA Network, both needed to be complementary. Indeed, from the beginning, it is 
officially clarified that the key role of the EU HTA Network would be to “reach agreement 
on a common vision of HTA Cooperation at EU level, and to trigger reflections at national 
level on how EU cooperation can support national activities” (European Commission 2014a). 
However, the network also needed “to reflect on the longer term scenario (post 2020) to find 
a sustainable way to secure scientific cooperation when funding from the Health Programme 
ends” (European Commission 2014a). The scientific cooperation till then would be organised 
with EUnetHTA by means of a third Joint Action. The proximity between both networks and 
their activities is also revealed through the designation of the rapporteur of the Strategy 
paper of the EU HTA Network, who would be the future coordinator of the Joint Action 3.
Hence, the objectives of the JA3 will be mostly defined within the EU HTA Network. In this 
sense, the third EUnetHTA Joint Action follows a different path than the previous ones. As 
EUnetHTA’s status has evolved to becoming the scientific and technical arm of the EU HTA 
Network, it’s objectives and activities will be entirely defined by the strategic objectives and 
MWP of the latter (European Commission 2014b: 3-4). The strategy of the EU HTA Network 
will be published in 2014 along the MWP 2014-2015. This paper also reflected on how 
the newly established network would henceforth take over the ‘ownership’ of constructing 
the future of EU HTA cooperation: “The goal of European cooperation is to increase use, 
quality and efficiency of HTA production in Europe and to promote HTA in decision-making, 
in accordance with national practices and legislative frameworks” (European Commission 
2014c). Moreover, the Strategy paper outlined that “the Network aims at designing and 
implementing a model of collaboration which could enable HTA bodies willing to do so: to 
rely more extensively on each other’s work to perform national HTA reports; to engage in 
joint work, for further national consideration and adaptation; to cooperate more efficiently 
in defining evidence requirements through the life cycle of technologies from scientific advice 
(during development and scientific evaluation - pre licencing ) to surveillance after introduc-
tion to healthcare practice” (European Commission 2014c: 6).
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The Strategy paper furthermore underscored how consensus on a range of HTA issues had 
been found. Indeed, the EU HTA Network would adopt a broad scope of HTA cooperation 
including the full-life-cycle of health technologies (from Horizon Scanning to post-marketing 
assessment) and the whole range of technologies (besides pharmaceuticals and medical 
devices it included also companion diagnostics, surgical procedures, preventive and health 
promotion programmes, Information and Communication Technology (ICT) tools and inte-
grated care processes). Moreover, all different domains of HTA would be considered and the 
network should provide support and input to a wide-range of decision-makers in health care. 
Hence, according to this document, the cooperation should facilitate joint HTA activities and 
enhance the exchange of experience and good practices. It should in this respect address the 
needs of different target groups: policy-makers providers, payers, regulators, developers of 
innovative health technologies and patients. (European Commission 2014c: 7-8).
This broad scope and life-cycle approach also explains the importance of elaborating coopera-
tion efforts with other networks and bodies, regulations or projects concerned by HTA. The 
EMA, represented in all meetings of the EU HTA Network is an example hereof and important 
work will be done with this agency with regard to the development of synergies between 
HTA and regulatory bodies and in particular with Early Dialogues. Besides the collaboration 
with the EMA, the EU HTA Network expressed the importance to seek cooperation with 
the reflection process on safe and timely access to medicinal products (STAMP), the MAST 
assessment model for telemedicine and eHealth, the Network of Competent Authorities 
responsible for Pricing and Reimbursement (NCAPR), the Pharmaceutical Committee, the 
Council reflection process under the Working Party at Senior level on Public Health, as well as 
with ongoing regulatory work taking place on a European level (e.g. Clinical Trials Directive, 
implementing Decision on the Post Authorisation Efficacy Studies (European Commission 
2013a; 2014a; 2014b; 2015a).
It is in this context that the Joint Action 3 will be developed as again submission for funding 
had to respect the timelines of the Work programme of the EU Health Programme. The ap-
praisal and dialogue phase take place for an important part in formal and informal meetings 
within the JA2 structure. The experiences and lessons learned from the JA2, form an impor-
tant input in the policy-formulation of Joint Action 3. Another input is, as outlined above, 
being provided directly by the EU HTA Network which will discuss all proposals for the JA3 
and contribute to the elaboration of its objectives and policy instruments. These objectives 
will be fully in line with those fixed by the EU HTA Network. The EUnetHTA network itself, as 
scientific and technical arm of future EU cooperation, becomes a policy instrument for the 
implementation of the strategic objectives of the EU HTA Network (European Commission 
2014a, 2014b; 2015a; 2015b). As such, the adoption of the Strategy paper almost coincides 
with the timelines of preparation and submission of a potential new Joint Action.
Establishing a sustainable network for HTA cooperation in Europe 293
The policy-formulation and consolidation phases can be situated in the drafting and adop-
tion of the Joint Action 3 project proposal which highlights two strategic objectives. First, it 
would seek to increase the use, quality and efficiency of joint HTA work at European level. 
Second, it would seek to support structural voluntary cooperation at scientific and technical 
level between HTA bodies. The first aim would be pursued by supporting evidence-based, 
sustainable and equitable choices in health care; ensuring re-use in regional and national HTA 
reports, avoiding duplication of assessments. The second strategic objective should be at-
tained by the development of a sustainable model for the scientific and technical mechanism 
of a permanent European cooperation on HTA after 2020 onwards.
Again, the importance of producing joint work and its uptake in national policy and decision-
making process had been brought to the fore. The need to have a structure permitting to 
maintain and develop the tools needed in this regard was once more underscored. The 
long-term objectives of ECTA/ECAHI had thus become short term project-based objectives 
which should be attained by 2020. This would be the first time in the EUnetHTA history that 
the establishment of a permanent sustainable structure had been linked to a deadline. With 
the establishment of the EU HTA Network, the EUnetHTA governance structure and means 
would however change, impacting the approach chosen by which these objectives would 
have to be reached (see section 6.3). The Commission proposal for a Regulation on HTA 
cooperation is the most tangible outcome of a changing EU policy towards sustainable HTA 
cooperation in Europe. In the following section we will examine the process which has led to 
the publication of the Regulation proposal in January 2018.
6.2.2.3. Policy-formulation at the EU Regulatory level
6.2.2.3.1. Preparing a new legislative proposal on HTA cooperation
With the work of the EU HTA Network and the Joint Action 3 being set in motion, a new 
policy-formulation process is underway and taking place, this time not on a network-level 
but on the EU institutional level. As of 2016, the Commission will develop several actions 
preparing the road for its Proposal of a Regulation on HTA cooperation which it will officially 
submit to the Council and the European Parliament in January 2018 (European Commission 
2018).
Indeed, before proposing a new legislative initiative, the European Commission needs to 
assess potential social, economic and environmental consequences its initiative may have 
in the Member States. As such an impact assessment takes place, analysing the pros and 
cons of various policy options (https://europa.eu/european-union/eu-law/decision-making/
procedures_en). In the case of HTA cooperation, the Commission proceeded by starting with 
an Inception Impact Assessment (IIA). The IIA has been implemented in 2016, outlining the 
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state of play of HTA Cooperation in Europe and recalling the work done in the different 
cooperation initiatives. The voluntary aspect of the cooperation had been highlighted since 
it had an impact on the uptake of the joint work which remained at the full discretion of the 
Member States. Indeed, the report underscored that: “While HTA bodies cooperate on de-
veloping common guidelines and even produce joint assessments, they can – and in practice 
do – still carry out parallel national processes. They can also decide whether to use or not the 
joint work (so called re-use or uptake). In the same way, also industry can decide whether 
and, if so, which health technologies they submit for joint assessments, thus possibly giving 
priority to products with a high profit margin over products with a high potential benefit for 
patients” (European Commission 2016:5).
Two main weaknesses of the cooperation efforts had been identified and which, according 
to the IIA, would justify action on behalf of the Commission. The first one was related to 
the limited impact of the cooperation efforts in national HTA processes. Explanatory reasons 
brought to fore legal, organisational and linguistic barriers. The second weakness was related 
to the lack of long-term sustainability of the cooperation model based on Joint Actions (Euro-
pean Commission 2016: 8). The Commission underscored how HTA cooperation depended 
largely on EU funding and how it would not be “rational to invest public funds into HTA co-
operation at European level, if the uptake of the work is not improved and the duplication of 
efforts is not avoided” (European Commission 2016: 9). It underscored how Member States 
still highly differed in their procedural frameworks and administrative capacity which had an 
impact on the duration of the procedure, the product scope and the amount of assessments 
carried out per year. Hence, the potential of HTA cooperation would not fully be exploited 
and a new approach should be envisaged. Implicitly, this approach conveyed the message 
that, in case of a status quo, EU funding would be withdrawn (European Commission 2016).
To address these challenges, the Commission believed it should adopt an innovative ap-
proach, more firmly imbedded in an EU legislative framework. As such, it proposed to base 
any new initiative on article 114(1) TFEU which allows for the adoption of measures aiming to 
improve the functioning of the Internal Market, whilst ensuring a high level of public health. 
Article 168 (4) (c) TFEU would complement the first legal basis mentioned. Any proposal 
should however take into account what is stipulated in Article 168 (7) TFEU referring to the 
respect of the responsibilities of the Member States for the definition of their health policies 
and for the organisation and delivery of their health services and medical care. Hence, any 
policy regarding pricing and reimbursement should remain outside a new legislative proposal 
of the Commission.
Choosing Article 114 TFEU to foster HTA cooperation had however consequences for the 
overall approach to the cooperation process as this represented a shift from a public health 
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approach towards an EU market integration one. The rationale outlined in the Impact As-
sessments also clearly indicates the latter. The disparities amongst HTA processes in different 
countries would here be presented as an obstacle to the free movement of health technolo-
gies, reducing business predictability and create unequal access of health technologies to 
patients:
“Most health technologies are products which benefit from the free movement of goods 
within the internal market. Despite this, a number of obstacles to their free movement 
have been outlined in section 2 of this report. The procedural and methodological dif-
ferences, along with the considerable duplication of HTA across the EU Member States, 
have a significant negative impact on when and where health technologies reach the 
market, thus reducing business predictability for companies, particularly SMEs. This, in 
turn, contributes to differences in patient access to innovative health technologies. These 
divergences and duplication also result in considerable additional costs for HTA bodies 
and industry alike.
The aims of this initiative cannot be achieved sufficiently without strengthened 
cooperation at EU level. As described in section 2, the diversity and multitude of ap-
proaches to HTA across the Member States means that, due to their scale and effect, 
only action at Union level can eliminate the obstacles described. Without action at 
EU level it is unlikely that national rules on how HTAs are carried out would 
be harmonised and thus the current fragmentation of the single market would 
persist.
(…) Without an EU initiative, it is unlikely long-term cooperation on HTA between Mem-
ber States would be significantly strengthened through bilateral or regional cross-border 
initiatives” (European Commission 2018a:41, bold added).
Although the legal basis, placing HTA cooperation into an EU Internal Market logic, had been 
clearly expressed in the Impact Assessment, this had not been discussed, as such, during the 
dialogue phase preceding the publication of the Impact Assessment accompanying the of-
ficial publication of the Commission proposal for a Regulation on HTA Cooperation. Hence, 
the fact that the new proposal would base itself on EU market law came as a surprise to most 
observers: “nobody of us knew that they had the idea to put the proposal on the basis of the 
market. (…) And I do understand why they wanted to do that because it is easier. (…) This 
came as a surprise” (Personal interview 22). Indeed, as we have seen in chapter 2, in the field 
of health care, the EU has only supporting powers to foster integration but no mandatory 
regulatory ones as in the field of the Internal Market. Hence, a Regulation in the field of HTA 
cooperation can only be legally justified with an Internal Market approach.
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However, as outlined in chapter 2, any legislative proposal in the field of EU health policy 
needs to respect the subsidiarity principle143. To address this issue, the Commission concluded 
already in the IIA of 2016 that: “The on-going cooperation – namely the Joint Actions and 
the HTA Network – demonstrated the benefits of the EU cooperation (both in economic 
terms and on the quality and quantity of reports and other tools), while this cooperation 
model did not remove the fragmentation of the national systems and the duplication of 
efforts. It is thus concluded – on the basis of the current experience – that the objectives 
cannot be sufficiently achieved at national level. An initiative strengthening cooperation and 
increasing synergies and reducing duplication of efforts would therefore be best pursued at 
EU level” (European Commission 2016:12, italics added). This rationale will remain the same 
during the consultation process and will be integrated in the Proposal for a Regulation on 
HTA Cooperation (European Commission 2018:4).
Hence, the general objective of a new legislative initiative sought to “Enable Member States 
to strengthen their cooperation on HTA in a sustainable manner”. This goal is fully in line 
with all the previous cooperation efforts. However, the two other main objectives that had 
been added, differed from the previous cooperation initiatives as they responded to EU 
common market objectives: “Ensure a better functioning of the Internal Market of health 
technologies” and “Contribute to a high level of human health protection, as stated in 
Article 168 TFEU and Article 35 of the Charter of Fundamental Rights”. The ‘traditional’ 
objectives of HTA cooperation showing a continuation since the EUR-ASSESS project, would 
now figure as sub-objectives for a new legislative proposal as mentioned in the IIA. Indeed, 
these resumed again the objectives of the Joint Actions and concerned the reduction of 
duplication of efforts; the promotion of convergence in HTA procedures and methodologies; 
the increase in uptake of joint work in Member States and the long-term sustainability of EU 
HTA cooperation (European Commission 2016: 13).
Finally, the IIA presented also five possible scenarios for a future sustainable HTA cooperation 
in Europe. These scenarios would be submitted to a public consultation before a full Impact 
Assessment of them would be made. The first proposed the status quo – Joint Action until 
2020. The second envisaged a long-term voluntary cooperation which would be financed 
by the EU beyond 2020; the third foresaw a mandatory cooperation on collection, sharing 
and use of common tools and data; The fourth, mandatory cooperation on production of 
143 The subsidiarity principle refers to the fact that “in areas which do not fall within its exclusive 
competences, the Union shall act only if and so far as the objectives of the proposed action cannot 
be sufficiently achieved by the Member States, either at a central level or at a regional and local 
level, but can rather, by reason of scale or effects of the proposed action, be better achieved at 
Union level” (Art. 5 (3) Treaty of the European Union) (see also chapter 2).
Establishing a sustainable network for HTA cooperation in Europe 297
joint REA reports and their uptake (cooperation on clinical/medical matters); and the fifth 
scenario targeted mandatory cooperation on production of joint Full HTA reports and their 
uptake (comprising economic, ethical, legal and organisational domains). (European Com-
mission 2016: 13-15). Hence, the level of engagement was different in each option, ranging 
from very low to very high. Only Options 1 and 2 could be implemented by non-regulatory 
means. The other three options required to proceed via a specific regulatory route (Directive 
or Regulation).
The Inception Impact Assessment can be considered as representing the appraisal phase of 
the (EU institutional) policy-formulation process on European HTA cooperation. The second 
phase – dialogue - will mostly take place during the public consultation process that ran 
from 21 October 2016 to 13 January 2017. Besides the online questionnaire, bi-lateral meet-
ings between various stakeholders and the Commission have been organised. An impact 
analysis of the policy options144, a mapping exercise of HTA methodologies in the EU and 
Norway145 and a mapping of HTA national organisations, programmes and processes in the 
EU and Norway146 have been carried out to assess the options as well as a separate, industry-
commissioned study147. The conclusions of those studies have been taken into consideration 
in the Impact Assessment (IA) which has been published in January 2018 alongside the 
Commission proposal for a Regulation on HTA Cooperation and which can be considered as 
the actual policy-formulation phase. In the following section we will examine in more detail 
the content of the Commission proposal and the various responses to that by the actors in 
the field.
6.2.2.3.2. Proposing a new EU legislative framework on HTA cooperation
The “Commission Proposal for a Regulation of the European Parliament and of the Council 
on health technology assessment and amending Directive 2011/24/EU on HTA cooperation” 
144 European Commission (2017a). Study on impact analysis of Policy Options for strengthened EU 
cooperation on Health Technology Assessment (HTA) Final. Available at: Report https://ec.europa.
eu/health/sites/health/files/technology_assessment/docs/2018_ia_policyoptions_en.pdf. Last ac-
cessed on 9 July 2019.
145 European Commission (2017b). Mapping of HTA methodologies in EU and Norway. Available at: 
https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/2018_mapping_meth-
odologies_en.pdf. Last accessed on 9 July 2019.
146 European Commission (2017c). Mapping of HTA national organisations, programmes and pro-
cesses in EU and Norway. Available at: https://ec.europa.eu/health/sites/health/files/technology_as-
sessment/docs/2018_mapping_npc_en.pdf. Last accessed on 9 July 2019.
147 Charles River Associates (2017). Report: Assessing the wider benefits of the EU’s proposal on 
strengthening cooperation on HTA. Prepared for EFPIA. Available at: https://www.efpia.eu/me-
dia/219813/cra-efpia-european-cooperation-on-hta-impact-assessment-final-report-july-2017-stc.
pdf. Last accessed on 9 July 2019.
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submitted on 31 January 2018, proposed to establish a new framework where HTA coop-
eration at the EU level would be organised according to four main pillars: 1) Joint Clinical 
Assessments; 2) Joint Scientific Advice; 3) the identification of emerging health technologies 
and 4) voluntary cooperation in non-clinical aspects of HTA (e.g. economic, social, ethical) 
(European Commission 2018: 11). As the proposal was made in the form of a Regulation, 
the text would become binding once adopted by the Council and the European Parliament 
(see chapter 2). Hence, whilst voluntary cooperation could still take place for assessments 
regarding non-clinical domains, use of cooperation outputs for clinical assessments would 
become mandatory to all EU Member States.
As underlying reason for the choice of this legislative instrument, the Commission argued 
that “the diversity and multitude of approaches to clinical assessments across the Member 
States means that, due to their scale and effect, only action at Union level can eliminate 
the obstacles described. Without action at EU-level it is unlikely that national rules on how 
HTAs are carried out would be further aligned and thus the current fragmentation of the 
Internal Market would persist” (European Commission 2018: 4). As such, the Commission 
had recourse to the subsidiarity principle arguing that although the cooperation efforts in 
the Joint Actions and the EU HTA Network have “illustrated benefits of EU cooperation, in 
terms of establishing the professional network, the tools and methodologies for cooperation 
and piloting joint assessments, this cooperation model has not contributed to the removal of 
the fragmentation of national systems and the duplication of efforts” (European Commission 
2018:4).
Moreover, the proposal underscored that “while Member States have carried out some 
joint assessments within the framework of the EU co-funded Joint Actions, the production 
of output has been inefficient, relying on project-based cooperation in the absence of a 
sustainable model of cooperation. Use of the results of the Joint Actions, including their joint 
clinical assessments, at Member State-level has remained low, meaning that the duplication 
of assessments on the same health technology by HTA authorities and bodies in different 
Member States within identical or similar timeframes has not been sufficiently addressed” 
(European Commission 2018: 17).
Besides respecting the subsidiarity principle, a new legislative proposal also needs to respond 
to the principle of proportionality as enshrined in Article 5 of the Treaty of the European 
Union stipulating that; “the content and form of Union action shall not exceed what is 
necessary to achieve the objectives of the Treaties”. This principle underpins the rationale of 
the Commission to only make the Joint Clinical Assessments mandatory and not a full core-
HTA. When defining ‘Joint Clinical Assessments’ (JCA) the Commission proposal referred to 
the HTA domains as defined by EUnetHTA. The Joint Clinical Assessments would correspond 
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with the domains used in the Relative Effectiveness Assessments: 1) the identification of a 
health problem and current technology, 2) the examination of the technical characteristics of 
the technology under assessment, 3) its relative safety, and 4) its relative clinical effectiveness 
(European Commission 2018: 16).
As such, the proposal would, according to the Commission, respect the principle of propor-
tionality as the proposal stipulated that it “does not oblige Member States to carry out an 
HTA on health technologies which are the subject of joint clinical assessments. However, 
where Member States do carry out HTAs on such health technologies, there is a requirement 
for mandatory use of the joint clinical assessment report and no repetition of the clinical 
assessment in Member States’ overall HTA processes” (European Commission 2018:13). 
Therefore, the proposal would constitute a “proportionate and necessary response” to prob-
lems such as duplication at national level of joint clinical assessments and, as such, reduce the 
administrative burden of health technology developers having the same technology being 
assessed in multiple Member States (European Commission 2018:4).
Proportionality was also reflected, still according to the Commission, in the fact that the 
scope of joint work in the proposal would be limited to certain types of medicinal products 
and medical devices allowing flexibility when it comes to timing of JCA for medical devices148 
(European Commission 2018: 5). Moreover, no new requirements had been introduced 
for health technology developers compared to what already existed in national legislation. 
However, the proposal aimed at ensuring that “when HTA is performed, the methodologies 
and procedures applied are more predictable across the EU and when subject to joint clini-
cal assessment such assessments are not repeated, avoiding duplication and discrepancies” 
(European Commission 2018: 5). A phase-in approach had been foreseen, allowing Member 
States and industry to adapt to the new system (European Commission 2018: 5).
148 The Commission proposal for a Regulation on HTA cooperation differentiated the HTA approach 
between medicinal products and medical devices. Regarding medicinal products JCA would regard 
“all medicinal products undergoing the central marketing authorisation procedure provided for 
under Regulation (EC) No 726/2004 of the European Parliament and of the Council, which incor-
porate a new active substance, and where those medicinal products are subsequently authorised 
for a new therapeutic indication (European Commission 2018: 11). For medical devices, JCA 
should be carried out only for “devices within the meaning of Regulation (EU) 2017/745 of the 
European Parliament and of the Council which are in the highest risk classes and for which the 
relevant expert panels have provided their opinions or views and which have been selected by the 
Coordination Group set up under this Regulation based on the following criteria: unmet medical 
need; potential impact on patients, public health, or healthcare systems (e.g. burden of disease, 
budget impact, transformative technology); significant cross-border dimension; Union-wide added 
value (e.g. relevance to a large number of Member States); the resources available to it” (European 
Commission 2018:11).
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The second pillar of the proposal regarding Joint Scientific Advice (JSA) - corresponding to 
the ‘Early Dialogues’ implemented by EUnetHTA - would adopt a similar approach as the 
JCA. The main difference would reside in the fact that the reports regarding JSA would not 
be published nor bind the health technology developer or the Member States at time of 
(joint) clinical assessment. Transparency would be assured by including information about 
the JSA in the annual reports of the Coordination group (European Commission 2019: 13). 
Horizon Scanning, as known in EUnetHTA, constituted the third pillar of the proposal where 
an annual study would be carried out to identify new emerging technologies “expected to 
have a major impact on patients, public health or healthcare systems” (European Commis-
sion 2018: 13).
The non-clinical domains, for which voluntary cooperation has been foreseen, correspond to 
the last five domains of the HTA Core Model: cost and economic evaluation, ethical analysis, 
organisational aspects, social aspects, and legal aspects. It would also apply to all health 
technologies other than medicinal products and medical devices, or devices not selected for 
JCA (European Commission 2018:13-14; www.eunethta.eu). Use of previous HTA research 
outputs on Real World Data or evaluation of innovative technologies (e.g. e-health, person-
alised medicines) as well as the assessment of non-clinical domains, should not be excluded 
from the cooperation efforts, according to the Commission proposal (European Commission 
2018: 14).
The choice to propose a Regulation on HTA cooperation with a mandatory uptake of Relative 
Effectiveness Assessments for some pharmaceuticals and medical devices, came as a surprise 
for most observers. Indeed, scenarios presented in the public consultation149 and in the IA 
online survey, did offer a more flexible option where uptake would be mandatory only for 
those who had decided to opt-in in the joint work (European Commission 2016c; 2017d). 
The latter seemed to present the preferences of most HTA stakeholders in both studies. One 
should notice that in the public consultation, the term ‘joint work’ was very broadly defined 
and comprised activities ranging from literature reviews to Early Dialogues REA and Full 
149 The scenarios in the Public Consultation were: 1) voluntary cooperation with voluntary uptake of 
joint work, 2) voluntary cooperation with mandatory uptake of joint work for the participants or 
3) mandatory cooperation with mandatory uptake of joint work.(European Commission 2016c).
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HTAs150. Hence, assessing real preferences regarding HTA domains which should fall under 
binding legislation was hard to assess.
In the IA online survey151, options had been clearly specified and were more in line with those 
of the IIA: besides project-based voluntary cooperation (option 2), some options did foresee 
binding legislation regarding cooperation on common tools and Early Dialogues (option 3), 
or the possibility to Opt-in for joint REAs plus option 3 and making uptake mandatory only 
for those who would choose to participate (option 4.1). Option 4.2 would be similar as 
Option 4.1 without the choice for participants to opt-in or not. Hence, in this case, joint 
REA combined with the previous options would be mandatory for all. Only the joint full HTA 
would remain voluntary. The last scenario (option 5), was considered in most studies the least 
feasible as it proposed a mandatory approach on all types of joint work including the Full 
HTA152 (European Commission 2017).
It is unclear which arguments have convinced the Commission of choosing the approach 
adopted in their Regulation proposal and to what extent the conclusions of the different 
studies have weighted in their policy-formulation process. Some of these studies and their 
design had indeed been contested. The IA had to assess, amongst others, the costs of joint 
collaboration and their economic and social/health impacts regarding the several options 
presented. However, this seemed to be a very challenging exercise. As activities amongst HTA 
agencies highly differ, the allocation of resources regarding the specific items investigated in 
the studies was for some agencies sometimes hard (or impossible) to measure. Moreover, the 
questionnaires comprised cooperation options in fixed combinations. They were presented 
as possible combinations of the options mentioned in the IIA. However, although the idea 
was to fine-tune options which were provisional, the study did not offer the possibility to as-
150 Joint work was specified in the questionnaire as: “’Joint Work’ refers to activities in which 
countries and/or organisations work together in order to prepare shared products or agreed 
outcomes. These may include, for example, literature reviews, structured information for rapid or 
full HTAs, Early Dialogues or scientific advice on R&D planning and study design. Joint work aims 
at supporting Member States in providing objective, reliable, timely, transparent, comparable and 
transferable information and enable an effective exchange of this information (according to HTA 
Network’s “Strategy for EU Cooperation on Health Technology Assessment” adopted in October 
2014)” (European Commission 2016c).
151 The online survey was part of the “Study on impact analysis of Policy Options for strengthened EU 
cooperation on Health Technology Assessment (HTA)” (European Commission 2017).
152 The policy options in the online survey were Policy Option 1: Baseline scenario - No EU action after 
2020; Policy Option 2: Voluntary cooperation supported by the Public Health Programme; Policy 
Option 3: Legislation covering Common Tools and Early Dialogues; Policy Option 4.1: Opt-in for 
Joint REA plus option 3; Policy Option 4.2: Mandatory Joint REA plus option 3; Policy Option 5: 
Option 4.2 and Opt-in for Full HTA (European Commission 2017).
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sess opinions regarding specific characteristics of the presented options. As such, no further 
elaboration of the policy-options was possible and respondents had to remain within the 
given grids, even though this would only partially reflect their preferences (European Com-
mission 2017e; Personal interview 20).
Similarly, the accuracy of the assessment regarding the costs of cooperation of each option 
had been questioned as, due to the survey format, no fine-tuning was possible. Respondents 
were for example asked to answer questions such as: “To what extent do you expect each 
policy option to impact on the total costs of a REA submission (if applicable)? (Total costs 
including costs for staff, (re)submission costs, administrative cost, costs for including stake-
holder, etc.)” (European Commission 2017e). Analysing the impact of a new activity requires 
to put it in relation with the degree of implementation before and after, as well as many 
other aspects such as the repartition of (external) funding sources, the division of labour 
in the future collaboration model, etc. Due to the rather rigid format of the questionnaire 
and the lack of information regarding some items (which could therefore not be taken into 
account), some respondents casted doubts on the accuracy of the outcome of the study (Per-
sonal interview 20). The European Commission acknowledged the limitations of the study 
and confirmed that “the results do not allow precise quantification but should be taken as 
general indications on the overall trends” (European Commission 2017e: 81).
Option 4.2 has been indicated by the authors of the report as the most preferred option 
to fulfil the general and specific objectives set out in the IA concerning HTA cooperation 
and which regarded Effectiveness, Efficiency, Coherence, Subsidiarity and Proportionality 
(see above). According to these criteria, it scored better as the Option 4.1 as, indubitably, 
convergence would be higher in case of a mandatory approach applicable to all Member 
States compared to an opt-in approach where some Member States would not adopt the 
measures. The same goes for all other criteria. Although, the mapping study did conclude 
that the transition would be possible for all European countries, taking into account the 
legal, administrative and timelines applicable in certain countries, it did not further assess 
the willingness of national administrations and HTA agencies to go for a full mandatory 
approach.
Whilst stakeholder participation had been an integral part of the consultation process, the 
actual participation of the various stakeholder groups in the consultation process and the IA 
study showed quite some representation disparities. Indeed, few contributions came from 
the patients, payers and health care providers. A majority of the contributions came from the 
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industry which clearly outnumbered representatives of HTA agencies153. However, the Com-
mission has organised a separate consultation round in which it has held some 25 meetings 
with different stakeholder groups so as to better understand their position (https://ec.europa.
eu/health/technology_assessment/events_en#anchor2).
The interests at stake in HTA cooperation clearly varied among the different stakeholder 
groups, each pursuing their own agenda. As such, the pharmaceutical industry highlighted 
how the diversity of HTA procedures (e.g. starting period, length, scope, data accepted) 
across the EU represented a hurdle for developers. The medical device industry underscored 
how HTA processes often played a limited role in market access processes. The latter would 
be country specific and no established HTA processes would often be in place. Hence, HTA 
cooperation would thus be of lesser importance to this stakeholder group. Medical device 
representatives also expressed their concern to have HTA processes being developed for 
medical devices based on a pharmaceutical product approach not addressing the specificities 
of their sector. Moreover, due to variable timelines of market access and assessments of 
products, a compulsory HTA process could, according to some, even become a “market bar-
rier with major implications on the development of new products” (European Commission 
2017d:13). Patients and health care providers would be favourable towards strengthened 
HTA cooperation. They, however, argued for more transparency in the assessment processes 
as well as a better involvement of these stakeholder groups in the HTA processes.
All stakeholder groups agreed with a large majority that EU HTA cooperation was “useful” 
or “to some extent useful” and that cooperation should be pursued (European Commission 
2017d:16-19). The most preferred policy option for future cooperation was the “voluntary 
participation with mandatory uptake”. The option “mandatory participation and manda-
tory uptake” gathered only a third of favourable positions and showed also the highest 
opposition with 66% indicating this as their least preferred option (European Commission 
153 The Public Consultation Process gathered in total some 249 replies (63 from individual/citizens 
and 186 from administrations, economic stakeholders, associations and organisations). The par-
ticipation of the various stakeholder groups did not follow an equal representation: the industry 
(Pharmaceutical and medical technologies) represented more than half of the responses (53%) 
followed by the public administrations (14%), patients and consumers (13%), healthcare providers 
(9%) and payers (3%) (European Commission 2017d). The online survey, aiming to assess the 
costs of HTA processes and effects of different policy options, also included an important share of 
the industry compared to the other stakeholder groups. Out of the 177 responses collected, 120 
came from the medical device industry, 20 from the pharmaceutical industry and 32 from Public 
administration, 2 from payer organisations and 1 from patient organisations and 2 from academia. 
Moreover, few representatives from ministries have participated in this consultation (6 replies) as 
the group on public administration comprised mostly HTA agencies (European Commission 2017).
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2017d: 23). In favour of the latter were in particular patient organisation indicating that 
this option would offer more commitment from Member States. Pharmaceutical companies 
supported harmonisation of relative effectiveness assessments at time of launch and pleaded 
for synergies between regulators, HTA bodies and payers regarding evidence requirements. 
Their preferred option actually laid outside the three options proposed (other) followed than 
by the “voluntary participation with a mandatory uptake” until the process had proven itself. 
Medical device companies emphasized their need for a differentiated approach adapted 
to their needs. Health care providers were divided as regards their preferred option. Some 
opting for a voluntary/voluntary approach, others preferring a voluntary participation with 
a mandatory uptake. Payers preferred the voluntary participation with voluntary uptake 
(European Commission 2017d: 23-24).
The public consultation and the online survey do refer to responses of public administrations. 
The reports states that the contributions from this group were provided mostly by HTA bod-
ies. It remains unclear to what extent opinions have been collected from representatives of 
Ministries of health of the Member States. Indeed, their contributions in the public consulta-
tion was very limited and even though it is mentioned that some discussions had been held 
between the Commission and representatives of Ministries of health, the latter did not seem 
to feel quite concerned by this topic at the time of the Consultation process (European Com-
mission 2017d). It is only after the Commission proposal publication that (fierce) reactions 
from some Member States have been expressed. Several countries (e.g. Germany, Czech 
Republic, France and Poland) calling upon the subsidiarity principle to challenge the proposal 
in front of the legal European authorities (Council 2018; 2019). Hence, with the publication 
of the Commission proposal for a Regulation on HTA cooperation, the policy-formulation 
process enters a different policy arena, as first the Parliament needs to pronounce itself on 
the proposal after which it will be debated in the Council. Although the Commission hoped 
for a smooth adoption process before the next Parliamentary elections in May 2019, the Pro-
posal encountered opposition on behalf of several Member States. At time of writing, a new 
European Parliament term had started. The European Parliament had voted on amendments 
in its first reading (European Parliament 2018) and proposal would still be under examination 
of the Council (first reading) as many unresolved issues would lay on the table.
6.2.3. Conclusion policy-formulation in European HTA cooperation
The formulation of a policy is an essential stage of the policy cycle and aims to identify, 
assess and select policy options addressing a specific policy problem. In the present case, 
the policy-formulation process sought to address the challenge of creating a sustainable 
European HTA cooperation structure allowing for the development and uptake of joint work. 
In the above sections we have analysed the HTA cooperation policy-formulation process since 
the EUnetHTA project and we have seen how each stage did built upon the work of the 
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latter. However, we have also seen how, gradually, the European Commission has become 
increasingly involved in this process to even take over the ownership of the cooperation 
initiative and propose a Regulation on HTA cooperation.
Herewith, not only the actors involved in the policy-formulation process would change, but 
also the policy objectives would gradually be adjusted. As such, whilst the first EUnetHTA 
project had been designed within the high-level group on medical services and health care, 
it demonstrated a continuity with the objectives of EUR-ASSESS an ECHTA/ECHAI. The 
EUnetHTA Joint Actions will mark an important difference in the policy-formulation pro-
cess, as the European Commission became a full-fledged partner in the process and had to 
approve the objectives of the initiatives. Moreover, it will introduce important changes in 
the networks activities by incorporating the development of, for example, joint REAs in the 
network’s objectives.
The adoption of the Cross-Border Health Care Directive will be another landmark in the 
policy-orientation and formulation process of HTA cooperation in Europe. Indeed, based on 
this new legislative instrument the EU HTA Network will be established and take over the 
strategic orientation of HTA cooperation in Europe. Although initially often considered as 
being the future sustainable network, EUnetHTA becomes the scientific and technical arm of 
the EU HTA Network and its work will be fully determined by the EU HTA Network. The latter 
will remain focused on elaborating a sustainable model for HTA cooperation and will serve 
as a hub for the Commission to develop a new legislative proposal for a Regulation on HTA. 
However, new objectives will enter the policy-formulation process, allowing to find a legal 
basis for a proposal in the EU legislative framework.
This proposal departs from the previous cooperation initiatives by introducing new (market-
orientated) objectives. Indeed, from a health policy approach, HTA cooperation will be 
regarded in the scope of market integration policies, as this is the only basis allowing the 
Commission to make a regulatory proposal in the field of public health policy. The general 
objectives of HTA cooperation are thus altered and turned towards an optimisation of Inter-
nal Market policies besides the (pre-existing) objectives turned towards improving human 
health protection. Whilst the approach adopted in the early cooperation initiatives and the 
EUnetHTA project and Joint Actions was predominantly turned towards the sustainability of 
health systems and increased patient access to new health technologies, the new Commis-
sion approach is turned towards Internal Market objectives herewith seeking to conciliate 
the industry interests with public health interests. Consequently, what used to be the main 
objectives of the previous cooperation projects in EUnetHTA and its predecessors become 
so-called ‘Operational objectives’ in the Regulation proposal (e.g. convergence in HTA tools, 
procedures and methodologies; reduce duplication of efforts for HTA bodies and industry; 
uptake and long-term sustainability of EU HTA cooperation (European Commission 2018:2).
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Hence, as for the agenda-setting process, at the surface, it seems that over the years the 
overall project objectives remain the same. However, a detailed scrutinisation of the policy-
formulation process brings to the fore how slowly but surely the European Commission 
takes over the strategic direction of HTA cooperation in Europe and re-orientates the overall 
policy-formulations which will lay the basis for the decision-making process regarding HTA 
cooperation. There were the sustainability of health systems and patient access had been 
driving the (early) cooperation efforts, industry interests find their place in the debates, po-
tentially altering the overall objectives of the (future) cooperation initiatives. From a voluntary 
soft governance approach, the HTA cooperation process is proposed to enter a mandatory 
legal EU framework, despite the opinions expressed in the public consultations indicating 
that this option would trigger the most opposition.
In principle, the Commission has followed the traditional Community approach before 
proposing a new legislative act. Indeed, an Inception Impact Assessment had been made 
followed by a public consultation and an Impact Assessment. However, again, a close exami-
nation of these studies brings to the fore how this process has maybe not been utilised to its 
full potential. Stakeholder groups have not been equally represented in this process; some 
groups (e.g. industry) being over-represented and others (ministries of health) being under-
represented. The general opinion in terms of preferences has not been taken into account. 
Moreover, the cost-effectiveness analysis did not permit to make a reliable assessment of the 
potential impact of the proposal due to the survey format which did not seem fit for purpose.
The analysis of the policy-formulation process shows how the insertion of HTA cooperation 
into EU legislative texts allowed for a shift in ownership of the cooperation process on the 
one hand as well as a shift of competences on the other. Indeed, shuffling HTA cooperation 
in the flanking measures of the Cross-Border Health Care Directive, offered the Commission 
the opportunity to create the EU HTA Network and thereby steering the strategic orientation 
of the cooperation. By means of this network, preparatory studies have been paving the way 
for a new Regulatory proposal of the Commission based on Internal Market principles and 
thereby potentially changing the nature of the cooperation initiatives.
In the next section we will examine how these policy-formulation processes have impacted 
the next stage of the policy-cycle: decision-making. We will first analyse the governance and 
decision-making processes in EUnetHTA before we turn to the EU (institutional) level. Specific 
attention will be given to the role of stakeholders and how they have been able to influence 
the overall process of European HTA cooperation.
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6.3. DeciSioN-makiNg iN europeaN hta cooperatioN
6.3.1. Decision-making in the EUnetHTA network
In chapter 4 we have outlined how the decision-making phase of the policy cycle refers to 
the stage in which one or more (or non) of the policy alternatives envisaged in the previous 
stages are adopted as the official course of action (Howlett, Ramesh and Perl 2009: 139). As 
an inherently political process, it involves key-actors which will have an impact on the final 
choices. The outcome of this stage is the object of the next stage: policy implementation. 
Beliefs and values of actors, the nature of the relevant subsystem and existing constraints, 
can all affect the decision-making process. Different theoretical models exist to conceptualise 
decision-making processes underscoring either the role of rationality (e.g. rational model), 
bargaining and negotiation (e.g. the incremental model), or conversely irrationality and 
unpredictability (e.g. ‘garbage can’ model) (see further Howlett, Ramesh and Perl 2009). 
Decisions do not take place in a single institution nor at a single point of time (Weiss 1980: 
399-401) and can be taken over a period of time at multiple levels and by multiple factors 
(see further e.g. Klijn 2001; Timmermans 2001). Finally, several decision-making processes 
can occur simultaneously and can mutually influence each other as well as actors’ positions 
on an issue (see further e.g. Klijn and Kloppenjan 2000, Howlett 2007, Howlett et al. 2009).
6.3.1.1. Decision-making in the EUnetHTA project
The governance structure of the EUnetHTA project (2008-2010) closely followed the recom-
mendations made by the ECHTA-ECAHI project. This is being confirmed by the final technical 
report of the EUnetHTA project which states that:
“The European Commission has funded three major projects over 1994 – 2002 that sought 
to support collaboration on HTA methods and working: EUR-ASSESS, HTA-Europe and 
ECHTA/ECAHI. The later projects stressed the need for a permanent structure to support 
HTA coordination in Europe to avoid duplication, maximise scarce resources, strengthen HTA 
in Member States and ultimately contribute to the better health of all European citizens. It 
was proposed that the structure to support HTA coordination should include all Members 
States via a Steering Committee, with an administrative group to support the activities of 
the network, mechanisms to involve relevant European expertise and funding support” 
(EUnetHTA 2009:2).
The governance structure of the EUnetHTA network in the 2008-2010 project still underwent 
influence from its project-based funding basis. The contract signed within the framework 
of the EU public health program required that a main partner would be responsible for the 
project. The National Board of Health of Denmark (the Danish representative in the HLG) 
‘naturally’ took this position. It was joint by 33 Associated Partners who all co-funded the 
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Project (and received funding for their activities) and 24 Collaborating Partners representing 
regional and national HTA agencies, research institutions and relevant international organisa-
tions (at the end of the project 6 other organisations joint the initiative). Ministries of Health 
in Member States, not involved in the Project, were however kept informed of progress. In 
total, the EUnetHTA project involved from 64 organisations in 33 countries, including some 
countries outside Europe154 (EUnetHTA 2009: 20-21; see also Annex 1).
In May 2006, a Standard Operating Procedure had been adopted and regulated the gover-
nance and management of the project. Comparing the governance structure proposed in 
this SOP to the one proposed in the ECHTA/ECAHI project brings to the fore many similarities:
Table 6.4. Comparison governance structures ECHTA/ECHAI project and EUnetHTA project
As in the early European HTA cooperation projects, the structure included a Steering Com-
mittee and an Executive Committee. The Steering Committee included one representative 
from each Associated Partner organisation and was chaired by the Director of the Main 
Partner (Project Leader). It was responsible for the strategic orientation of the project. The 
Steering Committee met only at the start and closure of project. The last meeting served also 
to prepare the post-2008 EUnetHTA activities (EUnetHTA 2009). The Executive Committee 
included the Main partner and Work Package Lead Partners. Its role focused on the delivery 
of the project. It was responsible for reporting the project activities to DG SANCO by issuing 
yearly technical reports. The Secretariat was hosted by the main partner and ensured daily 
work and coordination the activities between the different working groups.
As in the previous projects, the project structure was divided in Working Groups, each 
responsible for achieving one of the sub-objectives defi ned (see next section). The Working 
Groups were headed by so-called ‘Lead Partners’ (LP), some Working Groups having 2 Lead 
154 i.e. Canada, Australia, USA and Israel (EUnetHTA 2009: 21).
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Partners as the work in these WP was divided in two streams (WP2 and WP7). Lead partners 
were responsible to direct and oversee the work of each Working Group. The EUnetHTA 
governance approach was based on a soft governance principles as participation remained 
voluntary and regarded mostly interaction between HTA agencies, hence peers. The structure 
established since the EUnetHTA project sought to enable the researchers – the HTA doers – to 
do their work “whilst bringing the results into the policy-processes and being sustainable 
despite the project solution to make it happen. That has been quite a challenge!” (Personal 
interview 4).
The European Commission, playing only a role as a funding organism, did not have any 
formal role in the governance and management of the project. However, based on the 
contract, regular updates regarding the progress of the project were given to DG SANCO 
as well as to the HLG on Health Services and Medical Care (EUnetHTA 2009: 5). Similarly, 
no formal role was given to key stakeholders showing interest for the project (e.g. policy 
makers, patients health care professionals, and health technology manufacturers). However, 
the project started to establish contacts with these organisations and refl ections about their 
role in the network did take place and further developed in the establishment of dedicated 
structures.
As such, in 2008, a Stakeholder Forum has been established and the outcome of the fi rst 
discussions regarding their role in the cooperation initiatives did have an infl uence on post-
2008 EUnetHTA activities155 where stakeholder involvement will become more signifi cant. 
Although still rather closed in terms of membership, the EUnetHTA project responded 
however to some form of transparency in the sense that non-partners could have access 
to information published on the EUnetHTA public website (the organisation had also setup 
an intranet, only accessible for partner organisations) and subscribe to regular updates (EU-
netHTA 2009: 5). Some validation or commenting processes regarding project deliverables 
would also be open to stakeholders.
It is important to keep in mind that the project pursued two main strategic objectives: 
establishing a sustainable network of HTA cooperation in Europe and developing tools 
and information systems permitting to deliver common core HTAs as input for national 
decision-making processes. Although related, both objectives require a distinct governance 
approach. Besides the repartition of the topics addressed in the Working Groups (network 
development: WP1,2,3 and Tools and information systems: WP4,5,6,7), it is not clear how 
155 The opinions of the stakeholder forum will be included in a ‘topic catalogue’ for post 2008 project 
and which was being discussed during the last meeting of the Steering Committee of the EU-
netHTA project. (EUnetHTA 2009).
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this has been organised within the other governance bodies. The monthly meetings of the 
Executive Committee had to ensure the timely delivery of the project outputs and the coher-
ence between the work implemented in the different subgroups as sometimes coordination 
problems between subgroups could occur (EUnetHTA 2009). It seems that attention was 
primarily focused on the development and implementation of tools and methodologies.
The EUnetHTA project has been governed based on self-management with reporting ob-
ligations towards the European Commission. Strong ties also still existed with the HLG on 
health services and medical care. It is interesting to notice that in a contribution to a public 
consultation process launched by DG SANCO, the coordinator of the EUnetHTA project un-
derscores that “the ‘open method of coordination’ for healthcare and long-term care should 
be the non-legislative tool for the High Level Group on health services and medical care to 
continue developing the mechanisms for practical cooperation on HTA. (…) Concomitant to 
using the open method of coordination to develop the Network further into a committed 
collaboration, legal certainty of such collaboration should be provided” (EUnetHTA 2007). 
This statement indicates that although soft governance mechanisms, such as the OMC, seem 
to be an instrument of choice for setting up HTA collaboration in Europe, it does not deliver 
legal certainty this cooperation structure would require. We will see that this remains a point 
of concern in all subsequent collaboration projects. In the next section we will examine to 
what extent governance structures have developed in the EUnetHTA Joint Actions and in 
which manner this has affected decision-making processes. Special attention will be given to 
the role of stakeholders in this process.
6.3.1.2. Decision-making in the EUnetHTA Joint Actions
6.3.1.2.1. The principle EUnetHTA governance bodies
The EUnetHTA Collaboration was established in November 2008 by 25 founding partners 
from 13 EU MS, Norway, and Switzerland. The aim of this project was to take forward the 
Joint Action process between the Member States and the Commission. For this purpose, 
governance guiding principles have been adopted for the period covering the EUnetHTA Col-
laboration and the future JA1. These guiding principles have been endorsed by the EUnetHTA 
Plenary Assembly in December 2009 (EUnetHTA 2009a). The principles outlined different 
categories of participants: EUnetHTA Collaboration Partners156, EUnetHTA Collaboration 
156 Founding partners (having signed intent to establish the collaboration) and other publicly funded 
HTA organisations nominated by the respective Ministries of health (EUnetHTA 2009a).
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Associates157, Lead Partners158. The Coordinator of the EUnetHTA Collaboration and the first 
Joint Action was, as in the EUnetHTA project, the National Board of Health of Denmark.
A new Consortium Agreement will be integrated in the grant application for the Joint Action 
2. The purpose of this agreement was to facilitate the implementation of the JA 2 as defined 
in the grant agreement and to coordinate the interactions between the Partners appointed 
by the Ministries of Health. This document allowed to lay down the legal responsibilities of 
the partners and define the terms of their engagement and the consequences in case of a 
breach to these engagements. In other terms, it regarded the responsibility of the partners 
towards EUnetHTA (Personal interview 4; EUnetHTA 2012).
No major changes were introduced in this document compared to the governing prin-
ciples defined for the JA1. Amendments mainly regarded the rights of partners and the 
organigramme which had been simplified. Finally, some changes regarded the potential 
membership of founding EUnetHTA collaboration partners in the Plenary Assembly which 
replaced the Steering committee of the EUnetHTA project but also fulfilled the role of main 
governance and policy-setting body of the JA (EUnetHTA 2012: 12; EUnetHTA 2013: 6). 
Indeed, according to the project coordinators “you need to have a body that has the primary 
responsibility for strategy and policy and the direction you want to go as the consortium” 
(Personal interview 4).
Although this agreement was important for the governance structure of the Joint Action, it 
was the Grant Agreement with the Commission which was governing the relations between 
the Consortium (EUnetHTA as a whole) and the Commission (Personal Interview 4; personal 
correspondence, July 2016). The EUnetHTA Coordinator being the single point of contact 
between the Commission and the Consortium (EUnetHTA 2012: 13).
As only candidate, Denmark was being elected as coordinator for the second Joint Action 
on HTA. The Governance bodies remained the same as in JA1. During the preparatory phase 
of the JA2, the Commission had indicated its wish to have a formal position in the Execu-
tive Committee. It also expressed it desire to establish a more formal cooperation with the 
EMA and other EU institutions and networks of relevance (EUnetHTA 2011b). The adopted 
157 Nonprofit organisations producing or contributing to HTA and willing to be actively involved. 
Status is granted by executive committee and confirmed yearly on the basis of continuous active 
input (EUnetHTA 2009a).
158 Those leading the WPs, functions. In exceptional cases Co-Lead partners (must be approved by 
Plenary assembly). The number of functions/WPs are subject to change according to the needs 
(EUnetHTA 2009a).
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Consortium agreement specifi ed that the European Commission could participate in the 
meetings of the Plenary Assembly and Executive Committee however without voting rights 
(EUnetHTA 2012). The responsibility of the JA2 implementation laid by the coordinator and 
the Executive Committee. The Lead Partners were responsible for coordinating the work in 
the Work Packages. The Stakeholder Forum provided a consultative function in the Joint 
Action 2. A specifi c Stakeholder Involvement policy would be developed accompanied by 
Standard Operating Procedures which would guide the interaction with the stakeholders 
during the Joint Action 2 (EUnetHTA 2012: 14)
Table 6.5. Governance structure Joint Actions
The governance structure of the Joint Actions followed a similar structure as in the EUnetHTA 
project with a Plenary Assembly, as principle policy setting body, replacing herewith the Steer-
ing Committee in the EUnetHTA project; an Executive committee as strategic leadership/main 
executive body and a secretariat having the operational leadership. The Plenary Assembly 
(PA) was composed of the Head of each partner organisations (or its representative). Its 
Chair was elected by the members of the PA by absolute majority for 2 years and maximum 
2 terms. Lead Partners and Co-Lead Partners were not eligible for this position. As outlined 
above, the European Commission could participate in the meetings but had no voting rights. 
Decisions were taken by a majority vote of PA members, in case of ties, the decision of 
the chair would prevail. The Assembly met once a year. Extraordinary meetings could be 
convened on the basis of recommendations of the Executive Committee (EC) or on request 
of a minimum of one-third of the PA members.
The Chair was responsible for ensuring the liaison between the PA and Executive Committee. 
He was also as a non-voting member of the EC. The election of the Chair would take place 
by secret ballot with an absolute majority rule. The same would apply for the election of the 
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deputy chair (EUnetHTA 2009a). Whilst in the Joint Action 1 and 2, decisions would still be 
taken by the Plenary Assembly as the “principle governing body” (EUnetHTA 2012: 12), the 
role of the latter has changed in the Joint Action 3 where meetings became “mainly informa-
tive” (Personal Interview 30). This seems to be a direct consequence of the changing role of 
EUnetHTA since the setup of the EU HTA Network who would steer the policy orientation of 
HTA cooperation in Europe.
Another body having impact on the EUnetHTA course of actions was the Executive Com-
mittee (EC) composed of Lead Partners. Whilst the Plenary Assembly was conceived as the 
policy-making body, defining the implementation strategy would fall under the responsibili-
ties of the EC. This body was responsible for coordinating the activities, implementing the 
policy decisions and managing the affairs of the project. It was composed of representatives 
of the Lead Partners (LP), representatives of the Secretariat, three representatives of partner 
organisations (not being LP) and the chair of the Plenary Assembly (having no voting rights). 
Moreover, there could not be more than two partners from the same country. Members 
would be elected for one year and maximum two terms. This would, however, not apply for 
Lead Partners which could serve three years. The EC would be also responsible for supervis-
ing the Secretariat. The chair would be appointed by the members of the EC. They would 
meet every month, either face-to-face or by means of web-based conferences. All reports of 
the EC were made available to the partners. The EC would have the final decision-making 
power in case of difficulties encountered in a Work Package and if no solution would have 
been found by the Secretariat. If the EC could not resolve the problem, the Plenary Assembly 
would have to be involved (EUnetHTA 2009a).
Whilst the Plenary Assembly comprised all members, including members which did not 
demonstrate a high involvement in EUnetHTA, the members sitting on the Executive Com-
mittee would manifest a bigger involvement and also have a better access to information 
(Personal interview 30).The weight and role of these partners in the decisions of the EC 
could however vary according to their size and weight in national decision-making struc-
tures and their personal investment in EUnetHTA activities. This influence would however 
not necessarily translate the weight of EUnetHTA’s work in national agencies or national 
decision-making processes. Often, the opposite could be observed. As such, big national 
organisations could send middle-staff representatives to EUnetHTA. Although, their personal 
investment and competence could be of the highest level, and despite attempts to inform 
their ‘home-organisations’ about EUnetHTA’s activities, many acknowledged that few of 
their national colleagues would be aware of the European cooperation efforts (Personal 
interviews 1,14,18, 19, 20, 24, 25 27).
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Conversely, small HTA agencies would often send their top-ranking representatives to EU-
netHTA who would be more likely to translate EUnetHTA activities in the agency’s national 
activities and thus increasing the potential to have an impact on the national decision-making 
processes. Hence, although EUnetHTA represented an important activity for its members who 
would invest a significant amount of time and energy in it, the EUnetHTA activities would not 
always receive sufficient attention in the respective ‘home-organisations’ to impact national 
decision-making processes. (e.g. Personal interviews 1,14,18,19, 20, 24, 25 ,27).
The Secretariat in the EUnetHTA Joint Actions 1 and 2 was composed of a Secretariat Direc-
tor, a Secretariat Manager and staff members. It could not represent more than two partners 
from the same country. The secretariat would be bounded by the legal requirements of the 
Joint Actions. Its work would be led by the Director who would work under supervision of the 
European Commission. The Director would be co-responsible with the European Commission 
of implementing the policy decisions. He would act as facilitator of close coordination with 
the Work Packages with an emphasis on content matters. He would also be responsible for 
the external promotion of the project and could act on behalf of EUnetHTA, with however the 
obligation to report to the European Commission on major issues. The Secretariat Manager 
would be responsible for the coordination of the work of the Secretariat and the day-today 
management (EUnetHTA 2009a).
Compared to the early European cooperation initiatives, the governance of the EUnetHTA 
network was in particular marked by the role of the secretariat who became in practice 
the “other executive body” and had a preponderant role in the running of the network. 
As underscored by an EUnetHTA representative, the secretariat was the “operational heart, 
brain hands, legs and everything needed to make sure that is operationally, it’s impeccable 
because of many reasons. It is a big network, it is a complex matter. It is not only technical 
scientific, it is related to other policy processes, so this body needs to have the capability and 
competence that would have both understanding of the technical matter and HTA as such, 
the understanding of the policy processes, the understanding of management and organi-
sational structures and the tools and solutions that would be most effective to support the 
activities and keeping it not only functioning but progressing and making sure that we are 
meeting our own milestones, deliverables and keeping people on the project management 
road” (Personal interview 4). The secretariat was located in the Danish Health Authority from 
the EUnetHTA project till the Joint Action 3 when it has been relocated to the Zorginstituut 
Nederland, located in the Netherlands.
According to some members the relocation of the EUnetHTA secretariat also represented 
a governance shift: “The Danish secretariat was soft coordination rather than leadership. 
Now in the Netherlands, the secretariat has called themselves ‘Directorate’. It is maybe only 
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a name, but at the other hand, it may be understood as taking leadership”. Indeed, when 
taking over the network coordination, the Zorginstituut (ZIN) had decided to establish a 
Directorate composed of two entities: a Director’s office responsible for the daily work of 
the EUnetHTA’s Director and a Secretariat which would manage the EUnetHTA activities, 
the cross Work Package activities as well as the governance and activities of other bodies of 
the Consortium (EUnetHTA 2018:7). The Director, a ZIN representative, had previously been 
involved in EUnetHTA. He would be assisted by a project manager which for the first time 
in the EUnetHTA history would have no previous ties with HTA nor with EUnetHTA (www.
eunethta.com, personal interview 15).
Others also perceived a shift from a more horizontal governance approach to top-down 
leadership: “Very nicely they tell us, this is how things will be done now”; “(…) as of today, 
this is how it has to be done” (Personal interviews 12, 30). Moreover, the organisational 
structure on the renewed EUnetHTA website during the third Joint Action presents the 
organisational and governance structure by highlighting only the Executive Board and the 
Secretariat (https://www.eunethta.eu/about-eunethta/organisation/). Hence, the Danish 
secretariat would be considered by the members as operating through soft governance – co-
ordination – means. The Dutch secretariat would be perceived by applying a more top-down, 
hierarchical approach. This shift of governance methods could partly be explained by the 
changing nature of EUnetHTA in the Joint Action 3 where it became the technical and scien-
tific arm of the EU HTA Network working with an agenda decided by an “external” network 
and operating under its supervision. We have seen in this section how the nature and role 
of some governance bodies has changed in the course of the Joint Actions impacting the 
governance structure and decision-making processes. The same can be identified regarding 
the role of stakeholders in EUnetHTA, as we will outline in the next section.
6.3.1.2.2. Stakeholder involvement in EUnetHTA
A new body officially set up since the EUnetHTA Collaboration has been the Stakeholder 
Forum, established in 2010 and which was part of the governance structure of the JA. 
Stakeholder involvement marks a clear difference in governance structure of the Joint 
Actions compared to the early cooperation projects in which this was completely absent 
(Personal interview 10). The idea to extend the network to stakeholder groups entered the 
discussions of the EUnetHTA project in 2006. However, it took several years before a formal 
representative stakeholder body has been integrated in the governance structure of the first 
Joint Action (Personal interview 4). Indeed, since 2006, stakeholder groups themselves have 
started lobby activities to participate in the HTA cooperation activities. Often their efforts 
were backed by the European Commission considering their participation as important 
and seeking to include stakeholder participation in the governance structures of EUnetHTA 
(Personal interviews e.g. 4, 8, 12, 13, 15, 18, 20, 24).
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With the establishment of the Stakeholder Forum, the aim was to facilitate information ex-
change with stakeholders who could also participate in the Plenary Assembly meetings (EU-
netHTA 2013:6). The Stakeholder Forum would be composed of representatives of European 
Umbrella organisations (Policymakers (regional/national/hospital level), Patient organisations, 
Health care professionals, Payers, Industry). The participants of the Stakeholder Forum had 
to be invited by the Executive committee which also developed and applied the Stakeholder 
membership criteria. Members could hold their position for 3 years. Final decisions on issues 
regarding stakeholder involvement could only be taken by the Plenary assembly.
Integrating stakeholders in the work of EUnetHTA was however a challenging exercise as 
opinions diverged among members on the necessity and the practicalities of a stakeholder 
policy. “One of the big issues of the beginning were also the stakeholders. The industry, how 
would they be represented (…) but also the doctors, health care providers, that was kind 
of a tricky one” (Personal interview 8). Often positions regarding the role of stakeholders 
in HTA, reflected national practices. Some countries having legally organised stakeholder 
consultation/participation in HTA, others lacking any experiences with the latter. Sometimes 
stakeholder participation would not necessarily be legally organised but a pragmatic ap-
proach towards their inclusion at some stage of the HTA process would nevertheless be 
adopted. In other countries, the inclusion of stakeholders would be accepted but regarded 
as a “necessary evil” (Personal interviews e.g. 1, 12, 22, 23).
According to some observers, views on stakeholder participation in HTA processes also 
depends on the perspective one takes on a medicine/medical device: economic or public 
health. As such, one could consider a drug or medical device as a stronghold of economic 
growth, or one could view it as an essential element in public health (Personal interviews 
11, 20). From a public health perspective, the role of stakeholders is often considered to be 
mostly informative. In this regard, industry would be offering the data allowing the scientists 
to analyse it independently. Similarly, patient representatives could inform assessors about 
(medical) priorities that, according to them, should be taken into account in the market ac-
cess, pricing and reimbursement processes of health technologies. Having the industry indi-
cating its priorities (from a profit-making perspective) would, however, fall into the economic 
perspective of stakeholder participation in the development of a new health technology. 
Hence, either a health technology is being considered as serving economic development or it 
is being regarded as serving public health. Whilst both perspectives are fully legitimate, they 
do reflect very different perspectives. “But when you start mixing both, you get what we see 
now. (…). The multinationals increasingly dominate the economic reality and Europe has to, 
wants to follow that” (Personal interview 20).
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It is not clear which perspective has been adopted in the EUnetHTA Joint Actions as both 
have been present to a certain extent. Although an official stakeholder policy and Standard 
Operating Procedures had been developed, informally, there was an ongoing debate among 
the members to what extent stakeholders should participate in the process. As outlined 
above, individual positions often reflected national practices and cultural backgrounds. 
Finding a common ground on the issue remained challenging, some countries insisting on 
stakeholder participation in the HTA process (e.g. Austria, Great Britain) others being much 
more reluctant to that (e.g. Germany) (e.g. Personal interview 12, 23). Moreover, besides 
defining the role of the stakeholders and whether their inclusion should be for informative or 
collaborative purposes, some also brought to the fore that stakeholder participation would 
require the need for expertise, both on the side of the stakeholders as on the side of the 
agencies: “you need the right people who can engage in an in-depth dialogue. People who 
do not only have an academic mindset but who can also operate in a general dialogue. Not 
everybody is capable of doing that” (Personal interview 23).
To some, stakeholder representation hasn’t been equal in the EUnetHTA Joint Actions. The 
industry is often mentioned as the stakeholder group being the most influential in EUnetHTA 
decisions or strategic orientations, followed by the patients’ representatives. However, the 
role of industry participation in HTA assessment triggered a variety of reactions. Some would 
argue that as technology developers, they should be involved in the assessment process or at 
least keep an open dialogue with them. Moreover, including the industry to some extent in 
the assessment process would allow for a better acceptance of the assessment outcomes by 
the industry. Others, on the contrary, considered that being the manufacturer, the industry 
would have a conflict of interest and should therefore not be involved in the process so as to 
avoid bias in the assessments (e.g. Personal interviews 15, 23).
Health care providers and payers often underscore the little impact they have had on the 
EUnetHTA assessment processes (e.g. Personal interviews 12, 13, 20, 21, 24). Payers for 
example have stressed their desire to become more involved in the HTA processes in par-
ticular regarding issues such as the prioritisation of drugs eligible for assessments. They also 
underscored that their input could be of use to assess data and methodologies used in 
clinical studies (e.g. Clinical endpoints, surrogate end points, real world evidence collection 
etc.) as this would be taken into account in cost-effectiveness processes at a later stage. 
Moreover, inclusion of payers, has sometimes be considered a mean to access large (pay-
ers’) datasets which could potentially be of use for HTA assessments (Personal interview 13, 
personal observations debates EUnetHTA Forum 2018).
Although involved, to a certain extent, in assessments in Joint Action 2, the patient stake-
holder group representatives also called for an increased and more structured participation 
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in the EUnetHTA network especially in the Joint Action 3: “During the Joint Action 2, patient 
participation was organised in a more intelligent and more interesting manner than today as 
there was a real willingness on behalf of EUnetHTA to organise things by reflecting upon that 
on a European level. With the third Joint Action, we have fallen back at the national level and 
every agency does things the way it is used to on a national level” (Personal interview 12).
Indeed, whilst in the Joint Action 2, stakeholders benefited from an observer status in the 
Plenary Assembly of EUnetHTA and played a role in assessment processes, this ceased to 
be the case in the last Joint Action. As a consequence of the setup of the Stakeholder Pool 
in the EU HTA Network which led to the dissolution of the EUnetHTA Stakeholder Forum, 
stakeholder participation has been altered in the EUnetHTA Join Actions 3. According to 
patient representatives, as no specific governance process had been foreseen, conversely 
to the former Joint Action, patient participation became often organised at a local level by 
the agencies in charge of the assessments. However, lacking the experience of the coordi-
nated action in the JA2, patient participation (identifying qualified persons, dealing with the 
logistics of participation, reimbursements etc.) became often burdensome to local agencies 
which, instead of turning towards the European level (e.g. European umbrella organisations), 
organised stakeholder participation on a national basis applying the rules, habits and experi-
ences of the agency’s home-country (Personal interview 12).
Hence, with the launch of the Stakeholder Pool in the EU HTA network, the role of stake-
holders in the Joint Action 3 became again an issue of debate. Whilst in Joint Action 2, 
stakeholders had a say through the Stakeholder Forum and the Stakeholder Advisory Groups 
(SAG), this has changed in Joint Action 3, where stakeholders were only officially represented 
in the Stakeholder Pool of the EU HTA Network. Many stakeholders however pointed to the 
differences regarding the role and functioning of both structures. In the Joint Action 2, the 
Stakeholder Forum could appoint representatives to the SAGs who could provide advice 
on technical issues. Specific processes had been developed permitting to install dialogue 
and cooperation with stakeholders leading in some cases also to stakeholder consultation 
(Personal interview 1, 18, 23).
Even though this approach could, according to some, be improved, it seemed to have been 
preferred over the functioning of the Stakeholder Pool established by the European Com-
mission in the framework of the EU HTA Network (e.g. Personal interview 12, 18). “The 
stakeholder pool stems from the European Commission in the framework of the multiannual 
HTA Network. EUnetHTA consults the stakeholder pool in an opportunistic manner. It could 
very well consult other organisations, but it has abolished every structure that would permit 
it to interact with the interested parties as it has done so in the past: the industry, the [health 
care] professionals, the payers, the patients. There isn’t a structure anymore which allows 
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for this interaction, so now it happens in an anecdotal manner” (Personal interview 12). 
“Some expert meetings have been established [in Joint Action 2] allowing for dialogue, but 
unfortunately that has been completely scaled back in Joint Action 3 where there is thus no 
Stakeholder Forum anymore and where it is up to the work packages themselves to decide 
whether one want to establish a stakeholder consultation or not” (Personal interview 23).
Although several representatives of stakeholder groups have indicated to have discussed 
stakeholder participation with EUnetHTA before the launch of Joint Action 3, at mid-term 
of this project, many were dissatisfied and had the impression that the governance structure 
put in place did not allow for much interaction and cooperation with the stakeholders, as 
it had been in the past. The annual EUnetHTA conferences and the EU HTA Stakeholder 
Pool did not replace the Stakeholder Forum that existed before and which allowed a more 
continuous dialogue with the stakeholders (e.g. Personal interviews 12,13, 21, 24, 25). “The 
involvement of the members of our organisation to EUnetHTA’s work is at present – I assure 
you - zero. And this becomes a bit frustrating because, I believe they have started some 
two and a half years ago” (Personal interview 13). Some have the impression that attention 
to stakeholders is only given at time of the annual EUnetHTA conference, but that a real 
strategy towards stakeholder participation is still lacking.
The project-based approach has been brought to the fore as the underlying reason for the 
latter. As every three year a new Joint Action had to be developed developing new strategies 
etc., stakeholder participation could not be expected to be the top priority of project leaders 
(e.g. Personal interview 24). This is indeed also underscored by an EUnetHTA representa-
tive explaining how things changed with the Joint Action 3 where, besides the setup of a 
new project, there was a clear distinction established between strategy at the political level 
through EU HTA Network and the technical and production side through EUnetHTA. “The 
Stakeholder pool of the HTA Network was meant to be a resource, a pool for anything 
related to policy strategy and inclusion of stakeholders within HTA as such (…) There is a 
long period in which all partners needed to find their individual new roles. But also, we had 
to adapt to the very fast pace changing environment where we had to take up suggestions 
that were left to us from Joint Action 2, we had to look into suggestions we received from 
stakeholders, industry and patients. We needed to understand how can we include them, 
are there realistic processes? All these considerations we had to them take up and now we 
are trying to go one step at a time towards the stakeholders and see how we can find models 
that are stable on both sides” (Personal interview 15).
Indeed, the establishment of the stakeholder pool did influence the overall attitude towards 
stakeholder participation in HTA which was not only debated in the European HTA coopera-
tion process but was also a topic of debate in other HTA networks (e.g. HTAi). Although 
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the new EU HTA network does foresee an official body for stakeholder representation by 
means of the Stakeholder pool, in practice the influence of stakeholders on the strategic 
orientation of the network seems to be limited. In a typical EU HTA Network meeting, two 
representatives of the different stakeholder groups (payers, patients, industry and healthcare 
providers) would be invited to join the afternoon session. Each having five to ten minutes 
presentation time. This contrasts with the EUnetHTA Stakeholder Forum which would last a 
full day and was open to a bigger amount of stakeholder representatives. Hence stakeholder 
participation in the EU HTA Network is considered to be limited to informative purposes 
rather than being open to participatory purposes as had been the case in the EUnetHTA Joint 
Action 2 (Personal interview 21, 22, 23). “With time we have seen the process move from 
establishing a closer dialogue to a more closed doors policy where during the biggest part 
of the meeting the Member States debate internally with the Commission. At the end of the 
meeting a few updates will be given to stakeholders informing as such the Stakeholder Pool” 
(Personal Interview 23).
Despite some critical remarks on behalf of the stakeholder representatives, from the point of 
view of some HTA agencies, stakeholders have been well integrated both in the governance 
structures as in the different HTA assessments. The changes operated in the JA3 were consid-
ered to be beneficial for stakeholder involvement in EUnetHTA. Some agencies believed that 
the changes operated since the Joint Action 3 had actually improved the situation compared 
to the Joint Action 2: “This forum was considered not very successful since EUnetHTA re-
ceived little input from stakeholders. Also, the public consultations proved not valuable. 
Therefore, in JA3 EUnetHTA aimed for different involvement processes for stakeholders” 
(Written contribution 1, see also e.g. personal interview 28). This position contrasts with 
the one from the stakeholders who often believed more could have been done to include 
them better: “I think that we could have hoped for a much more developed stakeholder 
involvement after ten years of European collaboration” (Personal interview 24).
Hence, since the introduction of a dedicated stakeholder policy in EUnetHTA, the role of 
stakeholders has initially developed into a more inclusive approach, though no consensus 
existed on what should be their exact role and degree of participation in HTA processes. 
With the establishment of a new Stakeholder Pool by the EU HTA Network, the position 
of stakeholders in EUnetHTA as well as on the EU level has been restructured still failing to 
reach consensus on the matter. Indeed, different approaches regarding stakeholder involve-
ment continued to be displayed between HTA bodies and amongst the stakeholder groups 
themselves. Stakeholder involvement remained a topic of debate which has also played a role 
in the Commission proposal for a Regulation on HTA cooperation in Europe. The next section 
will outline how decision-making has been taken place at the EU level and how it has been 
envisaged in the Regulation proposal.
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6.3.2. Decision-making in the EU setting
With the Cross-Border Health Care (CBHC) Directive, the European Commission receives an 
official mandate to coordinate HTA cooperation in Europe. The governance structure of the 
newly established EU HTA Network has been laid down in the implementing decision of July 
2013 (OJEU 2013). It specifies first that “Members of the HTA Network shall be national 
authorities or bodies responsible for HTA designated by the participating Member”. Member 
States may also designate an expert to accompany the Member (this will be later extended 
to more than one). The Network will operate on the basis of the adopted Multiannual Work 
Programme (MWP) and will be supported in this by a scientific and technical cooperation. 
Working groups can be setup to examine specific questions and shall be disbanded as soon 
as their mandated is fulfilled (European Commission 2016b).
The EU HTA Network is chaired by a Commission representative, which will have no voting 
rights. Other Commission officials having interest in the proceedings may also attend meet-
ings and working groups of the Network. Participation of the European Medicines Agency is 
possible upon request of the Commission. Other European and international organisations 
can also be invited to attend the meetings as observers. The Commission provides the secre-
tariat of the HTA Network. The latter is responsible for drafting the agenda of the meetings 
which should be in line with the MWP adopted by the Network. Proposals can be made in 
this regard by Network Members, observers and the scientific and technical cooperation 
mechanism (European Commission 2016b).
From the start - and basing itself on the Article 15 of the CBHC Directive - the Commission 
insists on the importance of associating stakeholders to the HTA Network. At first, the HTA 
Network will rely on the Stakeholder Forum of EUnetHTA. However, in 2016, the involvement 
of stakeholders in the Network would not be based anymore on the technical mechanisms 
provided by the JA2 but on a Stakeholder Pool composed of representatives of different 
stakeholder groups who would receive an ‘observer’ status. The same status is given to 
European and international organisations whose activities would be relevant to the Network. 
Similarly, competent HTA Authorities of EEA/EFTA countries and of accession countries could 
participate in the meetings as observers without voting rights. EUnetHTA, as the scientific 
and technical cooperation mechanism would also be considered as a ‘third party’ which 
would be invited to attend the meetings but without holding voting rights (European Com-
mission 2016b).
The decision-making procedure will run “as far as possible” by consensus (European Com-
mission 2016a). A vote should be taken only if a Network Member requests so. In that 
case a majority of two-thirds of the Network’s Members present at the start of the vote 
would be needed to adopt a decision. Each Member State would have one vote. In normal 
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circumstances, decisions of the HTA Network would be made public. In some cases, deci-
sions could be kept confidential or could be subject to explicit public consultation (European 
Commission 2016b).
The EU HTA Network would develop as an entity working at a senior policy level and which 
main aim would be to gather policy makers to discuss the course of the European HTA 
cooperation process. This approach would differ fundamentally from the governance struc-
ture in the EUnetHTA projects represented mostly by HTA agencies. The underlying idea 
behind this approach would be to improve and facilitate uptake of joint work in the Member 
States. Indeed, by including national representatives of ministries of health, is was hoped 
that input of European HTA into national decision-making processes could be increased. As 
underscored by a Commission representative: “This network was a mean to translate this 
discussion from a technical to a strategic level” (Personal interview 8).
The strategic objectives were not anymore only defined by HTA agencies cooperating in EU-
netHTA but could be officially endorsed by the Health Ministries. The new EU HTA Network 
changed thus the governance approach from a bottom-up policy-making approach to a 
mixed model. If before, EUnetHTA members needed to advocate about their work in their 
local settings, in the new governance structure of the EU HTA Network they needed to follow 
the line established by their senior policy makers. Hence, even if the input which laid at the 
basis of the strategic orientation of the HTA Network would stem from the work established 
by EUnetHTA and the precedent projects, the HTA Network turned around the policy-making 
structure by laying the strategic orientation of European HTA collaboration in the hands of 
national policy-makers.
Another fundamental difference with the governance processes in EUnetHTA is the oppor-
tunity created by this new network to establish formal cooperation mechanisms between 
different networks from the EU. We have seen above how the Commission would refer to 
work established by networks or bodies such as the EMA, the reflection process on safe and 
timely access to medicinal products (STAMP), the MAST assessment model for telemedicine 
and eHealth, the Network of Competent Authorities responsible for Pricing and Reimburse-
ment (NCAPR), the Pharmaceutical Committee and the Council reflection process under the 
Working Party at Senior level on Public Health (European Commission 2013a; 2014a; 2014b; 
2015a). Chairing the meetings of the HTA Network and being in charge of the agenda, 
the Commission would be in a position where it could steer the activities of the EU HTA 
Network by ensuring coherence and consistency across the different initiatives related to 
HTA in Europe.
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In terms of governance, it is interesting to see how the Commission proposal for a Regula-
tion submitted in January 2018, considered the EU HTA Network as a transition body to 
prepare the ground for a more permanent structure coordinating HTA cooperation in Europe. 
Indeed, if adopted, the Regulation would allow for the establishment of a Member State-led 
coordination body which would govern the future sustainable European HTA cooperation 
structure (European Commission 2018). In the various consultation processes and Impact 
Assessments, different governance structures had been proposed regarding the future HTA 
collaboration. As such in the public consultation, the following options had been presented 
as to which structure could govern the collaboration 1) the European Commission 2) an exist-
ing EU agency 3) A new EU agency 4) Member States HTA bodies functioning on a rotational 
basis (5) Other. The first two options were considered the most preferable and corresponded 
to the outcome of a previously held online survey (European Commission 2017:122).
In its proposal for a Regulation, the Commission has opted for the establishment of the 
Coordination group which would be hosted in the premises of the European Commis-
sion. Moreover, the proposal outlines that the Coordination group would be composed of 
members designated by Member States and would represent their national authorities and 
bodies responsible for HTA. Member States would be allowed to designate more than one 
authority or body responsible for HTA as members of the Coordination group (Art. 3.1). 
The Coordination group would act by consensus, or where necessary by simple majority 
(Art. 3.3). It would be co-chaired by the European Commission and a chair elected by the 
members of the Coordination group. The rules and procedures of the Coordination group 
should be adopted by the group itself. Moreover, the Coordination group should coordinate 
and approve the work of the sub-groups which it should establish for: 1) Joint Clinical As-
sessments; 2) Joint Scientific Assessments; 3) identification of emerging health technologies; 
4) voluntary cooperation and 5) the preparation of annual work programs and reports. The 
Coordination group should also ensure cooperation with Union level bodies to facilitate 
additional evidence generation necessary for its work and ensure appropriate stakeholder 
involvement (Art 3).
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Table 6.6. Governance structure HTA Cooperation in Commission Proposal for a Regulation on HTA 
cooperation
Source: https://ec.europa.eu/health/sites/health/fi les/technology_assessment/docs/ev_20180209_co01_
en.pdf
The proposal furthermore states that a report regarding the support framework should 
be made no more than two years after the end of the transitional period foreseen in the 
proposal. “The report may in particular consider whether there is a need to move the support 
framework to a Union agency and introduce fee-paying mechanism through which health 
technology developers would also contribute to the fi nancing of joint work” (European 
Commission 2018: 21; italics added). Hence, although initially proposing a governance body 
by means of a coordination group and functioning as a high-level Member State-led expert 
group, the Commission did foresee the possibility to transform the governing body (i.e. 
Coordination group and sub-groups) in a Union agency, such as, the EMA.
The proposal also foresees the establishment of a Stakeholder network where “suitable 
stakeholder organisations” will be selected based on criteria established in a future call for 
applications”. These stakeholders will be invited to add-hoc meetings between the Stake-
holder network and the Coordination group in order to “update stakeholders on the work of 
the group” and provide for an exchange of information. Patient and clinical experts could be 
invited to attend meetings of the Coordination group as observers. The stakeholder network 
could also support the coordination group in the identifi cation of patient and clinical exper-
tise for the work of the sub-groups (European Commission 2018: 35-36).
It is not clear whether these provisions will respond to the requests of the stakeholders 
themselves, as outlined in the section above. However, with the Regulation proposal, many 
stakeholder groups have become even more interested in taking an active part in HTA 
cooperation: “the new Regulation suddenly makes the future system very real” (Personal in-
terview 15). Since the publication of the Commission proposal, many of them have adopted 
an offi cial position on the issue and would closely follow the developments of the adoption 
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procedure. In the section on policy implementation (6.4.3.3.) we will outline the latter in 
further detail.
6.3.3. Conclusion decision-making in European HTA cooperation
The initial EUnetHTA governance structure was based on a soft governance approach as par-
ticipation remained voluntary and regarded mostly interaction between HTA agencies, hence 
peers. The structure established since the EUnetHTA project sought to enable the researchers 
to develop their work which should be used as input in national policy processes. Despite 
the project-based approach, the coordinators aimed at establishing a sustainable structure 
allowing to continue the cooperation initiatives. The EUnetHTA governance bodies served to 
enable decision-making and implementation of the project objectives. The Plenary Assembly 
was conceived to be the principle policy-setting body with the Executive Committee defining 
the strategy to achieve it. The Secretariat would ensure the coordination and smooth imple-
mentation of the work. However, despite the various roles and responsibilities given to the 
governance bodies of the EUnetHTA network, the EUnetHTA governance structure did not 
permit to reach the ultimate aim of establishing a sustainable network. It was characterised 
by a project-based governance and management system running on a time-limited basis and 
requiring a resubmission of grant applications every 3 to 4 years.
This approach was increasingly considered by EUnetHTA and the European Commission as 
inadequate to establish a sustainable network allowing sufficient production and uptake of 
joint HTA work (Personal interview 4, 8, European Commission 2016; 2017a). At first, the 
EU HTA Network, has been considered as a mean to overcome this challenge. Moreover, 
by becoming responsible for the overall policy of HTA cooperation, it took over the role of 
the EUnetHTA Plenary Assembly. The work of the EU HTA Network eventually led to the 
2018 Commission proposal for a Regulation on HTA Cooperation which even envisaged the 
abolishment of this network which should be replaced by a high-level policy governance 
structure at EU level, not excluding the establishment of a Union agency.
These developments have not occurred overnight but result from a slow but consistent pro-
cess steered by the Commission allowing it to gain increasingly control over the networks’ 
course of action. Indeed, in the first EUnetHTA project, the Commission had no formal role, 
except for controlling the funding mechanisms and ensuring the project would fulfil the 
funding requirements. This will however change with the setup of the Joint Actions where 
the Commission becomes an official partner in the process. This did not automatically lead 
to any voting rights for Commission representatives in the various EUnetHTA governance 
bodies. However, as we have seen, upon request of the Commission, in the JA2, the latter 
obtained a seat in the Executive Committee of EUnetHTA and could thus supervise the course 
of action of the network. With the setup of the EU HTA Network, the Commission became 
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also responsible for setting the agenda of the latter and coordinating the implementation 
of it through its own secretariat. As outlined above, before the establishment of the EU HTA 
Network, the EUnetHTA Plenary Assembly was the principle body responsible for setting the 
HTA cooperation policy. This role has however shifted to the EU HTA Network with EUnetHTA 
itself becoming the scientific and technical arm this network.
Similarly, the role of stakeholders has gradually developed. Increased participation of stake-
holder in the HTA cooperation initiatives had been instilled by the Commission. However, 
although stakeholder groups formally had no say in the decision-making processes, the man-
ner in which stakeholders tried to influence these processes would differ. Some, managing to 
have more influence than others. In particularly the interests of the (pharmaceutical) industry 
seems to have been protected in the preparatory process of the Commission proposal for a 
Regulation in HTA cooperation. Part of the explanation hereof lays in the fact that putting 
the proposal on an Internal Market basis was the only legal manner for the Commission 
to propose such a Regulation. However, relationships between the Commission and the 
pharmaceutical industry predates HTA cooperation and the established lobby activities of the 
latter certainly also have contributed to the fact that their interests were taken into account 
in the decision-making processes.
In the next section we will develop how decisions taken in the various fora have been 
implemented through projects and instruments developed since the EUnetHTA project till 
the Commission proposal on HTA cooperation in Europe. We will examen how these actions 
related to one another and to which extent the various frameworks in which they have 
been implemented have been helpful to reach the envisaged aims. The section will address 
both procedural instruments - related to organisation, communication, capacity-building and 
evaluation matters - as well as substantive instruments - related to joint work, uptake and 
the life-cycle approach.
6.4. policy – implemeNtatioN iN europeaN hta cooperatioN
In chapter 4, we have outlined how policy implementation concerns the stage in the policy 
cycle where decisions are translated into concrete action. This stage comprises usually more 
actors than the previous one and its outcome will depend on the knowledge and resources 
available as well as on the policy instruments chosen (Howlett and al. 2009: 160). We have 
also explained how policy-implementation in the early European HTA cooperation projects 
(i.e. EUR-ASSESS, HTA-Europe, ECHTA/ECAHI) departed somehow from typical national 
public policy implementation processes as HTA cooperation was mostly project-based and 
involved multiple levels. The choice of policy design and policy instruments in policy imple-
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mentation is not a neutral exercise. The policy-mix that will be developed on the basis of 
the instruments selected will aim to resolve the policy problem or reach the policy objective 
(Bressers, 1998; Bressers and Klok 1988).
In the following section, we will examine the policy-implementation process of the EUnetHTA 
network. Based on Howlett (2000) we will seek to distinguish in the EUnetHTA project and 
Joint actions ‘substantive’ policy instruments from ‘procedural’ instruments. Substance of the 
policy outputs can be influenced by the former whereas the latter can affect “the processes 
associated with the delivery of the outputs” (Howlett, Ramesh and Perl 2009: 169). In chapter 
3, we have outlined how the choice of policy instruments can affect behaviour, interactions 
and activities of policy actors “in developing and choosing policy solutions” (Thatcher and 
Rein, 2004 in Howlett 2018). These tools can thus affect the members participations’ in 
networks which can potentially even lead to more profound changes in a networks organi-
sational structure (2018: 82). The activities and output of the various EUnetHTA projects will 
examined in the following sections according to the following scheme:
Procedural instruments Substantive instruments
Organisation
•	 Internal	(Project	Coordination)
•	 External	(Network	development)
Joint work
•	 Methodologies/tools
•	 Joint	assessments
Communication
•	 Internal	(information	management)
•	 External	(dissemination)
Uptake
•	 Re-use	of	joint	work
•	 Impact	on	decision-making	processes
Capacity-Building
•	 Internal	(training	partners)
•	 External	(training	stakeholders)
Life-Cycle Approach
•	 Horizon	Scanning
•	 Early	Dialogues
•	 Post-Launch	Evidence	GenerationEvaluation
•	 Internal	(project	implementation)
•	 External	(Evaluation	network	proposals)
Table 6.7. Procedural and substantive policy instruments in EUnetHTA
(Based on Howlett 2007; 2018)
6.4.1. Policy implementation in EUnetHTA: Procedural policy instruments
6.4.1.1. Procedural policy instruments: Organisation
The organisational structure and functioning of the network has received significant atten-
tion in the course of the different EUnetHTA Projects and Joint Actions since it represented 
one of the main objectives of the cooperation initiatives. Specific Work Packages dedicated 
their attention to the internal coordination of the network’s activities. The Secretariat and 
the Executive Committee played an important role in this regard. One could characterise the 
organisational structure as one of self-management when it comes to the work within the 
different work packages as each Lead Partner was free to decide about the most appropriate 
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working methods. The overall network coordination was ensured by the Secretariat who 
played a pivotal role in this regard (Personal interview 4).
The general structure of the EUnetHTA project and Joint Actions organising the various 
activities into different Work Packages was mainly determined by a format given by the 
European Commission. Although at times, an adaptation of this format had been proposed, 
the Commission-induced structure remained the same across the Joint Actions (Personal 
interview 22). The challenge was to avoid working in silo’s by promoting cross-section com-
munication (Personal interview 4). However, considering the overall structure and the fact 
that HTA agencies representatives could only be active in one or two Work Packages or 
activity centres, made meeting this challenge rather difficult (Personal Interview 30).
Managing a network firmly imbedded in scientific research and mainly composed of scientists, 
offered another challenge which, according to some, has impacted the internal management 
and course of action of EUnetHTA. Indeed, as explained in the previous chapters, EUnetHTA 
resulted from the initiative of HTA doers. The members taking the lead in the different Work 
Packages across the EUnetHTA project and Joint Actions most often came from a scientific 
background and had occupied management positions as a natural follow-up of their scien-
tific activities. Hence, EUnetHTA could be characterised as a network managed by scientists 
whose main tasks comprised the coordination of scientists (Personal interview 22).
Establishing common European HTA frameworks and methodologies among scientists from 
different European countries required to abandon some national or local procedures often 
developed by the same scientists who had dedicated a significant part of their professional 
occupation to the strict follow-up of these same procedures which ensure scientific robust-
ness. Although international cooperation remains a challenge in many different fields of 
activities, some believe this challenge may be even bigger for scientists. As such, strong 
management and coordination skills would be required to coordinate the activities and 
permit scientists to remain confident that new framework would still respond to scientific 
robustness (Personal interview 22). Even though, since the EUnetHTA project, personnel with 
specific project management skills had been appointed in the Secretariat, the actors active in 
the work packages of EUnetHTA remained HTA doers and the network could be qualified as 
a network of peers or as a network of scientists managed by scientists .
Besides the internal network coordination, an important aspect across all EUnetHTA’s projects 
and Joint Actions was “Network development”. Indeed, the overall strategic goal of the EU-
netHTA project was to “establish an effective and sustainable European Network for Health 
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Technology Assessment – EUnetHTA that informs policy decisions”159. This did not differ in 
any sense with HTA cooperation projects developed earlier. In chapter 4 we have observed 
how the goal to create a network of a permanent character, had to be reached by means of 
a project which, by definition, was limited time wise. The visions regarding the organisational 
structure of such a network differed among the stakeholders before the turn of the century. 
Moreover, we have underscored how, at that time, it was unclear whether the governance 
structure created for the purposes of the projects should be considered as the governance 
structure of a future sustainable network. The approach chosen in the EUnetHTA project 
(2006-2008) was in this sense identical to the early cooperation projects.
As outlined above, the Work Packages 1 and 2 of the EUnetHTA Project aimed at network 
development. The general objectives of Work Package 1 sought to establish “the organisa-
tional and structural framework for an effective and sustainable European network for HTA 
with a supporting secretariat”. A literal interpretation of this objective points towards the 
establishment of a framework distinct from the EUnetHTA project. In practice however, it 
seems that the organisation and structure of the EUnetHTA project was considered to be the 
framework of the – to be established – sustainable European network for HTA. Indeed, in 
the EUnetHTA project report, the EUnetHTA organisational structure, including a supporting 
secretariat, is listed as one of the key deliverables of Workgroup 1 (EUnetHTA 2009: 11).
The aim pursued by WP 1 to create a sustainable HTA collaboration was in a sense com-
plicated by the developments that took place on an EU level. As outlined in the previous 
sections, the European Commission introduced in 2008 the proposal for a “Directive on the 
application of patients’ rights in cross-border health care” (2011/24/EU) which mentioned 
the establishment of a voluntary network on Health Technology Assessment which would 
be coordinated by the EU Commission (Article 15, OJEU 2011). Time wise, the proposal was 
introduced at the end of the EUnetHTA project. The EUnetHTA Collaboration (2009) which 
sought to ensure the continuity of the work and bridge the gap with the future Joint Action, 
also aimed the establishment of a permanent HTA cooperation network (EUnetHTA 2009: 
23).
This aim is again mentioned in the project proposal of Joint Action 1 which sought “to put 
into practice an effective and sustainable HTA collaboration in Europe that brings added value 
at the European, national and regional level” (http://ec.europa.eu/chafea/projects/database.
html?prjno=20092302). It is interesting to underscore here the semantic changes in the 
wording of the objective: establish a “sustainable network” in the EUnetHTA project and a 
“sustainable Collaboration” in the Joint Action. Whilst the EUnetHTA project Work Package 
159 http://ec.europa.eu/chafea/projects/database.html?prjno=2005110.
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(WP) 1 dealt besides ‘Coordination’ also with the setup of a sustainable network, the JA1 
will address this issue in a separate WP 8 on ‘Strategy and Business model development’ 
(EUnetHTA 2013). The JA1 - WP 1 on ‘Coordination’ will conversely essentially deal with the 
coordination of the project. Hence, in the first Joint Action the objective of establishing a 
sustainable network framework will be dissociated from the project framework itself. This 
stems directly from Commission proposal to setup of a sustainable HTA Network as listed in 
the Cross-Border Health Care Directive Proposal.
The WP 8 of the first Joint Action would elaborate a strategy and future business model, 
presented in a 2012 report but never implemented (EUnetHTA 2012a). The ideas and sug-
gestions brought forward in this document will however feed into the discussions regarding 
the setup of a sustainable HTA Network. The 2012 WP8 report describes the potential busi-
ness model for EUnetHTA after JA2. It specifies that it concerns “a network organisation, 
and thus, a network business model. The business model development process for EUnetHTA 
builds upon commercial business model perspectives as well as network/alliance-specific pa-
rameters” (EUnetHTA 2013b:3). It considers EUnetHTA to be the future EU sustainable HTA 
network. It presents value propositions towards clients (i.e. HTA producers) which were fully 
in line with the output of the EUnetHTA projects and JA1160 (EUnetHTA:2013b). Moreover, it 
is proposed that the Work Packages of JA1 and JA2 evolve in so-called activity centres, each 
coordinating a specific activity. It is also envisaged that within a 10-years’ time span some 
agencies will have specialised in specific HTA fields (EUnetHTA 2013b: 15). The business model 
furthermore proposed listed a certain number of “Functions of the permanent EUnetHTA” 
161 (EUnetHTA 2012a, Italics added). Although the wording “permanent EUnetHTA” would 
disappear in the final draft, it did indicate the state of mind at the time of the JA1.
The proposed business model did also launch the discussion regarding the future legal entity 
of the network (EUnetHTA 2013b: 14). Here again, it was envisaged that EUnetHTA would 
be the entity which would evolve into the to be created ‘EU HTA Network’, underscoring the 
challenges to ensure the transition: “EUnetHTA is not a corporation, nor an EU agency. At 
160 Content production and related services around the EUnetHTA tools; Facilitation of transparency 
of methods and data used for HTA reports; Quality assurance of HTA methodology. It foresaw a 
potential for integration whilst preserving full national autonomy on national decision-making 
processes (EUnetHTA 2013b).
161 These functions are: 1. be a contact point for the HTA community in Europe 2. maintain a shared 
HTA Information and Communication system 3. develop common processes for performing and 
reporting HTA 4. pilot processes for the collaborative production of HTA information taking into 
account also European priorities in the healthcare field 5. facilitate adequate evidence genera-
tion 6. facilitate the establishment and continuous development of HTA institutions” (EUnetHTA 
2012a).
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this moment, EUnetHTA is a network of independent government nominated and founding 
partner organisations and does not have a legal entity. While this will be maintained during 
JA2, the question is how this can flexibly develop and adapt to future changes after JA2” 
(EUnetHTA 2013b: 14). Other issues, such as retribution measures to partners have also 
been brought fore, proposing a fee-based and credit system permitting to reward those 
that invested in the system (EUnetHTA 2013b: 8-10). As regards the financing of the future 
sustainable network, a MS/EU co-financing model had been proposed, leaving also the pos-
sibility open for other financial opportunities (grands, commercial fees).
Since the Commission Proposal for a Cross-Border Health Care Directive, the future of a 
sustainable European HTA network became intrinsically linked to the adoption process of the 
latter. Indeed, once adopted in 2011, this Directive would offer, as we have seen above, a 
legal basis to establish a European HTA cooperation mechanism. The internal organisation of 
Joint Action 2 (2012-2015) sought therefore to be aligned with the Directive. Hence, one of 
the three key objectives of the Joint Action 2 was “to develop a general strategy, principles 
and an implementation proposal for a sustainable European HTA collaboration according to 
the requirements of Article 15 of the Directive for cross-border healthcare” (www.eunethta.
eu). The input of Joint Action 2 with regard to the development of a sustainable permanent 
structure for HTA collaboration will be - content wise – however of lesser importance than 
the Joint Action 1.
This situation can be explained by the developments in the broader European context with 
the setup of the policy orientated EU HTA Network. Whilst during the JA1, the status of 
EUnetHTA with regard to the future sustainable network was still vague, during JA2 this 
has been clarified to a certain extent. Indeed, based upon the decision taken in the EU HTA 
Network, the deliverables of the JA2 recalled that, the EUnetHTA JA2 was mandated to be 
the scientific and technical level of the cooperation process working in synergy with the HTA 
Network established on the basis of Article 15 of the CBHC Directive (EUnetHTA 2014:5). 
However, besides strengthening the practical application of tools and methodologies, the 
JA2 needed to contribute to the development of a strategy for the actual implementation of 
a sustainable European cooperation on HTA.
Conversely to JA1, no specific Work Package had been dedicated in the JA2 to the reflection 
on the framework and governance of a future sustainable HTA collaboration structure as 
this also was being dealt with by the EU HTA Network. This however does not mean that 
no attention has been given to the latter. Indeed, one of the objectives of Work Package 1 
on ‘Coordination’ regarded the delivery of recommendations on the implementation of a 
sustainable European network for HTA (www.eunethta.eu). It is interesting to notice how 
the recommendations developed by the JA2 do not refer to the business model developed 
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in JA1. Although the model developed in the JA1 had not been implemented as such, some 
ideas had nevertheless been (partly) accomplished in JA2. One can cite as an example the 
proposal of establishing activity centres which have not been created officially. However, in 
practice, the international organisation did function according to this idea with some agen-
cies (often lead partners of Work Packages) coordinating the work in specific activities such 
as Relative Effectiveness Assessments or Early Dialogues (Personal Interview 30). Moreover, 
a similar idea lays at the basis of the structure presented in the Commission proposal for a 
Regulation on HTA cooperation (European Commission 2018).
Another example regards the functions of EUnetHTA and the differentiation in status of 
membership as described in the official EUnetHTA document outlining the recommendations 
on the implementation of a sustainable European cooperation on HTA. The latter focused 
mostly on the scientific and technical aspects of cooperation on HTA and aimed at “con-
tributing to the development of content and structure of a possible 3rd Joint Action on 
HTA”. It highlighted how distinct tasks should be defined and attributed to the strategic 
level and scientific/technical level “while ensuring synergy between the levels with a clear 
separation of their remits and mandates”. It emphasized the need for a transition from “pi-
loting of cooperation activities to routine implementation and uptake of the joint output in 
national/regional HTA production processes”. It also introduced three levels of commitment 
for partners, each associated with specific responsibilities and duties (EUnetHTA 2014:3)162. 
Finally, in the final technical report of the JA2, regarding the hosting facility of the future 
HTA sustainable structure, an assessment of potential options was suggested and which 
should also include “definitions of the role, function and specific tasks of the coordinator/
coordinating facility to support permanent cooperation” and explore sustainable funding 
mechanisms (EUnetHTA 2016:4).
The contribution of JA2 regarding the organisation and governance of a future sustainable 
network for HTA cooperation in Europe was thus primarily focused on the formulation of 
recommendations. These were however less explicit than the business model delivered in 
JA1, except for the level of commitments proposed by JA2 and which would nourish the 
reflections on the EU level, as we will see in the next section. Moreover, no references have 
162 The first level of commitment regarded sharing and exchange of information produced and meth-
ods applied individually by participating organisations. On the second level, partners would com-
mit themselves to contribute to the development, support and application of common tools (e.g., 
databases, models for structuring and reporting of HTA information, capacity-building activities) 
and scientific methods (e.g., methodological guidelines and templates) to support HTA production 
processes. On the third level, they would commit themselves to contribute to the production of 
joint assessment reports and application of the results of joint assessment reports in the national/
regional HTA production processes (EUnetHTA 2014: 11).
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been made to the reflection process of JA1 and its proposed business model. Not even 
when discussing the financial aspects of the sustainable mechanism (e.g. no reference to 
the proposed credit system of the business model of JA1). The recommendations would limit 
themselves to a statement that “an appropriate, feasible mechanism of financing permanent 
operations of such a system needs to be identified” (EUnetHTA 2016: 4). Since part of this 
question was being reflected upon in the EU HTA Network, EUnetHTA focused in the JA2 
still on seeking co-funding for the continuation of its activities via the EU budget (e.g. Health 
Programme, Horizon 2020, structural funds) which was still being considered key to secure 
sustainability of the EUnetHTA cooperation (EUnetHTA 2014: 7).
Hence, besides the formulation of recommendations, no concrete advancement regarding 
the governance and organisation of a future sustainable network on HTA cooperation would 
be made in the JA2. Once more, the objectives established for the second Joint Action would 
spill over to the third Joint Action which will run from 2016-2020. Here again, as in the EU-
netHTA project and the JA2, a specific WP 1 on ‘Network coordination’ would be dedicated 
to this aim. Indeed, besides the coordination of the activities of JA3, the Work Package 
1 would aim at providing “scientific and technical coordination support for European col-
laboration activities in HTA to the integration of the HTA activities in the whole life-cycle of 
technologies, which lead to the development of a final sustainable model for the scientific 
and technical mechanism of a permanent cooperation in HTA” (www.eunethta.eu). The 
difference with the previous Joint Actions is thus that EUnetHTA will reflect only upon the 
scientific and technical part of the sustainable cooperation as reflected in the first deliverable 
listed and which stated the establishment of a sustainable model for the scientific and techni-
cal mechanism of a permanent European cooperation on HTA (www.eunethta.eu).
6.4.1.2 Procedural policy instruments: Communication
Communication efforts in EUnetHTA followed a two-fold strategy: internally and externally. 
Internal communication projects were targeted at providing a basis upon which other activi-
ties could be developed and should ensure internal cohesion of the EUnetHTA undertakings. 
In this regard, various tools have been developed across the Joint Actions such as a clearing 
house function, an internet and intranet website and several databases (e.g. POP, EVIDENT). 
Internal communication efforts have first been targeted at exchanging relevant information 
regarding HTA itself. Indeed, HTA reports on the same technology or key policy question 
could show important variation across countries. The aim was thus to ensure a degree of 
harmonisation and standardisation regarding the structure of the reports as well as the 
underlying assessments. As such, information which would be relevant for other agencies 
could be more easily extracted (EUnetHTA 2009:15).
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From the establishment of a Clearinghouse functionality in the EUnetHTA project (EUnetHTA 
2009:11), new tools have been developed in JA1 and JA2 such as the POP database per-
mitting to enhance the efficiency of technical and scientific information exchange systems 
necessary to undertake joint work or support local assessments. Indeed, this tool permitted 
all agencies to be aware of all Present and Ongoing Projects (POP) of EUnetHTA members, 
which should not only enhance cooperation efforts but also reduce duplication of efforts 
(www.eunethta.eu/pop-database/). This tool has been of high importance as it represented 
an essential element in the establishment and implementation of joint assessments and has 
been continuously updated alongside other internal communication tools and methods. 
Indeed the intranet, internet and the information management infrastructure will be regu-
larly restructured across the three Joint Actions, allowing a better support “to the piloting 
of collaborative production of HTAs by partner agencies, and facilitate the tasks and team 
working of the other WPs” (www.eunethta.eu). Hence, internal communication means were 
developed to support the key-activities of the network. This could aim at facilitating the 
information flow between the Work Packages and the governance structures such as the 
Secretariat and the Executive Committee. It could also aim at offering technical support 
linked to initiatives of joint work as for example the POP database. Similarly, the EVIDENT 
database has been established to support cooperation in evidence collection and share infor-
mation on reimbursement and assessment status of new technologies or requests regarding 
additional evidence (studies) on technologies (see further on EVIDENT: www.eunethta.eu).
External information efforts of EUnetHTA were aimed at disseminating the activities and 
outcomes of the network so as to enhance the awareness about HTA and the cooperation 
efforts on the European level in this regard. Dissemination had already been identified in 
the EUR-ASSESS project as important for HTA development. This item remains meaningful 
enough to dedicate in each Joint Action a specific Work Package to it (i.e. WP 2 in JA1, JA2 
and JA3). Throughout the years the activities will diversify and intensify. As such dissemina-
tion has taken place by means of promotional materials and social media, the publication 
of articles in scientific journals, the presentation of EUnetHTA at scientific conferences and 
(stakeholder) Forums (EUnetHTA 2013: 37-40); www.eunethta.eu).These dissemination 
activities have been a mean to take stock of the activities done in the network on the de-
velopment of tools, methodologies and new initiatives or members. Moreover, it permitted 
to bring HTA cooperation in the spotlight and attract the attention of policymakers and 
stakeholders.
It should be highlighted that the organisation of conferences also allowed to shape dis-
course and peer-education on certain issues (e.g. REA, Early Dialogues, Regulation proposal). 
Moreover, this was also an opportunity for members to exchanges informally, create new 
relationships on which future collaborations could be built. Knowing each other better also 
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contributed to establish trust which has been often recognised as an important element 
to successfully develop joint work. It also allowed members to resolve particular problems 
by being able to communicate more easily and learn from the experiences of others (e.g. 
Personal interviews 1, 6 19). Finally, it contributed to the involvement of stakeholders in 
the project “to ensure that the results of the project are applicable and appropriate” to 
them. In this regard, the WP2 on Dissemination of the Joint Action 3 aimed at developing a 
“post-2020 model of European HTA network in terms of effective communication with the 
key stakeholders”. To this end, it is also been envisaged to establish a stakeholder analysis 
and registry (https://www.eunethta.eu/ja3-archive/work-package-2-dissemination/).
6.4.1.3. Procedural policy instruments: Capacity-building
The relationship between dissemination and capacity-building is at many levels quite narrow 
which explains why it has always been integrated in the Work Package on Dissemination in 
the Joint Actions. As for dissemination, capacity-building follows a two-fold objective: inter-
nal training of EUnetHTA partners on the various tools and methodologies being developed 
and external training of stakeholders and agencies with less experience in HTA. Though the 
EUnetHTA Project (2006-2008) still dedicated a specific WP 8 to support countries without 
or with a limited institutionalisation of HTA, the latter has been integrated in the general 
capacity-building activities in the Joint Actions (EUnetHTA 2013; www.eunethta.eu). More-
over, capacity-building also proceeded for an important part via peer-education where the 
more experienced partners would share their knowledge and experience to less experienced 
members of the network (Personal interviews 1, 11, 19, 22, 28, 30). “The way I view it is 
you get out what you put in. Like we went from being a brand-new agency, with no track 
record at all, to now being probably one of the most experienced members of the network” 
(Personal interview 19).
Besides peer-education, capacity-building has taken place though the development of tools 
and training materials such as a handbook on HTA capacity-building aiming to provide 
guidance and support on how to establish HTAs. Training seminars and e-learning courses 
accompanying the HTA tools and methodologies developed also sought to respond to the 
various needs of the members of the network (EUnetHTA 2009: 151-176). The aim here 
was to increase the awareness and “understanding of the usefulness of the EUnetHTA tools, 
methods and results among EUnetHTA partners and stakeholders” (www.eunethta.eu). In 
order to assess the needs of members, the network proceeded by the implementation of 
surveys so as to better understand how new tools or methodologies were being perceived by 
the end-users as well as specific needs of agencies that could be addressed by international 
cooperation (Moharra et al.2008: 28-29).Throughout the last Joint Actions specific attention 
has been given to capacity-building of stakeholders and newly established HTA agencies. This 
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also aimed at enhancing the impact of HTA reports in national decision-making processes by 
producing best practices among EUnetHTA members (EUnetHTA 2013a 33-48).
6.4.1.4. Procedural policy instruments: Evaluation
The evaluation processes in the EUnetHTA project and Joint Actions have been an integral 
part of the projects and also an explicit requirement from the EC Commission. Evaluation 
of the HTA cooperation could be made on two different levels: an evaluation on internal 
processes (mainly project implementation), and evaluation on external processes (e.g. con-
sultations process of different proposals made by EUnetHTA the EU Commission or other 
actors). Part of the internal evaluation processes have been organised in a formal way and 
were conducted by a specific WP on Evaluation (following the requirements of the grant 
agreement). This evaluation regarded mostly the implementation of the project’s strategic 
objectives and the sub-objectives defined in each WP. As such all tools and methods were 
being examined. The evaluation tools were mainly surveys, semi-structured interviews and 
documentary analysis. A comprehensive outline of the results of these evaluation processes 
will be given at the end of this chapter in the section on the fifth phase of the policy cycle 
(evaluation).
However, often internal evaluation has been conducted in a more or less informal way 
applying some form of single or double-loop learning processes (see chapter 4). “I think 
EUnetHTA is a learning organisation. So, we do evaluate; how did that go and where could 
we potentially find weaknesses and address them the next time. (…) I think it is probably 
mostly that kind of learning by doing and developing the way that we do things” (Personal 
interview 19). On-going internal evaluation leads to an adaptation of the process on the basis 
of the interim results. “The entire EUnetHTA works that way” (Personal interview 1). Indeed, 
the many pilot projects that have been set-up, have been adapted following formal and 
informal evaluation processes. Moreover, exchange of experiences in EUnetHTA - but also in 
other international HTA-related societies - also make up part of the evaluation processes to 
compare progress or situations dealt with in other agencies (e.g. Personal interviews 6, 30). 
Hence, soft governance evaluation methods have been applied in EUnetHTA, even though 
this has never been officially organised that way.
Regarding the evaluation on external processes, EUnetHTA has participated in several con-
sultation processes. On can cite here in particular the public consultation process launched in 
2016 by the EU Commission regarding the different scenarios of the future HTA cooperation 
in Europe and the participation of members and stakeholders in the preparatory phase of the 
Commission Proposal for a Regulation on HTA cooperation. For a more consistent approach 
in our analysis, we will discuss the latter as well in the final section of this chapter.
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6.4.2. Policy implementation in EUnetHTA: substantive policy instruments
In the previous section we have examined the procedural instruments used by EUnetHTA 
in the form of Organisation, Communication, Capacity-building and Evaluation. All these 
processes have can potentially influence the substance of the policy outputs (Howlett, Ra-
mesh and Perl 2009: 169). In this section, we will examine the instruments used which are 
directly concerned by the substance policy output. Although the various outputs have been 
developed at different points of time, we will adopt in this section the HTA approach of the 
life-cycle of a health technology, ranging from: Horizon Scanning, Joint Scientific Advice, 
joint work (i.e. methodologies, tools and assessments), (additional) evidence generation and 
uptake of joint work in national settings.
Already in the EUnetHTA Project (2006-2008) the question of (early) access to new health 
technologies has been raised. This question will remain high on the agenda throughout the 
subsequent projects and Joint Actions. Indeed, highly innovative and promising technologies 
with the potential of bearing a high value for the health care system often also represent 
high costs and their impact on the health systems is still uncertain. Market approval is based 
on quality and safety evidence collected in controlled setting (e.g. RCT) and analysed ac-
cording to clearly defined data (see chapter 5). Obtaining coverage for new technologies 
requires often additional data on clinical effectiveness, cost-effectiveness, impact and quality 
of life which again requires time and money to collect. Hence, once a promising technology 
is identified it can take long before sufficient evidence is gathered permitting to make a 
decision on its market authorisation and coverage.
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Figure 6.1. Assessment process based on health technology life-cycle
Since the launch of the EUnetHTA project, an increasing number of EU Member States had 
recourse to a new mechanism called “access with evidence generation” (AEG) herewith 
allowing a temporary access to the market for some health technologies whilst requiring 
simultaneously the generation of additional evidence to reduce uncertainty about the tech-
nology. This mechanism required thus to anticipate and gather relevant data as early and 
as quickly as possible to ensure the technology is safe and effi cient. If, initially, ‘evidence 
generation’ was being dealt with in EUnetHTA at the stage between market approval and 
national regulatory processes, gradually a life-cycle approach will be adopted comprising 
initial evidence generation (Early Dialogues) and post-launch evidence generation (including 
real world data). As with the other instruments developed, this process will develop in stages 
from Horizon Scanning (early awareness and alert systems), joint work in the form of use of 
common tools and methodologies, Relative Effectiveness Assessments and full HTAs. Output 
of collaborative work is often considered being of use when effective uptake of that work in 
national settings can be observed. In this section, we will outline the main policy instruments 
that have been developed by EUnetHTA in this regard and which have implied an ever-closer 
collaboration with the EMA.
6.4.2.1. Substantive policy instruments: Horizon Scanning
Providing timely access to new health technologies requires often a so-called Horizon Scan-
ning exercise to identify among all new and emerging technologies, those technologies 
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which seem the most promising, even if not all evidence has yet been generated to feed 
into the regulatory processes. Horizon Scanning can be defined as “the systematic identifica-
tion of health technologies that are new, emerging or becoming obsolete and that have 
the potential to effect health, health services and/or society” (www.eunethta.eu). Several 
Horizon Scanning Systems (HSS) have been developed over the course of years in Europe 
and abroad, such as Euroscan, an international network focusing, amongst others, on the 
development of methods for the early identification of health technologies (www.euroscan.
org)163. Horizon Scanning is closely connected with other stages preparing an HTA such as 
topic identification, selection and prioritisation. The importance to prioritise the assessment 
of health technologies had already been underscored in the very first project of HTA col-
laboration (EUR-ASSESS, see chapter 4).
In 2006, EUnetHTA addresses the issue of Horizon Scanning in a dedicated Work Package 
combining it with additional evidence generation. During the EUnetHTA project and the first 
Joint Action, both topics were however dealt with in two different strands of the same Work 
Package 7. Strand B focusing on the early identification of new and emerging technologies. 
Strand A concentrating its attention on the definition of conditions for providing timely 
access to promising technologies with evidence generation (EUnetHTA 2009:116). The first 
EUnetHTA initiatives regarding Horizon Scanning were aimed at developing a systematic 
review on existing Horizon Scanning programs and their working processes. Collaboration 
herein was established with other organisations such as EuroScan. The added value the 
EUnetHTA project aimed to achieve in this field was to develop a standardised form for 
information sharing, making it available to a wider audience (EUnetHTA 2009: 117).
During Joint Action 1, no real Horizon Scanning activities, as such, have been implemented as 
the efforts in Strand A were concentrated on developing a database on evidence generation 
on new technologies. This ‘EVIDENT database’ contained information on additional studies 
requested by European HTA bodies and gathered furthermore information on assessment 
and reimbursement of new technologies (EUnetHTA 2013:113). Stand B had focused on 
the development of the ‘POP database’ gathering information on ongoing and planned 
projects/assessments of new pharmaceutical and non-pharmaceutical technologies (EU-
netHTA2013:114). These databases, which had been developed using several consultation 
163 Other HS systems that have been developed in Europe and elsewhere are for example: EuroScan; 
HTAi – via the HTAi IG DEA interest group on disinvestment and early awareness; BeNeLuxA/
IHSI; The Nordic Pharmaceutical Forum; Cross-regional collaborations (e.g. Spain and Italy); the 
Canadian HTA agency (CADTH); the Australian Institute for Safety Compensation and Recovery 
Research (ISCRR).
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methods among EUnetHTA members, were considered to be an important tool to reduce the 
duplication of work among HTA agencies and foster collaboration on assessments.
Both databases could be considered as offering support to a Horizon Scanning activity since 
they permitted to present an overview of assessment projects planned as well as request 
for additional evidence made by agencies on some health technologies. This approach was 
however fully targeted on the need of HTA agencies and not necessarily on the need of the 
European health systems. The latter would be more interested in knowing what would be 
in the pipelines of pharmaceutical and medical device companies so as to prepare for e.g. 
potential health budget impacts. EUnetHTA, however, at this stage of development, needed 
to first allow for a comprehensive overview of planned and ongoing projects of HTA agencies 
and was less focused on pipe-line products.
In Joint Action 2, the importance of collecting evidence throughout the entire life cycle of 
health technologies will be underscored. However, again attention will be directed to other 
stages of evidence collection and in particular towards the so-called Early Dialogues which 
will be outlined in the next section. Indeed, the final report states that “By 2019 a standard 
process should be implementable for European HTAs, that would cover appropriate genera-
tion and assessment of evidence throughout the entire life cycle of health technologies (from 
Early Dialogues, through early assessments, additional evidence generation and assessment 
of technologies already established in the market to technologies which may be already out-
dated and could be replaced by newer, safer and more effective ones)” (EUnetHTA 2016:4).
Hence, although acknowledged of being an important exercise of HTA by EUnetHTA mem-
bers, Horizon Scanning had never been a priority topic for EUnetHTA till 2016 (Personal inter-
views 20, 24, 29). In Joint Action 3, this will however slightly change, as specific attention will 
be given to Horizon Scanning which will be treated separately from other evidence collection 
activities. Indeed, the WP7 will focus specifically on evidence collection (Early Dialogues and 
post-launch evidence collection), whereas Horizon Scanning will be integrated in the WP4 on 
joint production. As such, one of the objectives of this work package will be to “develop and 
refine a system of Horizon Scanning, topic selection and prioritisation in close collaboration 
with the Liaison Committee and relevant Work Packages” (www.eunethta.eu/ja3-archive/
work-package-4-joint-production/).
The increased attention given to Horizon Scanning could partly be explained as a result from 
the Commission proposal for a Regulation on HTA and which included a specific chapter 
on Horizon Scanning in relation to the early identification of emerging technologies (Euro-
pean Commission 2018). Horizon Scanning became more widely used in different settings 
and several HSS had been developed in Europe all seeking to increase the timeliness and 
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relevance of the activities they would support. Moreover, Horizon Scanning also served to 
better evaluated new medicines in the industry’s pipeline that could potentially have an 
important impact on the health budgets. Although pursuing similar objectives these systems 
would differ in their management, operational and administrative structures as well as their 
customer profiles. As such some would respond to needs of health systems other would 
seek to support procurement processes besides reimbursement decisions. EUnetHTA would 
seek to develop a new Horizon Scanning system aimed at responding to the needs of HTA 
agencies working in a European collaboration (Personal interviews 15,17)
In July 2018, as a response to the EU proposal for a Regulation on HTA cooperation and 
preparing the post 2020 scenario, the JA3 WP4 made recommendations for a new HSS 
which had been submitted to the EUnetHTA members as well as relevant stakeholders. 
These recommendations sought to cover several stages to be performed before the actual 
joint assessment and included: Horizon Scanning (HS), Topic Identification, Selection and 
Prioritisation (TISP). This system should support HTA activities throughout the technology 
lifecycle including early dialogue with technology developers, initial assessments, planning 
and additional evidence generation and reassessment (EUnetHTA 2018a:12).
Criteria for topic selection would be based on economic or resource impact, potential health 
benefits, severity or burden of disease, population size and the importance to policy and/or 
health care. During the prioritisation process, additional criteria would be applied so as to 
retain for assessment those technologies having a greater impact on the system’s or network 
capacity for assessment. The criteria proposed by EUnetHTA and in line with the scope of the 
EU proposal would focus on unmet medical need; potential impact on patients public health, 
or health care systems (e.g. burden of disease, budget impact, transformative technology); 
cross border potentials; union-wide added value (e.g. relevance to a large number of Member 
States); the resources available to perform assessments (EUnetHTA 2018a:23).
Although present in the workload of several EUnetHTA work packages since 2006, Horizon 
Scanning has never been a priority topic for the network. It is only in the Joint Action 3 that 
this topic receives new attention and becomes an integral part of an innovative model, based 
on a life cycle approach of health technologies. The integration of Horizon Scanning activities 
in the Commission proposal on HTA cooperation most probably also has played a role in the 
renewed attention for this topic in EUnetHTA. Moreover, the attention given by regional 
intergovernmental collaborations to Horizon Scanning could also have had an impact herein. 
Indeed, increasingly governments would start to develop the HSS to better evaluate the 
arrival of new products on the market and which could have an impact on the health budget. 
As we will outline below, some countries had decided to collaborate on economic evalua-
tions of technologies, including in their efforts also Horizon Scanning activities.
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6.4.2.2. Substantive policy instruments: Early Dialogues
Once a technology has been identified and prioritised for assessment, another process can be 
initiated in the pre-licensing phase of market entry. This process has been developed at dif-
ferent places and by different organisms and therefore responds to different denominations 
such as; (parallel) scientific advice, Early Dialogues or joint scientific consultation. The aim of 
this process is to establish a structured dialogue between pharmaceutical and medical device 
companies on the one side and regulatory and/or HTA bodies on the other, to provide infor-
mation about the evidence and information needs of HTA bodies and regulators. Indeed, as 
outlined in chapter 1, the evidence requirements for regulatory agencies such as the EMA 
and national HTA bodies can differ. Although accepted for EU market entry, a technology 
could see it commercialisation being delayed by additional evidence requests of HTA bodies. 
Hence patient access for innovative medicines or medical devices would be slowed down.
Although developed after the initiatives on additional evidence generation, which would 
target more specifically post-launch evidence, the initiative on Early Dialogues has evolved as 
one of the most successful EUnetHTA products. Single HTA Early Dialogues had been already 
developed by some HTA bodies since 2009 (e.g. NICE, GB-a). In 2010, Tapestry Networks, 
an American organisation, launched a multi-stakeholder project which would lay down the 
foundations of future initiatives in the field of parallel scientific advice or Early Dialogues. The 
initiative was based on recommendations of earlier projects seeking to develop stakeholder 
understandings regarding diabetes Type 2 and breast cancer (Bergmann et al. 2014).
The working groups of these projects concluded that public and private stakeholders in the 
drug development systems lacked “sufficient information to support and assess the develop-
ment of innovative medicines that address unmet needs at reasonable cost” (Bergmann 
et al. 2014: 305). Based on their recommendations, six pilot projects have been launched 
from 2010 to 2012, implementing multi-country, multi-stakeholder consultations on drug 
development. These projects permitted the establishment of common meetings between 
regulators, health technology assessors, payers, patients and medical experts aiming to 
deliver a joint advice regarding the drug development (Tapestry Networks 2012).
In 2010, a similar initiative had been initiated by the EMA. The so-called parallel scientific 
advices allowed for concertation between a pharmaceutical company and two or three 
HTA bodies. The process sought to enhance the understanding of stakeholder data needs 
(including patients’) and the differences between regulators and HTA bodies (Shan and 
Carter 2019). Hence, developers could receive simultaneous feedback on their development 
plan from the regulators and HTA bodies who would give, if possible, a common response. 
However, if their positions would diverge too much, each individual HTA body would give its 
contribution about evidence required (Tafuri et al. 2016; Personal interview 29).
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Hence, when EUnetHTA started its activities on Early Dialogues in 2012, experience in the 
matter existed but was still rather limited. The approach EUnetHTA sought to adopt, differed 
from the previous initiatives in the sense that it extended the number of HTA bodies partici-
pating in the discussions (6 to 10 HTA agencies in the first projects) (Harousseau et al. 2015). 
Moreover, EUnetHTA sought to reach a concerted single contribution of HTA bodies after 
a joint consultation between the industry, the regulators and the participating HTA bodies. 
“We wanted to create a model which would be more effective in terms of performance and 
more collaborative” (Personal interview 29). To this end, the common consultations with all 
stakeholders around the table would be preceded by meetings of HTA bodies to “see how 
far we could go in our coordination, in our common responses etc.” (Personal interview 29). 
In cases where no common response could be given because of the regulatory disparities 
that could not be overcome, a common response would be edited, indicating however the 
reserves expressed by specific parties facing specificities in their countries which should be 
taken into account by the developers (Personal interview 29).
At first, a small budget was provided to finance three Early Dialogues. Highly motivated, 
some HTA bodies initiated however two preparatory projects which they would finance 
themselves. As feedback of agencies and developers was highly positive, eight pilot projects 
have been implemented instead of the three initially foreseen (Personal interview 29). Hence, 
in order to extent the initiative, more budget was required. As the Joint Action was already 
set in motion and could not be amended in terms of objectives and budget, a separated 
project has been developed under the denomination of “Shaping European Early Dialogues – 
SEED”. Supported by the recommendations of the Health Forum, the European Commission 
decided to support this initiative by setting up a call for tenders which contained a certain 
number of specifications to which the project had to respond.
Some of these specifications aimed at ensuring the sustainability of the Early Dialogues and 
followed a soft governance approach (e.g. single / double loop learning approaches, stake-
holder consultations etc.). Although the Commission did have a say over the content of the 
project, it did leave the opportunity to the project initiators to further amend the approach 
based on learned lessons and past experiences.
For the Commission representatives, the parallel scientific advices and Early Dialogue did 
respond to a real need and also permitted to face a certain ‘battle of powers’ that existed at 
the European level between regulators and national/regional HTA bodies, each having their 
own expectations and requirements. The projects initiated by EMA and EUnetHTA did offer 
an opportunity to put all stakeholders around the table, “start talking to each other” and 
map out possible scenarios for parallel HTA scientific advice and regulatory scientific advice 
(Personal interview 8). Hence, besides the scientific reasons, there was also a political need to 
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support the initiative: “there was this opportunity – because EMA was a difficult case – and 
then we said: why don’t we try to find a hook for them to start talking to each other? So, we 
issued a call for tender”. (Personal interview 8).
With the Commission financial support, the SEED project avoided the “premature death” 
of a highly successful initiative. “The success had exhausted all our resources and we could 
not respond to all the requests. The SEED project avoided that [discontinuation of Early Dia-
logues] and allowed us to continue and to make new propositions for the future” (Personal 
interview 29). The SEED initiative, which started its first pilots in 2012, also allowed to install 
a sort of junction with the EUnetHTA Joint Action 2 launched the same year (Harousseau et 
al. 2015, Personal interview 29). The first pilots were followed-up by eleven Early Dialogues 
(9 on pharmaceuticals and 2 on medical devices) which were implemented during the Joint 
Action 2 (2012-2015) and exceed the number of Early Dialogues initially foreseen (Personal 
interview 29).
Membership of the SEED consortium and participating HTA bodies was overlapping with 
EUnetHTA. Hence, although in terms of participation, the SEED consortium resembled the 
membership profile of EUnetHTA, it remained a separate administrative entity. Moreover, 
some HTA agencies (e.g. GB-a) could be participating in the SEED project but not in the 
EUnetHTA Joint Action (Personal interview 29). This collaborative approach included besides 
HTA agencies and the industry also representatives of the EMA with whom a certain number 
of projects had been carried out in parallel, whilst the majority of Early Dialogues regarded 
multi-HTA bodies (EUnetHTA 2015b: 4). “We said, we first have to know how to work to-
gether before starting to work with the EMA” (Personal interview 29).
Participation was voluntary, advice was not binding and confidential which contributed 
to the success of the project amongst the partners from the industry who adopted a very 
positive approach to the project: “The motivation was there because often when you ask 
for reimbursement for a product, you notice that you have the market approval but the 
reimbursement authorities will have certain other requirements or do not agree with primary 
or secondary endpoints and you only figure that out at then. That is far too late because 
there is not much you can do about it.” (Personal interview 16). Moreover, organising a 
dialogue between representatives of clinical departments of the industry, the EMA and HTA 
agencies was also helpful for internal industry processes: “It was internally a real eye-opener 
for people of clinical departments and also regulatory who normally only exchange with 
EMA. They could see what the requirements are of reimbursement authorities. But it was 
also an eye-opener for representatives of EMA and the reimbursement authorities” (Personal 
interview 16).
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Indeed, before the parallel regulator-HTA bodies scientific advice organised by EMA since 
2010 and the SEED project, there had been no systematic exchanges on the issue between 
the EMA and HTA bodies. Both the initiatives on parallel scientific advice, initiated by EMA, 
and the Early Dialogues implemented by EUnetHTA, demonstrated however that evidence 
needs of different stakeholders could be aligned within single trial designs or development 
programmes while respecting their respective areas of authorities and competences (Tafuri 
et al. 2016). Hence, since 2012, EMA and EUnetHTA have started to collaborate more inten-
sively on the issue of evidence generation. Starting with bi-annual meetings, exchange has 
become more frequent and several collaborative projects have been put in place.
Pilots on the side of EMA and of EUnetHTA have been implemented comprising the collabo-
ration of both bodies where simultaneous feedback was given to medicine developers by the 
regulators and HTA bodies. The aim was to streamline data requirements in a single develop-
ment plan satisfying the needs of the regulators (risk/benefit evaluation) and HTA bodies 
(value assessments). EMA assessment reports (e.g. EPAR) have been adjusted to address the 
needs of HTA bodies. New common approaches have been investigated to collect robust 
data for post-authorisation processes. The use of patient registries164 have been examined 
in this regard. The collaboration between both bodies also regarded the development of 
the pilot projects on rapid relative effectiveness assessment of pharmaceuticals, discussed 
above. Finally, a discussion has been initiated regarding the wording of therapeutic indica-
tions (www.ema.europa.eu).
Ultimately, these initiatives have led to the establishment in July 2017 of a new common 
EMA-EUnetHTA platform for parallel consultation. This initiative replaced the parallel sci-
entific advice procedures. An importance difference in the new approach consisted in the 
fact that a single contact point had been created for the manufacturers which did not have 
to contact anymore EMA, EUnetHTA and/or HTA bodies individually. Consultations could 
take place before or after market authorisation. The objective would still be the same: give 
developers of medicines simultaneous and coordinated advice on their development plans 
and herewith facilitate the alignment of data requirements which would satisfy the needs of 
both regulators and HTA bodies. An EUnetHTA-led Early Dialogue Secretariat would become 
in charge of centralising the recruitment of HTA bodies participating in the procedure, which 
would also include patient and health care professionals (EMA 2017; www.ema.europe.eu).
Hence, starting at different places in different venues, the various initiatives of parallel scien-
tific advice and Early Dialogues have, to date, developed into a common procedure where 
guidelines, templates, fees etc have been developed and are implemented in a harmonised 
164 A patient registry collects information about patients who are affected by a particular condition 
(www.ema.europa.eu).
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manner between the EMA and EUnetHTA. An Early Dialogue Working Party has been es-
tablished which consists of European experts who are in charge of the evaluation of the 
applications and the drafting or revision of guidance (www.ema.europe.eu). Five HTA bodies 
have a full seat in this structure165, HTA bodies which are not members of the EDWP could 
participate in some Early Dialogues depending on their area or expertise and availability 
(EUnetHTA 2018:20). The Joint Action 3 would foresee the implementation of 33 to 35 Early 
Dialogues, a number which seemed easily attainable as many applications arrived in the 
course of the Joint Action (EUnetHTA 2018).
The synergies created by the cooperation between the EMA and EUnetHTA most likely 
encouraged other initiatives seeking to establish closer cooperation between the HTA arena 
and organisations, such as, the Heads of Medicine Agencies, the Commission Expert Group 
on Safe and Timely Access for Medicines to Patients (STAMP) or the Network of Competent 
Authorities responsible for Pricing and Reimbursement (NCAPR) (European Commission 
2014b; 2016d). In the light of these developments a reflection paper (European Commission 
2016a) had been written in 2016 on request of the EU HTA Network, and shortly after, 
a synergy group has been established. The aim of the latter was to provide an overview 
of activities carried out by different organisations and institutions and which could either 
overlap or where collaborative work would be of interest. The reflection paper had already 
identified in this regard issues, such as, the definition of unmet medical need, Horizon Scan-
ning, novel study designs. Hence, the idea was here to examine whether synergies could 
be created among agencies or institutions working in similar areas regarding market entry, 
post-marketing activities (e.g. evidence generation, ‘late dialogues’), or in any other area 
(e.g. initiatives on patient involvement, personalised medicines or orphan drugs). The work 
of the synergy group was still in its very early stage at time of this research, but it started the 
reflection for further steps to be taken in this regard (personal interview 26).
6.4.2.3. Substantive policy instruments: Joint work
Reducing duplication of efforts in order to promote more effective use of resources laid at the 
heart of all European cooperation efforts in HTA since 1992. Considering the high disparity 
between countries, the first projects (EUR-ASSESS, HTA-Europe) sought to gain insights in 
the different methodologies used and establish best-practices recognised by the partners in 
the different projects. From there, common tools and methodologies have been developed 
by the subsequent projects. These aimed at proving Member States with objective, reli-
able, timely, transparent, comparable and transferable information which could be used in 
165 HTA bodies with a full seat in 2019: HAS (France), G-BA (Germany), NICE (UK), AIFA (Italy), NIPN 
(Hungary), two HTA bodies would share a seat: RIZIV-INAMI (Belgium), ZIN (The Netherlands) 
(EUnetHTA 2018:20).
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decision-making processes (European Commission 2016:4). However, to reduce duplication, 
one of the most important objectives is not only to exchange information but also to be able 
to establish joint assessments which could effectively be used in national decision-making 
processes.
Already since the ECHTA/ECAHI project, a distinction had been made between the develop-
ment of common tools, methodologies on the one hand and joint assessments on the other 
(ECHTA/ECAHI 2001). EUnetHTA will proceed by a similar approach dealing with these issues 
in different work packages. In 2014, the term ‘joint work’ has been introduced and refers 
to a rather broad description including the development of common methodologies, tools 
and joint health technology assessments but also comprises literature reviews, structured 
information for rapid or full HTAs, Early Dialogues or scientific advice on R&D planning and 
study design (European Commission 2016: 4).
To lay the basis of a common approach and methodologies, the EUnetHTA project partners 
have started by adopting a new definition of HTA, amending herewith the widely used defini-
tion framed by INAHTA166. As such, the EUnetHTA definition would define Health Technology 
Assessment as: “a multidisciplinary process that summarises information about the medical, 
social, economic and ethical issues related to the use of a health technology in a systematic, 
transparent, unbiased, robust manner. Its aim is to inform the formulation of safe, effective, 
health policies that are patient focused and seek to achieve best value. Despite its policy 
goals, HTA must always be firmly rooted in research and the scientific method”. (EUnetHTA 
2008b: 13)
Addressing the problem of importing assessment results of HTAs done by different HTA 
agencies, the network partners first sought to develop a common HTA reporting structure. 
The need for standardisation in this regard had already been underscored by the previ-
ous European projects such as EUR-ASSESS and ECHTA/ECAHI (Lampe et al. 2008). The 
EUnetHTA project responded to this need by developing a reporting model permitting to 
establish a basis for the uptake of assessment elements in other health settings. Building 
upon work established by the early European cooperation projects, the Work Package 4 of 
the EUnetHTA Project developed a so-called Core HTA model comprising the nine domains 
originally identified in the EUR-ASSESS project, adding initially to these the domain of ‘ac-
curacy’, but which disappears at a later stage (Lampe et al. 2008b: 71-83). The domains 
comprised in 2008: 1. Current use of the technology (implementation level) 2. Description 
166 INAHTA definition of HTA: Technology assessment in health care is a multidisciplinary field of 
policy analysis. It studies the medical, social, ethical, and economic implications of development, 
diffusion, and use of health Technology (INAHTA 2007).
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and technical characteristics of technology 3. Safety 4. Accuracy 5. Effectiveness 6. Costs, 
economic evaluation 7. Ethical aspects 8. Organisational aspects 9. Social aspects 10. Legal 
aspects (Lampe et al. 2008b:18). In a later stage these domains will be reframed as: 1. Health 
problem and current use of technology (CUR) 2. Description and technical characteristics 
of technology (TEC) 3. Safety (SAF) 4. Clinical effectiveness (EFF) 5. Costs and economic 
evaluation (ECO) 6. Ethical analysis (ETH) 7. Organisational aspects (ORG) 8. Patients and 
Social aspects (SOC) 9. Legal aspects (LEG) (EUnetHTA 2016a:7).
The model was characterised by including an ontology of HTA, structured according to basic 
concepts as Domain, Topic and Issue, all three-combined forming a so-called Assessment 
element167.The Assessment elements would be further described in detailed in an Element 
card which would be generic in nature and could thus be used for the assessment of dif-
ferent technologies categories. An Element card included information about transferability 
potential, importance, information sources, reference materials and the relation of elements 
to one another. Inclusion in the common core HTA model would depend on the transfer-
ability of the assessments as well as on their importance since not all elements defined in the 
ontology would be relevant for or transferable to other settings (Lampe et al 2008b: 25-26).
The EUnetHTA project proposed two ways to use the HTA Core Model. One could either 
consider all domains of the Core Model, as it gave a summary of the findings of each domain 
which had been gathered in a multidisciplinary process. The second way allowed for a selec-
tive use of the assessment elements. In any case, no recommendations for use or non-use of 
the technology would be given. The Model has first been developed for what was considered 
as the most commonly assessed health technologies: medical/surgical interventions and 
diagnostic technologies. However, considering the variety of existing technologies, different 
forms of the model have been developed at a later stage to meet the specificities of other 
technologies (Lampe et al. 2008b: 16). Indeed, several pilot projects have been implemented 
since 2006. The experiences and lessons learned regarding the scientific assessment of the 
technologies have been taken into account in the subsequent versions of the HTA Core 
Model which has been adapted accordingly (see for details Pasternack 2009; Lampe 2009 
and EUnetHTA 2015c; 2016).
During the Joint Action 1 (2010-2012), the main concepts of the HTA Core Model would be 
kept mostly unchanged and the model would continue to be a methodological framework 
for the production and sharing of HTA information. It was still based upon: 1) an ontology 
167 This approach permits to address for each of the domains, specific topics and within these topics, 
specific issues. Similar Topics can be addressed in different Domains and similar Issues may exist in 
different Domains (Lampe et al. 2008b).
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containing a set of generic questions defining the contents of an HTA, 2) methodological 
guidance assisting in answering the questions and 3) a common reporting structure enabling 
standardised reporting of HTAs (EUnetHTA 2013: 52). The main novelty would be the de-
velopment of an online tool and services facilitating the production sharing and use of the 
Core Model168. Moreover, the elements cards have been replaced by so-called ‘results cards’. 
These contained the answers defined by the assessment elements and would be organised 
into ‘collections’. The collections could be either an official EUnetHTA assessment such as a 
standard ‘core HTA’ or a ‘rapid HTA’ (comprising only the first 4 domains). They could also 
refer to any other type of collection freely established by the user. Finally, the handbook 
developed at an earlier stage and which was an aid to the use of the HTA Core Model has 
been updated and made available online (EUnetHTA 2013: 53-55).
The Joint Action 2 followed up on the work described above by developing a set of guidelines 
for the production of full Core HTAs. The underlying rationale remained based on the belief 
that sharing and collaborating on HTA would enhance efficiency and relevance of informa-
tion for all users, avoid duplication and increase uptake of joint work. As such, besides 
the policy guidelines developed in JA1, a common set of procedures and standards will be 
developed during JA2 to ensure internal coordination and organisational aspects of common 
core HTAs169. Finally, the Work Package 8 of the JA2 was dedicated to the maintenance and 
update of the HTA Core Model infrastructure according to the different applications of the 
HTA Core Model (e.g. pharmaceuticals, medical devices, diagnostics) (EUnetHTA 2016a).
As discussed above, following the recommendations of the Pharma Forum, EUnetHTA had 
been designed as network to develop Relative Effectiveness Assessments (REA). The Joint Ac-
tion 1 will follow-up on this recommendation by adjusting the HTA Core Model to REA. One 
of the main adaptations regarded the introduction of a rapid model which would be limited 
168 The process of producing information into the online HTA Core Model was split up into five phases: 
1) Project definition (setting up the project, as well as its scope and participants); 2) Protocol 
design (selecting relevant questions and formulating the to match the scope); 3) Research (finding 
answers to the questions); 4) Entering results into a collection of core HTA information (consists 
of results cards and general texts for the whole collection); 5) Viewing and submitting results 
(emphasis on viewing at this point) (EUnetHTA 2013: 52).
169 The JA2 guidelines outline how the project should be organised by dividing the project group into 
different working teams, each working on different domains. Each of these teams is headed by a 
primary investigator (PI) who is responsible for the overall coordination and for the delivery of the 
final HTA production process. The PIs are assisted by one or more investigators. Besides the active 
researchers, each team is assisted by a group of internal reviewers who need to come from another 
organisation in another country than the investigators. Finally, an editorial team has to be set up 
for each HTA Core project (EUnetHTA 2015c:12-13).
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to the first four domains of the Core HTA Model170 (EUnetHTA 2013: 75). The domains 
have been however adapted to include only the items relevant and feasible for rapid assess-
ment. The domain on cost and economic considerations has been excluded based on the 
recommendations of the High Level Pharmaceutical Forum. The remaining domains (ethical, 
organisational, social and legal domains) have been replaced by a short checklist permitting 
a quick assessment of these issues (EUnetHTA 2013: 82). A (rapid) Relative Effectiveness 
Assessment (REA) has been defined as “an assessment of a specific technology within a 
limited timeframe in comparison with one or more relevant alternative interventions. It may 
assess a new pharmaceutical launched onto the market, or (re)assess a pharmaceutical for a 
new indication or when new relevant data are available” (Kleijnen et al. 2012).
Considering the specific environment of pharmaceuticals where market authorisation needs 
first to be received from the European Medicine Agency, the model for REA sought to be 
in line with the regulatory processes already in place171. As such, the submission file by the 
marketing authorisation holder and the European Public Assessment Report (EPAR) would 
constitute the primary sources of information for the REA. If needed, this would be comple-
mented by a full systematic literature search in reference databases. Specific guidelines for 
this model have been developed and regularly adapted (EUnetHTA 2013:82). Hence, as the 
extent of applications of the Core Model and the model on Rapid REA developed, so have 
the guidelines associated to them. In the course of 2008-2016, many guidelines have been 
developed focusing each on a specific issue of a specific application of these models172.
Despite the work realised to develop and adapt the models according to the needs and based 
on feed-back of those who tested them, no real generalised use of either the Rapid REAs or a 
full core HTA has been observed till the end of the Joint Action 2. Even the implementation of 
pilot projects did not face the same enthusiasm observed in the Early Dialogues, in particular 
on behalf of the industry partners (Personal interview 15). Indeed, agencies having tested 
170 The four domains investigated in a rapid relative effectiveness assessment are: Health problem 
and current use of technology; Description and technical characteristics of technology; Safety and 
Clinical effectiveness (EUnetHTA 2013: 75).
171 One of the underlying reasons to adopt a rapid model of assessments relates to the Transparency 
Directive requiring some countries to assess pharmaceuticals within a limited period of time (90-
180 days).
172 Besides the guidelines on each of the domains treated in the Core Model other examples are: 
Methods for health economic evaluations - A guideline based on current practices in Europe; 
Endpoints used for Relative Effectiveness Assessment Clinical Endpoint; Endpoints used in Relative 
Effectiveness Assessment Safety; Comparators & Comparisons, Direct and indirect comparisons; 
Internal validity of randomised controlled trials; Meta-analysis of diagnostic test accuracy studies 
(see for an extensive list http://eunethta.eu/eunethta-guidelines).
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the HTA Core Model found that the approach represented “a major shift in the content and 
work processes of a traditional HTA” (Pasternack et al. 2009: 26). Working with other agen-
cies thus implied a change of habits and procedures and required trust building between 
HTA bodies who would participate. Moreover, some agencies found that working with HTA 
bodies on a common HTA process did not always result in a gain of time as the reports often 
had to be adapted to local needs or requirements (e.g. Personal interviews 19, 20 22, 27).
The implementation of the pilots testing the core-HTA model and the REAs allowed for 
feed-back of peers who underscored certain challenges that needed to be overcome (e.g. 
Huic et al. 2013). Whilst problems related to practicalities could more easily be dealt with, the 
problems of a legal and scientific nature continued to slow down the willingness or capacities 
of some HTA bodies to take part in common core-HTAs or REAs (e.g. Personal interviews 
19, 22, 27). One of the difficulties was related to the heterogeneity regarding the status of 
HTA bodies in their respective countries. Some would be working under direct orders of the 
ministries, with assessment procedures and rules laid down in formal legal processes. Others 
would be able to decide independently on issues such as the choice of assessments and the 
methodologies used, making it easier to participate in a common assessment procedure (e.g. 
Personal interviews 11, 19, 20, 22, 30). Hence the room of manoeuvre to adapt to common 
assessments varied according to nature of the HTA bodies.
Aware of these challenges EUnetHTA has sought to address the technical, legal, logistic and 
administrative problems. As it could not impose the use of the models or joint assessments 
upon the network members, it has mostly concentrated its focus on increasing the qual-
ity of the project implementation to ensure the quality of the assessments. Since the first 
pilot core-HTAs in the EUnetHTA project, several collaborative models have been tested. The 
envisaged improvements focused on issues such as the organisation of the work (divided 
across agencies or not), communication means used during an assessment, methodologies, 
timeliness, etc. (EUnetHTA 2013:59). Each pilot project was evaluated internally and feed-
back of peers was used in the new pilots. Changes could concern organisational matters 
(e.g. interaction between domain teams) but also touched upon items such as topic selec-
tion, methodological guidance, suitability of the models for all applications, and planning 
exercises (EUnetHTA 2013).
Disagreement existed whether the quality of the model and its outcomes would be sufficient 
to allow for a broad use among all members or European HTA agencies. The model that 
has been applied during Joint Actions 2 and 3 operated according to the principle that one 
organisation served as authoring institution and as such became the lead author in the 
project. Others were selected as co-authoring institutions. They were assisted by review-
ers from two to five different institutions. To some, this model still needed to be further 
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improved to ensure a proper uptake in national agencies. “If you get a report for reviewing 
which is not ready, where half of the things are not provided, you cannot do a correct review. 
(…) Another [remark] is, if you have different ways of researching the literature in different 
reports, then you have to re-check all the time whether this is the right procedure. You can 
also see that the way and the quality of these different research procedures differ. If I need 
something, if we want to share something, we need to know what we get. If we have to 
check each paper very, very thoroughly, it is worthless, it is the same as any other systematic 
review. So, we cannot rely on and we cannot build on this activity” (personal interview 22).
Moreover, as outlined above, the HTA process has to be understood within the wider process 
of technology development and market access. As such HTA often has to respond to specific 
requirements of ministries or regulatory institutions. These requirements will influence the 
scientific approach chosen. Hence, although the establishment of trust amongst HTA bodies 
seems to be an important element to develop, it cannot resolve in itself the methodological 
disparities: “We believe that everywhere in Europe and in the world there are really good 
scientists. They know their work but they are all working on different processes and differ-
ent demands, different cultural demands and different political demands and requirements. 
These differences are those where we have a problem with” (personal interview 22).
Others also emphasise that the lack of participation and use of the outcomes of common 
HTAs is not only related to issues of quality, trust or willingness but also has to be related to 
the contextualisation of an HTA: “There is always a core of evidence which is the same across 
all these reports. It’s about what is the evidence available, what does the evidence look like, 
what is the result of that evidence that you will see in any HTA report, probably what is the 
core of that evidence. But then, there is all the discussion and the analysis around it, which 
probably starts to become unique to reach in HTA reports. I have always felt that we could 
create a core of information which is relevant to everyone and we would probably save a 
small amount of time if we weren’t all writing out the characteristics of all the clinical studies 
that have ever been done and presenting their results. But it is never going to get rid of that 
individual interpretation and analysis that you then need to fit into your decision-making 
framework. You can’t ‘uncontextualise’ that bit” (personal interview 27).
When looking at the nine domains of the core-HTA model, the last five are those in which 
context plays an important role173. Since the Joint Action 3, the focus of EUnetHTA shifted 
173 The nine domains of the HTA Core Model are: 1. Health problem and current use of technology 2. 
Description and technical characteristics of technology 3. Safety 4. Clinical effectiveness 5. Costs 
and economic evaluation 6. Ethical analysis 7. Organisational aspects 8. Patients and Social aspects 
9. Legal aspects (EUnetHTA 2016a:7).
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exclusively to the routinisation of REAs174. Indeed, the domains constituting a relative ef-
fectiveness assessment would be considered as segments where harmonisation could be 
achieved (personal interview 15). Economic, social, ethical and legal aspects of an assessment 
could be considered as part of the appraisal process by some HTA agencies or Member States 
where reaching common grounds would be an even bigger challenge in particular because 
of the need for contextualisation. Hence, although voluntary cooperation on domains laying 
outside the REAs remained a possibility within EUnetHTA, the focus of the EUnetHTA col-
laborative approach in the JA3 would be laying purely on the clinical side (personal interview 
15).
Since the introduction of REA in EUnetHTA, there had been some concern on how this would 
affect the other work of EUnetHTA (e.g. Core-HTA model). Nevertheless, during Joint Actions 
1 and 2, both models coexisted well while being developed in parallel as they were used for 
different purposes. The adhesion of new agencies, where assessment of pharmaceuticals 
played an important role did, however, impact the internal approach: “Their tradition was 
more about safety and effectiveness. They were not so keen in general to look at other 
collaborations. So, there has been an internal challenge on how to fix the use of different 
national needs and of different process needs together” (personal interview 18).
The Commission proposal for a Regulation on HTA cooperation in Europe would build on the 
approach that has been developed over the years in EUnetHTA and would propose European 
cooperation on relative effectiveness assessments, by including mandatory aspects in the 
proposal. Cooperation on other HTA domains would remain voluntary (European Commis-
sion 2018). Although, the other domains would still be recognised as important amongst the 
EUnetHTA members, the Commission proposal could have, according to some, a big impact 
on the further collaboration developments: “Now, of course if this Commission proposal 
174 The rapid REA take place in four phases: project planning (protocol), assessment, review and con-
sultation. Each of them comprising specific sections. As such the project planning phase comprises 
issues such as preliminary assessment of the draft submission file, scoping, search of information, 
formulating research questions, and planning methodologies. At the end of this phase, a final 
project plan is being developed comprising timelines and a list of all relevant questions to be 
addressed in the assessments as well as the methodologies intended to be used. The assessment 
phase includes finding answers to the questions using the outputs of the protocol phase, the 
methodological guidance in the REA Model, and the guidelines. As indicated by its name, the 
review phase is concerned by reviewing the assessment and comments and suggested from other 
reviewers are collected. The consultation phase permits to consult all stakeholders in the process 
(EUnetHTA members, the company applying for market authorisation physicians and/patients). 
Additional comments and opinions can be collected here (EUnetHTA 2015a: 12).
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goes through as it is, there is a risk that it will leave agencies to work only on the first four 
domains” (personal interview 18).
6.4.2.4. Substantive policy instruments: Additional Evidence Generation
Randomised controlled trials (RCTs) are commonly considered as the gold standard for 
evidence generation in technology assessments. However, in some case RCTs are either not 
available or not sufficient to inform decision-makers as they primarily address the ques-
tions of safety and efficacy under specific (controlled) circumstances. However, sometimes 
decision-makers would need more information regarding the efficacy and safety in a 
real-world environment within a specific target group which has or not been taken into 
account in the RCTs. Additional Evidence Procedures (AED), seek therefore to gather, in a 
limited time-frame, relevant data to confirm or infirm expectations. The way in which these 
procedures take place varies between countries in Europe and different policy frameworks 
and mechanisms have been developed allowing temporary access to promising technologies 
whilst requesting additional evidence to reduce uncertainty. These procedures could take the 
format of so-called ‘conditional reimbursements’ or ‘managed entry schemes’ (e.g. Klemp, 
Frønsdal and Facey 2011; Van de Wetering, Van Exel, Brouwer 2017).
At the start of the EUnetHTA project, no institutionalised collaborative framework existed 
in this area where exchange of experiences and information mostly proceeded via inform 
e-mail exchanges and person to person communication in informal networks (EUnetHTA 
2009: 122). To allow for a better understanding of the European disparities regarding AEG 
procedures, the EUnetHTA project - through its WP7 Strand A - first sought to provide an 
overview of the various national experiences, to identify the main barriers to evidence gen-
eration and to develop collaboration among HTA-agencies involved in these mechanisms. 
Following an in-depth study on national experiences, a 5-step policy framework has been 
developed. Coordination, methodological guidance, funding and a regulatory framework 
were identified as critical success factors (EUnetHTA 2009 ;136).
To promote a more efficient exchange system which would be less time-consuming and 
ensure more accuracy in the information and data to be exchanged, WP7 developed the 
so-called Eiffel toolkit, a web-based instrument permitting to structure the collaboration in 
the field of AEG. The collaboration was organised on three levels: (1) sharing information, 
(2) coordinated action, (3) joint action. The website allowed to either request information 
or post information via structured standardised forms stored in a database containing all 
available information (EUnetHTA 2009: 122). This tool has been further developed during the 
EUnetHTA collaboration project and the JA1 (EUnetHTA 2013: 105).
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During the JA1, criteria have been developed for the selection and prioritisation of new tech-
nologies which would be relevant for AEG. These criteria were aimed at HTA doers, study 
funders and other stakeholders and ensured a transparency of selection making (EUnetHTA 
2013: 113). The EVIDENT data-base discussed in the previous sections and which served as 
an aid to Horizon Scanning activities also served to support AEG. Besides the information 
regarding studies being planned or considered in an HTA body, the database also contained 
information on additional studies requested by HTA bodies in Europe and could even give 
information on assessment and reimbursement of new technologies in EU Member States 
(EUnetHTA 2013:113).
During the JA3, the topic of AEG will be dealt with in Strand B of the Work Package 5 which 
also addressed the issue of Early Dialogues. The general idea here would be to consider 
evidence needed for HTA throughout the life cycle of a technology. Early Dialogues did, in 
a sense, depart of the traditional HTA approach - considering only the evidence delivered 
by the manufactures – by identifying at an early stage evidence which would be required. 
Conversely, indicating evidence gaps post market authorisation would be a traditional activity 
of HTA bodies, however, till then, no joint approach between HTA bodies would have been 
adopted. In the Joint Action 3, the idea would therefore be to build upon the experience of 
the Early Dialogues and establish so-called ‘late dialogues’ where post-marketing evidence 
generation could be discussed between several HTA bodies and manufacturers (personal 
interview 29). As such, ‘Post-Launch Evidence Generation’ pilots (PLEG-pilots) have been 
implemented seeking to address the issue of evidence gaps and managed entry agreements 
by adopting a collaborative approach.
As in other fields of collaboration, the challenge would be to agree upon a common frame-
work and accepted evidence as the procedures would still highly differ. As such, registries 
for, example, would be accepted as post-launch evidence in Italy where their data collection 
would be financed and run by an HTA body (i. e. AIFA) whereas this would not be possible 
in other countries. Here again, differences in procedures would often stem from the differ-
ent statuses of HTA bodies (e.g. integrated or not in regulatory bodies) (Personal interview 
29). As in Early Dialogues, the PLEG-pilots would be implemented in collaboration with the 
EMA. However, no joint advice or opinion would be given in these projects. The first pilots 
implemented would target specifically on the use of registries and real-world data in the 
areas of rare diseases and cancer (EUnetHTA 2018). The tools developed would be based on 
the PARENT Joint Action175 which worked specifically on the issue of patient registries.
175 The Cross Border PAtient REgistries iNiTiative (PARENT), is a Joint Action which has been financed 
and implemented under the EU’s Health Programme 2008-2013.
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6.4.2.5. Substantive policy instruments: Uptake
In chapter 1, we have outlined the relation between HTA and national policy-making 
processes since HTA seeks to provide input in regulatory processes such as pricing and 
reimbursement of health technology, the establishment of clinical guidelines or hospital 
investments. Strengthening the link between HTA and health care policy-making in the EU 
Member States, is an objective which has been on the European HTA cooperation agenda 
since 1992, when the EUR-ASSESS project started to be elaborated. Indeed, the founders 
of the first HTA cooperation initiatives in Europe already underscored the importance of 
securing a strong relationship between the collaborative HTA project and domestic decision-
making processes as, in their opinion, this would also strengthen the development for HTA 
as such (see chapter 4).
The HTA-Europe project (1997-1999) further addressed this issue by publishing a book giv-
ing an overview of HTA practices and use in domestic decision-making processes of several 
European countries (see chapter 4). In 2006, as HTA was still a relatively young discipline 
but manifesting a fast development in many countries, the HTA-Europe project would be 
updated by the EUnetHTA project. As such, the Work Package 6 of the EUnetHTA project 
would publish in 2008 the book: Health Technology Assessment and Health Policy-Making 
in Europe. Current status, challenges and potential (Garrido et al. 2008). This publication 
established a systematic overview of the relation between HTA and policy-making in the EU 
Member States and highlighted the needs of HTA consumers aiming at providing input for 
policy processes176.
Ensuring the use of collaborative HTA projects outputs in national decision-making pro-
cesses, implied the uptake of those outputs in the HTA bodies operating in the domestic 
policy-making processes. The notion of ‘uptake’ refers to the use of collaborative HTA work 
in national-decision-making processes. Although the aim to facilitate the use of collaborative 
HTA outputs has been present since the EUnetHTA project, it is only during the Joint Action 2 
that a clear definition of the concept has been given. As such, ‘uptake’ points to a broad un-
derstanding of use of collaborative HTA products and regards “the general implementation 
of any EUnetHTA output in a national context and may include the usage and implementation 
of the EUnetHTA tools and Joint Assessments” (www.eunethta.eu). Hence, ‘uptake’ is not 
just limited to the use of joint assessments but also includes all other tools and methodolo-
gies developed by the EUnetHTA Network and used in a local/regional/national setting (e.g. 
176 The publication underscores the need for collaboration on HTA in Europe and outlines the policy 
processes in the EU countries under scrutiny. The relation between HTA, policy-making and regula-
tory processes is being examined. It also presents the state of play of HTA in Europe and brings to 
the fore the needs and demands from policy-makers (Garrido et al. 2008).
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use of the POP Database for local reports, submission templates, guidelines, the production 
of a local HTA report on the basis of the HTA Core Model or EUnetHTA guidelines).
Several tools have been developed to facilitate uptake of EUnetHTA outputs. The EUnetHTA 
project would develop a toolkit permitting to adapt the results of an existing HTA to a regional 
or national setting. The aim here was “to enable an HTA agency in one setting to make use 
of an HTA report produced elsewhere, thus saving time and money” (EUnetHTA 2011a:6). 
This toolbox comprised checklists, questions and resources enabling to assess the relevance, 
reliability and transferability of report. The users of the toolbox could determine whether e.g. 
the policy and/or research question posed in a report was sufficiently similar to the questions 
posed in its own setting. It could also assess the quality of the report and determine whether 
the information was applicable to the target setting and could thus inform policy-making177. 
The toolkit has been revised several times throughout the project and the subsequent Joint 
Actions and key elements of the adaptation toolkit had been integrated in the HTA Core 
Model online. Each revision resulted from feed-back of peers via evaluation rounds, in-house 
reflexion processes or surveys178 (EUnetHTA 2013:55).
As the first Joint Action focused on the establishment of tools and methodologies to un-
dertake joint work, less attention was being given to the specific issue of uptake in national 
decision-making processes. Whilst the JA1 still had to develop and test the methodologies, 
it is only during the Joint Actions 2 and 3, that the issue of ‘uptake’ will become increasingly 
important. Indeed, in JA2, a specific WP 5 has been dedicated to the issue of “applying the 
HTA Core Model for Rapid Assessment for national adaptation and reporting”. The aim here 
was “to test the capacity of national HTA bodies to produce structured core HTA information 
(full core/rapid HTAs) together and apply it in national context (including collection of data on 
costs and overall efficiency of the production in the network) (www.eunethta .eu).
177 For this purpose, the toolkit comprised two sections: speeding shifting and main toolkit. The 
speedy shifting focuses on the relevance of the report for adaptation. The main toolkit regards 
questions of reliability and transferability (EUnetHTA 2011a).
178 Before publishing the final deliverable in 2008, two evaluation rounds were organised to test 
different versions by means of a questionnaire, in-house reflection processes and a Delphi survey. 
Several agencies have tested the Adaptation toolkit by selecting one or more HTA reports from a 
different country to assess whether it fulfilled the needs of their own health services. Evaluation 
of the applicability of the toolkit has also been done by testing the toolkit on the first Core HTA 
on Drug eluting stents elaborated by WP 4. Finally, group work with WP 5 members on five topic 
areas and face-to-face or telephone interviews further completed the evaluation process of the 
Adaptation toolkit (www.eunethta.eu).
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During the Joint Action 2 the concept of ‘National Adaptation’ will be introduced pointing 
to a specific type of national uptake. It focused in particular on the use of joint assessments 
results (. i.e. full core-HTA or Rapid REAs) in a national or regional setting. Several modalities 
have been developed to support this, such as: summarising (i.e. Core HTA report is being 
summarised and used as background information), updating searches (i.e. search is being 
based on the original joint Core HTA search and further updated), adapting (i.e. systematic 
extraction of relevant HTA information from a joint assessment) or adopting (i.e. use of an as-
sessment without making any changes in the content)179. Examination from the twelve Rapid 
REA pilots implemented in the JA2, showed more than seventy cases of national uptake 
(www.eunethta.eu/national-uptake).
Despite these examples of uptake, the general feeling amongst the agencies, EUnetHTA 
and the Commission was that the use of joint work was too low (Personal interviews 8, 
9, 15). The governance structure of EUnetHTA, as an independent network without any 
established legal status, could however not impose the integration of the new core-HTA or 
REA model into the procedures of the national HTA bodies. It would thus be fully depended 
on the willingness of each HTA agency to adopt or not the framework and methodologies 
of the core-HTA model or the REA model. Adapting to common EUnetHTA methodologies 
and tools seems to have been done more easily by HTA agencies in small and middle-sized 
countries. Often their relative independence or strong ties with the ministries would be an 
asset in this regard. HTA expertise in these countries would be often concentrated in HTA 
bodies and representatives of ministries would be more inclined to take advise of representa-
tives of HTA bodies to determine the course of action of HTA bodies. In bigger countries 
such as France, the UK or Germany, changing legal or methodological aspects or procedures 
regarding HTA seems to have encountered much more difficulties. Moreover, in small or 
medium sized countries, the executive functions within an HTA body would often be carried 
out by representatives present in EUnetHTA executive or lead functions which facilitated 
decision-making regarding the adaptation of the local model to the EUnetHTA model (e.g. 
Personal interviews 11, 19, 22, 27).
However, even those bodies having formally adopted internal procedures according to 
EUnetHTA standards, did face internal difficulties as their employees had to adapt to new 
habits and procedures. “We have decided to adapt our HTAs in such a way that they would 
fit in the Core-HTA model with another layout. It was maybe accompanied with weeping and 
gnashing of teeth in the home base of our researchers (…) but you do need the authority 
of the chief of the institution to be able to do that” (personal interview 20). Hence, since 
179 To determine whether a report is based on national adaptation an explicit reference to the EU-
netHTA joint assessment has to be made (www.eunethta.eu/national-uptake).
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the EUnetHTA project, researchers having participated at the Core HTAs agreed that the 
general concept and structure of the Core HTA was feasible and that the content produced 
was useful for local HTAs. However, in practice, it remained difficult to increase the number 
of projects and see the results of those projects been implemented in the national settings.
This had in particular consequences for the industries’ approach regarding the (rapid) REAs 
and full core-HTAs. Conversely to the Early Dialogues, the enthusiasm of manufacturers 
to participate was rather limited. Several reasons could be brought forward to explain this 
situation. Most often, the lack of uptake has been brought forward as an explanation why 
manufactures hesitate to participate in these projects: “submitting files for a European as-
sessment which in the end will not be used by the Member States, or will just be looked at a 
bit, then put aside before they start doing their own national assessments… All advantages 
the industry sees in this process will be realised only if the reports will be used. If they are 
not used, it is a duplication of efforts for the industry: two processes, two times more work, 
conclusions on a European level which will differ of those on the national level. That makes 
it a rather complex issue without offering any advantage, zero advantage for the industry. 
So as long as the process remains voluntary for the agencies, it should be voluntary for the 
industry as well” (personal interview 24).
During the Joint Action 3 a specific work package (WP7) would be dedicated to the issue of 
‘national implementation and impact’. A systematic analysis would be made regarding the 
use of EUnetHTA tools, methodologies in national HTA bodies. Through internet surveys, 
qualitative interviews and focus groups, the members of the work package would seek to 
better understand the impact of EUnetHTA products in national HTA assessments and how 
joint assessments would be implemented in the different European countries (EUnetHTA 
2019). This analysis would examine both the use of EUnetHTA output for assessment pur-
poses and for dissemination activities and would regard the joint or collaborative assess-
ments published under JA3 (4 assessments of pharmaceutical technologies and 18 of other 
technologies (EUnetHTA 2019a)). The reports published in 2019, near the end of the Joint 
Action 3, pointed to an increase in use of EUnetHTA outputs for pharmaceutical technology 
assessments compared to Joint Action 2 (220 in JA3 of which 53% for assessments and 47% 
for dissemination purposes). For other technology assessments, 105 uses of assessments 
have been reported, with a majority in dissemination (EUnetHTA 2019a: 6).
When uptake took place, the implementation reports showed that most often the EUnetHTA 
assessments would be used as background information or additional information. Agencies 
would also use assessments and add local information or elements related to budget impact, 
cost-effectiveness analysis as well as organisational, legal or ethical aspects. Often assessments 
would also be used to inform the evaluation of a company submission (EUnetHTA 2019: 19). 
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For non-pharmaceutical technology assessments, the studies showed that most often the 
EUnetHTA outputs would be used without changes other than a translation. Hence, the 
work carried out by EUnetHTA would replace the agencies’ work (EUnetHTA 2019: 19). This 
would be less the case in pharmaceutical technology assessments. The reports, furthermore, 
underscore a good topic selection as the assessments’ topic are generally within the remit of 
the agencies (EUnetHTA 2019a: 10). At the end of the JA3, some 20 countries reported using 
EUnetHTA JA3 assessments. The reported number of uptake marked a significant difference 
compared to JA2 (EUnetHTA 2019a: 18).
The 2019 implementation study is however interesting as it would assess in detail the parts 
of EUnetHTA assessments used by HTA bodies and the challenges and barriers they would 
encounter when using EUnetHTA outputs. Regarding the former, HTA bodies would most of-
ten have recourse the domains of corresponding to EUnetHTA REAs: i.e. clinical effectiveness, 
safety, health condition and use of technology and description of technology (EUnetHTA 
2019:20). The collaborative work would mostly be used as background information. Ad-
ditional information regarding issues as budget impact, cost-effectiveness analysis or ethical, 
legal and organisational information would be added (EUnetHTA 2019a: 19). Barriers to 
uptake, as highlighted in the report, would point to the language requirements (i.e. use 
of national language as pre-requisite) as well as issues of the use of a specified reporting 
structure and the timing of the availability of EUnetHTA assessments as well as the fact that 
different assessment elements would be needed (EUnetHTA 2019: 21; EUnetHTA 2019a:21). 
For other technology assessments, barriers cited would concern language requirements, a 
different scope of assessments compared to the national assessment, as well as timing of 
the EUnetHTA assessment availability and too restrictive included evidence in the EUnetHTA 
REAs (EUnetHTA 2019:22).
6.4.3. Policy implementation of EU HTA cooperation processes
In this section we will examine the policy implementation of European HTA collaboration as 
it has developed on the EU side. We have seen in the sections above how, since 2008, HTA 
cooperation has been dealt with in line with the Cross-Border Health Care Directive. From 
2008 till 2014, policy implementation regarded mostly the insertion of means to support HTA 
cooperation in the public health Programme. As of 2014, policy implementation regarding 
HTA collaboration on an EU level would take mostly place through the EU HTA Network 
and structured by means of two multiannual work plans (MWP). The implementation of 
the course of action suggested in these plans would be done in close cooperation with the 
Joint Actions 2 and 3 run by EUnetHTA. This would be coherent with the way governance of 
European HTA cooperation had been outlined in the Strategy paper of the EU HTA Network 
which we have described above.
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Whist the EU HTA Network would be responsible for the strategic orientation of HTA co-
operation, EUnetHTA would act as its technical and scientific arm. Moreover, the first MWP 
(2014-2016) recalled that “In line with Art 15(7) of Directive 2011/24, measures adopted 
to implement this MWP shall not interfere with Member States’ competence in deciding on 
the implementation of Health Technology Assessment conclusions and shall fully respect the 
responsibilities of Member States for the organisation and delivery of health services and 
medical care” (European Commission 2013b:2).
Part of the work established by the EU HTA Network will be the preparation for a legislative 
proposal on HTA Cooperation as discussed above in the section on policy formulation. As at 
the time of writing this proposal still needed to be adopted we will examine in this section 
which have been the points of discussion and how these are related to the objectives and 
projects implemented by the different networks which have been involved in European HTA 
cooperation.
6.4.3.1. The EU HTA Network Multiannual Work Plans
One of the first activities implemented by the EU HTA Network has been the development 
of a Multi Annual Work Plans (MWP). The first MWP which would run from 2014-2016 
and has been developed during the Joint Action 2, outlined three key tasks which would 
be in line with the substantive policy instruments described above in the examination of 
EUnetHTA. The first MWP key task regarded the follow-up of the Joint Actions and the 
establishment of a sustainable cooperation on a scientific and technical level between HTA 
authorities and other players. Here we do find back the main objective pursued already in 
the early cooperation initiatives and by EUnetHTA: setting up a sustainable network for HTA 
cooperation in Europe.
The difference with the approach of the former initiatives is that the EU HTA Network will 
envisage a sustainable cooperation outside the existing project-based approaches by seeking 
to establish a structure including high-level national policy-making authorities, as would be 
proposed in the Commission Proposal for a Regulation on HTA Cooperation. Indeed, as 
underscored by a Commission representative, the question that increasingly came to the 
forefront in discussions on HTA cooperation was: “Can we rely on voluntary self-governance 
to strengthen this cooperation? (…) Because the problem is all about predictability, stability 
and planning. So, we can keep on relying on projects that last four years and need a year and 
a half for negotiations, half a year to start, they work for three years maximum and then half 
a year to close down. Is this something cost-effective and actual useful for Member States?” 
(Personal interview 8).
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The second key task in the MWP 2014-2016 would underscore the importance of uptake 
and re-use of joint HTA production. However, the EU HTA Network would limit itself at 
this stage solely to the formulation of recommendations “on what is necessary to enable 
competent authorities to increase re-use of joint HTA work at national/regional level”. It 
would also underscore the importance to encourage the industry to participate in joint work 
(e.g. of pharmaceutical rapid assessments) and to encourage national authorities to promote 
such joint work (European Commission 2013b: 6). We have seen how this issue will be taken 
up in the work plan of the third Joint Action where a specific work package will seek to 
advance on the issue of uptake and re-use of joint production (see above).
The third key task of the first MWP addressed the topic about the interaction between regula-
tory authorities and HTA bodies. The aim here would be to streamline the different processes 
in order to speed up patient access to treatment. Hence, synergy and de-fragmentation 
between regulatory authorities (EU and national level) and HTA bodies should be targeted 
according to the EU HTA Network. Besides improved patient access to treatment, improv-
ing business predictability and reduce administrative hurdles for technology providers and 
regulators still underpinned the EU HTA Network approach in seeking more synergy between 
Regulators and HTA agencies “while safeguarding the criteria applied for placing technolo-
gies on the EU market” (European Commission 2013b: 4). This issue too, would be further 
worked out in the third Joint Action as described in the section above.
The second and third key tasks have been implemented by means of the publication of reflec-
tion papers and have served as a basis for the work undertaken by EUnetHTA, in particularly 
in the Joint Action 3. The reflection paper on ‘Reuse of joint work in national HTA activities 
had been adopted in April 2015 underscoring the importance of this issue for the usefulness 
of the overall HTA cooperation process. It will also determine the approach the Commission 
will adopt while preparing its Proposal for a Regulation on HTA cooperation in Europe linking 
sustainability of the network with uptake of joint work:
“To enable the move from piloting to long term sustainability of “Joint Work” and more 
broadly the cooperation at EU level on HTA, it is essential to ensure the usefulness of the 
cooperative work. The usefulness of the cooperation is also reflected by the extent to which 
Joint Work, i.e. the “products” of the cooperation are valued and used by national and 
regional HTA bodies as well as by other stakeholders, for example patients, health care pro-
viders, payers (statutory health insurance) and industry. Only if national/regional HTA bodies 
and stakeholders can benefit from joint work in their national activities will they continue 
to invest resources in the cooperation after EU funding from the Health Programme ends. 
If the reuse is not happening to the desired extent, there is the risk that the EU cooperation 
remains an interesting exercise but with limited value for national/regional HTA activities. 
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Thus it will not be meeting the final objectives set out in Directive 2011/24 including, sup-
porting Member States in providing “objective, reliable, timely, transparent comparable 
and transferable information on the relative effectiveness […]” and avoiding duplication of 
assessments” (Art 15.2).”
The reflection documents would assess the different methodologies and tools that had been 
developed by EUnetHTA and which so far did not bring the desired results according to 
the authors of the document. The options envisaged in the paper to increase uptake of 
joint work would serve as a basis for the work carried out in the Joint Action 3180. Specific 
attention was also given to the life-cycle approach as still disparities among the HTA bodies 
in Europe existed. Although, according to the authors of the paper, these differences should 
be respected they also believed that the life-cycle approach in evidence generation (pre-
and post-launch) should benefit from a closer cooperation between regulators, HTA bodies, 
payers and providers181 (European Commission 2015c: 8). Similarly to the other subjects 
mentioned above, the life-cycle approach would be further elaborated in the Work Pack-
age 5 of the third Joint Action including herein the Early Dialogues as well as post-launch 
evidence generation and registries (www.eunethta.eu/ja3-archive/work-package-5-life-cycle-
approach-to-improve-evidence-generation).
The second HTA Reflection paper, adopted by the HTA Network in November 2016, dealt 
with the topic of “synergies between regulators and HTA issues on pharmaceuticals”. The 
reflexion made here sought to build further on the work establish by the SEED project and 
the Early Dialogues developed by EUnetHTA, as well as on work undertaken in the EMA 
and initiatives such as the IMI projects and the Expert Group on Safe and Timely Access to 
Medicines for Patients (STAMP). As starting point of the reflection process, the authors of 
the paper considered that “stronger synergies between developers of health technologies, 
180 The Reflection document referred for example to the establishment of a professional project 
management process and of a mechanism (including standard operating procedures) permitting a 
transparent topic selection and prioritisation process. Moreover, it recommended the implementa-
tion of a process facilitating the expertise by clustering (e.g. specific bodies are responsible for 
the assessment of specific types of technology assessment and are assisted herein by experts and 
appropriate stakeholders). Finally, an evaluation process measuring the uptake and the added 
value of European HTA cooperation has been recommended. Moreover, the reflection paper also 
made some specific recommendations regarding joint assessment reports, the HTA Core Model, 
Submission templates, Methodological standards for HTA, training material and ICT tools (POP 
database, EVIDENT database) (European Commission 2015c: 5-8).
181 In this respect, it highlights the necessity for cooperation between networks such as the Safe and 
Timely Access to Medicinal Products Expert Group (STAMP) and the EMA (European Commission 
2015c: 8).
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regulators, HTA bodies and decision makers can contribute to a timely and comprehensive 
access to information and data throughout the entire life cycle of health technology (from 
start to end) which can result in important benefits for healthcare systems” (European Com-
mission 2016a: 2). Three phases in this regard are being identified: the pre-marketing phase, 
market entry and the post-marketing launch phase.
The pre-marketing phase would explore ways to develop successful initiatives as the Early 
Dialogues and would aim at developing a single model for parallel advice, suitable for both 
regulatory and HTA needs182. Suggestions related to the second phase aimed at developing 
actions to support the production of joint work and ensure early exchange of information 
between regulators and HTA bodies. Information exchange between the EMA and HTA 
bodies could take place through the establishment of a legal arrangement for a structured 
process where assessments would include data relevant for HTA. Regarding the third phase, 
reflection was focused on post-marketing studies with the potential use of Real World Data 
(RWD). The idea of “late dialogues” was also evoked permitting to facilitate collaboration 
with technology providers in the post-marketing phase183 (European Commission 2016a: 
5-6). All these reflections have been further used in the Joint Action 3 which has sought 
to implement some of these proposals in pilot projects as outlined in the sections above. 
Moreover, these reflections will also lay at the basis of the Commission proposal for HTA 
Cooperation in Europe (European Commission 2018).
The second Multiannual Work Programme (2016-2020) adopted by the EU HTA Network 
at time of the start of the Joint Action 3, stipulated that “The HTA Network is expected to 
act as key strategic forum to contribute to defining the possible scope, sustainability and 
governance of the European cooperation on HTA, beyond Joint Action 3. (…) During the 
coming years, one of the main objectives for the HTA Network should be to take an active 
role in clarifying and ensuring conditions for a sustainable functioning of the scientific and 
technical cooperation when the EUnetHTA JA3 ends in 2020” (HTAN 2016:3). Moreover, 
it is underscored how at the time of drafting the work plan the third Joint Action was just 
being launched. Therefore again, the repartition of tasks between the EU HTA Network and 
EUnetHTA should still remain the same: the former focusing on the political and strategic 
objectives taking care not to duplicate activities foreseen by the Joint Action or other relevant 
initiatives but instead create synergies between them (HTAN 2016: 2).
182 Attention here would also be given to the definition of unmet medical needs, evidence limitations, 
Horizon Scanning programs etc. (European Commission 2016a).
183 Some other areas where collaboration between regulatory and HTA bodies could be useful have 
also been identified such as orphan medicinal products, personalised medicine and vaccines (Euro-
pean Commission 2016a: 6).
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Although not specified as such in the document, under “other relevant initiatives” one 
could understand regional (intergovernmental) initiatives which had been launched between 
several EU Member States and which would target Horizon Scanning activities, joint assess-
ments and in some cases even cost-effectiveness analysis and price negotiations. In most of 
these cooperation structures, membership would overlap with EUnetHTA membership. The 
main difference in initiatives such as; the Beneluxa Initiative184, the Finose collaboration185, 
The Valetta declaration186, or the Visegrad + 2187 would be the strong implications of relevant 
national ministries in those. These initiatives have been developed independently of the 
European Commission at a time where a new Commission proposal was being prepared. As 
it was unclear how these initiatives would further develop, the Commission would adopt – at 
least officially – a rather neutral position towards them even if it did attend meetings of some 
collaboration initiatives (Grubert 2018; www.globalpricing.com).
The EU HTA Network will therefore focus on delivering concrete outputs regarding the 
sustainability and governance of European governance. In this regard, different actions will 
be undertaken by the European Commission as described in the sections above (e.g. section 
6.2.2.3.0) and which follow the classical path of the development of a new legislative Com-
184 Beneluxa is an initiative created in 2015, which “aims for sustainable access to, and appropriate 
use of, medicines in the participating countries”. It seeks to “increase patients’ access to high 
quality and affordable treatments”. The cooperation activities take place in areas such as Horizon 
Scanning, mutual recognition of HTA, information sharing and policy exchange and pricing and re-
imbursement. In 2019, the following countries had joined the network: Belgium, the Netherlands, 
Luxembourg, Austria and Ireland (www. Beneluxa.org).
185 The Finose collaboration refers to a memorandum of understanding signed in June 2018 between 
national HTA agencies in Finland (Fimea), Norway (NoMA) and Sweden (TLV) aiming to produce 
joint assessment reports containing both clinical and economic assessments. Although Denmark 
had participated in a 2017 memorandum of understanding of high-priced hospital medicines, it 
did not take part in the Finose collaboration as its reimbursement decision-making system differed 
too much from the other three countries (Grubert 2018; www.remapconsulting.com).
186 The Valetta Declaration signed in May 2017 by Cyprus, Greece, Italy, Malta, Portugal and Spain 
established a collaboration in the field of the assessment and procurement of new medicines. The 
area of activities are: joint clinical assessments, economic evaluations and joint price negotiations; 
sharing information to input price negotiations and contracting; sharing information and best 
practices around biosimilar pricing and reimbursement; sharing pharmaco-therapeutic / effective-
ness assessments of drugs; Horizon Scanning. The focus is on drugs with a potential high impact 
on national budgets such as oncology drugs, orphan drugs, biosimilars. Other countries which 
have joined the group since are Croatia, Ireland, Romania and Slovenia. France has been granted 
an observer status (Grubert 2018; www.infarmed.pt; www.remapconsulting.com).
187 The Visegrad+2 group comprised the Czech Republic, Hungary, Poland, Slovakia, Croatia and 
Lithuania who agreed in March 2017 to cooperate to ensure fair and affordable access to medi-
cines for their citizens (Grubert 2018).
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mission proposal. Following the Inception Impact Assessment published in 2016, the public 
consultation, which ran till January 2017, and the Impact Assessment published in January 
2018, the European Commission publishes its Proposal for a Regulation on HTA cooperation 
in Europe outlined in section 6.2. In the next section we will focus our analysis on some key 
issues of debate in discussions on the Commission proposal involving the different stakehold-
ers in the HTA cooperation process.
6.4.3.2. The Commission proposal for a Regulation on HTA cooperation
Section 6.2 on the EU policy formulation process has outlined the Commission proposal for 
a Regulation on HTA cooperation in Europe. In this proposal, HTA cooperation is organised 
according to four pillars: Joint Clinical Assessments (JCA), Joint Scientific Consultations 
(JSC), the identification of emerging health technology and voluntary cooperation. To be 
implemented, the proposal should be adopted by the European Parliament and the Council 
with qualified majority, according to the Ordinary Legislative Procedure applicable in this 
case. This proposal brings to the fore some new key-player in the field of HTA cooperation: 
the European Parliament and Council.
As the first institution having to pronounce itself on the proposal, the European Parliament 
will propose a series of amendments first discussed in the ENVI Committee before being 
submitted to a vote and adopted in the plenary assembly of the European Parliament in 
October 2018. The debates on the text proposed, revealed the different controversial stand-
points present among the Member States, some of which already had been expressed by 
stakeholders in the aftermath of the proposal’s official publication. Indeed, although the 
European Economic and Social Committee delivered a positive opinion in May 2018, some 
countries (i.e. Czech Republic, Germany, France and Poland) had already raised their concern 
as regards the respect of the subsidiarity principle as outlined in the section on policy formu-
lation (Council 2018)188.
Although the proposal on HTA cooperation was a new topic on the European Parliament’s 
agenda, the issue of HTA had already been debated several times in this institution. In its 
2017 resolution on EU options for improving access to medicines, for example, the Parlia-
ment had already called on the Commission to propose a legislative framework on HTA, 
underscoring that “health technology assessments (HTA) must be an important and effective 
instrument for improving access to medicines, contributing to the sustainability of national 
healthcare systems, allowing for the creation of incentives for innovation, and delivering 
high therapeutic added value to patient; (…) the introduction of joint HTAs at EU level would 
188 All countries, except Poland, had submitted a reasoned opinion in this regard (Council of the 
European Union 2018).
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avoid the fragmentation of assessment systems, the duplication of efforts and the misalloca-
tion of resources within the EU” (European Parliament 2017: 29). Moreover, the resolution 
also brings to the fore the importance of relative effectiveness assessments and the need to 
harmonise transparent HTA criteria in this regard and to put in place a “European classifica-
tion system” to chart the therapeutic added value of new medicines. It also calls upon the 
Commission to strengthen Early Dialogues. (European Parliament 2017: 15).
As underscored by a Commission representative, inter-institutional cooperation permits 
a topic to be discussed in the different political venues. As such, Council conclusions are 
often prepared in cooperation with Commission representatives as has been the case in HTA 
cooperation: “It is a rather small world so, of course, at the more technical level, we talk to 
each other. When the Council makes a conclusion, the Commission is involved, it is consulted 
… it didn’t come out of the blue for us and you will see a lot of connections between the 
different conclusions, these documents, the documents of the HTA Network. So, it is not a 
coincidence that all the three institutions have HTA as a topic. And the same with Parliament, 
at technical level they ask advice, opinions. (…). The three institutions have different timings 
and objectives. Only when there will be an initiative form the Commission, there will be a 
formal process between the institutions” (Personal Interview 8)
The amendments adopted in the first reading of the Parliament demonstrate again the 
interest of this institution for this topic. The point of view of the Parliament will however 
differ from the approach the Commission had adopted in drafting the proposal by taking 
an Internal Market approach. The European Parliament will indeed attempt to reintegrate a 
public health approach in the Regulation proposal. As such, the first amendment seeks to 
enlarge the legislative basis from referring not only to Article 114 TFEU regarding the estab-
lishment and functioning of the internal market but also to Article 168 (4) TFEU regarding 
measures setting high standards of quality and safety for medicinal products and devices for 
medical use (European Parliament 2018). Similarly, instead of adopting the statement in the 
Commission proposal considering the development of health technologies as “a key driver 
of economic growth and innovation in the Union”, it proposes to add the qualification of the 
development of HTA as a “key to achieving the high level of health protection that health 
policies must ensure, for the benefit of all citizens” (European Parliament 2018).
Other amendments adopted in the first reading are of a more technical nature, precising 
some aspects of HTA, such as, amendment 10 underscoring the need for health profession-
als, patients and health institutions to have a better knowledge about the added therapeutic 
value of a new medicine compared to existing ones. Indeed, the Parliament confirms in its 
amendments its support to harmonise HTA criteria “to assess the added therapeutic value 
of medicines compared with the best available alternative taking into account the level of 
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innovation and value for the patients”, already expressed in earlier official statements and in 
which it advocated “to introduce compulsory relative effectiveness assessments at EU level as 
a first step for new medicines, and to put in place a European classification system to chart 
their therapeutic added value level, using an independent and transparent procedure that 
avoids conflicts of interests” (e.g. European Parliament 2017a).
The Parliament also stresses how HTA could be a tool for promoting high-quality innova-
tion “steering research towards addressing the unmet diagnostic, therapeutic or procedural 
needs of healthcare systems as well as steering clinical and social priorities” (European Parlia-
ment 2018). Other items, related to the importance of HTA, have been highlighted such 
as the possibilities for improved patient access to medicines, efficiency in use of resources, 
sustainability of health systems, more efficient research and greater predictability for the 
sector improving herewith its competitiveness (European Parliament 2018).
Many amendments seek for more explicitly in the text of the proposal which was considered 
by some as being too vague and leaving to many areas open for discussion or decisions taken 
by means of delegated or implementation acts (e.g. Personal interviews 11, 12, 15, 17, 21). 
Moreover, regarding the rules to be established in joint assessments, the parliament stresses 
the need to guarantee the highest quality standards and the alignment to the best available 
practice, avoiding herewith a convergence towards the lowest common denominator and 
having more experienced HTA bodies used to apply higher standards having to accept lower 
requirements (European Parliament 2018).
As to the mandatory aspects of the Regulation, the European Parliament proposed to give 
the right to Member States to complement the Joint Clinical Assessments with additional 
clinical evidence and analyses (e.g. different comparators). The case of orphan medicinal 
products has also been introduced in the text. The Parliament moreover argues for the need 
“to move towards a centralised authorisation system that assesses devices on the basis of 
safety, efficacy and quality” as, due to the increasing amount of medical devices addressing 
clinical conditions, more HTA cooperation would be needed to address to lack of clinical 
evidence in some cases. (European Parliament 2018).
With regard to the governance structure, the Parliament proposes that Joint Scientific Con-
sultations (JSC) could be conducted with the Coordination Group or with working groups 
set up for this purpose. Precisions regarding what these JSC should address are also given 
(e.g. clinical study design, comparators based on the best medical practice) as well as the 
evidence necessary to conduct the consultations (European Parliament 2018). Moreover, it 
is being proposed to establish a system of charges for health technology developers which 
would request JSC and JCA for research on unmet medical needs. The Parliament proposed 
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furthermore to add a new article regarding the establishment of a structured dialogue with 
stakeholder groups by means of a stakeholder forum.
The original text of recital 31 proposed to consider, two years after implementation of the 
Regulation, the possibility establish a Union agency and introduce a fee-paying mechanism 
for health technology developers. The European Parliament amends the text by deleting this 
possibility in the Regulation proposal. Instead, it proposed to submit an Impact Assessment 
study after the transitional period, which should evaluate, amongst others, “the progress 
made in relation to patients access to new health technologies and the functioning of the 
Internal Market, the impact on the quality of innovation and on the sustainability of health 
systems, as well as the appropriateness of the scope of the joint clinical assessments and the 
functioning of the support framework” (European Parliament 2018).
The Commission proposal also foresaw a certain role for the Commission in having the final 
say on inclusion or non-inclusion of a health Technology after a JCA. Indeed, in the Commis-
sion proposal, in case the Commission would conclude that a modified approved JCA report 
and summary report would not comply with the substantive and procedural requirements 
of the Regulation, the Commission would have a right to decline the name of the health 
technology in the List foreseen by the Regulation. The European Parliament, in its amend-
ments, proposes to restrict this right to only express itself of the procedural requirements 
laid down in the Regulation and in case of a negative opinion leave the health technology 
on the list, accompanied by the negative opinion of the Commission. As foreseen in the 
original proposal, the European Parliament confirms that, in case of the latter, the mandatory 
obligation of using the results of the JCA would not apply to the other Member States.
The European Parliament endorses the standpoint of the Commission stating that the the 
principles of subsidiarity and proportionality do apply in this case as the objectives of the 
Regulation “namely to approximate the rules of the Member States on carrying out clinical 
assessments of the health technologies falling under the scope of this Regulation, cannot be 
sufficiently achieved by the Member States alone but can rather, by reason of their scale and 
effects, be better achieved at Union-level” (European Parliament 2018). This approach has 
not been shared by all Member States which would have to pronounce themselves in the 
first reading of the Council.
As in the case of the European Parliament, the ENVI committee would coordinated the pre-
paratory work regarding the adoption procedure of the Regulation proposal, the Working 
Party on Pharmaceuticals and Medical Devices, would do so at the Council level including in 
its work the examination of the Parliament’s position. Several meetings have been organised 
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in this regard throughout 2018 and 2019 and were still ongoing at the time of writing our 
research conclusions (Council 2019).
In the future several scenarios may take place regarding the adoption procedure. The most 
likely is that the Council will add amendments of it own, in which case the text would return 
to the European Parliament for a second reading. Either the Parliament will adopt the Council 
amendments in which case the proposal would be adopted as such. The European Parlia-
ment has however a right to introduce new amendments in this second reading which would 
then be needed to be adopted by the Council in its second reading. In case of disagreement 
between the Council and the Parliament a so-called ‘trilogue’ could take place between 
the Commission, the Parliament and the Council seeking to find a comprise suitable for all. 
The next section will highlight some reactions of the different stakeholders which had been 
involved in the process since the first HTA cooperation projects. These reactions do also 
reflect many of the issues raised in the institutional debates.
6.4.3.3. Reactions on the Commission proposal for a Regulation on HTA 
cooperation
Although the initiative from the Commission to submit a proposal in the form of a Regulation 
came as a surprise for most observers and stakeholders, the need to frame the coopera-
tion and establish a legal basis for it had been expressed many times before (e.g. Personal 
interviews 4, 6, 17). Indeed, as underscored by some: “The Commission used the EUnetHTA 
network to reach a consensus on what HTA should become in Europe. But it remains a 
network of experts and Member States are represented but it is not a forum where you 
can implement these things on a short-term basis” (Personal Interview 17). The different 
scenarios presented in the consultation initiatives of the Commission also had prepared most 
actors in the field on the possibility to create new structures on which a sustainable coopera-
tion could take place. What came as a surprise, however, were the mandatory aspects related 
to the proposal for a Regulation under EU-law. “It was a surprise; we didn’t see it before 
it came out. I think, to a certain extent, people didn’t internalise what it means to put the 
cooperation on a legislative basis until they actually saw the proposal (…). “Then, when they 
saw what putting on a legislative basis meant, in terms of what the requirements of that 
were, I think they considered them to be more far reaching than they anticipated” (Personal 
interview 19).
Overall, smaller EU Member States seemed to adopt a more positive approach to the pro-
posal which is explained, according to some, by the fact that the gain in financial and project 
management may be more important in countries with less personnel and smaller structures 
dedicated to HTA. “We recognise as a small country with limited HTA resources and finances, 
the added value of such a cooperation and we really support it. (…) Just voluntary work is 
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not an option” (Personal interview 11). Agencies or countries supporting the Commission 
proposal would often bring forward the same arguments used by the Commission, such as, 
the need to avoid duplication and the gain of time and resources related to that. Also, the 
need for a better uptake would be underscored as well as an improved access for patients 
to innovative medicines. Other arguments brought to the fore were related to relative ef-
fectiveness assessments. Some underscoring the fact that the part of clinical effectiveness 
would be the ‘easiest’ to collaborate on, as the majority of Member States would often 
look at the same comparators (e.g. Personal interview 11, 12, 19). Other stressed that the 
results of relative effectiveness assessments could be used in the national processes for cost-
effectiveness and other economic evaluations and would therefore bring added value (e.g. 
Personal interview 11).
Although fears for a reduced quality of assessments have been expressed (e.g. personal 
interview 22), some observers actually underscored how a framework, as the one proposed 
by the Commission, could actually enhance the quality of HTA. In particular the cooperation 
on the Joint Scientific Consultations could make a difference, as it would prepare the ground 
for the Joint Clinical Assessments. In this view, agencies could require (more) robust evidence 
from the industry which should be able to present solid data to support their efficacy and 
relative effectiveness. In case they would default on this, a negative opinion could be issued 
regarding their product. “I think this should be the goal from the cooperation with EMA and 
HTA, but this is still not present in the narrative” (Personal interview 13).
Moreover, to guarantee scientific robustness, some believed that, as the Coordination group 
of the proposed structure would be responsible for the scientific work, Member States would 
have to appoint scientists in this group. These would be responsible for giving a strategic 
direction and would be maybe less driven by policy objectives (personal interview 19). More-
over, since much of the proposal had been based on the work developed and implemented 
by EUnetHTA, some welcomed the fact that the instruments used, would be those with 
which they would already be familiar. Other positive remarks towards the Regulation proposal 
were related to the role of the stakeholders in the process. Even though much of the actual 
implication of stakeholders still had to be defined by means of delegated acts, some believed 
that it would actually give the Commission “power to work with different stakeholders to 
define which place they will get in the new structure” (Personal interview 12).
The absence of clarification upfront, regarding some issues which would have to be defined 
at a later stage in delegated or implementing acts, was a point of discussion. Some actors 
in the HTA arena would be reassured by these matters while, to others, these would trigger 
concern: “The Regulation [proposal] has preferred to install a lot of freedom of defining 
mechanisms, methods and frameworks. So, the Regulation [proposal], as such, leaves still 
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many things open and some Member States fear this openness - or misinterpret this openness 
as a grab for power, which it is not. It is, I think, actually, the opposite intention. It is meant to 
empower Member States to define in a later stage the actual day to day business” (Personal 
interview 15). Others, however, would adopt the opposite standpoint and would fear that 
Member States would lose control over the issue (e.g. Personal Interview 17, 21). “What do 
you include in the Regulation, which conditions? And which guarantee do you include in it, 
especially for the Member State ‘drivenness’ (…) and what do you leave to the Commission 
in the delegated and implementing acts? (…) When it is about competence distribution, 
then one has to ask oneself whether you should leave this to the implementing acts or 
whether you wouldn’t have to attach this simply to the Regulation” (Personal interview 17). 
Reference is being made to other legislative texts (e.g. Falsified Medicines Directive) in which 
delegated and implementing acts also had to be defined after the adoption of the text. “We 
see now that the Commission is filling in all kind of details which go much further than what 
we thought the text was about. This gives eventually much more power to the Commission 
which in turn produces much more uncertainty towards the field” (Personal Interview 17).
The presence of a certain number of elements to be defined in delegated or implementing 
acts also triggered concern regarding the quality of the assessments: “as the rules haven’t 
been defined, some fear that it will not offer an equivalent [quality] level of what could exist 
at the national level”( Personal interview 21). According to others, however, this argument 
refers to a lack of trust that exists among Member States regarding the different meth-
odologies and processes used in HTA: “People think that whatever way they set up their 
system, they think themselves that it is the best one” (Personal interview 19). The latter is 
considered by some as something which is not necessarily justified: “So the perception of 
what constitutes a good assessment may differ a lot between two countries. But often it 
may be because of the people that are working there. So, the people, may have different 
perceptions or preferences. There is nothing objective about it. It is not really a scientific 
argument; it is more about people’s preferences and national habits. (…) I think the key 
issue is going to be: is it okay, in general, to use European joint work? That is the big thing” 
(Personal interview 18).
What the different agency representatives often did agree upon was the fact that, if the 
proposal would be adopted, it would change the work habits considerably: “It is very dif-
ferent to work independently from working as part of a network as that is the way you do 
business. (…) It would require a lot of change at a country level” (Personal interview 19). 
People underscore how work at a national/regional level follows specific timelines, reporting 
structures, reporting languages and prioritisation issues etc. “All of that has to change to the 
common methodology. Now, I don’t see that as an insurmountable obstacle, but it would 
change the way we do what we do” (Personal interview 19). Others refer to the highly 
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regulated environment in which HTA takes place and which is difficult to change: “People 
are used to act in some way according to the law (…). There are doubts if this obligatory 
use of common clinical assessments will fit this structure” (Personal interview 30). “The 
proposal forbids any amendment or additional clinical assessment and I am not sure that we 
can do that. (…) There are different national processes and national requirements from the 
health care system which require perhaps the inclusion of other studies and we cannot close 
assessments like this” (Personal interview 22).
To some, shifting joint work on clinical assessments to a mandatory level, simply comes too 
soon. “We are not ready yet. Why trying to go so fast? It is possible to share scientific work, 
but no mandatory joint assessments” (Personal interview 22). Others believe that JCA would 
not necessarily reduce the work of some agencies who would anyhow need to go through a 
company’s submission evidence procedurally: “They can introduce EUnetHTA assessments or 
pan-European clinical assessments reports into that process, but most of them can use only 
small bits of it as part of their approval process of the company submission. So, it is not really 
saving any of them any resources. It is not really deduplicating any of their work” (Personal 
interview 27).
Some fears have been expressed regarding the impact the mandatory process, proposed for 
clinical assessments, could have on the other domains of HTA (remaining on a voluntary basis 
in the Commission proposal). Some believed there could be a risk that collaboration on other 
HTA domains would be reduced. “I know that within EUnetHTA there are quite many people 
that are interested in working in all of the domains but there is also this type of approach 
saying: let’s just do the clinical stuff and then we are done with it” (Personal interview 18). 
Others however have another opinion on the issue and believe that countries which already 
do a full assessment would continue to do so and only use the part of joint clinical assess-
ments in their national processes, as it constitute often an input for the economic evaluation 
(e.g. Personal interview 19).
These dual views on the Regulation proposal can partly be explained by the fact that people, 
on the one hand, recognise that the cooperation does offer opportunities and a more solid 
legal framework. On the other hand, although it regards only a small part of the full HTA 
process (i.e. relative effectiveness), some fear that if decision-making on clinical effectiveness 
falls outside the national boundaries, it could have an impact on the remaining domains of 
the evaluation process and on the control of Member States herein, especially when it comes 
to timeliness and the quality of the advice (e.g. Personal interview 17). Timeliness is indeed 
one of the topics that often came to the fore in the different debates on the Regulation 
proposal. Although the Commission has sought to align this to the Market authorisation 
process of the EMA, for some this would still not be satisfying as it would delay national 
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processes, and thus delay patient access (e.g. Personal interview 27). Some would argue that 
for countries with a slow patient access process, the Regulation would actually speed up 
the availability of the medicines to patients. However, as underscored by others, timeliness 
is not only depending on the HTA part of the process but often also depends on the pricing 
and reimbursement processes: “the delay is probably currently more in the appraisal and 
decision-making and not in the assessment” (Personal interview 27).
Finally, doubts are being expressed upon the abilities of the Commission to coordinate the 
work through its secretariat. “They will never have the means to manage this network (…). 
This is a very technical and managerial exercise which is not administrative. That requires 
specific skills that need to be developed” (Personal interview 20). Others also refer how 
public health issues are often not the priority of the EU which may then affect the budget 
allocated to these issues (Personal interview 21). The reference to the possibility to create a 
Union Agency on HTA, as stated in the Commission proposal, is considered to some like an 
eye-opener regarding the real intentions of the Commission behind this initiative: “So, that 
is the whole story. We are going towards an ‘EMAbis’, which will operate as the EMA driven 
by strong industry interests” (Personal interview 20). The belief that industry interests would 
underpin the proposal has also been strengthened by the fact that EFPIA, a pharmaceutical 
umbrella organisation, supported the Commission proposal (Personal interview 24; EFPIA 
2018). According to some observers, this has raised the question among HTA actors, whose 
interests the proposal would serve most: the industry or the Member States? (e.g. Personal 
interview 13).
The pharmaceutical industry indeed welcomed the proposal as it would allow to align evidence 
generation in Europe and create consistency, transparency and synergies in clinical assess-
ments permitting to expedite patient access to medicines and create greater predictability on 
evidence generation requirement (EFPIA 2018). The medial device industry, however, would 
take a quite different stand on the proposal. Indeed, several questions have been raised as 
the regulatory situation of medical devices differs from the pharmaceutical one. First, the 
HTA process of medical devices follows different paths according to the EU Member States. 
Countries who do have an HTA process for medical devices will run an assessment only on a 
few products. The difference between the Member States can be explained by the fact that 
the aims of an HTA as well as the timing, the scope of products and evidence requirements 
of an assessment will differ.
Whilst HTA of pharmaceuticals will serve as an input in regulatory and pricing decision-
making processes, this not necessarily the case for medical devices. In the UK, for example, 
HTA will serve to provide guidance, or to make a productivity analysis to decide about the 
scope of patient groups or cost-effectivity issues. France will adopt a different approach 
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which would be close to HTA of pharmaceuticals and inform, amongst others, reimburse-
ment decision-making processes. Germany will start assessments only for specific products 
requesting reimbursements. As the aim of assessments will differ across counties, so will the 
timing of those assessments vary. In France, for example, it will take place at market access, in 
the UK this may happen at a later stage after market access. Medical device representatives, 
therefore, fear that, due to these different approaches, it will become very difficult to have 
a standardised approach towards HTA in medical devices (Personal interview 23). Moreover, 
some underscore that the development of a device and its use, once it has been marketed, 
will differ from pharmaceuticals. New technological developments can influence the latter 
and as such evaluation of devices is a continuous process requiring to frequently update 
the information about them. Hence, they wonder what the added value of the Regulation 
proposal would be for the assessments of medical devices especially considering the number 
of countries which do not have a specific HTA process for devices in place (Personal interview 
23).
Hence, the mandatory approach is here too a matter of concern. As underscored by some, 
“the proposal does not allow to refuse one of the pillars. Either one has to participate in 
everything or nothing” (Personal interview 24). The fact that this scenario has not been 
presented in the consultation process has astonished many players in the HTA field (e.g. 
Personal interview 24, 27, 30). “Maybe a Directive would have been enough. Maybe it is too 
early for a Regulation. I think that some recommendations, like in a Directive, may be even 
more effective than a strict Regulation. But on the other hand, only voluntary involvement 
will maybe not destroy EUnetHTA, but [it could lead to] only active organisations which will 
remain present and some less active which will go out saying that they have no benefit 
of this structure” (30). The inter-institutional debate will seek to advance on the various 
issues outlined above as many of these reactions may come up either in Council or in the 
Parliamentary discussions on the topic. The debate the Commission proposal has triggered, 
leads again to the question whether HTA cooperation should remain voluntary or should 
be structured into a more stringent framework. Implicitly it calls for answering the question 
whether HTA cooperation in Europe can be sustainable in a voluntary framework following 
soft governance principles.
6.4.3.4. Intergovernmental cooperation initiatives on HTA
While the European Commission and EUnetHTA continued to seek for a model guaranteeing 
sustainable HTA cooperation in Europe, several intergovernmental initiatives had been estab-
lished focusing on HTA-related issues in a regional context. These initiatives all had their own 
legal framework and procedural arrangements but shared the fact that they often resulted 
from a governmental initiative, gathered participating countries with similar public health 
systems and focused primarily on the issue of affordable access to medicines. Hence, instead 
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of pursuing a mandatory ‘one-size fits all’- approach, as put forward in the Commission 
proposal, these initiatives offered a cooperation structure where Member States remained 
free to opt-in or withdraw. All these cooperation initiatives are still in their early stages of 
development, therefore no solid analysis about their efficacy and effectiveness could yet 
be made. However, the rise of these initiatives which came almost simultaneously with the 
Commission implementation of the EU HTA Network and the subsequent work towards the 
Regulation proposal, requires attention when examining the governance of HTA cooperation 
in Europe.
One of the main reasons triggering the establishment of these initiatives could be found 
in the rising medicines prices creating a new challenge to health systems of even high-
income countries. This rationale already laid at the basis of the HTA cooperation initiatives 
examined above (see also chapter 1 and chapter 4). However, since the mid-2010s, the price 
increase of innovative medicines was explained by higher development costs, novel action 
mechanisms and a drug development focus targeted on smaller-sized patient populations 
(e.g. orphan drugs, oncology) (Paris and Colbert 2017). Hence, to gain bargaining power in 
the price negotiations with pharmaceutical companies, some countries sought to join forces. 
This cooperation was not only directed towards clinical effectiveness assessments to reduce 
process costs, it also targeted cost-effectiveness evaluations and joint price negotiations, to 
reduce reimbursement costs.
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The various initiatives such as the Beneluxa-initiative189 established in 2015, The Valetta 
Declaration190 signed in 2017, the Visegrad+2 group191 created in 2017 and FINOSE192 set 
up in 2018, all aimed at achieving affordable treatments and ensure fair patient-access to 
high quality treatments193 (Eatwell and Swierczyna 2019). Most of these initiatives included 
in their cooperation efforts similar activities as those implemented by EUnetHTA, using even 
EUnetHTA tools and guidelines, such as, Horizon Scanning, information sharing and best 
practices, clinical assessments (e.g. personal interview 17; www.beneluxa.org; Grubert 
2018). However, a point of distinction would be the joint price negotiations constituting 
a key-objective in these initiatives and which would be absent in EUnetHTA or the EU HTA 
Network. Indeed, to EUnetHTA, pricing and reimbursement decision-making had always 
been considered as a Member-State competence which should be respected. “For us as 
189 Beneluxa is an initiative created in 2015, which “aims for sustainable access to, and appropriate 
use of, medicines in the participating countries”. It seeks to “increase patients’ access to high 
quality and affordable treatments”. The cooperation activities take place in areas, such as, Horizon 
Scanning, mutual recognition of HTA, information sharing and policy exchange and pricing and re-
imbursement. In 2019, the following countries had joined the network: Belgium, the Netherlands, 
Luxembourg, Austria and Ireland (www. beneluxa.org).
190 The Valetta Declaration signed in May 2017 by Cyprus, Greece, Italy, Malta, Portugal and Spain 
established a collaboration in the field of the assessment and procurement of new medicines. The 
area of activities are joint clinical assessments, economic evaluations and joint price negotiations; 
sharing information to input price negotiations and contracting; sharing information and best 
practices around biosimilar pricing and reimbursement; sharing pharmaco-therapeutic / effective-
ness assessments of drugs; Horizon Scanning. The focus is on drugs with a potential high impact 
on national budgets such as oncology drugs, orphan drugs, biosimilars. Other countries which 
have joined the group since are Croatia, Ireland, Romania and Slovenia. France has been granted 
an observer status (Grubert 2018; www.infarmed.pt; www.remapconsulting.com).
191 The Visegrad+2 group comprised the Czech Republic, Hungary, Poland, Slovakia, Croatia and 
Lithuania who agreed in March 2017 to cooperate to ensure fair and affordable access to medi-
cines for their citizens (Grubert 2018).
192 The Finose collaboration refers to a memorandum of understanding signed in June 2018 between 
national HTA agencies in Finland (Fimea), Norway (NoMA) and Sweden (TLV) aiming to produce 
joint assessment reports containing both clinical and economic assessments. Although Denmark 
had participated in a 2017 memorandum of understanding of high-priced hospital medicines, it 
did not take part in the Finose collaboration as its reimbursement decision-making system differed 
too much from the other three countries (www.fimea.fi; Grubert 2018; www.remapconsulting.
com).
193 Similar initiatives have been established such as the Baltic Partnership Agreement (2012) including 
Latvia, Lithuania, Estonia, Romanian; the Bulgarian Initiative (2015) with Romania, Bulgaria; Sofia 
Declaration (2016) Bulgaria, Croatia, Estonia, Hungary, Latvia, FYR Macedonia, Romania, Serbia, 
Slovakia, Slovenia; the Spanish and Portuguese initiative (2017); the Nordic Council (2017) with 
Denmark, Finland, Norway, Sweden and the Nordic Pharmaceuticals Forum/ NLF (2015) including 
Denmark, Iceland, Norway, Sweden. (Ataíde and Granzow 2018).
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EUnetHTA, there is a clear line and we didn’t cross that line. We stay in the framework of 
clinical assessments. Anything in the other domains will always remain national Member 
States’ mandate” (personal interview 15).
Hence, different clusters of countries cooperating in HTA, including economic evaluations 
and price negotiations, developed in Europe since 2015. The rise of these regional clusters 
raises the question about the effectiveness of EUnetHTA; “One could say that [these regional 
initiatives] are HTA+ cooperation structures and that is a pity as we did have EUnetHTA for 
that. (…) So, it is a bit regretful, but maybe it says something about the success of EUnetH-
TA” (personal interview 13). Indeed, as underscored by Beneluxa initiative representatives, 
developments in EUnetHTA were sometimes considered to be too slow. Horizon Scanning is 
cited as an example: “As Member States, we need to be well prepared to make decisions. In 
fact, for years we are lagging behind the facts. (…) we need this now and EUnetHTA is not 
delivering a lot (personal interview 17). Moreover, the regional initiatives offer the advantage 
of being in full control of the process: “It has to do with the fact that you have a hold on your 
own information needs and what you do to fulfil these. In EUnetHTA, it remains to be seen 
whether you receive the information you would need” (personal interview 17).
Referring to the Commission proposal which also included a pillar on Horizon Scanning, the 
Beneluxa-initiative representatives indicated not to be in a position where they could wait for 
years before something would be set up. “It is not our intention to have our own little thing, 
because we too, would prefer doing a pan-European horizon scan which would be used 
by everybody. But we do start to work on it now, because we need it” (personal interview 
17). Moreover, finding the resources at a national level for an identified (domestic) need is 
sometimes easier than obtaining and sharing a pan-European budget. Hence, the underlying 
dynamics of the regional initiatives, based on strategies elaborated to respond to concrete 
policy needs, allows for faster/more efficient decision-making processes. Communication 
flows are shorter as direct communication between health ministries easily takes place. For 
governmental representatives, the dynamics and pace necessary to come to a decision in EU 
policy processes does often not correspond to the national political need. “We need specific 
instruments for that and we need thus completely different dynamics and pace (….) A coop-
eration such as Beneluxa is essentially a political intervention, a more strategic intervention. 
So, it is driven by different impulses and different interests” (personal interview 17).
As we have outlined above, appraisal processes are often considered to be context specific 
which makes some countries or HTA bodies reluctant to cooperate in a joint European as-
sessment/appraisal model. Examining the number of HTA bodies or governmental institu-
tions having signed one or more regional cooperation agreements in the field of economic 
evaluations and joint price negotiations shows nevertheless that a strengthening of the 
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cooperation efforts is not to be ruled out in these areas. Indeed, as underscored by an HTA 
agency representative: “If the drug company is using the same model across X number of 
countries and extrapolating them with data, why would you not look at doing collaborative 
appraisal of that model? (…) If you have countries where it makes sense to do joint work in 
the economic domain leading to the opportunity to do joint work at pricing and reimburse-
ment level, it would make sense for countries to work at the economic level because they 
have similar health systems and an economic model wouldn’t be any different between the 
countries” (personal interview 19).
Others underscore the importance of bargaining power in the negotiations with pharma-
ceutical companies and to a lesser extent with medical device companies. Especially smaller-
sized countries would potentially benefit from such a cooperation (personal interview 22). 
However, fears have also been expressed that this situation could also lead to health systems 
developing at different speeds and increasing inequality in health care in Europe (personal 
interview 25). Finding convergence between Member States with similar health care systems 
is easier and therefore maybe also more attractive to some than an overall pan-European ap-
proach. Moreover, some believe that these regional cooperation structures could also serve 
as a hub for others, either by joining existing initiatives, if their interests would be served by 
that. Or, simply by making new arrangements between a group of agencies having the same 
needs at a given time (personal interview 27).
We have seen how representatives of the pharmaceutical industry welcomed the European 
Commission proposal for a Regulation where joint clinical assessments would become man-
datory. This industry is however much more reluctant to the regional initiatives seeking to 
work on common cost-assessment evaluations and price negotiations. The context specificity 
of those assessments is often be brought to the fore as an argument not to pursue these 
type of cooperation initiatives (e.g. personal interview 24). However, as in EUnetHTA assess-
ments, here too, industry representatives fear that even if companies would participate in 
joint economic assessments, appraisals and price negotiations, some countries would still 
after the common process decide to re-evaluate the technology at the national level. “There 
is nothing we can do about it because, in any case, they do not ask for our opinion. They will 
collaborate all the way to price negotiations and eventually reimbursement. (…) If they need 
to cooperate, well they should do it effectively” (personal interview 24).
Hence, after having already been examined in the EUR-ASSESS project in the mid-1990s, the 
topic of cooperation in areas as economic evaluations and coverage is back on the agenda. 
Too sensitive to be dealt with in an EU legislative framework, it seems that Member States 
actually do identify benefits to strengthen cooperation efforts in this area as long as they re-
main in full control over the process and can chose to opt-in or out an assessment procedure. 
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The overlapping memberships of countries and HTA bodies in several European networks or 
regional clusters raises the question whether sooner or later a rapprochement between some 
of those initiatives will not become inevitable as conflict of interest and/or engagements may 
arise in the future.
6.4.4. Conclusion policy-implementation in European HTA cooperation
In this section we have outlined the many procedural and substantive instruments developed 
throughout the EUnetHTA project and Joint Actions as well as instruments developed on an 
EU-institutional level. These instruments have been developed to reach the objectives set out 
by these networks and discussed in the section on policy-formulation. The overall objective 
remained the same throughout the various initiatives: developing a sustainable network 
for HTA cooperation in Europe. The procedural instruments which have been implemented 
by EUnetHTA since 2006, have targeted organisational, communication, capacity-building 
and evaluation matters. The substantive instruments regarded the development of HTA-
related activities such as Horizon Scanning, Early Dialogues, joint work, post-launch evidence 
generation and uptake. On an EU level, implementation activities were closely associated 
with the legislative proposals impacting HTA cooperation. As such, at first implementation 
activities regarded the work plan of the EU HTA Network. Part of these activities regarded the 
reflections and preparation for a new Commission proposal on HTA cooperation in Europe.
In our examination of the first procedural instrument (i.e. Organisation) we have seen how 
EUnetHTA has sought to develop different (business) models to ensure sustainability for the 
cooperation efforts and how in 2014 a new entity has been set up at EU level by means of 
the EU HTA Network. The developments taking place on the EU level will become intrinsically 
linked to the organisational developments of EUnetHTA which will become the scientific and 
technical arm of the newly created policy-oriented EU HTA Network. This set-up and division 
of responsibilities would, in the perception of the Commission, be of temporary nature, as 
the Commission proposal on HTA cooperation in Europe would foresee the establishment 
of a new coordinating body at EU level with Member States’ appointed representatives and 
assisted by a Commission-led secretariat.
Hence, although the reflections developed by EUnetHTA regarding the organisational struc-
ture of a sustainable HTA network in Europe have not, as such, been implemented, we have 
seen how some aspects of this reflection process have been retained in the Commission 
proposal on HTA cooperation. We can cite as an example the activity centres of the busi-
ness model developed in JA1 which share similarities with the pillar structure of the future 
cooperation system as proposed by the Commission in its Regulation. The Joint Action 2 and 
3 will limit their contribution on organisational aspects of a sustainable HTA cooperation 
model to the formulation of recommendations. Indeed, due to the changing nature of the 
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network, their work became primarily focused on developing the scientific and technical 
coordination of HTA activities and products which will become the core-substance of the 
Commission Regulation (i.e. JSA, JSC, identification of emerging health technologies and 
voluntary cooperation). Hence, the development of a sustainable structure for HTA coopera-
tion in Europe has since the JA2 be shifted to the EU HTA Network and has eventually led to 
the Commission proposal for a Regulation on HTA cooperation in Europe.
The second procedural instrument of EUnetHTA regarded internal and external communi-
cation means. The internal communication activities within EUnetHTA aimed at ensuring 
smooth effective information flows and contribute to establish internal network cohesion. As 
such, various instruments have been implemented such as the POP – and EVIDENT data bases, 
intra- and internet sites and information management infrastructures facilitating information 
exchange between work packages, the secretariat and the governance structures of the 
network. These instruments also contributed to ensuring cohesion in reporting formats of 
the outputs produced by EUnetHTA. The external communication efforts took place through 
dissemination activities such as the publication of promotional material, scientific publica-
tions, participation at and organisation of conferences and (stakeholder) forums.
As in the early cooperation projects (e.g. EUR-ASSESS), which had already emphasized the 
importance of dissemination activities to support HTA development in general, EUnetHTA 
also sought to enhance awareness of HTA and attract the attention of policymakers and 
other stakeholders on the cooperation efforts. The dissemination activities have moreover 
also played an important role in shaping discourse and peer-education on certain issues 
such as Relative Effectiveness Assessments or Early Dialogues. Through the informal contacts 
and exchanges which took place during conferences and workshops, personal relationships 
have been established facilitating the establishment of trust between members and hence 
allowing members to become more efficient in their collaboration on joint work. It is hard to 
measure the part of awareness created by EUnetHTA regarding HTA cooperation in Europe. 
However, the communication instruments created, and the formal and informal communica-
tion means developed, certainly have contributed in the production of EUnetHTA outputs 
and on which an important part of the Commission proposal has been based (e.g. HTA 
methodologies, Early Dialogues, joint REAs).
The third procedural instrument we have identified regarded capacity-building. In EUnetHTA, 
this has been implemented in a two-fold strategy: internal training of members on tools and 
methodologies developed by the network and external training of stakeholders and agencies 
having less experience in HTA. Peer-education and exchange of best practices have played 
an important role herein with the more-experienced members sharing their knowledge with 
less-experienced members. Several instruments have been developed to support capacity-
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building activities such as the organisation of training seminars and workshops, e-learning 
and the publication of a handbook. These outputs resulted from needs expressed by the 
members through internal formal and informal evaluation processes. As in dissemination, 
capacity-building has, from the start, be considered of importance not just for internal net-
work purposes but also to increase the impact of HTA in national decision-making settings. 
Indeed, as in the early cooperation initiatives, after 2006 capacity-building was associated to 
the belief that if the quality of the outputs would increase, so would be the uptake of them.
The fourth procedural instrument regarding evaluation is, to some extent, closely related to 
capacity-building. Evaluation in EUnetHTA was driven by two processes: internal and external 
demands. Internally, the evaluation could take place in a formal and informal way. The formal 
evaluation process would focus on the implementation of the project objectives as required 
by the grant agreements and examining the state of play of tools, methodologies and pilot 
projects being implemented. Informal evaluation took often place during the implementa-
tion of the activities of the work packages and often fed into learning processes. As we 
have seen above, some qualified EUnetHTA as a ‘learning organisation’ which operated via 
single or double-loop learning processes. Adaptation and adjustment based on evaluation 
processes form an integral part of these processes. At the time of the Joint Actions, external 
evaluation processes have been also organised, often upon request of the European Com-
mission (e.g. public consultations). EUnetHTA’s input in those has been of high importance, 
in particular regarding the development of the Commission proposal for a Regulation on 
HTA cooperation.
The second part of this section examined what could be considered as the core-activities of 
EUnetHTA: the substantive policy instruments which have been classified above according to 
the life-cycle approach of a technology (i.e. Horizon Scanning; Early Dialogues; Joint work; 
Additional evidence Generation and Uptake). Although present since the early days of HTA 
collaboration, Horizon Scanning has never been a real priority for EUnetHTA. The EUnetHTA 
project would address this issue only by seeking to establish a systematic overview of existing 
Horizon Scanning Systems and their working processes. Joint Action 1 did not give real 
attention to this topic as the Work Package to which Horizon Scanning activities had been 
attributed, primarily dealt with the establishment of the EVIDENT and POP data bases. The 
importance of Horizon Scanning will be underscored in Joint Action 2 but, here too, atten-
tion of the Work Package involved was focused on other activities (e.g. Early Dialogues). The 
Joint Action 3 will treat Horizon Scanning separately from other evidence collection activities 
and would integrate the topic in the Work Package on Joint Production, herein developing a 
new model respecting a life-cycle approach of health technologies.
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Several factors seem to have contributed to this increased attention of Horizon Scanning 
by EUnetHTA. In the first stage of HTA cooperation development, Horizon Scanning was 
not a priority topic. The increased attention for the topic since the Joint Action 3 can be 
explained by the fact that, with the progress made on methodologies and tools for joint 
work, resources (e.g. time and manpower) became available to address other parts of the 
life cycle of a health technology. Moreover, attention on behalf of the Commission given to 
Horizon Scanning may also have played a role. Indeed, the third pillar of the Commission 
proposal for HTA cooperation regarding the ‘early identification of health technologies’, 
refers to Horizon Scanning.
The latter followed a more general trend which one could observe in regulatory processes 
as several regional intergovernmental cooperation initiatives (e.g. Beneluxa, The Valette 
declaration) started to integrate this exercise into their collaborative frameworks. Whereas, in 
EUnetHTA, Horizon Scanning was important to anticipate on assessments that could be done 
jointly, this exercise in the intergovernmental cooperation initiatives, sought to gain a better 
insight on new drugs and devices entering the market and which could potentially impact 
the health budgets. In a sense, Horizon Scanning remains a young field of activity within 
HTA cooperation structures. The approach chosen in each of these structures will therefore 
also vary, since the aims pursued will differ. Future developments may require establishing 
synergies between these approaches – should this respond to needs of regulators and the 
HTA arena.
Although similar initiatives existed before the launch of the SEED project by EUnetHTA 
members, the Early Dialogues, established by EUnetHTA, have permitted to develop syner-
gies between the Regulatory authorities and the HTA arena. The aim was to align data 
requirements in a single development plan which would responds to both the needs of the 
regulators and of the HTA bodies. Success factors were multiple and rested upon the fact 
that the dialogues brought mutual benefits to the participating actors. Indeed, cooperation 
from industry was assured as the project would offer predictability in their development 
plan. Coordinated and simultaneous advice given to the developers by the regulators and 
HTA bodies before market authorisation would facilitate data alignment and implementa-
tion of (expensive) clinical studies which would better match assessments requirements. This 
coordinated approach would also facilitate the assessment processes from both regulatory 
and HTA bodies and created favourable conditions to speed up the process of market- and 
thus patient access.
Voluntary participation and the non-binding advice certainly helped to overcome potential 
barriers any of the participating actors could have in the Early Dialogues. Moreover, the 
governance structure put in place to coordinate the activities and the cooperation between 
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EUnetHTA and EMA, has allowed for a smooth implementation of the Early Dialogues which 
would often outnumber the initial projects planned. From an ad hoc cooperation project 
between EUnetHTA members, the Early Dialogues have developed as one of the most suc-
cessful initiatives of the network creating synergies with European regulatory authorities. 
Representing the second pillar in the Commission proposal for an HTA Regulation on HTA 
cooperation in Europe, it did not trigger any controversial debate. On the contrary, the 
positive experience of the pilot projects and the governance structures put in place smoothly 
running the projects led to a general consensus on this topic.
Joint work has been defined as comprising common methodologies, tools, joint assessments, 
literature reviews, and scientific advice. To enable the implementation of joint health technol-
ogy assessments the EUnetHTA network has started to work on the methodologies and tools 
that lay at the basis of these assessments. Besides instruments such as the EVIDENT and the 
POP-database discussed above, HTA Core Model has been developed and would represent 
one of the key instruments to achieve joint assessments. The model would comprise nine 
domains which could be assessed jointly. Handbooks, online tools and services have been 
developed and updated to facilitate the use of the HTA Core Model which has first been 
tested and regularly adjusted by means of pilot projects.
The introduction of Relative Effectiveness Assessments in EUnetHTA following the recom-
mendations of the Pharmaceutical Forum in 2010, has given a new dynamic to EUnetHTA’s 
work which would however impact the implementation of the HTA Core Model. Indeed, 
collaboration on the first four domains of the Core Model as is the case in the REAs, seemed 
to be more attractive to HTA bodies, as there was less need to contextualise. Collaboration 
on issues such as cost-effectiveness, social, ethical and legal issues appeared to be more 
difficult to achieve. Conversely to the Early Dialogue projects, EUnetHTA faced difficulties to 
find participants to collaborate on Core HTA or REAs pilot projects. On behalf of HTA bodies, 
several reasons have been brought to the fore making participation difficult for some of 
them. Often domestic legal constraints have been a barrier, as these would require adapta-
tion of national processes to the EUnetHTA assessment models and processes. Even when 
legal or administration barriers would be overcome and participation in the joint assessments 
was being decided by the top management of an agency, difficulties to adjust to the models 
have been noticed. However, feasibility of implementing the model would be confirmed 
by participants in joint REAs or full HTAs, even though this would not always result in the 
expected workload reduction, as only small parts of the joint assessments could be used in 
the local setting and further adaptation would be required in many cases.
The lack of participation in joint assessments and the lack of uptake of the results of joint 
work have been a profound matter of concern since the Joint Action 2. Despite the different 
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tools to facilitate uptake and the studies implemented to understand the reasons for the lack 
of it, no significant advance has been made in this regard. As the cooperation in EUnetHTA 
was entirely based on voluntary participation, the network could not impose the use of its 
outputs to the network members. Moreover, the lack of uptake would impact the willingness 
of industry partners to participate in this process as, rather than deduplicating efforts, it 
would actually add up their workload. Reasons identified for the low uptake of EUnetHTA 
are multiple and point to issues such as legal constraints, timing of the availability of the 
reports, reporting formats and language requirements, willingness to adapt. No consensus 
exists whether these barriers would be surmountable.
The very nature of the EUnetHTA network and of the EU HTA Network rooted in voluntary self-
governance did not allow them to impose practices on their members. The soft governance 
means used, such as, discourse, persuasion, exchange of best practices and peer-education, 
have not permitted the EUnetHTA network to obtain from its members commitment to 
use on a broad scale the output of its products in their local and national assessments. The 
European Commission has considered the latter as reason to invoke the subsidiarity principle 
as, after two decades of cooperation on Member State level, the main objectives of creating 
a sustainable network and ensure use of its outputs had not been reached.
Its proposal to move the cooperation efforts in some fields (e.g. Clinical effectiveness) on a 
mandatory level, had not been welcomed by all actors in the field. The discussions on the 
Commission’s initiative revealed how the fear for loss of control of regulatory process still 
dominated Member States’ positions. It is interesting to notice how regional intergovern-
mental initiatives dealing, amongst others, on HTA and pricing issues have flourished in years 
leading up to the Commission proposal. To Member States and HTA bodies participating in 
these cooperation agreements, the latter were often considered as more reassuring as they 
operated on a voluntary basis. The flexible nature of the agreements would allow them to 
concentrate their efforts only on products and assessments considered of importance for 
them for national health system or health budget purposes. The similarity of their health 
systems, health markets and/or social insurance schemes would facilitate cooperation in mat-
ters and avoid some the barriers encountered in EUnetHTA (e.g. legal constrains, timeliness, 
participation national regulatory authorities etc.). Moreover, would Member States not be 
satisfied with the cooperation initiative, they could simply step out.
Whilst the Commission has sought for a compulsory one size fits all model, the regional 
intergovernmental initiatives proposed an opposite more voluntary ‘tailored-made’ approach 
to Member States. The choice of the Commission is in line with the traditional Community 
approach seeking to have a level playing field. Although initiatives in the EU exists where 
Member States can opt-in or not (under certain conditions) a cooperation framework (e.g. 
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The EURO zone, the Schengen agreements), the question remains whether this could lead 
to unequal development schemes across the EU Member States in the case of health policy. 
A voluntary opt-in system, as had been at times suggested, could entail the risk exists that 
health policy and access to health would develop at different speeds and would lead to an 
increase in health inequalities in Europe. To avoid this, the Commission has thus chosen for 
Regulation applicable to all keeping mandatory cooperation restricted to clinical assessment 
and leaving the possibility for further cooperation open on a voluntary basis. However, to do 
so, it had to disrupt health technology assessment from one of its natural bases (i.e. health 
policy) to enshrine it firmly in the remaining one: industrial policy. As such, the structure 
proposed in the Commission initiative may lack solidity at its very basis, refraining stakehold-
ers from putting their trust and support in it.
Hence, the least one could say about the Commission proposal for a Regulation on HTA 
cooperation in Europe, is that it has opened a debate permitting to clarify actors’ positions. 
Indeed, before this proposal, opinions converged about the usefulness of streamlining HTA 
processes and practices. However, by putting the cooperation in a mandatory legislative 
framework, the aims pursued by the Commission in supporting such a cooperation became 
more explicit. Keeping efforts at the level of exchange of best practices and providing meth-
odological guidance seemed to be below the Commission’s expectations. However, as the 
debates on the proposal are still ongoing and a final decision still has to be made by the 
Council and (eventually) by the European Parliament, the question remains to see whether 
the preparatory work of the various projects and Joint Actions will have been sufficient to lift 
up the cooperation structure to another level. We have seen in this section how the Parlia-
ment became more involved in this issue and supported the initiative by framing it into a 
public health policy issue. The outcome of the debates in the Council will show how Member 
States will approach this proposal. Although involved in HTA cooperation through the Joint 
Actions and different high-level policy networks since more than 2 decades, it seems that, at 
ministerial level, people were not entirely prepared for this proposal (e.g. Personal interviews 
17, 22, 27, 29, 30). Many of the reactions we have outlined above from different actors 
in the HTA field, could very well be echoed in the Council debates. It remains to be seen 
whether a compromise position will be found and on which basis HTA cooperation will 
be framed in the future EU setting. The future will show whether the amendments of the 
Parliament and the Council will be able to convince all parties involved of the benefits such 
a legal framework would offer to the health systems and end-users of health technologies: 
the patients.
In the following section, we will examine the how HTA cooperation has been developed 
by looking at it through the lens of the last part of the policy cycle on Evaluation. We will 
again follow the same structure as in the other sections of this chapter by analysing first how 
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evaluation has played a role in the EUnetHTA project and Joint Actions before we turn to the 
cooperation efforts on the EU level.
6..5. evaluatioN iN europeaN hta cooperatioN
6.5.1. Evaluation in the EUnetHTA network
Setting up a formal evaluation process in projects and Joint Actions has been a prerequisite 
specified in the grant agreements of the EU Commission. In the EUnetHTA project and the 
Joint Actions, the evaluation was done by members of the project organised in a dedicated 
Work Package (WP) on evaluation. The main task of this WP was to evaluate whether and 
to which extent the strategic objectives of the projects and the sub-objectives of the work-
ing groups had been reached. This structure comprising similar objectives will be repeated 
throughout the EUnetHTA Joint Actions as it has been part of the grant agreements framing 
the cooperation and its financial support. As such, in each EUnetHTA Joint Action, one Work 
Package will be exclusively dedicated to evaluation processes (www.eunethta.eu).
Whilst in the EUnetHTA Project an external independent evaluation process had been 
scheduled (but not implemented), in the Joint Actions, only internal evaluation processes 
(performed by staff directly involved in the project work) where required by the EU Com-
mission (EUnetHTA 2013b: 17; Lund et al. 2008). The evaluation tools were a combination 
of electronic surveys, semi-structured interviews and documentary analysis to assess the 
working of the project and identify any difficulties. The surveys targeted besides the Partners 
also the Steering group, participants of the Stakeholder Forum and the Secretariat. Regular 
feedback was given to the Commission and the project participants. In each project, specific 
questions had been formulated to steer the evaluation process.
As such, in the EUnetHTA Project, a certain number of factors had been identified to evaluate 
the success of the project in establishing the framework for developing an effective and 
sustainable network. These factors were: Production of deliverables in a timely manner; Ef-
fective working collaboration between Work Packages; High degree of member participation 
in the Work Packages; Effective communication; Sustained commitment to Project; User 
and stakeholder satisfaction with new routines and practice; Perceived added-value (Lund 
et al. 2008). Whilst the deliverables have been produced within the required deadlines, the 
evaluation revealed some key challenges to be addressed in the future. It is interesting to 
notice here, how these challenges identified in the early days of the EUnetHTA network, have 
remained presented throughout the cooperation efforts and became one of the underlying 
reasons of the Commission to present its proposal for a Regulation on HTA.
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As such the EUnetHTA project underscored how the tools that had been developed, still 
had to be tested in a real-life situation. Due to the large number of participants and the 
heavy workload, cooperation across Work Packages varied. Developing a more effective 
collaboration across WPs was however important due to the interconnectivity of the tools 
to be developed. Within the Work Packages, participants did not show an equal degree 
of participation. Face to face meetings were considered as an effective mean to remediate 
to that but difficult to organise especially in groups with a large number of participants. 
Sustained participation was shown only by a small group of core-participants (Lund et al. 
2008:4-6). The project also revealed some difficulties such as the effort needed to explain 
the HTA Core Model to all actors. Moreover, the question remained regarding the use of this 
model as it was already clear that politics or “old habits” could hamper the development of 
this model across the organisations. Moreover, the starting levels of HTA knowledge among 
the participants different also generating different expectations, needs and goals. Differ-
ences also existed at the level of financial capabilities, interests, organisational structures and 
competencies (Lund et al. 2008: 24).
The evaluation however did highlight the members’ commitment to the project who in-
deed declared perceiving benefits in the collaboration in particularly through the exchange 
of knowledge, experiences and the development of tools (Lund et al. 2008; EUnetHTA 
2009:21). Participants confirmed their belief that EUnetHTA could reduce duplication of 
reports provided that the tools would be further developed. The adaption tools were con-
sidered as potentially facilitating multinational use of HTA-reports. The produced handbook 
would help new HTA organisation to develop their activities. The policy study permitted a 
better understanding of the current situation. A structured monitoring/information system 
that was put in place would allow to get a better insight in new and emerging technolo-
gies. The establish communication platform and clearinghouse function would permit to 
strengthen the national and international position of organisation. English should remain the 
working language. Overall, “no one has expressed any doubt about EUnetHTA’s usefulness 
or expected discontinuation” (Lund et al. 2008: 5).
Hence, at the end of the EUnetHTA project, participants would see an added value in EU-
netHTA. However, as most of the work was still in an initial stage of development, this belief 
still had to be confirmed via tangible outputs. Concerns for the repartition of competences 
between work of a European structure and local authorities were at time already brought 
to the fore as members underscored how “EUnetHTA should remain a network and should 
not become a centralised organisation as inevitably, this would result in undermining local/
national autonomy” (Lund et al. 2008: 30).
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The evaluation of the Joint Action 1 addressed in particular the question whether the project 
had achieved its overarching objective of putting “into practice an effective and sustainable 
HTA collaboration in Europe that brings added value at the European, national and regional 
level”. It examined in particular whether EUnetHTA had been able to develop “a general 
strategy and a business model for sustainable European collaboration on HTA”. Moreover, as 
the importance to further development of HTA tools and methods had been outlined by the 
previous project, focus on the latter was one of the evaluation priorities. As such, part of the 
evaluation process would examine the application of those in the field (EUnetHTA 2013b:10).
The evaluation done in this JA was mainly conducted through self-completion question-
naires and documentary analysis. The conclusion of the process was that the project had 
produced the majority of the deliverables planned. However, as regarding the overarching 
strategic objective “Using the definitions provided by project participants and stakeholders 
it appeared the JA had not been successful in meeting this objective” (EUnetHTA 2013b: 
172). A second Joint Action was therefore planned “before evolving into the permanent 
network in 2015” (EUnetHTA 2013b: 172). The business model developed has been valued 
by most of the participants and it was expected that it would be further developed in the 
following JA2. Similarly, the evaluation shows the necessity to further develop the different 
EUnetHTA tools and methods. Whilst only fifty percent of the participants considered that 
“the JA had achieved what they wanted”, many did indicate that they did benefit from 
added value such as networking, informational sharing and improved awareness of HTA 
developments (EUnetHTA 2013b: 173). Some also reported to have recourse to the new 
tools developed and the expected that their use of the HTA Core Model, the POP database 
and the EVIDENT database would increase in the future. Further training on these tools was 
however considered a necessity (preferable in face-to-face meetings) (EUnetHTA 2013b).
The evaluation objectives of the Joint Action 2 remained focused on testing the capability 
of EUnetHTA to produce structured core HTA information and apply it in a national context. 
As such, the various models and tools developed have (again) been examined. The Joint 
Action 2 concludes that (still) further improvement of the tools and methodologies should be 
pursued. Moreover, the development of methodological guidelines should be “strategically 
re-organised with a focus on implementing partnerships with recognised scientific societies 
and scientific projects relevant to HTA” (EUnetHTA 2016: 4). Most barriers already identified 
in the earlier projects regarding difficulties related to uptake have been brought to the fore 
(EUnetHTA 2016: 3). However, with the establishment of the EU HTA Network, means to 
overcome those would be examined in cooperation with the EU-level policy network.
Indeed, since the creation of the EU HTA Network, EUnetHTA which will see part of its 
objectives (e.g. reflect upon a sustainable structure on HTA cooperation) being shared with 
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the newly established entity. Evaluation will therefore essentially be focused on the objec-
tives set at the start of the project. As such, evaluation processes have highlighted how 
the Joint Action had been able to deliver expected results in terms of pilot projects and 
methodological guidelines and tools and urges to move into the direction of the routinisation 
of common assessments194. The various studies implemented at EU level will take over part 
of the evaluation process regarding the implementation of EUnetHTA’s tools, methodologies 
and assessment models as we will examine in the section below. In particular, the question 
regarding the establishment of a sustainable structure will be examined in a broader EU-
led framework, including in this exercise external organisations as well as other European 
institutions (e.g. European Parliament). Here too, we will see how some of the issues already 
identified in the EUnetHTA project and Joint Action 1 and 2 will again be underscored by 
studies commissioned at the EU level.
6.5.2. Evaluation in EU setting
The evaluation processes of any policy or is often closely related to other parts of the policy 
cycle and in particular to the policy formulation process as the former can serve as input for 
the latter. In the case of HTA, the process set in motion by the Commission to propose a 
new legislative instrument for HTA cooperation in Europe, has proceeded by several studies 
commissioned by the Commission. Besides serving the policy-formulation process as we have 
seen in section 6.2., these studies have also allowed to evaluate the cooperation process as 
such. Many of the evaluation instruments used by the Commission have therefore already 
been discussed in other parts of this chapter. In this section we will therefore only focus on 
how some conclusions of these evaluation processes have been used to support the Com-
mission policy orientation regarding HTA cooperation in Europe.
194 The final technical report will highlight the following outputs of the JA2: “Twelve REAs (6 on 
pharmaceutical and 6 on other technologies); Three Core HTAs; Eleven Early Dialogues (9 on 
pharmaceuticals and 2 on medical technologies); Five methodological guidelines; Evidence submis-
sion templates for pharmaceuticals and medical devices; An updated and upgraded application 
package of the HTA Core Model; More than 40 instances of the national uptake of the results of 
the joint work performed in EUnetHTA JA2; A suit of process and procedural guidance to support 
various types of joint activities within the framework of European cooperation on HTA; Recom-
mendations on the implementation of a sustainable cooperation on HTA”(EUnetHTA 2016: 2-3). In 
the Joint Action JA3 80 joint reports and 35 Early Dialogues would be foreseen besides developing 
further guidelines, models and methodologies (www.eunethta.eu).
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Till 2013, the evaluation processes of HTA cooperation in Europe would be strictly related 
to EUnetHTA activities and other related HTA projects financed by the Commission195. As 
outlined in section 6.5.1., various evaluation studies had been carried out to monitor the 
progress made by EUnetHTA. These studies would highlight the challenges HTA cooperation 
would be facing as well as the progress made. Many barriers to achieve sustainability of HTA 
collaboration and the uptake of collaboration outputs had already been identified in the early 
days of EUnetHTA, and confirmed throughout the Joint Actions, as discussed in the previous 
section. However, specific evaluation processes would take place on an EU-level regarding 
the implementation of the Health programme financing EUnetHTA projects and Joint Ac-
tions. The report on the 2008-2013 Health programme has amongst others investigated on 
the interest and influence of various stakeholder groups regarding projects financed by this 
programme.
Based on findings drawn upon case studies of various projects amongst which EUnetHTA, 
the reports highlight the importance of governmental policymakers. It points to their high 
level of influence and generally low level of interest in health programme outcomes. Un-
derscoring how HTA would be one of the few topics of high interest to policy-makers, the 
report draw attention upon the fact that “a failure to effectively engage policy-makers when 
this would have been desirable is a common thread across many projects and Joint Actions. 
It is therefore a key priority to find ways in which their (often limited) interests can be taken 
advantage of in order to raise their awareness and ideally secure their backing for the imple-
mentation / use of the various novel approaches, interventions, data sets etc. produced by 
the HP” (European Commission 2015: 46). This advice has been followed to a certain extent 
with the creation of the EU HTA Network which sought to gather high-level policymakers to 
reflect upon the strategic orientation of HTA cooperation in Europe. We have seen, however, 
in the previous sections of this chapter how membership of this network would often overlap 
with EUnetHTA. Moreover, instead of high-level policymakers, often ministries would send 
representatives with “technical HTA skills’.
In 2013, to feed its reflection process on achieving sustainability of HTA cooperation in 
Europe, the European Commission – by means of the Agency for Health and Consum-
ers- asked the organisation Ecorys for an independent report on the state of play of HTA 
195 Other projects financed through the FP7 projects were ADHOPHTA - Adopting Hospital Based 
Health Technology Assessment in EU; ADVANCE_HTA - Advancing and strengthening the method-
ological tools and practices relating to the application and implementation of Health Technology 
Assessment (HTA); INTEGRATE-HTA - Integrated health technology assessment for evaluating com-
plex technologies; MEDTECHTA - Methods for Health Technology Assessment of Medical Devices: 
a European Perspective (European Commission 2015d: 76)
392 Chapter 6
cooperation. The aim pursued was to provide an economic and governance analysis “on 
alternative solutions for the set-up of a permanent secretariat for future cooperation in the 
field of HTA, taking into account possible synergies and costs for the Commission” (Ten Have 
et al. 2013: 7). The conclusions of the study again highlight that the “main bottlenecks are 
the organisational complexity of working with many partners in one network. Also, major 
differences in decision-making structures, data requirements and the level of conduct and 
implementation of HTA in individual EU Member States seem to obstruct intensifying the cur-
rent collaboration. Although the will for increased collaboration clearly exists, efficiency gains 
can be made” ((Ten Have et al. 2013: 41). Barriers perceived among HTA players to have 
the coordination of the collaboration being hosted in the Commission or in a subordinated 
agency had also been identified in this study. But no acceptable solution had been presented 
as all scenarios presented pros and cons. The report already pointed to the conciliation dif-
ficulties between efficacy and effectiveness on the one hand and scientific robustness and 
expertise on the other (Ten Have et al. 2013: 41-42).
The Inception Impact Assessment (IIA) led by the European Commission in 2016 gives a clear 
evaluation on an EU level of the state of play of HTA Cooperation by then and will serve 
the formulation process of the Commission proposal for a Regulation on HTA cooperation. 
Once more it is highlighted how most Member States share the vision that HTA cooperation 
could be beneficial for the national health systems and how the instruments developed by 
EUnetHTA have allowed for capacity-building, exchange of information and development of 
resources and specialised expertise. Support on behalf of the Council196 and the European 
Parliament197. have been highlighted as well as the position of various stakeholder groups 
which became, according to the IIA, increasingly interested and supportive to collaboration 
on HTA.
However, the low uptake and coexistence of parallel national HTA processes showed that 
the objectives reducing duplication of work of HTA bodies, as set by EUnetHTA, had not 
been achieved. Explanatory reasons brought to the fore we again the different procedural 
frameworks, methodologies and data requirements in Member States as well as (lack) of 
administrative capacity (European Commission 2016: 9-11). Hence, the IIA would conclude 
that “It is not rational to invest public funds into HTA cooperation at European level, if the 
uptake of the work is not improved and the duplication of efforts is not avoided” (European 
196 E.g. Council conclusions on Personalized medicine for patients (2015/C 421/03); Council conclu-
sions on innovation for the benefit of patients (2014/C 438/06); Council conclusions on Personal-
ized medicine for patients (2015/C 421/03).
197 E.g. European Parliament resolution on the Commission Work Programme for 2016 
(2015/2729(RSP)).
Establishing a sustainable network for HTA cooperation in Europe 393
Commission 2016:9). We have seen how this rationale laid at the basis of its future proposal 
for a Regulation on HTA cooperation.
The Public Consultation, which was held from October 2016 to January 2017 confirmed 
most of the findings in the IIA regarding the disparity that exists among HTA bodies in the 
(clinical and economic) methodologies and HTA procedures and how this still led to divergent 
outcomes of HTA reports, duplication of work, a decrease in business predictability, and a 
disincentive for innovation (European Commission 2017). Opinions regarding a future HTA 
framework have also be collected as discussed above (see also European Commission 2017). 
Many of these items have been re-discussed in the Impact Assessment, published simultane-
ously with the Commission proposal and which also based its conclusions on additional 
studies held198. Having presented various scenarios for future collaboration as discussed in 
the sections above, the Commission would surprise most key-players involved by proposing a 
mandatory structure which had not, as such, been submitted to stakeholders in the consulta-
tion processes or assessment report. Since the publication of its proposal, the Commission 
has continued to organise stakeholder meetings either with individual stakeholders or via the 
stakeholder pool of the EU HTA Network. As the proposal has not received a warm welcome 
by various actors in the field and triggered quite some discussion at a high-policy level in 
national governments, the European Commission continued to provide information about 
its standpoint and gathered information regarding actors’ positions on the issue. At the time 
of writing no final conclusions can be drawn upon the actors’ positions and the outcome 
of the Commission proposal. However, the move of the Commission has allowed to get a 
better picture of the issues at stake for all actors involved as well as the limits of a mandatory 
approach of harmonisation.
6.5.3. Conclusion evaluation in European HTA cooperation
In this section on policy evaluation, we have seen how various formal and informal evalu-
ation procedures have been implemented since the EUnetHTA project started in 2006. It is 
interesting to see how the first evaluation processes already revealed the barriers associated 
to the lack of uptake and thus the inability of EUnetHTA to reach one of its main objectives. 
Whereas at first, the limited participation of members in pilot project was identified as an 
explanatory reasons, soon other more structural reasons were brought to the fore: legislative 
and procedural national framework, financial and administrative capacities, lack of trust in 
quality of joint assessments, need for capacity-building, resistance to change etc. Hence de-
spite the continuous support for cooperation, expressed by HTA bodies, Member States and 
198 Mapping of HTA methodologies in EU and Norway; Mapping of HTA national organisations, pro-
grammes and processes in EU and Norway (https://ec.europa.eu/health/technology_assessment/
eu_cooperation_en) (European Commission 2017b; 2017c).
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even taken up in official declarations of the European Parliament and the Council, more than 
a decade later, none of these barriers seems to have been overcome by the means imple-
mented in EUnetHTA, neither by the establishment of the EU HTA Network which sought 
to involve high-level policymakers on the topic. Similarly, the establishment of a sustainable 
structure for HTA cooperation has not encountered consensus among key actors despite the 
various studies, public consultations and assessments implemented to advance on this issue. 
The Commission proposal based on these evaluations would even come up with a structure 
which had not been evaluated as such amongst the players concerned which would trigger 
fierce debates in many fora.
6.6. coNcluSioN
In this chapter we have outlined by means of the five stages of the policy-cycle the develop-
ments regarding HTA cooperation in Europe since 2006. The aim of this chapter was to lay 
down the data in a comprehensive manner so as to allow for a more structured examination 
of it. Indeed, as we have seen in chapter 4, HTA cooperation started as a rather simple 
initiative by HTA doers and has developed into a complex undertaking including many actors 
on several policy-making levels. From a rather unknown technical subject in the 1990s, HTA 
has become a well-known political ‘hot item’ in European and national public policy debates. 
Whist in the early days, HTA cooperation sought to develop and strengthen HTA activities, as 
such, on a national level, it has developed in the last decade to a competence’s distribution 
issue between the EU and the Member States.
This process has come as a surprise for some. However, the data in the present chapter 
demonstrates how this process has taken place through, what could be considered as, small 
insignificant steps forward in each stage of the policy-cycle. In the section on agenda-setting, 
we have seen how gradually new actors entered the scene, influencing the agenda-setting 
process and herewith the course of action of the cooperation process. Indeed, from an exclu-
sive HTA arena agenda point, HTA entered formally the EU agenda at time of the High Level 
Group on healthcare and medical services to finally being discussed in the formal Council and 
European Parliament regulatory decision-making processes. The role of the Commission has 
been preponderant herein and has also led to the transformation of the network in terms 
of membership, governance structures and policy objectives. Soft governance has been, 
in essence, the means by which it has done so. However, to ensure the continuity of the 
cooperation, it proposed mandatory (‘hard governance’) regulatory means.
In terms of membership several observations can be made. Whilst the EUnetHTA project 
would be essentially made up of members stemming from HTA arena, this would change 
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with the Joint Action format were the membership approach would seek to include more 
actively the ministries of health who should appoint partner organisations. Direct ministerial 
implication remained however quite low as the members appointed would be mostly HTA 
bodies’ representatives. The relationship between the latter and their home-base would 
vary. HTA agencies from smaller states would often send top-executives whereas those from 
medium-sized to larger EU countries would send middle-management staff. This would have 
repercussions on the transfer and use of EUnetHTA tools and methodologies at the national 
level, as top-management would be in a better position to adapt local habits to EUnetHTA 
guidelines.
Moreover, top-executives of smaller-sized countries would also have easier access to repre-
sentatives of ministries of health. As such, information flows between agencies and ministries 
would be more frequent. As technical expertise related to HTA questions would often lack 
at ministerial level, these countries would also send the representatives of their HTA bodies 
to represent their country in international networks or meetings. Hence, when an official 
standpoint of the ministry would be requested regarding international HTA matters (e.g. 
proposal for a Regulation on HTA cooperation), advice on behalf of HTA agency representa-
tives would be asked.
Lack of direct governmental implication in HTA cooperation has been one of the underly-
ing reasons which led the Commission to set up a new EU HTA Network aiming to gather 
national representatives at a senior policy-making level. Herewith, the Commission sought 
to facilitate and improve the uptake of joint work. In practice, however, overlap in terms of 
membership between both networks would be the case with both networks being mostly 
composed by HTA doers instead of HTA policy-makers. Under impetus of the Commission, 
stakeholder policy will also be developed, first in EUnetHTA but lacking real consensus 
regarding their level of engagement resulting thus in various experiences according to the 
projects and Joint Actions in which they were involved. The Stakeholder Pool established in 
the EU HTA Network did respond on paper to a balanced stakeholder involvement policy. 
However, in practice, the weight of the different stakeholder groups seems to have been 
unequal, with some (e.g. industry) having a longer culture of exchange and lobby activities 
with European institutions than others and thus more weight (at least in the perception of 
other stakeholder groups). Membership in the networks has thus shifted from a rather closed 
HTA-arena representatives, to more heterogeneous networks. The introduction of new actors 
has been of importance by the impact it would have on the other stages of the policy-cycle 
as new views of the cooperation initiatives would nourish the debates.
These changes would in particular affect the influence the Commission would have on the 
cooperation efforts. Indeed, whilst the EU HTA Network was conceived to be member-state 
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driven, in practice, the Commission found itself in a position to steer the course of actions as 
it was presiding the meetings, leading the secretariat and setting up the agenda. Moreover, 
the setup of this network would also alter the governance functions of EUnetHTA since HTA 
strategic policy-making would be shifted to the EU HTA Network, herewith taking over the 
traditional role of the EUnetHTA Plenary assembly, relegated since then, to a merely informa-
tive function. Even if the other EUnetHTA governance bodies will remain in place, EUnetHTA 
will have to follow an agenda set by the EU HTA Network. Indeed, since the setup of the 
EU HTA Network, it had been decided that the EUnetHTA would fulfil the role of scientific 
and technical arm of the newly established network and should remained focused on the 
cooperation outputs. The EUnetHTA secretariat will even become integrated in a Directorate 
in the Joint Action 3 which will work closely with the secretariat of the EU HTA Network (i.e. 
Commission representatives).
The room of manoeuvre for the Commission to support the cooperation process was pro-
vided by the Cross-Border Health Care Directive in which HTA cooperation had been inserted 
as one of the flanking measures allowing for the setup of the EU HTA network. As the objec-
tives of the EU HTA Network closely followed the objectives of the previous HTA cooperation 
initiatives, this network would become the forum to discuss the model for the establishment 
of a sustainable network for HTA cooperation in Europe. Previous business models and ideas 
developed in Joint Action 1 and 2 have only to a limited extent nourished the debates. 
Basing itself of the forum created by the EU HTA Network, the Commission will put forward 
its plans to structure the HTA cooperation into an EU legal framework. The Inception Impact 
Assessment, public consultation, and Impact Assessment will all be discussed in the network 
and will serve as a basis for the Commission to elaborate its proposal for a Regulation on 
HTA cooperation. This process built further upon the work of EUnetHTA, as through the 
exchange of best practices, peer education, and discourse, a common approach regarding 
HTA cooperation had been developed within the HTA arena. However, this approach needed 
to be further disseminated in other policy circles and in particular amongst decision-makers 
on a national and European level.
At first, the belief had been shared amongst EUnetHTA partners, that their network would 
become the sustainable cooperation mechanism to which the Article 15 in the Cross-Border 
Health Care Directive referred. Once the EU HTA Network had been set up, the latter seemed 
to be the future sustainable network structure. However, the Commission proposal fol-
lows a different path whereby both networks could be abolished (i.e. EUnetHTA and the 
EU HTA Network) and drive the cooperation efforts in a sustainable manner based on an 
EU regulatory framework through the establishment of a high-level coordination group or 
even, potentially, a Union agency. As such, HTA cooperation enters on the agenda of other 
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European institutions such the Council and the Parliaments which had already gradually be 
involved in the discussion on HTA cooperation in Europe.
Bringing in new actors in the cooperation process has impacted the policy-formulation process 
and objectives to be pursued. Especially since the establishment of the EU HTA Network and 
the search for a sustainable framework for cooperation, a new approach would be adopted 
by the Commission in its proposal for a Regulation on HTA cooperation. Whilst the overall 
objective of setting up a sustainable framework for HTA cooperation, remained the objective 
to ensure uptake of common HTA outputs, establishing the proposal on an Internal Market 
basis would introduce new (market-orientated) objectives. It is not clear what underpins the 
choice of the Commission to pursue this dual approach based on Internal Market harmonisa-
tion objectives, on the one hand, and public health objectives on the other. At present, the 
debates in the Council and in the Parliament will decide whether the Commission approach 
will be adopted fully or partially.
Finally, regarding the governance policies, the Commission has operated by shifting gradually 
from a voluntary soft governance approach, to a mandatory EU regulatory framework to 
ensure uptake of joint work. At first sight, one could herewith implicitly conclude that this 
move demonstrates the limits of voluntary soft governance cooperation frameworks in the 
field of HTA cooperation to reach harmonisation of practices. However, the reasons for the 
disappointing amount of joint work outputs and the lack of uptake, brought to the fore by 
commissioned or internal studies, do not fully explain the difficulties to reach the objectives 
set. Neither do they fully explain the positive results in Joint Scientific Advice. Moreover, 
the rise in regional cooperation initiatives which - conversely to the Regulation proposal 
approach – do integrate cost-effectiveness assessments and joint price negotiations could 
cast doubts upon the Commission approach to structure HTA cooperation the way it has 
been presented in the Regulation proposal.
In the next chapter, we will therefore examine the data set out in this chapter against the 
theoretical framework outlined in chapter 3. The aim will be to identify the role of soft 
governance in structuring HTA cooperation in Europe and in particular in reaching (or not) 
the objectives set by the various networks. This analysis based on the data set out in chapter 
4,5 and 6, should allow us to answer the research questions framed in the introduction.
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“National sovereignty withers when entrapped in the forms of the past.”
Jean Monnet, Memoirs
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7.0. iNtroDuctioN
After having set the theoretical framework in part A of this thesis and organised the data 
gathered in the research in part B, we will analyse in part C the data by using the research 
framework set out in chapter 3. This research framework is structured so as to allow detailed 
network analysis and builds further upon the notion of networks as a medium for the imple-
mentation of soft governance instruments. It is framed around three central concepts: gov-
ernance networks, network governance and metagovernance. The chapter is structured in 
three parts. The first part examines general and specific characteristics of the HTA networks. 
It will base the analysis on soft governance-related factors impacting the typology of gover-
nance networks and as such integrated in our research framework: incentives, membership, 
resources and governance modes. The analysis should enable us to determine whether in the 
case of European HTA cooperation networks, governance networks can be identified. This 
part will also seek to determine which factors related to typology of networks have played 
a role in structuring HTA cooperation by soft governance means in a European framework.
The second part will focus on network governance of HTA cooperation networks. It will base 
the examination on soft governance-related factors impacting the effectiveness of gover-
nance networks in terms of goal attainment. In chapter 3 we have integrated in the research 
framework four factors potentially impacting goal attainment of governance networks: 
social interaction, governance instruments, management and external events. Each of these 
factors will be examined according to their particular features listed down in the research 
framework (see below). Goal attainment can be explored by looking at process, outputs and 
outcomes. In this chapter will seek to identify how each of these factors had an impact on 
the HTA cooperation process, the outputs that have been produced by the networks and the 
outcomes that have been identified as a result of cooperation initiatives.
Both the typology of a governance network as the effectiveness of network governance 
inform about the presence of a form of metagovernance regarding European HTA coopera-
tion networks. This will be explored in the third part of this chapter. The implication of the 
European Commission in HTA cooperation networks has been present since the very first 
initiatives. This section will build further on the analysis made regarding the typology of 
governance networks and the effectiveness of network governance by highlighting the role 
of the Commission herein. The aim is to determine whether a form of metagovernance has 
been present in the development of European HTA cooperation networks.
The conclusion of this chapter will resume the main findings of the research based on the 
research framework It will highlight which soft governance-related factors in governance 
networks, network governance and metagovernance have had an impact on the develop-
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ment of HTA cooperation in Europe. These will used to answer the research questions in the 
final chapter of the thesis, presenting the overall research conclusions, policy recommenda-
tion and subjects for further research.
METAGOVERNANCE
GOVERNANCE  NETWORKS
Typology
NETWORK GOVERNANCE
Effectiveness (Goal attainment)
Network formation Incentives
Strategic calculations
Support/constrain
Social interaction Learning processes
Shared values and understanding
Trust
Goal consensus 
Membership Public, private, non-profit
Relation home organisation-network
Open/closed
Homogeneous/heterogeneous
Governance instruments Policy instruments
Legislative and regulatory instruments
Political instruments
Financial instruments
Resources Financial
Natural/physical
Social/political
Human 
Management Competences
Styles (project/process management)
Governance modes Horizontal power distribution
Asymmetric power distribution
Centralised power distribution
External events Ideological
Legal
Political
Economic
Table 7.1. Thesis research framework (2)
7.1. goverNaNce NetworkS: typology oF europeaN hta 
cooperatioN NetworkS
In part A of this thesis, we have outlined how networks present an adequate forum for the 
implementation of soft governance and have been used by the EU has a manner to pursue 
specific policy objectives. The data gathered in part B of the thesis has brought to the fore 
how the first HTA networks emanated from an HTA arena initiative at time of the Maastricht 
Treaty which marked the beginning of an official EU public health policy. At first, the HTA 
networks had no other relationship with the EU than through the request of financial sup-
port. This has however evolved into the establishment of an EU HTA network in which the 
role of the Commission became preponderant. This section will examine the attributes of 
the different networks that have been established in the course of the years and determine 
whether they respond to the characteristics of so-called governance networks.
In chapter 3 we have outlined key characteristics of networks influencing the typology of 
networks. In the present section we will use the data of part B of the thesis on the basis of 
these characteristics to first define the typology of the networks that have contributed to 
the development of HTA cooperation in Europe. We will focus in particular on the networks 
of the early cooperation initiatives which we will consider for the purpose of this analysis 
as a single entity (EUR-ASSESS, HTA-Europe and ECHTA/ECHAI), EUnetHTA and the EU HTA 
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Network. The aim of this section will be to identify the similarities and differences between 
those networks and determine whether and to which extent they can be considered as 
governance networks. Moreover, we will seek to assess whether the typology of a network 
has had an impact on the process of establishing a sustainable framework for HTA coopera-
tion in an EU setting. In doing so we will follow the structure of the research framework 
regarding the typology of networks based on the following elements: network formation, 
membership, resources, and governance. In the research framework outlined in chapter 3, 
each of these elements correspond to several attributes which will be used to structure our 
analysis in the present section.
7.1.1. Network formation of European HTA cooperation networks
In chapter 3, we have outlined several factors influencing network formation such as contex-
tual incentives, strategic calculations and support or constrain given to network formation. 
Contextual incentives could refer to issues such as interdependencies in terms of resources 
or strategic externalities or the need to deal with wicked problems. Strategic calculations 
and choices to form or participate in a network can be made for various reasons such as 
securing action capabilities or compensate for limited rationality or the presence of a cheap 
exit strategy. As such, strategic games such as the free rider problem, the assurance problem 
or the generosity problem can occur. Finally, support or constrain linked to dual loyalties 
towards the network and its home-organisation can lead to a constant search to balance 
between the need for more cooperation and the desire to maintain sovereignty and control 
over its course of action (see section 3.5.1).
The networks established in the early cooperation initiatives resulted from endogenous 
developments within the HTA arena, motivated by shared needs of developing knowledge 
and capacity on HTA. Hence the contextual incentives leading to the establishment of the 
first project-based networks laid in the diversity of approaches in a relatively young policy 
field. HTA arena representatives felt the need to enhance the quality and quantity of HTA, 
avoid duplication and allow a better allocation of resources. No intervention of actors outside 
the HTA arena has been identified. However, European Commission support has been deter-
minant to launch and maintain the project. The first initiative had already been reformulated 
upon Commission guidance to allow funding acceptance. Moreover, the request of ECHTA/
ECHAI project coordinators addressed to the European Commission to formalize EU support 
for HTA cooperation, would represent a first step towards the establishment of a sustainable 
network structure, supported by the EU and seeking to move away from a project-based 
approach (4.4.3).
The incentives for the Commission to support HTA cooperation in the 1990s differed how-
ever from incentives identified in the HTA arena and were related to the limited competences 
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of the EU in health policy and the desire to develop more efficient and cost-effective health 
systems in the Member States (section 4.2.2). No contextual incentives on behalf of Member 
States have been identified at this period, of time, in our research. Besides a cheap exit 
strategy, no real strategic calculations have been found for the creation of the first EUR-
ASSESS network and the subsequent projects (HTA-Europe, ECHTA/ECAHI). By developing 
their knowledge on HTA through collaboration, network members essentially sought to 
strengthen the position of HTA in national decision-making processes.
The contextual incentives to establish the EUnetHTA network closely followed those of the 
early cooperation initiatives as development of HTA knowledge and expertise and duplication 
of efforts across Member States remained a concern for HTA agencies. Capacity-building 
of countries having limited experience in HTA became more important in the course of the 
years. The inclusion of HTA as topic in the HLG and allowing for the HTA to qualify as political 
priority for the EU has been however a new factor playing a role in the establishment of 
EUnetHTA (6.1.1) as was the inclusion of HTA cooperation in the Cross-Border Health Care 
Directive in the 2008 Commission proposal facilitating the continuation of the network in 
the form of Joint Actions (6.1.1). Previous collaboration experiences served as a basis for the 
setup of the network which pursued similar objectives. Finally, the political support of the 
HLG and the financial support of the Commission also contributed to the establishment of 
the EUnetHTA network (6.1.1).
Strategic calculations would be more present in EUnetHTA compared to the previous projects. 
Still voluntary based, the cheap exit strategy remains present. However, other calculations 
also came to the fore which explain the need for support looked after, not only on behalf 
of national and European public authorities but also on behalf of organisations such as 
the WHO (6.2.1.1). In the early 2000s HTA was increasingly considered of importance to 
address challenges in national health systems, facing, amongst others, rising health-care 
costs. It remained however a complex issue in terms of expertise and the role it should have 
in national decision-making processes. By creating EUnetHTA, the project initiators envisaged 
to establish stronger ties between the domestic policy-making level and HTA. For network 
members, cooperation seemed to offer more advantages than to continue the work in isola-
tion. The incentives of the European Commission to support the EUnetHTA project were 
still in line with their position in the 1990s and aimed at strengthening the health systems. 
However, the importance of lifting HTA to the (European) policy-making level became an 
active strategy which became increasingly important over the years (6.1.1.; 6.1.2.).
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Network formation Early HTA initiatives EUnetHTA EU HTA Network
Incentives •	 	Limited	knowledge	
knowhow HTA useful 
for developing efficient 
and cost-effective health 
systems
•	 	Limited	use	HTA	in	MS
•	 	Address	rising	health	care	
costs MS
•	 	HTA	diversity	and	
duplication
•	 	HTA	diversity	and	
duplication
•	 	HTA	Capacity-building
•	 	HTA	is	EU	political	
priority
•	 	Continuation	of	
collaboration efforts
•	 	Commission	support
•	 	Develop	efficient	and	cost-
effective MS health systems
•	 	Rising	health	care	costs
•	 	HTA	duplication	&	lack	of	
sustainability EUnetHTA
•	 	Lack	of	uptake	EUnetHTA	
outputs
•	 	Develop	policy	level	input
•	 	Legal	framework
Strategic calculations •	 	Cheap	exist	strategy
•	 	Compensation	limited	
knowledge
•	 	Cheap	exit	strategy
•	 	Assurance	problem
•	 	Cooperation>maintain	
sovereignty
•	 	Enter	MS	health	systems
•	 	Develop	EU	health	policy
•	 	Establish	link	HTA-policy	
makers
•	 	Co-steer	HTA	cooperation
Support/constrain •	 	Home-organisations	
informed
•	 	Public	authorities	
informed
•	 	No	loyalty	concurrence
•	 	Support	from	Home	
organisation
•	 	Support	MS	Public	
authorities
•	 	Support	international	
public authorities
•	 	EU	support
•	 	Support	EU	legal	framework
•	 	Support	MS	public	
authorities
Table 7.2. Network formation European HTA cooperation networks
Similarly, to the establishment of EUnetHTA, the contextual incentives of the EU HTA Net-
work were related to the previous network experiences. However, in this case, the network 
establishment resulted from an EU initiative. As sustainability of HTA cooperation had not 
been achieved through the work of EUnetHTA, the Commission sought to establish a new 
network at a Member State policy-making level. The adoption of the Cross-Border Health 
Care Directive would give the Commission a legal basis and framework to establish a new 
network (5.1.3). In a sense, this approach was also in line with the formal request of the 
ECHTA/ECAHI representatives to establish a sustainable and properly funded coordinating 
body for EU-wide network on HTA asked for more than a decade earlier (4.4.3). HTA co-
operation had developed into a complex policy issue touching upon different policy fields 
involving actors on multiple levels. The strategic calculations at this point of time are based 
on the belief that HTA needed to be lifted at a higher policy-level to ensure effective ac-
tion leading to the realisation of the cooperation objectives. Moreover, by coordinating the 
secretariat and co-presiding the Network, the Commission had an opportunity to steer the 
direction of this network (6.3.2.). Developing EU public health (into new fields such as timely 
patient access) and strengthening the health systems would further underpin the efforts of 
the Commission to steer the cooperation process.
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7.1.2. Membership of European HTA cooperation networks
When examining membership policy in the different HTA cooperation networks, distinct 
approaches can be identified. In the first EUR-ASSESS, project members had been invited by 
the project initiators basing the membership upon geographical (EU) criteria (distinct from 
membership in existing international societies) (4.1.1.). Members were (except for Germany) 
exclusively representatives of the HTA arena. In the subsequent projects of the early coopera-
tion efforts, membership would be somehow extended, but the approach remained the same 
(predominantly HTA body representatives) (4.1.1; 4.3.3). The relationship of the network 
towards the home-organisation of members was of low intensity, although members would 
sit in middle- to top management ranked positions. Their involvement should be mainly 
considered as a personal contribution to the network and did not necessarily reflect the 
interests of their home-organisations (at least not officially), even if support for participation 
was given and backed by the ministry.
Membership Early HTA initiatives EUnetHTA EU HTA Network
Public, private, Non-
profit
•	 	HTA	arena	(mostly	public) •	 	HTA	arena
•	 	Few	ministries	(6)
•	 	Public	authorities	
responsible for HTA
Relation home 
organisation-network
•	 	Low •	 	Depending	on	size	MS
- Small MS: strong
- Big MS: Low
•	 	Unclear,	no	transparency	
on membership
Open-Closed
(socially & cognitively)
•	 	Socially	closed
•	 	Cognitively	rather	open
•	 	Project,	JA1,	JA2	socially	
closed, cognitively rather 
open
•	 	JA3,	socially	and	
cognitively open
•	 	Socially	Closed,	
Cognitively open
•	 	No	transparency	on	
membership
Homogeneous/ 
Heterogeneous
•	 	homogeneous •	 	homogeneous:	project,	
JA1, JA2
•	 	heterogeneous:	JA3
•	 	Stakeholder	pool	
heterogeneous (but no 
formal members)
•	 	unclear
•	 	Stakeholder	pool	
heterogeneous (but no 
formal members)
Table 7.3. Membership European HTA cooperation networks
These early cooperation networks could be characterised as closed networks in a social 
understanding as members could participate only upon invitation of the project initiators 
and (in most cases) with the approval of the respective health ministries (3.5.3; 4.3.3.). No 
representatives of a ministerial level did take part in the first networks, which could be quali-
fied as networks of peers. Although, the networks did not exclude any potential partners, 
the restrictive public knowledge about the new project-based network did not allow any easy 
access to potentially new members (4.3.3). The early cooperation networks established in 
the 1990s did demonstrate cognitive openness. Awareness regarding the outside reality was 
even driving the cooperation efforts both regarding the objectives pursued by the network 
as well as the availability of the means necessary to do so. Members participated and rep-
Data Analysis 409
resented the network in other HTA-related international societies or cooperation structures 
with a shared value system (4.1.1). However, no other stakeholder groups participated in 
the network which could be qualified as being homogeneous in its membership structure, 
consisting predominantly of HTA bodies representatives sharing similar profiles and academic 
and professional backgrounds (4.1.1.).
Membership in the EUnetHTA network differed across the different projects and Joint Ac-
tions. As such, in the EUnetHTA project, membership represented predominantly the HTA 
arena. The project distinguished itself from the Joint Actions in terms of membership by the 
number of partners outside the EU (and outside Europe such as Israel, the USA, Canada) as 
well as by the inclusion of international organisations (Annex 4). The main partner being 
the beneficiary of the European Commission grant was the Danish Health and Medicines 
Authority which remains so till the Joint Action 3, which will be led by the Zorginstituut 
Nederland. The Joint Action 1 counted 35 partner organisations, again mainly representing 
the HTA arena from EU countries. Membership remained very similar in the Joint Action 2 
which counted 39 partner organisations under which 3 Ministries of Health (of Malta, Cyprus 
and Slovakia) like in the Joint Action 1 (Malta, Spain and the Czech Republic) (Annex 4). The 
Joint Action 3 will mark a difference in terms of membership as it will open the network and 
include 81 partner organisations. Profiles of the member organisations will be more varied 
and not limited to HTA agencies and include members, such as, academic institutes, national 
medicines agencies, insurance funds, public health organisations or institutes. The number of 
Ministries of Health taking officially part in the cooperation remains low and concerns only 
small countries (Cyprus, Czech Republic, Slovak, Republic, Croatia, Slovenia and Ukraine). 
Apart from the Joint Action 3, the network structure of EUnetHTA is quite homogeneous. 
Socially, the structure remains closed, as membership is only possible upon recommendation 
of the ministries and concerns mainly HTA bodies. Cognitively, influences from external or-
ganisations do have an impact on EUnetHTA either via members participating in international 
societies or via the European Commission-led expert groups (5.3.3.2.; 6.4.2.3.; 6.4.2.4.)
Membership of the EU HTA Network remained unclear. The rules of procedures stipulated 
that members could be either representatives of national authorities or bodies responsible for 
HTA and designated by participating Member States (6.2.2.1.) Minutes of the meetings never 
precise the nature of the country representative participating in the meetings (HTA body, 
ministerial representative or other). Data collected through personal interviews indicated that 
overlap between EUnetHTA members and the EU HTA Network often existed (6.2.2.1.). The 
network remained closed as participation was possible only upon invitation and subsequent 
approval of the ministries. Moreover, transparency was lacking as to whom would take part 
in the network meetings. Strong ties still existed with the Joint Action 3 representatives. Due 
to lack of transparency, it is difficult to examine whether the network is homogeneous or 
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heterogeneous, although the former seems to be the case. The Stakeholder pool, gathering 
umbrella organisations from different stakeholder groups would bring heterogeneity in the 
network structure even though, these are no formal members of the network and do not 
take part in the network meetings199. Relation between the representatives and their home-
organisation is, for the same reasons, unclear. Especially the information flow between the 
network and Member States’ ministries cannot be clearly identified and no public record is 
available. Conversely to the early cooperation networks and EUnetHTA, the EU HTA network 
has been setup upon the initiative of what would become a metagovernor (i.e. the European 
Commission). The official membership structure should also distinguish this network from 
EUnetHTA and the early initiatives as it was not meant to be a network of peers. In practice, 
it has been difficult to verify this information and overlap between EUnetHTA and the EU HTA 
Network has been reported in terms of membership. The strong policy orientated objectives 
of EU HTA Network and the participation of policymakers should, at least theoretically, put it 
more firmly in the category of governance networks established to pursue public policy aims 
defined by public authorities.
7.1.3. Resources of European HTA cooperation networks
Resources of networks can vary between different type of means such as financial, natural/
physical, social/or political and human resources. In the HTA networks that have existed since 
the early initiatives, all these resources have played a role in the development of European 
cooperation in HTA. Financial means to set up and pursue the cooperation efforts mainly 
came from two sources: the European Health Programme of the European Commission and 
national governmental support (mostly in-kind). The former was given through grants which 
have been drastically adjusted upwards since the Joint Actions. As such, the grant approved 
by the European Commission for each Joint Action doubled compared to the previous Joint 
Action200. Time dedicated to HTA cooperation projects has been taken into the budgets 
of the participating HTA bodies, often financially supported by national public authorities. 
Development of tools, publications and organisation of meetings, seminars and conferences 
would be financed through the budget allocated by the European Commission grant. This 
would remain through the various projects since the early initiatives till the Joint Action 3. 
Costs of secretariat activities and personnel would be covered by funds stemming from the 
199 Stakeholders would be represented by specific organisations who would be allowed to participate 
at the end of the EU HTA Network meetings for presentation purposes (6.3.1.2.2.).
200 As such the grant approved by the European Commission for the Joint Action 1 was at the level of 
2 903 897,79 € for a project duration of 37 months. The Joint Action 2 received financial support 
up to 6 599 777,00 € for a project duration of 42 months and Joint Action 3: 11 999 798,74 €. 
(https://webgate.ec.europa.eu/chafea_pdb/health/projects/724130/summary).
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European Commission grant. Costs of secretariat premises would be covered by the hosting 
HTA body (6.3.1.2.1).
Resources Early HTA initiatives EUnetHTA EU HTA Network
Financial •	 European	Commission •	 European	Commission
•	 National	public	
Authorities
•	 European	Commission
•	 National	Public	
Authorities (?)
Natural/Physical •	 National	public	
authorities (secretariat 
premises ECHTA/ECAHI)
•	 National	public	
authorities (secretariat 
premises)
•	 European	Commission	
(secretariat premises)
Social/Political •	 -- •	 High	level	expert	groups
•	 Health	Council
•	 International	societies	
and organisations
•	 European	Commission
•	 National	public	
authorities
Human •	 HTA	representatives •	 HTA	representatives
•	 European	Commission	
representatives
•	 European	Commission	
representatives
•	 External	personnel
Table 7.4. Resources European HTA cooperation networks
Our research has not identified specific social or political support, apart from the HTA com-
munity itself, in the early cooperation initiatives. This will however change in the interlude 
period (2001-2006) with where high level expert groups such as the HLG on health services 
and medical care or the Pharmaceutical Forum increasingly offer support which will also be 
translated in political support by means of official statements of representatives of national 
public authorities, the European Commission and the Health Council as well as in draft 
legislative proposals of the Commission, some of which have been adopted by the European 
Parliament and the Council (5.1.2.2.; 5.3.3.1.; 5.3.3.2.; 6.1.1; 6.1.2.;6.2.2.; 6.2.2.3). The EU 
HTA Network distinguishes itself from the other networks as its establishment resulted from a 
European Commission initiative itself based on the Cross-Border Health Care Directive. Sup-
port from national public authorities was thus implicitly present. Social support was closely 
associated to support of the same kind to the EUnetHTA network (6.2.2).
Human resources have played an important role in the development of HTA cooperation in 
Europe. Much of the work implemented depended directly on the know-how of HTA body 
representatives who dedicated much time and energy in the network projects. Investment 
of the latter grew accordingly with the setup of new networks. Indeed, the number of new 
projects implemented by the networks has developed over the years requiring the investment 
of more people to implement them (4.4; 6.4). Since part of the work of the EU HTA Network 
has been implemented through the EUnetHTA network (the scientific and technical arm), 
human resources have been shared. Work related to the development of studies preparing 
the Commission legislative proposal was often done by Commission personnel or external 
persons commissioned (and paid for) by the European Commission.
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7.1.4. Governance modes of European HTA cooperation networks
Governance modes in the early cooperation projects such as EUR-ASSESS and ECHTA-ECHAI 
were characterised by a non-hierarchical coordination method. Although formal governance 
entities did exist (i.e. Steering Committee, Executive Committee, Subgroups) all members par-
ticipated in the decision-making process formally or informally (4.3.1.). Although the project 
initiators had an important role to play in terms of implementation and decision-making and a 
project coordinator had been appointed, the project heavily depended on the commitment of 
all for the implementation of the work. No hierarchical status structure existed, and all mem-
bers interacted on an equal basis which was also reflected in the Steering Committee compris-
ing all members (4.3.1.). Appointment of subgroups members was based on expertise. The 
Executive Committee resulted from practicalities linked to management and implementation 
functions (4.3.1.). Whilst the HTA-Europe project was based on the same governance structure 
as in EUR-ASSESS, the ECHTA-ECHAI network will differentiate itself from its predecessors by 
creating a Secretariat (4. 3.1.). However, offering administrative and organisational support, 
this body did not fundamentally alter the governance approach of the early initiatives which 
could be characterised as a participant-governed network as defined in section 3.5.3.
Governanc Modese Early HTA initiatives EUnetHTA EU HTA Network
 Power distribution •	 	Horizontal	coordination
•	 	Equal	status	
participants
•	 	Horizontal	coordination
•	 	Differentiated	status	
participants
•	 	No	equality	in	authority	
members
•	 	Member	State	horizontal	
coordination
•	 	BUT	Important	(top-down)	
Commission influence on 
agenda and policy setting, 
financial and human resources
Steering mechanism •	 	Decentralised	collective	
self-governance
•	 	Participant-governed
•	 	Lead-organisation	
governance
•	 	Network	Administrative	
Organisation
Table 7.5. Governance modes European HTA cooperation networks
The governance structure of the EUnetHTA network shows still many characteristics with 
the early HTA cooperation initiatives. However, points of distinction can also be identified 
over time within the different Joint Actions. As such, a main difference between the ECHTA/
ECAHI project and the EUnetHTA project has been the designation of a ‘main partner’ of 
the project. Resulting from a contract condition to be fulfilled, this appointment did affect 
the governance practices in EUnetHTA. The Secretariat would also be hosted in the premises 
of the main partner giving the latter a coordination role in which it distinguished itself from 
the other project partners (6.3.1.1.). The main partner chaired the Steering Committee 
responsible for the strategic orientation of the project and was also member of the Executive 
Committee. Moreover, as the formal contact point, it became also a privilege interlocutor of 
the European Commission (6.3.1.1.). Hence, through its leading role, its (informal) weight 
upon the network decision-making processes also distinguished it from the other members.
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The Standard Operating Procedures of the EUnetHTA Collaboration and Joint Action 1 as well as 
the Consortium Agreement integrated in the Joint Action 2, reflected a few differences with the 
former projects. As such, membership would be differentiated between ‘EUnetHTA Partners’ and 
‘EUnetHTA Associates’ (6.3.1.2.1). The formal agreements also clearly defined the responsibilities 
of each as well as the terms of engagements and consequences in case of breach of the agree-
ments (6.3.1.2.1). Besides formal differentiation in membership, weight upon decision-making 
processes also differed amongst the EUnetHTA Joint Action partners according to seize and 
weight in national decision-making structures and personal investment in EUnetHTA (6.3.1.2.1). 
Moreover, due to their role in the network structure, Lead Partners, united in the Executive Com-
mittee had significant influence in the network (6.3.1.2.1). The Executive Committee counted 
since the Joint Action 2 also a Commission representative amongst its members which did not 
hold any voting rights but could, informally, influence decision-making of the network.
Governance in the Joint Action 3 will distinguish itself from the previous Joint Actions by the 
role of the main partner which will be transformed in a ‘Directorate’ composed of a Director’s 
office and a Secretariat. The name change reflected a change of governance practices from 
a more horizontal soft governance approach in the previous projects and Joint Actions to 
a more top-down hierarchical governance approach in the Joint Action 3. Although this 
could have pointed to more authority of the lead-partner over the project, the data has 
shown that, in practice, EUnetHTA became subordinated to the EU HTA Network. Hence, 
EUnetHTA could be characterised till the Joint Action 2 as Lead-Organisation Governance. 
Although much of the governance structure remains in place in the Joint Action 3, much of 
the governance, policy orientation and project implementation of the EUnetHTA Network 
will be determined by the EU HTA Network (6.2.2.2).
The EU HTA Network resulted formally from the implementation of Article 15 of the Cross-
Border Health Care Directive. Governance structures have been determined by the legislative 
text and work organised according to the Multiannual Framework adopted by the network 
members. As chair of the network, responsible, amongst others, for setting the agenda 
and running the secretariat, the European Commission (DG Santé) could be characterised 
as the administrative entity establishing a rather centralised governance practice. Its role in 
coordinating the work and offering financial, physical and human resources, allowed for a 
certain degree of sustainability. Expertise to reflect upon a long-term sustainability coop-
eration structure has been gathered through EUnetHTA on the one hand and specialised 
EU commissioned studies on the other, all financed by DG Santé (6.2.2.3.1; 6.3.2.). With 
the establishment of the EU HTA Network, the policy-setting role of the EUnetHTA Plenary 
Assembly has been shifted to the former, alongside the transformation of EUnetHTA to a 
technical and scientific arm of the EU HTA Network. As such, governance of EUnetHTA for 
an important part shifted to the EU HTA Network.
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The 2018 Commission Regulation proposal outlined the potential establishment of a Mem-
ber State-led coordination body, co-chaired by the Commission, which should govern the 
future HTA cooperation structure and take the policy decisions. The Commission would host 
the cooperation structure and be responsible for running the Secretariat. Other key functions 
such as the official Commission approval for publishing results on the lists were also foreseen 
in the initial proposal. The creation of a Union agency for HTA envisaged by the Commission, 
after a transitional period, indicated a potential desire to move towards a similar structure 
as the EMA (6.3.2.). Although stakeholder participation has always been promoted by the 
Commission in HTA cooperation, the position and influence given to the latter by means 
of the Stakeholder pool would remain limited, with some stakeholder groups having more 
influential weight on decision-making processes than others (6.3.1.2.2; 6.3.3.).
7.1.5. Conclusion typology European HTA cooperation networks
This section has analysed the various networks seeking to establish sustainable European 
cooperation in HTA. The examination has proceeded according to (governance) network 
characteristics outlined in chapter 3 and constitute the first part of our research framework. 
The aim of the analysis was to identify the governance structures of HTA cooperation net-
works and to see whether these correspond to characteristics of governance networks. If 
indeed (some) of these networks could be qualified as governance networks, the following 
step would be to examine how these relate to the soft governance approach of the post 
2000 EU health policy.
In section 3.4.1. we have outlined a list of general characteristics of governance networks 
as brought to the fore in the literature on governance networks. The analysis made in this 
section allows us to compare the characteristics of the HTA cooperation networks with the 
general characteristics of governance networks. The table below brings to the fore that all 
three network structures examined do correspond to governance networks.
Indeed, all networks resulted from a desire of social actors to develop knowledge and experi-
ence in HTA. Cooperation could enhance HTA quality and quantity in domestic decision-
making processes, herewith strengthening the national health systems in Europe. As such, 
the networks aimed at contributing to a public purpose. The examination of the networks’ 
typologies has permitted to further distinguish the specific characteristics of the network 
structures. Section 7.1.1. has outlined the similarities and differences regarding the forma-
tion of these networks, each resulting from the emergence and interaction of the previous 
network(s). Contextual incentives, for example, differed and reflected consequences of work 
produced or not in the previous networks. Some incentives, however, were consistent in all 
network formations, such as the rising health care costs and the need to contribute to the 
efficiency and cost-effectiveness of the health systems. The voluntary basis of cooperation, 
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allowing for a cheap exit strategy, also played a role in each. Fluctuating incentives would be 
related to new policy contexts in either the Member States or the European Union as well as 
to strategic calculations to gather in an HTA cooperation network.
Characteristics Governance Networks
EUR-ASSESS, 
HTA-Europe, 
ECHTA/ECHAI
EUnetHTA 
(Project, JA1, 
JA2, JA3)
EU HTA 
Network
More or less stable pattern of relationships of social actors 
clustering around policy problem/resources, emerging, 
sustaining and changing though interactions1
+ ++ +
Stable horizontal relations of interdependent, autonomous 
actors (public private, civil society), not necessarily equal in 
authority and relationships2, 3
+/- ++ +
Interaction through negotiations based on deliberation, learning 
and common understanding2
++ ++ +/-
Interactions in regulative, normative, cognitive and imaginary 
framework2
+/- + +
Self-regulating within limits set by external agencies2 + ++ +
Actors aggregate different resources4 + + +
Contributes to public purpose2,3,4 +/- + ++
Table 7.6. Attributes Governance Networks applied to European HTA cooperation networks
1Klijn and Kloppenjan (2016), 2Sorenson and Torfing (2007), 3Klijn (2008), 4Huppé, Cneech and Knob-
lauch (2012)
The horizontal soft-governance coordination approach certainly favoured support from 
public authorities in Member States, which remained in control of their domestic health 
policies. Although no hierarchical top-down governance structure characterised any of these 
networks, we have seen that some member organisations would enjoy more authority than 
others, often depending on the size of the agency and the country of origin. One can cite as 
an example hereof the main partners, the European Commission and some HTA agencies of 
(size-wise) bigger EU Member States. Due to the need to enhance knowledge and capacity 
on the one hand and the fact that HTA corresponded to a small policy-field requiring specific 
expertise, members remained interdepend to fulfil the goals of the cooperation and to reach 
their own objectives when joining the networks.
Network members came predominantly from the (public) HTA arena, especially in the proj-
ects till the EUnetHTA Joint Action 3. The homogeneity of the networks resulted in a shared 
normative framework which remained a cognitively open network. This did not necessarily 
mean that a common approach towards specific projects would be systematically shared by 
all members and their home-organisations (e.g. quality requirements of joint work). Indeed, 
depending on the relationship between the network and the home-organisations, different 
standpoints towards proposed solutions or practices would remain. This would be observed 
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more often in (size-wise) bigger EU Member States. By sending top-management representa-
tives, stronger adhesion to joint work would be found in HTA bodies of smaller countries.
Stakeholders from the non-profit and private sectors increasingly took part in the coopera-
tion process, however, with unequal influence and participation. Public authorities mainly 
took part in the process by formally appointing members to the networks. Officially, the EU 
HTA Network should be composed of ministerial representatives, in practice however, the 
membership structure of this network seemed to resemble strongly the EUnetHTA network. 
Self-regulation was the rule but needed to respond to specific procedures specified in grant 
agreements, supervised by the European Commission which secured an important part of 
the financial resources. Other resources, such as in-kind contributions (e.g. personnel costs, 
premises) were covered by national authorities.
The governance modes implemented in all HTA networks were based on soft governance and 
voluntary cooperation. However, each network did display distinct characteristics in terms of 
governance structures. From a participant-governed network in the early initiatives, to a 
lead-organisation governance in EUnetHTA, European HTA cooperation has been organised 
in the EU HTA Network via a network administrative organisation, with the European Com-
mission acting as metagovernor`. The role of the Commission in the development of HTA 
networks has been determinant. From a simple grant allocator in the EUR-ASSESS project, to 
a full-fledged partner of the Joint Actions, the Commission did indirectly take part in steering 
the governance processes regarding the typology of the governance networks. As such, 
it has had an influence on the strategic calculations to pursue the cooperation initiatives, 
on its membership structure (e.g. openness, heterogeneity, stakeholders), on the available 
resources (financial support) as well as on the governance structures.
Having identified the network characteristics of each of the three main HTA cooperation 
networks, the next section will examine to which extent these networks have been effective 
in reaching the goals set.
7.2. Network goverNaNce: eFFectiveNeSS oF europeaN hta 
goverNaNce NetworkS
As outlined in chapter 3, soft governance modes have often been used by European institu-
tions to implement specific policy processes through governance networks. In section 3.6. 
we have framed the notion of effectiveness and recalled that effectiveness in governance 
networks cannot be measured in the same way as effectiveness of states and markets (Jessop 
2002: 236). We also have defined effectiveness of networks in terms goal attainment (3.6.2.) 
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which can be analysed through process, outputs and outcomes, all three being interrelated 
(3.6.1.) Processes can be examined by, for example, looking at negotiations that take place 
between actors or a network’s adaptation capacity. Trust, learning processes, shared values 
and understanding can play a role herein (3.6.2.) Outputs can be observed in the form of 
concrete, desired and targeted ‘products’ of the collaboration efforts. Measurement can be 
done by comparing the results to the goals set or the needs expressed (3.6.2.) Outcomes have 
been defined in the research framework as (un)desired effects of the cooperation efforts and 
can be divergent in nature (e.g. evolving social situation, developed problem-solving capacity 
or creation of new private or public entities) (3.6.2.).
To attain the overarching goal, sub-goals may be set as intermediate steps. The dynamics 
of goal pursuit could be represented as a chain of goal attainment. Goal attainment being 
understood as ‘the action or fact of achieving a goal towards which one has worked’ (3.6.1.). 
In the outline of the research framework we have indicated that this encompasses in our 
understanding goal setting and goal achievement (3.6.1). In the following sections we will 
examine effectiveness of HTA cooperation networks in the light of goal attainment as defined 
in chapter 3. We will do so by applying the elements highlighted in the research framework 
which allow to examine goal attainment through process, outputs, and outcomes.
The research framework includes the following factors which bear the potential to impact 
effectiveness of network governance: social interaction, governance, management, and 
external events. In this section we will look at each of these factors individually through 
the scope of specific features laid down in the research framework. Social interaction will 
be examined by focusing on learning processes, shared values and understanding, trust 
and goal consensus. Governance instruments will be explored by considering procedural 
and substantive policy instruments as well as legislative, political, and financial instruments. 
Impact of management on effectiveness of network governance will be analysed in this 
section by concentrating the examination on particular skills required for such undertakings 
by network managers as well as to the management style (i.e. process management versus 
project management). Finally, the section will present an overview of external events having 
had an impact on HTA cooperation and occurring in the time-lapse of the examination period 
of the HTA networks.
The aim of this analysis is to identify whether these factors were present in the European HTA 
cooperation process and whether they have played a role in the goal attainment process of 
European HTA cooperation networks. We will then examine to what extent social interac-
tion, governance, management and external effects have had an impact on 1) the process 
of establishing a sustainable network (overarching goal), 2) the production of cooperation 
outputs (sub-goals) and 3) cooperation outcomes.
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7.2.1. Social interaction in European HTA governance networks
Internal processes supporting or restraining cooperation in a network can be affected by 
social interaction. As such, social interaction has a potential impact on goal attainment, a 
process which takes place, amongst others through cooperation. Social interaction can take 
place in various ways. Attributes of social interaction included in our research framework 
comprise trust, shared values and understanding, learning processes and goal consensus. 
(3.5.1.). In this section we will examine to which extent these have been identified in the 
HTA cooperation networks and how they have favoured (or not) the process of establishing 
a sustainable network, the production of outputs and contribute to the development of 
specific outcomes. Although we will examine each of the social interaction attributes in a 
separate manner, the distinction is rather artificial as they are all interconnected and can 
mutually influence each other.
Moreover, each constituent of social interaction, can be affected by various elements related 
to the typology of a network (see section 7.1.). As such incentives and strategic calculations 
in network formation can affect the degree of trust or goal consensus. Similarly, an open 
or closed network can affect social interaction as it will have an impact on the number 
of members and their profiles. Moreover, homogeneity or heterogeneity of a governance 
network can impact the degree of shared values and understanding as well as trust, learning 
processes and goal consensus. Hence, even though we will examine the various attributes of 
social interaction separately, we will at times refer to interrelated features of other influenc-
ing factors regarding the typology or effectiveness of governance networks. In the following 
sub-section, we will first examine social interaction through the scope of learning processes 
and shared values and understanding. The next sub-section will focus on trust and goal 
consensus.
7.2.1.1. Social interaction: learning processes & shared values and 
understanding in European HTA governance networks
In governance networks based on soft governance and deliberative decision-making pro-
cesses, social interaction plays an important role with regard to goal attainment. As outlined 
in chapter 3, these networks cannot rely upon a hierarchical top-down decision-making 
structure. Instead, decisions are being made by deliberation and negotiation which take 
place in a regulative, normative, cognitive and imaginary framework. Such a framework fa-
vours learning processes and shared understandings on issues which will be of importance in 
reaching common decisions and developing policy instruments to reach the goal set (3.7.1.).
Learning processes in HTA cooperation networks often took place in the form of exchange 
of knowledge and information, allowing to establish best practices in HTA bodies and in 
Member States (4.2.1.). Attention went in particular to individuals and organisations having 
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less experience with HTA. Peer-education was here most common where more experienced 
partners would share their knowledge with less experienced ones. However, formalised 
learning processes have been implemented as well and led to the production of specific 
tools and training materials (e.g. handbook on HTA capacity-building, training seminars and 
e-learning materials) (6.4.1.3.; 6.4.2.3.).
These learning processes had a dual outcome. On the one hand, they would allow for the 
production of capacity-building tools which would facilitate the production of joint work 
such as methodologies, joint core-HTAs and joint REAs. On the other hand, they have con-
tributed to the development of a common understanding on the needs and goals of HTA 
cooperation. Moreover, values could be transmitted through learning processes and become 
more largely integrated in the network community. These shared values and common un-
derstanding would, amongst others, be reflected in the formulation of objectives which, in 
essence, have remained the same since the early cooperation initiatives (6.2.1.) In this sense, 
learning processes did contribute to the goal consensus process regarding the establishment 
of a sustainable European HTA cooperation network and the various tools which should be 
developed to support this overarching goal.
As these learning processes mostly concerned HTA doers, the impact they had on shared 
values and understanding also predominantly remained within the HTA arena. Our research 
has not identified any specific social interaction processes towards representatives of minis-
tries of health or other governmental institutions. The latter are however key actors in HTA 
processes as they will have to decide upon the use of HTA outputs in domestic pricing and 
reimbursement processes. Methodological and quality issues regarding HTA have a direct 
impact on the outcome of HTA and indirectly also impact regulatory processes since the HTA 
reports are used as input in pricing and reimbursement decisions on the national level. In this 
sense, policymakers at ministerial level would be concerned by HTA cooperation processes 
and could have been more actively involved in them.
Although the need for social interaction with ministerial representatives has been recognised 
by the networks, no specific activity has been established in this regard by them. This raises 
however questions as to the reasons and consequences hereof, especially with regard to 
the EU HTA Network. Interaction with policy-makers could have been expected in this case, 
since this network was conceived as a policy orientated network. Nevertheless, no particular 
learning processes or exchange of knowledge and experiences seem to have been envisaged 
nor established with ministerial representatives, to date. Explanatory arguments could be 
found relating to both the ministries and the networks. Considering the specific expertise 
required to understand HTA processes, ministries would often delegate their involvement in 
HTA networks to agencies’ representatives. Moreover, networks would implicitly count upon 
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HTA agency representatives to ensure the development of learning processes targeted at 
ministerial representatives.
In cases where social interaction between HTA agencies and ministries has been observed, it 
would be correlated to the size of the agency’s home-country and the management level of 
the HTA body-representative, active in the networks. The smaller the country and the higher 
the management-level, the more intense social interaction between ministries and HTA bod-
ies would be. Moreover, personal relationships between representatives of the ministries and 
HTA agencies also seem to have played a role in the development of social interaction at this 
level (6.4.2.5.).
Consequences of low social interaction intensity between ministries and HTA cooperation 
networks, could be measured in domestic and European regulatory and legislative processes. 
Qualitative data of our research points to potential impact of social interaction – or the lack 
thereof – on the adoption process of the Commission proposal for an EU Regulation on 
HTA cooperation. Considering the role of the Council in the EU legislative processes, social 
interaction could have had an influence on the positioning of EU Member States towards the 
proposal. We have seen in part B how some Member States have adopted critical standpoints 
regarding this proposal which would not always reflect the positioning of their countries’ 
HTA agencies, having participated in the process for many years (6.4.3.3.). More developed 
social interaction processes between the networks and ministerial representatives could have 
allowed to overcome the obstacles encountered at earlier stages in the collaborative pro-
cesses. However, social interaction cannot solely explain the positioning of Member States 
on the Commission proposal as other aspects also played a role herein.
The inclusion of stakeholders in the cooperation processes, although initiated in the first 
Joint Action, became effective only in the Joint Action 2 and triggered disappointments in 
Joint Action 3 (6.3.1.2.2; 6.4.1.3.). Indeed, predominantly composed of HTA bodies, ac-
tive stakeholder participation in the network activities was restricted. Projects were carried 
out by the network members and stakeholders would mostly be involved on a consultancy 
basis. This model, were little interaction would take place with the general network on a 
continuous basis, would have an impact on the development of learning processes and the 
establishment of a set of common values and understanding among stakeholders’ umbrella 
organisations and their members. The latter is of importance in the development of joint 
work and the uptake of it in a domestic setting.
Moreover, by enlarging the membership of the networks (e.g. JA2 & JA3), disparities arose 
not only among stakeholder groups but also within some stakeholder groups. Indeed, the 
data has brought forward how disparities could exists between umbrella stakeholder organi-
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sations participating in the network and their members. As such, HTA network values could 
be adopted by the umbrella organisations but would not be diffused to their members. 
Consequently, positioning of umbrella organisations, members of HTA networks, would not 
necessarily reflect the position of the stakeholder group as a whole. An example hereof could 
be found in EFPIA, which would consider joint work in HTA as valuable and beneficial for 
the pharmaceutical industry. This idea would however not always be shared by their own 
member organisations who would consider these issues only from a side-line and would not 
necessarily see sense in cooperating in joint assessments (6.3.1.2.2.).
Social interaction, or lack thereof, with some stakeholder groups has impacted the goal 
attainment process in several aspects. Inclusion of stakeholders in the HTA cooperation gov-
ernance processes has been strongly supported by the European Commission. One of the 
objectives of the creation of a Stakeholder Forum was to persuade a wider group of stake-
holders in HTA cooperation of the benefits of collaboration and the setup of a sustainable 
structure for European HTA cooperation. Through exchange of information, knowledge and 
experiences, it was hoped common values on the issue would be further shared. However, 
opinions diverged regarding the inclusion of stakeholders in the HTA processes and positions 
often reflected national practices (6.3.1.2.2.).
Despite the stakeholder policies implemented in EUnetHTA and the EU HTA Network, no 
harmonised stakeholder approach has been adopted in 2020. Divergent Member States’ po-
sitions regarding the level of stakeholder inclusion still characterises the debate. Hence, deci-
sions regarding the level of stakeholder inclusion in the European HTA networks undergoes 
influences from national processes. These varies according to the governmental perspectives 
on health technologies, considered either as an element of public health or seen as products 
serving economic growth (6.3.1.2.2.). Moreover, our analysis has not been able to identify 
any horizontal stakeholder interaction across the different stakeholder groups. No solid uni-
fied position or concertation regarding stakeholder policy on behalf of all stakeholder groups 
(payers, patients, health care providers and industry) has been observed.
To conclude, learning processes have allowed for the development of a set of shared values 
and understanding among HTA agency representatives representing the members of the 
HTA networks. Present since the first collaborative initiatives, learning processes have un-
dergone a development process whereby, besides informal exchanges of experiences and 
peer education, learning became increasingly structured in the form of capacity-building 
tools and processes. Moreover, these processes also underpinned the production of specific 
tools and methodologies, designed as sub-goals to prepare the establishment of a sustain-
able structure HTA cooperation in Europe. As such, social interaction, by means of learning 
processes and shared values and understanding, have had a positive impact on the goal 
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attainment process and the production of specific HTA collaboration outputs allowing for 
the development of joint work.
Social interaction between the European HTA networks and policymakers has been observed 
only in some cases. Lack of social interaction stemmed from the specificity of HTA whereby 
ministries often delegated their presence to HTA body representatives. European networks 
did not actively pursue interaction with governmental institutions implicitly assuming this 
would take place on the agency level. Consequently, social interaction between the networks 
and ministries was of a low intensity level and did not allow diffusion of learning processes 
and common values and understanding.
Moreover, the qualitative data of our research points to a correlation regarding social interac-
tion between agencies and governmental institutions and the size of the home-country and 
the management representation level participating in the HTA networks. Hence, absence 
of routinised social interaction between policy-makers and HTA collaboration networks has 
negatively impacted the goal attainment process of the HTA networks.
Social interaction EUR-ASSESS, 
HTA-Europe, 
ECHTA/ECHAI
EUnetHTA EU HTA Network
P JA1 JA2 JA3
Learning processes
HTA Arena ++ +++ +++ ++ + - 
Policymakers - - - - - No data available 
Stakeholders - - - +/- +/- - 
European Commission +/- + ++ ++ + + 
Shared values and understanding
HTA Network +++ +++ +++ ++ ++ ++ 
HTA Network-Policymakers - - - +/- +/- No data available 
HTA Network-Stakeholders - - - +/- +/- +/- 
Stakeholders-Stakeholders - - - + +/- +/- 
HTA Network-Commission ++ ++ ++ +++ ++ +++ 
Table 7.7. Social interaction in European HTA networks
(learning processes & shared values and understanding)
Social interaction as regards stakeholder groups seems to have taken place only in a verti-
cal manner between the HTA network governance structures and the different stakeholder 
groups. Impetus to establish and deepen the relationship with stakeholders has mainly 
stemmed from Commission officials. Stakeholder policy predominantly remained at an in-
formative or consultancy level and excluding any decision-making role in governance struc-
tures. Impact of learning processes to develop a system of shared values and understanding 
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remained limited as no real active role was given to stakeholders. Moreover, there where 
these learning processes took place and interaction did positively impact shared values and 
understanding, it would often remain at the umbrella organisation level and not further 
disseminate to their members. Hence, due to restricted stakeholder involvement in the coop-
eration process, effect of social interaction remained limited. In this sense, learning processes 
have had only a limited impact on goal attainment of the HTA networks.
7.2.1.2. Social interaction: Trust and goal consensus in European HTA 
governance networks
The importance of trust among actors cooperating towards a common goal is often brought 
forward in discussions on cooperation mechanisms. Trust has been explained in chapter 
3 as reflecting the willingness of network members to accept vulnerability based upon 
positive expectations of each other’s intensions or behaviours (Provan and Kenis 2008:238). 
Measuring the degree of trust, as well as its impact on such cooperation mechanisms, can 
however become a hazardous experience as it implicitly relates to sentiments, such as, reli-
ance, confidence, beliefs in abilities or statements made. Disregarding the examination of 
trust in cooperation processes could however lead to a flaw in a research on cooperation 
mechanisms as this seems often to be related to goal consensus.
Trust among members of participant-governed networks (horizontal power distribution) 
tends to be generally higher than in lead-organisation networks or network-administrative 
organisations and contributes to cooperation and goal achievement. However, reaching 
collective goals can also be set in type of networks with a lower trust density. In chapter 3 
we have also highlighted how trust is manageable and plays a role in generating collectively 
negotiated decisions. Moreover, trust can also be influenced by the typology of networks. As 
such, in homogenous networks, composed of actors with similar professional, educational or 
cultural backgrounds, members may be more inclined to trust each other and share common 
values and beliefs than in heterogeneous networks (3.5.1.).
Trust has not been equal across all HTA cooperation networks and seems indeed to have 
affected the goal setting and goal attainment processes. In the early cooperation initiatives, 
qualified as ‘participant-governed networks’, membership of the network corresponded to 
a sort of ‘community feeling’ and trust in the cooperation process and the network was 
high (4.6.). The ‘dual leadership’ of the project coordinators also indicates a certain level 
of trust between them. Indeed, if in EUR-ASSESS David Banta would demonstrate a high 
level of personal investment in the project and would stand more in the forefront of the 
project, Egon Jonsson would take over that position in the ECHTA/ECAHI project without 
this affecting the cooperation imitative and project outcomes (4.1.). The level of trust present 
in the early cooperation initiatives is also reflected in the decision-making processes which 
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similarly resulted mostly from informal dialogues and exchanges between members at dif-
ferent venues and at different points of time. Decisions were officially adopted by consensus 
in the governance bodies, after having been discussed and agreed upon in informal arenas. 
No tensions regarding potential disagreements about the objectives set and the manner to 
achieve them, have been reported (4.3.1.).
Similarly, goal consensus in the early cooperation initiatives was easily found. The overarch-
ing objective of the early cooperation initiatives regarded the establishment of a European 
network for HTA cooperation. The sub-objectives were conceived as means to achieve this 
goal. The main objective found consensus among the networks’ members, all sharing the 
belief that it would strengthen capacity- building and dissemination of HTA use and results. 
The impact of informal dialogues on the consensus-based decision-making processes in the 
(formal) governance structures, indicates how members had ‘positive expectations of each 
other’s behaviour and intensions’ (4.2.1.; 4.3.1.) The homogeneity of the network is found 
to have had a positive impact on trust and goal consensus processes in the early cooperation 
initiatives (7.1.2.).
The level of trust among members of EUnetHTA has fluctuated in the course of years. In 
the EUnetHTA project and first Joint Action, trust amongst network members and trust in 
the goal setting and goal attainment process, tended to be stronger than at later stages 
of EUnetHTA. The inclusion of an article on HTA cooperation in the Cross-Border Health 
Care Directive (2011/24/EU) has reinforced the trust-building process regarding the network’s 
objectives. The homogeneous structure of the network in its early days has had a positive 
impact on the trust building process. Conversely, the more heterogeneous the network 
became, the more signs of mistrust would appear regarding the feasibility of the project 
objectives (7.1.2.). Lack of trust would be expressed regarding issues such as, process and 
product quality and timeliness of product outputs. As such, the need and feasibility of essen-
tial cooperation features (e.g. joint assessments, uptake of joint work) would be questioned 
(6.4.2.3.; 6.4.2.5.). Hence, network structure has had an influence on the trust-building 
process of the HTA cooperation networks. Network homogeneity has displayed a positive 
impact on trust building, whilst network heterogeneity negatively impacted the latter.
Besides trust building, the network structure also affected the goal consensus process. We 
have seen above, how EUnetHTA has gradually enlarged membership, whereby the member-
ship structure became more heterogeneous. Although, this process can lead to enhanced 
knowledge and capacity, it could also lead to an ‘efficacy paradox’ as discussed in chapter 
3 (Voss et al. 2006) (3.5.1.). Knowledge expansion and innovation do, on the one hand, 
enhance the problem-solving capacity of a network. On the other hand, the diversity of 
membership also makes it harder to achieve consensus on the solutions proposed (3.5.2.).
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This efficacy paradox has been observed in EUnetHTA. Since the EUnetHTA project till the 
first Joint Action, Goal consensus was present in, what was then, a homogeneous network. 
Consensus on implementation strategy or solutions proposed to specific problems, was 
generally the case (6.2.1.1.; 6.3.1.1). In the later stages, when EUnetHTA membership was 
less homogeneous, goal consensus was more challenging to achieve. Although, by joining 
the network, members implicitly adhered to the general objective of establishing a sustain-
able network for HTA cooperation, consensus was harder to find on the means to achieve 
this. Certain topics, such as, duplication of efforts, became openly questioned, which had 
not been the case before. Similarly, some members put doubts on evaluation results regard-
ing (low) uptake as reported by the European Commission and EUnetHTA representatives. 
Moreover, the idea that HTA collaboration should lead to more uptake of joint work was not 
anymore unanimously shared (6.4.2.5.).
We have outlined in chapter 6 that uptake of joint work was entirely voluntary. The network 
could therefore not impose use of joint work to its members. Horizontal coordination implic-
itly relied on trust in members’ willingness and abilities to implement the collective outputs 
produced. We have seen that in small and middle-sized countries, integration of EUnetHTA 
tools and methodologies, as well as participation in joint HTAs, was higher than in (size-wise) 
bigger EU Member States. This depended partly on management and governance decisions 
from HTA agencies and partly on trust building processes.
Trust in HTA networks’ joint work can also be connected to the management level of HTA 
body representatives participating in the HTA networks. Smaller agencies often sending top-
mangers to the networks, bigger agencies usually having middle-management representing 
them. By co-developing the joint tools, methodologies and assessments and being trained by 
network members, top-management representatives would be more inclined to adapt their 
internal agency working habits to EUnetHTA standards (6.4.2.5.). Moreover, they would have 
the authority to adapt the internal processes accordingly. Hence, trust and goal consensus 
seem to correlate these governance and management decisions.
Moreover, trust - or the lack thereof - would also impact (active) participation of members in 
the development processes of common tools, methodologies and assessments. In the section 
on joint work (6.4.2.3.) we have seen how the investment in work packages was not equal 
across the EUnetHTA members and how the lack of involvement of some agencies resulted 
from the lack of trust in the quality of the work produced as well as doubts casted upon the 
reduction of efforts in joint HTA. The latter would furthermore explain the low uptake (see 
also 6.4.3.3). Hence, although uptake of joint work depends on many factors as discussed in 
section 6.4.2.5., trust - or the lack thereof - in the quality and usefulness of EUnetHTA tools, 
co-impacts this process.
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Trust and goal consensus also affected uptake via (lack of) stakeholder participation and 
adherence to the networks’ objectives. Our research has highlighted how the pharmaceutical 
industry had difficulties finding member organisations willing to cooperate in EUnetHTA joint 
assessments pilot projects. Many companies feared that participation would enhance their 
workload and, due to the low uptake, did not have trust in the potential benefits the process 
would offer them. Although goal consensus on HTA cooperation was present, lack of uptake 
would lead to a lack of trust, which in turn negatively impacted the production of joint work 
(outputs) (6.4.2.3.; 6.4.2.5.)
As outlined in the sections above, no direct implication of national decision-makers has 
been observed in our research and expert opinion would essentially be provided by network 
members (predominantly HTA agencies’ representatives). Although, in the EU HTA Network, 
there was room for a better inclusion of high-level policy makers, in practice, membership 
of EUnetHTA and the EU HTA Network often overlapped. As no transparent information has 
been available at time of the data collection regarding the nature of the participants in the 
EU HTA Network meetings, it is difficult to make an assessment regarding the level of trust 
and goal consensus of potential policymakers participating in this network.
To overcome the lack of goal achievement (both regarding sub-goals as the overarching 
goal), the Commission was of the opinion HTA cooperation needed EU action to eliminate 
obstacles to HTA convergence. It therefore proposed a Regulation on HTA cooperation with 
mandatory elements of uptake (6.2.2.3.1.). The Regulation proposal was based on results 
of a public consultation process and impact studies, justifying, according to the Commission 
the content of the proposal and the application of the subsidiarity principle. This Regulation 
proposal stumbled however on fierce opposition of some Member States. Some positions 
reflected opinions already expressed within EUnetHTA regarding the quality of some tools 
(e.g. joint HTAs), often considered inferior to their national standards (6.4.3.3.). Other critical 
reactions were related to the quality of the consultation process and the interpretation of the 
results. Trust, or the lack thereof has thus also played a role in the adoption process of the 
HTA Regulation proposal (6.4.4.).
Moreover, lack of trust in the Commission intentions with the Regulation proposal has been 
expressed with regard the implementing and delegated acts. Some Member States feared 
that by leaving some key issues to be decided upon at a later stage, they would lose grip 
on the system. This would explain their reluctancy to enter in vertical governance schemes 
leaving no possibility to opt-out. Hence, goal consensus as regard the setup of a sustain-
able structure for HTA cooperation as well as consensus on the means to reach that goal, 
diminished once the proposal was submitted to bigger target audience. The development 
of salience for regional HTA cooperation initiatives (e.g. Beneluxa) could be interpreted as 
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a response to the EU-led proposal, as these new initiatives would offer the possibility to 
Member States to remain in full control and cooperate with countries having similar health 
systems and HTA practices (6.4.3.4.).
For a better comprehension of the impact of social interaction on the effectiveness of HTA 
cooperation networks, it is also important to assess social interaction between the HTA 
networks and the EU Commission. In the early cooperation initiatives, trust still needed to 
be developed between both arenas. However, by granting financial support, it is safe to 
ascertain that a certain level of trust on behalf of the Commission was present at this stage 
of the networks’ development process (4.4.2.). Similarly, the ECHTA/ECHAI network’s call 
to the Commission, to create a sustainable network for HTA cooperation, also testifies of a 
certain level of trust on behalf of the HTA arena representatives towards this EU institution 
(4.4.3.). The establishment of the Joint Actions in which the European Commission receives 
a bigger role, implicitly points to a solid relationship between the partners based on mutual 
trust. Similarly, the partnership also indicates goal consensus as both sides of the partner-
ship subscribe the same contract. Through various processes of exchange of information 
and experiences, shared values and understanding about HTA cooperation developed. EU 
Commission representatives acquired a better understanding of HTA issues, and HTA arena 
representatives better understood the role HTA could play in the EU public health landscape.
Social interaction EUR-ASSESS, HTA-
Europe, ECHTA/ECHAI
EUnetHTA EU HTA Network
P JA1 JA2 JA3
Trust
HTA Network +++ +++ +++ ++ ++ ++ 
HTA Network-Policymakers + NA - +/- +/- No data available 
HTA Network-Stakeholders NA NA +/- +/- +/- +/- 
Stakeholders-Stakeholders NA NÁ +/- ++ + ++ 
HTA Network-Commission +++ +++ +++ +++ ++ +++ 
Goal consensus
HTA Network +++ +++ +++ ++ ++ ++ 
HTA Network-Policymakers + + + +/- +/- No data available 
HTA Network-Stakeholders NA NA +/- + + +/- 
Stakeholders-Stakeholders NA NA +/- + +/- +/- 
HTA Network-Commission ++ +++ +++ +++ ++ +++ 
Table 7.8. Social interaction in European HTA networks
(Trust and Goal consensus)
7.2.1.3. Conclusion social interaction
We have seen that social interaction has been developed in its various aspects throughout 
the cooperation process since the early 1990s. However, this process has limited itself es-
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sentially to the HTA arena. The early cooperation initiatives responded to a homogeneous 
network structure where membership was mostly composed of HTA doers. Goal consensus 
was easy to attain, decisions were taken by consensus and implementation methods had not 
been contested. In EUnetHTA, a similar membership structure characterised the EUnetHTA 
project and Joint Action 1, displaying similar results in terms of goal consensus and adhesion 
to policy decisions and implementation. However, with the enlargement of the network to 
new members of various profiles, opinions diverged as to the desirability, feasibility, and 
strategy of reaching the overarching objective. Hence, whilst homogeneity has demonstrated 
a positive impact of the diffusion of learning processes, shared values and understanding, 
trust and goal consensus, heterogeneity has negatively affected the latter.
Social interaction with stakeholders has mostly been developed in a vertical way (network-
stakeholder group) since the Joint Actions, but only to a certain extent. A horizontal develop-
ment of social interaction (stakeholder group-stakeholder group) may have taken place at 
some points resulting from individual efforts but has not been organised in an institutional 
way. The Stakeholder Forum and Stakeholder Pool of EUnetHTA and the EU HTA Network, 
have contributed to instil a certain degree of social interaction favouring the development of 
learning processes, shared values and understanding, trust and goal consensus. However, its 
impact on reaching the overarching goal of the network seems quite limited.
Moreover, representatives of (health) ministries, which ultimately would be representing 
their Member State in the formal decision-making fora regarding the institutionalisation of 
HTA cooperation in Europe, have not been included in the process of establishing social 
interaction. The debates on the 2018 Regulation proposal of the Commission would display 
disparities among Member States positions. These did not necessarily reflect opinions held by 
their HTA bodies representatives, members of the EUnetHTA network. Lack of social interac-
tion can partly explain this phenomenon.
Throughout the development process of the HTA networks, learning, shared values and 
understanding, trust-building and goal consensus processes have also taken place within the 
European arena. These have contributed to frame or re-frame policy problems and seek for 
common solutions underpinned by European support (3.5.1.). The Commission proposal to 
insert HTA cooperation in the Cross-Border Health Care Directive allowing for the creation 
of the EU HTA Network was the first attempt of the Commission to create a sustainable HTA 
cooperation network. The Commission proposal for a Regulation on HTA cooperation, has 
been another mean to attain that goal.
As long as cooperation remained voluntary, support of Member States and most HTA agen-
cies was assured. However, this would change once some aspects would potentially become 
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mandatory. Hence, although the need for HTA cooperation was shared by most network 
members and stakeholders, no consensus existed regarding the manner in which this should 
take place. Debates on the issue would essentially point to a lack of trust towards the quality 
of the assessments and the need and/or feasibility of generalised uptake of joint work. The 
cooperation process had not succeeded in creating consensus on a Member State level to 
shift part of Member State HTA competences to an EU-level (6.4.3.3.).
This section has outlined how social interaction plays an important role in the effectiveness 
of European HTA cooperation networks. It has underscored how social interaction has taken 
place to a certain degree and with certain actors in the field. As such, its impact on the 
establishment of a sustainable cooperation framework has remained limited as the social 
interaction with certain groups and in specific fields was of low intensity. The main reasons 
identified in this regard, point to the (non-) inclusion of key-actors in the process as well as 
the manner in which these processes have taken place (vertical versus horizontal processes). 
Social interaction has however had a positive impact on the creation of outputs in the form 
of new common tools and methodologies and to some extent in the production of joint 
assessments. The impact of social interaction – or the lack hereof – is important, in particular 
in the production of (un) expected outcomes such as the proposal for a Regulation in the 
field of HTA cooperation, the opposition created towards the latter and the establishment of 
regional cooperation initiatives.
Social interaction Establishment 
sustainable network 
(process)
Production outputs Cooperation 
outcomes
Learning processes + +++ ++
Shared values & understandings + + ++
Trust + ++ +++
Goal consensus + ++ +
Table 7.9. Social interaction in European HTA networks
7.2.2. Governance instruments in European HTA governance networks
In this section we will focus our attention on aspects of network governance laying outside 
the spectrum of social interaction and examine how governance through the use of specific 
policy, legal, political, economic and financial instruments have affected effectiveness of 
European HTA cooperation networks in the sense of goal attainment. As these instruments 
are based on soft governance, some of the characteristics brought to the fore will overlap 
with elements discussed in the section on social interaction.
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7.2.2.1. Policy instruments in European HTA governance networks
The manner in which policy decisions will be translated into concrete actions to reach the 
goal set, depends, amongst others, on the instruments chosen. In chapter 4 and chapter 6 
we have analysed the policy-implementation process according to the use of policy instru-
ments. These policy instruments have been classified into procedural and substantive policy 
instruments. The former referring to instruments affecting policy processes associated with 
the delivery of policy outputs and the latter referring to instruments bearing the potential to 
influence the substance of policy outputs (4.4.1.). As procedural instruments we have identi-
fied in the HTA cooperation networks, instruments related to organisation, communication, 
capacity-building and evaluation. Substantive policy instruments have been related to joint 
work, uptake and the life-cycle approach (4.4.1.; 4.4.2..; 6.4.1..;6.4.2.).
In this section we will first examine the networks’ procedural instruments and how they 
relate to HTA cooperation processes, outputs and outcomes. It will inform about the policy 
instruments’ potential in structuring the European HTA cooperation process and will serve as 
input to answer the thesis research questions. The second part will focus on the substantive 
policy instruments implemented through soft governance. It will inform us about their po-
tential in creating common tools, methodologies and practices underpinning European HTA 
cooperation. Moreover, it will address the potential of these policy instruments to establish 
synergies between HTA and EU regulatory processes.
7.2.2.1.1. Procedural policy instruments
In European HTA cooperation, the instruments used to implement policy objectives have 
been based on soft governance. When examining the governance approach in terms of 
organisational matters, we have identified two distinct processes. The first regarding the 
internal governance of the HTA cooperation networks. The second regarding the gover-
nance of external processes aiming to establish a sustainable HTA cooperation structure (e.g. 
Cross-Border Health Care Directive (2011/24/EU). In chapter 6 we have highlighted how both 
processes have often been intertwined as the project-based networks were, for a long time, 
being considered to become the future sustainable network. This has impacted the goal at-
tainment process in several ways. In this section we will focus on both processes distinctively 
by examining the instruments used in the internal and external processes separately.
The analysis of the internal processes regard policy instruments used in the organisation of the 
HTA cooperation networks aiming to offer organisational support to the realisation of the project 
objectives. Organisational policy instruments underpinned project implementation and should be 
distinguished from instruments used to steer the process of establishing a sustainable framework 
for European HTA cooperation. At times, however, confusion between both has been identified. 
This has had an impact on the instruments used to steer the internal network coordination.
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In the early cooperation initiatives, internal project coordination was clearly separated from 
the process of establishing a sustainable HTA cooperation framework. Network steering 
instruments were fully based on soft governance, characterised by horizontal coordination, 
and excluding all forms of hierarchical command-control organisational governance. The 
creation of Subgroups, pursuing specific objectives, resembled organisational structures 
functioning upon so-called management by objectives (4.2.1.). Whilst the project had set the 
goal of creating a sustainable HTA cooperation structure, steering activities were primarily 
focused on the achievement of the sub-objectives, set by the network members without 
any interference from other (political) arenas. Commission intervention has been observed 
in the ECHTA/ECAHI project, by its request of the addition of a project objective to the grant 
proposal submitted. However, reasons underpinning the request were essentially related to 
grant allocation and did not concern project content as such (4.2.3.).
The internal organisational of the EUnetHTA project and of the EUnetHTA Joint Action 1, 
would be similar to the first networks. Although, the soft governance steering mechanisms 
would change from a participants-governed organisation to a lead-organisation governance 
structure, the coordination of the networks would remain distinct from the - to be estab-
lished – sustainable HTA cooperation framework. The latter is highlighted by the distinction 
made between ‘network coordination’ from ‘network development’, dealt with in different 
work packages (6.4.1.1.). The establishment of workgroups pursuing the realisation of sub-
objectives still functioned according soft governance steering mechanism, coordinated by a 
secretariat operating through a lead-organisation.
External governance processes will gradually impact the internal organisational processes. We 
have seen how the integration of HTA cooperation in the Cross-Border Health Care Directive 
will create confusion regarding the role of EUnetHTA and later of the EU HTA Network. At 
first, EUnetHTA has been considered as being the – to be established – sustainable HTA 
network. Later, the EU HTA Network will be seen as such. Although the establishment of the 
EU HTA Network will bring some clarity as to the role of EUnetHTA (becoming the scientific 
and technical arm of the latter), this would not resolve the question regarding the status of 
the EU HTA Network and whether it should be considered as the future sustainable network 
or not. The internal organisation of the EUnetHTA Joint Action 2 was focused on alignment 
with the Directive. By becoming the technical and scientific arm of the EU HTA Network, its 
status has been clarified. This also had an impact on the organisational aspects. EUnetHTA 
would see its objectives and work programme being decided upon by the EU HTA Network 
which would also affect the governance modes and instruments used, even though, on 
paper, much remained the same.
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With the establishment of the EU HTA Network, governance of European HTA cooperation, 
in practice, seems to shift towards a more Commission-steered governance mechanism. 
Policy instruments used were: expert-level committees, stakeholder participation, impact 
assessments, public consultations. Whilst these instruments all remain soft governance 
instruments, some of those have been implemented in the light of establishing a Regulation 
proposal, stepping away of the soft governance approach by proposing a legal framework 
based on hard law. Hence, throughout the development stages of EUnetHTA and the EU HTA 
Network, the boundaries between the use of soft governance and ‘hard governance’ policy 
instruments became increasingly blurred.
The Regulation proposal, foreseeing the establishment of a new cooperation structure partly 
based on mandatory aspects of Joint Clinical Assessments, underscores how the Commission 
considered soft governance modes not efficient enough to reach the overarching goal of cre-
ating a sustainable HTA cooperation network allowing convergence of practices (6.4.3.2.). 
Despite the more centralised soft governance modes implemented till then, the Commission 
believed part of the cooperation efforts would need to shift to a form of hard governance. 
This rationale justified the choice of a Regulation as legislative framework, rather than other 
legislative means, such as, a Directive.
To counter arguments related to competence division in health care between the EU and its 
Member States, the Commission referred to the subsidiarity principle. The Inception Impact 
Assessment already highlighted the benefits of European HTA cooperation but underscored 
how instruments used in the networks, based on voluntary cooperation and horizontal steer-
ing mechanisms, did not permit to achieve the objectives set and that an increased level of 
cooperation to reach synergies and reduce duplication in HTA would be better pursued at 
EU level (6.2.2.3.1.). In other words, according to the Commission, voluntary cooperation 
could lead to the production of concrete outputs in terms of joint work, it could however not 
ensure the use of those in national regulatory processes. After years of voluntary cooperation 
at Member State level failing to accomplish the establishment of a sustainable European HTA 
cooperation structure, the Commission considered that EU action, comprising mandatory 
(hard governance) elements was required.
Hence, the internal organisational processes of the examined HTA cooperation networks, 
functioned according to soft governance principles. External processes have had an im-
pact on internal organisational processes and have often led to the establishment of new 
structures. During the collaboration process, the goal of establishing a sustainable HTA 
cooperation framework has increasingly been mixed with the networks’ project-based goals 
conceived to support the establishment of the sustainable HTA cooperation structure. The 
European Commission will seek to achieve the overarching goal, initially by creating the EU 
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HTA Network before proposing a Regulatory framework. Herewith, it will operate a shift 
from a soft governance approach to a coordination structure comprising hard governance 
implementation aspects.
A second procedural policy instrument can be identified in the internal communication means 
that have been developed to support the key-objectives of the networks. Communication 
in the early HTA networks was rather informal. In EUnetHTA, communication instruments 
would be reinforced. The various databases would allow for a more efficient communication 
and would support joint work (e.g. joint assessments, evidence generation). Internal com-
munication means (e.g., intranet for network members) facilitated exchanges on technical 
or substance matters. External communication, such as, dissemination of network activities 
and products, has been present since the early cooperation initiatives. Specific work pack-
ages have been dedicated to this aim. The organisation of seminars and conferences have 
certainly contributed to framing HTA cooperation in a wider environment. Whilst these activi-
ties did contribute to increased stakeholder information regarding HTA cooperation and the 
(legal) developments in the EU health policy field, impact on decision-makers has not been 
observed in our research.
Capacity-building has been another procedural policy instrument aiming to reach the goals 
of the HTA networks. The impact of capacity-building and learning processes on social 
interaction has been underscored in the previous section. Capacity-building instruments 
such as training seminars, handbooks, and peer-education have been present since the early 
cooperation initiatives and have contributed in HTA networks in the development of shared 
values and understanding (4.4.1.). These instruments were based on a soft governance 
approach and have contributed in developing common understanding towards the need 
for HTA cooperation among certain actors in the HTA arena. Section 7.2.1. has however 
also outlined how capacity-building, or the lack thereof among certain actors (e.g. national 
policymakers) has negatively affected the goal containment process.
Finally, as fourth procedural policy instrument, evaluation processes, often instilled by EU 
grant approval procedures have been implemented and allowed for single and double loop 
learning processes. Single loop learning processes were standard procedure in the develop-
ment of many tools and methodologies such as the POP database, the EVIDENT database, 
the handbook for HTA, joint REAs, core HTAs as well as the Early Dialogues (6.2.1.; 6.4.1.; 
6.4.2.). However, double loop learning processes leading to governance and/or organisational 
changes also have been observed. Most visible are the changes established from one Joint 
Action to another and the ones leading to creation of the EU HTA Network. The establish-
ment of new governance bodies such as the secretariat in the ECHTA/ECAHI project (4.3.1.) 
or the ‘directorate’ on the third EUnetHTA Joint Action (6.3.1.2.1.) are other examples hereof. 
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However, the Commission proposal for a Regulation could also be interpreted as resulting 
from double loop learning processes since EUnetHTA experiences in HTA cooperation have 
been used to develop a new framework pursuing the initial network goals (6.2.2.3.2.).
In this section we have examined the procedural instruments used in the various networks. 
We have looked in particular at instruments based on organisation, communication, capacity-
building and evaluation as these were instruments used in all networks and on which the 
data collection has been structured. To conclude this section, the following observations 
can be made: Organisation has had positive impact on the process of collaboration by the 
setup of networks based on soft governance mechanisms, setting objectives which remained 
consistent throughout the cooperation. However, organisation has had a negative impact on 
the process of cooperation due to the lack of clarity and certainty about the future of the 
project-based networks which slowed down the process of establishing a sustainable frame-
work, still not established to date. Organisation had a mitigated impact on the production of 
network outputs as it did offer a framework to develop tools and methodologies necessary 
for collaborative work on HTA but did not contribute to the generalized used of these in 
local settings. Organisation did contribute to the production of (unexpected) outcomes of 
the networks, such as, the 2018 HTA Regulation proposal and the development of regional 
(intergovernmental) cooperation structures. These could be considered as unexpected results 
partly occurring as a consequence of the non-establishment of a sustainable cooperation 
structure by the HTA networks and the lack of uptake of their outputs.
Governance Establishment 
sustainable network 
(process)
Production outputs Cooperation outcomes
Procedural policy instruments
Organisation + & - +/- + 
Communication + + - 
Capacity-Building + + NA 
Evaluation + + + 
Substantive policy instruments    
Horizon Scanning  - + 
Early Dialogues  +++ +++ 
Joint work  +/- + 
Evidence generation  + ++ 
Uptake   + 
Table 7.10. Procedural policy instruments in European HTA Networks
The impact of communication on the cooperation process has been positive on the col-
laboration process as such, particularly through external communication means in the form 
of dissemination of outcomes and the organisation of conferences. Internal communication 
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means have had a positive impact on the production of outputs as they facilitated exchanges 
on technical issues and network activities.
Capacity- building has been examined though instruments such as training seminars, hand-
books and peer-education which differed from learning processes in social interaction. The 
latter could be considered as an outcome of capacity-building tools. In this regard capacity-
building had a positive impact on the production of outputs and on outcomes and positively 
contributed to the goal attainment process.
Similarly, the evaluation exercises of the networks contributed to the collaboration process 
by preparing organisational adjustments or adapt content, tools and methodologies. In this 
sense it also positively contributed to the production of outputs such as joint work. As the 
internal evaluation also highlighted the discrepancies in the process of establishing a sustain-
able framework for HTA collaboration in Europe, it did have an influence on the elaboration 
of an HTA Regulation proposal, which could be considered as an outcome of the networks’ 
collaborative initiatives.
As underscored above, procedural instruments can have an influence on the substance of 
the policy outputs. In the following section we will examine substantive policy instruments 
in relation to their contribution to the European HTA cooperation process, outputs and 
outcomes.
7.2.2.1.2. Substantive policy instruments
In chapters 4 and 6 we have examined substantive instruments developed by the HTA net-
works and which contributed to the production of the networks’ outputs. These outputs 
where often comprised in the sub-goals set by the networks and considered necessary to 
achieve the overarching goal of creating a sustainable HTA cooperation network. In chapter 
6 we have explained how these outputs have been developed at different points of time. 
However, as they all correspond to a certain phase in a health technology life cycle, we will 
proceed the analysis by respecting these phases: Horizon Scanning, Joint Scientific Advice, 
joint work (i.e. methodologies, tools and assessments) (additional) evidence generation and 
uptake of joint work in national settings (6.4.2.).
Horizon Scanning
Horizon Scanning has been an activity addressed in the first HTA networks under the denomi-
nation of ‘priority-setting’ (EUR-ASSESS) or ‘Clearing-House function’ (ECHTA-ECHAI) (4.4.1). 
At the time, other collaborative frameworks, such as ‘Euroscan’, already existed and recourse 
to those was strongly encouraged by the networks. Indeed, this would allow them to focus 
on other aspects of the collaboration (e.g. harmonisation of methodologies). Nevertheless, 
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the importance for a concerted approach on Horizon Scanning had been underscored and 
the Subgroub on priority setting of the EUR-ASSESS project had even highlighted the need 
to work with stakeholders at this stage “to ensure commitment to the process and the 
outcomes” (4.4.1.). Stakeholders were however absent in the initial HTA networks. Even 
though their participation had been encouraged by the Commission representatives at a 
much later stage, it had never been specifically associated to Horizon Scanning.
Horizon Scanning had however been addressed in the EUnetHTA project where it aimed at 
establishing a systematic review of practices and start collaboration with organisations such 
as Euroscan and establish a common form for information sharing. In this project, horizon 
scanning had been defined as “the systematic identification of health technologies that are 
new, emerging or becoming obsolete and that have the potential to effect health, health 
services and/or society” (6.4.2.1). Despite defining the activity, no real Horizon Scanning proj-
ects have been implemented till Joint Action 3, where the topic received renewed attention. 
It built upon some instruments developed in Joint Action 1, such as the EVIDENT database. 
Hence, although recognised as being important for HTA, Horizon Scanning has never been a 
priority topic for EUnetHTA (6.4.2.1.). Collaborative work produced by the HTA cooperation 
networks in this area remained thus limited.
It is interesting to notice how the absence of Horizon scanning outputs produced by EU-
netHTA has actually given an incentive to regional cooperation initiatives (e.g. Beneluxa) to 
fill this gap. Domestic policymakers increasingly needed visibility regarding products in the 
industrial pile-line to better anticipate their potential budgetary and public health impact. 
Horizon Scanning has also been included in the Commission proposal for an HTA Regulation. 
Moreover, by including Horizon Scanning in the proposal for an HTA Regulation proposal, 
the Commission too, considered the activity as one of the pillars of HTA cooperation and 
implicitly recognised its importance in the HTA cooperation process.
The EUnetHTA Joint Action 3, will finally give renewed attention to the topic by developing an 
innovative Horizon Scanning system (HSS). The proposed HSS would link Horizon Scanning 
to topic identification, selection and prioritisation. This was actually already the approach 
discussed in EUR-ASSESS. To date, in terms of outputs, EUnetHTA has not (yet) produced an 
instrument allowing to support HTA collaboration by means of a HSS. Instead it joined a new 
organisation, the International Horizon Scanning Initiative (IHSI), launched by Beneluxa and 
which secretariat is hosted by the Zorginstituut Nederland (ZIN) sharing herewith personnel 
also involved in EUnetHTA (https://ihsi-health.org/team/).
Impact of Horizon Scanning on the collaboration process and outputs has not been identified 
in this research. This can be explained by the low number of Horizon Scanning activities 
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being developed in HTA cooperation networks. Importance of Horizon Scanning on HTA 
cooperation has been underscored by the Commission which inserted the topic in its HTA 
Regulation proposal. Moreover, other (regional) HTA cooperation organisations did launch 
Horizon Scanning initiatives to respond to a need of policy-makers. This could be considered 
as (un)expected outcomes of the European HTA networks which did not (sufficiently) address 
this topic.
Early Dialogues
The initiative on Early Dialogues has developed as one of the most successful EUnetHTA 
outputs. Indeed, starting as an ‘ad hoc activity’ of EUnetHTA members, not foreseen in the 
EUnetHTA Joint Actions before 2012, the initiative quickly outgrew the expectations of the 
project initiators. Several reasons have been brought to the fore to explain this phenom-
enon. First, establishing concerted dialogues between regulators and HTA agencies on the 
evidence requirements in the early phases of drug development, responded to a real need 
of all stakeholders involved. It offered enhanced visibility for the industry as well as for the 
assessors. As the process was still based on soft governance principles, proposing voluntary 
participation and voluntary use of the recommendations, adherence to the project on behalf 
of the industry was high. This consolidated the output production of Early Dialogues.
Moreover, Commission support was assured since the latter saw an interest in establishing 
collaborative mechanisms between the EMA and the European HTA networks. The develop-
ment process of the Early Dialogues also applied soft governance principles leaving the process 
to be adjusted according to lessons learned from past experiences. Stakeholder participation 
has been present from the start and included, besides the industry, also representatives of 
patient organisations (6.4.2.2.). The positive experiences of stakeholder participation in Early 
Dialogues have been shared with other HTA related discussions about stakeholder participa-
tion (e.g. stakeholder participation in REAs).
Finally, the success of the Early Dialogues can also be related to the presence of a shadow 
of hierarchy. The non-observation of scientific advice given by the HTA agencies and the 
European regulatory agency could lead to the non-approval of market access or have con-
sequences on the pricing and reimbursement negotiations. Requirements which should be 
observed by the technology developers could thus be imposed by the regulators and/or 
assessors at a later stage. The threat hereof, certainly favoured adherence to the process on 
behalf of the industry.
The Early Dialogues have led to several outputs and outcomes which have affected the HTA 
cooperation process as a whole. As outputs we can first list the many concerted scientific 
advises given to manufactures and used by the industry in their development process. The 
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establishment of a common platform for parallel consultations with a single-entry point, 
allows for coordinated advise on manufacturers’ development plans, facilitating herewith the 
alignment of data requirements between regulatory and HTA agencies. The adjustment of 
EMA assessment reports (e.g. EPAR) to HTA needs can be cited as another output. Moreover, 
the establishment of a formal Early Dialogue Working Party coordinating the collaboration 
efforts is another example hereof (6.4.2.2.).
The process of collaboration has also led to certain outcomes. Through Early Dialogues, 
cooperation between the EMA and HTA bodies has been established, which did not exist as 
such before. Indeed, the research has underscored how representatives of both arenas were 
not used to collaborate. The projects around Early Dialogues allowed for a better mutual 
understanding of the needs and challenges faced by each in this area. Cross-institutional 
learning processes have taken place based on the exchange of experiences. As stakeholder 
participation had been well developed in EMA regulatory processes, EUnetHTA could take 
advantage of the lessons learned. The synergies which have been established between 
both arenas favoured development of further collaboration initiatives in other fields (e.g. 
collaborative projects in the field of post-launch evidence generation, inclusion of patient 
registries in data collection) (6.4.2.2.). Finally, collaboration in Early Dialogues did also pro-
duce (unforeseen) outcomes in pharmaceutical companies, such as, enhanced collaboration 
between departments within a given company, not used to collaborate on these issues. 
Being confronted with external assessment bodies, worked as an ‘eye-opener’ to some, 
creating a better comprehension of the needs of each pharmaceutical division and leading 
to more efficient cooperation at subsequent stages of the market access process (6.4.2.2.).
Joint work
At the core of the European cooperation efforts in HTA lays the production of joint assess-
ments. These should serve as input in domestic decision-making processes regarding pricing 
and reimbursement of health technologies. The aim to produce joint HTAs had been already 
expressed in the EUR-ASSESS project recognising the need to develop common method-
ologies and establish a common reporting framework (4.4.1; 6.4.2.3.). The ECHTA/ECHAI 
project made a distinction between the development of common tools and methodologies 
on the one hand and joint assessments on the other. EUnetHTA would adopt a similar ap-
proach by addressing these items in different work packages. The term ‘joint work’ would be 
introduced only during the Joint Action 2 and would refer not just to joint methodologies, 
tools and assessments but would also comprise literature reviews, structured information for 
rapid or full core-HTAs, Early Dialogues and scientific advice.
Chapter 6 has outlined the different implementation stages of joint HTA production, 
transferrable into the national settings. Adopting a new HTA definition can be cited as one 
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of the outputs produced by EUnetHTA, creating herewith a basis and legitimisation of the 
cooperation efforts. The Core-HTA model has been a milestone in the development of joint 
assessment and responded to the needs expressed in the early cooperation initiatives for a 
standardised model. Similarly, the adaptation of the Core-HTA model for REAs is another 
important output produced. To ensure adequate implementation of the joint assessments, 
numerous methodologies and guidelines produced. Finally, tools such as the POP database 
and the EVIDENT database, were essential to support joint HTA production and constitute 
joint work of the HTA networks (6.4.2.1.; 6.4.2.3.).
Hence, concrete outputs have been produced and tested in pilot projects (6.4.2.3.). Many 
of these corresponded to sub-objectives of the cooperation networks (6.2.1.). They were 
considered necessary to achieve the overarching goal of establishing a sustainable network 
as they would constitute the basis for all collaborative work. By re-qualifying EUnetHTA into 
a scientific and technical arm of the EU HTA Network, the European Commission acknowl-
edged the need for the development of common tools, methodologies and guidelines as 
pre-requisite for the production of joint assessments and other forms of joint work. Although 
essential in the process of establishing a sustainable cooperation process, to date, most out-
puts have been implemented in a pilot project format and their impact thus remains limited.
Production of joint work, on the one hand, implicitly acknowledges the possibility to reach 
convergence in HTA through soft governance cooperation mechanisms. On the other hand, 
the limited uptake of joint work in national settings as well as the lack of consensus regard-
ing the need, the quality and the adaptability to domestic settings, restrains its impact on 
the goal achievement process of the networks. The impact of joint work as substantive 
policy instrument on the process of establishing a sustainable framework for European HTA 
cooperation is thus mitigated. This conclusion should, however, be taken with caution as it 
is time-related. A transition from pilot projects to routinisation of joint work could still take 
place in the future, provided that the uptake challenges would be overcome. Moreover, 
the fact that regional HTA cooperation initiatives have recourse to EUnetHTA processes of 
joint work (6.4.3.4.) would support the argument that these outputs may have a wider 
impact than initially anticipated and thus do contribute to HTA cooperation in Europe and 
the establishment of more sustainable systems.
Additional Evidence Generation
The importance of collaborating on additional evidence generation had been discussed initially 
in the EUnetHTA project. To date, the outputs produced by the EUnetHTA network and the 
EU HTA Network are rather limited. The Eifel toolkit could be cited as an output contributing 
to the establishment of additional evidence frameworks, but still in a pilot project format. 
The work on Early Dialogues and the synergies established with the EMA in this field, further 
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contributed to the development of a new coordinated approach in Post Launch Evidence 
Generation Projects (PLEG) (6.4.2.4.). These projects, though finding themselves in an early 
development stage, seem to respond to a need expressed by several stakeholder groups. 
Conversely to the Early Dialogues, cooperation on PLEGs comprises rather delicate issues, 
such as, the use - or not - of patient registries and real-world data (RWD). As standpoints 
on these issues differ among Member States, it remains to be seen whether a common 
approach can be adopted leading to establishment of a common framework applicable to 
national settings. Hence, additional evidence generation, as a substantive policy tool, has to 
date not had a significant impact on the process of establishing a European HTA cooperation 
framework.
Uptake
Talking about uptake first needs to clarify what one understands by this term. If initially the 
HTA networks targeted the use of joint assessments in national settings, this aim has been 
adjusted in the course of the cooperation process. Uptake has been defined during the Joint 
Action 2 as “the general implementation of any EUnetHTA output in a national context and 
may include the usage and implementation of the EUnetHTA tools and Joint Assessments” 
(6.4.2.5.). This definition would clearly impact the rate of uptake measured in evaluations, as 
it would comprise many more features of joint work. As such, use of the POP-database for 
local reports, or use of some aspects of a core-HTA or REA would already qualify as ‘uptake’ 
(6.4.2.5.). The concept of ‘national adaptation’, introduced in Joint Action 2, would target 
more specifically the use of joint assessments results in national or local settings (i.e. REAs 
or full core-HTAs) (6.4.2.5.). However, here too, partial use of the assessment results would 
qualify as uptake.
Opinions diverge regarding the figures brought forward on uptake (6.4.2.5.). Part of the dif-
ficulties in assessing uptake is related to evaluation methods. As outlined in chapter 6, mea-
suring uptake of joint work in medical devices or pharmaceutical products requires different 
approaches and need to take into account the different market access processes. Moreover, 
evaluation studies carried out so far have proceeded according to different definitions of up-
take. As such, figures brought forward are not necessarily comparable, making the it difficult 
to assess an evolution in the uptake process. Nevertheless, the last study made by EUnetHTA 
during JA3 did point to a significant increase in uptake compared to JA2. Barriers to uptake, 
highlighted in this study, pointed to language requirements, reporting structures, timing of 
assessment availability, need for different assessment elements or assessment scope. Previous 
studies had pointed to additional barriers such as legal constraints (6.4.2.5.).
Uptake has thus been a critical matter in HTA cooperation. The (perceived) lack of uptake 
has had an impact on the Commission decision to propose a mandatory legislative proposal 
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for HTA cooperation. The opposition expressed by Member States towards the mandatory 
uptake of clinical assessments results, demonstrated how this is still an issue of content. 
The latter seems to result from the voluntary uptake approach adopted for years in the HTA 
networks and which had led to disappointing results. Uptake lays at the heart of the negotia-
tions on the proposal for an HTA Regulation and it would be premature to draw conclusions 
at this stage. At first sight, the soft governance coordination approach proposing uptake on 
a voluntary basis, seems limited in the case of the European HTA networks examined in this 
research. However, in the sections above, we have underscored how some aspects of soft 
governance, such as social interaction, have not been implemented in a generalised manner, 
leaving some key-actors outside these processes.
Hence, concluding that soft governance cannot ensure uptake seems premature. Aspects 
related to the typology of governance networks, as well as some features related to network 
governance (e.g. social interaction, legislative instruments, management, external events) 
seem to play a role in the level of uptake. Hence, presence or absence of these elements in 
the cooperation process may have influenced the outcome of uptake. We can however draw 
the conclusion that the impact of uptake on the process of establishing a sustainable frame-
work in HTA cooperation is of high importance and is intrinsically linked to the sustainability 
of the process. To date, the (perceived) lack of uptake has had both a positive and negative 
impact in terms of outcomes. On the one hand it has instilled doubt in the feasibility of 
reaching the overarching networks’ goals and has had a negative impact on the adherence 
of some key-actors to the routinisation of joint work. On the other hand, it has underpinned 
the Commission decision to propose a Regulation as legislative instrument, seeking to secure 
uptake by mandatory means.
7.2.2.2. Legislative and regulatory instruments in European HTA governance 
networks
Our research has brought to the fore how national legal frameworks regarding HTA, pre-
sented real challenges in some countries (e.g. Poland, Germany) to EU HTA cooperation 
which, so far, have not been overcome (6.4.2.3.). Collaborating on joint assessments was not 
just a matter of consensus on methodologies and work processes. The simple nature of HTA 
agencies, working independently or taking direct orders from ministries, would also play role 
herein as they were bound - or not - to follow specific procedures. The cooperation processes 
set in motion in EUnetHTA have not been able to always take these into account, making it 
for some agencies difficult or impossible to use the EUnetHTA outputs as these would not 
fulfil the legal requirements applicable in their home countries (6.4.2.3.).
Moreover, the nature of the assessments (i.e. REAs or Core-HTAs) would also present more 
or less difficulties in terms of legal constrains. As we have outlined in chapter 6, a core-HTA 
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comprises nine domains, some of which (e.g. cost-effectiveness) are considered by Member 
States as being part of the appraisal process in pricing and reimbursement decision-making 
processes. Besides the resistance of some Member States to delegate this part of the assess-
ment processes outside the Member State, it also presented challenges linked to the need 
for contextualisation of assessments. Indeed, as outlined in chapter 6, uptake of EUnetHTA 
outputs was not only a matter of trust in the quality of the processes or willingness to adapt 
national procedures, the outcome of an HTA also needs to be inserted in a national context 
which, according to some network members, is unique (6.4.2.3.).
Focusing on relative effectiveness aspects of HTA has been the EUnetHTA strategy since the 
Joint Action 3 and has also laid at the core of the Commission proposal for an HTA Regula-
tion. Indeed, the idea was to circumvent those assessment domains which would be more 
inclined to encounter legal restrains in domestic markets. It was thought that the clinical 
effectiveness domains would trigger less opposition by Member States and would ease the 
uptake thereof. It is interesting to notice that the biggest discussion issue of the Commission 
Regulation proposal, remained the mandatory uptake of clinical effectiveness assessments. 
Moreover, the regional cooperation initiatives (e.g. Beneluxa) have developed their strategy 
by cooperating on these domains which seemed to be problematic in EUnetHTA and the EU 
HTA Network (e.g. Cost-effectiveness). Hence, although legal constrains have constituted a 
real obstacle to the development of joint assessments, it cannot, in itself, explain the reason 
of the low uptake201.
Being bound by a specific legislative framework seems however to play a role in the sense 
that cooperation in areas where such a framework was not present or still in the process of 
being established, cooperation and uptake of outputs seemed more successful. We can cite 
as examples hereof Horizon Scanning activities as well as the work done in cooperation with 
the EMA on Joint Scientific Advice/Early Dialogues. Even in the field of Additional Evidence 
Generation, which is linked to a highly regulated field, cooperation seems to encounter (so 
far) less resistance by agencies participating in the networks. This could be explained by the 
fact that these fields are in development in most countries and that the exchange of experi-
ence herein actually contributes in establishing the legal frameworks which will regulate 
these activities. Moreover, in the field of Joint Scientific Advice, the presence of a shadow of 
hierarchy would also play a role as explained above. Finally, the establishment of a synergy 
group could create favourable conditions for the development of collaborative outputs in this 
field and the adjustment of legal frameworks should this be required
201 One should however underscore at present, the regional cooperation initiatives are still too young 
to present solid data regarding uptake of their outputs.
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By creating links with established regulatory agencies (e.g. EMA) new frameworks have 
been developed, acceptable to all players. It remains a question to see whether a similar ap-
proach can be found in the so-called late-dialogues or other additional evidence generation 
processes as, here too, one could wonder whether a common approach to new types of 
evidence (e.g. Real World Data), will be found. The path followed with the Early Dialogues 
seems promising but was successful as it regarded cooperation with an established European 
Agency having authority in market access regulation procedures and would create conditions 
for the shadow of hierarchy to apply. Should late-dialogues seek to develop a commonly 
adopted framework applicable to all Member States, similar obstacles as in REAs could be 
encountered.
The debates around the HTA Regulation proposal demonstrate the impact of the EU legal 
framework on the cooperation processes. Indeed, some members have expressed their op-
position on the simple fact that the EU entered a field where competences laid exclusively by 
the Member States (6.4.3.3.). The arguments for the application of the subsidiarity principle 
have not convinced all actors as some would refute the Commission argument that twenty-
five years of cooperation showed that Member States alone did not permit to reach the 
objectives on which all had agreed (i.e. sustainable network of HTA cooperation in Europe). 
Hence, the soft governance approach, based on voluntary cooperation, exchange of best 
practices, capacity-building and persuasion, has so far not allowed to shift the competences 
division in the HTA policy field as foreseen by the treaties.
Legislative and regulatory instruments have had a negative impact on the process of col-
laboration as the legal constrains observed by some HTA agencies in some countries pre-
vented them from take into account the collaboration outputs in their domestic regulatory 
processes. However, in some areas (e.g. Early Dialogues) the presence of shadow of hierarchy 
would have a positive impact on the process of collaboration as well as on the production of 
collaboration outputs. The creation of the HTA Network synergy group could be cite as an 
example of an attempt to overcome disparities related to domestic legislative and regulatory 
frameworks.
7.2.2.3. Political instruments in European HTA governance networks
Governance networks are often established to respond to specific policy questions. Hence, 
interdependencies between networks and/or between state actors and networks often 
develop (3.7.5.). Use of political instruments by various actors concerned by a policy issue 
can be targeted to support or constrain network activities. When analysing effectiveness in 
terms of goal attainment in HTA cooperation networks, it is of interest to examine the role 
of political instruments herein. In this section we seek to identify which political instruments 
have been used in the governance of HTA cooperation initiatives. As there are many different 
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political instruments available, we seek here to highlight those that have been identified 
in our research and seek to determine in which way they have contributed or not to goal 
attainment.
Our research has brought to the fore several procedures and processes that could be quali-
fied as political instruments. Agenda alignment has been one of the first instruments used by 
the European Commission. We have seen in chapter 4 how the Commission has identified 
HTA cooperation as a mean to enter the health systems and has decided to support the 
initiatives. It has integrated HTA cooperation in the health programmes facilitating herewith 
also funding opportunities for HTA cooperation (4.1.3.; 4.2.3.). Agenda alignment has 
also played a role in securing further support for HTA cooperation and inter-institutional 
cooperation. Integrating HTA cooperation in the various expert committees (e.g. HLRP, HLG, 
G10, Pharmaceutical Forum) has permitted on the one hand to streamline agenda-setting 
processes as well as to push HTA cooperation further on the EU political agenda (5.1.2.). 
This instrument has had positive outcomes for HTA cooperation as we have seen how HTA 
has been qualified as a political priority and how it made its entrance in Council Conclusions 
allowing for further Commission proposals in the field of HTA cooperation.
The integration of HTA cooperation in the flanking measures of the Cross-Border Health 
Care Directive (2011/24/EU) can be cited as an outcome of agenda alignment. This has not 
only allowed for the establishment of the EU HTA Network, but also led to positioning of the 
European Parliament on the issue of HTA. Agenda alignment has again been used to create 
synergies between EUnetHTA and the EU HTA Network (6.2.2.2.). The Regulation proposal 
on HTA cooperation is, to date, the last outcome of agenda setting and agenda alignment 
processes including herein all European and national decision-making actors. Hence, agenda 
alignment has played a very important role in pursuing the objectives set in the various HTA 
cooperation networks. It has been key in the reaching sub-objectives and setting new ones. 
It has had a positive effect on the capacity of the networks to approach the overarching goal 
through the establishment of a chain of goal attainment (3.4.1.).
Agenda alignment has however not been a stand-alone process but has been accompanied 
by the implementation of other political processes. Besides the use of expert committees 
mentioned above and which have been very important during the interlude period of HTA 
cooperation (2001-2006), stakeholder involvement can be mentioned as another political 
instrument used (6.3.1.2.2.). We have seen how the latter has been instilled mainly upon 
Commission initiatives and how this has permitted to integrate other perspectives on HTA 
cooperation. Stakeholder integration was conceived to extend support for HTA coopera-
tion and allow for processes which would fit needs and expectations of the various actors 
involved in HTA. We have highlighted above how some stakeholder groups have been more 
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present in the cooperation processes than others, and how there was a low representation 
of national actors involved in regulatory and decision-making processes (6.3.1.2.2.; 6.3.3.). 
Hence, stakeholder involvement has clearly had an impact on goal attainment. It has per-
mitted to involve more actors in the process and extend the support for the creation of a 
sustainable network on HTA cooperation.
Consultation processes implemented in particular during the run-up to the Regulation 
proposal can also be cited as political instrument. These processes included online surveys, 
targeted at a large public ranging from representatives of the HTA agencies, to academ-
ics, civil servants and citizens. Consultation processes also comprised face-to-face meetings 
with stakeholders and Commission representatives as well as informal exchanges during 
conferences and working meetings with various actors in the HTA arena (6.2.2.3.1.). As 
the consultation processes were aimed at structuring a future strategy for sustainable HTA 
cooperation, they clearly had an impact on the goal attainment process. The nature of the 
impact is however mixed. Indeed, by reaching out to various actors, the Commission sought 
to define the terms of the proposal in such a way it would correspond to needs and expecta-
tions of the actors in the field. However, the evaluation process of a consultation is never a 
neutral exercise. We have seen in chapter 6 how some actors have the impression their needs 
have not been fully understood and others believing their interests have not been respected 
(6.2.2.3.2.).
The reactions on the Regulation proposal highlight the mixed opinions in the field towards 
the Commission suggestions and underscore how some opinions expressed during the 
consultation process have not been taken into account. It seems that the Commission has 
underestimated the level of disagreement towards some elements in the Regulation (e.g. 
mandatory uptake of clinical effectiveness assessments) (6.4.3.3.). The impact on the process 
outcome hereof may be quite important as fierce opposition could halt the process. Hence, 
consultation processes have had a mixed impact on HTA cooperation. One the one hand it 
has allowed to contribute to develop discourse and goal consensus regarding HTA coop-
eration and has legitimized a Commission proposal. However, by not taking into account 
some of the opinions expressed, opposition towards the proposal may not be overcome and 
political will may not be united to adopt the proposal in its original form.
Institutional communication is another political instrument that has come to the fore in our 
research. We will focus here only on official communication actions to distinguish this from 
any other communication actions that could fall into social interaction and which have been 
discussed above. Since the early days of HTA cooperation, the Commission has used official 
communication means to support and secure further development of HTA cooperation. 
These communication actions would follow the classical means available to the Commission. 
446 Chapter 7
Inserting HTA cooperation in official documents such as the Health program, Council conclu-
sions or European Parliament reports, and motions or other legal documents has legitimized 
action on behalf of the Commission.
Finally, the establishment of partnerships can also be cited as a political instrument used by 
the European Commission to support HTA cooperation. The Joint Actions made available for 
the cooperation have had a very significant impact on the developments. Indeed, moving 
from a project-format with the Commission as main funder to a Joint Action, still a project-
format but with the Commission becoming a full partner, allowed for more political and 
financial support also on behalf of Member States (6.2.1.2; 6.3.1.2.). Moreover, partnership 
creation with the EMA in the field of Early Dialogues has certainly be facilitated by the Joint 
Actions and the fact that the Commission took part in it (6.4.2.2.). Hence, the political weight 
given to HTA cooperation through participation of the Commission has had a positive impact 
on the cooperation initiatives in reaching the sub-goals of developing joint methodologies, 
tools and joint assessments as well as in the creation of synergies with European regulatory 
processes (6.4.2).
Recourse to political instruments such as agenda alignment, stakeholder involvement, con-
sultation processes, (institutional) communication and the establishment of partnerships has 
had a positive impact on the process of HTA collaboration. The establishment of a partner-
ship between the European Commission and the HTA arena in the form of Joint Action has 
had a positive impact on the production of outputs. Agenda alignment and Institutional 
communication and partnerships have positively impacted the creation of outcomes such as 
the Regulation proposal in the field of HTA collaboration.
7.2.2.4. Financial instruments in European HTA governance networks
Establishing a sustainable network for HTA has been, since the beginning, the overarch-
ing goal of the cooperation initiatives. Sustainability of a network will also depend on the 
financial resources available, which, in governance networks, often depend on the political 
support. The main financial instrument used by the Commission to support HTA cooperation 
has been the EU (Public) Health Program. We have seen above how objectives of the EU 
(public) health programs and those of the HTA cooperation project have always been aligned 
so that the projects could qualify for funding (4.2.; 6.2.). EU funding however has been 
essential for the development of the cooperation processes and the production of outputs. 
It has been complemented by national funding sources, mainly consisting of the allocation 
of HTA agencies’ personnel.
The biggest challenge in reaching the overarching goal of creating a sustainable HTA co-
operation structure has been to secure funding sources, other than those coming from the 
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EU health programs. Different strategies and business models have been developed in the 
course of the projects but which, to date, have not been implemented (6.4.1.1.). Propos-
als for industry contributions have also been made. The Impact Assessment made by the 
European Commission underscored the costs of assessments made at a national level and the 
gain to pull assessments together. It also underscored how EU support would be withdrawn 
should uptake of joint assessment be insufficient (6.2.2.3.1.). However, the financial instru-
ments cannot be dissociated from political decision-making and the establishment of a legal 
framework regarding HTA cooperation. As underscored in our research, as long as joint 
assessments are not mandatory or are not commonly used in the Member States, industry 
will hesitate to make financial contributions for a process in which it has no interests as this 
would be a duplication of time, efforts and financial investments (6.4.2.5.).
Governance Establishment 
sustainable network 
(process)
Production outputs Cooperation 
outcomes
Legislative & Regulatory instruments - - & + -
Political instruments
Agenda alignment ++  ++ 
Stakeholder involvement +/-   
Consultation processes + & -   
(Institutional) communication ++  + 
Partnerships +++ + ++ 
Financial instruments ++ & - +++ +/-
Table 7.11. Legislative, political and financial instruments in European HTA cooperation networks
Hence, on the one hand, due to the financial instruments available through the EU Health 
Program, the process of HTA cooperation has been able to develop and has led to the pro-
duction of concrete outputs. At the other hand, due to this financial support available, no 
real incentive allowed for the search of independent sustainable business models. In this 
sense the financial instruments have negatively impacted the cooperation process. As long 
as cooperation could continue on a voluntary basis, uptake would continue to depend on na-
tional decision-making procedures, preventing sometimes uptake of joint work (see above). 
With a low uptake, incentives for the industry to financially contribute to joint assessments 
would be absent. Hence, whilst financial instruments are crucial to the goal attainment set 
by all HTA cooperation networks, their efficacy will remain intertwined with political support 
and the establishment of a legal framework. Without the latter, HTA cooperation will likely 
follow the same course as most projects funded by public authorities which often disappear 
after public funding stops (3.5.2.).
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7.2.3. Management in European HTA governance networks
In chapter 3 we have outlined how there is a correlation between effectiveness of networks 
and management. However, as no consensus exists in the literature about what effective 
management methods would be, we will focus our analysis only on management com-
petences and management styles. The aim is to examine how these avec evolved in the 
different HTA networks and how they have affected effectiveness of these networks in terms 
of goal attainment.
7.2.3.1. Management competences in European HTA governance networks
Management competences are diverse and are often associated to skills of network man-
agers such as facilitation, coordination and mediation skills to guide interaction processes 
among actors in the network. We have seen in our research that network managers have 
played an important role in the development of HTA cooperation and how some of these 
managers or project leaders could be qualified as ‘policy entrepreneurs’. Management of 
HTA cooperation by policy entrepreneurs has been identified in both the HTA arena as in the 
EU health policy arena, from the first HTA cooperation activities till the EUnetHTA Joint Action 
2 (4.1.3.; 4.6.; 5.4.; 6.2.1.1.).
The research has underscored the importance of establishing a link between policy makers 
and networks to create a place for HTA in national and European decision-making processes 
(e.g. 6.2.1.1). The latter results from the very nature of HTA often considered as a bridge 
between research and decision-making (1.1). Hence, establishing and leading an HTA net-
work required a specific skill-set comprising, besides management skills, also a technical and 
political comprehension of HTA itself. As knowledge of, and experience in, HTA laid primarily 
with ‘HTA doers’, the cooperation initiatives naturally developed into networks of scientists 
managed by scientists (6.4.1.1.). This regarded both the general management positions as 
well as the management of the work packages (i.e. Lead-Partners being representatives 
of HTA agencies). Even though the EUnetHTA secretariat till the Joint Action 2 did count 
among its project managers, people trained in project management, these still came from 
an HTA background (6.3.1.2.). This would change in Joint Action 3, were an external project 
manager would be appointed having no previous links to HTA (6.3.1.2.1).
Policy entrepreneurs have played an important role by allowing HTA cooperation to enter 
the national and EU agenda setting processes. We have seen above how this has secured 
political and financial support. Management of HTA cooperation networks required thus 
to have a solid knowledge of HTA itself and abilities to translate this into policy objectives. 
In the first development phases of the HTA networks, management by HTA scientists has 
been effective in terms of attaining sub-objectives (e.g. development of tools, methodolo-
gies, network coordination, project implementation, recognition of necessity of cooperation 
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amongst national policymakers). However, it is questionable whether this approach has been 
effective enough in the later stages of the project (e.g. low implementation of REA pilot 
projects, long transition period of pilot projects to routinisation, low uptake of joint work, no 
consistent data collection regarding project implementation, no establishment of a sustain-
able network) (6.4.). Although reasons for lack of effectiveness in attaining sub-objectives 
have various explanations and depend on different factors, management does seem to have 
played a role in addressing those factors.
Ensuring the transition from a project-based approach into lasting sustainable network 
has been the biggest challenge and main goal of all network initiatives (6.4.1.1.). We have 
underscored in the section above that confusion has long existed whether EUnetHTA would 
become the sustainable HTA network mentioned in the Cross-Border Health Care Directive. 
The establishment of the EU HTA Network has further increased uncertainty as the new 
structure itself did not offer any sustainability but needed to propose a legislative basis for 
such a sustainable network. This had an impact on the management of the existing HTA net-
works. In the Joint Action 1, the idea prevailed that EUnetHTA would become the sustainable 
network. Coordination of EUnetHTA and the development of a new business model were 
therefore dissociated in the JA1. In all other EUnetHTA projects and initiatives, both sub-
objectives (i.e. coordination of EUnetHTA and establishment of a sustainable (new) network) 
were managed within the same work package (6.4.1.1.). The uncertainty that existed during 
the Joint Action 2 has certainly not favoured effective goal attainment as to establishing a 
sustainable network. During Joint Action 3, the status of EUnetHTA had been clarified as 
it became the scientific and technical arm of the EU HTA Network, limiting its contribution 
regarding the establishment of a sustainable HTA network to the formulation of ideas and 
recommendations. (6.4.1.1).
Management of the EU HTA Network has been difficult to assess in the research. One can 
only underscore that the secretariat was coordinated by the Commission. Management of 
the network activities could be resumed in the preparation of a new legislative proposal of 
the Commission and was thus part of Commission activities (6.2.2.3). A concrete outcome 
hereof has been the official Commission proposal of a Regulation on HTA cooperation 
(6.2.2.3.2.). Following its publication, continuous efforts on behalf of Commission represen-
tatives to explain the proposal to different stakeholders involved have accompanied the pro-
cess throughout the adoption phase. Activities of the EU HTA Network since the Commission 
proposal also mainly regarded only stakeholder meetings. Hence, since its establishment, 
management processes of the EU HTA Network seem to have been led by Commission 
institutional processes and Commission representatives (6.4.3.).
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This section underscores how management competences have had an impact on the goal 
attainment of HTA networks. A positive impact both on the process of HTA cooperation 
as well as in terms of outcomes of this process, has been observed in the first networks 
benefiting from management skills implemented by policy-entrepreneurs, securing political 
and financial support by EU and domestic policy-makers. Mixed results have been observed 
in the later development stages of EUnetHTA where outputs have been disappointing and 
where management has suffered from the simultaneous pursuit of a policy goal and techni-
cal and scientific sub-goals. The scientific profile of the managers of the early cooperation 
projects seemed to have favoured goal attainment as profound understanding of both HTA 
and policy-processes were necessary. The expansion of the network during the last Joint 
Actions required however different management skills differentiating technical and scientific 
project implementation of policy objectives. The establishment of the EU HTA Network seems 
to have tried to establish this differentiation by separating policy orientation from technical 
and scientific HTA activities. It remains questionable whether this new structure has been 
successful as the future of EUnetHTA and the EU HTA Network will depend on the outcome 
of the adoption process of the HTA Regulation proposal still under debate at the time of 
writing.
7.2.3.2. Management styles in European HTA governance networks: project 
management versus process management
Management can affect goal attainment which is the reason why this aspect has been inte-
grated into the research framework outlined in chapter 3. However, a systematic analysis of 
the management of HTA networks would require different research instruments than those 
we have used. As this has not been the prime target of our research, we will limit ourselves 
in this section to underscore some aspects which have born the potential of playing a role in 
goal effectiveness. The extent of their impact however will not be dealt with in the present 
research and remains a subject for further examination.
In the literature, no consensus exists whether a particular management style would lead to 
more or less effectiveness of a governance network. Often project management has been 
compared to process management, each referring to different goals and attributes (3.5.3.). 
One of the main differences between both is that projects are specific, time-limited, and 
target a particular goal. Implementation takes place through different phases whereby the 
project is initiated, defined, planned, executed and closed. Process management often refers 
to an on-going process whereby people can operate according to standard operational pro-
cedures defining the manner in which a goal can be attained, whereas project management 
defines the steps that need to be taken to achieve the goal.
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Our research has allowed to identify the presence of both project management and process 
management in the HTA cooperation networks. Establishing a sustainable HTA cooperation 
refers to a process which should be on-going, and management hereof would refer to pro-
cess management. The setup of an HTA project, limited in time and reaching specific goals 
in terms of output, was conceived to allow for the process of cooperation to be established 
and maintained throughout the years. Project management would thus characterise these 
time-limited projects. In the early cooperation initiatives, as well as in EUnetHTA, no strict dif-
ferentiation has however been made between the process of cooperation and the projects to 
establish this cooperation. These networks were often considered by their project managers 
and other members, as the framework in which the cooperation process would take place 
(6.4.1.1.). Hence, although the cooperation projects implemented aimed at establishing a 
cooperation process, both objectives have been mixed in the implementation phase, which 
has contributed to negatively impact goal attainment of HTA cooperation as defined in the 
various HTA networks.
With the establishment of the EU HTA Network it seems that a differentiation between 
both has been made to some extent. By reframing EUnetHTA as a project limited in time 
and pursuing objectives which should serve the establishment of a sustainable cooperation 
framework, the Commission distinguished process management from project management. 
The EU HTA Network would operate on the basis of process management in the quest 
to establish a sustainable HTA cooperation framework. EUnetHTA would become a project 
herein, operating via project management. The legal framework proposed by the Commis-
sion would allow for cooperation process to develop.
Our research has brought to the fore that network members often perceived the project-
based framework of Joint Actions to be an obstacle in establishing a sustainable framework. 
Indeed, the HTA cooperation initiatives since the beginning have taken place in the form of 
a project, limited in time, finances and personnel. Administrative procedures (submission, 
reporting and fundraising), indispensable in the implementation of projects are however 
time-consuming and reduce effective time of project implementation. Hence the time and 
budget limited framework could not match the objective of creating a sustainable coopera-
tion framework. Hence, by searching to transform a project into a process, the chances of 
being effective in goal attainment were slim. By creating the EU HTA Network, the Commis-
sion disentangled both and would subordinate the project to the process goals.
The HTA Regulation proposal sought to establish a legal framework in which a cooperation 
process could be developed. Such a framework could create visibility for the organisation 
of time-limited projects in terms of project objectives, administrative support and financing. 
As such, cooperation projects could take place and would refer to one of the four pillars of 
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the proposal (Joint Clinical Assessments, Joint Scientific Advice, Identification of emerging 
health technologies, Voluntary cooperation). This proposal has, as we have outlined above, 
created new obstacles but relating to different issues, primarily the question of the division 
of competences between the EU and the Member States (e.g. mandatory uptake of Joint 
Clinical Assessment results).
A legal framework at an EU-level, would also have the potential to serve as a support for 
other (regional) cooperation initiatives. Framing a cooperation process implicitly creates room 
for development. If a full mandatory approach would not be acceptable to key-actors in the 
process, other (intermediate) solutions could be envisaged without compromising the over-
arching goal. However, in the initial debates of the HTA Regulation proposal, the discussions 
seemed to be framed along the traditional community versus intergovernmental approaches. 
Indeed, the Commission had adopted in this case a community approach at a time where this 
comprised risk. As we will outline below, external events, such as the rise of Euroscepticism 
could affect EU decision making in the field of HTA. Moreover, in terms of process and project 
management, one could consider the adoption of the Regulation proposal as a project in 
itself. This would however contain the risk to lose sight of the process it should frame. A 
process allows for more creativity and room of manoeuvre in the setup of sub-goals than a 
project which is bounded by time and resources. At a time where the European integration 
process is severely being challenged (e.g. Brexit, rise of Eurosceptic parties in national govern-
ments), creativity on behalf of the Commission could allow for innovative problem-solving 
approaches to arise.
Management Establishment 
sustainable 
network (process)
Production outputs Cooperation 
outcomes
Competencies
Policy entrepreneurs +  + 
Management of scientists by scientists - ++ & - - 
Styles
Process management & project management + & - ++ & - - 
Table 7.12. Management in European HTA Networks
Project management as used in the early cooperation initiatives in EUnetHTA has on the 
hand have positive impact on the collaboration process as it has allowed for the goal setting 
process to take place. Moreover, the project-based approach also allowed for the produc-
tion of some collaboration outputs such as common tools, methodologies and pilot joint 
assessments. On the other hand, the confusion between the project aims and the process 
aim has led to a mixed approach of management styles which has negatively impacted the 
cooperation process and outcomes.
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7.2.4. External events affecting European HTA governance networks
Examine governance networks requires to take into account the broader environment since 
external events may require the network to adapt. External events can have diverse origins 
and can be of an economic, political, ideological or institutional nature. In this section we 
will focus our examination on some events which have come to the fore in our research and 
which have had an impact on one of the networks we have analysed. The events listed in 
this section do not seek to be exhaustive, as other events not identified in our research may 
have occurred.
HTA cooperation has developed against a background of the European integration process. 
Ideological approaches related to the latter seem to have impacted HTA cooperation to a 
certain extent. The initial project proposal of what would later become the EUR-ASSESS 
project, had been submitted in 1992, the same year of the signature of the Maastricht treaty 
which founded the European Union (2.1.1.). Under impetus of the Delors Commission, the 
European integration process gained new interest on behalf of Member States and citizens. 
European cooperation projects where often welcomed both in the domestic policy field 
as, of course, on the EU level. EUR-ASSESS has certainly benefited from this pro-European 
atmosphere but still had to overcome the difficulty of finding funding for a project in a policy 
field that hardly existed at the EU and domestic level. Moreover, the start of the EUR-ASSESS 
project corresponded to the initiation of a European public health policy (4.1.2.). We have 
seen in chapter 4, how the first proposal for European cooperation in HTA matched Com-
mission intentions to enter to health systems of the Member States (4.1.2.). A window of 
opportunity was thus created which allowed the first projects to be implemented.
In our research we have highlighted several legal developments which have laid down the 
basis for HTA cooperation to develop. First, we can cite here the Maastricht Treaty (1992) 
in which for the first time an article on public health had been included (2.1.1.). This article 
gave way for an official European public health policy to be developed. Based on the latter, 
a health program has been adopted which has also become the main funding source for 
HTA cooperation (4.2.2.). Second, the Lisbon Treaty (2007) has had a particular influence on 
HTA cooperation as it legitimized European cooperation projects in the field of health care 
based on soft policy means. We have seen, how this has given the possibility to the European 
Commission to propose a Directive on Cross-Border Health Care in which an article on HTA 
cooperation has been included. (5.1.3.). Based on this article, the EU HTA Network could 
be established (5.1.3.3.). Finally, the 2018 Commission proposal for a Regulation on HTA 
cooperation could, if adopted, be a milestone in the history of HTA cooperation framing 
the cooperation process in a sustainable manner. To date, this proposal is still in its adoption 
process and results needs to be awaited.
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Several political developments have also had an impact on HTA cooperation in Europe. 
Following the adoption of the Maastricht treaty, a specific Directorate for health has been 
established moving health policy from a unit level in DG enterprise to DG Sanco. This allowed 
for the development of an official EU public health policy. HTA has been identified by the 
Commission representatives as being important for EU public health and the sustainability 
of the health systems. Similarly, in the aftermath of the adoption of the Maastricht treaty, 
the EMA has been established (5.2.2.) and becoming the pharmaceutical gateway to the 
European Market. We have seen how the EMA has played an important role in creating 
synergies between the HTA arena and the European regulatory arena by means of Joint 
Scientific Advice (6.4.2.2.).
The EU governance turn in the early 2000s has created favourable conditions for the estab-
lishment of expert networks such as the High Level Group on health services and medical care 
(5.1.2.2.), the G10 process on medicines (5.3.3.1.) and the Pharmaceutical Forum (5.3.3.2.) 
which have on the one hand allowed for HTA to enter on the EU agenda and qualify HTA as 
a political priority for the EU. HTA as such has been included in official Council declarations 
securing herewith the inclusion of HTA in the EU Health programme (pre-requisite for obtain-
ing EU funding). Besides the Council, the European Parliament also supported HTA coopera-
tion by integrating it in its search to improve access to medicines (6.4.3.2.). Moreover, this 
institutional player also incorporated HTA in its motions and resolutions whereby it enhanced 
the political weight of HTA in the European policy-making processes. The implication of 
the European Parliament in the adoption process of the HTA Regulation proposal has also 
permitted the introduction of new amendments and the adoption of the text in the EP’s first 
reading (6.4.3.2.).
External events Establishment 
sustainable network 
(process)
Production outputs Cooperation outcomes
Ideological approaches ++
Legal developments ++   
Political developments +++   
Economic developments ++   
Table 7.13. External events in European HTA Networks
Finally, particular economic developments also have had an impact on HTA cooperation in 
Europe. In chapter 1 we have outlined how HTA has partly developed as a consequence 
of rising health care costs. This rationale became even more valid the more the coopera-
tion process developed. The financial crisis of 2007 has once more underscored the need 
to contain health care costs and as has enhanced the perceived need for European HTA 
cooperation. This period coincides with the establishment of the first Joint Actions which, 
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as we have seen, included the Commission as full partner and received formal support on 
behalf of the Member States. Finally, high prices of pharmaceuticals in specific disease areas 
also triggered reaction on behalf of domestic regulatory and reimbursement institutions and 
could be considered as one of the triggers for the regional cooperation initiatives to develop 
and to include in their cooperation agreements costs-effectiveness assessments, price ne-
gotiations and Horizon Scanning (6.4.3.4.). Whilst working on the basis of EUnetHTA tools, 
these cooperation initiatives could be considered by some Member States as an alternative 
to EUnetHTA and/or the future European legal framework. These regional networks could 
therefore compromise the collective Community approach aimed at in the HTA Regulation 
proposal as it offers EU Member States a flexible framework where the national competences 
will not be endangered. In this sense it has positively impacted HTA cooperation as such 
but negatively impacted the networks’ developments. It is too early to make projections 
on the potential of these regional initiatives in establishing a sustainable HTA cooperation 
framework.
7.2.5. Conclusion effectiveness of European HTA governance networks
In this section on effectiveness of HTA governance networks we have examined HTA coopera-
tion by confronting it to four factors potentially impacting goal attainment: social interaction, 
governance instruments, management, and external events. We have underscored which 
role each factor has played in the process of establishing a sustainable network of HTA 
cooperation as well as in the production of collaboration outputs and outcomes.
The examination of social interaction has brought to the fore how this process has taken 
place mainly within the HTA arena and to a lesser extent in the EU Commission. Social 
interaction has been observed on a much lower level of intensity within some stakeholder 
groups and reached predominantly members of umbrella organisations. Social interaction 
between the HTA arena and representatives of ministries has been identified in this research 
only in some cases and stood in relation with the level of management representing the HTA 
arena in the HTA cooperation networks.
The level of social interaction within the HTA arena and between the HTA arena and the 
EU Commission has had a positive impact on the effectiveness of the networks in estab-
lishing common tools, methodologies and (pilot) joint assessments. The low level of social 
interaction between the HTA arena and ministerial representatives has negatively impacted 
effectiveness in establishing a sustainable HTA cooperation framework. Moreover, the latter 
has contributed to unexpected outcomes such as the development of (intergovernmental) 
regional HTA cooperation initiatives.
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The impact of governance instruments on the effectiveness of the European cooperation 
networks has been examined by focusing on (procedural and substantive) policy instruments, 
legislative and regulatory instruments, financial instruments and political instruments. The 
examination has brought to the fore how procedural policy instruments have been effective 
in advancing the process of establishing a sustainable network of HTA cooperation through 
internal communication and evaluation processes and to a certain extent through internal 
organisational processes. However, the implementation of the latter has also negatively con-
tributed to the effectiveness of the networks as no clear distinction had been made between 
project goals of the network and the goal of creating a sustainable collaborative framework.
Substantive policy instruments have been effective in creating collaborative outputs such as 
common tools, methodologies and to a certain extent (pilot) joint assessments. However, use 
of these outputs in domestic decision-making processes remained very limited. Domestic leg-
islative and regulatory frameworks have mostly had a negative impact on the effectiveness of 
European HTA networks as adjustments to new commonly developed tools often appeared 
challenging. On the other hand, these instruments positively impacted the effectiveness of 
the networks in creating synergies between the EU regulatory framework and the HTA arena. 
Presence of a shadow of hierarchy furthermore contributed to the effectiveness of reaching 
the goals set in this area.
Political instruments identified in the research (i.e. agenda alignment, stakeholder involve-
ment, consultation processes, institutional communication and partnerships) positively 
impacted the effectiveness of the HTA cooperation networks in the process of establishing 
a sustainable framework for European cooperation. With the exception of the partnership 
established between the European Commission and the HTA networks, these instruments 
had little impact on the production of cooperation outputs. However some of these instru-
ments such as agenda alignment, institutional communication and consultation processes 
positively impacted effectiveness of HTA networks by contributing to outcomes such as the 
insertion of HTA cooperation objectives in the public health programme, the insertion of 
HTA cooperation in the Cross-Border Health Care Directive and the Commission Regulation 
proposal for HTA cooperation.
The main financial instrument identified has been the public health program, funding the 
essential part of the networks’ projects. This instrument has had both a positive and negative 
impact on effectiveness of the networks. On the one hand, financial resources were essential 
to start and pursue the cooperation initiatives producing joint work. On the other hand, by 
remaining available, no real incentives would be created to seek for alternative sustainable 
funding sources.
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The presence of policy entrepreneurs in the early cooperation initiatives and in the EUnetHTA 
Project, positively impacted effectiveness in creating goal consensus and translating the 
objectives in concrete project-based objectives. However, by developing into ‘networks of 
scientists managed by scientists’ the goal attainment process had been negatively impacted. 
Moreover, the confusion as regards the status of the networks (becoming or not the – to 
be created – sustainable network), led to a mixed management approach where no clear 
distinction would be made between process and project management.
Finally, our analysis has brought to the fore a few external events which have positively 
impacted the effectiveness of the networks in terms of goal attainment. These would related 
to ideological approaches as well as legal and political developments which have contributed 
pursuing the process of establishing a sustainable network for HTA cooperation in Europe. 
Some economic developments such as the rising health care costs related innovative health 
technology developments as well as financial crisis have had a positive impact on the devel-
opment of the HTA cooperation networks.
7.3. metagoverNaNce aND europeaN hta cooperatioN 
NetworkS
The European governance approach adopted with the White Paper on European governance 
(2001) comprised recourse to networking as governance instrument. The interest of net-
working was recognised by the impact it could have on addressing complex policy problems 
comprising multiple actors on multiple policy levels. The relationship between Europe and 
networks is however often asymmetrical in which the presence of the shadow of hierarchy 
may play a role. Networks, however, can also been used by private actors to seek access and 
influence the institutional level (see chapter 3). According to the White Paper on governance, 
cooperating with networks through the use of soft governance, could “enable them to 
contribute to decision-shaping and policy execution” (European Commission 2001b). The 
EU could have recourse to networks in various ways ranging from simple (financial) support 
to tighter forms of relationships aiming to develop specific policy objectives. The manner 
whereby the European Commission uses governance networks to implement specific policy 
objectives can relate to metagovernance.
The data outlined above in the sections on the typology of governance networks and ef-
fectiveness of network governance also informs about the role of the European Commission 
in the cooperation processes. In this section we will therefore only highlight to what extent 
the implication of the European Commission can be regarded as metagovernance. In section 
3.2. on metagovernance we have underscored that no standard form of metagovernance 
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exist. In the academic literature different perspectives are indeed presented as to the exact 
role of a metagovernor.
The role HTA cooperation could play in the development of a European public health policy 
had been identified in an early stage by representatives of the European Commission. As 
HTA was considered a mean to enter the domestic health system, salience for the matter has 
grown (4.1.2.) As such, serving European public health policy, support to HTA cooperation 
would be secured essentially by financial means (grants via the EU public health programme). 
Moreover, support-lending policies has further been structured through agenda-alignment 
and associated actions (e.g. inserting HTA objectives in the EU public health programme).
From 2001 to 2006, HTA cooperation has been promoted and supported essentially upon 
initiative of the European Commission through its high-level expert networks. These net-
works have permitted HTA to enter on the EU decision-making agenda. First, by inserting 
HTA as a topic in the High Level Process of Reflection on Patient Mobility and Healthcare. 
Then, proposing it as a priority topic of the High Level Group on health services and medical 
care, securing herewith the launch of the EUnetHTA project (5.1.2.). Moreover, by playing a 
crucial role in the content development of the European Cross-Border Health Care Directive, 
the HLG has indirectly also contributed to the insertion of HTA cooperation in this legislative 
framework. As such, the establishment of the EU HTA Network can be seen as an additional 
outcome of this expert network.
Similarly, as underscored by Commission representatives, a new health article, initially con-
ceived for the Constitutional Treaty (2004) and finally adopted in the Lisbon Treaty (2007) was 
entirely drafted according to a soft governance approach allowing the European Commission 
to lend support and coordinate cooperation initiatives such as HTA (5.2.). Developments in 
the field of the pharmaceutical sector have also played an important role in European HTA 
cooperation. Indeed, the choice of EUnetHTA as dedicated network to implement joint REAs 
resulted from a European Commission initiative, launched in the G10 process on medicines 
and then further developed in the Pharmaceutical Forum. We have outlined above how REA 
has become central in HTA cooperation. Renamed as Clinical Effectiveness Assessment, it 
has furthermore been integrated as one of the four pillars of the Commission proposal for a 
Regulation on HTA cooperation.
From financial support and policy alignment processes, the European Commission has 
stepped up its involvement in HTA cooperation by proposing to EUnetHTA the Joint Action 
cooperation format in which the Commission became an active partner. Its influence on 
agenda setting, financial support and informal decision-making processes has become of 
increasing importance and was determinant for the cooperation process to proceed. The 
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establishment of the EU HTA Network has even more changed the role of the European 
Commission in HTA cooperation. Although Member States are represented in this network, 
it is the Commission who presides the meetings of this policy-orientated network and who 
sets the agenda. We have outlined in chapter 6 how the activities of this network have been 
mainly driven towards the publication of the proposal for a Regulation on HTA Coopera-
tion. The latter has been prepared through the implementations of various studies, surveys, 
consultation procedures, conferences and Impact Assessment studies, all of them financed 
by the European Commission who also provided administrative support for the network.
When referring to descriptions of metagovernance as published in the academic literature, 
the Commission involvement shows many traits with what has been qualified as forms of 
metagovernance. As such, it has had a “major point of leverage to shape what happens via 
networks: public policy” (O’ Tools 2007:223). Scholars also have pointed how international 
institutions can influence networks through informal instruments and affect the position 
of network actors. Moreover, the role of international institutions regarding information 
diffusion could potentially affect motivations and commitments of network members. The 
latter could further impact the functioning and output production of the network (3.2.). 
In the sections above we have seen how this could be applied to the role of the European 
Commission in the HTA cooperation networks. Similarly, the establishment of connections 
between networks and key actors involved in a particular policy process, as underscored in 
the literature, has also been observed in HTA cooperation. The latter has not only played a 
role in the high level expert groups, the establishment of synergies between the EMA and 
EUnetHTA can also be cited as an example hereof.
The influence of a metagovernor can also be expressed by persuading network actors of the 
greater value of network cooperation compared to the pursuit of self-interested calculations. 
Through build-up of trust, commitment and good faith, participants perceptions can shift in 
favour of the establishment of stable and durable network solutions (3.2.). In the sections 
above we have highlighted how social interaction and the establishment of relations of trust 
have been quite high with the European Commission. Strong adhesion to the Commission 
Regulation proposal has also been identified among individual EUnetHTA members and did 
not always reflect their home-organisations for reasons explained above.
Hence, the manner in which the Commission has participated in supporting and steering 
the cooperation efforts whereby HTA cooperation has turned into a European policy field, 
shared all characteristics with metagovernance. As underscored by Triantafilou (2007:1950), 
although a metagovernor can influence the course of action of a network as well as its 
governance approaches, it does not have the ability to control the outcomes of political 
processes of networks. In the case of HTA cooperation, the current debate on the adoption 
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of the Regulation proposal does illustrate this point. The production of joint assessments, 
considered for a long time as insufficient by the Commission, is another example of the 
limited influence of the latter over the network outputs. It does furthermore display how 
the Commission has used a soft governance approach to prepare hard legislative proposals. 
Finally, the data gathered on HTA cooperation within an EU framework confirms how the 
European Commission, in the case of HTA cooperation has governed in networks rather 
than by networks (3.1.2.). Although the networks remained independent, the presence of a 
shadow of hierarchy has, at times, influenced the positioning of network actors.
7.4. coNcluSioN
In this chapter we have analysed the data outlined in part B based on the research framework 
developed in chapter 3. This research framework has allowed detailed network analysis 
and has been established upon three central concepts: governance networks, network 
governance and metagovernance. Networks have been considered as a forum in which 
soft governance instruments can be implemented. The data gathered in part B sets out the 
development of several HTA cooperation networks which have developed in Europe since the 
early 1990s. In this chapter we have concluded that these distinct networks could be quali-
fied as governance networks and corresponded to the general characteristics of governance 
networks outlined in chapter 3 (see also table 3.1.). As such, all three networks demonstrate 
a rather stable pattern of relationships of social actors clustering around the need for more 
(European) cooperation in the field of HTA. Actors remained autonomous but displayed inter-
relationships among them. Although equal in membership status and engaging in horizontal 
governance relationships, members of the networks were not all equal in terms of authority 
and weight in decision-making processes. Negotiations took place based on deliberation, 
learning processes and the development of a set of common understanding. The networks 
activities had created a regulative normative, cognitive and imaginary framework in which 
the interactions took place. Self-regulation was the rule within the boundaries of the project 
frameworks and within various degrees of influence of external actors (e.g. European Com-
mission). The actors aggregated different resources important for the cooperation initiatives 
to be pursued. These initiatives were considered contributing to public purpose.
The different HTA governance networks which have been established since the first European 
HTA collaborative project did show disparities as regards their typology in terms of incentives, 
membership, resources and governance practices. Although all networks aimed at contrib-
uting to a public purpose, the formation of the three main networks examined, showed 
however dissimilarities as to the contextual incentives, strategic calculations and support and 
constrain perceived. Incentives to join the networks were related to capacity-building, reduc-
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tion of assessment duplication and increased impact of HTA on national decision-making 
processes. Voluntary engagement and its related cheap exit strategy favoured participation 
as members could decide upon their investment level or cease further cooperation at any 
time. The support of the European Commission, HTA agencies and the implicit support of 
domestic policy-makers further positively affected the incentives to participate in the col-
laboration initiatives.
Whilst membership was mostly composed of HTA bodies in all networks, the degree of 
homogeneity and the networks’ openness to other members has evolved throughout their 
development processes. The degree of interaction between the networks and home-organi-
sations varied among members and pointed to a correlation between the size of the country 
of origin and the HTA body management level represented in the network. The smaller 
the country and the higher the agency management level represented in the networks, the 
stronger the relationship and interaction between the networks and the home-organisations. 
Stakeholder participation was absent in the first initiatives and after that fluctuated in terms 
of intensity of collaboration. Moreover, participation was not equal among the different 
stakeholder groups. No active participation of representatives of public authorities has been 
recorded in our research.
Financial resources were provided for by means of EU (public) health programme grants as 
well as by in-kind contributions of HTA agencies of domestic public authorities. The level 
of contribution and financial resources available, highly differed among the networks and 
in the different development stages (e.g. Joint Actions) of the same network. Although 
the financial resources available facilitated the cooperation initiatives, the nature of these 
resources also constituted a barrier to create a financial sustainability of the networks and 
of the HTA cooperation process. Recurrent grant support did not produce a real incentive 
to search for independent sustainable means to finance the cooperation initiatives. More-
over, the project grants reinforced the project-based approach, creating insecurity about 
long-term continuation of the cooperation process and requiring additional time-consuming 
project-based administrative activities (grant application, evaluations and reports). At times, 
the projects became considered as the cooperation process itself, leading to the adoption of 
a mixed management approach.
Other forms of resources have been of importance to develop the network activities and did 
vary amongst the networks. As such, the level of expertise has been important for capacity-
building and learning processes to develop. The level of expertise being interdepended with 
the capacity-building processes, contribution of human resources in terms of expertise thus 
diverged across the various networks. Physical and human resources (e.g. premises and 
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administrative support) provided for by national authorities or agencies have further played 
an essential role enabling European HTA cooperation to develop.
The networks’ governance modes all corresponded to soft governance steering mechanisms 
based on voluntary participation. However, each new cooperation network has functioned 
according to distinct governance modes which ranged from participant-governed networks, 
a lead-organisation governance structure to a configuration sharing many characteristics of a 
network-administrative organisation. The voluntary aspect of participation has ensured HTA 
bodies and public authorities to remain competent in national decision-making processes re-
garding the use - or not – of outputs produced by the networks. The horizontal self-steering 
governance approach displayed however its limitation as to the degree of convergence 
sought. Indeed, the more centralised the power-distribution, the more convergence of tools, 
methodologies and practices achieved.
The role of the European Commission as metagovernor further confirmed the limitations of a 
governance structure entirely based on horizonal governance steering modes. The increased 
participation of the Commission in structuring the strategic objectives of the networks has 
been largely accepted by the network members. However, resistance has been expressed to 
the HTA Regulation proposal which sought to step outside soft governance modes by fram-
ing part of HTA cooperation into hard law and (corresponding) top-down decision-making 
processes. The establishment of regional cooperation initiatives (e.g. Beneluxa, Visegrad+2) 
although cooperating in sensitive domains of Member State competences seem to indicate 
salience for an intergovernmental form of cooperation (rather than an EU community coop-
eration format) where commitment is decided upon by the Member States, and opting-out 
of the process always possible.
Regarding network governance examined by focusing on effectiveness of the governance of 
European HTA cooperation networks - considered in the light of goal attainment - the follow-
ing conclusions can be drawn. Factors, such as, social interaction, governance instruments, 
management and external events have had an impact on the effectiveness of European 
HTA cooperation in reaching the objectives set. This impact has been observed in terms of 
process, output and outcomes of the cooperation initiatives.
Social interaction has taken place mainly within the HTA arena and, on a lower intensity 
level, with stakeholders and public authority representatives. It had a positive impact on the 
effectiveness of the networks in terms of establishing common tools, methodologies and (pi-
lot) joint assessments. The effect of social interaction has been observed in the development 
of learning processes, mainly on the HTA agency level. Moreover, through the exchange of 
experiences and capacity-building exercises, a set of common values and understanding has 
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been developed, contributing to goal consensus and the build-up of trust. Social interaction 
has played a role in the evolution of the networks from an epistemic community essentially 
based on the collaboration of peers to networks interconnected to and co-steered by Eu-
ropean institutions. The diffusion of a set of common values and understanding regarding 
HTA cooperation proceeded from the HTA arena to Commission representatives and has 
been further diffused to high level expert networks. Consequently, political support to the 
cooperation process and infusion of new approaches (e.g. REAs) within the networks has 
occurred.
Lack of social interaction between social actors has however also been observed. The 
relatively closed structure of the networks prevented some key-players (e.g. policy-makers, 
stakeholders) to take actively part in the networks. As such, social interaction could not – or 
only in a limited manner - take place on these levels. When present, stakeholder interaction 
in the network mostly took place on a vertical level (network-stakeholder group). Horizontal 
stakeholder relationships across the various stakeholder groups (patients, payers, health care 
providers and industry) has not been observed on significant levels.
Moreover, the build-up of trust and goal consensus amongst domestic policy-makers has not 
been observed in our research. Similarly, no learning processes, nor a shared set of common 
values and understanding have been established with these social actors. The latter has had 
a negative impact on the process of creating a sustainable HTA cooperation framework 
in Europe and securing support for an HTA Regulation proposal in this area. Moreover, it 
has contributed to the development of unexpected outcomes such as the establishment of 
regional (intergovernmental) cooperation initiatives.
Governance instruments also have had an impact on the effectiveness of HTA cooperation 
networks both in a positive as in a negative way. As such, procedural and substantive policy 
instruments have impacted the process of cooperation through internal communication, 
evaluation and capacity-building processes allowing for single and double loop learning 
processes. This has led on several occasions at restructuring the cooperation efforts into 
new entities or cooperation approaches and giving a new impetus to the cooperation pro-
cess as such (e.g. creation of EUnetHTA and the EU HTA Network; moving from projects to 
Joint Actions). Substantive policy instruments have played a positive role in the cooperation 
process as concrete outputs have been produced in terms of tools, guidelines, and common 
assessments. However, some substantive policy instruments (e.g. Horizon Scanning) did not 
respond to domestic policy needs or were not produced in a timely manner. This contributed 
to disappointments in the cooperation process, mistrust in the quality of the outputs and the 
creation of separate regional (intergovernmental) cooperation initiatives seeking to alleviate 
the problems. As in social interaction, governance instruments have not (enough) included 
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active participation of stakeholders and national policy-makers. This has had an impact on 
the uptake of joint work.
Uptake of the collectively developed tools remained disappointing, creating doubts upon 
the feasibility and thus legitimacy of the overall goal of establishing a sustainable framework 
for HTA cooperation. As regards political instruments, positive and negative impacts on the 
HTA cooperation process in Europe have been found. Agenda alignment, inter-institutional 
communication and partnership development mostly having positively contributed to the 
cooperation process and the production of concrete cooperation outputs in terms of tools, 
methodologies and joint work. These instruments also paved the way for the establishment 
of regulatory frameworks at an EU level, offering support to HTA cooperation in Europe. 
Negative impacts of political instruments have been observed particularly in areas of domes-
tic regulatory frameworks, creating tensions and legal uncertainty regarding uptake of joint 
work in some Member States. Financial instruments also had both positive and negative im-
pacts. Repeated grant renewal through the EU Public health programme ensured continuity 
of the cooperation initiatives but did not generate networks’ need to establish an alternative 
sustainable financial mechanism for a European HTA cooperation framework.
In terms of management, positive impacts on the cooperation process has been found in the 
presence of policy-entrepreneurs and in the project leaders’ capacity to well understand the 
complexity of HTA and contribute to the production of concrete outputs. However, by having 
a network of scientists managed by scientists, no active participation of other key-actors in 
HTA has taken place, preventing the network from integrating in their approach insights of 
external actors, such as policy-makers. Moreover, the mixed management approach between 
process and project management has also negatively impacted the goal attainment process 
of establishing a sustainable HTA cooperation framework. Uncertainty about the networks’ 
vocation to become or not the future sustainable HTA cooperation framework has led, at 
times, to inconsistency in the management approach.
Finally, various (ideological, legal and economic) external events have also been identified as 
having impacted the effectiveness of HTA cooperation in reaching the goals set. Treaties such 
as the Maastricht Treaty and the Lisbon Treaty have had a positive impact on the cooperation 
processes. The Cross-Border Health Care Directive has paved the way for the establishment 
of EU HTA Network. Similarly, economic and financial crisis and rising health care cost further 
triggered the need for cooperation.
As regards the role of the European Commission in the HTA cooperation process in Europe, 
the following conclusions can be drawn. Active supporter of the cooperation efforts since 
the first European HTA network, its participation in the cooperation process has gradually 
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evolved. As a full-fledged partner of the Joint Actions, it has played an important role in 
structuring HTA cooperation in Europe. Besides political weight given to process and con-
structing the strategic orientation of it, its recourse to political, financial and legislative instru-
ments has been determinant. As such, agenda alignment has permitted HTA cooperation 
to be put on the European decision-making agenda, receive support from high-level expert 
committees, enter the public health programme allowing for financial support and being 
inserted as flanking measure in the Cross-Border Health Care Directive (2011/24/EU). The 
latter has led to the establishment of the EU HTA Network, preparing the legislative road to 
the HTA Regulation proposal made by the Commission in 2018 and which adoption process 
is, to date, still running. The manner in which the Commission has participated in supporting 
and steering the cooperation efforts whereby HTA cooperation has turned into a European 
policy field, shared all characteristics with metagovernance.
This chapter has examined data from our empirical research on European HTA cooperation 
process on the basis of the central concepts of thesis research framework: governance net-
works, network governance and metagovernance. Through network analysis, this approach 
has allowed to identified soft governance-related factors impacting the development of 
European HTA cooperation. In the next chapter, we will draw the overall conclusions of the 
research.

8 Conclusion 
 
“Statesmen are concerned to do good, 
and above all to extricate themselves from awkward corners; 
but they do not always have either the taste or the time for using their imagi-
nation. 
They are open to creative ideas 
and anyone who knows how to present such ideas 
has a good chance of having them accepted.”
Jean Monnet, Memoirs
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8.0. iNtroDuctioN
This research has addressed the governance of European cooperation processes in the field 
of Health Technology Assessment (HTA). It aimed at examining how these processes have 
been structured within the framework of the European Union. Cooperation in this field 
sought to establish convergence of practices so as to enhance the quality and quantity of 
assessments as well as their input in domestic decision-making processes. As such, it sought 
to reduce duplication of similar assessments in the EU and contribute to the development of 
more effective and efficient EU health systems. In twenty-five years of cooperation, several 
projects have been implemented aiming to develop common tools, methodologies and as-
sessment models and establish a sustainable HTA cooperation framework in Europe.
Salience for HTA cooperation on behalf of the European Commission has been present since 
the early cooperation initiatives emanating from within the HTA arena. However, since HTA is 
considered as a policy domain falling under the exclusive competences of EU Member States, 
EU support for convergence policies in the field of HTA is restricted by the Treaties to support 
lending and coordination policies. This research has sought to explore how HTA cooperation 
has been developed within an EU framework and to what extent it has been structured 
through soft governance.
The commonality between all cooperation initiatives studied in this research was networking. 
The intrinsic characteristics of networks offer favourable conditions for the implementation 
of soft governance modes and instruments. Networking has also been integrated in the new 
governance approach of the European institutions since the turn of the century. As such, EU 
support to HTA cooperation networks matched the new EU governance approach.
To examine the role of soft governance in structuring HTA cooperation within the EU frame-
work we have proceeded through network analysis. This approach allowed to connect HTA 
cooperation networks with EU soft governance modes applied in health policy. To this end 
we have developed a research framework structured according to three main concepts of 
networks: governance networks, network governance and metagovernance. The framework 
furthermore comprised soft governance-related factors potentially impacting a governance 
network’s typology as well as factors potentially impacting the effectiveness of network 
governance. Effectiveness has been defined in the sense of goal attainment, comprising goal 
setting and goal achievement.
A thorough examination of the development of the main European HTA cooperation 
networks has been made. For a systematic analysis of these, we have organised the data 
collected by means of five stages of a policy cycle (agenda-setting, policy-formulation, policy 
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decision- making, policy implementation and policy evaluation). This approach has enabled 
data collection and analysis capturing governance approaches in organisational develop-
ment, steering modes, policy-instruments, managerial styles and social interaction.
The examination period covered three distinct development stages of European HTA coop-
eration. The first, running from 1992-2001, regarded the initial cooperation efforts with the 
implementation of the projects EUR-ASSESS, HTA-Europe and ECHTA/ECAHI. The second, 
taking place from 2001 to 2005, addressed developments in the field of EU health policy 
which have been essential for the further development of HTA cooperation within the frame-
work of the European Union. The third covered the period since 2006 and regarded the 
attempts to setup a sustainable structure for HTA cooperation in Europe though networks 
such as EUnetHTA and the EU HTA Network.
As the research topic finds itself at the crossroad of two academic research fields – European 
governance and health policy –, Part A of this thesis has contextualised HTA within both 
fields and set out the theoretical basis of our research framework. In Part B we have outlined 
the data according to the three research periods mentioned above. Part C has analysed the 
data on the basis of the research framework. The present chapter will address the general 
conclusions of the research and will answer the research questions defined in the Introduction 
of the thesis. It will also underscore the strengths and limitations of the research, formulate 
research- as well as policy recommendations.
The research questions formulated in the introduction of this thesis comprised an overarch-
ing research question (RQ):
- Research Question: To what extent has soft governance structured HTA cooperation 
within the framework of the European Union?
 To delimitate the scope of this question, three sub-research questions have been formu-
lated, focussing each on a specific area of HTA cooperation:
- Sub-Research Question 1: Can convergence and harmonisation of HTA tools, methodolo-
gies and practices be achieved through soft governance in an EU setting?
- Sub-Research Question 2: Can national uptake of joint work in HTA be achieved through 
the use of soft governance in an EU setting?
- Sub-Research Question 3: Can synergies be established through soft governance be-
tween HTA and European regulatory processes of pharmaceuticals?
This chapter will present the conclusions of the research as follows: the first section will 
outline the role of soft governance in European HTA cooperation regarding the specific 
areas targeted in each sub-research question. The second section will answer the overarch-
ing research question regarding the extent in which soft governance has structured HTA 
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cooperation within the EU framework by setting out its impact. The latter will be addressed 
in three ways: 1) areas of ‘positive’ impact of soft governance on the European HTA coopera-
tion process in terms of goal attainment; 2) areas where a positive impact of soft governance 
has not been found or only in a limited way; 3) explanatory factors for the absence of positive 
soft governance impact regarding goal attainment.
Following these sections, limitations of the research will be indicated as well as areas were 
further research would be necessary. Policy recommendations in the field of European HTA 
cooperation will be proposed in the last part of the chapter and precede the final concluding 
remarks.
8.1. achieviNg coNvergeNce, uptake aND SyNergieS 
through SoFt goverNaNce iN europeaN hta 
cooperatioN
The research has demonstrated that HTA cooperation in Europe has been steered mainly 
through HTA networks. These networks operated according to soft governance modes and 
aimed at the establishment of a sustainable HTA cooperation framework allowing for conver-
gences of HTA practices in Europe and avoid duplication of efforts. Several soft governance 
instruments have been implemented to support that goal and will be outlined in detail in 
the sections below. The Open Method of Coordination, although reflected upon as potential 
instrument, has not been implemented as such.
To understand to what extent soft governance has shaped the cooperation efforts within 
the framework of the European Union, we have delimited the scope of this research to three 
areas in which HTA cooperation has taken place: development of common tools, methodolo-
gies and practices; uptake of joint work; synergies between the EU regulatory framework of 
pharmaceuticals and HTA. In the following sections we will address each of these areas by 
answering the three sub-research questions. The input will be used to answer the overarch-
ing research question and draw the general conclusions of the research.
8.1.1. The role of soft governance in convergence and harmonisation of 
HTA tools, methodologies and practices in an EU setting
One of the key-objectives of the collaborative HTA initiatives was the convergence of HTA 
practices and the production of joint work which could be used in national regulatory 
decision-making processes, herewith reducing duplication of work and enhance quality and 
quantity of HTA Europe-wide. This objective has remained in essence the same throughout 
all HTA cooperation networks. The data we have collected and examined brings to the fore 
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that concrete European collaborative HTA outputs have been produced in the form of com-
mon network tools, methodologies and practices. Examples hereof are the Core-HTA model, 
the (Rapid) REAs model, the POP-database, the EVIDENT data base, numerous guidelines, 
handbooks and other capacity-building tools. A substantial number of joint assessments 
have been produced within the networks, although often still in pilot format. Routinisation 
of joint (REA) assessments has been pushed only in Joint Action 3, more than twenty years 
after the start of the first cooperation initiatives. Moreover, although the networks have 
been able to develop joint work and create convergence in certain tools, methodologies, 
and assessments, not all members of the networks would adhere to the outputs produced. 
Finally, convergence of tools, methodologies and assessments underpinned the overarching 
objective of the networks to establish a sustainable HTA cooperation framework.
Soft governance has played a role in establishing some degree of convergence of tools, 
methodologies and practices within the HTA networks examined. The first argument to 
underpin this conclusion relates to the organisational framework in the form of governance 
networks. The establishment and functioning of European HTA cooperation networks serving 
the purpose of seeking convergence of HTA outputs, entirely follows a soft governance ap-
proach. These networks have been qualified as governance networks operating on the basis 
of soft governance principles such as voluntary participation of autonomous actors engaging 
in horizontal relationships where different levels of authority and weight in decision-making 
processes have been observed. Cooperation processes were based on deliberation, learning-
processes and the development of a common set of values and understanding. Moreover, 
receiving political, administrative and financial support from internal and external actors, 
these networks contributed to a public purpose recognised on both the domestic as the 
European level.
Specific aspects related to the typology of these governance networks have been identified 
as impacting the development of convergence in HTA outputs, translated in the form of 
tools, methodologies, and joint assessments. These aspects are associated to the network 
formation process, membership structure, resources and governance modes.
In terms of network formation, voluntary participation stimulated by incentives such as dedu-
plication of work, (personnel, financial and time) investments, peer-education and exchange 
of best practices, have been decisive for the setup of the networks. The homogeneous 
membership structure creating networks of peers, has favoured the establishment of a set of 
common values and understanding, pre-requisite to the production of joint work. Available 
financial resources through the EU (public) health programme have permitted the production 
of pilot projects systematically evaluated through single- or double loop processes. Expertise, 
increasingly present in the HTA cooperation networks, has been of prime importance for 
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the development of tools and guidelines. It has also played a crucial role in capacity-building 
processes necessary for the establishment and implementation of joint assessments. Other 
resources, such as, administrative support, availability of premises and administrative human 
resources further strengthened collaborative work aiming convergence of practices.
Convergence of practices requires adherence to the goal setting and goal attainment pro-
cesses. As entirely voluntary cooperation initiatives, convergence of tools, methodologies 
and practices would rely upon soft governance steering modes of the networks. The HTA 
governance networks distinguished themselves by the steering modes implemented, ranging 
from horizontal power distribution (e.g. EUR-ASSESS, HTA-Europe ECHTA-ECHAI function-
ing as Participant-Governed Networks), asymmetric power distribution (e.g. EUnetHTA 
functioning as Lead-Organisation Governance) to centralised power distribution (e.g. EU 
HTA Network/ Governance structure in the HTA Regulation proposal sharing many traits of 
a Network Administrative Organisation). A correlation between the degree of convergence 
and the steering modes has been observed. The more centralised the governance modes, the 
more convergence of tools, methodologies and practices targeted and attained.
Soft governance underpinning the development of convergence of tools, methodologies 
and practices have also been observed in network governance-related aspects such as social 
interaction, governance instruments, management and external events. Social interaction 
has been an important factor favouring the production of joint outputs. In particular learning 
processes and the development of a set of common values and understanding have been 
of high importance when developing collaborative tools. Consensus building, exchange of 
experience and best practices have favoured the production of joint work. Trust building has 
been another crucial element in producing outputs such as guidelines, joint assessments or 
common databases.
The soft governance instruments used, such as, internal communication, peer-review, single 
and double loop evaluation processes, further strengthened the convergence processes. 
Moreover, the political, financial and regulatory instruments have created a framework al-
lowing continuation of the projects aiming the convergence of HTA outputs. By requalifying 
EUnetHTA as the scientific and technical arm of the EU HTA Network, emphasis has been 
put on the need for routinisation of joint work. The latter should support the overarching 
objective of creating a sustainable HTA cooperation framework.
The (project) management approach organised in Work Packages based on voluntary par-
ticipation of network members, has had a dual impact on the process of convergences of 
practices. Although ‘management of scientists by scientists’ offered the advantage to induce 
the necessary expertise to establish convergence of tools, methodologies and practices, it 
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also prevented input from other actors, in particular those involved in domestic decision-
making processes. Moreover, the voluntary participation of agencies in the various work 
packages did not necessarily reflect their support to convergence of practices. As such, the 
joint work generated as a network did not necessarily represent adherence to this work by 
individual HTA bodies.
Finally, impact of soft governance on the convergence of European HTA tools, methodolo-
gies and practices has been observed in relation to the presence of a metagovernor (i.e. 
European Commission). Social interaction has played an important role in securing support 
for the cooperation initiatives on behalf of the European Commission developing its own 
policy agenda for HTA cooperation. Through policy instruments such as inter-institutional 
agenda alignment and high level expert networks, the European Commission has been able 
to influence the course of action by offering political, financial and administrative support 
aiming the convergence and harmonisation of HTA practices. By creating the EU HTA Net-
work, the European Commission has instilled a new impetus to achieve this aim. In particular, 
its proposal for a Regulation on HTA cooperation in Europe, comprising mandatory aspects 
regarding Joint Clinical Assessments highlights how the European Commission sought to 
steer the cooperation efforts towards HTA harmonisation in Europe.
To conclude, convergence of HTA tools, methodologies and practices can be achieved in 
an EU setting through soft governance. The research has brought to the fore specific soft 
governance features operating through governance networks, network governance and 
metagovernance and which have impacted the process of convergence of tools, method-
ologies and practices in a positive or negative way. As such, convergence is favoured by 
the establishment of governance networks based on voluntarism, soft governance steering 
modes, discourse, learning, capacity-building and the build-up of a set of common values 
and understanding. Moreover, convergence will be easier to achieve in a homogeneous, 
closed network structure comprising strong network-home organisation relationships. Avail-
able resources will support convergence processes. Soft governance steering modes impact 
the degree of convergence achieved. The more centralised the governance modes, the more 
convergence obtained.
Social interaction between network members provides the basis for learning-processes, shared 
values, trust and goal consensus, essential for the development and implementation of joint 
work. Management of a network of scientists by scientists had a dual impact on convergence 
by accelerating the development of common tools and methodologies and practices but 
decelerating adherence to the joint work by external actors not taking an active part in the 
networks. Presence of a metagovernor, by means of the European Commission, operating 
essentially through soft governance has been essential for the establishment of convergence. 
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Finally, although a certain level of convergence has been achieved, no harmonisation of HTA 
tools, methodologies and practices has been observed in our research, despite the presence 
of soft governance modes and instruments implemented through governance networks. 
Harmonisation of certain aspects of HTA has been targeted by the European Commission 
basing the process however on hard legislation rather than on soft governance.
8.1.2. The role of soft governance in national uptake of joint work in HTA
‘Uptake’ refers to the use of joint work in domestic decision-making processes. Debate 
regarding the exact level of uptake in national settings is still on-going. Systematic use of 
HTA outputs produced by the HTA governance networks has not been observed. Generally, 
uptake is considered to be rather low. Various studies, carried out in the past and presented 
in this research, have pointed to challenges such as quality, linguistic, legal, technical or time-
liness matters faced by the networks or HTA bodies to ensure uptake. The present research 
has examined the issue of uptake by taking another perspective and examine to what extent 
soft governance has played a role in the level of uptake measured. As such, several factors 
related to governance networks, network governance and metagovernance have come to 
the fore. These can be associated to the presence or absence of soft governance instruments 
in the processes seeking to ensure uptake.
Due to the division of competencies between the EU and its Member States regarding the 
organisation and management of domestic health systems, processes of uptake have been 
steered by soft governance, based on voluntarism and the absence of hierarchical top-down 
decision-making. Uptake of joint work could therefore not be imposed by the HTA gover-
nance networks. Domestic HTA bodies remained in charge of the HTA processes and were 
sole decision-makers as to include or not joint work in their assessments. The outcome of 
these decisions would impact diffusion of joint work in national regulatory processes. Several 
factors have been identified in our research as potentially impacting this decision-making. 
First, the management level of HTA agency representatives participating in the network 
activities, has come to the fore as a favourable factor in uptake. Qualitative data gathered 
in our research points to the fact that the higher the management level of an HTA agency 
representative involved in an HTA cooperation network, the better the chances to adjust to 
new tools, methodologies and other forms of joint work.
Second, the membership structure of the HTA cooperation networks can (partly) explain the 
disappointing levels of use of collaborative HTA outputs in domestic settings. The relationship 
between the governance networks and their members’ home organisations has, in many 
cases, been qualified of low intensity. Social interaction would in these circumstances remain 
limited to the network level and its effects (e.g. learning processes, setup of a common set 
of values and understanding, trust building and goals consensus) could not be produced in 
476 Chapter 8
representatives of home organisations not involved in the HTA governance networks. Adher-
ence of home organisations to joint work produced in HTA networks would consequently 
be harder to secure.
The third explanatory factor regarding the disappointing levels of uptake of joint work is to 
be found in the low level of active involvement of domestic (‘hard’) policy-makers. As HTA 
matters are often considered being technical issues requiring specific expertise, ministries 
tend to delegate representation in HTA collaborative initiatives to HTA agency representa-
tives. The size of the agency, the degree of interaction with the ministry, as well as the 
management level represented in the collaborative initiatives, all impact uptake. Our research 
has found that participation of senior HTA agency executives in the establishment of col-
laborative tools, methodologies and assessments created favourable conditions for uptake 
due to knowledge of, and trust in the outputs produced. Furthermore, senior HTA agency 
executives possessed the authority necessary to adapt domestic HTA processes and operate 
internal change. Consequently, chance for uptake of joint work would increase.
Moreover, social interaction between ministerial representatives and HTA bodies tended 
to be higher when senior agency representatives were involved in the HTA networks. The 
level of social interaction would have an impact on learning and capacity-building processes 
within the ministry as well as on the trust-building and goal consensus processes regarding 
HTA cooperation. Adherence of ‘hard’ policy makers to HTA collaboration becomes crucial in 
the development of new EU legislation since the ministerial level plays a decisive role in the 
adoption process of new legislative proposals. Hence, even if recourse to hard legislation is 
made to ensure uptake though mandatory means, soft governance remains of importance 
to prepare decision-making processes in sensitive, technical and complex issues, such as HTA.
Finally, limited stakeholder participation in the development of joint work may also impact 
the uptake of it. Participation of stakeholders in the HTA cooperation networks has mostly 
been restricted to informative purposes rather than to collaborative purposes. Social in-
teraction in the networks between HTA bodies and stakeholders has been rather limited. 
Transversal social interaction between stakeholder groups themselves has not been intense 
either. As a result, goal consensus has not always been observed amongst all stakeholder 
groups and salience to participate in pilot projects has, at times, been below expectations. 
Similarly, learning processes, the development of a set of common values and understanding, 
trust-building in the quality of the processes and their outputs, also have been impacted by 
the low level of social interaction.
Hence, no active soft governance instruments and steering mechanisms have been imple-
mented in HTA collaborative processes seeking to ensure uptake of joint work in domestic 
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HTA decision-making processes. Nevertheless, this research has established that soft gov-
ernance could play an important role in favouring the diffusion of joint work in national 
HTA and domestic pricing and reimbursement processes. Based on the data gathered in 
this research, there is no clear indication that soft governance alone would be sufficient 
to guarantee uptake of joint work in national settings. However, soft governance could 
provide solutions to overcome the challenges to uptake as recorded in various studies and 
relating to issues of quality, timeliness, legal constrains, linguistic barriers and other technical 
problems. Social interaction has come to the fore in our research as an important element to 
ensure political and peer support, necessary to surmount technical and strategical obstacles 
preventing uptake to occur. Moreover, even in cases where EU hard legislation would be 
used to support uptake of HTA joint work in domestic settings, soft governance would still 
be necessary to ensure adherence of EU Member States and national HTA bodies to the new 
legislative framework proposed.
8.1.3. The role of soft governance in the establishment of synergies 
between HTA and European regulatory processes
The research has outlined how the process of European cooperation in HTA has led to the 
establishment of synergies between the HTA arena and the EU regulatory framework in the 
field of pharmaceuticals. To date, a common EUnetHTA/EMA platform exists, offering to 
manufacturers the possibility to request via a single entry-point Joint Scientific Advice on 
behalf of HTA bodies and the European Medicines Agency. Dedicated governance bodies 
have been created to coordinate the latter, such as, an Early Dialogue Working Party and a 
Early Dialogue Secretariat. European and domestic regulatory processes and European Public 
Assessments Reports have been adapted accordingly.
Factors related to soft governance having positively contributed to the establishment of these 
synergies between the HTA arena and the EMA are related to the typology of HTA governance 
networks as well as to effectiveness of HTA network governance. As such, membership 
homogeneity of the network has played an important role. Early Dialogues comprised mainly 
three actors: HTA bodies, the pharmaceutical industry, and the EMA. The needs expressed 
were shared by the three social actors, each operating in a separated environment. Hence, 
goal consensus was easy to achieve. Conversely to other EUnetHTA outputs produced, the 
Early Dialogues have been set up by associating each partner and stakeholders closely to the 
project. Adherence of the industry participants was high due to the adequacy between the 
participants’ needs and the product outputs as well as the presence of a shadow of hierarchy. 
As such, the outcome of Joint Scientific Advice would allow industry representatives to adapt 
the product development process so as to be compliant with the requirements of the asses-
sors. However, by refraining from doing so, a company would risk seeing its market access 
procedure be delayed.
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Other factors having played a role in successfully creating synergies between the two arenas, 
were the available resources in expertise, (administrative) manpower and availability of prem-
ises. Political support on behalf of the Commission as well as of the HTA bodies themselves 
and EU Member States, has further favoured the smooth implementation of the cooperation 
initiatives.
As all key-actors were involved in the process, social interaction could take place between 
them. Learning processes and the development of a common set of values and understanding 
underpinned the establishment of trust in the process and in the partners. Capacity-building 
and evaluation processes further strengthened the establishment of synergies between the 
two arenas. As an entirely new initiative, some governance instruments such as the creation 
or adaptation of legislative and regulatory frameworks could be tailored to the needs of 
the HTA bodies and the EMA. Since no other similar system existed on a national level, no 
domestic legislative hurdles blocked further development. Moreover, process and project 
management have been dissociated. Each project serving as input for the larger process to 
be developed.
To conclude, soft governance has played an important role in the establishment of synergies 
between HTA and European regulatory processes. In this respect, the membership structure 
of the networks, the soft governance steering modes and availability of various types of 
resources has favoured the development of the process. Social interaction and the inclusion 
and active participation of stakeholders has further reinforced the synergies which have 
developed. Presence of a shadow of hierarchy consolidated adherence to decision-making 
and, as such, sustainability of the cooperation initiatives.
8.2. to what exteNt: DomaiNS aND explaNatory FactorS
In the previous section we have examined the role of soft governance in three different areas 
of HTA cooperation: convergence of tools, methodologies and practices, uptake of joint work 
or synergies between the HTA arena and EU regulatory processes of pharmaceuticals. We 
have highlighted in each specific area, which soft governance-related factors were associated 
to either a positive or negative impact regarding goal attainment of the HTA networks. The 
overarching goal of all networks being the establishment of a sustainable structure for HTA 
cooperation in Europe. Several sub-goals served as means to reach the overarching goal. The 
conclusions drawn permitted to answer the sub-research questions of this thesis.
In this section we will build upon these conclusions to address the overarching research ques-
tion regarding the extent to which soft governance has structured HTA cooperation within 
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the framework of the European Union. To this end we will first address domains where a 
positive impact of soft governance in European HTA cooperation has been observed and un-
derscore the reasons hereof. We will then highlight domains where a positive impact of soft 
governance in terms of goal attainment has not been observed. Finally, explanatory factors 
for the absence of positive impact of soft governance on European HTA processes in terms 
of goal attainment, will be underscored. The domains of impact of soft governance covering 
the three main areas of HTA cooperation display the extent to which soft governance has 
structured HTA cooperation within the framework of the European Union.
8.2.1. Domains and explanatory factors of positive impact of soft 
governance in European HTA cooperation
Impact of soft governance in structuring HTA cooperation within the EU framework has been 
examined in this research through a network analysis by focusing on typology and effective-
ness of HTA networks in terms of goal attainment. We have outlined how effectiveness can 
be measured in terms of processes, outputs and outcomes. In this section we will highlight 
the domains where goal attainment has been found and in which where soft governance 
has played a role.
Our analysis has brought to the fore five domains where a positive impact of soft governance 
has been measured in the European HTA cooperation networks.
These areas are:
1) Goal setting process of European HTA networks.
 The objectives set since the first HTA cooperation projects have been consistent and 
allowed HTA actors to remain united around a common goal, securing herewith the 
continuity of cooperation efforts. Social interaction, through learning processes and the 
development of a common set of values and understandings, has been an important 
factor herein. Horizontal coordination, and voluntary cooperation with a cheap exit 
strategy have favoured the continuation of cooperation efforts. Moreover, the availability 
of continuation of funding sources and the administrative support received from the 
Commission has also played a decisive role herein. Finally, the political support, trans-
lated in Council declaration, EP motions and Commission programmes has secured the 
development of the projects. The inclusion of HTA in legal frameworks (e.g. Cross-Border 
Health Care Directive) further assured continuation of the projects.
2) Development of HTA cooperation tools, methodologies and joint assessments.
 Common tools and methodologies have been developed in the networks. These were 
mostly related to support joint assessments (REAs or common core-HTAs) which initially 
were carried out as pilot projects and in a later phase became more routinised. Develop-
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ment of those resulted from learning processes, peer-education and exchange of best 
practices and evaluation through pilot projects. Procedural governance instruments (e.g. 
communication, evaluation) supported the development of substantive governance 
instruments (e.g. REAs, Early Dialogues, joint core HTAs) as the latter should prepare the 
establishment of a sustainable framework for HTA cooperation. The new repartition of 
the networks’ roles since the creation of the EU HTA Network, where EUnetHTA became 
the scientific and technical arm of the former, further highlights how the substantive 
governance instruments were needed to reach the overarching goal.
 Even though, no sustainable HTA cooperation framework exists to date, goal attainment 
of sub-goals (i.e. development of common tools (e.g. POP database), methodologies 
(e.g. HTA framework guidelines, handbooks) and practices (e.g. joint REAs, common 
core-HTA) has been demonstrated in this research. Factors favouring convergence were 
relate to network structure (homogeneity and closeness) as well as governance modes 
(the more centralised, the more convergence). Social interaction would support learning-
processes, shared values and understanding, trust and goal consensus, essential in the 
development of joint work. Project management had a two-fold impact on convergence. 
The expertise shared in a network of peers accelerated development of joint work, but 
lack of active stakeholder involvement decelerated adherence of external actors not 
involved in the process. As metagovernor, the European Commission actively supported 
convergence strategies, pushing the process even into the direction of a hard regulation 
proposal. As such, it has used its influence to steer HTA networks from the outside and 
use soft governance to pave the way for hard regulation.
3) Limited uptake of common HTA tools and methodologies in national HTA pro-
cesses.
 EUnetHTA tools and methodologies have been used in national HTA processes, in some 
EU member states. Although no general uptake of joint work has been observed, the re-
search did bring to the fore how some countries did use EUnetHTA tools, methodologies 
or (elements of) joint assessments in national HTAs. Social interaction did impact uptake 
there where it took place. Implication of top-management representatives of HTA agen-
cies allowed for learning processes and shared values and understandings to be trans-
mitted to the domestic HTA agencies. Presence of top-level managers in the networks’ 
activities allowed for adaptation processes to be decided upon in the domestic settings. 
Trust in the EUnetHTA outputs was a consequence of participation in the development of 
those. Through communication between top managers of HTA agencies and ministerial 
representatives, benefits of social interaction were transmitted to the ministerial level, in 
some countries, favouring acceptance of European tools and methodologies in domestic 
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HTA procedures. Overall impact of joint work in national HTA decision-making processes 
remained limited though, as we will further discuss in the section below.
4) Use of EUnetHTA outputs by regional cooperation networks (e.g. Beneluxa).
 Regional cooperation processes, although establishing separate cooperation structures 
have developed their common activities using tools and methodologies of EUnetHTA. 
Moreover, membership overlap between EUnetHTA and regional cooperation initiatives 
allowed to build upon shared values and understandings and experiences in HTA coop-
eration. Although this can be considered as an unforeseen outcome of the previously 
established HTA cooperation networks, it does underscore effectiveness of them in the 
production of common tools and methodologies based on a soft governance approach.
5) Establishment of synergies between EUnetHTA and the EMA.
 To date, a common platform has been established for parallel consultations between EU-
netHTA and the EMA. The synergies which have been established between both arenas 
result from soft governance processes. Dialogue between the HTA and regulatory arena 
(comprising internal-industrial dialogue), exchanges of experiences and best practices, 
voluntary cooperation, and horizontal coordination have underpinned the collabora-
tion processes and still characterise the functioning of the common platform. Network 
homogeneity favoured goal consensus. Stakeholders inclusion has been a specificity of 
the initiatives and impacted adherence and commitment to the initiatives. The latter was 
however also impacted the presence of a shadow of hierarchy. Although not compulsory, 
non-compliance with joint scientific advice could have costly consequences for technol-
ogy procedures during market access processes. The concordance between the needs 
and the outputs produced further favoured adherence to the cooperation initiatives. 
Similarly, the relatively less-complex content of Early Dialogues (compared to a full HTA 
based on the nine domains of the Core Model) certainly further contributed to the suc-
cessful establishment of synergies in this area. Social interaction has been determined 
and was favoured by the inclusion of all key-actors of the processes. As such learning 
processes and capacity-building could take place and were diffused to external actors. 
Other factors positively impacting synergies between the two arenas, were related to 
available resources (financial, human and administrative) and political support on behalf 
of national and European public authorities. The latter facilitated legislative and regula-
tory adaptation to the new initiatives.
8.2.2. Domains of absence of a positive impact of soft governance in HTA 
cooperation
The main goal established by all networks was the setup of a sustainable framework for HTA 
cooperation in Europe. Such a framework should facilitate the uptake of joint work produced 
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in a collaborative HTA framework. To date, no sustainable European HTA framework has 
been established and uptake of joint work in domestic decision-making processes remains 
limited. The first and overarching objective has been pursued by means of soft governance 
modes and instruments. Regarding uptake of joint work, recourse to soft governance is less 
evident although the few development processes seeking to establish uptake did point to a 
limited use of soft governance.
Hence, a positive impact of soft governance in terms of goal attainment has not been mea-
sured in the following two areas:
1) No establishment of a sustainable European framework for HTA cooperation
 HTA cooperation has remained project-based with each project and Joint Action being a 
follow-up of the previous one. The creation of the EU HTA Network turning EUnetHTA 
into its scientific and technical arm marks a point of departure in this regard. As a policy 
orientated network, the EU HTA Network would examine how a sustainable framework 
for HTA cooperation could be established, de facto demonstrating that no such a 
framework had been created throughout the previous projects. The 2018 Commission 
HTA Regulation proposal should produce the legal conditions for such a framework to 
be created, and herewith also established that no such a framework existed. Hence, 
soft governance has allowed the development of European HTA cooperation networks, 
which have prepared (some of) the instruments necessary for a sustainable framework 
to function. However, to date, soft governance approaches have not led to the creation 
of such a framework. The Commission Regulation proposal is an attempt to remedy to 
this. (Intergovernmental) regional cooperation initiatives can be considered as alternative 
ways to establish a sustainable cooperation mechanism. All proposals have used the 
outputs of the cooperation processes set in motion in the networks analysed.
2) No systematic uptake of joint work in the EU Member States
 The Commission HTA Regulation proposal came as a response to the absence of a sus-
tainable HTA cooperation framework and to what was considered by the Commission 
as a lack of uptake of joint work in national HTA processes. Besides a continuation of 
voluntary cooperation in the field of Joint Scientific Advice and Horizon Scanning and 
joint assessments, the Commission proposed a mandatory approach for Joint Clinical 
Assessments. Herewith, it implicitly acknowledged that soft governance would not be 
sufficient to ensure convergence of practices in joint assessments. By limiting the manda-
tory uptake to the clinical aspects of assessments, it hoped for a better acceptance of 
EU Member States as these fields would not directly touch upon economic matters. This 
did not prevent Member States considering the proposal as a breach of the subsidiarity 
principle. Although much attention has been given by the European Commission and 
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the networks to explanatory reasons for the lack of uptake in national HTA processes, no 
clear strategy to favour uptake has been identified in this research. Mostly, uptake should 
result from the transmission of common values and understandings from the networks 
to the HTA agencies comprising herein also qualitative and methodological issues. As 
such, one can consider that the approach regarding soft governance was underpinned by 
soft governance principles and instruments, even more so, as no hierarchical top-down 
governance approaches have been implemented. Hence, although soft governance was 
the underlying steering mechanism seeking to secure uptake of joint work in the EU 
Member States, no dedicated ‘uptake-strategy’ based on soft governance instruments 
has been developed in the various European HTA networks.
8.2.3. Explanatory factors for the absence of positive soft governance 
impact regarding goal attainment
Establishing a sustainable framework for HTA cooperation allowing for the use of joint work 
in national pricing and reimbursement processes has been the main objective since the early 
cooperation initiatives. The lack of goal attainment and the related lack of uptake underscore 
a lack of effectiveness of the HTA networks in this regard. Explanatory reasons for both are 
interconnected. In the section above we have highlighted how soft governance has not been 
identified as having a positive impact in these areas in terms of goal attainment.
In our research we have identified the following factors related to soft governance which had 
an impact on the outcomes of HTA networks regarding the lack of goal attainment:
1) Underrepresentation of domestic policymakers in European HTA cooperation 
networks.
 Active participation of policymakers has been missing in the HTA networks. Importance 
of this key-actor in HTA processes had already been underscored in the EUR-ASSESS and 
in the HLG project. However, in practice, participation of a policymaking level was limited 
to the nomination or approval of HTA agencies in the HTA cooperation networks. The 
absence of policymakers in networks’ activities also prohibited social interaction to take 
place. Consequently, impact of learning processes and capacity-building could not take 
place with policymakers nor could common values and understanding or trust be built up 
amongst them. Information about progress of network activities would depend on the 
relationship between HTA agencies and the ministries and the level of HTA representation 
in the HTA networks. As HTA serves as input for national regulatory processes regarding 
pricing and reimbursement of health technologies, this policymaking level should play 
an important role in the European cooperation of HTA. Finally, the adoption of any EU 
regulatory proposal has to be approved by the domestic health policymakers represented 
in the Council of the European Union. The active participation of ministerial representa-
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tives in European HTA networks could have secured domestic support for cooperation 
initiatives or could have disclosed in an early stage potential hurdles for any regulatory 
proposal in this regard. Moreover, the degree of involvement of governmental represen-
tatives is one of the distinctive traits between EUnetHTA and regional HTA cooperation 
initiatives.
2) Limited stakeholder policy in European HTA cooperation networks
 Four stakeholder groups have been identified in HTA governance networks: industry, 
patients, payers and health care providers. The involvement of stakeholders in HTA 
networks’ activities has however been limited and inequal across stakeholder groups. 
Industry and patient umbrella organisations have been most active and influential in 
the cooperation processes. Payers and health care providers have played a very limited 
role in the cooperation efforts. The early cooperation initiatives as well as the European 
Commission have often underscored the importance of including stakeholders in the co-
operation processes but with limited effects. Three conclusions can be drawn as regards 
stakeholder policy:
2a) Stakeholder involvement was limited to informative rather than collaborative 
purposes.
 In the HTA networks, no consensus existed as to the degree of participation of stakehold-
ers in the networks’ activities. National policies still dominated the members’ positioning 
on the matter. Diversity could be explained by the adoption of an economic or public 
health perspective in stakeholder involvement. Depending on the perspective, some 
stakeholder groups could be more or less influential than others (e.g. industry in an 
economic perspective; patients in a public health perspective). As stakeholder participa-
tion was limited, social interaction was minimal. Learning processes were difficult to 
establish as was the development of a set of shared values and understandings. The level 
of trust in active stakeholder involvement in HTA processes would depend on national 
experiences and no particular trust building processes have been developed at a Euro-
pean level. Moreover, there where social interaction did take place to a certain extent, 
it often concerned only the umbrella organisation, participating in the EUnetHTA activi-
ties. Transmission of social interaction benefits to member organisations was difficult to 
achieve. Consequently, awareness of HTA cooperation in Europe and adherence to HTA 
networks’ goals by a large set of stakeholder organisations was, most often, very low.
2b) Stakeholder coordination has mainly taken place at a vertical level (network-
stakeholder).
 No particular stakeholder coordination process has taken place at a horizontal level 
(stakeholder-stakeholder). The latter could have allowed for the development of a more 
inclusive stakeholder policy and the establishment of learning processes leading to the 
development of shared values and understandings and the build-up of trust. Goal con-
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sensus regarding both the ultimate aim of HTA cooperation as well as consensus on the 
role of stakeholders in this process could have reinforced the cooperation process as a 
whole and allowed for a stakeholder approach dissociated from national practices.
2c) Partial representation of reimbursement organisations (‘payers’) in European 
HTA networks. Payers play a crucial role in HTA processes and in European HTA pro-
cesses are constituted of social security systems and mutualities. The stakeholder group 
representing ‘payers’ in EUnetHTA and the EU HTA Network refer in fact only to additional 
reimbursement schemes which often do depend on decision-making processes of social 
security organisations. As outlined above, domestic policymakers, often key-actors in re-
imbursement decisions, did not actively participate in the networks and would therefore 
not approach joint tools, methodologies and assessments in the same way as those who 
were involved in the processes.
3) Ineffective interaction between HTA networks and members’ home organisa-
tions
 Social interaction remained at the level of network members and dissemination of its ef-
fects in home organisations was limited. Learning processes, the establishment of shared 
values and understandings, trust building and goal consensus would essentially take 
place at a network level. This would have several consequences on uptake of joint work. 
Depending on the size of the agencies, dissemination of the outputs of cooperation activi-
ties in the home organisations would be more or less intense. This seems to be correlated 
with the management-level representing an agency in the HTA Networks. The smaller the 
agency, the higher the management representation level in the HTA networks, the more 
network activities transmission into the home-organisation, the more chance of uptake 
of joint work. Indeed, integration of elements of collaborative processes would follow 
(top)management decision-making. The bigger the agency, (proportionally) the less 
transmission of information on network activities and its outputs to home-organisation’s 
employees and the less uptake of joint work. Middle-management representatives of 
(size-wise) bigger agencies, participating in the networks would have more difficulties to 
transmit social interaction benefits (e.g. transmission of learning processes and trust in 
the processes). Moreover, they would not enjoy the same authority as top-managers for 
whom it would be easier to instil change. Adherence to the network objectives from the 
home organisations would in these circumstances be more problematic, adaptation of 
internal work processes to requirements of collaborative projects more difficult to install, 
and uptake a bigger challenge to overcome.
4) Mixed management approach in HTA networks
 No adequate distinction between process- and project management has been made 
in HTA networks. Policy entrepreneurs have played an important role in the setup of 
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networks by understanding the complexity of HTA and the need to establish a link to 
policymaking. Policy-entrepreneurs have been identified in the early cooperation projects 
(e.g. EUR-ASSESS), the EUnetHTA project as well as at the European level. Cooperation 
between the network- and the EU level has led to alignment of policy-objectives and 
securing political and financial support. Management of the first networks followed a 
logic of management by objectives, pursued via Subgroups or Working groups. Manage-
ment of the EUnetHTA network became more complex, although the approach remained 
the same in the establishment of Work Packages pursuing the realisation of specific 
sub-objectives (e.g. development of tools, guidelines, Core Models, joint assessments). 
EUnetHTA has long been characterised to be a network of peers - HTA doers, scientists 
- and has been qualified in this research as a network of scientists managed by scientists.
 Till JA3, network coordination and the setup of a sustainable HTA network have been 
often considered as one objective. This has resulted in mixing two different manage-
ment approaches needed to reach what should be considered as two distinct objectives. 
The first, the establishment of a sustainable HTA cooperation framework responding to 
process management. The second, coordinating a project supporting the establishment 
of a sustainable framework on HTA cooperation, responding to project management. 
Mixing two approaches has not been effective in terms of goal attainment regarding 
the creation of a sustainable framework and uptake. The establishment of the EU HTA 
Network has permitted to make this differentiation by separating policy orientation form 
technical and scientific HTA activities. The EU HTA Network pursuing the establishment 
of a sustainable framework for HTA coordination (process management) and EUnetHTA 
focusing on the tools enabling the framework to operate (project management).
 Goal attainment of the HTA cooperation network has since the establishment of the EU 
HTA Network been divided between EU HTA network and EUnetHTA. To date, we cannot 
assess whether this will result in goal attainment of the establishment of a sustainable 
framework and uptake of joint work. The creation of the EU HTA Network resulted from 
the insertion of an article on HTA cooperation in the Cross-Border Health Care Directive. 
When drafting the article, confusion regarding the role of this network still existed, and 
EUnetHTA was often considered as the future sustainable network. The legal framework 
proposed by the Commission in its HTA Regulation should in principle allow for the 
establishment of a sustainable framework. However, the mandatory aspects regarding 
joint clinical assessments respond to a closed cooperation structure and stumble on 
resistance from Member States. A new legal framework could in principle have been 
designed in various ways and could have integrated mechanisms allowing for flexible 
approach in which various cooperation forms would be integrated including regional 
cooperation initiatives. To date, the Commission has opted for a rather classical approach 
in EU integration policies.
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8.3. Summary key FiNDiNgS
HTA cooperation in Europe has emanated from within the HTA arena, initially by the creation 
of informal networks, which could also be considered as epistemic communities. Through 
these networks, operating on the basis of soft governance steering mechanisms, diffusion of 
common values and understanding regarding HTA has taken place predominantly within the 
HTA arena. Salience for HTA cooperation has been found in the European Commission which 
has integrated this topic in EU high level expert networks turning HTA into a European policy 
issue. Although OMC has been envisaged at a certain stage to structure the cooperation 
efforts, European HTA cooperation has finally been developed by means of so-called Joint 
Actions, giving the European Commission the opportunity to develop from a funding institu-
tion in the early cooperation initiatives into a metagovernor of newly established European 
cooperation networks.
Soft governance has structured HTA cooperation within an EU framework by means of various 
forms of networking ranging from epistemic communities, high-level policy expert networks, 
to networks which could be qualified as governance networks. The development stages of 
the latter also refer to different governance steering mechanisms adopted in each, rang-
ing from participant-governed networks (Early cooperation initiatives), to lead-organisation 
networks (EUnetHTA) to network-administrative organisations (EU HTA Network). Although 
convergence of tools, methodologies and practices has taken place, no harmonisation of this 
has been observed in the EU Member States. Indeed, integration of commonly developed 
tools and methodologies into national HTA practices has not been generalised and has not 
been done in a harmonised manner. Decisions to do so remained fully at the discretion of 
HTA agencies. Production of joint HTAs, has been realised to some extent, however, no 
generalised nor harmonised use of those in the national decision-making processes has taken 
place.
Explanatory reasons related to governance aspects of the cooperation initiatives to explain 
the above, and as identified in this research, have pointed to the following factors: the net-
work composition (e.g. under representation of policymakers), stakeholder policy (informa-
tive rather than collaborative involvement, underrepresentation of stakeholders, stakeholder 
coordination policies), social interaction (e.g. network – ministries, network-network), and 
management approaches (e.g. project vs process management). These reasons complement 
elements identified in Commission and HTA networks’ studies regarding lack of uptake and 
lack of effectiveness in establishing sustainable network mechanism. The latter would point 
to qualitative, legal, technical, organisational, financial and timeliness factors.
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To overcome these barriers, the Commission has proposed to change the governance ap-
proach by submitting a Proposal for a Regulation on HTA cooperation, whereby an HTA 
coordination group would steer the overall work and sub-groups would deal with one of 
the four pillars of the proposal: Joint Clinical Assessments, Joint Scientific Consultations, 
Identifying emerging health technologies and voluntary cooperation in non-clinical domains. 
This mechanism would encompass mandatory elements of uptake related to joint clinical 
assessments of (some) medicines and medical devices. The choice for a Regulation has been 
motivated by an interpretation of the subsidiarity principle based on the fact that after more 
than 25 years of cooperation, no sustainable HTA cooperation framework has been estab-
lished and diversity of HTA approach still exists in EU Member States despite the cooperation 
outputs created by the networks, such as common tools, methodologies and Core Models 
of joint assessments.
Whilst reasons for the lack of goal attainment - regarding the establishment of a sustain-
able HTA cooperation framework and in particular uptake of joint work - underpinning the 
Commission proposal for a Regulation, are often sought for in external network aspects, this 
research demonstrates that part of the explanation can be found in the governance aspects 
of the cooperation initiatives. As such, the lack of goals attainment of the cooperation initia-
tives in terms of uptake and the creation of a sustainable network, lays not necessarily in the 
recourse to soft governance but rather in the manner of implementing it. In order words, 
lack of effectiveness of some of the HTA goal attainment processes is not necessarily a result 
of the lack of effectiveness of soft governance as such. Hence, adapting the soft governance 
approaches of HTA cooperation could be a means to overcome the other barriers identified 
by the networks and the European Commission, and listed above, without having to resort 
to hard governance legislative means.
Soft governance through social interaction seems to have played an important role in up-
take of joint work. There where this has been observed, learning processes, shared values 
and understandings, capacity-building and trust have been able to overcome barriers to 
national use of common HTA cooperation outputs. The level of (managerial) representation 
participating in the HTA networks, the size of the HTA agencies, and their country of origin 
play a role in the interaction and transmission of the results of HTA network and the national 
decision-making level.
Lack of active participation of the ministerial level as well as an inadequate stakeholder 
policy, based on informative rather than collaborative purposes has further contributed to 
the low level of uptake in the Member States. Moreover, in the case of HTA cooperation, 
process- and project management have for a long time been mixed, creating confusion as 
regard the networks’ raison d’être: developing tools and methodologies to be used in a 
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future sustainable framework or becoming the sustainable network. Both objectives requir-
ing a different management approach. The disentanglement of the objectives by creating the 
policy-orientated EU HTA Network alongside the EUnetHTA Joint Action was an attempt of 
the European Commission to resolve this problem. The Regulation proposal on HTA coopera-
tion, a manner of creating the sustainable cooperation mechanism within the EU framework. 
To date, no success has been recorded in either way.
The area in which cooperation has led to positive results in terms of effectiveness of soft 
governance regards the synergies created between the European regulatory framework and 
HTA in the field of Joint Scientific Advice. Presenting a less complex area of cooperation 
(advice on (pre-marketing) evidence generation versus nine assessment domains for a full 
core-HTA), the inclusive participatory stakeholder approach, and the presence of a shadow 
of hierarchy have been positive factors contributing to effectiveness of soft governance 
cooperation mechanisms in this field. Evidence generation throughout the full life cycle of a 
technology becomes however of increasing importance in many EU Member States seeking 
to develop solid methodological approaches, capable to answer the upcoming challenges 
in this area. The cooperation initiated in European settings could offer a unique chance to 
develop a common framework and thereby avoid further fragmentation of methodologies 
underpinning HTA in the EU.
8.4. policy recommeNDatioNS
The findings of this research could serve to inform policymaking in the field of HTA coopera-
tion but also in other areas where recourse to soft governance is made.
Many studies have underscored the need for cooperation in HTA considering the important 
disparities that exist in this area in Europe and the benefits it would offer to the health 
systems. In our examination of the various HTA networks which have pursued this idea, 
we have highlighted the challenges to achieve this goal in such a complex area as HTA. 
Indeed, the complexity stems not only from technical and methodological issues but also 
from political and policy ones as HTA finds itself on the crossroad of science and policy and 
in the midst of two regulatory processes: European market authorisation and national pricing 
and reimbursement. Recent research related to evidence requirements throughout the life 
cycle of a health technology, further underscore the need to develop European standards, 
acceptable to all. The new and costly developments of health technologies and the need to 
further develop research in fields such as rare diseases, personalised medicines or even the 
use of artificial intelligence in health care will even more require strong cooperation between 
regulators and HTA agencies in the EU.
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Cooperation does not necessarily involve loss of sovereignty or national competences but 
rather an exchange of experiences and best practices allowing for the establishment of new 
and improved standards available to all. Soft governance can be a mean to establish coopera-
tion initiatives in a safe environment for national policymakers, provided the latter actively 
cooperate in the process.
This research has underscored how, in sensitive areas such as health policy which refer to 
exclusive competences of EU Member States, soft governance processes should include 
hard policy-makers. A successful example of the latter can be found in the Bologna pro-
cess, structured on the basis of soft governance. The latter has led to the establishment of 
a European Higher Education Area uniting 48 countries in Europe building a common set of 
values and norm and leading to structural reforms such as adaptation of higher education 
system to make them more compatible and qualitative (e.g. adopting a common Bachelor – 
Master – PhD track) (Veiga and Amaral 2010; http://www.ehea.info/index.php).
Second, when establishing cooperation processes based on soft governance in sensitive 
policy areas, a clear stakeholder policy should be defined in an early stage of the 
process. We have underscored how stakeholder policy approaches are politically not neutral 
and will require social interaction processes to clarify position of all actors involved. No clear 
definition of the stakeholders’ role and expected inputs may jeopardise implementation of 
collaboration outputs. Although in some cases, stakeholder policy could be restricted to 
informative purposes, an inclusive participatory stakeholder approach would instil adherence 
of the stakeholder group and/or allow manifestation of barriers that should be overcome to 
guarantee successful policy implementation. Moreover, horizontal stakeholder coordination 
should be encouraged for creative problem-solving approaches to occur.
Third, in highly sensitive areas such as health policy and HTA cooperation, a European 
legislative framework should leave space for the development of flexible coop-
eration structures. At present, in a Union of 27 Member States, where the European 
integration objective loses ground and an increasing number of countries are governed by 
anti-EU policymakers, Europe needs to become creative in the cooperation approaches it 
proposes. Whereas the Community method can still be effective in many areas, convergence 
of practices in sensitive policy areas should respect the political will of Member States in 
strengthening integration policies or not.
In the case of HTA cooperation, where consensus exists on the benefits of cooperation, 
a one-size fits all approach does not federate Member States. The various consultation 
processes have highlighted how a flexible cooperation approach (including mandatory 
aspects of uptake) would appeal more to Member States. Such an integration policy 
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has already been implemented in policy areas such as border control (e.g. Schengen agree-
ments) and monetary integration (e.g. Eurozone). In HTA, a legislative framework offering 
flexibility to Member States could also offer the perspective of including intergovernmental 
cooperation initiatives (e.g. Visegrad + 2, Beneluxa) in a common EU cooperation framework 
in the long run. Should these continue to develop at their own pace, HTA agencies joining 
several of these initiatives would be exposed to potential overlap and conflicting interests. 
As these initiatives respond to different regulatory frameworks but could address similar 
issues, outcomes could again diverge. Integration on one level could lead to fragmentation 
on another level. Hence, in case of extensive membership overlap, coordination between 
regional organisations would become necessary.
Fourth, additional evidence generation throughout the life cycle of a product is a 
new area with potential for further development in the years to come. Cooperation in this 
area has already been initiated and builds further upon the synergies created between the 
HTA and European regulatory processes. However, this area comprises many methodological 
challenges to resolve and early cooperation would therefore be highly recommended 
so as to streamline quality requirements as well as methodological and legal ap-
proaches, rather than letting disparities develop in areas such as Real World Evidence 
and conditional reimbursements. A soft governance approach responding to some key-
aspects of effectiveness in network governance should be observed.
Fifth, HTA is a highly specialised field requiring specific expertise often given in an academic 
environment and further developed within HTA agencies. Initial training given to future 
HTA scientists is enshrined in the domestic HTA approaches in terms of quality requirements 
and methodological implications of those. Although in the data collection of this research, 
attention has been given to the collection of potential cooperation in HTA education, no 
significant initiatives have been developed by the HTA networks in the field of academic 
cooperation. However, if new collaborative approaches could be developed in HTA, 
transmission of those should also take place in the initial academic training of HTA 
scientists.
Finally, HTA cooperation is based on policy and scientific coordination of activities taking 
place on multiple levels and with multiple actors. Synergies have been created in the HTA 
arena bringing about consensus on HTA tools, methodologies and practices between a 
certain amount of HTA agencies. This consensus is however not shared with all HTA actors 
in the HTA arena as disagreements still exists. Synergies between the European regulatory 
and HTA arena have also been developed and could serve as a basis for further work on 
evidence generation including issues such as Real-World Data and post-marketing addi-
tional evidence generation. However, to pursue the cooperation efforts and increase their 
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effectiveness in terms of goal attainment, synergies at other levels should be developed. In 
particular between the HTA arena and Member States’ high-level policy-making level (e.g. 
Ministries of health, Ministries of social security). Moreover, the dual economic and public 
health profile of health technologies leads to contrasting and sometimes conflicting policy-
making approaches towards HTA. For a consistent policy of HTA cooperation on a European 
level, synergies between Directorate Generals of the European Commission would be 
highly recommended.
8.5. reSearch coNtriButioNS
This research has proceeded to a systematic examination of the European cooperation 
process in HTA from an EU governance perspective. It has identified factors impacting ef-
fectiveness of soft governance implemented in European HTA networks aiming to establish 
a sustainable HTA cooperation framework within the EU. As, to our knowledge, no other 
study has examined European HTA cooperation in the light of soft governance within the EU 
framework, the thesis has filled this research gap.
Moreover, analysing soft governance in HTA cooperation through the prism of network 
analysis has proven valuable in highlighting the practical impacts of this governance mode 
in the area. The research framework established by cross-checking different strands of 
academic research regarding network governance has permitted to identify the typology 
of the different HTA networks as well as factors favouring or hindering effectiveness of the 
networks operating through soft governance mechanisms. Amongst the factors included in 
the research framework and affecting goal attainment, social interaction has been identified 
as playing a particular role in the HTA networks. Moreover, It has underscored how effective-
ness of soft governance does not only depend on the instruments used but also on the 
manner in which they are implemented.
Hence, the network analysis based on the research framework has provided insight in soft 
governance mechanisms that contribute (or not) to convergence of practices in the field of 
HTA cooperation and has underscored the circumstances in which this can (or not) occur. 
The conclusions drawn with regard to European HTA cooperation can also give insight in the 
effectiveness of soft governance in other policy fields falling under exclusive Member States’ 
competences and in which some degree of convergence is sought. Moreover, networking is 
often used in the EU context and this research has given insight in how the Commission can 
develop and act as metagovernor in some cases. It also demonstrates how the EU can use 
soft governance as a strategic instrument to pursue hard regulation objectives.
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Organising the data collected by using the five stages of the policy cycle, has operated posi-
tively and allowed to break up a complex process into smaller stages, easier to analyse and 
compare amongst each other. The policy cycle also made possible the systematic comparison 
of networks operating in different periods of time as well as the systematic comparison of 
policy developments between the EU level and the HTA arena. This analysis has highlighted 
how both levels mutually influenced each other in the elaboration of specific policy fields, 
such as, HTA and EU health policy, through networking at multiple levels
Finally, this thesis has given a unique outline of the history of HTA cooperation in Europe 
since it originated. It has highlighted its connectivity with EU health policy by giving a parallel 
description of the developments in both arenas and underscoring how they mutually influ-
enced each other. This account furthermore illustrates the evolution of a new policy area in 
the EU and has outlines the development path of new legislative tools within an EU setting.
8.6. reSearch limitatioNS & poteNtial New reSearch 
aveNueS
The limitations of this research reside first in the low number of respondents on a ministe-
rial level. Although contacts have been made, the ongoing debate on the HTA Regulation 
proposal at time of the field work, made participation for ministerial representatives harder 
to accept. Although, information has been collected via HTA arena representatives having 
first-hand experience with the ministerial level, the low respondence rate of some key actors 
leads to the fact that some positions are not sufficiently reflected in the research. An example 
hereof is this issue of uptake, where positions have been expressed by the HTA arena and the 
European Commission. The opinions regarding uptake reflecting the ministerial level have 
not been integrated in this research. This limitation does however reflect the low involvement 
of this important policy actor in the overall cooperation process.
Exploring Governance of European HTA cooperation at a time where the European Commis-
sion decided to propose a Regulation on HTA cooperation made it more difficult to take the 
necessary distance of what became a hot topic in European health policy. Besides influencing 
the respondence rate of interviewees, the debate also influenced the content of the personal 
interviews. Whilst in some cases, respondents became very cautious in sharing their experi-
ences – or even refused taking part in it - , in most cases the proposal led to a stronger 
positioning of actors in the field, eager to share their experiences, thoughts and opinions 
about the cooperation efforts.
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By adopting a holistic approach of the network activities, some issues have not been looked 
at into more depth. The topic of uptake of Joint Scientific Advice could be cited as examples 
hereof and were initially considered as case-studies for the thesis. Ultimately the choice has 
been made to integrate these as activities of the networks, as both issues could be a thesis 
topic on a standalone basis and are subject for further research.
Finally, the thesis has restricted its focus on European cooperation initiatives and has not 
integrated in its analyses similar experiences taking place in other places worldwide. Conver-
gence of HTA approaches in Canada could be cited as an example hereof. As each of these 
situations take place in particular policy environments, only partially comparable to the EU 
framework, we have decided to keep the focus exclusively on Europe. However, it would 
have been interesting to make a comparable analysis of similar initiatives elsewhere. This too, 
would be subject for further research.
Similarly, the research has not given attention to the impact of the cooperation efforts in 
countries where HTA is organised on a regional/local basis and having more than one agency 
participating in any of the networks. Further research as to how the European cooperation 
initiatives would impact national approaches to HTA could be of interest.
Finally, as mentioned under the policy recommendation, no specific attention has been given 
to academic collaboration on HTA. As outlined above, initial training of HTA doers is of high 
importance in the methodological approach one will take on HTA. Many issues identified 
as hurdles to convergence of HTA approach are related to methodological approaches on 
which quality qualifications are made and which prohibit some players to put their trust in 
collaborative HTA assessments. Further research in academic approaches and the link to 
domestic policymaking would thus be of outmost interest for European HTA cooperation.
8.7. coNcluDiNg remarkS
Soft governance applied in EU policy often triggers the question whether it serves European 
integration or on the contrary restrains it. The conclusions of this research indicate that 
no clear-cut answer can be given and arguments can be found to comfort both positions. 
What this thesis does display is that soft governance can be used as a strategic instrument 
to pursue either goal. In the case of HTA cooperation, the European Commission has used 
soft governance as an instrument to prepare the ground for the convergence of practices 
by means of hard regulation. Some EU Member States used soft governance to benefit 
from external expertise and resources while remaining in control of national policy-making 
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processes, refusing convergence at a European level. With the HTA Regulation proposal lay-
ing on the table, the denouement of the process is still open.
Soft governance in EU policy making is often implemented within a context of integration 
struggles. The outcome will mostly depend on the way soft governance will be operation-
alised. The arsenal of soft governance instruments does indeed contain some powerful 
instruments favouring integration strategies. If used to pursue the convergence of practices, 
the challenge will lay in the choice and handling of those instruments. As they are ‘soft’, no 
handbook or rule-set exists to guide the users. Impact of soft governance will largely depend 
on interpersonal skills, social competences, governance, management and communication 
abilities of the operators to translate expertise into policy. Presence of policy entrepreneurs is 
paramount to create political salience for the issue, bringing about the convergence of the 
politics and policy streams and rendering effective policy-making achievable.
The belief that soft and hard governance are mutually exclusive often implicitly underpins 
the debate regarding the convergence capacity of soft governance. Dichotomy between soft 
and hard governance is found in their implementation capacity, highlighting the compli-
ance challenges related to soft governance (e.g. Citi and Rhodes 2007). At first sight, the 
case of European HTA cooperation would corroborate these assertions. Similarly, need for 
a shadow of hierarchy to enhance effectiveness of soft governance - herewith signifying its 
implementation limitations - (Héritier and Rhodes 2011) is also substantiated in our research. 
The junction between the two modes will often only be found in soft governance being a 
strategy to prepare hard regulation and subsequent harmonisation (e.g. Kröger 2009). In the 
case of HTA cooperation this too seems indeed to be verified.
The network analysis we have made in the case of HTA cooperation points however to deeper 
ties between the two governance modes and opens new reflexion paths as to the place of 
soft governance in EU integration policies. The limitations of soft governance found in our 
research emerge as a consequence of the absence of adequate soft governance implementa-
tion rather than inherent weaknesses of soft governance modes. Instead of opposing both 
modes or considering one mainly as subordinated to another in terms of integration capacity, 
the case of HTA cooperation displays how both governance approaches can – and maybe 
should – be complementary in health policy and could be implemented side by side. Soft 
governance creates integration capacity on the one hand by consensus building, essential for 
hard regulation to be adopted. On the other hand, by offering flexibility and gradualism in 
the convergence of policies, it potentially also allows for the development of more innovative 
approaches of integration.
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Soft and hard governance are also often synonyms for the division of competences between 
the EU and its Member States. Combining both governance approaches requires however 
that one steps away from the traditional disputes about competences division. Competence 
division stands at the core of EU integration processes and should retain a central place. 
Nevertheless, integration processes are not static and respond to political, economic, and 
societal challenges. Consequently, introducing elasticity in competences distribution would 
be highly recommended. Soft governance can create opportunities and provide frameworks 
whereby actors elaborate common policies in areas where a joint approach would serve 
common interests, while remaining in charge of their national policy.
To date, EU integration debates in health policy remain enshrined in Member States’ refusal 
to converge part of their policies at an EU level. Keeping full responsibility for the organisa-
tion of their health systems is considered a question of national interests, comprising besides 
health care also financial and economic concerns. Regretfully, discussions consequently 
tend to be focused on legalistic competence issues rather than on health care interests of 
European citizens. Economic considerations often prevail over health care concerns. Health 
becomes the subject of national trade-offs between industry, payers and patients, health care 
providers often only participating on the margin.
At times where cross-border health threats reveal shortcomings of national responses, where 
research, development, production and marketing of health technologies are globalised, 
where all players seek to optimise their economic and financial interests, individual EU 
Member States’ responses may however not be sufficient to address the issues at stake and 
secure the best interests of their citizens. New challenges may require new responses. Reas-
sessing the scope of EU competences in health policy should therefore not be fully dismissed 
and new opportunities for collaboration should be envisaged within innovative frameworks. 
Legal certainty would facilitate the choice of governance approaches and instil transparency 
in governors’ intentions. Flexibility coupled to commitment should be guiding the roadmap 
towards convergence in those areas where the interests of European citizens would be better 
served by enhanced European cooperation.
Soft governance is a powerful tool to support public policy dedicated to serve public inter-
est. It presents many features allowing for the convergence of positions whilst preserving 
national interests. It should however be ‘handled with care’ so that it could express itself in 
all its dimensions and bring the public interest back into the debate. Governance networks 
can serve as a medium for interest mediation, shift actors’ beliefs and values as well as their 
positioning. Consensus building and common policy development are feasible objectives, 
provided all stakeholders participate in the process. At a time where the EU integration 
process is under strain by multiple challenges, soft governance would deserve renewed at-
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tention as it could provide the flexibility and gradualism needed in convergence strategies. 
This would require, however, that it be granted a different status and functionality within the 
EU governance modes, whereby it would be conceived as a real alternative to classic modes 
of integration rather than ‘sub-ordinated’ to them and essentially utilised to pave the way for 
such long established, but perhaps no longer uniformly applicable models.
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aNNex 1 - liSt memBerS euNethta
EUnetHTA Project202
EU Member States:
1. Main Partner
 DACEHTA – Danish Centre for Evaluation and HTA, Denmark
Associated Partner (AP) & Collaborating Partners (CP)203
2. Ludwig Boltzman Institute of Health Technology Assessment, LBI@HTA (former ITA) 
(AP), Austria
3. Gesundheit Österreich GmbH, Austrian Health Institute (CP) , Austria
4. Hauptverband der Österreichischen Sozialversicherungsträger (CP), Austria
5. KCE - Belgian Health Care Knowledge Centre (AP), Belgium
6. Ministry of Health Cyprus (AP), Cyprus
7. CAST - Center for Anvendt Sundhedstjenesteforskning og Teknologivurdering, Univer-
sity of Southern Denmark, Center for Applied Research and Technology Assessment 
(AP), Denmark
8. DSI- Danish Institute for Health Services Research (AP), Denmark
9. HTA and Health Service Research, Center of Public Health (CP), Denmark
10. University of Tartu, Department of Public Health (AP), Estonia
11. FinOHTA - Finnish Office for HTA (AP), Finland
12. HAS - Haute Autorité de santé / French National Authority for Health (AP), France
13. CEDIT - Commitee for Evaluation and Diffusion of Innovative Technologies, Direction de 
la Politique Médicale (CEDIT) (CP), France
14. DAHTA@DIMDI- German Agency for HTA at the German Institute for Medical Docu-
mentation and Information (AP), Germany
15. University of Lübeck, Institute for Social Medicine (AP), Germany
16. Technische Universitaet Berlin (AP), Germany
17. University of Bremen, Interdisciplinary Centre for HTA (AP), Germany
18. German HTA Association (CP), Germany
19. IQWIG - Institute for Quality and Efficiency in Health Care (CP), Germany
202 Source: Lund Håheim L, Imaz I, Laubli M, Gasparetto T, GonzálezEnríquez J, Trofimovs I, Dahlgren 
H, Liberati A, Berti E, Mørland B. (2008). Report on the internal evaluation of European network 
for Health Technology Assessment – EUnetHTA: 48-51.
203 AP – Associated Partner, financially and technically contributing to the project, Member of the 
project’s Steering Committee; CP- Collaborating Partner, advisory and scientific excellence role.
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20. Public Health Genomics European Network (PHGEN), German Center for Public Health 
Genomics (DZPHG) (CP), Germany
21. HunHTA - Unit of Health Economics and Health Technology Assessment (AP), Hungary
22. HIQA - Health Information and Quality Authority (AP), Ireland
23. ASSR Regione Emilia-Romagna - Agenzia Sanitaria e Sociale Regione Emilia-Romagna 
(AP), Italy
24. Agenas.- Agenzia Nazionale per i Servizi Sanitari Regionali (CP from 2007), Italy
25. Università Cattolica del Sacro Cuore, Policlinico universitario “A. Gemelli”, Health 
Technology Assessment Unit and Laboratory of Health Economics (Institute of Hygiene) 
(AP), Italy
26. Regione Veneto (AP), Italy
27. VSMTVA - Health Statistics and Medical Technology State Agency (AP), Latvia
28. Ministry of Health of the Republic of Lithuania (AP), Lithuania
29. Agency for HTA in Poland, AHTAPol (CP), Poland
30. CEESTAHC - Central and Eastern European Society for Technology Assessment in Health 
Care (CP), Poland
31. Institute of Molecular Medicine (CP), Portugal
32. National School of Public Health and Health Services Management (CP from 2007), 
Romania
33. Institute of Public Health of the Republic of Slovenia (AP), Slovenia
34. AETS - Agencia de Evaluación de Tecnologias Sanitarias (AP), Spain
35. AETSA - Andalusian Agency for Health Technology Assessment (AP), Spain
36. CAHTA - Catalan Agency for Health Technology Assessment and Research (AP), Spain
37. Galician Agency for Health Technology Assessment (AP), Spain
38. OSTEBA - Basque Office for Health Technology Assessment (AP), Spain
39. Servicio Canario de la Salud (AP), Spain
40. UETS - Unidad de Evaluación de Tecnologías Sanitarias, Agencia Laín Entralgo (AP), 
Spain
41. SBU - Swedish Council on Technology Assessment in Health Care (AP), Sweden
42. CVZ - College voor zorgverzekeringen (AP), The Netherlands
43. ZonMw (AP), The Netherlands
44. NCCHTA - National Coordinating Centre for HTA (AP), The United Kingdom
45. CRD - Centre for Reviews and Dissemination, University of York (CP), The United 
Kingdom
46. NICE - National Institute for Health and Clinical Excellence (CP from 2007), The United 
Kingdom
EEA Countries:
47. Directorate of Health (CP), Iceland
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48. NOKC - Norwegian Knowledge Centre for the Health Services (AP), Norway
Other countries
49. SNHTA - Swiss Network for Health Technology Assessment (CP), Switzerland
50. Ministry of Health (CP), Serbia
51. MSAC - Medical Services Advisory Committee (CP), Australia
52. CADTH (former CCOHTA) - Canadian Agency for Drugs and Technologies in Health 
(CP), Canada
53. ICTAHC - Israeli Center for Technology Assessment in Health Care (CP), Israel
54. AHRQ - Agency for Healthcare Research and Quality, Center for Outcomes & Evidence 
(CP), USA
55. CMTP - Center for Medical Technology Policy (CP from 2007), USA
International organisations:
56. Cochrane Collaboration - The Cochrane Collaboration Secretariat (AP)
57. Council of Europe - Directorate General III - SOCIAL COHESION (CP)
58. European Observatory on Health Systems and Policies (CP)
59. EuroScan - European Information Network on New and Changing Health Technologies 
(CP)
60. G-I-N Executive - Guidelines International Network (CP)
61. HTAi - HTAi Secretariat (CP)
62. INAHTA - INAHTA Secretariat (CP)
63. OECD - Organisation for Economic Cooperation and Development (CP)
64. WHO - Health Evidence Network (HEN) (CP)
EUnetHTA Joint Action 1204
1. Main Beneficiary:
 Danish Health and Medicines Authority - DHMA 
Associated Partners:
2. Agencja Oceny Technologii Medycznych - Agency for Health Technology Assessment in 
Poland, Poland
3. Agenzia Italiana del Farmaco (Italian Medicines Agency), Italy
4. Agenzia Nazionale Per i Servizi Sanitari Regionali, Italy
5. Belgian Health Care Knowledge Centre/Federaal Kenniscentrum voor de Gezond-
heidszorg, Belgium
204 http://ec.europa.eu/chafea/projects/database.html?prjno=20092302
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6. Centre for Applied Health Services Research and Technology Assessment, University of 
Southern Denmark, Denmark
7. College voor Zorgverzekeringen, Netherlands
8. Deutsches Institut für Medizinische Dokumentation und Information, Germany
9. Gesundheit Österreich GmbH / Bundesinstitut für Qualität im Gesundheitswesen, Aus-
tria
10. Hauptverband der Österreichischen Sozialversicherungsträger // Evidenzbasierte 
Wirtschaftliche Gesundheitsversorgung EWG (Evidence Based Economic Health 
Care), Austria
11. Haute Autorité de Santé, France
12. Health Information and Quality Authority, Ireland
13. Institute for Healthcare Quality Improvement and Hospital Engineering (until 
30/04/2011), Hungary
14. Institute of Public Health of the Republic of Slovenia - NIPH, Slovenia
15. Instituto De Salud Carlos III, Spain
16. Ludwig Boltzmann Gesellschaft GmbH - Ludwig Boltzmann Institut für Health Technol-
ogy Assessment, Austria
17. Medicines Pricing and Reimbursement Agency (until 31/10/2011), Latvia
18. Ministry of Health, the Elderly and Community Care - MHEC, Malta
19. Ministry of Health - MOH-CZ, Czech Republic
20. National Authority of Medicines and Health Products, Portugal
21. National Center of Public Health Protection, Bulgaria
22. National Institute for Health and Clinical Excellence, United Kingdom
23. National Institute for Health and Welfare, Finland
24. National Institute for Strategic Health Research (until 30/04/2011), Hungary
25. National School of Public Health, Greece
26. State Health Care Accreditation Agency, Lithuania
27. Stiftung für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Foundation for Qual-
ity and Efficiency in Health Care, Germany
28. Swedish Council on Technology Assessment in Health Care, Sweden
29. The Norwegian Knowledge Centre for the Health Services, Norway
30. University of Southampton (NIHR Evaluation, Trials and Studies Coordinating Centre), 
United Kingdom
31. University of Tartu, Estonia
32. Region Del Veneto, Italy
33. Ministry of Health and Social Policy, Spain
34. National Institute for Quality and Organizational development Health - GYEMSZI (from 
01/05/2011), Hungary
35. National Health Service - NHS (from 01/11/2011), Latvia
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EUnetHTA Joint Action 2205
1. Main Beneficiary:
 Danish Health and Medecines Authority, Denmark
Associated Partners:
2. Agencja Oceny Technologii Medycznych – AHTAPOL, Poland
3. Agencija Za Kvalitetu i Akreditaciju u Zdrastvu AQAHC, Croatia
4. Agenzia Nationale per Servizi Sanitari Regionale AGENAS, Italy
5. Agenzia Sanitaria e Sociale Regionale * Regione Emilia-Romagna - ASSR RER, Italy
6. Centre Fédéral d’Expertise des Soins de Santé – KCE, Belgium
7. College voor Zorgverzekeringen CVZ, Netherlands
8. Deutsches Institut für Medizinische Dokumentation und Information DIMDI, Germany
9. Lääkealan Turvallisuusja Kehittmämiskeskus FIMEA, Finland
10. Gesundheit Österreich GmbH – GÖG, Austria
11. Haute Autorité de Santé HAS, France
12. Health Information and Quality Authority HIQA, Ireland
13. Department of Health Technology Assessment - HSR/DHTA, Denmark
14. Inštitut Za Ekonomska Raziskovanja IER, Slovenia
15. Instituto de Salud Carlos III – ISCIII, Spain
16. Agenzia Italiana Farmaco – AIFA, Italy
17. Ludwig Boltzmann Gesellschaft GmbH LBGG, Austria
18. Hauptverband der Österreichischen Socialversicherungsträger – HVB, Austria
19. Ministry for Health, the Elderly and Community Care – MHEC, Malta
20. Ministerstvo Zsravotnictví eské Republiky MZ, Czech Republic
21. Ministry of Health of Cyprus – MOH, Cyprus
22. Autoriadade Nacional do Medicamento e Produtos de Saude I.P. INFARMED, Portugal
23. National Center of Public Health and Analyses NCPHP, Bulgaria
24. National Institute for Health and Clinical Excellence – NICE, United Kingdom
25. Terveyden Ja Hyvinvoinnin Laitos THL, Finland
26. Gyógyszerészeti és Egészségügyi Minség és Szervezetfejlesztési Intézet GYEMSZI, Hun-
gary
27. Inštitut Za Varovanje Zdravja – NIPH, Slovenia
28. National School of Public Health Special Research Account – NSPH, Greece
29. National School of Public Health, Management and Professional Development in Health 
Bucharest NSPHMPDHB, Romania
30. University of Southampton NETSCC, United Kingdom
31. Regione del Veneto REGVEN, Italy
205 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20112301/summary
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32. Nadácia ZRAK SLOVAHTA (until 13/05/2013), Slovakia
33. State Health Care Accreditation Agency under the Ministry of Health of Lithuania 
VASPVT, Lithuania
34. Stiftung für Qualität und Wirtschaftlichkeit im Gesundheitswesen IQWIG, Germany
35. Statens Beredning för Medicinsk Utvärdering SBU, Sweden
36. Nacionlais Veselbas Dienests – NHS, Latvia
37. Nasjonalt Kunnskapssenter for Helsetjenesten NOKC, Norway
38. Tartu Ülikool TARTU, Estonia
39. Ministry of Health of the Slovak Republic, Slovakia
EUnetHTA Joint Action 3206
1. Main Beneficiary
 ZIN - National Health Care Institute, Netherlands
Partner Organisations and Institutions
2. ACSS IP - Administração Central do Sistema de Saúde, I.P., Portugal
3. AEMPS - Agencia Española de Medicamentos y Productos Sanitarios, Spain
4. AETSA - Andalusian HTA Agency, Spain
5. AETS-ISCIII - The Instituto De Salud Carlos III, Spain
6. Agenas - National Agency for Regional Health Services, Italy
7. AIFA - Italian Medicines Agency, Italy
8. AOTMiT - Agency for Health Technology Assessment and Tariff System, Poland
9. AQuAS - Agency for Health Quality and Assessment of Catalonia, Spain
10. AVALIA FNS - Fundacion Profesor Novoa Santos, Spain
11. AVALIA-T - Galician Agency for HTA, Spain
12. AWTTC - All Wales Therapeutics and Toxicology Centre, United Kingdom
13. BIOEF - Basque Foundation for Health Innovation and Research, Spain
14. CHIF - Croatian Health Insurance Fund, Croatia
15. CIPH - Croatian Institute of Public Health, Croatia
16. CRUF/AOUIVR - Centro Regionale Unico sul Farmaca del Veneta, Italy
17. DEFACTUM (formerly CFK) – DEFACTUM, Denmark
18. DGFDM IT - Sede del Ministro – Ministero della salute, Italy
19. DGFPS MSPSI - Directorate General for Pharmacy and Health Care Products, Spain
20. DIMDI - German Institute for Medical Documentation and Information, Germany
21. DPA/MoH Malta - Directorate for Pharmaceutical Affairs, Malta
22. EKAPTY SA - National Evaluation Center of Quality and Technology in S.A.- EKAPTY, 
Greece
206 https://eunethta.eu/about-eunethta/eunethtanetwork/.
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23. EKAPTY-NKUA - National and Kapodistrian University of Athens, Greece
24. EOF - National Organization for Medicines, Greece
25. EOPYY - National Organisation for Healthcare Provision, Greece
26. EUR - Erasmus Universiteit Rotterdam, Netherlands
27. FIMEA - Finnish Medicines Agency, Finland
28. FPS - Fundación Pública Andaluza Progreso y Salud, Spain
29. Funcanis - Fundación Canaria de Investigación Sanitaria, Spain
30. GBA - Gemeinsamer Bundesausschuss, Germany
31. GOG - Gesundheit Österreich GmbH/Geschäftsbereich, Austria
32. HAS - French National Authority for Health (Haute Autorité de Santé), France
33. Hdir - Norwegian Directorate of Health, Norway
34. HI - The Institute of Hygiene, Lithuania
35. HIQA - Health Information and Quality Authority, Ireland
36. HIS - Healthcare Improvement Scotland, United Kingdom
37. HVB - Hauptverband der Österreichischen Sozialversicherungsträger (Association of 
Austrian Social Insurance Institutions), Austria
38. IFET - Institute of Pharmaceutical Research and Technology, Greece
39. INFARMED - National Authority of Medicines and Health Products, Portugal
40. IPH - Scientific Institute of Public Health, Belgium
41. IQWIG - Institute for Quality and Efficiency in Health Care, Germany
42. JAZMP - Public Agency of the Republic of Slovenia for Medicinal Products and Medical 
Devices, Slovenia
43. KCE - Belgian Health Care Knowledge Centre, Belgium
44. LBI-HTA - Ludwig Boltzmann Institute for Health Technology Assessment, Austria
45. MIZ - Ministry of Health of the Republic of Croatia, Croatia
46. MoH Cyprus - Ministry of Health of Cyprus, Cyprus
47. MoH Czech - Ministry of Health of the Czech Republic, Czech Republic
48. MoH Slovak Republic - Ministry of Health of the Slovak Republic, Slovakia
49. MoH Slovenia - Ministry of Health of the Republic of Slovenia, Slovenia
50. MoH Ukraine - HTA Department of SEC of Ministry of Health of Ukraine, Ukraine
51. MPA - Medical Products Agency, Sweden
52. NCPE - National Centre for Pharmacoeconomics, St. James Hospital, Ireland
53. NCPHA - National Center of Public Health and Analyses, Bulgaria
54. NICE - National Institute for Health and Care Excellence, United Kingdom
55. NIJZ - National institute of Public Health (NIJZ), Slovenia
56. NIPHB - Institutu National De Sanatate Publica (INSP), Romania
57. NIPHNO (formerly NOKC) - The Norwegian Institute of Public Health, Norway
58. NIPN - National Institute of Pharmacy and Nutrition, Greece
59. NOMA - Norwegian Medicines Agency, Norway
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60. NSPHMPDB - National School of Public Health, Management and Professional Develop-
ment, Romania
61. NVD - National Health Service, Latvia
62. OCSC - Onassis Cardiac Surgery Centre, Greece
63. Osteba - Basque Office for Health Technology Assessment- Ministry for Health, Spain
64. RER - Regione Emilia-Romagna, Italy
65. RIZIV-INAMI - Rijksinstituut voor Ziekte- en Invaliditeitsverzekering, Belgium
66. SBU - Swedish Agency for Health Technology Assessment and Assessment of Social 
Services, Sweden
67. SESCS - Evaluation AND Planning Unit – Directorate of the Canary Islands Health Ser-
vice, Spain
68. SNHTA - Swiss Network for HTA, Switzerland
69. SU - Health Services Management Training Center, Greece
70. SUKL - State Institute for Drug Control, Czech Republic
71. THL - National Institute for Health and Welfare, Finland
72. TLV - Dental and Pharmaceutical Benefits Agency, Sweden
73. UBB - Babes-bolayi University, Cluj School of Public Health, Romania
74. UCSC GEMELLI - University Hospital A. Gemelli, Italy
75. UMIT - University for Health Sciences, Medical Informatics and Technology, Austria
76. UniBA FOF - Comenius University in Bratislava, Slovakia
77. UTA - Institute of Family Medicine and Public Health, Estonia
78. UU - Utrecht University, Netherlands
79. UVTA/AOP - Unita di Valutazione Technology Assessment, Italy
80. VASPVT - State Health Care Accreditation Agency, Lithuania
81. Veneto/CRUF - Regione Del Veneto – Area Sanita E’ Sociale, Italy
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Interview 1  Representative of EUnetHTA/ZIN, Zorginstituut Nederland, The Netherlands
Interview 2  Former Representative of EUR-ASSESS, HTA-Europe, ECHTA-ECHAI, The 
Netherlands/US
Interview 3  Former Representative of the European Commission, DG Sanco, Belgium
Interview 4  Representatives of EUnetHTA (project, JA1, JA2), Danish Health and Medicines 
Authority, Denmark
Interview 5  Former consultant European Commission, the Netherlands
Interview 6  Former Representative of CAHTA, Agency for Health Quality and Assessment 
of Catalonia, Spain
Interview 7  Representative of EUnetHTA (project, JA1, JA2), Denmark
Interview 8  Representatives of European Commission, DG Santé, Belgium
Interview 9  Representatives of European Commission DG Santé – HTA team, Belgium
Interview 10  Former Representative of EUR-ASSESS, HTA-Europe, ECHTA-ECHAI, The 
Netherlands/US
Interview 11  Representative of AAZ, Agency for Quality and Accreditation in Health Care 
and Social Welfare, Croatia
Interview 12  Representatives of Eurordis, France
Interview 13  Representative of AIM, International Association of Mutual Benefit Societies, 
Belgium
Interview 14  Representative of AQuAS, Agència de Qualitat i Avaluació Sanitàries de Cata-
lunya, Spain
Interview 15  Representative of EUnetHTA (JA3), The Netherlands
Interview 16  Representative of Sanofi-Genzyme, The Netherlands
Interview 17  Representatives of the Dutch Ministry of Health- Ministerie van Volksgewond-
heid, Welzijn en Sport, The Netherlands
Interview 18  Representative of THL, Terveyden Ja Hyvinvoinnin Laitos – Finland
Interview 19  Representative of HIQA, Health Information and Quality Authority – Ireland
Interview 20  Former Representative of KCE, Belgian Health Care Knowledge Centre – Bel-
gium
Interview 21  Representative of CPME, Standing Committee of European Doctors, Belgium
Interview 22  Representative of IQWiG, Stiftung für Qualität und Wirtschaftlichkeit im 
Gesundheitswesen, Germany
Interview 23  Representative of Medtech Europe, Belgium
Interview 24  Representative of EFPIA, Belgium
Interview 25  Representative of UEMO, European Union of General Practitioners, Belgium
Interview 26  Representative of synergy group/AIFA, Agenzia Italiana Farmaco – Italy
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Interview 27  Representative of NICE, National Institute for Health and Clinical Excellence – 
United Kingdom
Interview 28  Representative of HSMTC, , Health Services Management Training Center, 
Semmelweis University – Hungary
Interview 29  Representative of HAS, Haute Autorité de Santé - France
Interview 30  Representative of AOMiT, Agency for Health Technology Assessment and 
Tariff System, Poland
Written contribution 1  Representative of Ministry of Health of the Slovak Republic – 
Slovakia
Written contribution 2  Representative of LBI-HTA - Austria
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Summary
Since its onset, Health Technology Assessment in Europe is characterised by the presence of 
multiple HTA bodies operating in different domestic health policy-systems based on divergent 
underlying values and decision-making processes. To address these diversities, promote ef-
ficiency and enhance input of HTA in national regulatory processes, HTA bodies have sought 
to cooperate and reach some form of convergence of assessment practices. The start of 
these cooperation initiatives would coincide with the launch of an EU public health policy. 
Gradually both processes would come together and mutually reinforce each other. Since 
1994, several European HTA networks have been created seeking to establish a sustainable 
framework for HTA cooperation in Europe. In 2018, the European Commission has proposed 
a Regulation on HTA cooperation which adoption process is, to date, ongoing.
In this thesis HTA cooperation has been examined in relation to EU governance. EU compe-
tences in the field of HTA are restricted to support-lending and coordination policies. The 
research project has therefore examined the role of soft governance in structuring HTA coop-
eration within the framework of the European Union. Yet, as HTA aims to give input in do-
mestic regulatory processes, it needs to respond to (hard) regulatory policy requirements. The 
question thus arises to what extent cooperation and convergence of practices on a European 
level can be structured through soft governance. This question is the overarching research 
question of the thesis. Various national HTA regulations may indeed hinder the establishment 
and implementation of new common European HTA agreements. To delimitate the scope of 
this research question, three sub-research questions have been formulated, focussing each 
on the role of soft governance in a specific area of HTA cooperation: 1) convergence and 
harmonisation of HTA tools, methodologies and practices; 2) uptake of joint work; and 3) 
synergies between the HTA arena and the EU regulatory processes of pharmaceuticals.
The conjunction between EU health policy and HTA cooperation is situated in networks. 
European HTA cooperation has mainly taken place through networking. Networks, by their 
intrinsic characteristics, offer favourable conditions for the implementation of soft gover-
nance modes and instruments. Moreover, networking responds to the new governance 
approach of the EU adopted at the turn of the millennium. The role of soft governance 
in European HTA cooperation has therefore been examined through the prism of network 
analysis. The research has been structured according to qualitative research methods (e.g. 
semi-structured personal interviews with key-actors in the field, academic and grey literature, 
personal observations in international conferences) and based on a research framework 
constructed according to the concepts of governance networks, network governance, and 
metagovernance.
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The thesis is composed of three parts. Part A establishes the theoretical and research frame-
work. Finding itself at the intersection of two different academic fields – EU governance and 
health policy – the research topic first needs to be contextualised. Therefore, the thesis first 
addresses how HTA originated and how HTA cooperation relates to national and European 
regulatory processes (e.g. market authorisation and pricing and reimbursement decisions) 
and places it within the wider EU health policy and governance architecture. Attention is 
given here to the allocation of competencies, the subsidiarity principle and the implementa-
tion of soft governance through the so-called New Modes of Governance (NMG) developed 
since 2001 in the EU governance architecture. As networking is one of the approaches used 
by the EU to implement NMG, this part further develops how networks relate to national and 
European governance and policy-making approaches and can be considered as an adequate 
forum to implement soft governance. This part concludes with the setup of a research frame-
work established by using input from different academic schools (e.g. political science, policy 
analysis, and organisational studies) and intended to examine the role of soft governance in 
European HTA cooperation by means of network analysis.
Part B outlines the findings of the empirical research on European HTA cooperation. It is 
structured according to three distinct development stages of HTA cooperation in Europe. The 
first period is situated from 1992 to 2001 and relates to establishment of the initial coopera-
tion networks such as EUR-ASSESS, HTA-Europe and ECHTA/ECHAI. The data underscores 
how the onset of European HTA cooperation corresponded to the launch of an EU public 
health policy and how both processes became interconnected. Moreover, the role of policy 
entrepreneurs from the two arenas has been of prime importance for the further develop-
ment of the cooperation initiatives. The second stage of HTA cooperation runs from 2001 to 
2006 and highlights how three different EU policy streams have affected HTA cooperation: 
the EU health policy stream providing the institutional framework of HTA cooperation; the 
EU social policy stream, providing soft governance instruments in HTA cooperation; and the 
EU pharmaceutical policy stream, providing key content to HTA cooperation. The third devel-
opment stage covers the period since 2006 and outlines how several networks have sought 
to setup a sustainable structure for HTA cooperation in Europe. Although concrete outputs 
have been produced supporting cooperation initiatives, the main objective pursued by the 
networks has, to date, not been reached. The European Commission has proposed a Regula-
tion on HTA Cooperation to this end. Other initiatives have furthermore been developed to 
address this challenge by establishing regional (intergovernmental) cooperation frameworks.
Part C examines the empirical findings by applying network analysis based on the research 
framework developed in Part A. It highlights how the various cooperation networks can be 
considered as governance networks, responding however to different governance modes 
and network characteristics. Moreover, it examines effectiveness of network governance in 
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establishing a sustainable framework for HTA cooperation in Europe and highlights domains 
in which soft governance has had a positive impact on cooperation objectives as well as 
explanatory factors hereof. Finally, it underscores how the European Commission can be 
considered as metagovernor in European HTA cooperation networks. The final chapter ad-
dresses the research questions and presents the overall research conclusions.
The research has brought to the fore that HTA cooperation has been co-constructed by the 
HTA arena and the European Commission mainly through soft governance means. Domains 
in which a positive impact of soft governance on the cooperation processes have been found 
were related to the goal setting process of European HTA networks; the development of HTA 
cooperation tools, methodologies, and joint assessments. In some countries, uptake of com-
mon HTA tools and methodologies has been observed. Use of network outputs has also been 
identified in regional (intergovernmental) cooperation networks. Finally, soft governance has 
had a positive impact on the establishment of synergies between EUnetHTA and the EMA.
Factors favouring convergence were related to network structure (homogeneity and close-
ness) as well as governance modes (the more centralised, the more convergence). Social in-
teraction would support learning-processes, shared values and understanding, trust and goal 
consensus, essential in the development of joint work. The role of policy entrepreneurs from 
both the HTA and the EU arena in steering the cooperation initiatives also has had a positive 
impact on convergence. Finally, the presence of a shadow of hierarchy as well as the active 
support of the European Commission as metagovernor, further supported convergence of 
practices, using soft governance also as a mean to prepare the ground for hard regulation.
Absence of positive impact of soft governance has been found in the lack of establishment of 
a sustainable European framework for HTA cooperation as well as the absence of systematic 
uptake of joint work in the EU Member States. Explanatory factors hereof were related 
to the network composition (e.g. under representation of policymakers), stakeholder policy 
(informative rather than collaborative involvement, underrepresentation of stakeholders, 
stakeholder coordination policies), low social interaction between some actors (e.g. network 
– ministries, network-network), and mixed management approaches (e.g. project vs process 
management). These factors complement elements identified in previous studies related to 
uptake and (in)effectiveness of establishing a sustainable network mechanism.
The conclusions of this thesis bring to the fore that soft governance by offering flexibility and 
gradualism can be a powerful instrument to instil convergence in policy areas of limited EU 
competences. Lack of effectiveness of soft governance has been attributed in this research 
to the manner in which soft governance instruments have been implemented rather than 
inherent weaknesses of soft governance itself. The findings of this thesis may be relevant 
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for cooperation initiatives in other health policy fields (e.g. additional evidence generation, 
rare diseases, personalised medicines or the use of artificial intelligence in health care). Policy 
recommendations point to the importance of active participation of (hard) policy-makers 
when seeking convergence in areas referring to exclusive competences of EU Member States. 
Moreover, a clear transparent stakeholder policy should be defined early and be based on an 
inclusive participatory stakeholder approach. Finally, European legislative frameworks should 
allow the development of flexible cooperation structures.
This thesis invites to reconsider the role of soft governance in EU integration policies. Instead 
of being essentially utilised as a means to pave the way for hard legislation, it could be 
granted a different status and functionality within the EU governance modes and conceived 
as a real alternative to classic modes of integration rather than ‘sub-ordinated’ to them.
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SameNvattiNg
Sinds het begin wordt Health Technology Assessment in Europa gekenmerkt door de 
aanwezigheid van vele HTA-instanties in verschillende nationale gezondheidssystemen ge-
baseerd op uiteenlopende onderliggende waarden en besluitvormingsprocessen. Om deze 
diversiteit aan te pakken, de efficiëntie te bevorderen en de inbreng van HTA in nationale 
regelgevingsprocessen te vergroten, hebben HTA-instanties getracht samen te werken en 
een vorm van convergentie van assessmentpraktijken te bereiken. De start van deze sa-
menwerkingsinitiatieven viel samen met de lancering van een EU-volksgezondheidsbeleid. 
Geleidelijk komen beide processen samen en gaan elkaar versterken. Sinds het begin van de 
samenwerkingsinitiatieven zijn er verschillende Europese HTA-netwerken opgericht met het 
doel een duurzaam kader voor HTA-samenwerking in Europa tot stand te brengen. In 2018 
heeft de Europese Commissie een verordening over samenwerking op het gebied van HTA 
voorgesteld, het proces is tot op heden nog in gang.
Dit onderzoek heeft HTA-samenwerking bestudeerd in relatie tot EU-governance. De bev-
oegdheden van de EU op het gebied van HTA zijn beperkt tot ondersteunings- en coördi-
natiebeleid. In dit onderzoek is daarom gekeken naar de rol van soft governance207 bij het 
structureren van HTA-samenwerking binnen het kader van de Europese Unie. Aangezien 
HTA ernaar streeft input te leveren in binnenlandse regelgevingsprocessen, moet het echter 
voldoen aan eisen die harde besluitvormingen met zich mee brengen. De vraag rijst dus in 
hoeverre samenwerking en convergentie van praktijken op Europees niveau kan worden 
gestructureerd door middel van soft governance. Deze vraag fungeert als overkoepelende 
onderzoeksvraag. Onderlinge verschillen in nationale HTA-regelgevingen kunnen namelijk 
de totstandkoming en uitvoering van nieuwe gemeenschappelijke Europese HTA-overeen-
komsten belemmeren. Om het bereik van deze onderzoeksvraag af te bakenen, zijn er drie 
deelonderzoeksvragen geformuleerd, die elk gericht zijn op de rol van soft governance in 
een specifiek gebied van HTA-samenwerking: 1) convergentie en harmonisatie van HTA-
instrumenten, methodologieën en praktijken; 2) ‘uptake’ van gezamenlijk werk; en 3) syner-
gieën tussen de HTA-arena en de EU-regelgevingsprocessen voor farmaceutische producten.
De samenhang tussen het EU-gezondheidsbeleid en de HTA-samenwerking bevindt zich in 
netwerken. Europese HTA-samenwerking heeft voornamelijk plaatsgevonden via netwerken. 
Netwerken bieden door hun intrinsieke kenmerken een gunstig kader voor de implementatie 
207 In deze Nederlandse vertaling van de samenvatting gebruiken we het Engelstalig begrip ‘soft gov-
ernance’ (letterlijk vertaald een ‘zachte wijze van besturen’) aangezien de Nederlandse vertaling 
van governance (‘besturen’) de betekenis niet geheel dekt en soft governance als zodanig in het 
Nederlands een gangbaar begrip is.
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van ‘soft governance’ modaliteiten en instrumenten. Netwerken maakt ook deel uit van de 
nieuwe Europese bestuursaanpak die rond de millenniumwisseling is aangenomen. De rol van 
soft governance in de Europese HTA-samenwerking is daarom onderzocht via het prisma van 
netwerkanalyse. Het onderzoek is gestructureerd volgens kwalitatieve onderzoeksmethoden 
(bv. semigestructureerde persoonlijke interviews met sleutelfiguren uit het veld, academische 
en grijze literatuur, persoonlijke observaties tijdens internationale conferenties) en gebaseerd 
op een onderzoekskader dat is opgesteld volgens drie hoofdconcepten: bestuursnetwerken 
(governance networks), netwerk governance en metagovernance.
Het proefschrift bestaat uit drie delen. Deel A legt het theoretische en onderzoekskader vast. 
Aangezien het onderzoek zich op het snijvlak van twee verschillende wetenschapsgebieden 
bevindt - gezondheidsbeleid en EU governance – is het nodig om het onderzoeksonderwerp 
in de context te plaatsen. Het proefschrift gaat daarom eerst in op hoe HTA-samenwerking tot 
stand is gekomen en hoe het zich verhoudt tot nationale en Europese regelgevingsprocessen 
(bijv. marktautorisatie en prijs- en vergoedingsbesluiten) en plaatst deze binnen de bredere 
EU-architectuur voor gezondheidsbeleid en governance. Hierbij wordt aandacht besteed 
aan de competentieverdeling tussen de EU en de lidstaten, het subsidiariteitsbeginsel en de 
implementatie van soft governance via de zogenaamde New Modes of Governance (NMG), 
ontwikkeld sinds 2001 in de EU governance architectuur. Aangezien netwerken een van 
de benaderingen is die de EU gebruikt om NMG te implementeren, wordt in dit deel ook 
ingegaan op de manier waarop netwerken zich verhouden tot nationale en Europese vormen 
van beleid en hoe netwerken kunnen worden beschouwd als geschikt forum om soft gover-
nance te implementeren. Dit deel wordt afgesloten met de opzet van een onderzoekskader 
ontwikkeld met behulp van input uit verschillende academische scholen (bijv. politicologie, 
beleidsanalyse en organisatiestudies). Dit framework zal worden gebruikt om de rol van 
soft governance in de Europese HTA-samenwerking door middel van netwerkanalyse te 
onderzoeken.
Deel B schetst de bevindingen van het empirisch onderzoek naar Europese HTA-samenwerking. 
Het is gestructureerd volgens drie verschillende ontwikkelingsfasen van HTA-samenwerking 
in Europa. De eerste periode ligt tussen 1992 en 2001 en heeft betrekking op de oprichting 
van de eerste samenwerkingsnetwerken zoals EUR-ASSESS, HTA-Europe en ECHTA/ECHAI. 
De bevindingen benadrukken hoe het begin van de Europese HTA-samenwerking overeen-
kwam met de lancering van een EU-volksgezondheidsbeleid en hoe beide processen met 
elkaar verweven raken. Het belang van ‘policy entrepreneurs’ uit de twee arena’s voor de 
verdere ontwikkeling van de samenwerkingsinitiatieven wordt hier ook zichtbaar. De tweede 
fase van HTA-samenwerking loopt van 2001 tot 2006 en laat zien hoe drie verschillende 
Europese beleidsstromen de HTA-samenwerking hebben beïnvloed: de EU-beleidsstroom 
op gezondheidsgebied die het institutionele kader voor HTA-samenwerking plaatst; de EU 
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sociale beleidsstroom, die soft governance-instrumenten introduceert in HTA-samenwerking; 
en de EU farmaceutische beleidsstroom, die essentiële inhoud biedt voor HTA-samenwerking. 
De derde ontwikkelingsfase beslaat de periode sinds 2006 en schetst hoe verschillende 
netwerken hebben getracht een duurzame structuur voor HTA-samenwerking in Europa op 
te zetten. Alhoewel er concrete resultaten zijn geboekt ter ondersteuning van samenwerk-
ingsinitiatieven, is de belangrijkste doelstelling van de netwerken tot dusver niet bereikt. De 
Europese Commissie heeft daartoe een verordening inzake HTA-samenwerking voorgesteld. 
Daarnaast zijn er ook andere initiatieven ontwikkeld om deze uitdaging aan te gaan zoals 
bijvoorbeeld regionale (intergouvernementele) samenwerkingskaders.
Deel C onderzoekt de empirische bevindingen door netwerkanalyse toe te passen op basis 
van het onderzoekskader dat is ontwikkeld in deel A. In dit deel wordt benadrukt hoe de 
verschillende samenwerkingsnetwerken kunnen worden beschouwd als bestuursnetwerken 
(governance networks) en hoe ze zich van elkaar onderscheiden in netwerkkenmerken 
en bestuursmodaliteiten. Verder wordt ook de doeltreffendheid van netwerkgovernance 
onderzocht ten aanzien van het tot stand brengen van een duurzaam kader voor HTA-
samenwerking in Europa en worden domeinen belicht waarop soft governance een positieve 
invloed heeft gehad op de samenwerkingsdoelstellingen en de verklarende factoren hiervan. 
Ten slotte wordt in dit deel ook onderstreept hoe de Europese Commissie kan worden 
beschouwd als ‘metagovernor’208 in Europese HTA-samenwerkingsnetwerken. Het laatste 
hoofdstuk beantwoordt de onderzoeksvragen en presenteert de algemene conclusies van 
het onderzoek.
Het onderzoek heeft uitgewezen dat de HTA-arena en de Europese Commissie gezamen-
lijk de HTA-samenwerking tot stand hebben gebracht, voornamelijk door middel van soft 
governance. Domeinen waarin een positieve impact van soft governance op de samenwerk-
ingsprocessen is gevonden, houden verband met het doelbepalingsproces van Europese 
HTA-netwerken; de ontwikkeling van HTA-samenwerkingsinstrumenten, methodologieën en 
gezamenlijke assessments. In sommige landen zijn gemeenschappelijke HTA-instrumenten en 
HTA-methodologieën in nationale praktijken opgenomen. Het gebruik van netwerkoutputs 
is ook vastgesteld in regionale (intergouvernementele) samenwerkingsnetwerken. Ten slotte 
heeft soft governance een positieve invloed gehad op de totstandbrenging van synergieën 
tussen EUnetHTA en de EMA.
Factoren die convergentie bevorderen, hebben betrekking op de netwerkstructuur (ho-
mogeniteit en nabijheid) en de bestuursmodaliteiten (hoe meer gecentraliseerd, hoe meer 
convergentie). Sociale interactie heeft invloed gehad op leerprocessen, het tot stand brengen 
208 Letterlijke vertaling: ‘metabestuurder’
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van gezamenlijke normen en waarden, vertrouwen en consensus op het te bereiken doel, 
essentieel bij de ontwikkeling van gezamenlijk werk. De rol van beleidsondernemers (‘policy 
entrepreneurs’) uit zowel de HTA als de EU-arena bij het aansturen van de samenwerking-
sinitiatieven heeft ook een positieve invloed gehad op de convergentie. Ten slotte heeft de 
aanwezigheid van een ‘shadow of hierarchy’ en de actieve steun van de Europese Commissie 
als ‘metagovernor’, de convergentie van praktijken verder ondersteund, waarbij soft gover-
nance ook als middel werd gebruikt om de basis te leggen voor harde regelgeving.
Er is geen positief effect van soft governance vastgesteld in het opzetten van een duurzaam 
Europees kader voor HTA-samenwerking, noch in een systematische ‘uptake’ van netwerk-
producten in de EU-lidstaten. Verklarende factoren hiervan zijn gerelateerd aan de netwerksa-
menstelling (bijv. onder vertegenwoordiging van nationale beleidsmakers), stakeholderbeleid 
(informatieve in plaats van collaboratieve betrokkenheid, ondervertegenwoordiging van 
stakeholders, stakeholdercoördinatiebeleid), gebrek aan sociale interactie tussen bepaalde 
actoren (bv. netwerk - ministeries, netwerk-netwerk) en management benaderingen (bijv. 
project- versus procesmanagement). Deze factoren vullen elementen aan die in eerdere stud-
ies zijn geïdentificeerd met betrekking tot uptake en (on) effectiviteit van het opzetten van 
een duurzaam Europees HTA samenwerkingskader.
Uit het onderzoek komt naar voren dat soft governance, door flexibiliteit en geleidelijkheid te 
bieden, een effectief middel kan zijn om convergentie te bewerkstelligen op beleidsterreinen 
waar de EU beperkte bevoegdheden heeft. Gebrek aan effectiviteit van soft governance 
wordt in het kader van dit proefschrift toegeschreven aan de manier waarop soft governance-
instrumenten zijn geïmplementeerd en niet aan inherente zwakheden van soft governance 
zelf. De bevindingen van dit proefschrift kunnen relevant zijn voor samenwerkingsinitiatieven 
op andere gebieden van het gezondheidsbeleid (bijv. ‘additional evidence generation’, 
zeldzame ziekten, ‘personalised medicines’ of het gebruik van kunstmatige intelligentie in 
de gezondheidszorg). Beleidsaanbevelingen wijzen op het belang van actieve deelname 
van (harde) beleidsmakers bij het zoeken naar convergentie op gebieden die verwijzen 
naar exclusieve bevoegdheden van EU-lidstaten. Bovendien moet een duidelijk transparant 
stakeholderbeleid vroegtijdig worden gedefinieerd en gebaseerd zijn op een inclusieve par-
ticipatieve benadering van stakeholders. Ten slotte moeten Europese wetgevingskaders de 
ontwikkeling van flexibele samenwerkingsstructuren mogelijk maken.
In de conclusie van dit proefschrift wordt voorgesteld de rol van soft governance in het EU-
integratiebeleid te heroverwegen. In plaats van in wezen te worden gebruikt als middel om 
de weg vrij te maken voor harde wetgeving, zou het een andere status en functionaliteit kun-
nen krijgen binnen de EU governance modaliteiten en zou het kunnen worden beschouwd 
als een goed alternatief voor klassieke integratiemethoden.
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